<SEC-DOCUMENT>0001171843-24-006946.txt : 20241213
<SEC-HEADER>0001171843-24-006946.hdr.sgml : 20241213
<ACCEPTANCE-DATETIME>20241213164531
ACCESSION NUMBER:		0001171843-24-006946
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		88
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241213
DATE AS OF CHANGE:		20241213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Edesa Biotech, Inc.
		CENTRAL INDEX KEY:			0001540159
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37619
		FILM NUMBER:		241549047

	BUSINESS ADDRESS:	
		STREET 1:		100 SPY COURT
		CITY:			MARKHAM
		STATE:			A6
		ZIP:			L3R 5H6
		BUSINESS PHONE:		(905) 475-1234

	MAIL ADDRESS:	
		STREET 1:		100 SPY COURT
		CITY:			MARKHAM
		STATE:			A6
		ZIP:			L3R 5H6

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stellar Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20120120
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>edsa20240930_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:edsa="http://www.edsa.com/20240930" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:srt="http://fasb.org/srt/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"><head>
	<title>edsa20240930_10k.htm</title>


	<!-- Generated by ThunderDome Portal - 12/13/2024 5:51:59 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:DocumentFiscalPeriodFocus" id="ixv-11437">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:DocumentFiscalYearFocus" id="ixv-11438">2024</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:CurrentFiscalYearEndDate" id="ixv-11439">--09-30</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:AmendmentFlag" id="ixv-11440">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityCentralIndexKey" id="ixv-11441">0001540159</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c998" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2022-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="c979" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonFraction id="c646" contextRef="i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c757" format="ixt:date-monthname-day-year-en">October 31, 2033</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c756" format="ixt:date-monthname-day-year-en">March 31, 2025</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c751" format="ixt:date-monthname-day-year-en">February 28,  2032</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c750" format="ixt:date-monthname-day-year-en">March 31, 2025</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c746" format="ixt:date-monthname-day-year-en">September 30, 2031</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c745" format="ixt:date-monthname-day-year-en">March 31, 2025</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c740" format="ixt:date-monthname-day-year-en">October 31, 2030</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c739" format="ixt:date-monthname-day-year-en">September 30, 2030</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c734" format="ixt:date-monthname-day-year-en">February  28, 2030</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c730" format="ixt:date-monthname-day-year-en">December 31, 2028</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c729" format="ixt:date-monthname-day-year-en">August 31, 2027</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="c725" format="ixt:date-monthname-day-year-en">March 31, 2025</ix:nonNumeric>
<ix:nonFraction id="c569" contextRef="d_2022-10-01_2023-09-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c568" contextRef="d_2023-10-01_2024-09-30" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFiveMember" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="c679" format="ixt:date-monthname-day-year-en">September 30, 2027</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFourMember" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="c676" format="ixt:date-monthname-day-year-en">March 31, 2027</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantThreeMember" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="c673" format="ixt:date-monthname-day-year-en">February 28, 2026</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantTwoMember" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="c670" format="ixt:date-monthname-day-year-en">December 31, 2025</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantOneMember" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="c667" format="ixt:date-monthname-day-year-en">January 31, 2025</ix:nonNumeric>
<ix:nonFraction id="c498" contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c459" contextRef="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember" unitRef="USD" name="edsa:PaymentsForLicensingAndRoyalties" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c458" contextRef="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember" unitRef="USD" name="edsa:PaymentsForLicensingAndRoyalties" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c456" contextRef="i_2016-12-31_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember" unitRef="USD" name="us-gaap:FiniteLivedLicenseAgreementsGross" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c455" contextRef="d_2022-10-01_2023-09-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember" unitRef="USD" name="us-gaap:PaymentsToSuppliers" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c454" contextRef="d_2023-10-01_2024-09-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember" unitRef="USD" name="us-gaap:PaymentsToSuppliers" scale="6" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c452" contextRef="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-TheConstructsMember" unitRef="USD" name="edsa:PaymentsForMilestoneRoyaltyAndSublicensing" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c451" contextRef="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-TheConstructsMember" unitRef="USD" name="edsa:PaymentsForMilestoneRoyaltyAndSublicensing" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2022-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="c405" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-04-01_2020-04-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" name="edsa:LicenseAgreementRenewalPeriod" id="c368" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c313" contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" name="edsa:LicenseAgreementRenewalPeriod" id="c311" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c304" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c277" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c83" contextRef="i_2023-09-30" unitRef="USDPerShare" name="us-gaap:CommonStockNoParValue" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c82" contextRef="i_2024-09-30" unitRef="USDPerShare" name="us-gaap:CommonStockNoParValue" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2022-10-01_2023-09-30" name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="c81">Unlimited</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="c80">Unlimited</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="c36" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="ecd:NonRule10b51ArrTrmntdFlag" id="c35" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="ecd:NonRule10b51ArrAdoptedFlag" id="c34" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="ecd:Rule10b51ArrTrmntdFlag" id="c33" format="ixt:fixed-false">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="ecd:Rule10b51ArrAdoptedFlag" id="c32" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="edsa-20240930.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2023-10-01_2024-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantsToPurchaseCommonSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-10-01_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantsToPurchaseCommonSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">edsa:ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">edsa:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-01_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">edsa:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">edsa:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-01_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-04</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="CAD"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2044Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2042Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2041Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2040Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2039Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2044Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2043Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2042Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2042Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2041Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2040Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2039Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2039Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2038Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2037Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2036Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2035Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2034Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2033Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2032Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2031Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2030Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2029Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2028Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2027Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2026Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2025Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-CanadaEmergencyBusinessAccountProgramMember_LineOfCreditFacilityAxis-CIBCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:CanadaEmergencyBusinessAccountProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">edsa:CIBCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:The2023SIFAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:The2023SIFAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:The2023SIFAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:The2023SIFAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2022-10-01_2023-09-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-09-30_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2019PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">edsa:The2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_PlanNameAxis-The2019PlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">edsa:The2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFiveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFourMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantThreeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-27_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassBWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-02_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-02</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-11-02_2022-11-02_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-11-02</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">edsa:CaliforniaSubsidiary401kMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">edsa:CaliforniaSubsidiary401kMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementRelatedToPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementRelatedToPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2016-12-31_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementRelatedToPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">edsa:DrugSubstanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">edsa:DrugSubstanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-04-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">edsa:DrugSubstanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-TheConstructsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-TheConstructsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-04-30_TypeOfArrangementAxis-TheConstructsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TheConstructsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">edsa:TheConstructsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TheConstructsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">edsa:TheConstructsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-04-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-04-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-04-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edsa:FurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edsa:FurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-09-30_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-CapitalizedCostsPropertyPlantAndEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edsa:CapitalizedCostsPropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-30</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-11-01_2022-11-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-30_ClassOfWarrantOrRightAxis-ThreeYearWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ThreeYearWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-11-30_ClassOfWarrantOrRightAxis-TwelveMonthWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:TwelveMonthWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-03-01_2023-09-30_CounterpartyNameAxis-CanaccordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-03-31_CounterpartyNameAxis-CanaccordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-31_CreditFacilityAxis-RevolvingCreditFacilityMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">edsa:PardeepNijhawanMedicineProfessionalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_CreditFacilityAxis-RevolvingCreditFacilityMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">edsa:PardeepNijhawanMedicineProfessionalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2023-10-31_CreditFacilityAxis-LineOfCreditMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">edsa:PardeepNijhawanMedicineProfessionalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-10-31_CreditFacilityAxis-UnsecuredLineOfCreditMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">edsa:UnsecuredLineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">edsa:PardeepNijhawanMedicineProfessionalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-02-28_GovernmentAssistanceTypeAxis-The2021SIFAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:The2021SIFAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">edsa:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-31_CounterpartyNameAxis-CanaccordMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-08-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-10-01_2024-12-13_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">edsa:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-13</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001540159</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
<div>&#160;</div>

<div>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin: 0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>UNITED STATES</b><br/>
<b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Washington, D.C. 20549</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt 0pt 0pt 1pt; text-align: center;"><b>FORM <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:DocumentType" id="c2">10-K</ix:nonNumeric></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:DocumentAnnualReport" id="c3" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric> </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>For the fiscal year ended <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:DocumentPeriodEndDate" id="c4" format="ixt:date-monthname-day-year-en">September 30, 2024</ix:nonNumeric></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>OR</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:DocumentTransitionReport" id="c5" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>For the transition period from&#160; &#160; &#160; to </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Commission file number: <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityFileNumber" id="c6">001-37619</ix:nonNumeric></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; font-variant: normal; margin: 0pt; text-align: center;"><b><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityRegistrantName" id="c7">EDESA BIOTECH, INC.</ix:nonNumeric></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">(Exact name of registrant as specified in its charter)</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 50%; text-align: center;"><b>British Columbia, <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityIncorporationStateCountryCode" id="c8" format="ixt-sec:countrynameen">Canada</ix:nonNumeric></b></td>
			<td style="width: 50%; text-align: center;"><b>N/A</b></td>
		</tr>
		<tr>
			<td style="text-align: center;">(State or other jurisdiction of incorporation or organization)</td>
			<td style="text-align: center;">(I.R.S. Employer Identification No.)</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 50%; text-align: center;"><b><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityAddressAddressLine1" id="c9">100 Spy Court</ix:nonNumeric>, <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityAddressCityOrTown" id="c10">Markham</ix:nonNumeric>, ON, <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityAddressCountry" id="c11" format="ixt-sec:countrynameen">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityAddressPostalZipCode" id="c12">L3R 5H6</ix:nonNumeric></b></td>
			<td style="width: 50%; text-align: center;"><b>(<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:CityAreaCode" id="c13">289</ix:nonNumeric>) <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:LocalPhoneNumber" id="c14">800-9600</ix:nonNumeric></b></td>
		</tr>
		<tr>
			<td style="text-align: center;">(Address of principal executive offices and zip code)</td>
			<td style="text-align: center;">(Registrant&#8217;s telephone number, including area code)</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;"><b>Securities registered pursuant to Section 12(b) of the Act:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Title of each class</b></p>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 32%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Trading Symbol</b></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Name of each exchange on which registered</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:Security12bTitle" id="c15">Common Shares, without par value</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:TradingSymbol" id="c16">EDSA</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: top; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">The <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:SecurityExchangeName" id="c17" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;"><b>Securities registered pursuant to Section 12(g) of the Act: None</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityWellKnownSeasonedIssuer" id="c18">No</ix:nonNumeric> &#9746;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityVoluntaryFilers" id="c19">No</ix:nonNumeric> &#9746;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityCurrentReportingStatus" id="c20">Yes</ix:nonNumeric> &#9746; No &#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityInteractiveDataCurrent" id="c21">Yes</ix:nonNumeric> &#9746; No &#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 10%; margin-right: 10%;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Large accelerated filer</p>
			</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9744;</p>
			</td>
			<td style="vertical-align: middle; width: 26%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accelerated filer</p>
			</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9744;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityFilerCategory" id="c22" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9746;</p>
			</td>
			<td style="vertical-align: middle; width: 26%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Smaller reporting company</p>
			</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntitySmallBusiness" id="c23" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 26%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 34%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Emerging growth company</p>
			</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityEmergingGrowthCompany" id="c24" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:IcfrAuditorAttestationFlag" id="c25" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued statements. <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:DocumentFinStmtErrorCorrectionFlag" id="c26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to Section 240.10D-1(b). &#9744;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:EntityShellCompany" id="c27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> No &#9746;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As of March 31, 2024, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s outstanding common shares held by nonaffiliates was approximately $<ix:nonFraction id="c28" contextRef="i_2024-03-31" unitRef="USD" name="dei:EntityPublicFloat" scale="0" format="ixt:num-dot-decimal" decimals="0">11,056,198</ix:nonFraction>, which was calculated based on 3,215,968&#160;common shares outstanding as of that date, of which 2,664,144&#160;common shares were held by nonaffiliates at the closing price of the registrant&#8217;s common shares on The Nasdaq Capital Market on such date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -18pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">As of December 11, 2024, the registrant had <ix:nonFraction id="c29" contextRef="i_2024-12-11" unitRef="Share" name="dei:EntityCommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,467,658</ix:nonFraction> common shares issued and outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>DOCUMENTS INCORPORATED BY REFERENCE: NONE</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#160;</p>
</div>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>EDESA BIOTECH, INC.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>ANNUAL REPORT ON FORM 10-K</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Year Ended September 30, 2024</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Table of Contents</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Item</b></p>
			</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#P1" style="-sec-extract:exhibit;"><b>PART I</b></a></p>
			</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%; text-align: right;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I1" style="-sec-extract:exhibit;">1.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I1" style="-sec-extract:exhibit;">Business</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I1">4</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I1A" style="-sec-extract:exhibit;">1A.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I1A" style="-sec-extract:exhibit;">Risk Factors</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I1A">22</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I1B" style="-sec-extract:exhibit;">1B.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I1B" style="-sec-extract:exhibit;">Unresolved Staff Comments</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I1B">41</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I1C" style="-sec-extract:exhibit;">1C.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I1C" style="-sec-extract:exhibit;">Cybersecurity</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I1C">41</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I2" style="-sec-extract:exhibit;">2.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I2" style="-sec-extract:exhibit;">Properties</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I2">42</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I3" style="-sec-extract:exhibit;">3.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I3" style="-sec-extract:exhibit;">Legal Proceedings</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I3">42</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I4" style="-sec-extract:exhibit;">4.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I4" style="-sec-extract:exhibit;">Mine Safety Disclosures</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I4">42</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#P2" style="-sec-extract:exhibit;"><b>PART II</b></a></p>
			</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I5" style="-sec-extract:exhibit;">5.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I5" style="-sec-extract:exhibit;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I5">43</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I6" style="-sec-extract:exhibit;">6.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I6" style="-sec-extract:exhibit;">[Reserved]</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I6">43</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I7" style="-sec-extract:exhibit;">7.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I7" style="-sec-extract:exhibit;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I7">43</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I7A" style="-sec-extract:exhibit;">7A.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I7A" style="-sec-extract:exhibit;">Quantitative and Qualitative Disclosures about Market Risk</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I7A">49</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I8" style="-sec-extract:exhibit;">8.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I8" style="-sec-extract:exhibit;">Financial Statements and Supplementary Data</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I8">49</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I9" style="-sec-extract:exhibit;">9.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I9" style="-sec-extract:exhibit;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I9">49</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I9A" style="-sec-extract:exhibit;">9A.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I9A" style="-sec-extract:exhibit;">Controls and Procedures</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I9A">49</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I9B" style="-sec-extract:exhibit;">9B.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I9B" style="-sec-extract:exhibit;">Other Information</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I9B">50</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 23pt;"><a href="#I9C" style="-sec-extract:exhibit;">9C.</a></p>
			</td>
			<td style="vertical-align: middle; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I9C" style="-sec-extract:exhibit;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></p>
			</td>
			<td style="vertical-align: middle; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I9C">50</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#P3" style="-sec-extract:exhibit;"><b>PART III</b></a></p>
			</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I10" style="-sec-extract:exhibit;">10.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I10" style="-sec-extract:exhibit;">Directors, Executive Officers and Corporate Governance</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I10">51</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I11" style="-sec-extract:exhibit;">11.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I11" style="-sec-extract:exhibit;">Executive Compensation</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I11">54</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I12" style="-sec-extract:exhibit;">12.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I12" style="-sec-extract:exhibit;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I12">63</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I13" style="-sec-extract:exhibit;">13.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I13" style="-sec-extract:exhibit;">Certain Relationships and Related Transactions, and Director Independence</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I13">65</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I14" style="-sec-extract:exhibit;">14.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I14" style="-sec-extract:exhibit;">Principal Accounting Fees and Services</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I14">66</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#P4" style="-sec-extract:exhibit;"><b>PART IV</b></a></p>
			</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I15" style="-sec-extract:exhibit;">15.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I15" style="-sec-extract:exhibit;">Exhibits and Financial Statement Schedules</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I15">67</a></td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 23pt;"><a href="#I16" style="-sec-extract:exhibit;">16.</a></p>
			</td>
			<td style="vertical-align: top; width: 88%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#I16" style="-sec-extract:exhibit;">Form 10-K Summary</a></p>
			</td>
			<td style="vertical-align: top; width: 7%; text-align: right;"><a class="tocPGNUM" href="#I16">72</a></td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 5%;">&#160;</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="#Signatures" style="-sec-extract:exhibit;"><b>SIGNATURES</b></a></p>
			</td>
			<td style="vertical-align: middle; width: 88%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%; text-align: right;"><a class="tocPGNUM" href="#Signatures">73</a></td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<div>&#160;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>FORWARD-LOOKING STATEMENTS AND OTHER MATTERS</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act) and, as such, may involve known and unknown risks, uncertainties and assumptions. Forward-looking statements are based upon our current expectations, speak only as of the date hereof, are subject to change and include statements about, among other things: the status, progress and results of our clinical programs; our ability to obtain regulatory approvals for or successfully commercialize any of our product candidates; our business plans, strategies and objectives, including plans to pursue collaboration, licensing or other similar arrangements or transactions; our expectations regarding our liquidity and performance, including our expense levels, sources of capital and ability to maintain our operations; the competitive landscape of our industry; and general market, economic and political conditions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Forward-looking statements are those that predict or describe future events or trends and that do not relate solely to historical matters. You can generally identify forward-looking statements as those statements containing the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or other similar expressions. You should not rely on our forward-looking statements as they are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate because the matters they describe are subject to assumptions, known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond our control.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are discussed in this report in the Part I, Item 1A. Risk Factors and elsewhere in this report. Risks and uncertainties include, among others:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to obtain funding for our operations;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our estimates regarding our expenses, revenues, anticipated capital requirements and our needs for additional financing;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the timing of the commencement, progress and receipt of data from any of our preclinical and clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the expected results of any preclinical or clinical trial and the impact on the likelihood or timing of any regulatory approval;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the therapeutic benefits, effectiveness and safety of our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the timing or likelihood of regulatory filings and approvals;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">changes in our strategy or development plans;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the volatility of our common share price;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the rate and degree of market acceptance and clinical utility of any future products;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the effect of competition;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to protect our intellectual property as well as comply with the terms of license agreements with third parties;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to comply with the continued listing requirements of Nasdaq;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to identify, develop and commercialize additional products or product candidates;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">reliance on key personnel; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">general changes in economic or business conditions.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Except as required by law, we undertake no obligation to update forward-looking statements. You should review the factors and risks and other information we describe in the reports we will file from time to time with the SEC.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As used in this Annual Report on Form 10-K, &#8220;Edesa,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Edesa Biotech, Inc. and our consolidated subsidiaries, except where the context otherwise requires.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our logo and other trademarks or service marks of Edesa Biotech, Inc. appearing in this Annual Report on Form 10-K are the property of Edesa Biotech, Inc. This Annual Report on Form 10-K contains additional trade names, trademarks and service marks of other companies. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply relationships with, or endorsement or sponsorship of us by, these other companies.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">3</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b><a id="P1" title="P1" href="#"></a>PART 1</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I1" title="I1" href="#"></a>Item 1. BUSINESS.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Overview</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects. We prioritize our efforts on disease indications where there is compelling scientific rationale, no approved therapies or where there are unmet medical needs, and where there are large addressable market opportunities, among other factors. Our clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In Medical Dermatology we are developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. CXCL10 has been shown to play a key role in the disease, and neutralization of CXCL10 has been demonstrated to both prevent and reverse depigmentation in animal models. To date, EB06 has demonstrated a favorable safety and tolerability profile. We have received regulatory approval from Health Canada to conduct a Phase 2 proof of concept study of EB06 in patients with moderate-to-severe nonsegmental vitiligo and we are in discussions with the U.S. Food and Drug Administration (FDA) for the same study. Our medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. This asset is at the partnering stage.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our most advanced Respiratory drug candidate is EB05 (paridiprubart). Paridiprubart represents a new class of emerging therapies called Host-Directed Therapeutics (HDTs) that are designed to modulate the body&#8217;s own immune response when confronted with infectious diseases or even chemical agents. EB05 is currently being evaluated in a U.S. government-funded platform study investigating three novel threat-agnostic HDTs in hospitalized adult patients with Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. Certain development expenses, including manufacturing scale-up, for our EB05 program are also eligible for reimbursement from the Government of Canada under a 2023 grant and funding award. In addition to EB05, we are also preparing an investigational new drug application (IND) in the United States to conduct a future Phase 2 study for EB07 (paridiprubart) in patients with pulmonary fibrosis.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Competitive Strengths</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We believe that we possess a number of competitive strengths that position us to become a leading biopharmaceutical company focused on immuno-inflammatory diseases, including:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Validated technology and drug development capabilities.</i>&#160;We believe that the strength of our technologies and our drug development capabilities have been validated by our favorable clinical data, our multiple arrangements with third parties to develop and commercialize their clinical-stage drug candidates, more than C$37 million in competitive government grant and funding awards, and selection for a U.S. government-funded clinical study by experts from the Biomedical Advanced Research and Development Authority (BARDA), the Centers for Disease Control and Prevention, Department of Defense, FDA and National Institutes of Health.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Innovative pipeline addressing large underserved markets. </i>Our product candidates include novel clinical-stage compounds and antibodies that have significant scientific rationale for effectiveness. By initially targeting large markets that have significant unmet medical needs, we believe that we can drive adoption of new products and improve our competitive position. For example, vitiligo affects up to 2% of the world&#8217;s population and ARDS is associated with approximately 10% of ICU admissions globally, yet both diseases have limited treatment options.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Intellectual property protection and market exclusivity.</i>&#160;We have opportunities to develop our competitive position through patents, trade secrets, technical know-how and continuing technological innovation. We have exclusive license rights in our target indications to multiple patents and pending patent applications in the U.S. and in various foreign jurisdictions. In addition to patent protection, we intend to utilize trade secrets and market exclusivity afforded to new chemical entities and biologics, where applicable, to enhance or maintain our competitive position.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Experienced leadership.</i>&#160;Our leadership team possesses core capabilities in dermatology, infectious diseases, gastrointestinal medicine, drug development and commercialization, chemistry, manufacturing and controls, and finance. Our founder and Chief Executive Officer, Pardeep Nijhawan, MD, FRCPC, AGAF, is a board-certified gastroenterologist and hepatologist with a successful track record of building life science businesses, including Exzell Pharma Inc., which was sold to BioLab Pharma in 2022, and Medical Futures, Inc., which was sold to Tribute Pharmaceuticals in 2015. In addition to our internal capabilities, we have also established a network of key opinion leaders, contract research organizations, contract manufacturing organizations and consultants. As a result, we believe we are well positioned to efficiently develop novel treatments for inflammatory and immune-related diseases.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Our Business Strategy</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our business strategy is to develop and commercialize innovative drug products that address unmet medical needs for large, underserved markets with limited competition. Key elements of our strategy include:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Prioritize the development and commercialization of later-stage product candidates.</i>&#160;Our goal is to obtain regulatory approval and commercialize multiple clinical assets in our pipeline. We focus on disease indications that we believe have clear regulatory pathways and interest from potential licensing or development partners. Given the high capital requirement for pivotal clinical studies, our preferred strategy is to seek public and private partners for Phase 3 clinical testing and scale-up. We also plan to evaluate opportunities to apply, as applicable, for expedited regulatory review and orphan drug programs, which could potentially lead to accelerated clinical development and commercialization timelines for our product candidates.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Maximize our current portfolio opportunity by expanding use across multiple indications. </i>We aim to identify clinical-stage assets that have the potential to treat multiple diseases. Our assets are designed to modulate pathways that are implicated across a number of immune and inflammatory/allergic conditions. For example, we believe that our monoclonal antibody candidates have potential utility in additional indications, including chronic conditions like&#160;pulmonary fibrosis.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Maximize the commercial potential of our product candidates via direct marketing or strategic arrangements. </i>If our product candidates are successfully developed and approved, we plan to either build commercial infrastructure capable of directly marketing the products, or alternatively, outsource the sales and marketing of our products. We also plan to evaluate strategic licensing or partnering arrangements with pharmaceutical companies for the further development or commercialization of our drugs, where applicable, such as in areas or regions outside North America where a partner may contribute additional resources, infrastructure and expertise.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>In-license promising product candidates. </i>We are applying our cost-effective development approach to advance and expand our pipeline. Our current product candidates are in-licensed from academic institutions or other biopharmaceutical companies, and, from time to time, we plan to identify, evaluate and potentially obtain rights to and develop additional assets. Our objective is to maintain a well-balanced portfolio with product candidates across various stages of development. We do not currently intend to invest significant capital in basic research, which can be expensive and time-consuming.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Respiratory </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>Acute Respiratory Distress Syndrome </i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">ARDS is a life-threatening form of respiratory failure characterized by an exaggerated and dysfunctional immune response, rapid onset of widespread inflammation in the lungs, and hypoxia (an absence of enough oxygen in the tissues to sustain bodily functions). ARDS can be precipitated by a number of conditions including viral and bacterial pneumonia, sepsis, chest injury and even mechanical ventilation, among other causes. ARDS has historically accounted for 10% of ICU admissions, representing more than 3 million patients globally each year. Based on the prevalence data of ARDS, we estimate that there are as many as 600,000 ARDS-related admissions to ICUs each year in the seven major markets (U.S, UK, Germany, France, Spain, Italy, Japan) and Canada. According to medical literature, ICU stays for ARDS patients in the U.S. range from 7 to 21 days on average, at an average cost of more than $100,000 per patient.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">For moderate to severe cases of ARDS, treatments remain limited and patients suffer high mortality rates. Countering the exaggerated innate immune response in ARDS patients has been a key area of interest among researchers. One of the most studied targets has been Toll-like receptor 4 (TLR4) - a key component of the innate immune system and an important mediator of inflammation. Since TLR4 detects molecules found in pathogens and also binds to endogenous molecules produced as a result of injury, it is a key receptor on which both infectious and noninfectious stimuli converge to induce a proinflammatory response.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>EB05 (paridiprubart)</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">EB05 is an intravenous formulation of paridiprubart, a first-in-class monoclonal antibody (mAb) that has been engineered to alter inflammatory signaling by binding to and blocking the activation of TLR4. Specifically, paridiprubart dampens TLR4 signaling by blocking receptor dimerization (and subsequent intracellular signaling cascades). The drug has demonstrated the ability to block signaling irrespective of the presence or concentration of the various molecules that frequently bind with TLR4, known as ligands. Based on this broad mechanism of action and clinical results to date, we believe that paridiprubart could ameliorate TLR4-mediated inflammation cascades in ARDS patients, thereby reducing lung injury, ventilation rates and mortality.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In the signal-finding Phase 2 part of a Phase 2/3 clinical study evaluating EB05 in hospitalized Covid-19 patients at various disease severity levels, EB05 demonstrated a statistically significant and clinically meaningful trend for 28-day mortality for all randomized subjects in the critically ill cohort (the intent to treat, or ITT, population). The 28-day death rate in the EB05 plus standard of care (SOC) arm was 7.7% versus 40% in the placebo + SOC arm in critically severe patients on ECMO therapy (extracorporeal membrane oxygenation) or Invasive Mechanical Ventilation (IMV) plus organ support with ARDS at baseline (p=0.04). The Survival Analysis using Cox&#8217;s Proportional Hazard Model also demonstrated that patients treated with EB05 + SOC had an 84% reduction in the risk of dying when compared to placebo + SOC at 28 days. The Phase 2 study demonstrated that EB05 appears to be well-tolerated and consistent with the observed safety profile to date. The FDA has granted EB05 a fast-track designation for the treatment of hospitalized Covid-19 patients.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>U.S. Government Funded Study</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In June 2024, EB05 was selected through a competitive process by BARDA, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as one of three drug candidates for evaluation in a U.S. government-funded Phase 2 platform study. The randomized, double-blinded, placebo-controlled, multi-center clinical trial is investigating novel threat-agnostic host-directed therapeutics, including EB05, in hospitalized adult patients with ARDS due to a variety of causes. The BARDA-funded study is being managed under a BARDA contract with PPD Development, LP, a clinical research business of Thermo Fisher Scientific, Inc. For the EB05 cohort of the study, patients are being randomized one-to-one to either EB05 + SOC or to a placebo + SOC control arm. We are providing drug products to the study as well as technical support at our own expense.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Phase 3 Study</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Given the BARDA-sponsored study opportunity, we have shifted our clinical focus for EB05 to general ARDS from Covid-19 induced ARDS. Our plan is to await the results of the BARDA-funded study before continuing with our Canadian government-supported Phase 3 study, which had exclusively recruited ARDS patients hospitalized with Covid-19. As a result, we have discontinued enrollment in a Covid-19 focused Phase 3 study and plan to file a new study design with FDA and Health Canada based on the results of the BARDA-funded ARDS study. We believe this strategy provides a more efficient and cost-effective path toward a commercially approved therapy for general ARDS, increases the potential commercial opportunity for EB05 and better aligns our development programs with government goals for HDTs as well as interest from potential strategic commercialization and licensing partners. Any changes we have made and make in the future to our clinical plans and enrollment criteria may limit how data from previously enrolled subjects are utilized by the company for regulatory purposes.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Federal Funding from the Government of Canada</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2023, our wholly owned subsidiary Edesa Biotech Research, Inc. (Edesa Biotech Research) entered into a multi-year contribution agreement (the 2023 SIF Agreement) with the Canadian government&#8217;s Strategic Innovation Fund, or SIF. Under the 2023 SIF Agreement, the Government of Canada committed up to C$23 million in partially repayable funding toward (i) conducting and completing a Phase 3 clinical study of our investigational therapy EB05 in critical-care patients with ARDS caused by Covid-19 or other infectious agents, and (ii) submitting EB05 for governmental approvals and manufacturing scale-up, following, and subject to, completing the Phase 3 study and (iii) conducting two non-clinical safety studies to assess the potential long-term impact of EB05 exposure. Of the C$23 million committed by SIF, up to C$5.75 million is not repayable. The remaining C$17.25 million is conditionally repayable starting in 2029 only if and when we earn gross revenue. Edesa Biotech Research has agreed to complete the project by December 31, 2025. In the event that we or Edesa Biotech Research breach our obligations under the 2023 SIF Agreement, subject to applicable cure, the SIF may exercise a number of remedies, including suspending or terminating funding under the 2023 SIF Agreement, demanding repayment of funding previously received and/or terminating the 2023 SIF Agreement. The performance obligations of Edesa Biotech Research under the 2023 SIF Agreement are guaranteed by us. As a result of the opportunity created by U.S. government-funded study, we are in discussions with the Government of Canada to amend our 2023 SIF Agreement, including extending the project timeline and completion date. There can be no assurance that the government will accept our proposals or, if rejected, seek the applicable remedies described above.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our previously completed Phase 2 study of EB05 was also funded, in part, by SIF. Under a February 2021 agreement (the 2021 SIF Agreement), the Government of Canada committed C$14.1 million in nonrepayable funding for an international Phase 2 study and certain pre-clinical experiments. In the event that we or Edesa Biotech Research breach our obligations under the 2021 SIF Agreement, subject to applicable cure, the SIF may exercise a number of remedies, including demanding repayment of funding previously received and/or terminating the agreement. The performance obligations of Edesa Biotech Research under the contribution agreement are guaranteed by us. All potential funding available under the 2021 SIF Agreement has been received.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As of the date of this filing, we have met all of our performance and reporting requirements under our SIF Agreements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>Pulmonary Fibrosis and EB07 (Paridiprubart)</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">There is significant evidence that targeting TLR4 in fibrotic conditions could result in therapeutic benefit for patients. Third party preclinical research has demonstrated that blocking&#160;TLR4 in animal models has been shown to reduce and in some cases reverse fibrosis. Similarly, TLR4 knockout mice display attenuated fibrosis. In addition, concentrations of agonists that bind to and activate TLR4 are often good predictors of disease severity and progression.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We are preparing an IND in the U.S. for our EB07 (paridiprubart) product candidate to conduct a future Phase 2 proof of concept study in subjects with pulmonary fibrosis. This project represents a potential additional use for our anti-TLR4 monoclonal antibody candidate in a chronic disease with limited treatment options and high mortality and morbidity. Initiating recruitment in the EB07 study is subject to, among other limitations, funding, regulatory approvals, drug manufacturing and activation of clinical investigational sites.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Medical Dermatology</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>Vitiligo</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Vitiligo is a chronic autoimmune disease that causes the loss of skin pigmentation in patches. It occurs when melanocytes, the pigment-producing skin cells, die or stop producing melanin. The extent of color loss from vitiligo is unpredictable and can affect the skin on any part of the body. It is estimated that vitiligo prevalence is between 0.5 to 2% of the global population. Vitiligo patients are not born with lesioned skin. Rather, unpigmented spots appear over time, with about 50% of patients having symptom onset before 20 years of age. There are two main forms of vitiligo: segmental, where depigmentation is limited to one area and side of the body, and nonsegmental (generalized), where patches of pale skin occur on both sides of the body, often symmetrically. Nonsegmental vitiligo is the most common type of vitiligo.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">At present, there is only one FDA-approved therapeutic indicated for repigmentation in vitiligo, a Janus Kinase (JAK) inhibitor cream (ruxolitinib); however, there is an increased risk of serious infections and malignancies associated with ruxolitinib. Similarly, off-label non-surgical therapies tend to be time-consuming, expensive, or prone to causing side effects. Common treatments include topical drugs, phototherapies and surgical interventions. Based on the availability and limitations of current treatments, we believe there is a significant need for well targeted and systemic immunotherapies.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>EB06</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">EB06 is a fully human monoclonal antibody candidate that binds specifically and selectively to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A and CXCR3B. CXCL10 plays an important role in both the innate and adaptive immune responses in patients with vitiligo. EB06 is currently formulated for intravenous administration, with plans for a potential subcutaneous formulation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We believe that there is a significant scientific rationale to target CXCL10 in order to reduce disease symptoms and progression in vitiligo patients. CXCL10 is highly expressed in vitiligo patients and has been shown to play both a key role in the trafficking of anti-melanocytic T-cells to the epidermis (adaptive immune system response) as well as in inducing apoptosis (death) of melanocytes (innate immune response). Furthermore, neutralization of CXCL10 has been demonstrated to both prevent and reverse depigmentation in animal models.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We believe that EB06 has a number of anticipated advantages compared to other treatments available and under development for vitiligo, including: a) EB06&#8217;s mechanism of action addresses both the adaptive and innate immune systems&#8217; roles in disease maintenance and progression; b) EB06 is designed to treat both lesional and non-lesional skin; c) as a systemic therapy, EB06 can treat larger body surface areas, including patients with lesions on &gt;10% of their body surface area; d) EB06 is administered less frequently than topicals and oral medications; and e) targeted immunotherapies, like EB06, are designed to provide patients a safer and more effective option than drugs with known off-target effects or even Black Box warnings.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We have approval from Health Canada to conduct a Phase 2 study of EB06 in moderate to severe nonsegmental vitiligo patients. As planned, the double-blind, placebo-controlled trial will evaluate the safety and efficacy of EB06 in approximately 150 subjects, who will be administered intravenous infusions of either EB06 or placebo during the treatment period, followed by a follow-up period. The primary efficacy outcome measurement will be the percentage of patients achieving &#8805;50% decrease (improvement) from baseline in facial Vitiligo Area Scoring Index (F-VASI50). F-VASI is a composite measurement of the overall area of facial vitiligo patches and degree of depigmentation within patches. To conduct the planned study at U.S. investigational centers, we must first manufacture the drug and submit related data to the FDA as part of an IND application. Based on feedback from the FDA and key opinion leaders, we may modify our Canadian study design and submit conforming amendments to our clinical trial application (CTA) in Canada, before proceeding with enrollment. The manufacturing of clinical-grade drug batches and initiation of the patient enrollment is subject to funding. We anticipate topline results for this Phase 2 study could be available within as few as 12 to 18 months following regulatory clearance in the U.S.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In three previous clinical studies of 65 healthy volunteers and non-vitiligo subjects in total, EB06 has demonstrated a favorable safety and tolerability profile. The first Phase 1 study was a double-blind, placebo-controlled, ascending, single-dose study in 20 healthy subjects. Participants received single intravenous doses of EB06, ranging from 0.1 to 20 mg/kg. No deaths or serious adverse events (AEs) were reported. EB06 was generally safe and well tolerated at doses up to 20 mg/kg. A second Phase 1 study evaluated the effect of single doses of EB06 to generate proof-of-principle data on the neutralization of CXCL10 in an inflammatory setting in humans using an experimentally nickel-induced allergic contact dermatitis model. For this double-blind, placebo-controlled study, 16 subjects were exposed to single intravenous doses of 180 and 720 mg of EB06. No deaths or serious AEs were reported, and EB06 was generally safe and well tolerated. A third, open-label, single-arm Phase 2 study investigating multiple administrations of EB06 in patients with primary biliary cirrhosis with an incomplete response to ursodeoxycholic acid (UDCA) was also completed. A total of 29 patients were treated with 10 mg/kg intravenous doses of EB06 every two weeks, for a total of 6 doses. No serious treatment-related AEs were reported. In addition, in a variety of pre-clinical in vitro and in vivo experiments, EB06 demonstrated the ability to neutralize the biological activity of CXCL10. In animal toxicology studies, EB06 was well-tolerated.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>Allergic Contact Dermatitis</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Contact dermatitis is a common occupational and work-related skin condition. The disease can be either irritant contact dermatitis or ACD. Based on market research, we believe that together these conditions cost up to $2 billion annually in the U.S. as a result of lost work, reduced productivity, medical care and disability payments. Based on the prevalence data of contact allergy in the general population, which we sourced from scientific literature and market reports, we estimate that there are as many as 30 million people in the seven major markets (US, UK, Germany, France, Spain, Italy, Japan) and Canada with ACD, and of these, we estimate that 40% have chronic exposure or frequent recurring exposure to a causative allergen. Based on the mechanism of action and topical delivery, we believe that the total addressable patient population for EB01 is as high as five million people in the seven major markets and Canada.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">ACD is caused by an allergen interacting with skin and usually occurs on areas of the body that are open to the environment, with a high prevalence on the hands and face. Common allergens associated with ACD include plants, metals, plastics and resins, rubber additives, dyes, biocides, and various cosmetics. The disease is characterized by inflammation, erythema (redness), pruritus (itchiness), and blistering of the skin. Inflammation can vary from mild irritation and redness to open sores, depending on the type of irritant, the body part affected and the degree of sensitivity. ACD can become chronic if not treated or if the causative allergen is not removed. In many chronic cases, the causative allergen is unknown or difficult to avoid (as an example, the allergen is present in the workplace). The immune mechanisms involved in ACD are well documented. During the initial contact with the offending allergen, the immune system is sensitized. Upon subsequent contact, a delayed-type hypersensitivity reaction (Type IV) occurs at the point of contact between the skin and the allergen. As a cell-mediated response, the immune reaction primarily involves the interaction of T cells with antigens rather than an antibody response.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>EB01 (daniluromer)</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">EB01 is a potential first-in-class, topical vanishing cream containing a novel, non-steroidal anti-inflammatory compound. Daniluromer exerts its anti-inflammatory activity through the inhibition of certain pro-inflammatory enzymes known as secretory phospholipase 2, or sPLA2. These enzymes are secreted by immune cells upon their activation and produce arachidonic acid via phospholipid hydrolysis, which, in turn, initiates a broad inflammatory cascade. The sPLA2 enzyme family plays a key role in initiating inflammation associated with many diseases, and we believe that targeting the sPLA2 enzyme family with enzyme inhibitors will have a superior anti-inflammatory therapeutic effect because the inflammatory process will be inhibited at its inception rather than after inflammation has occurred. Our ACD development program is at the partnering stage following completion of a Phase 2b clinical study.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In a Phase 2b clinical study of EB01 we evaluated multiple concentrations of our drug candidate, EB01, as a monotherapy for chronic moderate-to-severe ACD. The double-blind, placebo-controlled trial evaluated the safety and efficacy of EB01 in approximately 200 subjects, who were treated for 28 days with either EB01 cream (2.0%, 1.0% or 0.2%) or a placebo/vehicle cream. The primary efficacy outcome measurement was the mean percent improvement in symptoms from baseline at day 29 on the Contact Dermatitis Severity Index (CDSI). A key secondary efficacy measurement was the success rate of subjects achieving a score of "clear" or "almost clear" with at least a 2-point improvement from baseline after treatment at day 29 on the Investigator's Static Global Assessment (ISGA) scale. The 1.0% EB01 cream demonstrated statistically significant improvement over placebo. For the primary endpoint, patients with 1.0% EB01-treated lesions demonstrated a 60% average improvement in symptoms from baseline at day 29 on the CDSI versus 40% for placebo/vehicle (p=0.027). For the ISGA secondary efficacy endpoint, 53% of patients with 1.0% EB01-treated lesions achieved a score of "clear" or "almost clear" with at least a 2-point improvement from baseline after treatment at day 29 (p=0.048). Only 29% of patients in the placebo group reached the same endpoint. No serious treatment-related adverse events were reported across all concentrations. The 2.0% and 0.2% formulations did not show significant differences compared to placebo.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Other Future Product Candidates</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We are seeking to advance additional product candidates as well as add new disease indications for current product candidates, and from time to time we may request approval from regulators in various jurisdictions to initiate new clinical studies or amend the scope of current clinical studies. In addition, we plan to continue to identify, evaluate and potentially obtain rights to and develop additional clinical assets across various stages of development, focusing primarily on inflammatory and immune-related diseases.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Intellectual Property and Key Licenses </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We have an exclusive license from Yissum Research Development Company, the technology transfer company of Hebrew University of Jerusalem Ltd. (Yissum), for patents and patent applications that cover&#160;EB01 in the U.S., Canada, Australia and various countries in Europe. Method of use patents, for which we hold an inbound license from Yissum and an affiliate of Yissum, have been issued for use in dermatologic and gastrointestinal conditions and infections that will expire in 2024. We expect to seek patent term extension in the U.S. related to time under IND, which could add up to three to five years of additional protection. Additional patents subject to the license agreement have been filed by Yissum which we believe, if issued, could potentially prevent generic substitution until after 2033.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We also hold an exclusive license from NovImmune SA, for patents and patent applications that cover our product candidates that utilize our anti-TLR4 and anti-CXCL10 monoclonal antibody technology in the U.S., Canada and various other countries. Composition of matter patents, for which we hold an inbound license from NovImmune, have been issued that will expire as late as 2033 and 2028, respectively. We expect to seek patent term extension in the U.S. related to time under IND, which could extend protection. We have also filed additional method of use patent applications which we believe, if issued, could potentially prevent biosimilar substitution until as late as 2041. We have also filed provisional patent applications for use of these monoclonal antibody technologies in vitiligo (EB06) and systemic sclerosis and pulmonary fibrosis (EB07).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In the event we are successful in commercializing a new drug candidate, we believe we would be eligible for data/market exclusivity, in addition to exclusivity rights granted through patent protection. We would be eligible for up to five years of exclusivity for EB01 and up to 12 years of exclusivity for EB05/EB07 and EB06 after approval in the U.S., and, for any of these drug products, eight years of exclusivity after approval in Canada and ten years of exclusivity after approval in the European Union (EU).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We expect patents and other proprietary intellectual property rights to be an essential element of our business. We intend to protect our proprietary positions by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions, and improvements. We also rely on trade secrets, know-how, continuing technological innovation and other in-licensing opportunities to develop and maintain our proprietary position. Our success will depend, in part, on our ability to obtain and maintain proprietary protection for our product candidates, technology, and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing our proprietary rights.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>License Agreement with NovImmune SA</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In April 2020, through Edesa Biotech Research, we entered into an exclusive license agreement (the NovImmune License Agreement) with NovImmune SA (NovImmune), which operates under the brand Light Chain Bioscience, whereby we obtained exclusive rights throughout the world to certain know-how, patents and data relating to the monoclonal antibodies targeting TLR4 and CXCL10 (the Constructs). We will use the exclusive rights to develop products containing these Constructs (the Licensed Products) for therapeutic, prophylactic and diagnostic applications in humans and animals. Unless earlier terminated, the term of the NovImmune License Agreement will remain in effect for 25 years from the date of first commercial sale of Licensed Products. Subsequently, the NovImmune License Agreement will automatically renew for 5-year periods unless either party terminates the agreement in accordance with its terms.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the NovImmune License Agreement, we are exclusively responsible, at our expense, for the research, development manufacture, marketing, distribution and commercialization of the Constructs and Licensed Products and to obtain all necessary licenses and rights. We are required to use commercially reasonable efforts to develop and commercialize the Constructs in accordance with the terms of a development plan established by the parties. In exchange for the exclusive rights to develop and commercialize the Constructs, we issued to NovImmune $2.5 million of newly designated Series A-1 Convertible Preferred Shares (all of which were subsequently converted into common shares) pursuant to the terms of a securities purchase agreement entered into between the parties concurrently with the NovImmune License Agreement. In addition, we are committed to payments of various amounts to NovImmune upon meeting certain development, approval and commercialization milestones as outlined in the NovImmune License Agreement up to an aggregate amount of $356 million. We also have a commitment to pay NovImmune a royalty based on net sales of Licensed Products in countries where we directly commercialize Licensed Products and a percentage of sublicensing revenue received by us in the countries where we do not directly commercialize Licensed Products.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The NovImmune License Agreement provides that NovImmune will remain the exclusive owner of existing intellectual property in the Constructs and that we will be the exclusive owner of all intellectual property resulting from the exploitation of the Constructs pursuant to the license. Subject to certain limitations, we are responsible for prosecuting, maintaining and enforcing all intellectual property relating to the Constructs. During the term of the agreement, we also have the option to purchase the licensed patents and know-how at a price to be negotiated by the parties. If we default or fail to perform any of the terms, covenants, provisions or its obligations under the NovImmune License Agreement, NovImmune has the option to terminate the NovImmune License Agreement, subject to providing us with an opportunity to cure such default. The NovImmune License Agreement is also terminable by NovImmune upon the occurrence of certain bankruptcy related events pertaining to us.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In connection with the NovImmune License Agreement and pursuant to a purchase agreement entered into by the parties in April 2020, we acquired from NovImmune its inventory of the TLR4 antibody for an aggregate purchase price of $5.0 million.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><i>License and Development Agreement with Pendopharm&#160;</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In August 2017, Edesa Biotech Research entered into an exclusive license and development agreement with Pendopharm, a division of Pharmascience Inc. (the Pendopharm License Agreement). Pursuant to the Pendopharm License Agreement, we granted to Pendopharm an exclusive license throughout Canada to certain know-how, patents and data for the sole purpose of obtaining regulatory approval for certain pharmaceutical products to allow Pendopharm to distribute, market and sell the licensed products for human therapeutic use in certain gastrointestinal conditions. If Pendopharm elects not to seek regulatory approval of the applicable product, the applicable product will be removed from the license rights granted to Pendopharm and will revert to us. If Pendopharm elects to seek regulatory approval in Canada for the sale and marketing of the applicable product, Pendopharm will be responsible for obtaining regulatory approval for the applicable licensed product in Canada. In exchange for the exclusive rights to market, import, distribute, and sell the pharmaceutical products, Pendopharm is required to pay us a royalty in respect of aggregate annual net sales for each pharmaceutical product sold in Canada. Unless earlier terminated, the term of the Pendopharm License Agreement will expire, on a licensed product by licensed product basis, on the later to occur of (i) the date that is 13 years after the first commercial sale of the licensed product in Canada; (ii) the date of expiry of the last valid licensed patent in Canada relating to the licensed product; or (iii) the date of expiry of any period of exclusivity granted to the licensed product by a regulatory authority in Canada. The Pendopharm License Agreement shall also terminate upon the termination of certain other license agreements that we have with third parties. Pendopharm also has the right to terminate the Pendopharm License Agreement for convenience upon 120 days&#8217; notice to us.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>License Agreements with Yissum and Inventor</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In June 2016, Edesa Biotech Research, entered into an exclusive license agreement with Yissum, which was subsequently amended in April 2017, May 2017 and October 2022 (collectively, the Yissum License Agreement). Pursuant to the Yissum License Agreement, as amended, we obtained exclusive rights throughout the world to certain know-how, patents and data relating to a pharmaceutical product for the following fields of use: therapeutic, prophylactic and diagnostic uses in topical dermal applications and anorectal applications. Unless earlier terminated, the term of the Yissum License Agreement will expire on a country by country basis on the later of (i) the date of expiry of the last valid licensed patent in such country; (ii) the date of expiry of any period of exclusivity granted to a product by a regulatory authority in such country or (iii) the date that is 15 years after the first commercial sale of a product in such country.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the Yissum License Agreement, we are exclusively responsible, at our expense, for the development of the product, including conducting clinical trials and seeking regulatory approval for the product, and once regulatory approval has been obtained, for the commercialization of the product. We are required to use our commercially reasonable efforts to develop and commercialize the product in accordance with the terms of a development plan established by the parties. Subject to certain conditions, we are permitted to engage third parties to perform our activities or obligations under the agreement. In exchange for the exclusive rights to develop and commercialize the product for topical dermal applications and anorectal applications, we are committed to payments of various amounts to Yissum upon meeting certain milestones outlined in the Yissum License Agreement up to an aggregate amount of $18.4 million. In addition, in the event of a divestiture of substantially all of our assets, we are obligated to pay Yissum a percentage of the valuation of the licensed technology sold as determined by an external objective expert. We also have a commitment to pay Yissum a royalty based on net sales of the product in countries where we, or an affiliate of ours, directly commercializes the product and a percentage of sublicensing revenue received by us and our affiliates in the countries where we do not directly commercialize the product.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Yissum License Agreement provides that Yissum shall remain the exclusive owner of the licensed technology and that we are responsible for preparing, filing, prosecuting and maintaining the patents on the licensed technology in Yissum&#8217;s name. Notwithstanding the foregoing, we will be the exclusive owner of all patents and other intellectual property that is made by, or on our behalf, after the date of the agreement, including all improvements to the licensed technology. If we default or fail to perform any of the terms, covenants, provisions or our obligations under the Yissum License Agreement, Yissum has the option to terminate the Yissum License Agreement, subject to providing us with an opportunity to cure such default. We have the right to terminate the Yissum License Agreement if we determine that the development and commercialization of the product is no longer commercially viable. Subject to certain exceptions, we have undertaken to indemnify Yissum against any liability, including product liability, damage, loss or expense derived from the use, development, manufacture, marketing, sale or sublicensing of the licensed product and technology.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In March 2021, through Edesa Biotech Research, we entered into a license agreement with the inventor of the same pharmaceutical product, which was subsequently amended in September 2023 (together, the Inventor License Agreement), to acquire global rights for all fields of use beyond those named under the Yissum License Agreement. As a result of the Inventor License Agreement, we now hold exclusive global rights to the pharmaceutical product that forms the basis of EB01 for all fields of use in humans and animals. We are required to use commercially reasonable efforts to develop and commercialize the product in accordance with the terms of a development plan established by the parties. We are exclusively responsible, at our expense, for the development of the product. We are committed to remaining payments of up to an aggregate amount of $69.1 million, primarily relating to future potential commercial approval and sales milestones. In addition, if we fail to file an IND application or foreign equivalent for the product within a certain period of time following the date of the agreement, we are required to remit to the inventor a fixed license fee on a quarterly basis as long as the requirement to file an IND remains unfulfilled. We also have a commitment to pay the inventor a royalty based on net sales of the product in countries where we, or an affiliate, directly commercialize the product and a percentage of sublicensing revenue received by us and our affiliates in the countries where we do not directly commercialize the product. Unless earlier terminated, the term of the Inventor License Agreement will expire on a country by country basis on the later of (i) the date of expiry of the last valid licensed patent in such country or (ii) the date that is 15 years after the first commercial sale of a product in such country. If we default or fail to perform any of the terms, covenants, provisions or our obligations under the Inventor License Agreement, the inventor has the option to terminate the Inventor License Agreement, subject to providing us with an opportunity to cure such default. We have the right to terminate the Inventor License Agreement if we determine that the development and commercialization of the product is no longer commercially viable. Subject to certain exceptions, we have undertaken to indemnify the inventor against any liability, including product liability, damage, loss or expense derived from the use, development, manufacture, marketing, sale or sublicensing of the licensed product and technology.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Manufacturing and Marketing</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We rely, and expect to continue to rely for the foreseeable future, on third-party contract manufacturing organizations, or CMOs, to produce both our synthetic chemical and biological product candidates for clinical testing, as well as for commercial manufacture if our product candidates receive marketing approval. Additional contract manufacturers are used to fill, label, package and distribute investigational drug products. We believe that this strategy will enable us to direct operational and financial resources to the development of our product candidates rather than diverting resources to establishing manufacturing infrastructure. Our current arrangements with our manufacturers are subject to customary industry terms and conditions, and manufacturing is performed on an as-requested basis. While we have not experienced significant shortages of raw materials to date, as a result of increased industry demand, CMOs have generally reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, and longer lead times may be required for scheduling future production runs. We believe that we have sufficient supplies on hand to complete the Phase 3 clinical study for EB05.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">To supply future clinical studies and potential commercialization of our product candidates, we are engaged in discussions with various CMOs regarding long-term supply agreements. These supply agreements typically require significant financial commitments, including upfront amounts prior to commencement of manufacturing, progress payments through the course of the manufacturing process as well as payments for technology transfer and other start-up costs. Based on our discussions with CMOs and industry announcements regarding future expansion plans, we believe there will be sufficient supplies of raw materials and manufacturing capacity to service our near-term and future product needs.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Because we are focused on the discovery and development of drugs, we do not have any marketing or distribution capabilities, nor are we at a stage where we would have any customers for our investigational medicines. If we receive marketing approval or emergency use authorization in the U.S., Canada or Europe for a product candidate, we plan to either build the capabilities to commercialize the product candidate in the applicable region with our own focused, specialized sales force, or alternatively, outsource the sales and marketing infrastructure necessary to market and sell our products. We also plan to utilize strategic licensing, collaboration, distribution or other marketing arrangements with third parties for the further development or commercialization of our products and product candidates, where applicable, such as in areas or regions outside North America where a partner may contribute additional resources, infrastructure and expertise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Competition </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The pharmaceutical and biotechnology industry is highly competitive, and the development and commercialization of new drugs is influenced by rapid technological developments and innovation. We face competition from companies developing and commercializing products that will be competitive with our drug candidates, including large pharmaceutical and smaller biotechnology companies, many of which have greater financial and commercial resources than we do. For our EB01 product candidate, our potential competitors include, among others, Aclaris Therapeutics, Inc., Dermavant Sciences, Inc., Incyte Corporation, Leo Pharma A/S, Pfizer Inc., Sanofi S.A., Astria Therapeutics, Inc. and Sun Pharmaceutical Industries Ltd. For our EB05 product candidate, there are numerous competing therapies, including prophylactic vaccines for the SARS-Cov2 and influenza viruses, experimental stem cell therapies, novel therapeutics and repurposed commercial drugs. Our potential competitors include, among others: Aqualung Therapeutics Corporation, Eli Lilly and Company, InflaRx N.V., Enzychem Lifesciences Corp., Merck &amp; Co, Inc., Mesoblast Limited, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG and Veru Inc. For any future product for vitiligo or fibrotic diseases, potential competitors, include, among others: Bausch Health, Eli Lilly and Company, Incyte Corporation, Boehringer Ingelheim AG, UCB, Chemomab Therapeutics Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Leo Pharma A/S, Merck &amp; Co., Inc., Mitsubishi Tanabe Pharma Corporation, Vyne Therapeutics Inc, and Sanofi S.A. Some of the competing product development programs may be based on scientific approaches that are similar to our approach, and others may be based on entirely different approaches. Potential competitors also include new entrants to the market, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization of products similar to ours or that otherwise target indications that we are pursuing. Key factors affecting the success of any approved product will be its efficacy, safety profile, drug interactions, method of administration, pricing, reimbursement and level of promotional activity relative to those of competing drugs. We believe that our product candidates will compete favorably with respect to such factors. However, we may not be able to maintain our competitive position against current and potential competitors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Government Regulation</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We plan to conduct clinical studies and seek approvals for our product candidates in the U.S., Canada, EU and other jurisdictions. Therefore, we currently are, and may in the future be, subject to a variety of national and regional regulations governing clinical trials as well as commercial sales and distribution of our products, if approved.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">To conduct clinical trials for our product candidates, we rely on third parties, such as contract research organizations, medical institutions and clinical investigators. Although we have entered into agreements with these third parties, we continue to be responsible for confirming that each of our clinical trials is conducted in accordance with our investigational plan or research protocol, as well as International Conference on Harmonization Good Clinical Practices, or GCP, which include guidelines for conducting, recording and reporting the results of clinical trials.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The FDA in the U.S., Health Canada in Canada, the European Medicines Agency (EMA) in the European Union and comparable regulatory agencies in foreign countries impose substantial requirements on the clinical development, manufacture and marketing of pharmaceutical products and product candidates. These agencies and other federal, state, provincial and local entities regulate research and development activities and the testing, manufacture, packaging, importing, distribution, quality control, safety, effectiveness, labeling, storage, record-keeping, approval and promotion of our products and product candidates. All of our product candidates will require regulatory approval before commercialization. In particular, therapeutic product candidates for human use are subject to rigorous preclinical and clinical testing and other statutory and regulatory requirements of the U.S., Canada, the EU and foreign countries. Obtaining these marketing approvals and subsequently complying with ongoing statutory and regulatory requirements require substantial time, effort and financial resources.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>U.S. Regulations</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In the U.S., the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act as well as the Public Health Service (PHS) Act for biological drugs. The process required by the FDA before our product candidates may be marketed in the U.S. generally involves the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Pre-clinical testing</i>. Drug developers complete extensive pre-clinical laboratory tests, animal studies and formulation studies, performed in accordance with the FDA&#8217;s Good Laboratory Practice regulations and other applicable requirements. These studies typically assess efficacy, toxicology and pharmacokinetics.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Submission to the FDA of an IND, which must become effective before human clinical trials may begin. As part of an IND application to the FDA, trial sponsors submit the results of pre- clinical tests, together with manufacturing information and analytical data. The IND automatically becomes effective 30-days after receipt by the FDA, unless the FDA, within the 30-day time frame, has questions or concerns about the proposed study. In such a case, the IND sponsor and the FDA must resolve any outstanding items before the clinical trial can begin. A separate submission to an existing IND must also be made for each successive phase of a clinical trial conducted during product development.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Approval by a central or institutional review board (IRB), or ethics committee at each clinical trial site before each trial may be initiated. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completion. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Multiple Phases of Human Clinical Trials. Drug developers conduct adequate and well-controlled human clinical trials that establish the safety and efficacy of the product candidate for the intended use, typically in the following three stages, which are often sequential but may overlap:</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 1: The clinical trials are initially conducted in a limited population to test the product candidate for safety, dose tolerance, absorption, metabolism, distribution and excretion in healthy human volunteers or, on occasion, in patients, such as cancer patients. Phase 1 clinical trials can be designed to evaluate the impact of the product candidate in combination with currently approved drugs.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 2: These clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, to determine the efficacy of the product candidate for specific targeted indications and to determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information before beginning a larger and more expensive Phase 3 clinical trial.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Phase 3: These clinical trials are commonly referred to as pivotal clinical trials. If the Phase 2 clinical trials demonstrate that a dose range of the product candidate is effective and has an acceptable safety profile, Phase 3 clinical trials are then undertaken in large patient populations to further evaluate dosage, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Product Candidate Chemistry, Controls and Manufacturing.</i>&#160;Concurrent with clinical trials, companies typically complete additional animal and laboratory studies, develop additional information about the chemistry and physical characteristics of the drug, and finalize a process for manufacturing the product in commercial quantities in accordance with FDA&#8217;s current Good Manufacturing Practices (cGMP) requirements. The manufacturing process must consistently produce quality batches of the drug, and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate the effectiveness of the packaging and that the compound does not undergo unacceptable deterioration over its shelf life.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>U.S. Review and Approval Processes</i></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">After the completion of clinical trials of an investigational drug or biologic product, an NDA or BLA is prepared and submitted to the FDA. FDA approval must be obtained before commercial marketing and distribution of the product may begin in the U.S. The NDA or BLA must include results of product development, laboratory, and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will file the NDA or BLA and, even if filed, that any approval will be granted on a timely basis, if at all.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Under the Prescription Drug User Fee Act, as amended (PDUFA), each NDA or BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes annual program fees on prescription drugs, including biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. No user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the application also includes a non-orphan indication.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Within 60 days following submission, the FDA reviews the NDA or BLA to determine if it is substantially complete before the agency files it. The FDA may request additional information or may refuse to file any NDA or BLA that it deems incomplete or not properly reviewable at the time of submission. In this event, the NDA or BLA must be resubmitted with the additional information. The resubmitted application also is subject to an initial filing review before the FDA files it. Once the submission is filed, the FDA begins an in-depth substantive review of the NDA or BLA. Under PDUFA, FDA has agreed to performance goals to review 90% of original standard NDAs or BLAs within 10 months of the 60-day filing date and 90% of original priority NDAs or BLAs within 6 months of the 60-day filing date, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs and BLAs. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the NDA/BLA sponsor otherwise provides additional information or clarification regarding information already provided in the NDA or BLA submission. The FDA reviews the NDA or BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with GMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations when making decisions. During the product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary to assure that the benefits of the biologic outweigh the potential risks of the product to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure a product&#8217;s safe use (ETASU). An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific registries. If the FDA concludes that a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Before approving an NDA or BLA, the FDA will typically inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in substantial compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites, to assure that the clinical trials were conducted in compliance with GCP requirements. To assure GMP, GLP and GCP compliance, an applicant must incur significant expenditure of time, money, and effort in the areas of training, record keeping, production, and quality control.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the NDA or BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently from how we interpret the same data. If the agency decides not to approve the NDA or BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may resubmit, addressing all of the deficiencies identified in the letter, withdraw the application, or request a hearing.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">o</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If a product candidate receives regulatory approval, the FDA will issue an approval letter. The approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings, or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to assess further a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Satisfaction of FDA regulations and requirements or similar requirements of state, local and foreign regulatory agencies typically take several years, and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. Typically, if a product candidate is intended to treat a chronic disease, as is the case with some of our product candidates, safety and efficacy data must be gathered over an extended period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Orphan Designation and Exclusivity</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the U.S., or a patient population greater than 200,000 individuals in the U.S. and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the U.S. will be recovered from sales in the U.S. for that drug or biologic. Orphan drug designation must be requested before submitting a BLA or NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product marketing exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same use or indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA or NDA application user fee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the U.S. may be lost if the FDA later determines that the request for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Expedited Development and Review Programs</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The FDA has several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">A new drug is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. Rolling review means that the agency may review portions of the marketing application before the sponsor submits the complete application.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In addition, a new drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to intensive guidance on an efficient drug development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review staff in a cross-disciplinary review, where appropriate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review, once an NDA or BLA is submitted, if the drug that is the subject of the marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#8217;s goal date to take action on the marketing application is six months compared to ten months for a standard review. Products are eligible for Accelerated Approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Accelerated Approval is usually contingent on a sponsor&#8217;s agreement to conduct additional post-approval studies to verify and describe the product&#8217;s clinical benefit. The FDA may withdraw approval of a drug or an indication approved under Accelerated Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, as a condition for Accelerated Approval, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period. After the 120-day period has passed, all advertising and promotional materials must be submitted at least 30 days prior to the intended time of initial dissemination or publication.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Emergency Use Authorizations</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">While, in most cases, a therapeutic must be approved by FDA before the product may be sold, when there is a public health emergency involving chemical, biological, radiological, or nuclear agents, including infectious diseases like Covid-19, new therapeutics may be distributed pursuant to an Emergency Use Authorization, or EUA. Under an EUA, FDA may authorize the emergency use of an unapproved medical product or an unapproved use of an approved product for certain emergency circumstances to diagnose, treat, or prevent serious or life-threatening diseases or conditions when certain statutory criteria have been met, and after the Secretary of the Department of Health and Human Services has issued a declaration of emergency or threat justifying emergency use.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">To receive an EUA, the product sponsor must demonstrate that the product &#8220;may be effective&#8221; in the prevention, diagnosis, or treatment of an applicable disease or condition. Additionally, FDA must determine that the product&#8217;s known and potential benefits outweigh the known and potential risks. Further there must be no adequate, approved, and available alternative product for the indication. Potential alternative products may be unavailable if there are insufficient supplies to meet the emergency need. FDA may establish additional conditions on an EUA that are necessary to protect public health, including conditions related to information that must be disseminated to health care providers and patients, the monitoring and reporting of adverse events, and record keeping. Conditions may also relate to how a product is distributed and administered and how a product is advertised. Importantly, EUAs are not full marketing approvals. Rather, EUAs are only effective for the duration of the applicable EUA declaration. Full approval of the product under applicable standards would be necessary to continue to distribute the product absent an EUA. EUAs may also be revised or revoked by FDA at any time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>U.S. Patent Term Restoration</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Depending upon the timing, duration, and specifics of the FDA approval of the use of our current and potential product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Biosimilars and Exclusivity</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated approval pathway for biological products shown to be highly similar to, or interchangeable with, an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The BPCIA includes, among other provisions: A 12-year exclusivity period from the date of first licensure, or BLA approval, of the reference product, during which approval of a 351(k) application referencing that product may not be made effective; a 4-year exclusivity period from the date of first licensure of the reference product, during which a 351(k) application referencing that product may not be submitted; and, an exclusivity period for certain biological products that have been approved through the 351(k) pathway as interchangeable biosimilars. The BPCIA also establishes procedures for identifying and resolving patent disputes involving applications submitted under section 351(k) of the PHSA.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The BPCIA is complex and its interpretation and implementation by the FDA remains unpredictable. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate effect, implementation, and meaning of the BPCIA is subject to uncertainty.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Disclosure of Clinical Trial Information</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to register and disclose certain clinical trial information on the website www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of a clinical trial are then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Pediatric Information </i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the Pediatric Research Equity Act (PREA), BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any biological product with orphan product designation except a product with a new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by FDA to be substantially relevant to the growth or progression of a pediatric cancer that is subject to a BLA submitted on or after August 18, 2020.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Best Pharmaceuticals for Children Act (BPCA) provides a six-month extension of any non-patent exclusivity for a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#8217;s determination that information relating to the use of a new drug or biologic in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>FDA Post-Approval Requirements</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Once an NDA or BLA is approved, maintaining post-approval compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register the establishments where the approved products are made with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMP and other laws. Rigorous and extensive FDA regulation of products continues after approval, particularly with respect to GMP. We rely, and expect to continue to rely, on third parties for the production and distribution of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the GMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements include reporting of GMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution by the manufacturer. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain GMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA or BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Failure to comply with the applicable U.S. requirements after approval may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Other Regulatory Requirements</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The federal anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. This statute has been broadly interpreted to apply to manufacturer arrangements with prescribers, purchasers and pharmacy benefit managers, among others. Several other countries, including the United Kingdom, have enacted similar anti-kickback laws and regulations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The federal Physician Payments Sunshine Act requirements under the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, referred to together as the Affordable Care Act, require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report to the Department of Health and Human Services information related to payments and other transfers of value made to or at the request of covered recipients, such as physicians and teaching hospitals, and physician ownership and investment interests in such manufacturers. Among other payments, the law requires payments made to physicians and teaching hospitals for clinical trials be disclosed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to future potential sales or marketing arrangements and claims involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines, or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures to the extent that those laws impose requirements that are more stringent than the Physician Payments Sunshine Act. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>Canada Regulations</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Health Canada is the Canadian federal authority that regulates, evaluates and monitors the safety, effectiveness, and quality of drugs, medical devices, and other therapeutic products available to Canadians. Health Canada&#8217;s regulatory process for review, approval and regulatory oversight of products is similar to the regulatory process conducted by the FDA. To initiate clinical testing of a drug candidate in human subjects in Canada, a Clinical Trial Application (CTA) must be filed with and approved by Health Canada. In addition, all federally regulated trials must be approved and monitored by research ethics boards. The review boards study and approve study-related documents and monitor trial data.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Prior to being given market authorization for a drug product, a manufacturer must present substantive scientific evidence of a product&#8217;s safety, efficacy and quality as required by the Food and Drugs Act (Canada) and its associated regulations, including the Food and Drug Regulations. This information is usually submitted in the form of a New Drug Submission (NDS). Health Canada reviews the submitted information, sometimes using external consultants and advisory committees, to evaluate the potential benefits and risks of a drug. If after the review, the conclusion is that the patient benefits outweigh the risks associated with the drug, the drug is issued a Drug Identification Number (DIN), followed by a Notice of Compliance (NOC), which permits the market authorization holder (i.e., the NOC and DIN holder) to market the drug in Canada. Drugs granted an NOC may be subject to additional postmarket surveillance and reporting requirements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">All establishments engaged in the fabrication, packaging/labeling, importation, distribution, and wholesale of drugs and operation of a testing laboratory relating to drugs are required to hold a Drug Establishment License to conduct one or more of the licensed activities unless expressly exempted under the Food and Drug Regulations. The basis for the issuance of a Drug Establishment License is to ensure the facility complies with cGMP as stipulated in the Food and Drug Regulations and as determined by cGMP inspection conducted by Health Canada. An importer of pharmaceutical products manufactured at foreign sites must also be able to demonstrate that the foreign sites comply with cGMP, and such foreign sites are included on the importer&#8217;s Drug Establishment License.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Regulatory obligations and oversight continue following the initial market approval of a pharmaceutical product. For example, every market authorization holder must report any new information received concerning adverse drug reactions, including timely reporting of serious adverse drug reactions that occur in Canada and any serious unexpected adverse drug reactions that occur outside of Canada. The market authorization holder must also notify Health Canada of any new safety and efficacy issues that it becomes aware of after the launch of a product.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Employees</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As of the date of this filing, we have 16 full-time employees: nine employees are primarily engaged in research and development, and seven employees are engaged in management, administration, business development and finance. All employees are located in Canada or the U.S. None of our employees are members of any labor unions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We take pride in the diversity of our workforce and being an equal opportunity employer. As a growth-oriented company focused on innovation, we strive to foster diversity and inclusion. As of the date of this filing, women represented more than 50% of all employees, and individuals from underrepresented racial or ethnic groups, or who are foreign born, represented more than 50% of our employees.&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Corporate Information</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We are a British Columbia, Canada corporation founded in 2007 and operate through our wholly owned subsidiaries, Edesa Biotech Research, Inc., an Ontario, Canada corporation and Edesa Biotech USA, Inc., a California, USA corporation. In June 2019, we acquired the Ontario corporation through a reverse acquisition and changed our name to Edesa Biotech, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our executive offices are located at 100 Spy Court, Markham, Ontario, L3R 5H6, Canada. Our phone number is 289-800- 9600. Our registered and records office is 2900 - 550 Burrard Street, Vancouver, British Columbia, V6C 0A3, Canada. Our website address is www.edesabiotech.com. The contents of our website or social media postings are not part of our Securities and Exchange Commission (SEC) reports for any purpose or otherwise incorporated by reference. Any references to website addresses contained in this report are intended to be inactive textual references only.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Available Information</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We file or furnish periodic reports and amendments thereto, including our annual reports on Form 10-K, our quarterly reports on Form 10-Q and current reports on Form 8-K, proxy statements and other information with the SEC. Such reports and other information filed or furnished by us with the SEC are available free of charge on our website at www.edesabiotech.com/investors/sec-filings as soon as reasonably practicable after such reports are available on the SEC&#8217;s website at www.sec.gov. Our filings are also available at the Canadian Securities Administrators&#8217; SEDAR website at www.sedar.com. Investors and other interested parties should note that we may also use our website and our social media channels to publish information about us that may be deemed material to investors. We encourage investors and other interested parties to review the information we may publish through our website and social media channels.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Smaller Reporting Company</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We are currently a &#8220;smaller reporting company&#8221; as defined by Rule 12b-2 of the Exchange Act, and are thus allowed to provide simplified executive compensation disclosures in our filings, are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that an independent registered public accounting firm provide an attestation report on the effectiveness of internal control over financial reporting and have certain other reduced disclosure obligations with respect to our SEC filings.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><a id="I1A" title="I1A" href="#"></a>Item 1A. RISK FACTORS.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><i>Certain factors may have a material adverse effect on our business, prospects, financial condition and results of operations. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our financial statements and the related notes, before deciding to invest in our securities. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business and cause the market price of our securities to decline. In addition, many of the following risk factors could be exacerbated by any worsening of the global business and economic environment or the resurgence of Covid-19 or other public health threats. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects could be materially and adversely affected. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See </i>&#8220;<i>Forward-Looking Statements And Other Matters</i>&#8221;<i> for a discussion of some of the forward-looking statements that are qualified by these risk factors. </i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Summary of Risks</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>The following summarizes key risks and uncertainties that could materially adversely affect us. You should read this summary together with the more detailed description of each risk factor contained below.</i></p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We are a late-stage biopharmaceutical company with no products approved for commercial sale, and we have incurred significant losses since our inception and expect to continue to incur losses and may never generate profits from operations or maintain profitability.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We will need substantial additional funding to finance our operations through regulatory approval of one or more of our product candidates. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs, commercialization efforts or other operations.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We depend heavily on the success of our drug product candidates. If we are unable to obtain regulatory approval or commercialize one or more of these experimental treatments, or experience significant delays in doing so, our business will be materially harmed. We cannot give any assurance that we will receive regulatory approval for such product candidates or any other product candidates, which is necessary before they can be commercialized.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A successful sPLA2, anti-TLR4 or anti-CXCL10 drug has not been developed to date and we can provide no assurances that we will be successful or that there will be no adverse side effects.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Even if one of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and any of our other current or future product candidates, we may not be successful in commercializing the applicable product candidate if it receives marketing approval.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Even if we are able to commercialize one of our product candidates, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We face substantial competition, which may result in others discovering, developing or commercializing products to treat our target indications or markets before or more successfully than we do.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We will be dependent on third parties for manufacturing, including optimization, technology transfers and scaling up of clinical scale quantities of all of our product candidates.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The manufacturing of our monoclonal antibody candidates is complex and subject to a multitude of risks. These manufacturing risks could substantially increase our costs and limit supply of these drug candidates for clinical development, and commercialization.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We rely on third parties to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such clinical trials.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Even if we complete the necessary clinical trials, the marketing approval process is expensive, time consuming and uncertain. If we are not able to obtain, or if there are delays in obtaining, required marketing approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Even if we obtain marketing approval for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products, and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If we are unable to obtain and maintain patent protection for our licensed technology and products, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our licensed technology and products may be adversely affected.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The ownership of our common shares is highly concentrated, which may prevent you and other shareholders from influencing significant corporate decisions and may result in conflicts of interest that could cause our common shares price to decline.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If we fail to meet all applicable Nasdaq Capital Market requirements and Nasdaq determines to delist our common shares, the delisting could adversely affect the market liquidity of our common shares and the market price of our common shares could decrease and our ability to access the capital markets could be negatively impacted.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Risks Related to Our Business, Financial Position and Capital Requirements </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We are a late-stage biopharmaceutical company with no products approved for commercial sale, and we have incurred significant losses since our inception and expect to continue to incur losses and may never generate profits from operations or maintain profitability.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Since inception, we have incurred significant operating losses. At September 30, 2024, we had an accumulated deficit of $58.6 million. We have historically financed operations primarily through issuances of common shares, the exercise of common share purchase warrants, convertible preferred shares, convertible loans, government grants and tax incentives. We have devoted substantially all of our efforts to research and development, including clinical trials, and have not completed the development of any of our drug candidates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We expect to continue to incur significant expenses and operating losses without corresponding revenue for the foreseeable future as we continue the development of, and seek marketing approvals for our product candidates, prepare for and begin the commercialization of any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company in the U.S. and Canada. The net losses we incur may fluctuate significantly from quarter to quarter and year to year.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Based on our current plans, we do not expect to generate significant revenue unless and until we or a current or potential future licensee obtains marketing approval for, and commercializes, one or more of our product candidates, which may require several years. Neither we nor a licensee may ever succeed in obtaining marketing approval for, or commercializing our product candidates and, even if marketing approval is obtained, we may never generate revenues that are significant enough to generate profits from operations. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Failure to become and remain profitable would impair our ability to sustain operations and adversely affect the price of our securities and our ability to raise capital.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><i>Our recurring losses from operations have raised substantial doubt regarding our ability to continue as a going concern.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We have recognized recurring losses, and at September 30, 2024, we had an accumulated deficit of $58.6 million. We anticipate operating losses to continue for the foreseeable future due to, among other things expenses related to ongoing activities to research, develop and commercialize our product candidates. We expect that our cash and cash equivalents at September 30, 2024, together with the proceeds from the sale of Preferred Shares (as defined below) to PN MPC (as defined below), net proceeds from the HCW ATM (as defined below) and reimbursement of eligibility R&amp;D expenses under the 2023 SIF Agreement, will not be sufficient to fund our operating and capital requirements at least 12 months from the filing of this Form 10-K. Our forecast of the period of time through which our current financial resources will be adequate to support our operations and the costs to support our general and administrative and research and development activities are forward-looking statements and involve risks and uncertainties. The financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of our clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate some or all of our planned clinical trials. These factors among others create a substantial doubt about our ability to continue as a going concern.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We will need substantial additional funding to finance our operations through regulatory approval of one or more of our product candidates. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs, commercialization efforts or other operations.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We expect our research and development expenses to increase substantially in the future, particularly for any drug candidates beyond Phase 2 clinical development or if we expand the number of drug candidates in clinical studies. In addition, if we obtain marketing approval for any of our product candidates that are not then subject to licensing, collaboration or similar arrangements with third parties, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We cannot be certain that additional funding will be available on acceptable terms, or at all. In addition, future debt financing into which we may enter may impose upon us covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, redeem our shares, make certain investments and engage in certain merger, consolidation or asset sale transactions. In addition, any debt financing would require us to dedicate a portion of our cash resources to the payment of interest and principal, thereby reducing money available to fund working capital, capital expenditures, product development and other general corporate purposes.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">If we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates, restrict our operations or obtain funds by entering into agreements on unattractive terms, which would likely have a material adverse effect on our business, share price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that would likely result in our securityholders losing some or all of their investment in us. In addition, our ability to achieve profitability or to respond to competitive pressures would be significantly limited.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Raising additional capital may cause dilution to our investors, restrict our operations or require us to relinquish rights to our technologies or product candidates.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, licensing, collaboration or similar arrangements, grants and debt financings. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common shares. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences that are not favorable to us or our existing shareholders. If we raise additional funds through licensing, collaboration or similar arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or to grant licenses on terms that may not be favorable to us. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development of our product candidates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">To continue to grow our business over the longer term, we plan to commit substantial resources to research and development, clinical trials of our product candidates, and other operations and potential product acquisitions and in-licensing. We have evaluated and expect to continue to evaluate a wide array of strategic transactions as part of our plan to acquire or in license and develop additional products and product candidates to augment our internal development pipeline. Strategic transaction opportunities that we may pursue could materially affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both. In addition, we may pursue development, acquisition or in-licensing of approved or development products in new or existing therapeutic areas or continue the expansion of our existing operations. Accordingly, we expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations, or for general corporate purposes. Strategic transactions may require us to raise additional capital through one or more public or private debt or equity financings or could be structured as a collaboration or partnering arrangement. We have no arrangements, agreements, or understandings in place at the present time to enter into any acquisition, in-licensing or similar strategic business transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We partially rely on government grants to contribute to our EB05 (paridiprubart) development program. If we are unable to satisfy our contractual obligations and manage our covenants or meet expected milestones, the development of EB05 may be extended, delayed, modified, or terminated and we may be required to repay all or part of the grant earlier than expected.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In February 2021, we and Edesa Biotech Research signed the 2021 SIF Agreement whereby the Government of Canada agreed to contribute C$14.1 million in nonrepayable funding for an international Phase 2 study and certain pre-clinical experiments. In the event that we or Edesa Biotech Research breach our obligations under the 2021 SIF Agreement, subject to applicable cure, the SIF may exercise a number of remedies, including demanding repayment of funding previously received and/or terminating the agreement. The performance obligations of Edesa Biotech Research under the contribution agreement are guaranteed by us. All potential funding available under the 2021 SIF Agreement has been received. As of the date of this filing, we have met all of our performance and reporting requirements under the 2021 SIF Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">On October 12, 2023, we and Edesa Biotech Research signed the 2023 SIF Agreement whereby the Government of Canada agreed to contribute up to C$23 million from the SIF in partially repayable funding toward of the development and commercialization of our investigational therapy EB05. Under the 2023 SIF Agreement, we agreed to complete the project, to be conducted exclusively in Canada except as permitted otherwise under certain circumstances, on or before December 31, 2025. We also have agreed to certain financial and non-financial covenants and other obligations in relation to EB05, including the achievement of certain headcount requirements in Canada, the maintenance of a collaboration with a Canadian research institute or post-secondary institutions, and the maintenance of certain research and development expenditures in Canada. In an event of default, such as our breach of our covenants and obligations under either the 2023 SIF Agreement or the 2021 SIF Agreement, the Government of Canada may suspend or terminate its contribution to the project, or require repayment. As a result, if we default on our obligations under the SIF agreements, we may not have sufficient funds available to continue the Phase 3 clinical study of our investigational therapy EB05, and we cannot be certain that we will be able to obtain additional capital to fund the program. We are currently not in default of our obligations per the terms of either SIF agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In June 2024, EB05 was selected through a competitive process by the Biomedical Advanced Research and Development Authority (BARDA), as one of three drug candidates for evaluation in a U.S. government-funded Phase 2 platform study. The randomized, double-blinded, placebo-controlled, multi-center clinical trial is investigating novel threat-agnostic host-directed therapeutics, including EB05, in hospitalized adult patients with ARDS due to a variety of causes. We are providing drug products to the study as well as technical support at our own expense. Given the BARDA-sponsored study opportunity, we have shifted our clinical focus for EB05 to general ARDS from Covid-19 induced ARDS. Our plan is to await the results of the BARDA-funded study before continuing with our Canadian government-supported Phase 3 study, which had exclusively recruited ARDS patients hospitalized with Covid-19. As a result, we have discontinued enrollment in a Covid-19 focused Phase 3 study and plan to file a new study design with FDA and Health Canada based on the results of the BARDA-funded ARDS study. We believe this strategy provides a more efficient and cost-effective path toward a commercially approved therapy for general ARDS, increases the potential commercial opportunity for EB05 and better aligns our development programs with government goals for HDTs as well as interest from potential strategic commercialization and licensing partners. Any changes we have made and make in the future to our clinical plans and enrollment criteria may limit how data from previously enrolled subjects are utilized by the company for regulatory purposes.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Any failures on our part to satisfy any of our obligations under the above agreements could adversely affect or terminate our development of EB05.&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We depend heavily on the success of our drug product candidates. If we are unable to obtain regulatory approval or commercialize one or more of these experimental treatments, or experience significant delays in doing so, our business will be materially harmed. We cannot give any assurance that we will receive regulatory approval for such product candidates or any other product candidates, which is necessary before they can be commercialized.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We have not completed development of and/or obtained regulatory approval for any of our product candidates. Development will require the commitment of substantial financial resources, extensive product candidate development, and clinical trials. This process takes years of effort without any assurance of ultimate success.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our ability to generate product revenues, which may not occur for multiple years, if at all, will depend heavily on the successful development and commercialization of our drug product candidates. The success of our product candidates will depend on a number of factors, including, but not limited to:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to obtain additional capital from potential future licensing, collaboration or similar arrangements or from any future offering of our debt or equity securities;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to identify and enter into potential future licenses or other collaboration arrangements with third parties and the terms of the arrangements;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our timing to obtain applicable regulatory approvals;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">successful completion of clinical development;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the ability to provide acceptable evidence demonstrating a product candidates&#8217;&#160;safety and efficacy;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">receipt of marketing approvals from applicable regulatory authorities and similar foreign regulatory authorities;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the availability of raw materials to produce our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">obtaining and maintaining commercial manufacturing arrangements with third-party manufacturers or establishing commercial-scale manufacturing capabilities;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">establishing sales, marketing and distribution capabilities;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">generating commercial sales of the product candidate, if and when approved, whether alone or in collaboration with others;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">acceptance of the product candidate, if and when approved, by patients, the medical community and third-party payors;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">effectively competing with other therapies; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">maintaining an acceptable safety profile of the product candidate following approval.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any of our product candidates, which would materially harm our business. Many of these factors are beyond our control. Accordingly, we may never be able to generate revenues through the license or sale of any of our product candidates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our product development efforts with respect to our product candidates may fail for many reasons, including but not limited to:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the failure of the product candidate in clinical studies;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">adverse patient reactions to the product candidate or indications of other safety concerns;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">insufficient clinical trial data to support the effectiveness or superiority of the product candidate;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the inability to manufacture sufficient quantities of the product candidate for development or commercialization activities in a timely and cost-efficient manner; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">changes in the regulatory environment, including pricing and reimbursement, that make development of a new product or of an existing product for a new indication no longer attractive.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Deterioration in general economic conditions in the U.S., Canada and globally, including the effect of prolonged periods of inflation on our suppliers, third-party service providers and potential partners, could harm our business and results of operations.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our business and results of operations could be adversely affected by changes in national or global economic conditions. These conditions include but are not limited to inflation, rising interest rates, availability of capital markets, energy availability and costs, the negative impacts caused by pandemics and public health crises, negative impacts resulting from the military conflict between Russia and the Ukraine, and the effects of governmental initiatives to manage economic conditions. Impacts of such conditions could be passed on to our business in the form of higher costs for labor and materials, higher investigator fees, possible reductions in pharmaceutical industry-wide spending on research and development and acquisitions and higher costs of capital.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our primarily operating entity, Edesa Biotech Research, Inc., was formed in July 2015. To date, our operations have been limited to organization and staffing, developing and securing our technology, entering into licensing arrangements, raising capital and undertaking preclinical studies and clinical trials of our product candidates. We have not yet demonstrated our ability to successfully complete development of any product candidate, obtain marketing approval, manufacture a commercial-scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Assuming we obtain marketing approval for any of our product candidates, we will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays and may not be successful in such a transition. Any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We are exposed to risks related to currency exchange rates.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We conduct a significant portion of our operations outside of the U.S. Because our financial statements are presented in U.S. dollars, changes in currency exchange rates have had and could have in the future a significant effect on our operating results when our operating results are translated into U.S. dollars.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws, privacy laws and other laws governing our operations. If we fail to comply with these laws, it could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act (FCPA), and other anti-corruption laws that apply in countries where we do business and may do business in the future. We are also subject to other laws and regulations governing our international operations, including regulations administered by the government of the U.S. and authorities in the EU, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws. If we are not in compliance, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Similarly, compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and our failure to comply with data protection laws and regulations could lead to government enforcement actions, which would cause our business and reputation to suffer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We are subject to numerous environmental, health and safety laws and regulations. Our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations produce hazardous waste products. We expect to contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and collaborators, including intentional failures to comply with FDA or Office of Inspector General regulations or similar regulations of comparable non-U.S. regulatory authorities, provide accurate information to the FDA or comparable non-U.S. regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable non-U.S. regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. Such actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse impact on our business, financial condition, results of operations and prospects including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, loss of eligibility to obtain marketing approvals from the FDA, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with any of these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our operating results.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We expect to expand our capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We expect to experience growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, finance and administration and, potentially, sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. We may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. If we are not able to effectively manage our growth and expand our organization, we might be unable to implement successfully the tasks necessary to execute effectively on our planned research, development and commercialization activities and, accordingly, might not achieve our research, development and commercialization goals.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We are highly dependent on Dr. Pardeep Nijhawan, our CEO and Secretary; and Michael Brooks, our President; as well as other principal members of our management and scientific teams. Although we have employment agreements with each of our executives, these agreements do not prevent our executives from terminating their employment at any time. The unplanned loss of the services of any of these persons could materially impact the achievement of our research, development, financial and commercialization objectives. If we lose the services of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Recruiting and retaining qualified personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous biotechnology and pharmaceutical companies for similar personnel. We could have difficulty attracting experienced personnel to our Company and may be required to expend significant financial resources in our employee recruitment and retention efforts. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will harm our ability to implement our business strategy and achieve our business objectives.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Despite the implementation of security measures, our computer systems and those of third parties with which we contract are vulnerable to damage, including damage from cyberattacks, ransomware attacks, computer viruses, unauthorized access, human error and technological errors, natural disasters and telecommunication and electrical failures. System failures, accidents or security breaches could cause interruptions in our operations, and could result in a material disruption of our clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The loss of clinical trial data could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our product research, development and commercialization efforts could be delayed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Risks Related to Clinical Development, Regulatory Approval and Commercialization</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, Health Canada (HC) or the European Medicines Agency (EMA), or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization our product candidates.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In connection with obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical trials are expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials. In particular, the small number of subjects and patients in early clinical trials of our product candidates may make the results of these clinical trials less predictive of the outcome of later clinical trials. The design of a clinical trial can determine whether our results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced or completed. There is no assurance that we will be able to design and execute a clinical trial to support marketing approval. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Pre-clinical studies or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional pre-clinical studies or clinical trials, or to discontinue clinical trials altogether. Ultimately, we may be unable to complete the development and commercialization of any of our product candidates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Interim results, top-line, initial data may not accurately reflect the complete results of a particular study or trial.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We may publicly disclose interim, top-line or initial data from time to time that is based on a preliminary analysis of then- available efficacy and safety data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimates, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. Interim, top-line and initial data should be viewed with caution until the final data are available. In addition, the information we may publicly disclose regarding a particular preclinical or clinical study is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant regarding a particular drug, drug candidate or our business. If the interim, top-line or initial data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed or delayed, which could harm our business, financial condition, operating results or prospects.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Any product candidate we advance into and through clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent their regulatory approval or commercialization or limit their commercial potential.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Unacceptable adverse events caused by our product candidates in clinical trials could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications and markets. This, in turn, could prevent us from commercializing the affected product candidate and generating revenues from its sale. We have not yet completed testing of any of our product candidates for the treatment of the indications for which we intend to seek product approval in humans, and we currently do not know the extent of adverse events, if any, that will be observed in patients who receive any of our product candidates. If any of our product candidates cause unacceptable adverse events in clinical trials, we may not be able to obtain regulatory approval or commercialize such product or, if such product candidate is approved for marketing, future adverse events could cause us to withdraw such product from the market.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>If clinical trials for our product candidates are prolonged or delayed, we may incur additional costs, and may not be able to commercialize our product candidates on a timely basis or at all.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We cannot predict whether we will encounter problems with any of our ongoing or planned clinical trials that will cause us or any regulatory authority to delay or suspend those clinical trials. A number of events, including any of the following, could delay the completion of our ongoing and planned clinical trials and negatively impact our ability to obtain regulatory approval for, and to market and sell, a particular product candidate:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">conditions imposed by the FDA or any foreign regulatory authority regarding the scope or design of our clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delays in obtaining, or the inability to obtain, required approvals from institutional review boards, or IRBs, or other reviewing entities at clinical sites selected for participation in our clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">insufficient supply or deficient quality of product candidates supply or materials to produce our product candidates or other materials necessary to conduct our clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delays in obtaining regulatory agreement for the conduct of the clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">lower than anticipated enrollment and retention rate of subjects in clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">serious and unexpected drug-related side effects experienced by patients in clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">failure of third-party contractors to meet their contractual obligations in a timely manner;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">pre-clinical or clinical trials may produce negative or inconclusive results, which may require us or any potential future collaborators to conduct additional pre-clinical or clinical testing or to abandon projects that we expect to be promising;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">even if pre-clinical or clinical trial results are positive, the FDA or foreign regulatory authorities could nonetheless require unanticipated additional clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">regulators or institutional review boards may suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delays in establishing the appropriate dosage levels;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">product candidates may not have the desired effects; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the lack of adequate funding to continue clinical trials.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Additionally, changes in standard of care or regulatory requirements and guidance may occur and we may need to amend clinical trial protocols to reflect these changes. Such amendments may require us to resubmit our clinical trial protocols to IRBs for re-examination, which may impact the cost, timing or successful completion of a clinical trial. Such changes may also require us to reassess the viability of the program in question.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We do not know whether our clinical trials will begin or continue as planned, will need to be restructured or will be completed on schedule, if at all. Delays in clinical trials will result in increased development costs for our product candidates. In addition, if we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our product candidates may be affected and our ability to generate product revenues will be delayed. Furthermore, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>The clinical trial designs, endpoints and outcomes that will be required to obtain marketing approval for our drug candidates are uncertain. We may never receive marketing approval for our drug candidates.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">To our knowledge, there are currently no FDA-approved drug treatment options specifically approved for many of the disease indications we are targeting with our drug candidates. Accordingly, there may not be well-established development paths and outcomes. The FDA, Health Canada or any other regulatory authority may determine that the designs or endpoints of any trial that we conduct, or that the outcome shown on any particular endpoint in any trial that we conduct, are not sufficient to establish a clinically meaningful benefit for our drug candidates, or otherwise, to support approval, even if the primary endpoint(s) of the trial is met with statistical significance. If this occurs, our business could be materially harmed. Moreover, if the regulatory authorities require us to conduct additional clinical trials beyond the ones that we currently contemplate, our finances and results from operations will be adversely impacted. If our clinical studies meet their respective primary endpoints, we plan to seek marketing approval. We cannot predict whether each of these regulatory agencies will agree that our study data and information will be sufficient to meet the requirements for filing a marketing application or the standards for approval. If the regulatory agencies determine that more data and information are needed, it could delay and/or negatively impact our ability to obtain regulatory approval to market and sell a particular product candidate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>If the commercial opportunity in vitiligo, chronic ACD, ARDS, or pulmonary fibrosis is smaller than we anticipate, our future revenue from our drug candidates will be adversely affected and our business will suffer.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">It is critical to our ability to grow and become profitable that we successfully identify patients with vitiligo, chronic ACD ARDS or pulmonary fibrosis. Our estimates of the number of people who have these conditions as well as the subset who have the potential to benefit from treatment with EB06, EB01, EB05 or EB07, are based on a variety of sources, including third-party estimates and analyses in the scientific literature, and may prove to be incorrect. Further, new information may emerge that changes our estimate of the prevalence of these diseases or the number of patient candidates for these drug candidates. The effort to identify patients for our other potential target indications is at an early stage, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for our drug candidates may be limited or may not be amenable to treatment with our drug candidates, and new patients may become increasingly difficult to identify or access. If the commercial opportunity for these conditions is smaller than we anticipate, our future financial performance may be adversely impacted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>While we have chosen to test our product candidates in specific clinical indications based in part on our understanding of their mechanisms of action, our understanding may be incorrect or incomplete and, therefore, our product candidates may not be effective against the diseases tested in our clinical trials.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our rationale for selecting the particular therapeutic indications for each of our product candidates is based in part on our understanding of the mechanism of action of these product candidates. However, our understanding of the product candidates&#8217; mechanism of action may be incomplete or incorrect, or the mechanism may not be clinically relevant to the diseases treated. In such cases, our product candidates may prove to be ineffective in the clinical trials for treating those diseases, and adverse clinical trial results would likely negatively impact our business and results from operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>A successful sPLA2, anti-TLR4 or anti-CXCL10 drug has not been developed to date and we can provide no assurances that we will be successful or that there will be no adverse side effects.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our sPLA2, anti-TLR4 and anti-CXCL10 product candidates employ novel mechanisms of action. To our knowledge no drug companies have successfully commercialized an sPLA2 inhibitor, an anti-TLR4 antibody or an anti-CXCL10 antibody and as a result the efficacy and long-term side effects are not known. There is no guarantee that we will successfully develop and/or commercialize any of these therapies, and/or that our product candidates will have no adverse side effects.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Even if one of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">If any product candidate receives marketing approval, the approved product may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If an approved product does not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. Our ability to negotiate, secure and maintain third-party coverage and reimbursement for our product candidates may be affected by political, economic and regulatory developments in the U.S., Canada, the EU and other jurisdictions. Governments continue to impose cost containment measures, and third-party payors are increasingly challenging prices charged for medicines and examining their cost effectiveness, in addition to their safety and efficacy. These and other similar developments could significantly limit the degree of market acceptance of any of our future product candidates that receive marketing approval.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and any of our other current or future product candidates, we may not be successful in commercializing the applicable product candidate if it receives marketing approval.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We do not have a sales or marketing infrastructure and have no experience as a company in the sale or marketing of pharmaceutical products. To achieve commercial success for any approved product, we must either develop a sales and marketing organization or outsource these functions to third parties. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. If we enter into arrangements with third parties to perform sales and marketing services, our product revenues or the profitability of these product revenues to us could be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We face substantial competition, which may result in others discovering, developing or commercializing products to treat our target indications or markets before or more successfully than we do.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and any products we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Competitors may also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Many of our competitors have significantly greater financial resources and expertise than we do. Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are more effective, safer, have fewer or less severe side effects, are approved for broader indications or patient populations, or are more convenient or less expensive than any products that we develop and commercialize. Our competitors may also obtain marketing approval for their products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market. If approved, our product candidates will compete for a share of the existing market with numerous other products being used to treat ACD, ARDS, vitiligo, SSc or any other indications for which we may receive government approval.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Even if we are able to commercialize one of our product candidates, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted and, in some markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our ability to commercialize EB01, EB05, EB06, EB07 or any other product candidate successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third- party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. We will need to increase our insurance coverage when and if we begin conducting more expansive clinical development of our product candidates, and we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products manufactured and distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#8217; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We will be dependent on third parties for manufacturing, including optimization, technology transfers and scaling up of clinical scale quantities of all of our product candidates.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We have no direct experience in manufacturing any of our product candidates, and currently lack the resources or capability to manufacture any of our product candidates on a clinical or commercial scale. As a result, we will be dependent on third parties for manufacturing, including optimization, technology transfers and scaling up of clinical scale quantities of all our product candidates. We believe that this strategy will enable us to direct operational and financial resources to the development of our product candidates rather than diverting resources to establishing manufacturing infrastructure; however our use of third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We do not currently have any agreements with third-party manufacturers for the long-term clinical or commercial supply of any of our product candidates and may in the future be unable to scale-up and/or conclude agreements for commercial supply with commercial third-party manufacturers on acceptable terms, or at all. Even if we are able to establish and maintain arrangements with third-party manufacturers, they may encounter difficulties in achieving volume production, laboratory testing, quality control or quality assurance or suffer shortages of qualified personnel, any of which could result in our inability to manufacture sufficient quantities to meet clinical timelines for a particular product candidate, to obtain marketing approval for the product candidate or to commercialize the product candidate. We may compete with other companies for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">If the third parties that we contract to manufacture product for our preclinical tests and clinical trials cease to continue to do so for any reason or if we elect to change suppliers, we likely would experience delays in advancing these clinical trials while we identify and qualify replacement suppliers and we may be unable to obtain replacement suppliers on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the drug substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively. Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and competitive basis.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>The manufacturing of our monoclonal antibody candidates is complex and subject to a multitude of risks. These manufacturing risks could substantially increase our costs and limit supply of these drug candidates for clinical development, and commercialization.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The manufacture of our monoclonal antibody candidates requires processing steps that are more complex than those required for most small molecule drugs. As a result of the complexities in manufacturing biologics, the cost to manufacture biologics in general, and our monoclonal antibody candidates in particular, is generally higher than traditional small molecule chemical compounds, and the manufacturing processes are less reliable and are more difficult to reproduce. Although we are working with third parties to develop reproducible and commercially viable manufacturing processes for our product candidates, doing so is a difficult and uncertain task, and there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost overruns, potential problems with process scale-out, process reproducibility, stability issues, lot consistency, and timely availability of reagents or raw materials.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We may make changes as we continue to evolve the manufacturing processes for our product candidates for advanced clinical trials and commercialization, and we cannot be sure that even minor changes in these processes will not cause our product candidates to perform differently and affect the results of our ongoing clinical trials, future clinical trials, or the performance of the product once commercialized. In some circumstances, changes in manufacturing operations, including to our protocols, processes, materials or facilities used, may require us to perform additional preclinical or comparability studies, or to collect additional clinical data from patients prior to undertaking additional clinical studies or filing for regulatory approval for a product candidate. These requirements may lead to delays in our clinical development and commercialization plans for our product candidates, and may increase our development costs substantially.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We may also decide to transfer certain manufacturing process know-how and certain intermediates to other contract manufacturing organizations. Transferring manufacturing testing and processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. We and any CMOs or third parties that we engage for manufacturing our product candidates will need to conduct significant development work to transfer these processes and manufacture each of our product candidates for clinical trials and commercialization. In addition, we may be required to demonstrate the comparability of material generated by any CMO or third parties that we engage for manufacturing our product candidates with material previously produced and used in testing. The inability to manufacture comparable drug product by us or our CMO could delay the continued development of our product candidates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We also must develop satisfactory methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate the effectiveness of the packaging and that the compound does not undergo unacceptable deterioration over its shelf life. If we fail at any of these tasks, we may not be able to obtain approval or successfully commercialize our product candidates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We rely on third parties to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such clinical trials.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We do not independently conduct clinical trials for our product candidates. We rely on third parties, such as contract research organizations, clinical data management organizations, medical institutions, drug distributers and clinical investigators, to perform this function. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it would delay our product development activities. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Our product development costs will increase if we experience delays in testing or obtaining marketing approvals. Our reliance on these third parties for clinical development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials complies with standards, commonly referred to as Good Clinical Practice, and is conducted in accordance with the general investigational plan and protocols for the trial.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>If we are not able to establish or maintain additional partnerships or</i></b>&#160;<b><i> collaborations, we may have to alter our development and commercialization plans.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The development of our product candidates and clinical programs and the potential commercialization will require substantial additional capital. Given the high capital requirement for pivotal clinical studies, our preferred strategy is to seek public and private partners for Phase 3 clinical testing and scale-up. We face significant competition in seeking appropriate partners and collaborators. Whether we reach additional definitive agreements for a collaboration or partnership will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or Health Canada, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator or partner &#160;may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may not be able to negotiate collaborations or partnerships on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of product candidates, reduce or delay one or more of our development programs, delay potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Even if we complete the necessary clinical trials, the marketing approval process is expensive, time consuming and uncertain. If we are not able to obtain, or if there are delays in obtaining, required marketing approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, Health Canada and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market EB01, EB05, EB06, EB07 or any other Edesa product candidate from regulatory authorities in any jurisdiction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and effectiveness. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Regulatory authorities may determine that EB01, EB05, EB06, EB07 or any of our other product candidates is not effective, is only moderately effective or has undesirable or unintended side effects, toxicities, safety profiles or other characteristics that preclude us from obtaining marketing approval or that prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical studies, clinical trials or other trials. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Even if we obtain marketing approval for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we manufacture and market our products, and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Even if marketing approval of a product candidate is granted, an approved product and our manufacturer and marketer are subject to ongoing review and extensive regulation, including the possible requirement to implement a risk evaluation and mitigation strategy or to conduct costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to ensure that quality control and manufacturing procedures conform to cGMP, which include requirements relating to quality control, quality assurance and documentation. Accordingly, assuming we receive marketing approval for one or more of our product candidates, we and our contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Thus, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We may not qualify for or ultimately benefit from various expedited regulatory review programs or other special designations.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We have obtained a Fast Track designation in the U.S. for EB05 as a treatment for ARDS in critically ill Covid-19 patients, and we may seek additional designations for EB05 or our other product candidates; however, we may never receive such designations. If we believe we meet eligibility requirements, we intend to apply for various regulatory incentives in the U.S., such as breakthrough therapy designation, fast track designation, accelerated approval and priority review, where available, that provide for expedited review and/or other benefits, and we may also seek similar designations elsewhere in the world. Similarly, we may seek orphan drug designation in the U.S. and other jurisdictions for our product candidates, but we may be unable to obtain such designation or to obtain or maintain the benefits associated with orphan drug designation, including market exclusivity. Often, regulatory agencies have broad discretion in determining whether or not product candidates qualify for such regulatory incentives and benefits and we cannot guarantee we would be successful in obtaining beneficial regulatory designations by FDA or other regulatory agencies. Even if approved, expedited designations may not result in faster development processes, reviews or approvals compared to drugs considered for approval under conventional FDA procedures. In addition, the FDA may later decide that any of our development programs no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. If we are not able to obtain or maintain such designations for EB05 or other product candidates, it could delay and/or negatively impact our ability to obtain regulatory approval.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Regulators have broad discretion regarding emergency use authorizations for medical products, and such authorizations may only be valid during a public health emergency.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">While, in most cases, a therapeutic must be approved by FDA before the product may be sold, when a public health emergency is declared, subject to certain conditions, FDA may authorize the emergency use of an unapproved medical product under an Emergency Use Authorization (EUA). Similar systems are in place in Canada and the EU. In the event that our clinical study of EB05 is successful, and if we believe we meet eligibility requirements, we intend to submit an application with the regulators for emergency use. Regulators typically do not have review deadlines with respect to such submissions and, therefore, the timing of any potential approval of an emergency use submission would be uncertain. Regulators may refuse to approve our application. In addition, even if granted, the regulators may revoke an emergency use where it is determined that the underlying health emergency no longer exists or warrants such authorization. If we are unsuccessful in obtaining an EUA, or if any granted EUA is revoked after a short period of time, it could have a material adverse effect on our future business, financial condition and operating results.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Increasing use of social media platforms could give rise to liability, breaches of data security and privacy laws, or reputational damage.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We believe that our potential patient population is active on social media. Social media practices in the pharmaceutical and biotechnology industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, a product candidate, which could result in reporting obligations. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us or our product candidates on any social networking website.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In addition, our employees or third parties with whom we contract, such as our CROs or CMOs, may knowingly or inadvertently make use of social media in a manner that may give rise to liability, lead to the loss of trade secrets or other intellectual property or result in public exposure of personal information of our employees, clinical trial patients, customers and others or information regarding our product candidates or clinical trials. Any of these events could have a material adverse effect on our business, prospects, operating results and financial condition and could adversely affect the price of our common shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Risks Related to Our Intellectual Property</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We are dependent on license relationships with third parties for our key drug development programs.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In 2016, we entered into the Yissum License Agreement to obtain exclusive rights to certain know-how, patents and data relating to a pharmaceutical product. We are using the exclusive rights to develop the product for therapeutic, prophylactic and diagnostic uses in topical dermal applications and anorectal applications, including for the development of EB01 to treat ACD. In 2021, we also entered into the Inventor License Agreement to acquire global rights for all fields of use beyond those named under the Yissum License Agreement. If we default or fail to perform any of the terms, covenants, provisions or our obligations under the Yissum License Agreement, Yissum has the option to terminate the Yissum License Agreement, subject to advance notice to cure such default. Any termination of this license agreement would have a materially adverse impact on our business and results from operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In April 2020, we entered into the NovImmune License Agreement to obtain exclusive rights throughout the world to certain know-how, patents and data relating to the monoclonal antibodies targeting TLR4 and CXCL10. We are using these rights to develop EB05 as a potential treatment for ARDS and other disease indications. If we default or fail to perform any of the terms, covenants, provisions or our obligations under the NovImmune License Agreement, including milestone payments, NovImmune has the option to terminate the NovImmune License Agreement, subject to advance notice to cure such default. Any termination of this license agreement would have a materially adverse impact on our business and results from operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">If we are unable to obtain and maintain patent protection for our licensed technology and products, or if the scope of the patent protection is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our licensed technology and products may be adversely affected.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our success will partially depend on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to our proprietary technology and products. We intend to protect our proprietary position by filing patent applications in the U.S., in Europe and in certain additional jurisdictions related to our novel technologies and product candidates that are important to our business. This process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, if we license technology or product candidates from third parties in the future, these license agreements may not permit us to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering the licensed technology or product candidates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of any patents issued to us will likely be highly uncertain. Patent applications that we file may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may also diminish the value of patents issued to us, narrow the scope of our patent protection or make enforcement more difficult or uncertain.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We may become involved in lawsuits or other enforcement proceedings to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and potentially unsuccessful.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file claims, which can be expensive and time consuming to prosecute. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property or that our patent and other intellectual property rights are invalid or unenforceable, including for antitrust reasons. As a result, in a patent infringement proceeding, a court or administrative body may decide that a patent of ours is invalid or unenforceable, in whole or in part, or may construe the patent&#8217;s claims narrowly and so refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the competitor technology in question. Even if we are successful in a patent infringement action, the unsuccessful party may subsequently raise antitrust issues and bring a follow-on action thereon. Antitrust issues may also provide a bar to settlement or constrain the permissible settlement terms.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">36</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the intellectual property and other proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology. The risks of being involved in such litigation and office proceedings may also increase as our product candidates approach commercialization, and as our business gains greater visibility. Third parties may assert infringement claims against us based on existing or future intellectual property rights and to restrict our freedom to operate. Third parties may also seek injunctive relief against us, whereby they would attempt to prevent us from practicing our technologies altogether pending outcome of any litigation against us. We may not be aware of all such intellectual property rights potentially relating to our product candidates prior to their assertion against us. If we are found to infringe a third party&#8217;s intellectual property rights, we could incur substantial monetary damages. A finding of infringement could also prevent us from commercializing our product candidates, lose market exclusivity, require substantial license payments, or force us to cease some of our business operations, which could materially harm our business.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Intellectual property litigation could cause us to spend substantial resources and could distract our personnel from their normal responsibilities.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and likely would distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments that could have a substantial adverse effect on the price of our securities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Accordingly, costs and lost management time, as well as uncertainties resulting from the initiation and continuation of patent litigation or other proceedings, could have a material adverse effect on our ability to compete in the marketplace.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We partially rely on trade secrets and know-how, including unpatented know-how, technology and other proprietary and confidential information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into nondisclosure and confidentiality agreements with parties who have access to them. However, we cannot guarantee that we have executed these agreements with each party that may have or have had access to our trade secrets or that the agreements we have executed will provide adequate protection. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary or confidential information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, particularly unpatented know-how, were to be obtained or independently developed by a competitor, our competitive position would be harmed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">37</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Risks Related to Owning Our Securities</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>The price of our common shares may continue to be volatile.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Market prices for securities of clinical-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile, and the market price of our common shares has been subject to significant fluctuations. This volatility can be exacerbated by low trading volume. Some of the factors that may cause the market price of our shares to fluctuate include:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">sales or potential sales of substantial amounts of our common shares;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">announcements about us or our competitors, including funding announcements, corporate or business updates, updates on manufacturing of our products, clinical trial results, regulatory approvals or new product introductions;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">developments concerning our product manufacturers;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">litigation and other developments relating to our licensed patents or other proprietary rights or those of our competitors;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">governmental regulation and legislation;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">change in securities analysts&#8217;&#160;estimates of our performance, or failure to meet analysts&#8217;&#160;expectations;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the terms and timing of any future collaborative, licensing or other arrangements that we may establish;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our ability to raise additional capital to carry through with our development plans and current and future operations;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the timing of achievement of, or failure to achieve, our manufacturing, pre-clinical, clinical, regulatory and other milestones, such as the commencement of clinical development, the completion of a clinical trial or the receipt of regulatory approval;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">actions taken by regulatory agencies with respect to our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">uncontemplated problems in the supply of the raw materials used to produce our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">introductions or announcements of technological innovations or new products candidates by us, our potential future collaborators, or our competitors, and the timing of these introductions or announcements;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">market conditions for equity investments in general, or the biotechnology or pharmaceutical industries in particular;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">actual or anticipated fluctuations in our results of operations;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">hedging or arbitrage trading activity that may develop regarding our common shares;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">regional or worldwide recession;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">sales of our common shares by our executive officers, directors and significant shareholders;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">changes in accounting principles; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the loss of any of our key scientific or management personnel.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common shares. In the past, following periods of volatility in the market price of a company&#8217;s securities, shareholders have often instituted class action securities litigation. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>If we fail to meet all applicable Nasdaq Capital Market requirements and Nasdaq determines to delist our common shares, the delisting could adversely affect the market liquidity of our common shares and the market price of our common shares could decrease and our ability to access the capital markets could be negatively impacted.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our common shares are listed on The Nasdaq Capital Market. We must satisfy the continued listing requirements of Nasdaq, to maintain the listing of our common shares on The Nasdaq Capital Market.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">There can be no assurance that we will be able to continue to maintain compliance with the Nasdaq continued listing requirements, and if we are unable to maintain compliance with the continued listing requirements, our securities may be delisted from Nasdaq, which could reduce the liquidity of our common shares materially and result in a corresponding material reduction in the price of our common shares. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees, suppliers and business development opportunities. Such a delisting likely would impair your ability to sell or purchase our common shares when you wish to do so. Further, if we were to be delisted from Nasdaq, our common shares may no longer be recognized as a &#8220;covered security&#8221; and we would be subject to regulation in each state in which we offer our securities. Thus, delisting from Nasdaq could adversely affect our ability to raise additional financing through the public or private sale of equity securities, would significantly impact the ability of investors to trade our securities and would negatively impact the value and liquidity of our common shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">38</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We do not currently intend to pay dividends on our common shares in the foreseeable future, and consequently, any gains from an investment in our common shares will likely depend on appreciation in the price of our common shares.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We have never declared or paid cash dividends on our common shares and do not anticipate paying any cash dividends to holders of our common shares in the foreseeable future. Consequently, investors must rely on sales of their common shares and warrants after price appreciation, which may never occur, as the only way to realize any future gains on their investments. There is no guarantee that our common shares will appreciate in value or even maintain the price at which the shareholders have purchased their shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>A sale of a substantial number of our common shares in the public market could cause the market price of our common shares to drop significantly, even if our business is doing well.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The price of our common shares could decline as a result of sales of a large number of our common shares or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In addition, in the future, we may issue additional common shares, warrants or other equity or debt securities convertible into common shares in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing shareholders and could cause the price of our common shares to decline.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common shares, the price of our common shares could decline.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The trading market for our common shares relies in part on the research and reports that equity research analysts publish about us and our business. We do not control these analysts. The price of our common shares could decline if one or more equity analysts downgrade our common shares or if analysts issue other unfavorable commentary or cease publishing reports about us or our business.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our directors and executive officers have control over us and could delay or prevent a change of corporate control.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As of December 11, 2024, Dr. Nijhawan, our Chief Executive Officer, beneficially owns 19.99% of our outstanding common shares and all of our executive officers and directors, including Dr. Nijhawan, beneficially own 23.9% of our common shares. As a result, such individuals will have the ability, acting together, to significantly influence the election of our directors and the outcome of corporate actions requiring shareholder approval, such as: (i) a merger or a sale of our company, (ii) a sale of all or substantially all of our assets, and (iii) amendments to our Articles. This concentration of voting power and control could have a significant effect in delaying, deferring or preventing an action that might otherwise be beneficial to our other shareholders and be disadvantageous to our shareholders with interests different from those individuals.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">See &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; below for more information regarding the ownership of our outstanding common shares by our executive officers, directors and holders of more than 5% of our common stock, together with their affiliates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our Articles allow for our board of directors to create new series of preferred shares without further approval by the shareholders, which could adversely affect the rights of the holders of our common shares.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As previously approved by our shareholders, our board of directors (&#8220;Board&#8221;) has the authority to authorize up to an unlimited number of a new series of our preferred shares and to fix and determine the special rights and restrictions of that series without further shareholder approval, subject to the terms set out in the Articles and unless otherwise required by the Business Corporations Act (British Columbia). As a result, our board of directors could authorize the creation of a series of our preferred shares that would grant to holders of the preferred shares a right to our assets upon liquidation before a distribution to the holders of our common shares. In addition, our board of directors could authorize the creation of a new series of our preferred shares that is convertible into our common shares, which could result in dilution to existing shareholders.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">On October 30, 2024, we filed Amended Articles to amend the rights, preferences, restrictions and other matters pertaining to our newly designated Series A-1 Convertible Preferred Shares (the &#8220;Preferred Shares&#8221;). The Preferred Shares have no par value and a stated value of $10,000 per share and rank, with respect to redemption payments, rights upon liquidation, dissolution or winding-up of the Company, or otherwise, senior in preference and priority to our common shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">39</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Our common shares rank junior to the preferred shares in the event of a liquidation, dissolution or winding-up of the Company.</i></b><b> </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In the event of any liquidation, dissolution or winding-up of the Company, a holder of the Preferred Shares will be entitled to receive, before any distribution or payment may be made with respect to the holders of our common shares, an amount equal to 100% of the stated value, plus a return equal to 10% of the stated value per Preferred Share per annum, calculated daily.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Any issuance of our common shares upon conversion of the Preferred Shares will cause dilution to our then existing stockholders and may depress the market price of our common shares.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The Preferred Shares accrue an annual return equal to 10% of the stated value per Preferred Share payable&#160;by the issuance of our common shares at the conversion price&#160;upon a buy-back by the Company, liquidation or on conversion at the conversion price (calculated daily). Each Preferred Share is convertible into a number of our common shares calculated by dividing (i) the sum of the stated value of such Preferred Share plus a return equal to 10% of the stated value per Preferred Share per annum, calculated daily, by (ii) a fixed conversion price of $3.445.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The issuance of our common shares upon conversion of the Preferred Shares will result in immediate and substantial dilution to the interests of holders of our common shares, and such dilution will increase over time in connection with the accrual of the annual return on the Preferred Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We may incur future indebtedness that will rank senior to the Preferred Shares or issue additional series of preferred shares that rank on a parity with, or senior to, the Preferred Shares as to dividend payments and liquidation preference.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We may incur substantial amounts of additional debt and other obligations that will rank senior to the Preferred Shares, and the terms of the Preferred Shares do not limit the amount of such debt or other obligations that we may incur. The terms of the Preferred Shares will not prohibit us from issuing additional series of preferred shares that would rank on parity with the Preferred Shares. The Articles allow for our board of directors to create new series of preferred shares without further approval by our shareholders, which could adversely affect the rights of the holders of the Preferred Shares and our common shares. The issuances of other series of preferred shares could have the effect of reducing the amounts available to the Preferred Shares in the event of liquidation. If we issue preferred shares with voting rights that dilute the voting power of our common shares, the market price of our common shares could decrease, adversely affecting the value of the Preferred Shares. Additional issuances and sales of preferred shares, or the perception that such issuances and sales could occur, may cause prevailing market prices for our common shares to decline and may adversely affect our ability to raise additional capital in the financial markets at times and prices favorable to it.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>Failure to maintain effective internal control over financial reporting could have a material adverse effect on our share price.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC require an annual management assessment of the effectiveness of our internal control over financial reporting. As a smaller reporting company as defined in Rule 12b-2 under the Exchange Act, we are currently exempt from the auditor attestation requirement of Section 404(b). If we lose this eligibility, we will incur increased personnel and audit fees in connection with the additional audit requirements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">If we fail to maintain the adequacy of our internal control over financial reporting, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 and the related rules and regulations of the SEC. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins its Section 404 reviews, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common shares could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness or significant deficiencies in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also adversely affect investor confidence in the reliability of our financial reports and restrict our future access to the capital markets.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">40</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>The ownership of our common shares is highly concentrated, which may prevent you and other shareholders from influencing significant corporate decisions and may result in conflicts of interest that could cause our common shares price to decline.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">The ownership of our common shares is highly concentrated among insiders and affiliates. Accordingly, these shareholders will have substantial influence over the outcome of corporate actions requiring shareholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of the Company&#8217;s assets or any other significant corporate transaction. These shareholders may also delay or prevent a change of control of the Company, even if such a change of control would benefit the other shareholders of the Company. The significant concentration of share ownership may adversely affect the trading price of our common shares due to investors&#8217; perception that conflicts of interest may exist or arise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><i>We may be deemed a passive foreign investment company, and as a result, U.S. shareholders may be subject to special taxation rules that restrict capital gains treatment, unless the shareholders make a timely tax election to treat the company as a qualified electing fund.</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">A special set of U.S. federal income tax rules applies to a foreign corporation that is deemed a passive foreign investment company (PFIC) for U.S. federal income tax purposes. Based on our audited financial statements, income tax returns, and relevant market and shareholder data, we believe that we likely will not be classified as a PFIC in the September 30, 2024 taxable year. There can be no assurance, however, that we will not be considered to be a PFIC for any particular year in the future because PFIC status is factual in nature, depends upon factors not wholly within our control, generally cannot be determined until the close of the taxable year in question, and is determined annually. If we are deemed to be a PFIC during the current or a future taxable year, U.S. shareholders would be subject to special taxation rules related to gain on sale or disposition of our shares and excess distributions unless they make a timely election to treat our shares as a qualified electing fund (QEF election). A QEF election cannot be made unless we provide U.S. shareholders the information and computations needed to report income and gains pursuant to a QEF election. Without a QEF election, U.S. shareholders may not be able to use capital gains tax treatment and may be subject to potentially adverse tax consequences. Given the complexities of the PFIC and QEF election rules, U.S. shareholders may need to incur the time and expense of consulting a tax adviser about these rules.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><a id="I1B" title="I1B" href="#"></a>Item 1B. UNRESOLVED STAFF COMMENTS.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">None.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><a id="I1C" title="I1C" href="#"></a>Item 1C. CYBERSECURITY. </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Risk Management and Strategy</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In the ordinary course of our business, we, and third parties upon which we rely, collect, use, store and transmit confidential, sensitive, proprietary, personal and protected health information. The secure maintenance of this information is important to our operations and business strategy. To this end, we have implemented various cybersecurity plans and processes designed to manage cybersecurity risks relating to our third party hosted services, communications systems, hardware and software, and our critical data, including data related to our clinical trials and investigational products.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">One of our strategies to mitigate cybersecurity risks is to utilize expert third-party software-as-a-service, human resource, and clinical providers to store and manage personally identifiable information, rather than maintaining and processing such data within our enterprise. We select reliable, reputable service providers that maintain cybersecurity programs of their own and other measures to comply with privacy and security requirements, including when applicable Canada&#8217;s Personal Information Protection and Electronic Document Act (PIPEDA) and the U.S. Health Insurance Portability and Accountability Act (HIPAA). Depending on the nature of the services provided, the sensitivity and quantity of information processed and the identity of the service provider, we may also contractually impose certain security obligations on the provider.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our executive leadership exerts operational oversight of our cybersecurity as part of our overall risk management function. We engage an expert IT and security provider to assist us with managing security risk and responding to cybersecurity threats or incidents. We have designed our business applications and hosting services to minimize the impact that cybersecurity incidents could have on our business and utilize back-up and recovery systems where appropriate. We also use other technology-based tools that are designed to mitigate and detect cybersecurity risks. In addition, we provide our employees with cybersecurity training, including topics such as phishing, password protection and reporting cyber incidents.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">41</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Governance</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Our board of directors oversees our risk management strategy with respect to cybersecurity threats. The board, through its audit committee, holds regular meetings, at least quarterly, to discuss issues including our cybersecurity threats. The meetings involve presentations and reports from our executive leadership and security provider, concerning our cybersecurity risk management activities, including any critical cybersecurity risks, ongoing cybersecurity initiatives and strategies, and applicable regulatory requirements and industry standards. Management also notifies the audit committee of any cybersecurity incidents (suspected or actual) and provides updates on the incidents as appropriate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b>Material Effects of</b>&#160;<b>Cybersecurity</b>&#160;<b>Incidents</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">As of the date of this report, we have not identified any cybersecurity event or risks from&#160;cybersecurity&#160;threats that, individually or in the aggregate, would materially affect us. Notwithstanding, we, or third parties upon which we relay, may not be successful in preventing or mitigating a&#160;cybersecurity&#160;incident that could have a material adverse effect on us or our business strategy, results of operations or financial condition. For further information, refer to Section 1A, Risk Factors, for a discussion of risks related to&#160;cybersecurity&#160;and technology, including, without limitation, the risk factor under the heading &#8220;<i>We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively</i>&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><a id="I2" title="I2" href="#"></a>Item 2. PROPERTIES.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We currently lease approximately 2,800 square feet of office space for our executive offices in Markham, Ontario, from 1968160 Ontario Inc., an entity affiliated with Dr. Nijhawan. Pursuant to the lease, as amended and extended on December 31, 2022, the term of the lease expires on December 31, 2024. We anticipate extending the lease prior to the expiration. We believe our current offices are sufficient to meet our needs. We may seek to negotiate new leases or evaluate additional or alternate space to accommodate operations. We believe that appropriate alternative space is readily available on commercially reasonable terms.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><a id="I3" title="I3" href="#"></a>Item 3. LEGAL PROCEEDINGS.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">From time to time, we may be involved in legal proceedings, claims and litigation arising in the ordinary course of business, including contract disputes, employment matters and intellectual property disputes. We are not currently a party to any material legal proceedings or claims outside the ordinary course of business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"><b><a id="I4" title="I4" href="#"></a>Item 4. MINE SAFETY DISCLOSURES.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Not applicable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">42</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b><a id="P2" title="P2" href="#"></a>PART II</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I5" title="I5" href="#"></a>Item 5. MARKET FOR REGISTRANT</b>&#8217;<b>S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Market Information</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our common shares trade on The Nasdaq Capital Market in the United States under the symbol &#8220;EDSA&#8221;.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Holders</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">As of December 11, 2024, we had 3,467,658 common shares outstanding, with 14 shareholders of record. The number of record shareholders was determined from the records of our stock transfer agent and does not reflect persons or entities that hold their shares in nominee or &#8220;street&#8221; name through various brokerage firms.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Securities Authorized for Issuance Under Equity Compensation Plans</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">See Part III, Item 12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; of this report.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Dividends</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We have not declared any dividends on our common shares since our incorporation and do not anticipate that we will do so in the foreseeable future. Our present policy is to retain future earnings, if any, for use in our operations and the expansion of our business. Any future determination to pay dividends will be made at the discretion of our board of directors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I6" title="I6" href="#"></a>Item 6. RESERVED.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I7" title="I7" href="#"></a>Item 7. MANAGEMENT</b>&#8217;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">This discussion contains forward-looking statements that involve risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements as a result of many important factors, including those set forth in Part I of this Annual Report on Form 10-K under the caption &#8220;Risk Factors.&#8221; Please see &#8220;Forward-Looking Statements and Other Matters&#8221; in Part I above. We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Annual Report.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Overview </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our approach is to acquire, develop and commercialize drug candidates based on mechanisms of action that have demonstrated proof-of-concept in human subjects. We prioritize our efforts on disease indications where there is compelling scientific rationale, no approved therapies or where there are unmet medical needs, and where there are large addressable market opportunities, among other factors. Our clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In Medical Dermatology we are developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. CXCL10 has been shown to play a key role in the disease, and neutralization of CXCL10 has been demonstrated to both prevent and reverse depigmentation in animal models. To date, EB06 has demonstrated a favorable safety and tolerability profile. We have received regulatory approval from Health Canada to conduct a Phase 2 proof of concept study of EB06 in patients with moderate-to-severe nonsegmental vitiligo and we are in discussions with the U.S. Food and Drug Administration (FDA) for the same study. Our medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. This asset is at the partnering stage.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our most advanced Respiratory drug candidate is EB05 (paridiprubart). Paridiprubart represents a new class of emerging therapies called Host-Directed Therapeutics (HDTs) that are designed to modulate the body&#8217;s own immune response when confronted with infectious diseases or even chemical agents. EB05 is currently being evaluated in a U.S. government-funded platform study investigating three novel threat-agnostic HDTs in hospitalized adult patients with Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. Certain development expenses, including manufacturing scale-up, for our EB05 program are also eligible for reimbursement from the Government of Canada under a 2023 grant and funding award. In addition to EB05, we are also preparing an investigational new drug application (IND) in the United States&#160;to conduct a future Phase 2 study for EB07 (paridiprubart) in patients with pulmonary fibrosis.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">43</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Operating and Financial Review and Prospects</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and include the accounts of the Company and our wholly owned subsidiaries, Edesa Biotech Research, Inc. and Edesa Biotech USA, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our operations have been funded primarily through issuances of common shares, exercises of common share purchase warrants, convertible preferred shares, convertible loans, government grants and tax incentives. We have devoted substantially all of our efforts to research and development, including clinical trials, and have not completed the development of any of our drug candidates. We expect that our cash and cash equivalents, at September 30, 2024, together with the proceeds from the sale of Preferred Shares to&#160;PN MPC, net proceeds from the HCW ATM and reimbursements of eligible R&amp;D expenses under the 2023 SIF Agreement will not be sufficient to fund our operating expenses for one year after the date of this filing and therefore management has concluded that substantial doubt exists about our ability to continue as a going concern.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We will need to raise additional capital and/or reduce our operating expenses to support the Company&#8217;s operations for at least the next 12 months.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As a clinical-stage biopharmaceutical company, we expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue the development of, and seek marketing approvals for our product candidates, prepare for and begin the commercialization of any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company in the United States and Canada. To fund operations, we may seek additional financing through the sale of equity, government grants, debt financings or other capital sources, including potential future licensing, collaboration or similar arrangements with third parties or other strategic transactions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Results of Operations</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Fiscal Year Ended September 30, 2024 Compared to the Fiscal Year Ended September 30, 2023</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our total operating expenses decreased by $2.2 million to $7.0 million for the year ended September 30, 2024 compared to $9.2 million for the prior year:</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Research and development (R&amp;D) expenses decreased by $1.9 million to $2.9 million for the year ended September 30, 2024 compared to $4.8 million for the prior year primarily due to decreased external research expenses related to the company&#8217;s completed dermatitis study and a reduction in labor costs and noncash share-based compensation, which were partially offset by an increase in expenses related to manufacturing of paridiprubart. Our R&amp;D expenses consist primarily of employee-related expenses, including salaries, benefits, taxes, travel, and share-based compensation expense for personnel in R&amp;D functions; expenses related to process development and production of product candidates paid to contract manufacturing organizations, including the cost of acquiring, developing, and manufacturing research material; costs associated with clinical activities, including expenses for contract research organizations; and clinical trials and activities related to regulatory filings for our product candidates, including regulatory consultants.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">General and administrative (G&amp;A) expenses decreased by $0.3 million to $4.1 million for the year ended September 30, 2024 compared to $4.4 million for the prior year primarily due to a decrease in noncash share-based compensation, which was partially offset by an increase in salaries and related costs. Our G&amp;A expenses consist primarily of salaries and related costs for our employees in administrative, executive and finance functions. G&amp;A expenses also include professional fees for legal, accounting, audit, tax and consulting services, insurance, office, and travel expenses.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Total other income was unchanged at $0.8 million for the years ended September 30, 2024 and September 30, 2023 and was composed of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">44</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Grant income increased by $0.1 million to $0.7 million for the year ended September 30, 2024 compared to $0.6 million for the year ended September 30, 2023, reflecting an increase in grant income associated with reimbursable expenses under the 2023 SIF Agreement.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Interest income decreased by $0.1 million to $0.2 million for the year ended September 30, 2024 compared to $0.3 million for the prior year primarily due to lower cash balances.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Miscellaneous other income was $15,000 for the year ended September 30, 2024 related to loan forgiveness on the CEBA loan that was repaid in the year.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Foreign exchange loss was unchanged at $21,000 for both the year ended September 30, 2024 and September 30, 2023.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">For the year ended September 30, 2024, our net loss was $6.2 million, or $1.93 per common share, compared to a net loss of $8.4 million, or $2.93 per common share, for the year ended September 30, 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Capital Expenditures</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our capital expenditures primarily consist of computer and office equipment. There were no significant capital expenditures for the years ended September 30, 2024 and 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Liquidity and Capital Resources</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As a clinical-stage company we have not generated significant revenue, and we expect to incur operating losses as we continue our efforts to acquire, develop, seek regulatory approval for and commercialize product candidates and execute on our strategic initiatives. Our operations have historically been funded through issuances of common shares, exercises of common share purchase warrants, convertible preferred shares, convertible loans, government grants and tax incentives.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our primary use of cash is to fund our operating expenses, which consist of R&amp;D and G&amp;A expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in accounts payable and accrued expenses. Net cash used in operating activities was $4.9 million and $6.6&#160;million for the years ended September 30, 2024 and 2023, respectively. We incurred net losses of $6.2 million and $8.4 million for those same years.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In October 2024, we entered into an At The Market Offering Agreement with H.C. Wainwright &amp; Co., LLC as a sales agent (HCW ATM) pursuant to which we may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $3.87 million in gross proceeds. Subsequent to September 30, 2024, we sold a total of 220,269 common shares pursuant to the agreement for net proceeds of $0.6 million after deducting sales agent commissions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2024, we entered into a Securities Purchase Agreement with Pardeep Nijhawan Medicine Professional Corporation (PN MPC), an entity controlled by Pardeep Nijhawan, the Company&#8217;s Chief Executive Officer, Secretary and member of the board of directors of the Company, pursuant to which the Company agreed to issue and sell to PN MPC in a private placement, up to $5 million of shares (Preferred Shares) of the Company&#8217;s newly designated Series A-1 Convertible Preferred Shares, stated value $10,000 per share, each of which is initially convertible into approximately 2,903 common shares (Conversion Shares), at a conversion price of $3.445 per Conversion Share, and warrants (Warrants) to purchase common shares (Warrant Shares) at an exercise price of $3.445 per Warrant Share. The Preferred Shares and the Warrants were being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of common shares equal to 75% of the underlying Conversion Shares at a combined purchase price of $10,272.13 per Preferred Share and related Warrants. Under the Purchase Agreement, PN MPC has purchased 150 Preferred Shares initially convertible into an aggregate of 435,414 Conversion Shares and Warrants to purchase up to an aggregate of 326,560 Warrant Shares for an aggregate purchase price of $1,540,819. The Warrants expire five years from the issuance date. We have the right to require PN MPC to purchase additional Preferred Shares and Warrants (up to an aggregate investment of $5.0 million); provided however, no more than an aggregate of $2.0 million of Preferred Shares and Warrants may be issued and sold pursuant to the Purchase Agreement without shareholder approval in accordance with applicable Canadian securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2023, we entered into the 2023 SIF Agreement with the Canadian Government&#8217;s SIF. Under the 2023 SIF Agreement, the Government of Canada committed up to C$23 million in partially repayable funding. Of the C$23 million committed by SIF, up to C$5.8 million is not repayable by us. The remaining C$17.2 million is conditionally repayable starting in 2029 only if and when we earn gross revenue. In February 2021, we entered into the 2021 SIF Agreement, pursuant to which we were eligible to receive cash reimbursements up to C$14.1 million in the aggregate for certain R&amp;D expenses related to our EB05 clinical development program. All potential funding available under the 2021 SIF Agreement has been received. For the years ended September 30, 2024 and 2023, we recorded grant income of $0.7 million and $0.6 million respectively related to the 2023 SIF Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2023, we entered into $10.0 million revolving credit agreement with PN MPC, an entity controlled by Pardeep Nijhawan, our Chief Executive Officer and Secretary and member of our board of directors (Credit Agreement), providing an unsecured revolving credit facility, with a credit limit of $3.5 million (Credit Limit) which was available immediately. The line of credit bore interest at the Canadian Imperial Bank of Commerce US Base-Interest Rate plus 3% per annum and has a maturity date of March 31, 2026, unless terminated earlier by either party with 90 days&#8217; notice. Advances under the line of credit were tied to a borrowing base (Borrowing Base) consisting of eligible grant receivables from SIF, future potential license fee receivables and any other accounts receivable. At no time could the aggregate principal amount of all advances outstanding have exceeded the lesser of (i) the Credit Limit and (ii) an amount equal to 85% of the Borrowing Base. The Credit Agreement was terminated in October 2024. Prior to the termination of the Credit Agreement, we had not borrowed any funds thereunder. We incurred no termination penalties in connection with the termination of the Credit Agreement.&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">45</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In August 2022, we filed a $150.0 million shelf registration statement. In March 2023, we entered into an equity distribution agreement with Canaccord, as sales agent, pursuant to which we may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $20 million in gross proceeds, subject to certain offering limitations that currently allow us to offer and sell common shares having an aggregate gross sales price of up to $8.4 million (Canaccord ATM). For the fiscal year ended September 30, 2024, we sold a total of 171,916 common shares pursuant to the agreement for net proceeds of $0.6 million after deducting commissions and costs of $0.1 million. The Canaccord ATM was terminated in October 2024.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In November 2022, we completed a private placement of units consisting of 384,475 common shares, 12-month warrants to purchase up to an aggregate of 192,248 common shares and 3-year warrants to purchase up to an aggregate of 192,248 common shares. The gross proceeds from this offering were approximately $3.0 million, before offering expenses.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">At September 30, 2024, we had an accumulated deficit of $58.6 million and negative working capital of $0.2 million, including $1.0 million in cash and cash equivalents. Subsequent to the September 30, 2024, we received proceeds of $1.5 million from the sale of Preferred Shares to the PN MPC. We expect that our cash and cash equivalents at September 30, 2024, together with the proceeds from the sale of Preferred Shares to the PN MPC, net proceeds from the HCW ATM and reimbursements of eligible R&amp;D expenses under the 2023 SIF Agreement will not be sufficient to fund our operating expenses for one year after the date of this filing and therefore management has concluded that substantial doubt exists about our ability to continue as a going concern. Management has flexibility to adjust this timeline by making changes to planned expenditures related to, among other factors, the size and timing of clinical trial expenditures and manufacturing campaigns, staffing levels, and the acquisition or in-licensing of new product candidates. To help fund our operations and meet our obligations in the future, we plan to seek additional financing through the sale of equity, government grants, debt financings or other capital sources, including potential future licensing, collaboration or similar arrangements with third parties or other strategic transactions. If we raise additional funds by issuing equity securities, our shareholders will experience dilution. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt financing or additional equity that we raise may contain terms, such as liquidation and other preferences that are not favorable to us or our existing shareholders. If we raise additional funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development of our product candidates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We expect to continue to incur substantial additional operating losses for at least the next several years as we continue to develop our product candidates and seek marketing approval and, subject to obtaining such approval, the eventual commercialization of our product candidates. If we obtain marketing approval for our product candidates, we will incur significant sales, marketing and outsourced manufacturing expenses. In addition, we expect to incur additional expenses to add operational, financial and information systems and personnel, including personnel to support our planned product commercialization efforts. We also expect to incur significant costs to comply with corporate governance, internal controls and similar requirements applicable to us as a public company. To continue to grow our business over the longer term, we plan to commit substantial resources to research and development, clinical trials of our product candidates, and other operations and potential product acquisitions and in licensing. We have evaluated and expect to continue to evaluate a wide array of strategic transactions as part of our plan to acquire or in license and develop additional products and product candidates to augment our internal development pipeline. Strategic transaction opportunities that we may pursue could materially affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both. In addition, we may pursue development, acquisition or in licensing of approved or development products in new or existing therapeutic areas or continue the expansion of our existing operations. Accordingly, we expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations, or for general corporate purposes. Strategic transactions may require us to raise additional capital through one or more public or private debt or equity financings or could be structured as a collaboration or partnering arrangement. We have no arrangements, agreements, or understandings in place at the present time to enter into any acquisition, in licensing or similar strategic business transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">46</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Cash Flows</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Net cash used in operating activities</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Net cash used in operating activities was $4.9 million for the year ended September 30, 2024 compared to $6.6&#160;million for the year ended September 30, 2023 primarily due to a decrease in R&amp;D and G&amp;A expenses.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Net cash used in investing activities</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">There was no cash used in investing activities for the years ended September 30, 2024 and September 30, 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Net cash provided by financing activities</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Net cash provided by financing activities was $0.6 million for the year ended September 30, 2024 as compared to $4.8&#160;million for the year ended September 30, 2023. In the current year, we received proceeds of $0.7 million from the Canaccord ATM, partially offset by issuance costs of $0.1 million and the repayment of debt of $29,000. In the comparative period, we received proceeds of $3.0 million from a private placement completed in November 2022, $1.3 million from the Canaccord ATM and $0.8 million from the exercise of warrants, partially offset by issuance costs of $0.3 million.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Research and Development</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our primary business is the development of innovative therapeutics for inflammatory and immune-related diseases with clear unmet medical needs. We focus our resources on R&amp;D activities, including the conduct of clinical studies and product development, and expense such costs as they are incurred.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">R&amp;D expenses, which have historically varied based on the level of activity in our clinical programs, are significantly influenced by study initiation expenses and patient recruitment rates, and as a result are expected to continue to fluctuate, sometimes substantially. Our R&amp;D expenses were $2.9 million and $4.8 million for the years ended September 30, 2024 and 2023, respectively. The decrease was due primarily to lower external research expenses related to our ongoing clinical studies.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Foreign Exchange Risk</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our exposure to foreign exchange risk is primarily related to fluctuations between the Canadian dollar and the U.S. dollar. We have balances in Canadian dollars which are subject to foreign currency fluctuations relating to the impact of translating to U.S. dollars for financial statements presentation. We also periodically exchange U.S. dollars for Canadian dollars since most operating expenses are incurred in Canadian dollars. The fluctuation of the U.S. dollar in relation to the Canadian dollar will have an impact upon our profitability and may also affect the value of our assets and the amount of shareholders&#8217; equity. We have not entered into any agreements or purchased any instruments to hedge possible currency risks. At September 30, 2024, we had assets denominated in Canadian dollars of approximately C$0.04 million and the U.S. dollar exchange rate as at this date was equal to 1.3517 Canadian dollars. Based on the exposure at September 30, 2024, a 10% annual change in the Canadian/U.S. exchange rate would have a nominal impact on our net loss and other comprehensive loss.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Concentration of Credit Risk</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We are potentially subject to financial instrument concentration of credit risk through our cash and cash equivalents, and accounts and other receivable. We place our cash and cash equivalents in money market mutual funds of U.S. government securities or financial institutions believed to be credit worthy and perform periodic evaluations of their relative credit standing.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">47</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Accounts and other receivable include Harmonized Sales Tax (HST) refunds receivable from the Canada Revenue Agency and reimbursements receivable from the Canadian government&#8217;s SIF. We assess the collectability of our accounts receivable through a review of our current aging and payment terms, as well as an analysis of our historical collection rate, general economic conditions and credit status of the government agencies. As of September 30, 2024 and 2023, all outstanding accounts and other receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Significant Accounting Policies and Estimates</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our consolidated financial statements, which are indexed under Item 15 of this Annual Report on Form 10-K, have been prepared in accordance with accounting principles generally accepted in the United States, which require that the management make certain assumptions and estimates and, in connection therewith, adopt certain accounting policies. Our significant accounting policies are set forth in Note 3 in the Notes to Consolidated Financial Statements. Of those policies, we believe that the policies discussed below may involve a higher degree of judgment or may otherwise be more relevant to our financial condition and results of operations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Accounts and other receivables</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Accounts and other receivables include HST refunds receivable and reimbursements receivable from the Canadian government&#8217;s SIF. As of September 30, 2024, all outstanding accounts, grants and HST refunds receivable&#160;were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Intangible assets</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Intangible assets represent the exclusive world-wide rights to know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights, acquired by entering into the NovImmune License Agreement. Unless earlier terminated, the term of the NovImmune License Agreement will remain in effect for 25 years from the date of first commercial sale of licensed products containing the Constructs. Subsequently, the NovImmune License Agreement will automatically renew for 5-year periods unless either party terminates the agreement in accordance with its terms. We recognize intangible assets at their historical cost, amortized on a straight-line basis over their expected useful lives, which is 25 years, and subject to impairment review at the end of each reporting period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Right-of-Use assets</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We recognize operating lease right-of-use (ROU) assets and operating lease liabilities on the balance sheet for operating leases with terms longer than 12 months. We follow the ongoing practical expedient not to recognize operating lease right-of-use assets and operating lease liabilities for short-term leases. The ROU assets are initially measured at cost and amortized using the straight-line method through the end of the lease term. The lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using our incremental borrowing rate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Share-based compensation</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We have equity incentive plans under which various types of equity-based awards including share options, restricted shares and restricted share unit awards may be granted to employees, non-employee directors and non-employee consultants and warrants that may be granted as compensation to non-employees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">We measure the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We recognize compensation expense for all share-based awards based on the estimated grant-date fair values. For restricted share unit awards to employees, the fair value is based on the 5-day volume weighted average price (VWAP) of our common shares up to the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The fair value of share options is determined using the Black-Scholes option pricing model. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention of paying cash dividends. We elected an accounting policy to record forfeitures as they occur. See Note 8 for a discussion of the assumptions used by us in determining the grant date fair value of options granted under the Black-Scholes option pricing model, as well as a summary of the share option activity under our share-based compensation plan for all years presented.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The provisions of our share-based compensation plans do not require us to settle any options or restricted share units by transferring cash or other assets, and therefore we classify the awards as equity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">48</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Translation of foreign currency transactions</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our reporting currency is the U.S. dollar. The financial statements of our wholly owned Canadian subsidiary is measured using the Canadian dollar as the functional currency. Assets and liabilities of the Canadian operation have been translated at year-end exchange rates and related revenue and expenses have been translated at average exchange rates for the year. Accumulated gains and losses resulting from the translation of the financial statements of the Canadian operation are included as part of accumulated other comprehensive loss, a separate component of shareholders' equity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">For other transactions denominated in currencies other than our functional currency, the monetary assets and liabilities are translated at the year-end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. Non-monetary balance sheet and related income statement accounts are remeasured into U.S. dollar using historical exchange rates. All of the exchange gains or losses resulting from these other transactions are recognized in the statements of operations and comprehensive loss.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Recent Accounting Pronouncements</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Recent accounting pronouncements are contained in Note 3 to the financial statements, which are indexed under Item 15 of this Annual Report on Form 10-K.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I7A" title="I7A" href="#"></a>Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We are a smaller reporting company and are not required to provide disclosure under this item.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I8" title="I8" href="#"></a>Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The financial statements and related financial information required to be filed hereunder are indexed under Item 15 of this Annual Report on Form 10-K and are incorporated herein by reference.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I9" title="I9" href="#"></a>Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Not applicable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I9A" title="I9A" href="#"></a>Item 9A. CONTROLS AND PROCEDURES.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Disclosure Controls and Procedures</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our management is responsible for establishing and maintaining disclosure controls and procedures to provide reasonable assurance that material information related to our Company, including our consolidated subsidiaries, is made known to senior management, including our Chief Executive Officer and the Chief Financial Officer, by others within those entities on a timely basis so that appropriate decisions can be made regarding public disclosure.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and our Principal Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2024. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Our Chief Executive Officer and Chief Financial Officer concluded that the disclosure controls and procedures as of September 30, 2024, were effective.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Management</b>&#8217;<b>s Annual Report on Internal Control over Financial Reporting</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our management is responsible for designing, establishing and maintaining a system of internal controls over financial reporting (as defined in Exchange Act Rule 13a-15(f)) to provide reasonable assurance that the financial information prepared by us for external purposes is reliable and has been recorded, processed and reported in an accurate and timely manner in accordance with accounting principles generally accepted in the United States. Our board of directors is responsible for ensuring that management fulfills its responsibilities. The audit committee of our board of directors fulfills its role of ensuring the integrity of the reported information through its review of the interim and annual financial statements. Management reviewed the results of their assessment with our audit committee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">49</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Management has used the criteria issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in &#8220;Internal Control - Integrated Framework (2013)&#8221; to evaluate the effectiveness of our internal control over financial reporting. Management has assessed the effectiveness of our internal control over financial reporting and concluded that such internal control over financial reporting was effective as of September 30, 2024.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Attestation Report of Our Registered Public Accounting Firm</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Because we are a non-accelerated filer, this Annual Report does not include an attestation report from our independent registered public accounting firm. We are not required to provide an attestation report on our internal control over financial reporting until such time as we are an accelerated filer or large accelerated filer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Changes in Internal Control over Financial Reporting</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">There were no changes in our internal control over financial reporting that occurred during the year ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="ecd:MtrlTermsOfTrdArrTextBlock" id="c30" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I9B" title="I9B" href="#"></a>Item 9B. OTHER INFORMATION.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><span style="-sec-ix-hidden:c32"><span style="-sec-ix-hidden:c33"><span style="-sec-ix-hidden:c34"><span style="-sec-ix-hidden:c35">None</span></span></span></span>&#160;of the Company's directors and officers adopted, modified, or terminated a Rule 10b-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended September 30, 2024 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<div>&#160;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I9C" title="I9C" href="#"></a>Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Not applicable.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">50</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b><a id="P3" title="P3" href="#"></a>PART III</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><a id="I10" title="I10" href="#"></a>Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Directors</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Our directors and their ages as of the date of this filing are set forth below. Each director is elected annually to serve until the next annual meeting of shareholders, or until his or her successor is duly elected.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b>&#160;</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Age</b>&#160;</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Position(s) Held</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Director Since</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Joan Chypyha (1) (2)</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">58</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">May 23, 2023</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sean MacDonald&#160;</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">48</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">June 7, 2019</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Patrick Marshall (1) (3)</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">53</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">May 23, 2023</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pardeep Nijhawan, MD</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">54</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, Chief Executive Officer and Corporate Secretary</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">June 7, 2019</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Frank Oakes (2) (3)</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">74</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">April 9, 2010</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Charles Olson, DSc (2) (3)</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">67</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">May 23, 2023</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Carlo Sistilli, CPA, CMA (1)</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">68</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board Chair</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">June 7, 2019</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(1) Member of Audit Committee.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(2) Member of Compensation Committee.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">(3) Member of Nominating and Corporate Governance Committee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">There are no family relationships between any of our directors or executive officers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Biographies and Qualifications&#160;</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The biographies of our directors and certain information regarding each director&#8217;s experience, attributes, skills and/or qualifications that led to the conclusion that the director should be serving as a director of our Company are as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Joan Chypyha</b> has more than 30 years of experience in the pharmaceutical industry including executive and operational positions in business development, sales and marketing, and general management. She is the President of Alto Pharmaceuticals, Ltd., a specialty pharmaceutical company focused on dermatology, women's health and elder care, which she founded in 2009. Alto is also a major shareholder in Pepper and Pink Inc., a manufacturer of brand and private label personal care products for major retailers in Canada. From July 2015 to June 2017, she was the President of Cipher Pharmaceuticals, Inc., having previously served as Vice President of Marketing and Sales. Ms. Chypyha&#8217;s professional career also includes executive positions at Rhei Pharmaceuticals Ltd. and Barrier Therapeutics Canada, Inc., following sixteen years at Hoffman-La Roche, where she held progressively senior positions. Since February 2018, she has served as a director and a member of the audit committee of Ovation Science Inc., a research and development company that develops topical and transdermal consumer products. She is a past advisory board member of Up Cannabis Inc (from August 2017 to January 2019). Ms. Chypyha currently served as the President of the Canadian Dermatology Industry Association, from 2015 to 2023, and is a Co-Chair of DiTiDE (Dermatology Industry Taskforce on Inclusiveness, Diversity &amp; Equity), a group she co-founded in 2020. She has also previously served on boards of other non-profits and business organizations, including the Canadian Healthcare Licensing Association. Ms. Chypyha earned her Bachelor&#8217;s Degree from the University of Toronto and a Master&#8217;s Degree in Business Administration from Queen's University. Ms. Chypyha&#8217;s qualifications to serve on our Board include her extensive operational experience in founding, managing and building companies, previous board experience and her extensive experience in the dermatology industry.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Sean MacDonald </b>has been a member of our Board since June 2019, and served as Chairman of the Board from June 2019 until May 2023. He previously served on the board of our principal operating subsidiary, Edesa Biotech Research, from September 2017 to June 2019. In his career, he has led and closed multiple licensing transactions, financings, acquisitions and divestments, and led corporate strategy for several pharmaceutical and biotechnology companies. Since April 2024, Mr. MacDonald has served as the Chief Executive Officer of Domain Therapeutics Inc., a biotechnology company and from January to March 2024, Mr. MacDonald served as their Chief Business Officer. From April 2022 to February 2024, he served as an advisor to investors and biotechnology companies, including Raya Therapeutic Inc. From August 2021 to April 2022, he was the Chief Business Officer of iOnctura SA, a Swiss clinical-stage oncology company. From April 2019 to August 2021, he was the Head of Business Development for Cosmo Pharmaceuticals NV, a European gastroenterology focused pharmaceutical company; and from October 2018 to August 2021 he was the chief executive of Corbin Therapeutics, a Montreal-based biotech company focused on treating neuroinflammation. Mr. MacDonald held various operational and executive leadership roles from October 2012 to October 2018 at Pharmascience Inc., one of Canada's largest pharmaceutical companies, including Vice President of Business Development and Corporate Development. He received his BSc in Molecular Biology and MBA from the University of Ottawa. Mr. MacDonald's qualifications to serve on our Board include his extensive operational experience and background in the pharmaceutical/biotechnology industry.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">51</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Patrick Marshall </b>has more than 20 years of experience raising capital, building and launching new products and services, developing strategy and completing mergers and acquisitions to support growth in private and public companies. Since 2010 he has been a managing director at VRG Capital, having previously held various executive roles in several of the firm&#8217;s portfolio companies since 2000, including Wheels Group Inc., a North American third-party logistics company acquired by Radiant Logistics, Inc. in 2015, and Thomas International Ltd., a global provider of psychometric and aptitude tests acquired by Palamon Capital Partners in 2018. Mr. Marshall is a cofounder and current board member of Crawford Bowman Ltd, a privately held Canadian company focused on over-the-counter and nutritional supplements markets. He is an advisor to Jouleia Inc, a start-up focused on accelerating the transition to low-carbon homes. He is a current board member and past President (January 2016 -December 2023) of Adrem Brands Inc., a privately held Canadian company focused on the over-the-counter and nutritional supplements markets. Prior to 2000, he held fundraising, business development and strategy roles for various international enterprises and non-governmental organizations. Mr. Marshall is a cofounder, advisor and former board member of Together Project (2016-2023) and a trustee of Lakefield College School (since 2012). He received his Bachelor of Arts in Sociology from Queen's University and Master of Business Administration from the University of Exeter. Mr. Marshall&#8217;s qualifications to serve on our Board include his experience managing and building companies, strategic transactions, raising capital and prior board experience.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Pardeep Nijhawan, MD, FRCPC, AGAF </b>has served as our Chief Executive Officer, Corporate Secretary and a member of our Board since June 2019, having previously founded and led our principal operating subsidiary, Edesa Biotech Research, since January 2015. Dr. Nijhawan is a seasoned pharmaceutical entrepreneur with more than 20 years of experience in cross- functional leadership roles in finance, marketing, corporate strategy and business development. In 2002 Dr. Nijhawan founded Medical Futures Inc., and served as its CEO. He sold Medical Futures to Tribute Pharmaceuticals in 2015. In 2014, he founded Exzell Pharma, a specialty Canadian-based pharmaceutical organization that markets and commercializes approved products. He sold Exzell Pharma to BioLab Pharma in 2022. Dr. Nijhawan also founded Digestive Health Clinic in 2000 and led it to become one of Canada&#8217;s largest provider of private endoscopy services. He continues to serve on the Board of Digestive Health Clinic. From January 2021 until June 2024, he served on the advisory board of Private Debt Partners, a Canadian alternative asset management firm. Dr. Nijhawan received his MD from the University of Ottawa and completed his internship at Yale University, and his internal medicine residency and fellowship at the Mayo Clinic. Dr. Nijhawan&#8217;s qualifications to serve on our Board include his extensive executive leadership and experience in the life sciences industry and his knowledge of our business as its chief executive.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Frank Oakes </b>has more than 40 years of executive leadership experience. He has been a member of our Board since April 2010 and served as the Chairman of the Board until June 2019. From 1999 to 2019, he also served as the President and Chief Executive Officer of our legacy operating subsidiary, which he founded. Prior to founding Stellar Biotechnologies, Inc., he was the Chief Executive Officer of The Abalone Farm, Inc., where he led the company through the research and development, capitalization, and commercialization phases of development to become the largest abalone producer in the United States at the time. Mr. Oakes has consulted and lectured around the world. He received his BS degree from California State Polytechnic University, San Luis Obispo and is a graduate of the Los Angeles Regional Technology Alliance University&#8217;s management program. Mr. Oakes qualifications to serve on our Board include his extensive operational experience building companies and management teams and leading a U.S. and Canadian publicly listed life science company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Charles Olson, DSc </b>is a CMC consultant with more than 40 years of biotech experience. Since April 2024 he has been the Senior Vice President of CMC at NervGen, responsible for the process development and manufacture of their peptide product in clinical development for nerve regeneration as a result of spinal cord injury. From September 2021 to April 2023 he was Chief Operating Officer at Dendreon Corporation, where he was responsible for the commercial manufacturing of Provenge, a commercial cell-based product for prostate cancer, overseeing multiple sites and several hundred employees. From September 2017 to August 2021, he was a senior Vice President of Operations at Applied Molecular Transport. From April 2010 to August 2017, Dr. Olson held various leadership roles at Anthera Pharmaceuticals Inc., including Chief Technology Officer. He has also been a Principal Biotechnology Consultant for Compass Biotechnology LLC since 2006. Dr. Olson previously held senior and executive management positions at NGM Biopharmaceuticals Inc., Coherus BioSciences Inc., Nexbio Inc., Cell Genesys, Inc., Biomarin Pharmaceuticals, Inc, and Onyx Pharmaceuticals, Inc. From December 2016 to June 2019, Dr. Olson served on the Board of Edesa Biotech, Inc. (then operating as Stellar Biotechnologies, Inc.), having previously served on Stellar&#8217;s scientific advisory board. After graduate school, Dr. Olson was a Research Scientist at Kaiser Hospitals, followed by Scientist and Senior Scientist positions at Genentech and Bayer, respectively. He holds a B.A. in biology and chemistry from Westmont College, an M.A. in chemistry from the University of California at Santa Barbara and a D.Sc. in biochemistry. Dr. Olson qualifications to serve on our Board include his extensive scientific, manufacturing operations, process development and senior management and board experience in the biopharmaceutical industry.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">52</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Carlo Sistilli, CPA, CMA </b>has more than 35 years of financial experience and has held a variety of executive positions in accounting and finance during his career. He has been a member of our Board since June 2019, having previously served as a board observer of our principal operating subsidiary, Edesa Biotech Research, since September 2017. Mr. Sistilli has served as the Chief Financial Officer of Arista Homes since March 2003 to present. Prior to Arista, Mr. Sistilli was a founder and served as CFO and a board member of an Internet start-up company in the automotive sector, and played a key role in taking the company public on the Alberta Ventures Exchange. Earlier in his career, Mr. Sistilli was the Controller and a member of the senior management team of a major regional trust company, which Mr. Sistilli helped sell to Manulife Financial. From January 2021 to February 2024, he served on the Board and audit committee of Aleafia Health Inc. In addition to his professional career, Mr. Sistilli is an officer and a member of the Board of Mother of Mercy Centre. Mr. Sistilli holds a Bachelor of Arts from York University, with a major in economics, Certified Management Accountant Designation and a Chartered Professional Accountant Designation. Mr. Sistilli&#8217;s qualifications to serve on our Board include his knowledge of Edesa&#8217;s business and his background in accounting and finance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Executive Officers</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Set forth below is certain information with respect to the names, ages, and positions of our executive officers as of the date of this filing. Biographical information pertaining to Dr. Nijhawan, who is a director and an executive officer, may be found in the above section entitled &#8220;Directors.&#8221; The executive officers serve at the pleasure of our Board of Directors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Age</b>&#160;</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Position(s) Held</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Date of Appointment</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pardeep Nijhawan, MD</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">54</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, Chief Executive Officer and Corporate Secretary</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">June 7, 2019</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stephen Lemieux, CPA</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">49</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">July 15, 2023</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Michael Brooks, PhD</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">46</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 44%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 16%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">June 7, 2019</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Stephen Lemieux, CPA</b> was appointed Chief Financial Officer in July 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers &amp; acquisitions. Prior to joining the Company, Mr. Lemieux held senior financial leadership positions at healthcare and biopharmaceutical biotechnology companies, where he guided financial strategies, optimized capital structures and supported significant corporate transactions and sales growth. From July 2021 until June 2023, Mr. Lemieux served as CFO of Titan Medical Inc., and from April 2019 to July 2021 as CFO and Secretary of NeuPath Health. Previously, he was the CFO and Secretary of Cipher Pharmaceuticals (TSX: CPH) from September 2016 to March 2019 and during his tenure served as Interim-CEO from November 2016 to April 2017. Prior to Cipher, he was CFO at Nuvo Pharmaceuticals and Crescita Therapeutics. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management &amp; Professional Accounting degree from the University of Toronto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Michael Brooks, PhD </b>was appointed President of Edesa in June 2019, having served as Vice President of Corporate Development and Strategy for our principal operating subsidiary, Edesa Biotech Research, since January 2015. Prior to joining Edesa, Dr. Brooks held positions of increasing responsibility at Cipher Pharmaceuticals Inc from 2010 to 2015 and served most recently as the company&#8217;s Director of Business Development. Prior to joining Cipher, Dr. Brooks was a Postdoctoral fellow at the University of Toronto. Dr. Brooks holds a Hons B.Sc. degree in Microbiology and a PhD in Molecular Genetics from the University of Toronto. Dr. Brooks received his MBA degree from the Rotman School of Management where he was a Canadian Institute for Health Research (CIHR) Science-to-Business Scholar.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">53</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Code of Ethics</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We have adopted a Code of Ethics and Business Conduct that applies to all of our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of our Code of Ethics and Business Conduct is available on the Investor Relations section of our website at edesabiotech.com/investors/governance, in the Corporate Governance section, under the Governance Documents section. We intend to satisfy the SEC&#8217;s disclosure requirements regarding amendments to, or waivers of, our Code of Ethics and Business Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions by posting such information on our website identified above. Copies of our Code of Ethics and Business Conduct may be obtained, free of charge, by writing to our Corporate Secretary, Edesa Biotech, Inc., 100 Spy Court, Markham, ON Canada L3R 5H6.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Insider Trading <span style="-sec-ix-hidden:c36">Policy</span></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company has an insider trading policy governing the purchase, sale and other dispositions of the Company&#8217;s securities that applies to all Company personnel, including directors, officers,&#160;and employees. The Company believes that its insider trading policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company. A copy of the Company&#8217;s insider trading policy is filed as Exhibit 19.1 to this Form 10-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b style="font-size: 10pt; text-align: justify;">Information about our Board Committees</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our Board of Directors has appointed an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee. The Board of Directors has determined that each director who serves on these committees is &#8220;independent,&#8221; as that term is defined by the listing rules of Nasdaq and rules of the SEC. The Board of Directors has adopted written charters for its Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. Copies of these charters are available on our website at www.edesabiotech.com/investors/governance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Audit Committee</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our Audit Committee is composed of Joan Chypyha, Patrick Marshall and Carlo Sistilli (chair). The purpose of the Audit Committee is to oversee our accounting and financial reporting processes and the audits of our financial statements. In that regard, the Audit Committee assists the Board in monitoring: (a) the integrity of our financial statements; (b) our independent auditor&#8217;s qualifications, independence, and performance; (c) the performance of our system of internal controls, financial reporting, and disclosure controls; and (d) our compliance with legal and regulatory requirements. To fulfill this obligation and perform its duties, the Audit Committee maintains effective working relationships with the Board, management, and our independent auditor.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Carlo Sistilli is the Chair of our Audit Committee and has extensive financial experience. He holds a Bachelor of Arts from York University, with a major in economics, Certified Management Accountant Designation and a Chartered Professional Accountant Designation. He has held a variety of executive positions in accounting and finance during the past 35 years. The Board has determined that Mr. Sistilli is an &#8220;audit committee financial expert&#8221; as defined in Item 407(d)(5)(ii) of Regulation S-K.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Compensation Committee</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our Compensation Committee is composed of Joan Chypyha (chair), Frank Oakes and Charles Olson. The purpose of the Compensation Committee is to assist the Board&#8217;s oversight relating to the compensation of our Chief Executive Officer and our other Named Executive Officers. It has responsibility for evaluating and recommending to the independent members of the Board for approval, our compensation plans, policies and programs as such plans, policies and programs affect executive officers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Nominating and Corporate Governance Committee</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our Nominating and Corporate Governance Committee is composed of Patrick Marshall, Frank Oakes (chair) and Charles Olson. The purpose of the Nominating and Corporate Governance Committee is to identify individuals qualified to become Board members; recommend to the Board individuals to serve as directors; advise the Board with respect to Board composition, procedures and committees; lead the Board in its annual review of the Board and management&#8217;s performance; develop, recommend to the Board and annually review a set of corporate governance principles applicable to the Company; and oversee any related matters required by the federal securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Delinquent Section 16(a) Reports</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Section 16(a) of the Exchange Act requires our directors, executive officers and persons who beneficially own more than 10% of our outstanding common shares to file reports with the SEC regarding their share ownership and changes in their ownership of our common shares. Based on our records and representations from our directors and executive officers, we believe that all Section 16(a) filing requirements applicable to our directors and executive officers were complied with during the fiscal year ended September 30, 2024, except for the following: due to administrative error, Pardeep Nijhawan filed a late Form 4 on January 12, 2024 to report&#160;a grant of restricted share units, which vested in full upon grant, pursuant to the 2019 Plan (as defined below) on January 8, 2024.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I11" title="I11" href="#"></a>Item 11. EXECUTIVE COMPENSATION.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Executive Compensation</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Our named executive officers for the year ended September 30, 2024 were Pardeep Nijhawan, MD, Director, Chief Executive Officer and Corporate Secretary; Stephen Lemieux, CPA, Chief Financial Officer; and Michael Brooks, PhD, President.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">54</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Summary Compensation Table</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The following table sets forth information regarding the compensation awarded to, earned by or paid to the named executive officers for the years ended September 30, 2024 and September 30, 2023.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 32%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Name and Principal Position</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fiscal Year</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Salary ($)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Bonus ($)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stock Awards ($) (1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options Awards ($) (1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>All Other Compensation ($)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total ($)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 32%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pardeep Nijhawan, MD</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">357,696</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">72,434</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,598</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(4)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">464,728</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 32%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Director, Chief Executive Officer and Corporate Secretary</i></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">341,391</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">99,340</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(3)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">74,229</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,601</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(4)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">549,561</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 32%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 32%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stephen Lemieux, CPA</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">330,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,097</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(6)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">368,097</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 32%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Chief Financial Officer</i></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">82,500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,922</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(5)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,396</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,126</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(6)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">155,944</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 32%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 32%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Michael Brooks, PhD</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">335,340</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,906</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,741</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(8)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">428,987</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 32%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>President</i></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">320,054</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">93,160</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(7)</sup>&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">49,488</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">26,060</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(8)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">488,762</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The amounts shown in these columns represent the aggregate grant date fair value of the restricted share units and share option awards computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification 718, not the actual amounts paid to or realized by the named executive officers during the covered fiscal year. The assumptions used in determining grant date fair value of these awards are set forth in Note 8 to our audited consolidated financial statements for the year ended September 30, 2024 included in this Annual Report.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Includes 30,159 restricted share units with an aggregate grant date fair value of $144,454 issued as partial payment of salary.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(3)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Includes 14,186 restricted share units with an aggregate grant date fair value of $79,440 issued as partial payment of the bonus with the balance paid in cash.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(4)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Represents (i) $32,412 in car allowance and (ii) $2,186 in health insurance in 2024. Represents (i) $32,415 in car allowance and (ii) $2,186 in health insurance in 2023. All compensation to Dr. Nijhawan was paid in Canadian dollars and was converted from US dollars using the average foreign exchange rate for each bi-weekly pay period of the year from oanada.com.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(5)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Represents the aggregate grant date fair value of 2,486 restricted share units issued as partial payment on consulting invoices for services prior to Mr. Lemieux&#8217;s appointment as Chief Financial Officer.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(6)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Represents $24,000 in car allowance in 2024. Represents (i) $5,000 in car allowance and (ii) $8,126 in consulting fees for services prior to Mr. Lemieux&#8217;s appointment as Chief Financial Officer in 2023. All compensation to Mr. Lemieux was paid in Canadian dollars and was converted from US dollars using the average foreign exchange rate for the year from oanda.com.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(7)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Includes 13,315 restricted share units with an aggregate grant date fair value of $74,560 as partial payment of the bonus with the balance paid in cash.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(8)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Represents (i) $24,000 in car allowance and (ii) $1,741 in health insurance in 2024. Represents (i) $24,000 in car allowance and (ii) $2,060 in health insurance in 2023. All compensation to Dr. Brooks was paid in Canadian dollars and was converted from US dollars using the average foreign exchange rate for each bi-weekly pay period of the year from oanda.com.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Narrative Disclosure to Summary Compensation Table Employment Agreements </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Amended and Restated Employment Agreement with Pardeep Nijhawan effective as of August 4, 2023, as amended December 7, 2023</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On August 4, 2023, the Company entered into an amended and restated employment agreement with Pardeep Nijhawan, the Company&#8217;s Chief Executive Officer that superseded prior employment agreements (as amended, the Nijhawan Employment Agreement).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Pursuant to the Nijhawan Employment Agreement, Dr. Nijhawan serves as the Company&#8217;s Chief Executive Officer as well as Chief Executive Officer of each of the Company&#8217;s subsidiaries, Edesa Biotech Research and Edesa Biotech USA, Inc. and a director of Edesa Biotech Research. Dr. Nijhawan&#8217;s employment will continue for an indefinite term until terminated in accordance with the Nijhawan Employment Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Pursuant to the Nijhawan Employment Agreement, Dr. Nijhawan is entitled to a base salary of $357,700 per year effective May 13, 2023 and is eligible to receive a target annual bonus of 40% of his base salary, subject to the achievement of corporate and personal targets as determined by the Company and the Board of Directors. Dr. Nijhawan&#8217;s base salary is subject to annual review by the Board of Directors. Dr. Nijhawan and the Board may agree that Dr. Nijhawan may receive a portion of his base salary in equity-based awards pursuant to the Company&#8217;s Equity Incentive Compensation Plan, in amounts and on the terms determined by the Board. Dr. Nijhawan is also entitled to an automobile allowance of $2,701.50 per month and is eligible to participate in the Company&#8217;s group insured benefits program, as may be in effect from time-to-time for employees generally, and executive employees specifically. Dr. Nijhawan is eligible for equity-based awards pursuant to the Company&#8217;s Equity Incentive Compensation Plan, as determined by the Board of Directors or Compensation Committee, commensurate with Dr. Nijhawan&#8217;s position and any business milestones that may be established by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">55</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">If Dr. Nijhawan&#8217;s employment is terminated for &#8220;Cause&#8221; (as such term is defined in the Nijhawan Employment Agreement), subject to applicable law, Dr. Nijhawan is entitled to his base salary and vacation pay earned through the date of termination, and all of Dr. Nijhawan&#8217;s non-vested equity-based awards will be automatically extinguished. All vested equity-based awards shall be subject to the terms of the Company&#8217;s Equity Incentive Compensation Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">If Dr. Nijhawan is terminated without &#8220;Cause&#8221;, subject to Dr. Nijhawan signing a general release of claims, Dr. Nijhawan is entitled to: (i) a lump sum payment equal to Dr. Nijhawan&#8217;s then current base salary for 12 months plus one additional month for every completed year of service since August 1, 2017 (the Nijhawan Severance Period) which shall not exceed 24 months, inclusive of, and not in addition to, his notice and severance entitlements, if any, pursuant to applicable law, (ii) a lump sum payment of the annual bonus to which Dr. Nijhawan is entitled for the calendar year immediately preceding the date of termination, if such bonus has not already been paid, (iii) a lump sum payment equal to Dr. Nijhawan&#8217;s annual bonus entitlement, prorated over Dr. Nijhawan&#8217;s length of service in the calendar year in which his employment is terminated, calculated in accordance with the terms of the Nijhawan Employment Agreement, (iv) payment of Dr. Nijhawan&#8217;s annual bonus entitlement during the full Nijhawan Severance Period, calculated in accordance with the terms of the Nijhawan Employment Agreement, (v) continuation of Dr. Nijhawan&#8217;s benefits and car allowance and any other benefit required to be maintained by law in accordance with the terms of the Nijhawan Employment Agreement, and (vi) subject to applicable law, all vested equity-based awards granted to Dr. Nijhawan shall be exercisable in accordance with the terms of the applicable Equity Incentive Compensation Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In the event that Dr. Nijhawan is terminated or constructively terminated, which includes a material change in Dr. Nijhawan&#8217;s title, responsibilities, authority or status or a material reduction of his compensation, without &#8220;Cause&#8221; upon or within a 12-month period following a &#8220;Change of Control&#8221; (as such term is defined in the Nijhawan Employment Agreement), Dr. Nijhawan is entitled to (i) a change of control payment equal to 24 months of the value of Dr. Nijhawan&#8217;s then current base salary as of the date of termination, (ii) a lump sum payment of the annual bonus to which Dr. Nijhawan is entitled for the calendar year immediately preceding the date of termination, if such bonus has not already been paid, (iii) a lump sum payment equal to Dr. Nijhawan&#8217;s annual bonus entitlement, prorated over Dr. Nijhawan&#8217;s length of service in the calendar year in which his employment is terminated, calculated in accordance with the terms of the Nijhawan Employment Agreement, (iv) payment of Dr. Nijhawan&#8217;s annual bonus entitlement during the full Nijhawan Severance Period, calculated in accordance with the terms of the Nijhawan Employment Agreement, (v) continuation of Dr. Nijhawan&#8217;s benefits and car allowance and any other benefit required to be maintained by law in accordance with the terms of the Nijhawan Employment Agreement, and (vi) subject to applicable law, all vested equity-based awards granted to Dr. Nijhawan shall be exercisable in accordance with the terms of the applicable Equity Incentive Compensation Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Dr. Nijhawan may resign from his employment at any time by providing the Company with a minimum of 60 days advance notice, in writing. Dr. Nijhawan&#8217;s notice may be waived by the Company, subject only to providing Dr. Nijhawan with payment of his base salary and continuation of benefits until the end of the notice period. If Dr. Nijhawan resigns from his employment, subject to applicable law, (i) all non-vested equity based awards held by Dr. Nijhawan shall be automatically extinguished and (ii) Dr. Nijhawan shall not be entitled to any bonus or pro rata bonus payment not already awarded on or before the date of termination. All vested equity-based awards shall be subject to the terms of the applicable Equity Incentive Compensation Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">During the term of Dr. Nijhawan&#8217;s employment and for 12 months following the cessation of Dr. Nijhawan&#8217;s employment, Dr. Nijhawan is prohibited from competing with the business of the Company in North America. In addition, for 24 months following the cessation of Dr. Nijhawan&#8217;s employment, Dr. Nijhawan is prohibited from soliciting customers or prospective customers for any purpose competitive with the business of the Company, encouraging any customer to cease doing business with the Company and soliciting the employment or engagement of certain of Company&#8217;s employees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Prior Employment Agreement with Pardeep Nijhawan effective as of June 7, 2019 and amended March 19, 2021 and April 12, 2022</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Prior to the Nijhawan Employment Agreement, on June 14, 2019 but effective as of June 7, 2019, we entered into an employment agreement with Pardeep Nijhawan (as amended, the Nijhawan Prior Employment Agreement). Pursuant to the Nijhawan Prior Employment Agreement, Dr. Nijhawan agreed to serve as our Chief Executive Officer for an indefinite term until Dr. Nijhawan&#8217;s employment was terminated in accordance with the agreement. As compensation for his services to us, Dr. Nijhawan received a base salary of $320,000 per year effective for the period January 1, 2021 to March 23, 2022 and a base salary of $331,200 per year effective for the period March 24, 2022 to May 12, 2023 and was eligible to receive a target annual bonus of 40% of his base salary, subject to achieving corporate and personal targets to be determined by us. Dr. Nijhawan also received an automobile allowance of approximately $2,700 per month and was eligible to participate in our group insured benefits program, as may be in effect from time-to-time for our employees generally, and executive employees specifically. Dr. Nijhawan was eligible for future share and/or option grants, as may have been determined by our Compensation Committee, commensurate with Dr. Nijhawan&#8217;s position and any business milestones which may have been established by the Compensation Committee and subject to availability of shares and/or options for grant under our Equity Incentive Compensation Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">56</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the Nijhawan Prior Employment Agreement, if Dr. Nijhawan&#8217;s employment with us was terminated for &#8220;Cause&#8221; (as such term is defined in the Nijhawan Prior Employment Agreement), subject to applicable law, our only obligation would have been to provide Dr. Nijhawan with his base salary and vacation pay earned through the date of termination and all of Dr. Nijhawan&#8217;s vested or non-vested share options which had not been exercised by Dr. Nijhawan as of the date of termination would have been automatically extinguished. If Dr. Nijhawan was terminated by us without &#8220;Cause&#8221;, our obligation would have been to provide Dr. Nijhawan with (i) a lump sum payment equal to Dr. Nijhawan&#8217;s then current base salary for twenty-four months (the Nijhawan Prior Severance Period), (ii) a lump sum payment of the annual bonus to which Dr. Nijhawan would have been entitled for the fiscal year immediately preceding the date of termination, if such bonus had not already been paid, (iii) a lump sum payment equal to Dr. Nijhawan&#8217;s annual bonus entitlement, prorated over Dr. Nijhawan&#8217;s length of service in the fiscal year in which his employment was terminated, calculated in accordance with the terms of the Nijhawan Prior Employment Agreement, (iv) payment of Dr. Nijhawan&#8217;s annual bonus entitlement during the full Nijhawan Prior Severance Period, calculated in accordance with the terms of the Nijhawan Prior Employment Agreement, (v) continuation of Dr. Nijhawan&#8217;s benefits and car allowance and any other benefit required to be maintained by law in accordance with the terms of the Nijhawan Prior Employment Agreement and (vi) subject to applicable law, all share options granted to Dr. Nijhawan would have been exercisable in accordance with the terms of the applicable share option plan. Dr. Nijhawan could have resigned from his employment at any time by providing us with a minimum of sixty days advance notice, in writing. Dr. Nijhawan&#8217;s notice could have been waived by us, subject only to providing Dr. Nijhawan with payment of his base salary and continuation of benefits until the end of the notice period. If Dr. Nijhawan had resigned from his employment, subject to applicable law, (i) all non-vested share options and all vested share options held by Dr. Nijhawan which had not been exercised by Dr. Nijhawan as of the date of termination would have been automatically extinguished and (ii) Dr. Nijhawan would not have been entitled to any bonus or pro rata bonus payment not already paid on or before the date of termination.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">During the term of Dr. Nijhawan&#8217;s employment with us and for twelve months following the cessation of Dr. Nijhawan&#8217;s employment with us, Dr. Nijhawan was prohibited from competing with our business in North America. In addition, for twenty-four months following the cessation of Dr. Nijhawan&#8217;s employment with us, Dr. Nijhawan was prohibited from soliciting customers or prospective customers for any purpose competitive with our business, encouraging any customer to cease doing business with us and soliciting the employment or engagement of certain of our employees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Employment Agreement with Stephen Lemieux effective as of July 15, 2023</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On June 26, 2023 but effective as of July 15, 2023, we entered into an employment agreement with Stephen Lemieux (the Lemieux Employment Agreement). Pursuant to the Lemieux Employment Agreement, Mr. Lemieux will serve as our Chief Financial Officer for an indefinite term until Mr. Lemieux&#8217;s employment is terminated in accordance with the agreement. As compensation for his services to us, Mr. Lemieux will receive a base salary of $330,000 per year and is eligible to receive a target annual bonus of 40% of his base salary, subject to achieving corporate and personal targets to be determined by us. Mr. Lemieux also receives an automobile allowance of $2,000 per month and is eligible to participate in our group insured benefits program, as may be in effect from time-to-time for our employees generally, and executive employees specifically. Mr. Lemieux is eligible for future equity-based awards, as determined by our Compensation Committee, commensurate with Mr. Lemieux&#8217;s position and any business milestones which may be established by the Compensation Committee and subject to availability of shares and/or options for grant under our Equity Incentive Compensation Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">If Mr. Lemieux&#8217;s employment with the Company is terminated for &#8220;Cause&#8221; (as such term is defined in the Lemieux Employment Agreement), subject to applicable law, the Company&#8217;s only obligation shall be to provide Mr. Lemieux with his base salary and vacation pay earned through the date of termination and all of Mr. Lemieux&#8217;s non-vested equity-based awards as of the date of termination will be automatically extinguished. All vested equity-based awards will be subject to the terms of the applicable equity incentive compensation plan. If Mr. Lemieux is terminated by the Company without &#8220;Cause&#8221;, subject to Mr. Lemieux executing a general release of claims in a form reasonably required by the Company, the Company&#8217;s obligation shall be to provide Mr. Lemieux with (i) a lump sum payment equal to Mr. Lemieux&#8217;s then current base salary for twelve months plus one additional month for every completed year of service since July 15, 2023, not to exceed an aggregate of twenty- four months (the Lemieux Severance Period), (ii) a lump sum payment of the annual bonus to which Mr. Lemieux is entitled for the calendar year immediately preceding the date of termination, if such bonus has not already been paid, (iii) a lump sum payment equal to Mr. Lemieux&#8217;s annual bonus entitlement, prorated over Mr. Lemieux&#8217;s length of service in the calendar year in which his employment is terminated, calculated in accordance with the terms of the Lemieux Employment Agreement, (iv) payment of Mr. Lemieux&#8217;s annual bonus entitlement during the full Lemieux Severance Period, calculated in accordance with the terms of the Lemieux Employment Agreement, (v) continuation of Mr. Lemieux&#8217;s benefits and car allowance and any other benefit required to be maintained by law in accordance with the terms of the Lemieux Employment Agreement and (vi) subject to applicable law, any and all vested equity-based awards shall be exercisable in accordance with the terms of the applicable equity incentive compensation plan. If Mr. Lemieux&#8217;s employment is terminated or &#8220;constructively terminated&#8221; (as such term is defined in the Lemieux Employment Agreement) by the Company without &#8220;Cause&#8221; upon or within a twelve month period following a Change of Control (as such term is defined in the Lemieux Employment Agreement), Mr. Lemieux shall be entitled to the payments and benefits provided as described in clauses (ii) to (v) above, plus a change of control payment equal to twenty-four months of his then current base salary. Mr. Lemieux may resign from his employment at any time by providing the Company with a minimum of sixty days advance notice, in writing. Mr. Lemieux&#8217;s notice may be waived by the Company, subject only to providing Mr. Lemieux with payment of his base salary and continuation of benefits until the end of the notice period. If Mr. Lemieux resigns from his employment, subject to applicable law, (i) all non-vested equity-based awards held by Mr. Lemieux as of the date of termination shall be automatically extinguished and all vested equity-based awards will be subject to the terms of the applicable equity incentive compensation plan and (ii) Mr. Lemieux shall not be entitled to any bonus or pro rata bonus payment not already awarded on or before the date of termination.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">57</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">During the term of Mr. Lemieux&#8217;s employment with us and for twelve months following the cessation of Mr. Lemieux&#8217;s employment with us, Mr. Lemieux is prohibited from competing with our business in North America. In addition, for twenty-four months following the cessation of Mr. Lemieux&#8217;s employment with us, Mr. Lemieux is prohibited from soliciting customers or prospective customers for any purpose competitive with our business, encouraging any customer to cease doing business with us and soliciting the employment or engagement of certain of our employees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Prior Consulting Agreement with Stephen Lemieux effective December 22, 2022, terminated July 15, 2023</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Prior to the Lemieux Employment Agreement, on December 21, 2022, the Company entered into a consulting agreement with Stephen Lemieux to provide, as an independent contractor, advice and services related to finance, accounting, financial reporting, financial planning and analysis and similar services as requested by the Company from time to time at a rate of C$135 per hour. The agreement contained customary confidentiality, nondisclosure and proprietary information provisions. The consulting agreement was terminated upon Mr. Lemieux&#8217;s appointment as Chief Financial Officer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Amended and Restated Employment Agreement with Michael Brooks effective as of August 4, 2023</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On August 4, 2023, the Company entered into an amended and restated employment agreement with Michael Brooks, the Company&#8217;s President, that superseded prior employment agreements (the Brooks Employment Agreement).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Pursuant to the Brooks Employment Agreement, Dr. Brooks serves as the Company&#8217;s President as well as President and a director of the Company&#8217;s subsidiary, Edesa Biotech Research. Dr. Brooks&#8217; employment will continue for an indefinite term until terminated in accordance with the Brooks Employment Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Pursuant to the Brooks Employment Agreement, Dr. Brooks is entitled to a base salary of $335,340 per year effective May 13, 2023 and is eligible to receive a target annual bonus of 40% of his base salary, subject to the achievement of corporate and personal targets as determined by the Company and the Board of Directors. Dr. Brooks&#8217; base salary is subject to annual review by the Board of Directors. Dr. Brooks is also entitled to an automobile allowance of $2,000 per month and is eligible to participate in the Company&#8217;s group insured benefits program, as may be in effect from time-to-time for employees generally, and executive employees specifically. Dr. Brooks is eligible for equity-based awards pursuant to the Company&#8217;s Equity Incentive Compensation Plan, as determined by the Board of Directors or Compensation Committee, commensurate with Dr. Brooks&#8217; position and any business milestones that may be established by the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">58</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">If Dr. Brooks&#8217; employment is terminated for &#8220;Cause&#8221; (as such term is defined in the Brooks Employment Agreement), subject to applicable law, Dr. Brooks is entitled to his base salary and vacation pay earned through the date of termination, and all of Dr. Brooks&#8217; non-vested equity-based awards will be automatically extinguished. All vested equity-based awards shall be subject to the terms of the Company&#8217;s Equity Incentive Compensation Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">If Dr. Brooks is terminated without &#8220;Cause&#8221;, subject to Dr. Brooks signing a general release of claims, Dr. Brooks is entitled to: (i) a lump sum payment equal to Dr. Brooks&#8217; then current base salary for 12 months plus one additional month for every completed year of service since September 1, 2015 (the Brooks Severance Period) which shall not exceed 24 months, inclusive of, and not in addition to, his notice and severance entitlements, if any, pursuant to applicable law, (ii) a lump sum payment of the annual bonus to which Dr. Brooks is entitled for the calendar year immediately preceding the date of termination, if such bonus has not already been paid, (iii) a lump sum payment equal to Dr. Brooks&#8217; annual bonus entitlement, prorated over Dr. Brooks&#8217; length of service in the calendar year in which his employment is terminated, calculated in accordance with the terms of the Brooks Employment Agreement, (iv) payment of Dr. Brooks&#8217; annual bonus entitlement during the full Brooks Severance Period, calculated in accordance with the terms of the Brooks Employment Agreement, (v) continuation of Dr. Brooks&#8217; benefits and car allowance and any other benefit required to be maintained by law in accordance with the terms of the Brooks Employment Agreement, and (vi) subject to applicable law, all vested equity-based awards granted to Dr. Brooks shall be exercisable in accordance with the terms of the applicable Equity Incentive Compensation Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In the event that Dr. Brooks is terminated or constructively terminated, which includes a material change in Dr. Brooks&#8217; title, responsibilities, authority or status or a material reduction of the Employee&#8217;s compensation, without cause upon or within a 12-month period following a &#8220;Change of Control&#8221; (as such term is defined in the Brooks Employment Agreement), Dr. Brooks is entitled to (i) a change of control payment equal to 24 months of the value of Dr. Brooks&#8217; then current base salary as of the date of termination, (ii) a lump sum payment of the annual bonus to which Dr. Brooks is entitled for the calendar year immediately preceding the date of termination, if such bonus has not already been paid, (iii) a lump sum payment equal to Dr. Brooks&#8217; annual bonus entitlement, prorated over Dr. Brooks&#8217; length of service in the calendar year in which his employment is terminated, calculated in accordance with the terms of the Brooks Employment Agreement, (iv) payment of Dr. Brooks&#8217; annual bonus entitlement during the full Brooks Severance Period, calculated in accordance with the terms of the Brooks Employment Agreement, (v) continuation of Dr. Brooks&#8217; benefits and car allowance and any other benefit required to be maintained by law in accordance with the terms of the Brooks Employment Agreement, and (vi) subject to applicable law, all vested equity-based awards granted to Dr. Brooks shall be exercisable in accordance with the terms of the applicable Equity Incentive Compensation Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Dr. Brooks may resign from his employment at any time by providing the Company with a minimum of 60 days advance notice, in writing. Dr. Brooks&#8217; notice may be waived by the Company, subject only to providing Dr. Brooks with payment of his base salary and continuation of benefits until the end of the notice period. If Dr. Brooks resigns from his employment, subject to applicable law, (i) all non-vested equity based awards held by Dr. Brooks shall be automatically extinguished and (ii) Dr. Brooks shall not be entitled to any bonus or pro rata bonus payment not already awarded on or before the date of termination. All vested equity-based awards shall be subject to the terms of the applicable Equity Incentive Compensation Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">During the term of Dr. Brooks&#8217; employment and for 12 months following the cessation of Dr. Brooks&#8217; employment, Dr. Brooks is prohibited from competing with the business of the Company in North America. In addition, for 24 months following the cessation of Dr. Brooks&#8217; employment, Dr. Brooks is prohibited from soliciting customers or prospective customers for any purpose competitive with the business of the Company, encouraging any customer to cease doing business with the Company and soliciting the employment or engagement of certain of Company&#8217;s employees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Prior Employment Agreement with Michael Brooks effective as of June 7, 2019 and amended March 19, 2021 and April 12, 2022</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Prior to the Brooks Employment Agreement, on June 14, 2019 but effective as of June 7, 2019, we entered into an employment agreement with Michael Brooks, PhD (as amended, the Brooks Prior Employment Agreement). Pursuant to the Brooks Prior Employment Agreement, Dr. Brooks agreed to serve as our President for an indefinite term until Dr. Brooks&#8217; employment was terminated in accordance with the agreement. As compensation for his services to us, Dr. Brooks received a base salary of $300,000 per year effective for the period January 1, 2021 to March 23, 2022 and a base salary of $310,500 per year effective for the period March 24, 2022 to May 12, 2023 and was eligible to receive a target annual bonus of 40% of his base salary, subject to achieving corporate and personal targets to be determined by us. Dr. Brooks also received an automobile allowance of $2,000 per month and was eligible to participate in our group insured benefits program, as may be in effect from time-to-time for our employees generally, and executive employees specifically. Dr. Brooks was eligible for future share and/or option grants, as may have been determined by our Compensation Committee, commensurate with Dr. Brooks&#8217; position and any business milestones which may have been established by the Compensation Committee and subject to availability of shares and/or options for grant under our Equity Incentive Compensation Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">59</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">If Dr. Brooks&#8217; employment with us was terminated for &#8220;Cause&#8221; (as such term is defined in the Brooks Prior Employment Agreement), subject to applicable law, our only obligation would have been to provide Dr. Brooks with his base salary and vacation pay earned through the date of termination and all of Dr. Brooks&#8217; vested or non-vested share options which had not been exercised by Dr. Brooks as of the date of termination would have been automatically extinguished. If Dr. Brooks was terminated by us without &#8220;Cause&#8221;, our obligation would have been to provide Dr. Brooks with (i) a lump sum payment equal to Dr. Brooks&#8217; then current base salary for months plus one additional month for every completed year of service since September 2015, not to exceed an aggregate of twenty-four months (the Brooks Prior Severance Period), (ii) a lump sum payment of the annual bonus to which Dr. Brooks was entitled for the fiscal year immediately preceding the date of termination, if such bonus had not already been paid, (iii) a lump sum payment equal to Dr. Brooks&#8217; annual bonus entitlement, prorated over Dr. Brooks&#8217; length of service in the fiscal year in which his employment was terminated, calculated in accordance with the terms of the Brooks Prior Employment Agreement, (iv) payment of Dr. Brooks&#8217; annual bonus entitlement during the full Brooks Prior Severance Period, calculated in accordance with the terms of the Brooks Prior Employment Agreement, (v) continuation of Dr. Brooks&#8217; benefits and car allowance and any other benefit required to be maintained by law in accordance with the terms of the Brooks Prior Employment Agreement and (vi) subject to applicable law, all share options granted to Dr. Brooks would have been exercisable in accordance with the terms of the applicable share option plan. If Dr. Brooks&#8217; employment was terminated or &#8220;constructively terminated&#8221; (as such term is defined in the Brooks Prior Employment Agreement) by us without &#8220;Cause&#8221; upon or within a twelve month period following a Change of Control (as such term is defined in the Brooks Prior Employment Agreement), Dr. Brooks would have been entitled to the payments and benefits provided as described in clauses (ii) to (v) above, plus a change of control payment equal to twenty-four months of the his then current base salary. Dr. Brooks could have resigned from his employment at any time by providing us with a minimum of sixty days advance notice, in writing. Dr. Brooks&#8217; notice could have been waived by us, subject only to providing Dr. Brooks with payment of his base salary and continuation of benefits until the end of the notice period. If Dr. Brooks had resigned from his employment, subject to applicable law, (i) all non-vested share options and all vested share options held by Dr. Brooks which had not been exercised by Dr. Brooks as of the date of termination would have been automatically extinguished and (ii) Dr. Brooks would not have been entitled to any bonus or pro rata bonus payment not already paid on or before the date of termination.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">During the term of Dr. Brooks&#8217; employment with us and for twelve months following the cessation of Dr. Brooks' employment with us, Dr. Brooks was prohibited from competing with our business in North America. In addition, for twenty-four months following the cessation of Dr. Brooks' employment with us, Dr. Brooks was prohibited from soliciting customers or prospective customers for any purpose competitive with our business, encouraging any customer to cease doing business with us and soliciting the employment or engagement of certain of our employees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Outstanding Equity Awards at September 30, 2024</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="12" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Option Awards</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Name</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Award grant date</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of securities underlying unexercised options (#) exercisable</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of securities underlying unexercised options (#) unexercisable (1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 2%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Option exercise </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>prices</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Option expiration date</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pardeep Nijhawan, MD</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">9/26/17</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,785</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">9/26/27</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">12/28/18</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">232</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">12/28/28</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">10/13/20</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,572</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52.08</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">10/13/30</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">4/22/21</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17,143</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38.15</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">4/22/31</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2/28/22</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,224</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">776</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.97</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2/28/32</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7/20/23</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,147</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,996</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.79</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7/20/33</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stephen Lemieux, CPA</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7/20/23</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,457</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,258</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.79</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7/20/33</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Michael Brooks, PhD</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">8/28/17</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,488</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">8/28/27</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">9/26/17</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,472</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">9/26/27</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">12/28/18</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">232</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">12/28/28</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2/12/20</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,856</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2/12/30</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">10/13/20</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,143</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52.08</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">10/13/30</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">4/22/21</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,429</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">38.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">4/22/31</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2/28/22</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,523</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">692</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.97</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">2/28/32</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7/20/23</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,772</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,657</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 8%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.79</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">7/20/33</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our options vesting policy is described in the Outstanding Equity Awards Narrative Disclosure section.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The option will vest over a period of three years, with monthly vesting on a pro-rata basis beginning on the date of grant.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">60</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Outstanding Equity Awards Narrative Disclosure</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Equity Incentive Compensation Plan</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We adopted an Equity Incentive Compensation Plan in 2019 (as amended, the 2019 Plan) which amended and restated prior plans. Under the 2019 Plan, we are authorized to grant options, restricted shares and restricted share units (RSUs) to any of our officers, directors, employees, and consultants and those of our subsidiaries and other designated affiliates. The number of shares available for issuance under the 2019 Plan is 642,737, including (i) 164,736 shares initially authorized and reserved for issuance under the 2019 Plan (including the shares available for the exercise of outstanding options and RSUs under the Company&#8217;s prior plans, as of the effective date of the 2019 Plan), (ii) 213,858 shares authorized and reserved for issuance pursuant to Amendment No. 1 to the 2019 Plan, (iii) 197,143 shares authorized and reserved for issuance pursuant to Amendment No. 2 to the 2019 Plan and (iv) 67,000 shares authorized and reserved for issuance pursuant to Amendment No. 3 to the 2019. The purpose of the 2019 Plan is to advance the interests of the Company by encouraging equity participation through the acquisition of common shares of the Company. The 2019 Plan is to be administered by the Compensation Committee of our Board of Directors, except to the extent (and subject to the limitations set forth in the 2019 Plan) the Board elects to administer the 2019 Plan, in which case the 2019 Plan shall be administered by only those members of the Board who are &#8220;independent&#8221; members of the Board. The administrator of the 2019 Plan has the power to, among other things:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">allot common shares for issuance in connection with the exercise of options;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">grant options, restricted shares or restricted share units;</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">amend, suspend, terminate or discontinue the plan; and</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delegate all or a portion of its administrative powers as it may determine to one or more committees.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Options to purchase 383,080 common shares at prices ranging from C$15.12 and $4.10 to $596.82 are outstanding at September 30, 2024. RSUs eligible for conversion to 44,345 common shares are outstanding at September 30, 2024.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Options granted during the year ended September 30, 2024 to employees under the 2019 Plan totaled 500 options to purchase common shares at an exercise price of $4.10. Options granted during the year ended September 30, 2023 to directors, officers and employees under the 2019 Plan totaled 118,579 options to purchase common shares at exercise prices ranging from $5.79 to $10.01. There were 46,602 RSUs granted during the year ended September 30, 2024. There were 46,602 RSUs granted during the year ended September 30, 2023. All RSUs were immediately vested and were for payment of salary, bonuses or consulting fees to the certain members of the executive team.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Options Vesting Policy</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Vesting requirements for option awards are determined by the independent members of the Board of Directors. Options granted by the Company during the year ended September 30, 2024 and 2023 generally had monthly vesting for directors in equal proportions over 12 months beginning on the grant date, monthly vesting for officers and current employees in equal proportions over 36 months beginning on the grant date and monthly vesting for new employees in equal proportions over 36 months beginning on the monthly anniversary of the grant date following 90 days of employment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Policies and Practices Related to Grants of Share Options or Similar Awards</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We did not granted options, share appreciation rights, or other similar option-like instruments in the fiscal year ended September 30, 2024; however, it is our policy not to time any grants of equity awards in relation to the release of material non-public information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">61</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Retirement Benefits</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Executive officers and employees of our California subsidiary are eligible to receive the Company&#8217;s non-elective contribution of 3% of eligible compensation under a 401(k) plan to provide retirement benefits.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Other than the funds contributed under our 401(k) plan to our U.S. employees, no other funds were set aside or accrued by us during the years ended September 30, 2024 and 2023 to provide pension, retirement or similar benefits for our named executive officers.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Director Compensation</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The following table sets forth information regarding the compensation of our non-employee directors for the year ended September 30, 2024.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fees Earned or Paid in Cash ($)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Option Awards ($) (1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total ($)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Joan Chypyha</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51,500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">51,500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sean MacDonald</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Patrick Marshall</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Frank Oakes</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Charles Olson, DSc</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Carlo Sistilli, CPA, CMA</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">65,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">There were no share options grants in the year ended September 30, 2024. As of September 30, 2024, (i) Ms. Chypyha, Mr. Marshall and Dr. Olson each held 2,858 share options, (ii) Mr. MacDonald and Mr. Sistilli each held 11,773 share options and Mr. Oakes held 11,909 share options.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The compensation was paid in Canadian dollars and was converted from US dollars using the average foreign exchange rate for each month of the year from oanda.com.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Narrative to Director Compensation Table</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Non-Employee Director Compensation Policy</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The board adopted a compensation policy effective June 7, 2019 and amended it effective March 24, 2022. As compensation for their services on the Board of Directors, each non-executive board member received annual remuneration as noted below and prorated during the effective periods. The Chief Executive Officer does not receive any additional compensation for his services on the Board of Directors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">From March 24, 2022 through September 30, 2024, each non-executive director received annual base remuneration of $35,000 and the Board Chair received annual remuneration of $65,000, inclusive of compensation for his services on committees of the Board of Directors. Each member of the Company&#8217;s Audit Committee received annual remuneration of $7,500, and the Chair of the Audit Committee received $15,000 annually for his services. Each member of the Company&#8217;s Compensation Committee and Nominating and Corporate Governance Committee received annual remuneration of $4,500 for each committee on which they serve, and the Chairs of each of the Compensation Committee and Nominating and Corporate Governance Committee received $9,000 annually for their services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">62</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I12" title="I12" href="#"></a>Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Equity Compensation Plan Information&#160;</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The following table provides certain information as of September 30, 2024 about our common shares that may be issued under our equity compensation plans, which consists of our 2019 Equity Incentive Compensation Plan in effect at September 30, 2024:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Plan Category</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of securities to be issued upon exercise of outstanding options and rights</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted-average exercise price of outstanding options and rights</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(a)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(b)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(c)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity compensation plans approved by security holders</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">459,801</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24.93</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">141,099</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Equity compensation plans not approved by security holders</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">N/A</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">N/A</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">N/A</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">459,801</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24.93</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">141,099</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Includes 383,080 common shares issuable upon the exercise of outstanding options and 76,761 common shares issuable upon the conversion of outstanding RSUs.</p>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The weighted-average exercise price does not consider shares issuable upon the conversion of outstanding RSUs, which have no exercise price.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Warrants and other equity held by directors, officers and employees outside of the compensation plans are not included in the table above.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Security Ownership of Certain Beneficial Owners and Management</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The following tables sets forth certain information as of December 11, 2024, with respect to the beneficial ownership of our common shares by: (1) all of our directors; (2) our named executive officers listed in the Summary Compensation Table; (3) all of directors and executive officers as a group; and (4) each person known by us to beneficially own more than 5% of our outstanding common shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">We have determined beneficial ownership in accordance with the rules of the SEC, based on a review of filings with the SEC and information known to us. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with respect to all common shares that they beneficially own, subject to applicable community property laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">Common shares subject to options, warrants or restricted share units currently exercisable or exercisable within 60 days of December 11, 2024 are deemed outstanding for computing the share ownership and percentage of the person holding such options, warrants and restricted share units, but are not deemed outstanding for computing the percentage of any other person. The percentage ownership of our common shares of each person or entity named in the following table is based on 3,467,658 common shares outstanding as of December 11, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">63</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Directors and Officers</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>Name and Address of Beneficial Owner (1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Shares Beneficially Owned</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percentage of Shares Beneficially Owned</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Joan Chypyha</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,887</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(2)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Sean MacDonald</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13,826</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(3)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Patrick Marshall</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,323</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(4)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Pardeep Nijhawan, MD</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">730,357</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(5)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19.99</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Frank Oakes</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,909</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(6)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Charles Olson, DSc</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,858</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(7)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Carlo Sistilli, CPA, CMA</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,295</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(8)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Stephen Lemieux, CPA</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,148</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(9)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">*</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;">Michael Brooks, PhD</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">81,830</td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">(10)</sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; vertical-align: top;"><sup style="vertical-align:top;line-height:120%;">&#160;</sup></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-indent: -9pt;"><b>All directors and named executive officers as a group (9 persons)</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>867,433</b></td>
			<td style="width: 2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); vertical-align: top;"><sup style="vertical-align:top;line-height:120%;"><b>(11)</b></sup></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>23.9</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>%</b></td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">* Percentage of shares beneficially owned does not exceed one percent.</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Unless otherwise indicated, the address of each beneficial owner is c/o Edesa Biotech, Inc., 100 Spy Court, Markham, ON Canada L3R 5H6.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consists of (i) 29 common shares and (ii) 2,858 common shares issuable upon exercise of options exercisable within sixty days of December 11, 2024.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(3)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consists of (i) 2,053 common shares and (ii) 11,753 common shares issuable upon exercise of options exercisable within sixty days December 11, 2024.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(4)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consists of (i) 2,858 common shares issuable upon exercise of options exercisable within sixty days December 11, 2024 held by Patrick Marshall and.(ii) 465 common shares held by Quidnet Inc. for which Patrick Marshall has sole voting and dispositive power over all such shares.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(5)</p>
			</td>
			<td style="width: auto; padding: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consists of (A)(i) 84,973 common shares, (ii) 48,776 common shares issuable upon exercise of options exercisable within sixty days of December 11, 2024 and (iii) 47,645 common shares issuable upon the conversion of restricted share units held by Pardeep Nijhawan; (B)(i) 341,702 common shares (ii) 16,305 common shares issuable upon exercise of warrants exercisable within sixty days of December 11, 2024 and (iii) 56,925 common shares issuable upon conversion of preferred shares within sixty days of December 11, 2024 held by Pardeep Nijhawan Medicine Professional Corporation for which Pardeep Nijhawan has sole voting and dispositive power over all such shares; (C) 32,013 common shares held by The Digestive Health Clinic Inc. for which Pardeep Nijhawan has sole voting and dispositive power over all such shares; (D) 53,104 common shares held by 1968160 Ontario Inc. for which Pardeep Nijhawan has sole voting and dispositive power over all such shares and (E)(i) 32,609 common shares and (ii) 16,305 common shares issuable upon exercise of warrants exercisable within sixty days of December 11, 2024 held by The New Nijhawan Family Trust 2015 for which each of Pardeep Nijhawan and Nidhi Nijhawan, as trustees, have voting and dispositive power over all such shares.&#160; Excludes (i) 326,560 common shares underlying warrants held by Pardeep Nijhawan Medicine Professional Corporation which are subject to a 19.99% beneficial ownership blocker, (ii) 378,489 common shares underlying Preferred Shares held by Pardeep Nijhawan Medicine Professional Corporation which are subject to a 19.99% beneficial ownership blocker and (iii) 11,050 common shares underlying restricted share units held by Pardeep Nijhawan which are subject to a 19.99% beneficial ownership blocker.</td>
		</tr>

</tbody></table>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(6)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consists of 11,909 common shares issuable upon exercise of options exercisable within sixty days of December 11, 2024.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(7)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consists of 2,858 common shares issuable upon exercise of options exercisable within sixty days of December 11, 2024.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(8)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consists of (i) 11,773 common shares issuable upon exercise of options exercisable within sixty days of December 11, 2024 held by Carlo Sistilli and (ii) 522 common shares held by York-Cav Enterprises Inc. for which Carlo Sistilli, as President and Director, has sole voting and dispositive power over all such shares.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(9)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consists of (i) 5,662 common shares issuable upon exercise of options exercisable within sixty days of December 11, 2024 and (ii) 2,486 common shares issuable upon the conversion of restricted share units.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(10)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Consists of (i) 4,354 common shares, (ii) 63,858 common shares issuable upon exercise of options exercisable within sixty days of December 11, 2024, (iii) 303 common shares issuable upon exercise of warrants exercisable within sixty days of December 11, 2024 and (iv) 13,315 common shares issuable upon conversion of restricted share units.</p>
			</td>
		</tr>

</tbody></table>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 27pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">(11)</p>
			</td>
			<td style="width: auto; padding: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consists of (i) 551,824 common shares, (ii) 162,325 common shares issuable upon exercise of options exercisable within sixty days of December 11, 2024, (iii) 32,913 common shares issuable upon exercise of warrants exercisable within sixty days of December 11, 2024, (iv) 63,446 common shares issuable upon conversion of restricted share units and (v) 56,925 common shares issuable upon conversion of Preferred Shares within sixty days of December 11, 2024.</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">64</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Shareholders Known by Us to Own 5% or More of Our Common Shares</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name and Address of Beneficial Owner</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Shares Beneficially </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Owned</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percentage of Shares Beneficially Owned</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lumira Capital II, L.P. and Lumira Capital II (International), L.P. (1)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">234,786</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup>&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.8</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Consists of (i) 214,913 common shares held by Lumira Capital II, L.P. and (ii) 19,873 common shares held by Lumira Capital II (International), L.P. and beneficially owned by affiliates of Lumira Capital II, L.P. and Lumira Capital II (International), L.P. The address of both entities is 141 Adelaide Street West, Suite 770, Toronto, Ontario, Canada M5H 3L5. We relied in part on the SEC Schedule 13D/A filed with the SEC on January 13, 2023 for this information.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I13" title="I13" href="#"></a>Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Related Party Transactions</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The following is a description of transactions since October 1, 2022 to which we have been a participant in which the amount involved exceeded or will exceed the lesser of (i) $120,000 and (ii) one percent of the average of our total assets at year end for the last two completed fiscal years in which any of our directors, executive officers or holders of more than 5% of our voting securities, or any members of their immediate family, had or will have a direct or indirect material interest, other than compensation arrangements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Right-of-Use Lease Agreement</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In January 2017, Edesa Biotech Research entered into a right-of-use lease agreement with 1968160 Ontario Inc., a company related to Dr. Nijhawan, our Chief Executive Officer, for office space that serves as our principal executive office. The original lease expired on December 31, 2022 and we executed a two-year term extension through December 31, 2024. Monthly rents during the term ranged from C$8,320 to C$9,020 plus HST. Rents of approximately $78,000 and $82,000 were incurred during the years ended September 30, 2024 and 2023, respectively. Rents of approximately $30,000 and $15,000&#160;were payable at September 30, 2024 and September 30, 2023, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Credit Agreement</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On October 20, 2023, the Company entered into the Credit Agreement with PN MPC, an entity controlled by Dr. Nijhawan, our Chief Executive Officer, providing for the Line of Credit in the principal amount of up to $10 million, with the Credit Limit of $3.5 million, which was available immediately upon the execution of the Credit Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Line of Credit bore interest at the Canadian Imperial Bank of Commerce US Base-Interest Rate plus 3% per annum and has a maturity date of March 31, 2026, unless terminated earlier by either party with 90 days&#8217; notice. The Company had the right at any time, and from time to time, to prepay all or any portion of each advance without premium or penalty.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Additionally, the Company agreed to pay a monthly standby fee for the term of the Credit Agreement, calculated as of the last business day of each month, on the difference between the Credit Limit at such time and the principal amount of outstanding advances, based on an annual interest rate of 1.5%. Prior to termination, $51,000 of standby fees had accrued.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Credit Agreement was terminated in October 2024. Prior to the termination of the Credit Agreement, we had not borrowed any funds thereunder. We incurred no termination penalties in connection with the termination of the Credit Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Preferred Shares</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2024, we entered into a Securities Purchase Agreement with PN MPC, an entity controlled by Pardeep Nijhawan, the Company&#8217;s Chief Executive Officer, Secretary and member of the board of directors of the Company, pursuant to which the Company agreed to issue and sell to PN MPC in a private placement, up to $5.0 million of Preferred Shares, each of which is initially convertible into approximately 2,903 Conversion Shares, at a conversion price of $3.445 per Conversion Share, and Warrants to purchase Warrant Shares at an exercise price of $3.445 per Warrant Share. The Preferred Shares and the Warrants were sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of common shares equal to 75% of the underlying Conversion Shares at a combined purchase price of $10,272.13 per Preferred Share and related Warrants. Under the Purchase Agreement, PN MPC has purchased 150 Preferred Shares initially convertible into an aggregate of 435,414 Conversion Shares and Warrants to purchase up to an aggregate of 326,560 Warrant Shares for an aggregate purchase price of $1,540,819. The Warrants expire five years from the issuance date. We have the right to require PN MPC to purchase additional Preferred Shares and Warrants (up to an aggregate investment of $5.0 million); provided however, no more than an aggregate of $2.0 million of Preferred Shares and Warrants may be issued and sold pursuant to the Purchase Agreement without shareholder approval in accordance with applicable Canadian securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">65</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Director Independence</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In evaluating the independence of our Board members and the composition of the committees of our Board of Directors, the Board of Directors utilizes the definition of &#8220;independence&#8221; as that term is defined by the Exchange Act and the Nasdaq Listing Rules. Using this standard, the Board of Directors has determined that Joan Chypyha, Sean MacDonald, Patrick Marshall, Frank Oakes, Charles Olson and Carlo Sistilli are &#8220;independent directors.&#8221; Accordingly, our Board of Directors is composed of a majority of independent directors as required by the rules of Nasdaq. Pardeep Nijhawan is not an independent director due to his position as our Chief Executive Officer. We have established an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee, each of which are composed of independent directors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I14" title="I14" href="#"></a>Item 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The following table shows the aggregate fees billed for audit and other services provided for the years ended September 30, 2024 and 2023 rendered by MNP LLP.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>Principal Accountant Fees and Services</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Type of Service</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Year Ended 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Year Ended 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Audit Fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">138,434</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">137,260</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Audit - related fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">102,882</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">108,300</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax Fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,360</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,076</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Total</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">243,676</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">255,636</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Audit Fees</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Audit fees consisted of fees incurred for professional services rendered for audits and interim reviews of the years ended September 30, 2024 and 2023. Audit-related fees include assurance and related services that were incurred for procedures related to registrations and offerings.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Tax Fees</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Tax fees consisted of fees incurred for professional services rendered for tax compliance related to tax returns during the years ended September 30, 2024 and 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Pre-Approval Policies and Procedures</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Audit Committee is directly responsible for the appointment, compensation and oversight of our auditors. It has established procedures for the receipt, retention, and treatment of complaints received by us regarding accounting, internal accounting controls, or auditing matters, and the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters. The Audit Committee also has the authority and the funding to engage independent counsel and other outside advisors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Audit Committee pre-approves all audit and permissible non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services. Pre-approval is generally provided for up to one year, and any pre-approval is detailed as to the particular service or category of services and is generally subject to an amount or range of estimated fees. All proposed engagements of the auditor for audit and permitted non-audit services are submitted to the Audit Committee for approval prior to the beginning of any such services. Our auditors are required to periodically report to the Audit Committee regarding the extent of services provided by the independent registered public accounting firm in accordance with the pre-approval, and the fees for the services performed to date. The Audit Committee may also pre-approve particular services on a case-by-case basis. The Audit Committee pre-approved 100% of the audit and non-audit services performed by our independent registered public accounting firm for the years ended September 30, 2024 and 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">66</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b><a id="P4" title="P4" href="#"></a>PART IV</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a id="I15" title="I15" href="#"></a>Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following documents are filed as a part of this Annual Report:</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Financial Statements</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The list of consolidated financial statements and notes required by this Item 15 (a) (1) is set forth in the &#8220;Index to Financial Statements&#8221; on page F-1 of this Annual Report.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Financial Statement Schedules</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">All schedules have been omitted because the required information is included in the financial statements or notes thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Exhibits</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The exhibits listed on the Exhibit Index below are filed as part of this Annual Report.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">67</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>EXHIBIT INDEX</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit No.</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420419012862/tv515762_ex2-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2.1*</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420419012862/tv515762_ex2-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Share Exchange Agreement, dated as of March 7, 2019, by and between Stellar Biotechnologies Inc., Edesa Biotech Inc. and the Edesa Shareholders (included as Exhibit 2.1 to the Company's Current Report on Form 8-K filed on March 8, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofincorporation.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.1</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofincorporation.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Incorporation of the Company, dated June 12, 2007 (included as Exhibit 1(a) to the Company's Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofamendment2008.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.2</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofamendment2008.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Amendment of the Company, dated April 15, 2008 (included as Exhibit 1(b) to the Company's Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofcontinuation.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.3</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofcontinuation.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Continuation of the Company, dated November 25, 2009 (included as Exhibit 1(c) to the Company's Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofchangename.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.4</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000121716012000029/certificateofchangename.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Change of Name of the Company, dated April 7, 2010 (included as Exhibit 1(f) to the Company&#8217;</span><span style="text-decoration: underline; ">s Registration Statement on Form 20-F filed on February 3, 2012, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419013878/edsa_ex36.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.5</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419013878/edsa_ex36.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certificate of Change of Name of the Company, dated June 7, 2019 (included as Exhibit 3.6 to the Company's Annual Report on Form 10-K filed on December 12, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">3.6</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex31.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Articles of Edesa Biotech, Inc. (included as Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on October 31, 2024).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_755936.htm" style="-sec-extract:exhibit;">3.7</a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_755936.htm" style="-sec-extract:exhibit;">Notice of Articles of Edesa&#160;Biotech, Inc. (filed herewith).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010204/edsa_ex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.1</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010204/edsa_ex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Specimen of common share certificate (included as Exhibit 4.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Registration Statement on Form S-3 filed on August 30, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420000145/edsa_ex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.2</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420000145/edsa_ex41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Class A Purchase Warrant issued to investors (included as Exhibit 4.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on January 6, 2020, and incorporated herein by reference).</span>&#160;</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420000145/edsa_ex4-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.3</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420000145/edsa_ex4-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Warrant issued to Brookline Capital Markets, a division of Arcadia Securities, LLC (included as Exhibit 4.3 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on January 6, 2020, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420418025796/tv492944_ex4-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.4</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420418025796/tv492944_ex4-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Warrant (included as Exhibit 4.2 to the Company's Registration Statement on Form S-1 filed on May 8, 2018, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">68</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465921029184/tm218114d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.5</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465921029184/tm218114d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Underwriter Warrant (included as Exhibit 4.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K/A filed on February 26, 2021, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.6</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Pre-Funded Warrant (included as Exhibit 4.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on March 23, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.7</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Private Placement Warrant (included as Exhibit 4.2 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on March 23, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.8</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex4-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Placement Agent Warrant (included as Exhibit 4.3 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on March 23, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.9</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Class A Warrant (included as Exhibit 4.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on November 3, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex4-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.10</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex4-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Class B Warrant (included as Exhibit 4.2 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on November 3, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_755937.htm" style="-sec-extract:exhibit;">4.11</a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="ex_755937.htm" style="-sec-extract:exhibit;">Description of Securities&#160;(filed herewith).</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_ex412.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.12</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_ex412.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Share Purchase Warrant issued to H.C. Wainwright &amp; Co., Inc. designees on June 7, 2019 (included as Exhibit 4.12 to the Company&#8217;</span><span style="text-decoration: underline; ">s Annual Report on Form 10-K filed on December 15, 2023, and incorporated herein by reference). </span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000117184324005928/exh_41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">4.13</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000117184324005928/exh_41.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Common Share Purchase Warrant issued to Pardeep Nijhawan Medicine Professional Corporation or its assigns on October 30, 2024 (included as Exhibit 4.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on October 30, 2024, and incorporated herein by reference). </span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420414068912/v392175_ex10-14.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.1</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420414068912/v392175_ex10-14.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Advance Notice Policy, adopted October 31, 2013 (included as Exhibit 10.14 to the Company's Annual Report on Form 10-K filed on November 14, 2014, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.2@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement by and between the Company and Pardeep Nijhawan, dated June 14, 2019 (included as Exhibit 10.2 to the Company's Current Report on Form 8-K/A filed on June 20, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.3@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement by and between the Company and Michael Brooks, dated June 14, 2019 (included as Exhibit 10.3 to the Company's Current Report on Form 8-K/A filed on June 20, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.4@</span></a></p>
			</td>
			<td style="vertical-align: middle; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000114420419031709/tv523853_ex10-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Indemnification Agreement, by and between the Company and each of its directors and executive officers (included as Exhibit 10.4 to the Company's Current Report on Form 8-K/A filed on June 20, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">69</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419012009/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.5@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419012009/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on October 25, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421004573/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.6@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421004573/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment No. 1 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on April 23, 2021, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.7</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lease, dated as of January 1, 2017, by and between the Registrant and 1968160 Ontario Inc. (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on August 30, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.8+</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Exclusive License Agreement, dated as of June 29, 2016, by and between the Registrant and Yissum Research Development Company (included as Exhibit 10.2 to the Company's Current Report on Form 8-K filed on August 30, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.9</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">First Amendment to Exclusive License Agreement, dated April 3, 2017, by and between the Registrant and Yissum Research Development Company (included as Exhibit 10.3 to the Company's Current Report on Form 8-K filed on August 30, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.10</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Second Amendment to Exclusive License Agreement, dated May 7, 2017, by and between the Registrant and Yissum Research Development Company (included as Exhibit 10.4 to the Company's Current Report on Form 8-K filed on August 30, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_ex1011.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.11+</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495422016633/edsa_ex1011.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Third Amendment to Exclusive License Agreement, dated October 26, 2022, by and between the Registrant and Yissum Research Development Company (included as Exhibit 10.11 to the Company&#8217;</span><span style="text-decoration: underline; ">s Annual Report on Form 10-K filed on December 16, 2022 and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex106.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.12+</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495419010201/edsa_ex106.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">License and Development Agreement, dated as of August 27, 2017, by and between the Registrant and Pendopharm, a division of Pharmascience Inc. (included as Exhibit 10.6 to the Company's Current Report on Form 8-K filed on August 30, 2019, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.13+</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">License Agreement by and between Edesa Biotech Research, Inc. and NovImmune SA dated April 17, 2020 (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on April 23, 2020, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.14+</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420004346/edsa_ex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Purchase Agreement by and between Edesa Biotech Research, Inc. and NovImmune SA dated April 17, 2020 (included as Exhibit 10.2 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on April 23, 2020, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420013236/edsa_ex1021.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.15@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420013236/edsa_ex1021.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement by and between the Company and Kathi Niffenegger, dated December 1, 2020 (included as Exhibit 10.21 to the Company&#8217;</span><span style="text-decoration: underline; ">s Annual Report on Form 10-K filed on December 7, 2020, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421001111/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.16+</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421001111/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Strategic Innovation Fund Agreement among Edesa Biotech Research, Inc., Edesa Biotech, Inc., and her Majesty the Queen in right of Canada as represented by the Minister of Industry, dated February 2, 2021 (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on February 3, 2021, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421003044/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.17+</span>&#160;</a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421003044/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Exclusive License Agreement, dated as of March 16, 2021, by and between Edesa Biotech Research, Inc. and Dr. Saul Yedgar (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on March 22, 2021, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.18@</span>&#160;</a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Employment Agreement, entered into on March 19, 2021, by and between Par Nijhawan and Edesa Biotech, Inc. (included as Exhibit 10.3 to the Company&#8217;</span><span style="text-decoration: underline; ">s Quarterly Report on Form 10-Q filed on May 14, 2021, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.19@</span>&#160;</a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Employment Agreement, entered into on March 19, 2021, by and between Kathi Niffenegger and Edesa Biotech USA, Inc. (included as Exhibit 10.4 to the Company&#8217;</span><span style="text-decoration: underline; ">s Quarterly Report on Form 10-Q filed on May 14, 2021, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex105.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.20@</span>&#160;</a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495421005647/edsa_ex105.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Employment Agreement, entered into on March 19, 2021, by and between Michael Brooks and Edesa Biotech, Inc. (included as Exhibit 10.5 to the Company&#8217;</span><span style="text-decoration: underline; ">s Quarterly Report on Form 10-Q filed on May 14, 2021, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.21</span>&#160;</a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922037020/tm2210153d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Securities Purchase Agreement, dated March 21, 2022, by and between the Company and the Purchaser (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on March 23, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.22@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Employment Agreement, entered into on April 12, 2022, by and between Par Nijhawan and Edesa Biotech, Inc. (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Quarterly Report on Form 10-Q filed on May 13, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.23@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Employment Agreement, entered into on April 12, 2022, by and between Kathi Niffenegger and Edesa Biotech USA, Inc. (included as Exhibit 10.2 to the Company&#8217;</span><span style="text-decoration: underline; ">s Quarterly Report on Form 10-Q filed on May 13, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.24@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495422006659/edsa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment to Employment Agreement, entered into on April 12, 2022, by and between Michael Brooks and Edesa Biotech USA, Inc. (included as Exhibit 10.3 to the Company&#8217;</span><span style="text-decoration: underline; ">s Quarterly Report on Form 10-Q filed on May 13, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.25</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of Non-U.S. Subscription Agreement (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on November 3, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.26</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Form of U.S. Subscription Agreement (included as Exhibit 10.2 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on November 3, 2022, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">70</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423001577/edsa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.27</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423001577/edsa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Lease Extending and Amending Agreement dated as of December 31, 2022 by and between Edesa Biotech Research, Inc. and 1968160 Ontario, Inc. (included as Exhibit 10.3 to the Company&#8217;</span><span style="text-decoration: underline; ">s Quarterly Report on Form 10-Q filed on February 10, 2023 and incorporated herein by reference).</span><span style="text-decoration: underline; ">&#160;</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465923037164/tm2310425d1_ex1-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.28</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465923037164/tm2310425d1_ex1-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Equity Distribution Agreement, dated as of March 27, 2023, by and between Edesa Biotech, Inc. and Canaccord Genuity LLC (included as Exhibit 1.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on March 27, 2023, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423007162/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.29@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423007162/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment No. 2 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on May 24, 2023, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423008484/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.30@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423008484/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Employment Agreement by and between the Company and Stephen Lemieux, dated June 26, 2023 (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on June 27, 2023, and incorporated herein by reference).</span><span style="text-decoration: underline; ">&#160;</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423010380/edsa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.31@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423010380/edsa_ex103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Employment Agreement, by and between the Company and Pardeep Nijhawan, dated August 4, 2023 (included as Exhibit 10.3 to the Company&#8217;</span><span style="text-decoration: underline; ">s Quarterly Report on Form 10-Q filed on August 9, 2023, and incorporated herein by reference).</span><span style="text-decoration: underline; ">&#160;</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423010380/edsa_ex104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.32@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423010380/edsa_ex104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amended and Restated Employment Agreement, by and between the Company and Michael Brooks, dated August 4, 2023 (included as Exhibit 10.4 to the Company&#8217;</span><span style="text-decoration: underline; ">s Quarterly Report on Form 10-Q filed on August 9, 2023, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_ex1033.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.33+</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_ex1033.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Strategic Innovation Fund Agreement, dated October 12, 2023, by and among Edesa Biotech Research, Inc., Edesa Biotech, Inc., and his Majesty the King in right of Canada as represented by the Minister of Industry (included as Exhibit 10.33 to the Company&#8217;</span><span style="text-decoration: underline; ">s Annual Report on Form 10-K filed on December 15, 2023, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465923110653/tm2328896d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.34</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000110465923110653/tm2328896d1_ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Credit Agreement, effective as of October 20, 2023, by and between the Company and Pardeep Nijhawan Medicine Professional Corporation (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on October 23, 2023, and incorporated herein by reference).</span><span style="text-decoration: underline; ">&#160;</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_ex1035.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.35+</span></a></p>
			</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_ex1035.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">First Amendment to Exclusive License Agreement, dated as of September 21, 2023, by and between Edesa Biotech Research, Inc. and Dr. Saul Yedgar (included as Exhibit 10.35 to the Company&#8217;</span><span style="text-decoration: underline; ">s Annual Report on Form 10-K filed on December 15, 2023, and incorporated herein by reference). </span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_ex1036.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.36@</span></a></p>
			</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_ex1036.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">First Amendment to Amended and Restated Employment Agreement, by and between the Company and Pardeep Nijhawan, dated December 7, 2023 (included as Exhibit 10.36 to the Company&#8217;</span><span style="text-decoration: underline; ">s Annual Report on Form 10-K filed on December 15, 2023, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495424007083/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.37@</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495424007083/edsa_ex101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Amendment No. 3 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on May 30, 2024, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000117184324005515/exh_11.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.38</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000117184324005515/exh_11.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">At The Market Offering Agreement, dated October 4, 2024, by and between Edesa Biotech, Inc. and H.C. Wainwright &amp; Co., LLC (included as Exhibit 1.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on October 4, 2024, and incorporated herein by reference).</span>&#160;</a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000117184324005928/exh_101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">10.39</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000117184324005928/exh_101.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Securities Purchase Agreement, dated October 30, 2024, by and between Edesa Biotech, Inc. and Pardeep Nijhawan Medicine&#160;</span><span style="text-decoration: underline; ">Professional Corporation (included as Exhibit 10.1 to the Company</span><span style="text-decoration: underline; ">&#8217;</span><span style="text-decoration: underline; ">s Current Report on Form 8-K filed on October 31, 2024, and incorporated herein by reference).</span>&#160;</a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_755571.htm" style="-sec-extract:exhibit;">19.1</a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_755571.htm" style="-sec-extract:exhibit;">Insider Trading Policy (filed&#160;herewith).</a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420013236/edsa_ex21.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">21</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495420013236/edsa_ex21.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Subsidiaries of Edesa Biotech, Inc. (included as Exhibit 21 to the Company&#8217;</span><span style="text-decoration: underline; ">s Annual Report on Form 10-K filed on December 7, 2020, and incorporated herein by reference).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_754891.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">23.1</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_754891.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Consent of MNP LLP (filed herewith).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="#power_of_attorney" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">24.1</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="#power_of_attorney" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Power of Attorney (included on signature page).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_754102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">31.1</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_754102.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed</span><span style="text-decoration: underline; ">&#160;herewith).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_754103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">31.2</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_754103.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</span></a></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: middle; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_754104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">32.1**</span></a></p>
			</td>
			<td style="vertical-align: top; width: 93%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="ex_754104.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">71</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_754105.htm" style="-sec-extract:exhibit;">32.2**</a></p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_754105.htm" style="-sec-extract:exhibit;">Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></p>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_ex971.htm" style="-sec-extract:exhibit;">97.1</a></p>
			</td>
			<td style="vertical-align: top; width: 93%;"><a href="http://www.sec.gov/Archives/edgar/data/1540159/000165495423015632/edsa_ex971.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline; ">Incentive Compensation Repayment (Clawback) Policy (included as Exhibit 97.1 to the Company&#8217;</span><span style="text-decoration: underline; ">s Annual Report on Form 10-K filed on December 15, 2023, and incorporated herein by reference)</span>.</a></td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.INS</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Instance Document</p>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.SCH</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.CAL</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Calculation Linkbase Document</p>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.DEF</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.LAB</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Label Linkbase Document</p>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.PRE</p>
			</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Presentation Linkbase Document</p>
			</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">&#160;</td>
			<td style="vertical-align: top; width: 93%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="1" style="vertical-align: top; width: 7%;">104</td>
			<td style="vertical-align: top; width: 93%;">Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">* All schedules and exhibits to the Share Exchange Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the Securities and Exchange Commission upon request.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">** The information in this exhibit is furnished and deemed not filed with the Securities and Exchange Commission for purposes of section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of Edesa Biotech, Inc. under the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">@ Management contract or compensatory plan or arrangement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">+ Portions of this exhibit have been omitted pursuant to Rule 601(b)(10)(iv) of Regulation S-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b><a id="I16" title="I16" href="#"></a>Item 16. FORM 10-K SUMMARY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">72</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b><a id="Signatures" title="Signatures" href="#"></a>SIGNATURES</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>EDESA BIOTECH, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: December 13, 2024</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Pardeep Nijhawan</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Pardeep Nijhawan, MD</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Director, Chief Executive Officer and Corporate Secretary (Principal Executive Officer)</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: December 13, 2024</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Stephen Lemieux</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stephen Lemieux</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&#160;</td>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Chief Financial Officer</i></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Financial Officer)</i></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b><a id="power_of_attorney" title="power of attorney" href="#"></a>POWER OF ATTORNEY</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pardeep Nijhawan and Stephen Lemieux, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Signature</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Pardeep Nijhawan</i></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, Chief Executive Officer, and</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 13, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Pardeep Nijhawan</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Corporate Secretary (Principal Executive Officer)</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Stephen Lemieux</i></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 13, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Stephen Lemieux</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial and Accounting Officer)</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Joan Chypyha</i></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 13, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Joan Chypyha</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Sean MacDonald</i></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 13, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Sean MacDonald</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Patrick Marshall</i></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 13, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Patrick Marshall</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Frank Oakes</i></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 13, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Frank Oakes</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Charles Olson</i></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 13, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Charles Olson</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Carlo Sistilli</i></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chairman of the Board of Directors</p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 13, 2024</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Carlo Sistilli</b></p>
			</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 32%;">&#160;</td>
			<td style="vertical-align: middle; width: 1%;">&#160;</td>
			<td style="vertical-align: middle; width: 33%;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">73</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<div>&#160;</div>

<div>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>EDESA BIOTECH, INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>INDEX TO FINANCIAL STATEMENTS</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
			<td style="vertical-align: top; width: 7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#Report" style="-sec-extract:exhibit;">Report of Independent Registered Public Accounting Firm &#8211;&#160;MNP LLP, Toronto Canada, PCAOB ID <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:AuditorFirmId" id="c39">1930</ix:nonNumeric></a></p>
			</td>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#Report">F-2</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#Balance_sheets" style="-sec-extract:exhibit;">Consolidated Balance Sheets at September 30, 2024 and 2023</a></p>
			</td>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#Balance_sheets">F-4</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#Statements_of_operations" style="-sec-extract:exhibit;">Consolidated Statements of Operations and Comprehensive Loss for the years ended September 30, 2024 and 2023</a></p>
			</td>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#Statements_of_operations">F-5</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#Cash_flows" style="-sec-extract:exhibit;">Consolidated Statements of Cash Flows for the years ended September 30, 2024 and 2023</a></p>
			</td>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#Cash_flows">F-6</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#Equity" style="-sec-extract:exhibit;">Consolidated Statements of Changes in Shareholders&#8217;&#160;Equity for the years ended September 30, 2024 and 2023</a></p>
			</td>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#Equity">F-7</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 93%;">&#160;</td>
			<td style="vertical-align: middle; width: 7%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#Notes" style="-sec-extract:exhibit;">Notes to Consolidated Financial Statements</a></p>
			</td>
			<td style="vertical-align: top; width: 7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><a class="tocPGNUM" href="#Notes">F-8</a></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div style="text-align: right;"><img alt="mnplogo.jpg" src="mnplogo.jpg"/></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><a id="Report" title="Report" href="#"></a>&#160;<b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">To the Board of Directors and Shareholders of Edesa Biotech, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Opinion on the Consolidated Financial Statements</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have audited the accompanying consolidated balance sheets of Edesa Biotech, Inc. (the &#8220;Company") as of September 30, 2024, and 2023, and the related consolidated statements of operations and comprehensive loss, changes in shareholders&#8217; equity, and cash flows for each of the years in the two-year period ended September 30, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of September 30, 2024 and 2023, and the results of its consolidated operations and its consolidated cash flows for each of the years in the two-year period ended September 30, 2024, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Material Uncertainty Related to Going Concern</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 of the consolidated financial statements, the Company has incurred a net comprehensive loss, negative cash flows from operations and has a net working capital deficiency which raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Basis for Opinion</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<div style="text-align: center;">
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 50%;">
			<div style="text-align: left;"><img alt="footerv1.jpg" src="footerv1.jpg"/></div>
			</td>
			<td style="width: 50%;">
			<div style="text-align: right;"><img alt="footerv2.jpg" src="footerv2.jpg"/></div>
			</td>
		</tr>

</tbody></table>
</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">F-2</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Critical Audit Matters</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Going Concern</i></b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Critical Audit Matter Description</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net working capital deficiency as at September 30, 2024 that raise substantial doubt about its ability to continue as a going concern. The ability of the Company to continue as a going concern is ultimately dependent on its product candidates receiving approval from the Food and Drug Administration, Health Canada and the regulatory authorities of other countries in which its products are proposed to be sold and whether it is able to successfully market the approved products. Management intends to continue to fund its business by way of equity financing. However, the Company has not concluded that these plans alleviate the substantial doubt related to its ability to continue as a going concern. This matter is also described in the &#8220;Material Uncertainty Related to Going Concern&#8221; section of our report.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We identified the Company&#8217;s ability to continue as a going concern as a critical audit matter because auditing the Company&#8217;s going concern assessment is complex and involves a high degree of auditor judgment to assess the reasonableness of the cash flow forecasts.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Audit Response</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We responded to this matter by performing procedures over management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern. Our audit work in relation to this included, but was not restricted to, the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:58pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We evaluated management&#8217;s process for preparing the business plan with forecasted cash flows included in the going concern assessment;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:58pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We assessed the completeness, accuracy, and relevance of underlying data used in management&#8217;s forecast;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:58pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We evaluated the reasonableness of the underlying assumptions included in the forecasted cash flows used by management in their business plan considering the Company&#8217;s current and past performance, the consistency with external market and industry data, and whether these assumptions were consistent with evidence obtained in other areas of the audit; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:58pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We assessed the adequacy of the going concern disclosures included in Note 1 of the consolidated financial statements and considered if these are appropriate to reflect the assessments that management has performed.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:97.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:AuditorName" id="c40">MNP LLP</ix:nonNumeric></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chartered Professional Accountants</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Licensed Public Accountants</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
			</td>
			<td colspan="2" style="vertical-align:top;width:4.5%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:53.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have served as the Company&#8217;s auditor since 2019.</p>
			</td>
			<td style="vertical-align:middle;width:47.3%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:43.5%;">&#160;</td>
			<td style="vertical-align:top;width:11.5%;">&#160;</td>
			<td style="vertical-align:middle;width:47.3%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:53.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="dei:AuditorLocation" id="c41">Toronto, Canada</ix:nonNumeric></p>
			</td>
			<td style="vertical-align:middle;width:47.3%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:43.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 13, 2024</p>
			</td>
			<td style="vertical-align:top;width:11.5%;">&#160;</td>
			<td style="vertical-align:middle;width:47.3%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:43.5%;">&#160;</td>
			<td style="vertical-align:top;width:11.5%;">&#160;</td>
			<td style="vertical-align:middle;width:47.3%;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td style="width: 50%;">
			<div><img alt="footer2.jpg" src="footer2.jpg"/></div>
			</td>
			<td style="width: 50%;">
			<div style="text-align: right;"><img alt="logosmall.jpg" src="logosmall.jpg"/></div>
			</td>
		</tr>

</tbody></table>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><b><a id="Balance_sheets" title="Balance sheets" href="#"></a>EDESA BIOTECH, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Consolidated Balance Sheets</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Current assets:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c45" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" format="ixt:num-dot-decimal" decimals="0">1,037,320</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c46" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" format="ixt:num-dot-decimal" decimals="0">5,361,397</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts and other receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c47" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">270,908</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c48" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">626,543</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c49" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">367,394</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c50" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">448,912</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c51" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,675,622</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c52" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">6,436,852</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Non-current assets:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c54" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c55" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:num-dot-decimal" decimals="0">8,702</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Long-term deposits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c56" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:DepositsAssetsNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">41,151</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c57" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DepositsAssetsNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">173,490</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Intangible asset, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c58" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:num-dot-decimal" decimals="0">2,078,848</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c59" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:num-dot-decimal" decimals="0">2,180,020</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Right-of-use assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"><ix:nonFraction id="c60" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:num-dot-decimal" decimals="0">18,361</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"><ix:nonFraction id="c61" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:num-dot-decimal" decimals="0">91,373</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c62" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:num-dot-decimal" decimals="0">3,813,982</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c63" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:num-dot-decimal" decimals="0">8,890,437</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liabilities and shareholders' equity:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Current liabilities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable and accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c65" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,812,960</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c66" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,747,150</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Short-term right-of-use lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c67" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">19,867</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c68" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">74,714</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c69" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,832,827</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c70" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,821,864</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Non-current liabilities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Long-term right-of-use lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c72" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c73" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">19,773</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c74" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">1,832,827</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c75" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">1,841,637</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commitments <i>(Note 7)</i></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&#160;</i></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Shareholders' equity:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Capital shares</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Authorized <span style="-sec-ix-hidden:c80"><span style="-sec-ix-hidden:c81">unlimited</span></span> common and preferred shares <span style="-sec-ix-hidden:c82"><span style="-sec-ix-hidden:c83">without</span></span> par value</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Issued and outstanding:&#160;<ix:nonFraction id="c84" contextRef="i_2024-09-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c85" contextRef="i_2024-09-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,247,389</ix:nonFraction></ix:nonFraction> common shares (September 30, 2023 - <ix:nonFraction id="c86" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c87" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,075,473</ix:nonFraction></ix:nonFraction>)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c88" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:num-dot-decimal" decimals="0">47,236,024</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c89" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:num-dot-decimal" decimals="0">46,643,151</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Additional paid-in capital</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c90" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:num-dot-decimal" decimals="0">13,576,757</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c91" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:num-dot-decimal" decimals="0">13,039,265</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated other comprehensive loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c92" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">242,613</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c93" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">214,648</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accumulated deficit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c94" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">58,589,013</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c95" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">52,418,968</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total shareholders' equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c96" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">1,981,155</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c97" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">7,048,800</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total liabilities and shareholders' equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c98" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">3,813,982</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c99" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">8,890,437</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><a id="Statements_of_operations" title="Statements of operations" href="#"></a>EDESA BIOTECH, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>Consolidated Statements of Operations and Comprehensive Loss</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Expenses:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c103" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">2,881,967</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c104" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">4,794,549</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c105" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">4,132,777</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c106" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">4,428,209</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Loss from operations</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c107" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">7,014,744</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c108" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">9,222,758</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Other income (loss):</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Reimbursement grant income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c110" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:GovernmentAssistanceNonoperatingIncome" scale="0" format="ixt:num-dot-decimal" decimals="0">698,277</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c111" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:GovernmentAssistanceNonoperatingIncome" scale="0" format="ixt:num-dot-decimal" decimals="0">581,039</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c112" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:InterestIncomeOther" scale="0" format="ixt:num-dot-decimal" decimals="0">153,498</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c113" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:InterestIncomeOther" scale="0" format="ixt:num-dot-decimal" decimals="0">289,846</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Misc other income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c114" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="0" format="ixt:num-dot-decimal" decimals="0">14,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c115" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:OtherNonoperatingIncome" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Foreign exchange loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c116" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">21,042</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c117" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">21,742</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c118" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">845,499</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c119" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">849,143</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Loss before income taxes</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c120" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">6,169,245</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c121" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">8,373,615</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c122" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="0">800</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c123" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="0">800</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net loss</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c124" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">6,170,045</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c125" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">8,374,415</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exchange differences on translation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c126" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">27,965</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c127" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">1,046</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Net comprehensive loss</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c128" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">6,198,010</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c129" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">8,375,461</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average number of common shares</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c130" contextRef="d_2023-10-01_2024-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,197,423</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c131" contextRef="d_2022-10-01_2023-09-30" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,858,929</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Loss per common share - basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c132" contextRef="d_2023-10-01_2024-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">1.93</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c133" contextRef="d_2022-10-01_2023-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.93</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><a id="Cash_flows" title="Cash flows" href="#"></a>EDESA BIOTECH, INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Consolidated Statements of Cash Flows</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from operating activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c137" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">6,170,045</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c138" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">8,374,415</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Adjustments for:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Depreciation and amortization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c140" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:num-dot-decimal" decimals="0">186,049</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c141" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:num-dot-decimal" decimals="0">183,471</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c142" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="0">537,492</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c143" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="0">1,246,457</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Gain on payable forgiveness</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c144" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" decimals="0">14,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c145" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" decimals="0" sign="-">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Changes in working capital items:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts and other receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c147" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">356,339</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c148" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">562,770</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c149" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">197,136</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c150" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">301,504</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable and accrued liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"><ix:nonFraction id="c151" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">17,590</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">(<ix:nonFraction id="c152" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">556,270</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c153" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">4,890,205</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c154" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">6,636,483</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash flows from financing activities:</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from issuance of common shares and warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c156" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:num-dot-decimal" decimals="0">729,387</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c157" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:num-dot-decimal" decimals="0">4,345,017</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Proceeds from exercise of warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c158" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c159" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:num-dot-decimal" decimals="0">770,532</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Payments for issuance costs of common shares and warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c160" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">107,824</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c161" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">285,438</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Repayment of debt</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c162" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" decimals="0">29,532</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c163" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" decimals="0" sign="-">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by financing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c164" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:num-dot-decimal" decimals="0">592,031</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c165" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:num-dot-decimal" decimals="0">4,830,111</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effect of exchange rate changes on cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c166" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">25,903</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c167" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="0">76,850</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net change in cash and cash equivalents</p>
			</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td class="q2qselectedlineitem" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c168" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">4,324,077</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c169" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">1,729,522</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents, beginning of year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c170" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="0">5,361,397</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c171" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="0">7,090,919</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Cash and cash equivalents, end of year</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c172" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="0">1,037,320</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c173" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="0">5,361,397</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><a id="Equity" title="Equity" href="#"></a>EDESA BIOTECH, INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Consolidated Statements of Changes in Shareholders</b>&#8217;<b> Equity</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares #</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Shares</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Additional Paid-in Capital</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Other Comprehensive Loss</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated Deficit</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total Shareholders' Equity</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 26%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2022</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c176" contextRef="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,380,280</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c177" contextRef="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">42,473,099</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c178" contextRef="i_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">11,176,345</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c179" contextRef="i_2022-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">213,602</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c180" contextRef="i_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">44,044,553</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 0.9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c181" contextRef="i_2022-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">9,391,289</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common shares and warrants in equity offering</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c182" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">580,876</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c183" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" scale="0" format="ixt:num-dot-decimal" decimals="0">3,400,191</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c184" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" scale="0" format="ixt:num-dot-decimal" decimals="0">944,828</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c185" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c186" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c187" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" scale="0" format="ixt:num-dot-decimal" decimals="0">4,345,019</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common shares upon exercise of warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c188" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="edsa:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,760</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c189" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="0">994,618</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c190" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">224,087</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c191" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="0">770,531</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common shares upon exercise of restricted share units</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c192" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" decimals="0">13,557</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c193" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" decimals="-1">75,920</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c194" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" decimals="-1" sign="-">75,920</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c195" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c197" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">300,677</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c198" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">28,358</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c199" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueStockIssuanceCosts" scale="0" format="ixt:fixed-zero" decimals="0" sign="-">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c200" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueStockIssuanceCosts" scale="0" format="ixt:fixed-zero" decimals="0" sign="-">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c201" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">329,035</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c204" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="0">1,246,457</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c205" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c207" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="0">1,246,457</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss and comprehensive loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c210" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c211" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">1,046</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c212" contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">8,374,415</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c213" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">8,375,461</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c214" contextRef="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,075,473</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c215" contextRef="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">46,643,151</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c216" contextRef="i_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">13,039,265</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c217" contextRef="i_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">214,648</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>)</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c218" contextRef="i_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">52,418,968</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>)</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c219" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">7,048,800</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance of common shares&#160;</p>
			</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c220" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">171,916</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c221" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="0">729,387</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c222" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c223" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c224" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c225" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="0">729,387</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issuance costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c227" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">136,514</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c228" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueStockIssuanceCosts" scale="0" format="ixt:fixed-zero" decimals="0" sign="-">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c229" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueStockIssuanceCosts" scale="0" format="ixt:fixed-zero" decimals="0" sign="-">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c230" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueStockIssuanceCosts" scale="0" format="ixt:fixed-zero" decimals="0" sign="-">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c231" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="edsa:StockIssuedDuringPeriodValueStockIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">136,514</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c233" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c234" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="0">537,492</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c235" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c237" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="0">537,492</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net loss and comprehensive loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c239" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c240" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c241" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">27,965</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c242" contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">6,170,045</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c243" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">6,198,010</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c244" contextRef="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,247,389</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c245" contextRef="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">47,236,024</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c246" contextRef="i_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">13,576,757</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c247" contextRef="i_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">242,613</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>)</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c248" contextRef="i_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">58,589,013</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>)</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c249" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">1,981,155</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b><a id="Notes" title="Notes" href="#"></a>EDESA BIOTECH, INC.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:NatureOfOperations" id="c250" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>1. Nature of operations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Edesa Biotech, Inc. (the Company or Edesa) is a biopharmaceutical company focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The Company is organized under the laws of British Columbia, Canada and is headquartered in Markham, Ontario. It operates under its wholly owned subsidiaries, Edesa Biotech Research, Inc., an Ontario, Canada corporation, and Edesa Biotech USA, Inc., a California, USA corporation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s common shares trade on The Nasdaq Capital Market in the United States under the symbol &#8220;EDSA&#8221;.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Going Concern</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These consolidated financial statements have been prepared on a going concern basis which presumes the realization of assets and the discharge of liabilities in the normal course of operations for at least the next twelve months.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the year ended September 30, 2024, the Company incurred a comprehensive loss of $<ix:nonFraction id="c252" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">6.2</ix:nonFraction> million resulting in an accumulated deficit of $<ix:nonFraction id="c253" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">58.6</ix:nonFraction> million. For the year ended September 30, 2024, the Company had a net cash outflow from operating activities of $<ix:nonFraction id="c254" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">4.9</ix:nonFraction> million and ended the year with $<ix:nonFraction id="c255" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" format="ixt:num-dot-decimal" decimals="-6">1.0</ix:nonFraction> million in cash and cash equivalents and a net working capital deficit of $<ix:nonFraction id="c256" contextRef="i_2024-09-30" unitRef="USD" name="edsa:WorkingCapitalDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">0.2</ix:nonFraction> million. Subsequent to the year end, the Company received proceeds of $<ix:nonFraction id="c257" contextRef="d_2024-10-01_2024-12-13_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.5</ix:nonFraction> million from the sale of Preferred Shares to the Pardeep Nijhawan Medicine Professional Corporation (PN MPC). The Company&#8217;s ability to continue as a going concern is dependent on obtaining additional funding through financings, other strategic activities as well as via grants, to fund the development of its drug candidates. There can be no assurance that the Company will be successful in raising the necessary financing. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company&#8217;s ability to continue as a going concern.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and, therefore, be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements. These adjustments could be material.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Liquidity</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s operations have historically been funded through issuances of common shares, exercises of common share purchase warrants, convertible preferred shares, convertible loans, government grants and tax incentives.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In August 2022 the Company filed a $<ix:nonFraction id="c258" contextRef="i_2022-08-31" unitRef="USD" name="edsa:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-7">150.0</ix:nonFraction> million shelf registration statement, under which the Company entered into an equity distribution agreement with Canaccord for $<ix:nonFraction id="c259" contextRef="i_2024-08-31_CounterpartyNameAxis-CanaccordMember" unitRef="USD" name="edsa:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-7">20.0</ix:nonFraction> million in gross proceeds, subject to certain offering limitations that&#160;allowed&#160;the Company to offer and sell common shares having an aggregate gross sales price of up to $<ix:nonFraction id="c260" contextRef="i_2024-08-31_CounterpartyNameAxis-CanaccordMember" unitRef="USD" name="edsa:EquityOfferingLimitationAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.4</ix:nonFraction> million (Canaccord ATM). The Canaccord ATM was terminated in October 2024.&#160;In October 2024, the Company entered into an At The Market Offering Agreement with H.C. Wainwright &amp; Co., LLC as a sales agent (HCW ATM) pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $<ix:nonFraction id="c261" contextRef="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember" unitRef="USD" name="edsa:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-4">3.87</ix:nonFraction> million in gross proceeds.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s primary use of cash and cash equivalents is to fund operating expenses, which consist of research and development (R&amp;D) and general and administrative (G&amp;A) expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change in accounts payable and accrued expenses. Net cash used in operating activities was $<ix:nonFraction id="c262" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">4.9</ix:nonFraction> million and $<ix:nonFraction id="c263" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">6.6</ix:nonFraction>&#160;million for the years ended September 30, 2024 and 2023, respectively. The Company incurred net losses of $<ix:nonFraction id="c264" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">6.2</ix:nonFraction> million and $<ix:nonFraction id="c265" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">8.4</ix:nonFraction> million for the years ended September 30, 2024 and 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2024, the Company entered into a Securities Purchase Agreement with PN MPC, an entity controlled by Pardeep Nijhawan, the Company&#8217;s Chief Executive Officer, Secretary and member of the board of directors of the Company, pursuant to which the Company agreed to issue and sell to PN MPC in a private placement, up to $<ix:nonFraction id="c266" contextRef="d_2024-10-01_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-6">5</ix:nonFraction> million of shares (Preferred Shares) of the Company&#8217;s newly designated Series A-1 Convertible Preferred Shares, stated value $<ix:nonFraction id="c267" contextRef="i_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000</ix:nonFraction> per share, each of which is initially convertible into approximately <ix:nonFraction id="c268" contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,903</ix:nonFraction> common shares (Conversion Shares), without par value, of the Company (Common Shares) at a conversion price of $<ix:nonFraction id="c269" contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.445</ix:nonFraction> per Conversion Share, and warrants (Warrants) to purchase Common Shares (Warrant Shares) at an exercise price of $<ix:nonFraction id="c270" contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.445</ix:nonFraction> per Warrant Share. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of Common Shares equal to <ix:nonFraction id="c271" contextRef="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="Pure" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="-2" format="ixt:num-dot-decimal" decimals="2">75</ix:nonFraction>% of the underlying Conversion Shares at a combined purchase price of $<ix:nonFraction id="c272" contextRef="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,272.13</ix:nonFraction> per Preferred Share and related Warrants. Under the Purchase Agreement, PN MPC&#160;has purchased <ix:nonFraction id="c273" contextRef="d_2024-10-01_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">150</ix:nonFraction> Preferred Shares initially convertible into an aggregate of <ix:nonFraction id="c274" contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" format="ixt:num-dot-decimal" decimals="INF">435,414</ix:nonFraction> Conversion Shares and Warrants to purchase up to an aggregate of <ix:nonFraction id="c275" contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">326,560</ix:nonFraction> Warrant Shares for an aggregate purchase price of $<ix:nonFraction id="c276" contextRef="d_2024-10-01_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">1,540,819</ix:nonFraction>. The Warrants expire <span style="-sec-ix-hidden:c277">five</span> years from the issuance date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2023, the Company entered into a multi-year contribution agreement (2023 SIF Agreement) with the Canadian Government&#8217;s Strategic Innovation Fund (SIF). Under the 2023 SIF Agreement, the Government of Canada committed up to C$<ix:nonFraction id="c278" contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="CAD" name="us-gaap:GovernmentAssistanceAwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">23</ix:nonFraction> million in partially repayable funding. Of the C$<ix:nonFraction id="c279" contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="CAD" name="us-gaap:GovernmentAssistanceAwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">23</ix:nonFraction> million committed by SIF, up to C$<ix:nonFraction id="c280" contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="CAD" name="edsa:GovernmentAssistanceAwardAmountNotRepayable" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.8</ix:nonFraction> million is not repayable by the Company. The remaining C$<ix:nonFraction id="c281" contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="CAD" name="edsa:GovernmentAssistanceAwardAmountRepyable" scale="6" format="ixt:num-dot-decimal" decimals="-5">17.2</ix:nonFraction> million is conditionally repayable starting in 2029 only if and when the Company earns gross revenue. See Note 9. In February 2021, the Company signed a contribution agreement with the Canadian government&#8217;s SIF (2021 SIF Agreement), the Company was eligible to receive cash reimbursements up to C$<ix:nonFraction id="c282" contextRef="i_2021-02-28_GovernmentAssistanceTypeAxis-The2021SIFAgreementMember" unitRef="CAD" name="us-gaap:GovernmentAssistanceAwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">14.1</ix:nonFraction> million in the aggregate for certain R&amp;D expenses related to the EB05 clinical development program. All potential funding available under the 2021 SIF Agreement has been received. For the years ended September 30, 2024 and 2023, the Company recorded grant income of $<ix:nonFraction id="c283" contextRef="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="USD" name="us-gaap:GovernmentAssistanceNonoperatingIncome" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.7</ix:nonFraction> million and $<ix:nonFraction id="c284" contextRef="d_2022-10-01_2023-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="USD" name="us-gaap:GovernmentAssistanceNonoperatingIncome" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million respectively related to the 2023 SIF Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2023, the Company entered into a $<ix:nonFraction id="c285" contextRef="i_2023-10-31_CreditFacilityAxis-RevolvingCreditFacilityMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember" unitRef="USD" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" format="ixt:num-dot-decimal" decimals="-7">10.0</ix:nonFraction> million revolving credit agreement with Pardeep Nijhawan Medicine Professional Corporation (Credit Agreement), providing an unsecured revolving credit facility, with a credit limit of $<ix:nonFraction id="c286" contextRef="i_2023-10-31_CreditFacilityAxis-UnsecuredLineOfCreditMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember" unitRef="USD" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.5</ix:nonFraction> million (Credit Limit) which is available immediately. The line of credit bears interest at the Canadian Imperial Bank of Commerce US Base-Interest Rate plus <ix:nonFraction id="c287" contextRef="d_2023-10-01_2023-10-31_CreditFacilityAxis-LineOfCreditMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:num-dot-decimal" decimals="2">3</ix:nonFraction>% per annum and has a maturity date of <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_CreditFacilityAxis-RevolvingCreditFacilityMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember" name="us-gaap:DebtInstrumentMaturityDate" id="c288" format="ixt:date-monthname-day-year-en">March 31, 2026</ix:nonNumeric>, unless terminated earlier by either party with 90 days&#8217; notice. Advances under the line of credit are tied to a borrowing base (Borrowing Base) consisting of eligible grant receivables from SIF, future potential license fee receivables and any other accounts receivable. At no time shall the aggregate principal amount of all advances outstanding exceed the lesser of (i) the Credit Limit and (ii) an amount equal to <ix:nonFraction id="c289" contextRef="i_2023-10-31_CreditFacilityAxis-RevolvingCreditFacilityMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember" unitRef="Pure" name="edsa:DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal" scale="-2" format="ixt:num-dot-decimal" decimals="2">85</ix:nonFraction>% of the Borrowing Base. No amounts have been drawn upon from the Credit Agreement. The Credit Agreement was terminated in October 2024.</p>

<ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:exclude>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In March 2023, the Company entered into an equity distribution agreement with Canaccord, as sales agent, pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $<ix:nonFraction id="c290" contextRef="i_2023-03-31_CounterpartyNameAxis-CanaccordMember" unitRef="USD" name="edsa:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-7">20</ix:nonFraction> million in gross proceeds, subject to certain offering limitations that currently allows the Company to offer and sell common shares having an aggregate gross sales price of up to $<ix:nonFraction id="c291" contextRef="i_2023-03-31_CounterpartyNameAxis-CanaccordMember" unitRef="USD" name="edsa:EquityOfferingLimitationAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.4</ix:nonFraction> million. At September 30, 2024, the Company sold a total of <ix:nonFraction id="c292" contextRef="d_2023-03-01_2023-09-30_CounterpartyNameAxis-CanaccordMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">171,916</ix:nonFraction>&#160;common shares pursuant to the agreement for gross proceeds of approximately $<ix:nonFraction id="c293" contextRef="d_2023-03-01_2023-09-30_CounterpartyNameAxis-CanaccordMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.7</ix:nonFraction>&#160;million.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In November 2022, the Company completed a private placement of units consisting of <ix:nonFraction id="c294" contextRef="d_2022-11-01_2022-11-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">384,475</ix:nonFraction> common shares, 12-month warrants to purchase up to an aggregate of <ix:nonFraction id="c296" contextRef="i_2022-11-30_ClassOfWarrantOrRightAxis-TwelveMonthWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">192,248</ix:nonFraction> common shares and 3-year warrants to purchase up to an aggregate of <ix:nonFraction id="c298" contextRef="i_2022-11-30_ClassOfWarrantOrRightAxis-ThreeYearWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">192,248</ix:nonFraction> common shares. The gross proceeds from this offering are approximately $<ix:nonFraction id="c299" contextRef="d_2022-11-01_2022-11-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-6">3.0</ix:nonFraction> million, before offering expenses.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="c300" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>2. Basis of preparation</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Edesa Biotech Research, Inc. and Edesa Biotech USA, Inc. All intercompany balances and transactions have been eliminated upon consolidation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c302" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>3. Significant accounting policies</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:UseOfEstimates" id="c639190829575506" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Use of estimates</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period or year. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are valuation of accounts and other receivable; valuation and useful lives of property and equipment; intangible assets; right-of-use assets; deferred income taxes; the determination of fair value of share-based compensation; the determination of fair value of warrants in order to allocate proceeds from equity issuances; and forecasting future cash flows for assessing the going concern assumption.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="edsa:FunctionalAndReportingCurrenciesPolicyTextBlock" id="c966581253800766" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Functional and reporting currencies</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company&#8217;s and its wholly owned subsidiary&#8217;s, Edesa Biotech USA, Inc., functional currency. The functional currency of the Company&#8217;s wholly owned subsidiary, Edesa Biotech Research, Inc., as determined by management, is Canadian dollars.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c836664419973752" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Cash and cash equivalents</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Cash and cash equivalents consist of demand deposits with financial institutions held in checking, savings and money market mutual funds and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="c1422156294653866" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Accounts and other receivables</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company assesses the collectability of its accounts receivables through a review of its current aging and payment terms, as well as an analysis of its historical collection rate, general economic conditions and credit status of the government agencies. Accounts and other receivables include reimbursement grant income for the Company&#8217;s federal grant with the Canadian government&#8217;s SIF and Harmonized Sales Tax (HST) refunds receivables. As of September 30, 2024, all outstanding accounts, grants and HST refunds receivables were deemed to be fully collectible, and therefore, <span style="-sec-ix-hidden:c304">no</span> allowance for doubtful accounts was recorded.</p>
</ix:nonNumeric>

<ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:exclude>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c1387511810497948" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Property and equipment&#160;</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Property and equipment are recorded at historical cost less accumulated depreciation and any accumulated impairment losses. Depreciation is recorded to write off the cost of assets less their residual values over their useful lives, using the declining balance and straight-line methods. Maintenance and repair expenditures that do not improve or extend the life are expensed in the period incurred. Any gain or loss arising on the disposal or retirement of an item of property and equipment is recognized as the difference between the sales proceeds and the carrying amount of the asset. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. The Company capitalizes expenditures greater than $<ix:nonFraction id="c305" contextRef="d_2024-09-30_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-CapitalizedCostsPropertyPlantAndEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" decimals="-3">5,000</ix:nonFraction>. The Company changed its depreciation policy to straight line depreciation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The depreciation policy for the principal asset categories are calculated as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Computer equipment <ix:nonFraction id="c306" contextRef="d_2023-10-01_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="Pure" name="edsa:DepreciationDecliningBalanceMethodPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="1">30</ix:nonFraction>% declining balance method or straight line <ix:nonNumeric contextRef="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c307" format="ixt-sec:duryear">3</ix:nonNumeric> years</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Furniture and equipment <ix:nonFraction id="c308" contextRef="d_2023-10-01_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember" unitRef="Pure" name="edsa:DepreciationDecliningBalanceMethodPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="1">20</ix:nonFraction>% declining balance method&#160;or straight line for <ix:nonNumeric contextRef="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c309" format="ixt-sec:duryear">4</ix:nonNumeric> years</p>
			</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="c327390431310141" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Intangible assets</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Intangible assets represent the exclusive world-wide rights to know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights, acquired by entering into a license agreement with a pharmaceutical development company. Unless earlier terminated, the term of the license agreement will remain in effect for <ix:nonNumeric contextRef="i_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="c310" format="ixt-sec:duryear">25</ix:nonNumeric> years from the date of first commercial sale of licensed products containing the Constructs. Subsequently, the license agreement will automatically renew for <span style="-sec-ix-hidden:c311">five</span>-year periods unless either party terminates the agreement in accordance with its terms. Intangible assets are stated at their historical cost, amortized on a straight-line basis over their expected useful lives, which is <ix:nonNumeric contextRef="i_2024-09-30" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="c312" format="ixt-sec:duryear">25</ix:nonNumeric> years, and subject to impairment review at the end of each year.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="c668638655877454" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Impairment of long-lived assets</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Long-lived assets are tested for impairment when indicators of impairment exist. When a significant change in the expected timing or amount of the future cash flows of the financial asset is identified, the carrying amount of the financial asset is reduced and the amount of the write-down is recognized as a loss.&#160;</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c694622031279516" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Right-of-Use assets and liabilities</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company recognizes right-of-use (ROU) assets and liabilities on the balance sheet for operating leases with terms longer than 12 months. The Company follows the ongoing practical expedient not to recognize ROU assets and liabilities for short-term leases. The ROU assets are initially measured at cost and amortized using the straight-line method through the end of the lease term. The ROU liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the Company's incremental borrowing rate.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c1411762973614573" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Fair value measurement</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company uses the fair value measurement framework for valuing financial assets and liabilities. See Note 11.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="c795091054421726" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Reimbursement Grant Income</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Reimbursement grant income is recognized based on the reimbursement rate included in the government contribution agreement when allowable expenses have been incurred.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c270227033747032" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Research and development</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Research and development expenses principally consist of (i) contract research organizations for clinical trial management services, (ii) contract manufacturing organizations for manufacturing the drug compound(s) for use in clinical trials and (iii) salaries of employees directly involved in research and development efforts. Research and development costs are expensed as incurred.</p>
</ix:nonNumeric>

<ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:exclude>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c928472350889880" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Share-based compensation</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company has equity incentive plans under which various types of equity-based awards including share options, restricted shares and restricted share unit awards may be granted to employees, non-employee directors and non-employee consultants and warrants that may be granted as compensation to non-employees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company recognizes compensation expense for all share-based awards based on the estimated grant-date fair values. For restricted share unit awards to employees, the fair value is based on the 5-day volume weighted average price (VWAP) of the Company&#8217;s common shares up to the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The fair value of share options is determined using the Black-Scholes option pricing model. The Company utilizes a dividend yield of <span style="-sec-ix-hidden:c313">zero</span> based on the fact that the Company has never paid cash dividends and has no current intention of paying cash dividends. The Company elected an accounting policy to record forfeitures as they occur. See Note 8 for a discussion of the assumptions used by the Company in determining the grant date fair value of options granted under the Black-Scholes option pricing model, as well as a summary of the share option activity under the Company&#8217;s share-based compensation plan for all years presented.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The provisions of the Company&#8217;s share-based compensation plans do not require the Company to settle any options or restricted share units by transferring cash or other assets, and therefore the Company classifies the awards as equity.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="c938865703043656" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Translation of foreign currency transactions</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s reporting currency is the U.S. dollar. The financial statements of the wholly owned Canadian subsidiary is measured using the Canadian dollar as the functional currency. Assets and liabilities of the Canadian operation have been translated at year-end exchange rates and related revenue and expenses have been translated at average exchange rates for the year. Accumulated gains and losses resulting from the translation of the financial statements of the Canadian operation are included as part of accumulated other comprehensive loss, a separate component of shareholders&#8217; equity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">For other transactions denominated in currencies other than the Company&#8217;s functional currency, the monetary assets and liabilities are translated at the year-end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. Non-monetary balance sheet and related income statement accounts are remeasured into U.S. dollar using historical exchange rates. All of the exchange gains or losses resulting from these other transactions are recognized in the statements of operations and comprehensive loss.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:IncomeTaxPolicyTextBlock" id="c271959260953430" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Income taxes</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company assesses the likelihood of the financial statement effect of a tax position that should be recognized when it is more likely than not that the position will be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information available as of the reporting date. The Company is subject to examination by taxing authorities in Canada and the U.S. Management does not believe that there are any uncertain tax positions that would result in an asset or liability for taxes being recognized in the accompanying financial statements. The Company recognizes tax-related interest and penalties, if any, as a component of income tax expense.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company accounts for income taxes on a tax jurisdictional basis. The Company files income tax returns in Canada, the provinces of British Columbia and Ontario, the U.S. and the state of California.</p>
</ix:nonNumeric>

<ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:exclude>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c1519160923970575" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Earnings (loss) per share</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Basic earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the year.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The computation of diluted earnings (loss) per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings (loss) per share. The dilutive effect of convertible securities would be reflected in diluted earnings per share by application of the &#8220;if converted&#8221; method. The dilutive effect of outstanding share options and warrants and their equivalents would be reflected in diluted earnings per share by application of the treasury stock method. However, conversion of outstanding share options and warrants would have an antidilutive effect on loss per share for the years ended September 30, 2024 and 2023 and are therefore excluded from the computation of diluted loss per share. See Note 8 for share options and warrants at September 30, 2024 and 2023.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c1216021672145377" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Segmented information</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s operations comprise a single reportable segment engaged in the research and development, manufacturing and commercialization of innovative pharmaceutical products. As the operations comprise a single reportable segment, amounts disclosed in the consolidated financial statements for net loss, comprehensive loss, depreciation and total assets also represent segmented amounts.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c1664667839609038" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Adoption of recent accounting pronouncements</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On October 1, 2022, the Company adopted Accounting Standards Update ASU 2021-10 Disclosure by Business Entities About Government Assistance, modifying ASC Topic 832, Government Assistance. The amendments in ASU 2021-10 require disclosure of information about certain types of government assistance received. The Company expanded its disclosures related to government assistance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Future accounting pronouncements</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In November 2023, the FASB issued Accounting Standards Update ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of&#160;Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation&#160;table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c331" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>4. Property and equipment</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Property and equipment, net consisted of the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c349" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2023</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c351" contextRef="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:num-dot-decimal" decimals="0">46,945</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c352" contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:num-dot-decimal" decimals="0">46,945</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c353" contextRef="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:num-dot-decimal" decimals="0">5,603</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c354" contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:num-dot-decimal" decimals="0">5,603</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c355" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:num-dot-decimal" decimals="0">52,548</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c356" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:num-dot-decimal" decimals="0">52,548</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c357" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:num-dot-decimal" decimals="0">52,548</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c358" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:num-dot-decimal" decimals="0">43,846</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciable assets, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c359" contextRef="i_2024-09-30" unitRef="USD" name="edsa:PropertyPlantAndEquipmentNetIncludingAssetsNotInService" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c360" contextRef="i_2023-09-30" unitRef="USD" name="edsa:PropertyPlantAndEquipmentNetIncludingAssetsNotInService" scale="0" format="ixt:num-dot-decimal" decimals="0">8,702</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets not in service</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c361" contextRef="i_2024-09-30" unitRef="USD" name="edsa:PropertyPlantAndEquipmentAssetsNotInService" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c362" contextRef="i_2023-09-30" unitRef="USD" name="edsa:PropertyPlantAndEquipmentAssetsNotInService" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c363" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c364" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:num-dot-decimal" decimals="0">8,702</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Depreciation expense amounted to $<ix:nonFraction id="c347" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="0">8,702</ix:nonFraction> and $<ix:nonFraction id="c348" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:Depreciation" scale="0" format="ixt:num-dot-decimal" decimals="0">4,328</ix:nonFraction> for the years ended September 30, 2024 and 2023, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="c365" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>5. Intangible assets</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Acquired license</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In April 2020, the Company entered into a license agreement with a pharmaceutical development company to obtain exclusive world-wide rights to know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights. Unless earlier terminated, the term of the license agreement will remain in effect for <ix:nonNumeric contextRef="i_2020-04-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="c367" format="ixt-sec:duryear">25</ix:nonNumeric> years from the date of first commercial sale of licensed products containing the Constructs. Subsequently, the license agreement will automatically renew for <span style="-sec-ix-hidden:c368">five</span>-year periods unless either party terminates the agreement in accordance with its terms.</p>

<ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:exclude>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the license agreement, the Company is exclusively responsible, at its expense, for the research, development manufacture, marketing, distribution and commercialization of the Constructs and licensed products and to obtain all necessary licenses and rights. The Company is required to use commercially reasonable efforts to develop and commercialize the Constructs in accordance with the terms of a development plan established by the parties.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company has determined that the license has multiple alternative future uses in research and development projects and sublicensing in other countries or for other disease indications. The value of the acquired license is recorded as an intangible asset with amortization over the estimated useful life of <ix:nonNumeric contextRef="i_2020-04-30" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="c369" format="ixt-sec:duryear">25</ix:nonNumeric> years and evaluation for impairment at the end of each reporting period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The required upfront license payment of $<ix:nonFraction id="c370" contextRef="d_2020-04-01_2020-04-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember" unitRef="USD" name="edsa:UpfrontLicensePayment" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.5</ix:nonFraction> million was paid by issuance of Series A-1 Convertible Preferred Shares, which have been fully converted to common shares. The value of the license includes acquisition legal costs. See Note 7 for license commitments.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Intangible assets, net consisted of the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="c386" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024 </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023 </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Constructs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c388" contextRef="i_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TheConstructsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" format="ixt:num-dot-decimal" decimals="0">2,529,483</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c389" contextRef="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TheConstructsMember" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" format="ixt:num-dot-decimal" decimals="0">2,529,483</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated amortization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c390" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" format="ixt:num-dot-decimal" decimals="0">450,635</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c391" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" format="ixt:num-dot-decimal" decimals="0">349,463</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intangible assets, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c392" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:num-dot-decimal" decimals="0">2,078,848</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c393" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:num-dot-decimal" decimals="0">2,180,020</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Amortization expense amounted to $<ix:nonFraction id="c377" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" format="ixt:num-dot-decimal" decimals="-6"><ix:nonFraction id="c378" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" format="ixt:num-dot-decimal" decimals="-6">101,172</ix:nonFraction></ix:nonFraction> for each of the years ended September 30, 2024, and 2023, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Total estimated future amortization of intangible assets for each fiscal year is as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="c394" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c396" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" format="ixt:num-dot-decimal" decimals="0">101,172</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c397" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" format="ixt:num-dot-decimal" decimals="0">101,172</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c398" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" format="ixt:num-dot-decimal" decimals="0">101,172</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c399" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" format="ixt:num-dot-decimal" decimals="0">101,172</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c400" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" format="ixt:num-dot-decimal" decimals="0">101,172</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c401" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="0" format="ixt:num-dot-decimal" decimals="0">1,572,988</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c402" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" format="ixt:num-dot-decimal" decimals="0">2,078,848</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:LesseeOperatingLeasesTextBlock" id="c403" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>6. Right-of-Use Asset and Liabilities</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Related party ROU asset and liability</i>&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company leases a facility used for executive offices from a related company. The original lease expired in December 2022 and the Company executed a <span style="-sec-ix-hidden:c405">two</span>-year term extension through December 31, 2024.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The components of lease cost were as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:LeaseCostTableTextBlock" id="c420" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use lease cost, included in general and administrative on the Statements of Operations</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c422" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="0">78,073</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c423" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="0" format="ixt:num-dot-decimal" decimals="0">82,358</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Lease terms and discount rates were as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="edsa:LeaseTermAndDiscountRateTableTextBlock" id="c424" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remaining lease term (months):</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2024-09-30" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="c426" format="ixt-sec:durmonth">3</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="i_2023-09-30" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="c427" format="ixt-sec:durmonth">15</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Estimated incremental borrowing rate:</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c428" contextRef="i_2024-09-30" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">9.2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>%</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c429" contextRef="i_2023-09-30" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:num-dot-decimal" decimals="3">9.2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>%</b></td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The approximate future minimum lease payments under operating leases at September 30, 2024 were as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="c430" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c432" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" format="ixt:num-dot-decimal" decimals="0">20,019</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c433" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" format="ixt:num-dot-decimal" decimals="0">20,019</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less imputed interest</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c434" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" format="ixt:num-dot-decimal" decimals="0">152</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of right-of-use lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c435" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="0" format="ixt:num-dot-decimal" decimals="0">19,867</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value included in current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c436" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">19,867</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value included in long-term liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c437" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Cash flow information was as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="edsa:LeasesCashFlowInformationTableTextBlock" id="c438" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for amounts included in the measurement of right-of-use lease liabilities, included in accounts payable and accrued liabilities on the Statements of Cash Flow.</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c440" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:num-dot-decimal" decimals="0">77,954</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c441" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:num-dot-decimal" decimals="0">79,222</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c442" escape="true">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>7. Commitments</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and other commitments</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company has commitments for contracted research organizations who perform clinical trials for the Company&#8217;s ongoing clinical studies and other service providers. Aggregate future contractual payments at September 30, 2024 are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="c467" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c469" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" format="ixt:num-dot-decimal" decimals="0">212,667</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c470" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" format="ixt:num-dot-decimal" decimals="0">34,667</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c471" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" format="ixt:num-dot-decimal" decimals="0">34,666</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c472" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:ContractualObligationDueInFourthYear" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"><ix:nonFraction id="c473" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:ContractualObligationDueInFifthYear" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c474" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:ContractualObligation" scale="0" format="ixt:num-dot-decimal" decimals="0">282,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>License and royalty commitments</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In April 2020, through its Ontario subsidiary, the Company entered into a license agreement with a third party to obtain exclusive world-wide rights to certain know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights. An intangible asset for the acquired license has been recognized. See Note 5 for intangible assets. Under the license agreement, the Company is committed to payments of up to an aggregate amount of $<ix:nonFraction id="c450" contextRef="i_2020-04-30_TypeOfArrangementAxis-TheConstructsMember" unitRef="USD" name="edsa:MaximumContingentObligation" scale="6" format="ixt:num-dot-decimal" decimals="-6">356</ix:nonFraction> million contingent upon meeting certain milestones outlined in the license agreement, primarily relating to future potential commercial approval and sales milestones. The Company also has a commitment to pay royalties based on any net sales of products containing the Constructs in the countries where the Company directly commercializes the products containing the Constructs and a percentage of any sublicensing revenue received by the Company and its affiliates in the countries where it does not directly commercialize the products containing the Constructs. <span style="-sec-ix-hidden:c451"><span style="-sec-ix-hidden:c452">No</span></span> milestone, royalty or sublicensing payments were made to the third party during the years ended September 30, 2024 and 2023. In connection with this license agreement and pursuant to a purchase agreement entered into in April 2020, the Company acquired drug substance of one of the Constructs for an aggregate purchase price of $<ix:nonFraction id="c453" contextRef="i_2020-04-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember" unitRef="USD" name="us-gaap:PurchaseObligation" scale="6" format="ixt:num-dot-decimal" decimals="-6">5.0</ix:nonFraction> million. <span style="-sec-ix-hidden:c454"><span style="-sec-ix-hidden:c455">No</span></span> expense was recorded during the years ended September 30, 2024 and September 30, 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In 2016, through its Ontario subsidiary, the Company entered into a license agreement with a third party to obtain exclusive rights to certain know-how, patents and data relating to a pharmaceutical product. The Company will use the exclusive rights to develop the product for therapeutic, prophylactic and diagnostic uses in topical dermal applications and anorectal applications. <span style="-sec-ix-hidden:c456">No</span> intangible assets have been recognized under the license agreement with the third party. Under the license agreement, the Company is committed to payments of various amounts to the third party upon meeting certain milestones outlined in the license agreement, up to an aggregate amount of $<ix:nonFraction id="c457" contextRef="i_2016-12-31_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember" unitRef="USD" name="edsa:MaximumContingentObligation" scale="6" format="ixt:num-dot-decimal" decimals="-5">18.4</ix:nonFraction> million. Upon divestiture of substantially all of the assets of the Company, the Company shall pay the third party a percentage of the valuation of the licensed technology sold as determined by an external objective expert. The Company also has a commitment to pay the third party a royalty based on net sales of the product in countries where the Company, or an affiliate, directly commercializes the product and a percentage of sublicensing revenue received by the Company and its affiliates in the countries where it does not directly commercialize the product. <span style="-sec-ix-hidden:c458"><span style="-sec-ix-hidden:c459">No</span></span> license or royalty payments were made to the third party during the years ended September 30, 2024 and 2023, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In March 2021, through its Ontario subsidiary, the Company entered into a license agreement with the inventor of the same pharmaceutical product to acquire global rights for all fields of use beyond those named under the 2016 license agreement. For the years ended September 30, 2024 and 2023, the Company recorded expenses of $<ix:nonFraction id="c460" contextRef="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" unitRef="USD" name="edsa:MilestoneExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">100,000</ix:nonFraction> and $<ix:nonFraction id="c461" contextRef="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" unitRef="USD" name="edsa:MilestoneExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">50,000</ix:nonFraction>, respectively, as a result of meeting milestones outlined in the 2021 license agreement. The Company is committed to remaining payments of up to an aggregate amount of $<ix:nonFraction id="c462" contextRef="i_2024-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" unitRef="USD" name="edsa:MaximumContingentObligation" scale="6" format="ixt:num-dot-decimal" decimals="-5">68.9</ix:nonFraction> million, primarily relating to future potential commercial approval and sales milestones. In addition, if the Company fails to file an investigational new drug application or foreign equivalent (IND) for the product within a certain period of time following the date of the agreement, the Company is required to remit to the inventor a fixed license fee quarterly as long as the requirement to file an IND remains unfulfilled.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Retirement savings plan 401(k) contributions</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Executive officers and employees of the California subsidiary are eligible to receive the Company&#8217;s non-elective safe harbor employer contribution of <ix:nonFraction id="c463" contextRef="d_2023-10-01_2024-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember" unitRef="Pure" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" format="ixt:num-dot-decimal" decimals="2">3</ix:nonFraction>% of eligible compensation under a 401(k) plan to provide retirement benefits. Employees are <ix:nonFraction id="c464" contextRef="d_2023-10-01_2024-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="0">100</ix:nonFraction>% vested in employer contributions and in any voluntary employee contributions. Contributions to the 401(k) plan were $<ix:nonFraction id="c465" contextRef="d_2023-10-01_2024-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt:num-dot-decimal" decimals="0">17,870</ix:nonFraction> and $<ix:nonFraction id="c466" contextRef="d_2022-10-01_2023-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt:num-dot-decimal" decimals="0">16,872</ix:nonFraction> during the years ended September 30, 2024 and 2023, respectively.</p>

<ix:exclude><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p></ix:exclude>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c475" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>8. Capital shares</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Equity offerings</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On November 2, 2022, the Company completed a private placement of units consisting of <ix:nonFraction id="c477" contextRef="d_2022-11-02_2022-11-02_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">384,475</ix:nonFraction> common shares, Class A warrants to purchase up to an aggregate of <ix:nonFraction id="c478" contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassAWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">192,248</ix:nonFraction> common shares and Class B warrants to purchase up to an aggregate of <ix:nonFraction id="c479" contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassBWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">192,248</ix:nonFraction> common shares. Net proceeds from the offering were $<ix:nonFraction id="c480" contextRef="d_2022-11-02_2022-11-02_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.9</ix:nonFraction> million, which were allocated between the relative fair values of the common shares (using a fair value of $<ix:nonFraction id="c481" contextRef="d_2022-11-02_2022-11-02_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.7</ix:nonFraction> million) and the common share purchase warrants (using a total fair value of $<ix:nonFraction id="c482" contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.2</ix:nonFraction> million). The warrants became exercisable December 23, 2022. The Class A warrants have an exercise price of $<ix:nonFraction id="c483" contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassAWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">10.50</ix:nonFraction> per share and will expire on <ix:nonNumeric contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassAWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="c484" format="ixt:date-monthname-day-year-en">December 23, 2025</ix:nonNumeric>. The Class B warrants have an exercise price of $<ix:nonFraction id="c485" contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassBWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.00</ix:nonFraction> per share and expired on <ix:nonNumeric contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassBWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="c486" format="ixt:date-monthname-day-year-en">December 23, 2023</ix:nonNumeric>. The warrants are considered contracts on the Company&#8217;s own shares and are classified as equity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Equity distribution agreement</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On March 27, 2023, the Company entered into the Canaccord ATM, pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $<ix:nonFraction id="c487" contextRef="i_2023-03-27_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember" unitRef="USD" name="edsa:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-7">20.0</ix:nonFraction> million in gross proceeds, subject to certain offering limitations that currently allow the Company to offer and sell common shares having an aggregate gross sales price of up to $<ix:nonFraction id="c488" contextRef="i_2023-03-27_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember" unitRef="USD" name="edsa:EquityOfferingLimitationAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.4</ix:nonFraction> million. The Company has no obligation to sell any of the common shares and may at any time suspend sales or terminate the equity distribution agreement in accordance with its terms. During the year ended September 30, 2024, the Company sold a total of <ix:nonFraction id="c489" contextRef="d_2023-10-01_2024-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">171,916</ix:nonFraction> common shares pursuant to the agreement for gross proceeds of approximately $<ix:nonFraction id="c490" contextRef="d_2023-10-01_2024-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.7</ix:nonFraction> million. During the year ended September 30, 2023, the Company sold a total of <ix:nonFraction id="c491" contextRef="d_2022-10-01_2023-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">196,401</ix:nonFraction> common shares pursuant to the agreement for gross proceeds of approximately $<ix:nonFraction id="c492" contextRef="d_2022-10-01_2023-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.3</ix:nonFraction> million. The Canaccord ATM was terminated on October 3, 2024.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>At The Market Offering Agreement</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 14pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On October 4, 2024, the Company entered into an At The Market Offering Agreement with H.C. Wainwright &amp; Co., LLC as a sales agent (HCW ATM) pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $<ix:nonFraction id="c493" contextRef="i_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember" unitRef="USD" name="edsa:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-4">3.87</ix:nonFraction> million in gross proceeds. The Company has no obligation to sell any of the common shares and may at any time suspend sales or terminate the equity distribution agreement in accordance with its terms. Subsequent to the year ended September 30, 2024, the Company sold a total of <ix:nonFraction id="c494" contextRef="d_2024-10-01_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">220,269</ix:nonFraction> common shares pursuant to the agreement for net proceeds of approximately $<ix:nonFraction id="c495" contextRef="d_2024-10-01_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million after deducting sales agent commissions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Black-Scholes option valuation model</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company uses the Black-Scholes option valuation model to determine the fair value of share-based compensation for share options and compensation warrants granted and the fair value of warrants issued. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company calculates expected volatility based on historical volatility of the Company&#8217;s share price. When there is insufficient data available, the Company uses a peer group that is publicly traded to calculate expected volatility. The Company adopted interest-free rates by reference to the U.S. treasury yield rates. The Company calculated the fair value of share options granted based on the expected life of <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c496" format="ixt-sec:duryear">5</ix:nonNumeric> years considering expected forfeitures during the option term of <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c497" format="ixt-sec:duryear">10</ix:nonNumeric> years. Expected life of warrants is based on warrant terms. The Company did not and is <span style="-sec-ix-hidden:c498">not</span> expected to declare any dividends. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company&#8217;s warrants and share options.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Warrants</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">A summary of the Company&#8217;s warrants activity is as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c7C4025B2-7ACE-4B79-8DAB-5A47A66C42F6" escape="true" continuedAt="BC983EAF-A4FD-4A39-BD52-AAA9AAF76D1C">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Warrant Shares (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Exercise Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2022</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c649" contextRef="i_2022-09-30" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">521,718</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c650" contextRef="i_2022-09-30" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">28.00</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c651" contextRef="d_2022-10-01_2023-09-30" unitRef="Share" name="edsa:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">384,496</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c652" contextRef="d_2022-10-01_2023-09-30" unitRef="USDPerShare" name="edsa:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.75</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c653" contextRef="d_2022-10-01_2023-09-30" unitRef="Share" name="edsa:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">100,760</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c654" contextRef="d_2022-10-01_2023-09-30" unitRef="USDPerShare" name="edsa:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.65</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c655" contextRef="d_2022-10-01_2023-09-30" unitRef="Share" name="edsa:ClassOfWarrantOrRightExpiredDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">84,545</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c656" contextRef="d_2022-10-01_2023-09-30" unitRef="USDPerShare" name="edsa:ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">37.29</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c657" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">720,909</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c658" contextRef="i_2023-09-30" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">19.51</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c659" contextRef="d_2023-10-01_2024-09-30" unitRef="Share" name="edsa:ClassOfWarrantOrRightExpiredDuringPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">111,192</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c660" contextRef="d_2023-10-01_2024-09-30" unitRef="USDPerShare" name="edsa:ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.26</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c661" contextRef="i_2024-09-30" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">609,717</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c662" contextRef="i_2024-09-30" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">21.74</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The weighted average contractual life remaining on the outstanding warrants at September 30, 2024 is <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="edsa:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" id="c513" format="ixt-sec:durmonth">29</ix:nonNumeric> months.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table summarizes information about the warrants outstanding at September 30, 2024:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<ix:continuation id="BC983EAF-A4FD-4A39-BD52-AAA9AAF76D1C">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Warrants (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Prices </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiry Dates</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c665" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantOneMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,687</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c666" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantOneMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">22.40</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c667">January 2025</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c668" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantTwoMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">173,614</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c669" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantTwoMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">10.50</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c670">December 2025</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c671" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantThreeMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">15,627</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c672" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantThreeMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">56.00</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c673">February 2026</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c674" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFourMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">27,399</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c675" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFourMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">31.94</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c676">March 2027</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;"><ix:nonFraction id="c677" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFiveMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">391,390</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c678" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFiveMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">24.64</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c679">September 2027</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c680" contextRef="i_2024-09-30" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">609,717</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 59%;">&#160;</td>
		</tr>

</tbody></table>
</ix:continuation>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">There were no warrants issued during the year ended September 30, 2024. The fair value of warrants issued during the year ended September 30, 2023 were estimated using the Black-Scholes option valuation model using the following assumptions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="c681" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended September 30,2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Class A Warrants</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Class B Warrants</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c683" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.54</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c684" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.76</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (years)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><ix:nonFraction id="c685" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.14</ix:nonFraction></p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><ix:nonFraction id="c686" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.14</ix:nonFraction></p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected share price volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c687" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="4">90.73</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c688" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="3">89.70</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c689" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.00</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c690" contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.00</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Share options</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company adopted an Equity Incentive Compensation Plan in 2019 (the 2019 Plan) administered by the independent members of the Board of Directors, which amended and restated prior plans. Options, restricted shares and restricted share units are eligible for grant under the 2019 Plan. The total number of shares available for issuance under the terms of the 2019 Plan is <ix:nonFraction id="c538" contextRef="i_2024-09-30_PlanNameAxis-The2019PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">642,737</ix:nonFraction>. The remaining number of shares available to grant at September 30, 2024 is <ix:nonFraction id="c539" contextRef="i_2024-09-30_PlanNameAxis-The2019PlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">141,099</ix:nonFraction>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s 2019 Plan allows options to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the option term is not to exceed <ix:nonNumeric contextRef="d_2024-09-30_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2019PlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c540" format="ixt-sec:duryear">10</ix:nonNumeric> years and the exercise price of each option is determined by the independent members of the Board of Directors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Options have been granted under the 2019 Plan allowing the holders to purchase common shares of the Company as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c691" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Options (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Exercise Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Grant Date Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2022</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c693" contextRef="i_2022-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">314,853</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c694" contextRef="i_2022-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">32.62</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c695" contextRef="i_2022-09-30" unitRef="USDPerShare" name="edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">23.94</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c696" contextRef="d_2022-10-01_2023-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">118,579</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c697" contextRef="d_2022-10-01_2023-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">7.47</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c698" contextRef="d_2022-10-01_2023-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.23</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c699" contextRef="d_2022-10-01_2023-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">12,779</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c700" contextRef="d_2022-10-01_2023-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">22.76</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c701" contextRef="d_2022-10-01_2023-09-30" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">16.23</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c702" contextRef="d_2022-10-01_2023-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">38</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c703" contextRef="d_2022-10-01_2023-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,973.20</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c704" contextRef="d_2022-10-01_2023-09-30" unitRef="USDPerShare" name="edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,973.20</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c705" contextRef="i_2023-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">420,615</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c706" contextRef="i_2023-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">25.60</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c707" contextRef="i_2023-09-30" unitRef="USDPerShare" name="edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">18.84</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c708" contextRef="d_2023-10-01_2024-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">500</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c709" contextRef="d_2023-10-01_2024-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.10</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c710" contextRef="d_2023-10-01_2024-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.10</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c711" contextRef="d_2023-10-01_2024-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,401</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c712" contextRef="d_2023-10-01_2024-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">15.00</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c713" contextRef="d_2023-10-01_2024-09-30" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">10.70</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c714" contextRef="d_2023-10-01_2024-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">35,674</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c715" contextRef="d_2023-10-01_2024-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">33.18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c716" contextRef="d_2023-10-01_2024-09-30" unitRef="USDPerShare" name="edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">25</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c717" contextRef="i_2024-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">383,040</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c718" contextRef="i_2024-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">24.93</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c719" contextRef="i_2024-09-30" unitRef="USDPerShare" name="edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">18.33</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">There were <span style="-sec-ix-hidden:c568"><span style="-sec-ix-hidden:c569">no</span></span> options exercised during the years ended September 30, 2024 or September 30, 2023.&#160;The intrinsic value of options outstanding at September 30, 2024 was $<ix:nonFraction id="c570" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:num-dot-decimal" decimals="0">200.00</ix:nonFraction>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The weighted average contractual life remaining on the outstanding options at September 30, 2024 is&#160;<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c571" format="ixt-sec:durmonth">80</ix:nonNumeric> months.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table summarizes information about the options under the 2019 Plan outstanding and exercisable at September 30, 2024:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="c720" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Options (#) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable at<br/>
			September 30, 2024 (#) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Range of Exercise Prices </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiry Dates</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c722" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">374</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c723" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">374</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c724" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">246.96</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c725">March 2025</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c726" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">37,719</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c727" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">37,719</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c728" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">15.12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c729">August 2027</span> - <span style="-sec-ix-hidden:c730">Dec 2028</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c731" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">43,031</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c732" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">43,031</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c733" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">22.12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c734">Feb 2030</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c735" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">51,006</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c736" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">51,006</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c737" contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">52.08</ix:nonFraction> - <ix:nonFraction id="c738" contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">56.49</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c739">September 2030</span> - <span style="-sec-ix-hidden:c740">Oct 2030</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c741" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">81,041</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c742" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">81,013</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c743" contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">36.75</ix:nonFraction> - <ix:nonFraction id="c744" contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">40.18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c745">March 2025</span> - <span style="-sec-ix-hidden:c746">Sep 2031</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c747" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">58,753</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c748" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">52,957</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c749" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">25.97</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c750">March 2025</span> - <span style="-sec-ix-hidden:c751">Feb 2032</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black; text-align: right;"><ix:nonFraction id="c752" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">111,116</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"><ix:nonFraction id="c753" contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">62,288</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c754" contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.10</ix:nonFraction> - <ix:nonFraction id="c755" contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:num-dot-decimal" decimals="INF">10.01</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c756">March 2025</span> - <span style="-sec-ix-hidden:c757">Oct 2033</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c758" contextRef="i_2024-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">383,040</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c759" contextRef="i_2024-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">328,388</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 23%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 23%;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The options exercisable at September 30, 2024 had a weighted average exercise price of $<ix:nonFraction id="c610" contextRef="i_2024-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">27.55</ix:nonFraction> and an intrinsic value of $<ix:nonFraction id="c611" contextRef="i_2024-09-30" unitRef="USDPerShare" name="edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">66.00</ix:nonFraction> and a weighted average remaining life of <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c612" format="ixt-sec:durmonth">76</ix:nonNumeric> months. There were <ix:nonFraction id="c613" contextRef="i_2024-09-30" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" format="ixt:num-dot-decimal" decimals="INF">54,652</ix:nonFraction> options at September 30, 2024 that had not vested with a weighted average exercise price of $<ix:nonFraction id="c614" contextRef="i_2024-09-30" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">9.24</ix:nonFraction> and an intrinsic value of $<ix:nonFraction id="c615" contextRef="i_2024-09-30" unitRef="USDPerShare" name="edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">134.00</ix:nonFraction> and a weighted average remaining life of <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" id="c616" format="ixt-sec:durmonth">102</ix:nonNumeric> months.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The fair value of options granted during the years ended September 30, 2024 and 2023 was estimated using the Black-Scholes option valuation model using the following assumptions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c760" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c762" contextRef="d_2023-10-01_2024-09-30" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.92</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c763" contextRef="d_2023-10-01_2024-09-30" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.62</ix:nonFraction>% - <ix:nonFraction id="c764" contextRef="d_2023-10-01_2024-09-30" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.18</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (years)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c765" format="ixt-sec:duryear">5</ix:nonNumeric></p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><ix:nonNumeric contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c766" format="ixt-sec:duryear">5</ix:nonNumeric></p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected share price volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c767" contextRef="d_2023-10-01_2024-09-30" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">97.26</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c768" contextRef="d_2023-10-01_2024-09-30" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" format="ixt:num-dot-decimal" decimals="3">95.3</ix:nonFraction>% - <ix:nonFraction id="c769" contextRef="d_2023-10-01_2024-09-30" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" format="ixt:num-dot-decimal" decimals="4">97.34</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c770" contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.00</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c771" contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.00</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company recorded $<ix:nonFraction id="c627" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.5</ix:nonFraction> million and $<ix:nonFraction id="c628" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.2</ix:nonFraction> million of share-based compensation expenses for the years ended September 30, 2024 and 2023, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As of September 30, 2024, the Company had approximately $<ix:nonFraction id="c629" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million of unrecognized share-based compensation expense, which is expected to be recognized over a period of <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c630" format="ixt-sec:durmonth">24</ix:nonNumeric> months.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Restricted share units</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company's 2019 Plan allows restricted share units (RSUs) to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the RSU term is not to exceed <ix:nonNumeric contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c631" format="ixt-sec:duryear">10</ix:nonNumeric> years. The fair value is based on the 5-day VWAP of the Company's common shares up to the date of grant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The following is a summary of changes in the status of RSUs from October 1, 2022 through September 30, 2024:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="c772" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of RSU (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Grant Date Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2022</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c774" contextRef="i_2022-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c775" contextRef="i_2022-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:fixed-zero" decimals="INF">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 65.6%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c776" contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">46,602</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c777" contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.60</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Converted to common shares</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c778" contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">13,557</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c779" contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.60</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c780" contextRef="i_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">33,045</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c781" contextRef="i_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.60</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c782" contextRef="d_2023-10-01_2024-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">30,159</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c783" contextRef="d_2023-10-01_2024-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.56</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c784" contextRef="i_2024-09-30" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">63,204</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c785" contextRef="i_2024-09-30" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:num-dot-decimal" decimals="INF">5.10</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table summarizes information about the RSUs under the 2019 Plan outstanding and exercisable at September 30, 2024:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" id="c786" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of RSU (#) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiry Date</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fully-vested RSUs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c788" contextRef="i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">63,204</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">August 2033 - September 2034</p>
			</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The RSUs that were granted in the current year was for compensation to the Company&#8217;s Chief Executive Officer who is receiving 50% of his salary in RSUs. In the comparative period, RSUs were granted in lieu of cash bonuses for certain employees and in lieu of payments on consulting invoices for services prior to the appointment of the new Chief Financial Officer. All RSUs that were granted vested immediately upon the grant date. The outstanding RSUs can be converted to common shares by the holder at any time prior to the expiry date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">There is <span style="-sec-ix-hidden:c646">no</span> future unrecorded compensation expense for the RSUs.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:GovernmentAssistanceTextBlock" id="c789" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>9. Government Contributions</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>SIF</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Reimbursement grant income for the Company&#8217;s federal grant with the Canadian government&#8217;s SIF is recorded based on the claim period of eligible costs.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2023, the Company entered into the 2023 SIF Agreement with the Canadian Government. Under the 2023 SIF Agreement, the Government of Canada committed up to C$<ix:nonFraction id="c791" contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="CAD" name="us-gaap:GovernmentAssistanceAwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">23</ix:nonFraction> million in partially repayable funding toward (i) conducting and completing the Company&#8217;s Phase 3 clinical study of its experimental drug EB05 in critical-care patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 or other infectious agents, (ii) submitting EB05 for governmental approvals and manufacturing scale-up, following, and subject to, completing the Phase 3 study and (iii) conducting two non-clinical safety studies to assess the potential long-term impact of EB05 exposure (the Project). Of the C$<ix:nonFraction id="c792" contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="CAD" name="us-gaap:GovernmentAssistanceAwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-6">23</ix:nonFraction> million committed by SIF, up to C$<ix:nonFraction id="c793" contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="CAD" name="edsa:GovernmentAssistanceAwardAmountNotRepayable" scale="6" format="ixt:num-dot-decimal" decimals="-5">5.8</ix:nonFraction> million is not repayable by the Company. The remaining C$<ix:nonFraction id="c794" contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="CAD" name="edsa:GovernmentAssistanceAwardAmountRepayable" scale="6" format="ixt:num-dot-decimal" decimals="-5">17.2</ix:nonFraction> million is conditionally repayable starting in 2029 only if and when the Company earns gross revenue. The repayable portion would be payable over fifteen (<ix:nonNumeric contextRef="d_2023-10-01_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" name="edsa:GovernmentAssistancePeriodOfRepayment" id="c795" format="ixt-sec:duryear">15</ix:nonNumeric>) years based on a percentage rate of the Company&#8217;s annual revenue growth. The maximum amount repayable under the Agreement is <ix:nonFraction id="c796" contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="Pure" name="edsa:GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.4</ix:nonFraction> times the original repayable amount. In addition, the Company is entitled to partial reimbursement of certain eligible expenses under the Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the Agreement, the Company agreed to certain financial and non-financial covenants and other obligations in relation to the Project. Pursuant to the Agreement, certain customary events of default, such as the Company&#8217;s or Edesa Biotech Research&#8217;s breach of their covenants and obligations under the Agreement, their insolvency, winding up or dissolution, and other similar events, may permit the Government of Canada to declare an event of default under the Agreement. Upon an event of default, subject to applicable cure, the Government of Canada may exercise a number of remedies, including suspending or terminating funding under the Agreement, demanding repayment of funding previously received and/or terminating the Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The funding and any associated conditional repayments are not secured by any assets of Edesa Biotech Research or the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Agreement will expire on the later of December 31, 2042 or the date of the last repayment, unless earlier terminated, subject to certain provisions that extend three (<ix:nonNumeric contextRef="d_2023-10-01_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" name="edsa:GovernmentAssistanceExpirationPeriodAfterLastRepayment" id="c797" format="ixt-sec:duryear">3</ix:nonNumeric>) years beyond the term or early termination of the Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the October 2023 SIF Agreement the Company recorded grant income of $<ix:nonFraction id="c798" contextRef="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="USD" name="us-gaap:GovernmentAssistanceNonoperatingIncome" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.7</ix:nonFraction> million and $<ix:nonFraction id="c799" contextRef="d_2022-10-01_2023-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember" unitRef="USD" name="us-gaap:GovernmentAssistanceNonoperatingIncome" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million for the years ended September 30, 2024 and September 30, 2023, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Canada Emergency Business Account</i></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">During year ended September 30, 2024, the Company recognized a $<ix:nonFraction id="c800" contextRef="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-CanadaEmergencyBusinessAccountProgramMember_LineOfCreditFacilityAxis-CIBCMember" unitRef="CAD" name="us-gaap:DebtInstrumentDecreaseForgiveness" scale="0" format="ixt:num-dot-decimal" decimals="0">20,000</ix:nonFraction> Canadian dollar gain from loan forgiveness related to its Canada Emergency Business Account (CEBA) loan. This forgiveness was granted upon successful repayment of $<ix:nonFraction id="c801" contextRef="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-CanadaEmergencyBusinessAccountProgramMember_LineOfCreditFacilityAxis-CIBCMember" unitRef="CAD" name="us-gaap:RepaymentsOfLongTermDebt" scale="0" format="ixt:num-dot-decimal" decimals="0">40,000</ix:nonFraction> Canadian dollar of the loan balance, in accordance with CEBA program terms. The forgiven amount is recorded as other income in the consolidated statements of operations. The CEBA loan has been fully repaid and closed with CIBC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c802" escape="true">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>10. Income Tax</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The reconciliation of the combined Canadian federal and provincial statutory income tax rate to the approximate effective tax rate is as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c885" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss before recovery of income taxes</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c887" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="edsa:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">6,169,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c888" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="edsa:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">8,374,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canadian federal and provincial statutory income tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c889" contextRef="d_2023-10-01_2024-09-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">26.5</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>%</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c890" contextRef="d_2022-10-01_2023-09-30" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="3">26.5</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected income tax recovery</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c891" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">1,635,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c892" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">2,219,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effect of foreign currency and foreign tax rate differences</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c893" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">58,200</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c894" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">207,200</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c895" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">147,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c896" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">339,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share issuance cost booked through equity or capitalization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c897" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="edsa:EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" scale="0" format="ixt:num-dot-decimal" decimals="0">36,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c898" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="edsa:EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">89,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital losses limitation - U.S.</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c899" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="edsa:EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c900" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="edsa:EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" scale="0" format="ixt:num-dot-decimal" decimals="0">899,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c901" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">38,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c902" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">94,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c903" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="0">1,549,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c904" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="0">1,372,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax (recovery) expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c905" contextRef="d_2023-10-01_2024-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="0">800</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c906" contextRef="d_2022-10-01_2023-09-30" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:num-dot-decimal" decimals="0">800</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p></ix:exclude>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Components of the net deferred tax asset or liability</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Deferred taxes are provided as a result of temporary differences that arise due to the difference between the income tax values and the carrying amount of assets and liabilities. Approximate deferred tax assets and liabilities are as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c907" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital losses carried forward - Canada</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c909" contextRef="i_2024-09-30_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="0" format="ixt:num-dot-decimal" decimals="0">15,547,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c910" contextRef="i_2023-09-30_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="0" format="ixt:num-dot-decimal" decimals="0">13,943,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital losses carried forward - U.S.</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c911" contextRef="i_2024-09-30_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="0" format="ixt:num-dot-decimal" decimals="0">742,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c912" contextRef="i_2023-09-30_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="0" format="ixt:num-dot-decimal" decimals="0">731,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c913" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" format="ixt:num-dot-decimal" decimals="0">1,504,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c914" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" format="ixt:num-dot-decimal" decimals="0">1,371,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share issuance and financing costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c915" contextRef="i_2024-09-30" unitRef="USD" name="edsa:DeferredTaxAssetsShareIssuanceAndFinancingCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">381,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c916" contextRef="i_2023-09-30" unitRef="USD" name="edsa:DeferredTaxAssetsShareIssuanceAndFinancingCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">585,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c917" contextRef="i_2024-09-30" unitRef="USD" name="edsa:DeferredTaxAssetsRightofuseLeaseLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">5,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c918" contextRef="i_2023-09-30" unitRef="USD" name="edsa:DeferredTaxAssetsRightofuseLeaseLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">25,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other temporary differences</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c919" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="0" format="ixt:num-dot-decimal" decimals="0">21,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c920" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="0" format="ixt:num-dot-decimal" decimals="0">44,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Subtotal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c921" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:num-dot-decimal" decimals="0">18,200,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c922" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:num-dot-decimal" decimals="0">16,699,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c923" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="0">18,074,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c924" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="0">16,466,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total net deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c925" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="0" format="ixt:num-dot-decimal" decimals="0">126,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c926" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="0" format="ixt:num-dot-decimal" decimals="0">233,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c927" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" format="ixt:num-dot-decimal" decimals="0">2,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c928" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" format="ixt:num-dot-decimal" decimals="0">3,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c929" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="0" format="ixt:num-dot-decimal" decimals="0">5,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c930" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="0" format="ixt:num-dot-decimal" decimals="0">24,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant Income receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c931" contextRef="i_2024-09-30" unitRef="USD" name="edsa:DeferredTaxLiabilitiesGrantIncomeReceivable" scale="0" format="ixt:num-dot-decimal" decimals="0">71,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c932" contextRef="i_2023-09-30" unitRef="USD" name="edsa:DeferredTaxLiabilitiesGrantIncomeReceivable" scale="0" format="ixt:num-dot-decimal" decimals="0">153,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred share issuance costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c933" contextRef="i_2024-09-30" unitRef="USD" name="edsa:DeferredTaxLiabilitiesDeferredShareIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">48,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c934" contextRef="i_2023-09-30" unitRef="USD" name="edsa:DeferredTaxLiabilitiesDeferredShareIssuanceCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">53,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c935" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">126,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c936" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DeferredTaxLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">233,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred taxes</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c937" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c938" contextRef="i_2023-09-30" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:fixed-zero" decimals="0">-</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Realization of the deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. It is more likely than not that a tax benefit will not be realized. Accordingly, net deferred tax assets have been fully offset by a valuation allowance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Non-capital losses, capital losses, and research and development credits generated by Edesa Biotech USA, Inc. prior to changes in share ownership that occurred as a result of the reverse acquisition are substantially limited. It is unlikely that tax losses totaling $<ix:nonFraction id="c854" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" scale="6" format="ixt:num-dot-decimal" decimals="-5">32.7</ix:nonFraction>&#160;million and credits totaling $<ix:nonFraction id="c855" contextRef="i_2024-09-30" unitRef="USD" name="us-gaap:TaxCreditCarryforwardValuationAllowance" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million will be utilized to offset potential future taxable income before expiration and they are excluded from deferred tax assets above.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p></ix:exclude>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The approximate Canadian non-capital losses carried forward at September 30, 2024 expire as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="c537D2A42-9AA7-49F8-96D7-689351A148B1" escape="true" continuedAt="c573F4D9C-5E35-42C7-ABA5-C78DCD05F77B">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c941" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2025Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">16,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c942" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2026Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">41,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c943" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2027Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">84,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c944" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2028Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">171,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c945" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2029Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">507,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2030</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c946" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2030Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">633,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2031</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c947" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2031Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">504,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2032</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c948" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2032Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">496,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2033</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c949" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2033Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">79,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2034</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c950" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2034Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">1,432,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2035</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c951" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2035Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">1,628,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2036</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c952" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2036Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">1,637,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2037</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c953" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2037Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">1,564,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2038</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c954" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2038Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">2,580,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2039</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c955" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2039Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">1,279,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2040</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c956" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2040Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">5,904,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2041</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c957" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2041Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">9,366,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2042</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c958" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2042Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">16,191,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2043</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c959" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2043Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">7,890,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2044</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c960" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2044Member" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">6,260,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">C$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c961" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="CAD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">58,262,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Share issuance and financing costs will be fully amortized in 2027.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The U.S. non-capital losses carried forward at September 30, 2024 totaled approximately $<ix:nonFraction id="c877" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-4">3.42</ix:nonFraction>&#160;million, which do not expire for federal taxes. The U.S. state research and development tax credits carried forward at September 30, 2024 totaled approximately $<ix:nonFraction id="c878" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million, which do not expire for state taxes. The approximate U.S. state non-capital losses carried forward at September 30, 2024 expire as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<ix:continuation id="c573F4D9C-5E35-42C7-ABA5-C78DCD05F77B">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2039</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c964" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2039Member" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">70,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2040</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c965" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2040Member" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">150,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2041</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c966" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2041Member" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">68,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2042</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c967" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2042Member" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">6,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2044</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c968" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2044Member" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">41,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c969" contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">335,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:continuation>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="c970" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>11. Financial instruments</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>(a) Fair values</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">F-22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<div>&#160;</div>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>EDESA BIOTECH, INC.</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>Notes to Consolidated Financial Statements</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>For the Years Ended September 30, 2024 and 2023</b></p></ix:exclude>

<ix:exclude><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p></ix:exclude>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">There are three levels of inputs that may be used to measure fair value:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 3 - Unobservable inputs for the asset or liability that are supported by little or no market activity.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The carrying value of certain financial instruments such as cash and cash equivalents, accounts and other receivable, accounts payable and accrued liabilities approximates fair value due to the short-term nature of such instruments.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>(b) Interest rate and credit risk</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not believe that the results of operations or cash flows would be affected to any significant degree by a significant change in market interest rates, relative to interest rates on cash and cash equivalents due to the short-term nature of these balances.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company is also exposed to credit risk at year end from the carrying value of its cash and cash equivalents and accounts and other receivable. The Company manages this risk by maintaining bank accounts with Canadian Chartered Banks, U.S. banks believed to be credit worthy and money market mutual funds of U.S. government securities. The Company&#8217;s cash is not subject to any external restrictions. The Company assesses the collectability of accounts and receivables through a review of the current aging and terms, as well as an analysis of historical collection rates, general economic conditions and credit status of government agencies. Credit risk for the reimbursement grant and HST refunds receivable are not considered significant since amounts are due from the Canadian government&#8217;s SIF and the Canada Revenue Agency.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>(c) Foreign exchange risk</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company and its subsidiary have balances in Canadian dollars that give rise to exposure to foreign exchange (FX) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks. At September 30, 2024, the Company and its Canadian subsidiary had assets denominated in Canadian dollars of approximately C$<ix:nonFraction id="c972" contextRef="i_2024-09-30" unitRef="CAD" name="us-gaap:AssetReportingCurrencyDenominatedValue" scale="6" format="ixt:num-dot-decimal" decimals="-4">0.04</ix:nonFraction> million and the U.S. dollar exchange rate at this date was equal to <ix:nonFraction id="c973" contextRef="i_2023-09-30" unitRef="Pure" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" format="ixt:num-dot-decimal" decimals="INF">1.3517</ix:nonFraction> Canadian dollars. Based on the exposure at September 30, 2024, a 10% annual change in the Canadian/U.S. exchange rate would impact the Company&#8217;s loss and other comprehensive loss by approximately $<ix:nonFraction id="c974" contextRef="i_2024-09-30" unitRef="USD" name="edsa:SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss" scale="6" format="ixt:num-dot-decimal" decimals="-4" sign="-">0.04</ix:nonFraction> million.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>(d) Liquidity risk</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="c975" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>12. Related party transactions</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">During each of the years ended September 30, 2024 and 2023, the Company paid cash of $<ix:nonFraction id="c977" contextRef="d_2023-10-01_2024-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">78,000</ix:nonFraction> and $<ix:nonFraction id="c978" contextRef="d_2022-10-01_2023-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">82,000</ix:nonFraction>, respectively, for a ROU lease from a company controlled by the Company's CEO. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by both parties. On December 31, 2022, the Company executed a <span style="-sec-ix-hidden:c979">two</span>-year lease extension through December 31, 2024 in accordance with the terms of the original lease agreement. Rents of approximately $<ix:nonFraction id="c980" contextRef="i_2024-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember" unitRef="USD" name="us-gaap:AccruedRentCurrentAndNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">30,000</ix:nonFraction> and $<ix:nonFraction id="c981" contextRef="i_2023-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember" unitRef="USD" name="us-gaap:AccruedRentCurrentAndNoncurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">15,000</ix:nonFraction> were payable at September 30, 2024, and September 30, 2023, respectively.&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company agreed to pay a monthly standby fee for the term of the Credit Agreement, which amounted to $51,000 in September 2024 and nil in September 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2023-10-01_2024-09-30" name="us-gaap:SubsequentEventsTextBlock" id="c982" escape="true">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>13. Subsequent events</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On October 4, 2024, the Company entered into an At The Market Offering Agreement with H.C. Wainwright &amp; Co., LLC as a sales agent (HCW ATM) pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $<ix:nonFraction id="c984" contextRef="i_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember" unitRef="USD" name="edsa:EquityOfferingMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-4">3.87</ix:nonFraction> million in gross proceeds. The Company has no obligation to sell any of the common shares and may at any time suspend sales or terminate the equity distribution agreement in accordance with its terms. Subsequent to the year ended September 30, 2024, the Company sold a total of <ix:nonFraction id="c985" contextRef="d_2024-10-01_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">220,269</ix:nonFraction> common shares pursuant to the agreement for net proceeds of approximately $<ix:nonFraction id="c986" contextRef="d_2024-10-01_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million after deducting sales commissions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2024, the Company entered into a Securities Purchase Agreement with PN MPC, an entity controlled by Pardeep Nijhawan, the Company&#8217;s Chief Executive Officer, Secretary and member of the board of directors of the Company, pursuant to which the Company agreed to issue and sell to PN MPC in a private placement, up to $<ix:nonFraction id="c987" contextRef="d_2024-10-01_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:num-dot-decimal" decimals="-6">5</ix:nonFraction> million of shares (Preferred Shares) of the Company&#8217;s newly designated Series A-1 Convertible Preferred Shares, stated value $<ix:nonFraction id="c988" contextRef="i_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,000</ix:nonFraction> per share, each of which is initially convertible into approximately <ix:nonFraction id="c989" contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,903</ix:nonFraction> common shares (Conversion Shares), without par value, of the Company (Common Shares) at a conversion price of $<ix:nonFraction id="c990" contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.445</ix:nonFraction> per Conversion Share, and warrants (Warrants) to purchase Common Shares (Warrant Shares) at an exercise price of $<ix:nonFraction id="c991" contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">3.445</ix:nonFraction> per Warrant Share. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of Common Shares equal to <ix:nonFraction id="c992" contextRef="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="Pure" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="-2" format="ixt:num-dot-decimal" decimals="2">75</ix:nonFraction>% of the underlying Conversion Shares at a combined purchase price of $<ix:nonFraction id="c993" contextRef="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">10,272.13</ix:nonFraction> per Preferred Share and related Warrants. Under the Purchase Agreement, PN MPC has purchased <ix:nonFraction id="c994" contextRef="d_2024-10-01_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">150</ix:nonFraction> Preferred Shares initially convertible into an aggregate of <ix:nonFraction id="c995" contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" format="ixt:num-dot-decimal" decimals="INF">435,414</ix:nonFraction> Conversion Shares and Warrants to purchase up to an aggregate of <ix:nonFraction id="c996" contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">326,560</ix:nonFraction> Warrant Shares for an aggregate purchase price of $<ix:nonFraction id="c997" contextRef="d_2024-10-01_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">1,540,819</ix:nonFraction>. The Warrants expire <span style="-sec-ix-hidden:c998">five</span> years from the issuance date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As a result of the foregoing transactions&#160;and as of the date of this filing, the Company believes it has shareholders&#8217; equity of at least $2.5 million and therefore satisfies the minimum Nasdaq listing requirement set forth in Nasdaq Listing Rule 5550(b)(1).</p>
</ix:nonNumeric>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;">&#160;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center;">F-22</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.7
<SEQUENCE>2
<FILENAME>ex_755936.htm
<DESCRIPTION>EXHIBIT 3.7
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<div style="text-align: right;"><b>Exhibit 3.7</b></div>

<div style="text-align: center;">
<div><img alt="exh37_01.jpg" src="exh37_01.jpg"></div>
</div>

<div>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div style="text-align: center;"><img alt="exh37_02.jpg" src="exh37_02.jpg"></div>

<div style="text-align: center;">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="exh37_03.jpg" src="exh37_03.jpg"></div>
</div>
</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>3
<FILENAME>ex_755937.htm
<DESCRIPTION>EXHIBIT 4.11
<TEXT>
<html><head>
	<title>ex_755937.htm</title>
	<!-- Generated by ThunderDome Portal - 12/10/2024 10:40:30 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 4.11</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DESCRIPTION OF THE REGISTRANT</b>&#8217;<b>S SECURITIES REGISTERED PURSUANT </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following description of our capital shares summarizes the material terms and provisions of our capital shares based on the provisions of our Amended and Restated Articles (as amended, the &#8220;Articles&#8221;). The following description of our capital shares does not purport to be complete and is subject to, and qualified in its entirety by, (i) our Articles which is an exhibit to the Annual Report on Form 10-K filed with the Securities and Exchange Commission, of which this Exhibit 4.11 forms a part and (ii) the British Columbia <i>Business Corporations Act</i>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>General </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are authorized to issue an unlimited number of common shares and preferred shares, no par value. As of December 11, 2024, there were 3,467,658 common shares outstanding and 150 preferred shares outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Shares</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The holders of our common shares are entitled to one vote for each share held of record on all matters submitted to a vote of the shareholders. Our shareholders do not have cumulative voting rights in the election of directors. Subject to preferences that may be applicable to any outstanding preferred shares, the holders of common shares are entitled to receive ratably only those dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common shares are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding preferred shares. Holders of common shares have no preemptive or other subscription or conversion rights. There are no redemption or sinking fund provisions applicable to our common shares. Common shares outstanding, and to be issued, are, and will be, fully paid and non-assessable. Additional shares of authorized common shares may be issued, as authorized by our board of directors from time to time, without shareholder approval, except as may be required by The Nasdaq Capital Market.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Preferred Shares</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Pursuant to our Articles and the provisions of the British Columbia <i>Business Corporations</i> <i>Act</i>, our board of directors has the authority, without further action by the shareholders (unless such shareholder action is required by applicable law or the rules of The Nasdaq Capital Market), to designate and issue an unlimited number of preferred shares in one of more series, to establish from time to time the number of shares to be included in each such series, to fix the designations, powers, preferences and rights of the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. Preferred shares, if issued, will be fully paid and non-assessable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The board of directors&#8217; authority to determine the terms of any such preferred shares include, without limitation: (i) the designation of each series and the number of preferred shares that will constitute each such series; (ii) the dividend rate or amount, if any, for each series; (iii) the price at which, and the terms and conditions on which, the preferred shares of each series may be redeemed, if such shares are redeemable; (iv) the terms and conditions, if any, upon which preferred shares of such series may be converted into shares of other classes or series of shares of the Company, or other securities; and (v) the maturity date, if any, for each such series; but no such special rights or restriction shall contravene any other provision of Part 26 of the Articles of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The issuance of preferred shares may or may not have a dilutive effect on the voting rights of shareholders owning common shares, depending on the rights and preferences set by the board of directors. Preferred shares may be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. However, except for such rights relating to the election of directors on a default in payment of dividends as may be attached to any series of the preferred shares by the board of directors or in connection with convertible preferred shares, the holders of preferred shares shall not be entitled, as such, to receive notice of, or to attend or vote at, any general meeting of shareholders of the Company. Section 61 of the British Columbia <i>Business Corporations Act</i> provides that the special rights attached to preferred shares may not be prejudiced or interfered with unless the shareholders holding such class of shares consent to such matter by a special resolution of such holders of preferred shares. Additionally, the issuance of preferred shares may have the effect of decreasing the market price of our common shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Series A-1 Convertible Preferred Shares</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On October 30, 2024, the Company filed Amended and Restated Articles to amend our authorized share structure to create a series of preferred shares, without par value, designated as &#8220;Series A-1 Convertible Preferred Shares&#8221; (the &#8220;Series A-1 Shares&#8221;). We are authorized to issue up to 500 Series A-1 Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Series A-1 Shares have a stated value of $10,000 per share and rank, with respect to redemption payments, rights upon liquidation, dissolution or winding-up of the Company, or otherwise, senior in preference and priority to our common shares. Until the three-year anniversary of the day of issuance, holders of the Series A-1 Shares are entitled to an annual return equal to 10% of the stated value per Series A-1 Share, payable&nbsp;by the issuance of common shares at the conversion price&nbsp;upon a buy-back by the Company, liquidation or on conversion at the conversion price (calculated daily). Holders of the Series A-1 Shares will be entitled to dividends, on an as-if converted basis, equal to and in the same form as dividends actually paid on our common shares when and if actually paid.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Each Series A-1 Share is convertible into a number of our common shares calculated by dividing (i) the sum of the stated value of such Series A-1 Share plus a return equal to 10% of the stated value per Series A-1 Share per annum, calculated daily, by (ii) a fixed conversion price of $3.445. A holder of the Series A-1 Shares will not have the right to convert any portion of its Series A-1 Shares if the holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of common shares outstanding immediately after giving effect to such conversion. The Series A-1 Shares do not have the right to vote on any matters except as required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the event of any liquidation, dissolution or winding-up of the Company, a holder of Series A-1 Shares shall be entitled to receive, before any distribution or payment may be made with respect to our common shares, an amount equal to 100% of the stated value, plus a return equal to 10% of the stated value per Series A-1 Share per annum, calculated daily.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Beginning three years after the date of issuance, we may buy-back some or all outstanding Series A-1 Shares for a cash payment per share equal to the stated value, plus all unpaid accrued dividends.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Anti-takeover Provisions of our Articles of Incorporation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In addition to the board of directors&#8217; ability to issue preferred shares, our Articles, as amended, contain other provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and which may have the effect of delaying, deferring or preventing a future takeover or change in control of our Company unless such takeover or change in control is approved by our board of directors. These provisions include advance notice procedures for shareholder proposals and a supermajority vote requirement for business combinations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Advance Notice Procedures for Shareholder Proposals</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Effective October 31, 2013, our board of directors adopted an advance notice policy (the &#8220;Advance Notice Policy&#8221;) with immediate effect for the purpose of providing our shareholders, directors and management with a clear framework for nominating our directors in connection with any annual or special meeting of shareholders. The Advance Notice Policy was approved by the shareholders at our annual meeting on February 13, 2014.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Purpose of the Advance Notice Policy</i>. Our directors are committed to: (i) facilitating an orderly and efficient annual general or, where the need arises, special meeting, process; (ii) ensuring that all shareholders receive adequate notice of the director nominations and sufficient information with respect to all nominees; and (iii) allowing shareholders to register an informed vote having been afforded reasonable time for appropriate deliberation. The purpose of the Advance Notice Policy is to provide our shareholders, directors and management with a clear framework for nominating directors. The Advance Notice Policy fixes a deadline by which holders of record of our common shares must submit director nominations to the Company prior to any annual or special meeting of shareholders and sets forth the information that a shareholder must include in the notice to the Company for the notice to be in proper written form in order for any director nominee to be eligible for election at any annual or special meeting of shareholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><i>Terms of the Advance Notice Policy</i>. The Advance Notice Policy provides that advance notice to the Company must be made in circumstances where nominations of persons for election to our board of directors are made by shareholders of the Company other than pursuant to: (i) a &#8220;proposal&#8221; made in accordance with Division 7 of Part 5 of the British Columbia <i>Business Corporations Act</i>; or (ii) a requisition of the shareholders made in accordance with section 167 of the British Columbia <i>Business Corporations Act</i>. Among other things, the Advance Notice Policy fixes a deadline by which holders of record of our common shares must submit director nominations to the secretary of the Company prior to any annual or special meeting of shareholders and sets forth the specific information that a shareholder must include in the written notice to the secretary of the Company for an effective nomination to occur. No person will be eligible for election as a director of the Company unless nominated in accordance with the provisions of the Advance Notice Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the case of an annual meeting of shareholders, notice to the Company must be made not less than 30 nor more than 65 days prior to the date of the annual meeting; provided, however, that in the event that the annual meeting is to be held on a date that is less than 50 days after the date on which the first public announcement of the date of the annual meeting was made, notice may be made not later than the close of business on the 10th day following such public announcement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the case of a special meeting of shareholders (which is not also an annual meeting), notice to the Company must be made not later than the close of business on the 15th day following the day on which the first public announcement of the date of the special meeting was made.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our board of directors may, in its sole discretion, waive any requirement of the Advance Notice Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Provisions of British Columbia Law Governing Business Combinations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">All provinces of Canada have adopted National Instrument 62-104 entitled &#8220;<i>Take-Over Bids and Issuer Bids</i>&#8221; and related forms to harmonize and consolidate take-over bid and issuer bid regimes nationally (&#8220;NI 62-104&#8221;). The Canadian Securities Administrators, or CSA, have also issued National Policy 62-203 entitled &#8220;<i>Take-Over Bids and Issuer Bids</i>&#8221; (the &#8220;National Policy&#8221;) which contains regulatory guidance on the interpretation and application of NI 62-104 and on the conduct of parties involved in a bid. The National Policy and NI 62-104 are collectively referred to as the &#8220;Bid Regime.&#8221; The National Policy does not have the force of law, but is an indication by the CSA of what the intentions and desires of the regulators are in the areas covered by their policies. Unlike some regimes where the take-over bid rules are primarily policy-driven, in Canada the regulatory framework for take-over bids is primarily rules-based, which rules are supported by policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A &#8220;take-over bid&#8221; or &#8220;bid&#8221; is an offer to acquire outstanding voting or equity securities of a class made to any person who is in one of the provinces of Canada or to any securityholder of an offeree issuer whose last address as shown on the books of a target is in such province, where the securities subject to the offer to acquire, together with the securities &#8220;beneficially owned&#8221; by the offeror, constitute in the aggregate 20% or more of the outstanding securities of that class of securities at the date of the offer to acquire. For the purposes of the Bid Regime, a security is deemed to be &#8220;beneficially owned&#8221; by an offeror as of a specific date if the offeror is the beneficial owner of a security convertible into the security within 60 days following that date, or has a right or obligation permitting or requiring the offeror, whether or not on conditions, to acquire beneficial ownership of the security within 60 days by a single transaction or a series of linked transactions. Offerors are also subject to early warning requirements, where an offeror who acquires &#8220;beneficial ownership of&#8221;, or control or direction over, voting or equity securities of any class of a reporting issuer or securities convertible into, voting or equity securities of any class of a target that, together with the offeror&#8217;s securities, would constitute 10% or more of the outstanding securities of that class must promptly publicly issue and file a news release containing certain prescribed information, and, within two business days, file an early warning report containing substantially the same information as is contained in the news release.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition, where an offeror is required to file an early warning report or a further report as described and the offeror acquires or disposes of beneficial ownership of, or the power to exercise control or direction over, an additional 2% or more of the outstanding securities of the class, or disposes of beneficial ownership of outstanding securities of the class below 10%, the offeror must issue an additional press release and file a new early warning report. Any material change in a previously filed early warning report also triggers the issuance and filing of a new press release and early warning report. During the period commencing on the occurrence of an event in respect of which an early warning report is required and terminating on the expiry of one business day from the date that the early warning report is filed, the offeror may not acquire or offer to acquire beneficial ownership of any securities of the class in respect of which the early warning report was required to be filed or any securities convertible into securities of that class. This requirement does not apply to an offeror that has beneficial ownership of, or control or direction over, securities that comprise 20% or more of the outstanding securities of the class.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Related party transactions, issuer bids and insider bids are subject to additional regulation that may differ depending on the particular jurisdiction of Canada in which it occurs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Transfer Agent and Registrar</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The transfer agent and registrar for our common shares is Computershare Investor Services Inc. located at 100 University Avenue, 8th Floor, Toronto, Ontario M5J 2Y1, and its telephone number is 1-800-564-6253.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Listing on The Nasdaq Capital Market</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our common shares are listed on The Nasdaq Capital Market under the symbol &#8220;EDSA.&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>ex_755571.htm
<DESCRIPTION>EXHIBIT 19.1
<TEXT>
<html><head>
	<title>ex_755571.htm</title>
	<!-- Generated by ThunderDome Portal - 12/10/2024 12:58:30 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 19.1</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EDESA BIOTECH, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INSIDER TRADING POLICY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 3pt;"><b>As Amended and Restated by the Board on December 12, 2024</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">The following Insider Trading Policy (&#8220;<b>Policy</b>&#8221;) has been approved by the Board of Directors (the &#8220;<b>Board</b>&#8221;) of <b>EDESA BIOTECH, INC. </b>(together with its subsidiaries, the &#8220;<b>Company</b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>1.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PURPOSE OF THE POLICY.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">This Policy provides guidelines with respect to transactions in the Company&#8217;s securities and the handling of confidential information about the Company and the companies with which the Company does business. The Board has adopted this Policy to promote compliance with federal, state and foreign securities laws that prohibit certain persons who are aware of material nonpublic information about a company from: (i) trading in securities of that company; or (ii) providing material nonpublic information to other persons who may trade on the basis of that information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>2.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TRANSACTIONS SUBJECT TO THE POLICY.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">This Policy applies to transactions in the Company&#8217;s securities (collectively referred to in this Policy as &#8220;<b>Company Securities</b>&#8221;), including the Company&#8217;s common shares, options to purchase common shares, or any other type of securities that the Company may issue, including (but not limited to) preferred shares, convertible debentures and warrants, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Company&#8217;s Securities. For purposes of this Policy, gifts or other transfers to Family Members (as defined below) or Controlled Entities (as defined below), whether for estate planning or otherwise, or to charities or other third parties, are subject to the requirements and restrictions outlined in this Policy and require pre-clearance in accordance with the &#8220;Pre-Clearance Procedures&#8221; section of this Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;"><u><b>Definition of Material Information. </b></u>U.S. and Canadian securities laws prohibit &#8220;<b>insider trading</b>&#8221; and impose restrictions on the trading of shares or other securities issued by the Company by individuals who are in possession of undisclosed &#8220;<b>Material Information</b>&#8221; relating to the Company. Information is considered &#8220;material&#8221; if a reasonable investor would consider that information important in making a decision to buy, hold or sell securities. Any information that could be expected to affect the Company&#8217;s share price, whether it is positive or negative, should be considered material. There is no bright-line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by enforcement authorities with the benefit of hindsight. While it is not possible to define all categories of material information, some examples of information that ordinarily would be regarded as material are:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Projections of future earnings or losses, or other earnings guidance;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Changes to previously announced earnings guidance, or the decision to suspend earnings guidance;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A pending or proposed merger, acquisition, tender offer, joint venture, divestiture or leveraged buy-out;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A pending or proposed acquisition or disposition of a significant asset;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A pending or proposed joint venture;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Determination of significant research or clinical results;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clinical development milestones;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Public offerings or private sales of debt or equity securities;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A Company restructuring;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain related party transactions;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A change in dividend policy, the declaration of a share split, or an offering of additional securities;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Bank borrowings or other financing transactions out of the ordinary course;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The establishment of a repurchase program for Company Securities;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A change in management;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Labor disputes, including strikes or lockouts;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A change in auditors or notification that the auditor&#8217;s reports may no longer be relied upon;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A change in accounting method;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Launch of a significant new product, process, or service;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pending or threatened significant litigation, or the resolution of such litigation;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Criminal indictments or material civil litigation or government investigation;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cybersecurity risks and incidents;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Impending bankruptcy or the existence of severe liquidity problems;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The gain or loss of a significant customer or supplier, or obtaining or losing important contracts;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant disputes with major suppliers or customers; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The imposition of a ban on trading in Company Securities or the securities of another company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;"><u><b>When Information is Considered Public</b>.</u> Information that has not been disclosed to the public is generally considered to be nonpublic information. In order to establish that the information has been disclosed to the public, it may be necessary to demonstrate that the information has been widely disseminated. Information generally would be considered widely disseminated if it has been disclosed through newswire services, a broadcast on widely-available radio or television programs, publication in a widely-available newspaper, magazine or news website, or public disclosure documents filed with the appropriate regulatory body that are available on the Securities and Exchange Commission (&#8220;<b>SEC</b>&#8221;) website. By contrast, information would likely not be considered widely disseminated if it is available only to the Company&#8217;s employees, or if it is only available to a select group of analysts, brokers and institutional investors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">Once information is widely disseminated (such as to a national wire service through a press release, or an SEC filing), it is still necessary to afford the investing public with sufficient time to absorb the information. While there are no formal rules around what is a sufficient period of time, this generally means two full trading days after the information was widely disclosed. For purposes of clarity, in the event that the Company releases information prior to the opening of trading on a particular trading day, that day shall be deemed the first trading day for purposes of this policy. If, for example, the Company releases information prior to the opening of trading on a Tuesday morning that is otherwise a normal trading day, insiders should not effect trades in Company Securities until after the close of trading on Wednesday. Depending on the particular circumstances, the Company may determine that a longer or shorter period should apply to the release of specific Material Information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">The purpose of this Policy is to ensure that persons having knowledge of Material Information not generally disclosed to the public, or &#8220;<b>Inside Information,</b>&#8221; do not take advantage of such information through trading in Company Securities or in the securities of other companies with which the Company does business. This Policy is also intended to ensure that the Company&#8217;s directors, officers and employees act, and are perceived to act, in accordance with applicable laws and the highest standards of ethical and professional behavior. This Policy is not intended to provide an in-depth legal analysis of insider trading rules but rather to serve as a guideline for the purpose of limiting the possibility of illegal or inappropriate use of Inside Information regarding the Company. The onus of complying with this Policy and the relevant insider trading and other securities legislation lies with each individual director, officer and employee of the Company and its subsidiaries, each of whom is expected to be familiar with this Policy and applicable securities legislation and to comply fully with them. An employee who violates this Policy may face disciplinary action up to and including termination of his or her employment. A breach of this Policy may also violate certain securities laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>3.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PERSONS SUBJECT TO THE POLICY.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">This Policy applies to all directors, officers and employees of the Company and of its affiliates (including subsidiaries), and to any other person who may be in possession of, or have access to Inside Information regarding the Company. For the purposes of this Policy, the term &#8220;<b>employee</b>&#8221; includes all permanent, contract, secondment and temporary agency employees who are on long-term assignments with the Company, as well as to consultants to the Company. The Compliance Officer may also designate, from time to time, other persons who may be subject to this Policy. This Policy also applies to Family Members and Controlled Entities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>4.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>ADMINISTRATION OF THE POLICY.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">The Chief Financial Officer shall serve as the Compliance Officer for the purposes of this Policy. All determinations and interpretations by the Compliance Officer shall be final and not subject to further review.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>5.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>STATEMENT OF POLICY.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:18pt;">It is the policy of the Company that no director, officer or employee of the Company (or any other person designated by this Policy or by the Compliance Officer as subject to this Policy) who is aware of Inside Information relating to the Company may, directly, or indirectly through other persons (including, but not limited to, Family Members or Controlled Entities):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Engage in transactions in Company Securities, except as otherwise specified in this Policy;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recommend the purchase or sale of any Company Securities;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disclose Inside Information to persons within the Company whose jobs do not require them to have that information, or outside of the Company to other persons, including, but not limited to, family, friends, business associates, investors and expert consulting firms, unless any such disclosure is made in accordance with the Company&#8217;s policies regarding the protection or authorized external disclosure of information regarding the Company; or</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:24pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Assist anyone engaged in the above activities.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">In addition, it is the policy of the Company that no director, officer or employee of the Company (or any other person designated as subject to this Policy) who, in the course of working for the Company, learns of Material Information about a company (1) with which the Company does business, including a customer or supplier of the Company or (2) that is involved in a potential transaction or business relationship with Company, may trade in that company&#8217;s securities until the information becomes public or is no longer material.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">There are no exceptions to this Policy, except as set forth in Section 6 below, and as otherwise specifically noted herein. Transactions that may be necessary or justifiable for independent reasons (such as the need to raise money for an emergency expenditure), or small transactions, are not excepted from this Policy. The securities laws do not recognize any mitigating circumstances, and, in any event, even the appearance of an improper transaction must be avoided to preserve the Company&#8217;s reputation for adhering to the highest standards of conduct.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>6.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CERTAIN EXCEPTIONS</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">This Policy does not apply to the following transactions, except as specifically noted:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;"><u>Share Option Exercises</u>. This Policy does not apply to the exercise of any employee share option acquired pursuant to the Company&#8217;s equity plans, or to the exercise of a tax withholding right pursuant to which a person has elected to have the Company withhold shares subject to an option to satisfy tax withholding requirements. This Policy does apply, however, to any sale of shares as part of a broker-assisted cashless exercise of an option, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;"><u>Restricted Share Unit Awards</u>. This Policy does not apply to the vesting or settlement of restricted share units, or of a tax withholding right pursuant to which you elect to have the Company withhold shares to satisfy tax withholding requirements upon the vesting of any restricted share unit. However, this Policy does apply to any market sale of shares you receive once the restricted share unit has vested and/or settled.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;"><u>Transactions with the Company</u>. This Policy does not apply to the purchase of Company Securities from the Company or the sale of Company Securities to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">Any exceptions to the Policy may only be made by advance written approval of each of: (i) the Compliance Officer and (ii) the Chairman of the Audit Committee of the Board. Any such exceptions shall be immediately reported to the remaining members of the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>7.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TRADING PROCEDURES FOR DIRECTORS, OFFICERS AND EMPLOYEES.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">In order to prevent insider trading violations, the following procedures must be followed by all directors, officers, employees, of the Company or any of its affiliates (including subsidiaries), and any other person designated by this Policy or by the Compliance Officer as subject to this Policy:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(a)<b>&nbsp;&nbsp;&nbsp;&nbsp;General Prohibition Against Using Undisclosed Material Information</b>: All directors, officers and employees of the Company who have knowledge of Inside Information relating to the Company or its business are expressly prohibited from buying or selling, exercising options to buy or sell or &#8220;tipping&#8221; someone else to buy or sell (or not to buy or sell), Company Securities unless and until such information has been publicly disclosed and disseminated. If this Inside Information relates to any other company with which the Company is negotiating or doing business, you may not trade in the securities of such company on the basis of such information, nor may you communicate such information to others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(b)<b>&nbsp;&nbsp;&nbsp;&nbsp;Family Members and Others</b>: This prohibition applies to family members who reside with you (including, but not limited to, a spouse, a child, a child away at college, stepchildren, grandchildren, aunt, uncle, niece, nephew, parents, stepparents, grandparents, siblings and in-laws), anyone else who lives in your household and any family members who do not live in your household but whose transactions in Company Securities are directed by you or are subject to your influence or control, such as parents or children who consult with you before they trade in Company Securities (collectively referred to as &#8220;<b>Family Members</b>&#8221;). You are responsible for the transactions of these Family Members and therefore should make them aware of the need to confer with you before they trade in Company Securities, and you should treat all such transactions for the purposes of this Policy and applicable securities laws as if the transactions were for your own account. This Policy does not, however, apply to personal securities transactions of Family Members where the purchase or sale decision is made by a third party not controlled by, influenced by or related to you or your Family Members.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(c)<b>&nbsp;&nbsp;&nbsp;&nbsp;Transactions by Entities that You Influence or Control: </b>This Policy applies to any entities that you influence or control, or where you or a Family Member are a beneficiary, including any corporations, partnerships, retirement plans or trusts (collectively referred to as &#8220;<b>Controlled Entities</b>&#8221;), and transactions by these Controlled Entities should be treated for the purposes of this Policy and applicable securities laws as if they were for your own account.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(d)<b>&nbsp;&nbsp;&nbsp;&nbsp;Prohibition Against Buying and Selling Company Common Shares Within a Six-Month Period</b>. Purchases and sales (or sales and purchases) of Company common shares occurring in any six-month period in which a mathematical profit is realized result in &#8220;short-swing profits.&#8221; The prohibition against short-swing profits is found in Section 16 of the Securities Exchange Act of 1934, as amended. Section 16 was drafted as a prohibition against profitable &#8220;insider trading&#8221; in a company&#8217;s securities within any six-month period regardless of the presence or absence of material nonpublic information that may affect the market price of those securities. Each executive officer, director and 10% shareholder of the Company is subject to the prohibition against short-swing profits under Section 16. Such persons are required to file Forms 3, 4 and 5 reports reporting his or her initial ownership of the Company&#8217;s common shares and any subsequent changes in such ownership. The Sarbanes-Oxley Act of 2002 requires officers and directors (&#8220;<b>insiders</b>&#8221;) who must report transactions on Form 4 to do so by the end of the second business day following the transaction date. Profit realized, for the purposes of Section 16, is calculated generally to provide maximum recovery by the Company. The measure of damages is the profit computed from any purchase and sale or any sale and purchase within the short-swing (i.e. six- month) period, without regard to any setoffs for losses, any first-in or first-out rules, or the identity of the common shares. This approach sometimes has been called the &#8220;lowest price in, highest price out&#8221; rule and can result in a realization of &#8220;profits&#8221; for Section 16 purposes even when the insider has suffered a net loss on his or her trades. Each insider is <u>personally</u> responsible for complying with the provisions of Section 16, and failure by an insider to comply strictly with his or her reporting requirements will result in an obligation by the Company to publicly disclose such failure. Moreover, Congress has granted the SEC the authority to seek monetary court-imposed fines on insiders who fail to timely comply with their reporting obligations. An insider must disclose his or her holdings at the time he or she attains insider status and must disclose all subsequent changes in such holdings during the time the individual is an insider (and, in certain circumstances, for up to six months after the individual ceases to be an insider). Penalties for failure to timely file may range from $5,000 to $100,000 per violation. Moreover, if the SEC obtains a cease-and-desist order prohibiting future violations of the reporting requirements under Section 16, each day that a filing is late may be treated as a separate offense, thereby multiplying the penalty amount by the number of days that the form is delinquent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:37pt;">(e)<b>&nbsp;&nbsp;&nbsp;&nbsp;Pre-Clearance Procedures: </b>All persons who are subject to this Policy, as well as the Family Members and Controlled Entities of such persons, may not engage in any transaction in Company Securities without first obtaining pre- clearance of the transaction from the Compliance Officer. A request for pre-clearance must be submitted to the Compliance Officer at least two business days in advance of the proposed transaction. The Compliance Officer is under no obligation to approve a transaction submitted for pre-clearance, and may determine not to permit the transaction. If a person seeks pre-clearance and permission to engage in the transaction is denied, then he or she should refrain from initiating any transaction in Company Securities, and should not inform any other person of the restriction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 42pt;text-indent:36pt;">When a request for pre-clearance is made, the requestor should carefully consider whether he or she may be aware of any Inside Information about the Company, and should describe fully those circumstances to the Compliance Officer. The requestor should also indicate whether he or she has effected any non-exempt &#8220;opposite-way&#8221; transactions within the past six months for purposes of the Section 16 analysis discussed above. The requestor should also be prepared to comply with Rule 144 of the U.S. Securities and Exchange Commission and file Form 144, if necessary, at the time of any sale.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 42pt;text-indent:36pt;">Approvals are effective for five (5) business days after receipt of written approval (if such approval is not otherwise rescinded) and the Trade must be completed within this period (or a new approval must be obtained). Once a blackout period (as defined below) begins, any approval for trades that were previously pre-cleared are automatically rescinded and all pending pre-clearance requests are automatically deemed denied.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(f)<b>&nbsp;&nbsp;&nbsp;&nbsp;Blackout Periods</b>: All persons subject this Policy who have access to Inside Information relating to the Company or its business in the normal performance of their duties are subject to &#8220;<b>blackout periods</b>&#8221; during which they will be prohibited from trading in Company Securities. A blackout period will normally be instituted by the Chief Executive Officer, Compliance Officer, or other designated Company spokesperson through a communication, in most instances by email, to those affected. Once notified of the existence of a blackout period, except as noted above, you and your Family Members or Controlled Entities may not trade in Company Securities until you have been notified that the blackout period has been terminated. All persons subject this Policy who are made aware of a &#8220;<b>blackout period</b>&#8221; are prohibited from &#8220;tipping&#8221; internally or externally to anyone else that the Company is subject to a &#8220;<b>blackout period.</b>&#8221; Exceptions to the prohibition against trading during &#8220;<b>blackout periods</b>&#8221; may only be made with the prior approval of the Compliance Officer after consultation with legal counsel, and after determination that the person making the request does not possess any Inside Information. Although the Company may from time to time impose a blackout period because of developments, known to the Company and not yet disclosed to the public, <b><i>each person is individually responsible at all times for compliance with the prohibitions against insider trading.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(g)<b>&nbsp;&nbsp;&nbsp;&nbsp;Quarterly Trading Restrictions</b>:<b> </b>Except as otherwise provided in this Policy and subject to blackout periods, persons subject to this Policy, as well as their Family Members or Controlled Entities, may only conduct any transactions involving the Company&#8217;s Securities during an &#8220;<b>Open Trading Window</b>&#8221;. For purposes of this Policy, an Open Trading Window will commence at the close of trading on the first full trading day following the public disclosure of the Company&#8217;s financial results for a particular fiscal quarter or year, as applicable, and end at the close of trading on the last day of each fiscal quarter or year, as applicable. For example, with respect to the release of financial results for the Company&#8217;s second fiscal quarter, the Open Trading Window would start at the close of trading on the first full trading day following the public release of the Company&#8217;s second quarter financial results and end at the close of trading on June 30. For the Company&#8217;s fiscal year end release of financial results, the Open Trading Window would start at the close of trading on the first full trading day following the release of the Company&#8217;s fiscal year financial results and end at the close of trading on December 31. For purposes of clarity, in the event that the Company releases its financial results for a particular fiscal quarter or year prior to the opening of trading on a particular trading day, that day shall be deemed the first full trading day for purposes of this Policy. For example, if the Company releases its financial results for a particular fiscal quarter or year prior to the opening of trading on a Tuesday morning that is otherwise a normal trading day, the Open Trading Window would start at the close of trading on that day.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(h)<b>&nbsp;&nbsp;&nbsp;&nbsp;Trading In General</b>: No director, officer or employee of the Company, as well as their Family Members or Controlled Entities, shall trade in securities of the Company without first checking with the Chief Executive Officer or Compliance Officer to see if a blackout period is in effect. <b><i>Trading in the Company</i></b>&#8217;<b><i>s securities during the Open Trading Window should not be considered a </i></b>&#8220;<b><i>safe harbor,</i></b>&#8221;<b><i> and all directors, officers and other persons should use good judgment at all times.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;">Notwithstanding the general rules set forth in this Section 7, insiders may trade outside of the Open Trading Window provided that such trades are made pursuant to an approved pre-established plan, which alternative is discussed below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(i)<b>&nbsp;&nbsp;&nbsp;&nbsp;Rule 10b-1 Plans</b>:<b> </b>Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, provides an affirmative defense, under certain conditions, against allegations that an insider traded in Company Securities while aware of material nonpublic information. Among other things, Rule 10b5-1 requires the use of a contract, instruction or plan that meets certain conditions specified in Rule 10b5-1 (a &#8220;<b>10b5-1 Plan</b>&#8221;). Persons subject to this Policy are permitted to enter into a 10b5-1 Plan only during an Open Trading Window and when they are not aware of Inside Information about the Company. Pre-clearance is required prior to entry into a 10b5-1 Plan, termination of a 10b5-1 Plan, or a modification of a 10b5-1 Plan. A copy of a 10b5-1 Plan must be submitted to the Compliance Officer for review and pre-clearance at least three business days prior to the anticipated entry into a 10b5-1 Plan. The 10b5-1 Plan document must be reviewed and pre-cleared by the Compliance Officer prior to being signed. The Company has discretion to refuse approval of any 10b5-1 Plan document for any reason and need not provide any reason for such refusal. Once a 10b5-1 Plan is adopted, the insider must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded, or the date of any trade. The 10b5-1 Plan must include a cooling-off period consistent with applicable SEC rules before trading can commence.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(j)<b>&nbsp;&nbsp;&nbsp;&nbsp;Prohibitions Against Certain Transactions.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:113pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Prohibition on Short Sales. </b>Neither you, your Family Members nor your Controlled Entities may sell any Company Securities that are not owned by such person at the time of the sale (a &#8220;short sale&#8221;) including a &#8220;sale against the box&#8221;&nbsp;(a sale with delayed delivery).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:113pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Trading in Standardized Options</b>. An &#8220;option&#8221;&nbsp;is the right either to buy or sell a specified amount or value of a particular underlying interest at a fixed exercise price by exercising the option before its specified expiration date. An option which gives a right to buy is a &#8220;call&#8221;&nbsp;option, and an option which gives a right to sell is a &#8220;put&#8221;&nbsp;option. Standardized options (which are so labeled as a result of their standardized terms) offer the opportunity to invest using substantial leverage and therefore lend themselves to significant potential for abusive trading on material inside information. Standardized options also expire soon after issuance and thus necessarily involve short-term speculation, even where the date of expiration of the option makes the option exempt from certain SEC restrictions.</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The writing of a call or the acquisition of a put also involves a &#8220;bet against the company&#8221; and therefore presents a clear conflict of interest for you. As a result, neither you, your Family Members nor Controlled Entities may trade in standardized options relating to Company Securities at any time.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:113pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Hedging Transactions</b>. Certain forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts, allow &#8220;insiders&#8221;&nbsp;to lock in much of the value of his or her stockholdings, often in exchange for all or part of the potential for upside appreciation in the stock. These transactions allow &#8220;insiders&#8221;&nbsp;to continue to own the covered securities, but without the full risks and rewards of ownership. When that occurs, the &#8220;insiders&#8221;&nbsp;may no longer have the same objectives as the Company&#8217;s other shareholders. Therefore, neither you, your Family Members nor your Controlled Entities may engage in any such transactions.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:113pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Margin Accounts and Pledges</b>. Securities held in a margin account may be sold by the broker without the customer&#8217;s consent if the customer fails to meet a margin call. Similarly, securities pledged or hypothecated as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when you are aware of material nonpublic information or otherwise are not permitted to trade in Company Securities, neither you, your Family Members nor your Controlled Entities may hold Company Securities in a margin account or pledge Company Securities as collateral for a loan unless such transaction has been pre-approved by the Compliance Officer.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>8.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MAINTAINING CONFIDENTIALITY.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">Persons subject to this Policy have ethical and legal obligations to maintain the confidentiality of information about the Company and to not engage in transactions in Company Securities while in possession of Inside Information. Each individual is responsible for making sure that he or she complies with this Policy, and that any Family Member or Controlled Entity whose transactions are subject to this Policy also comply with this Policy. Any director, officer or employee privy to Inside Information is prohibited from communicating such information to anyone else, unless it is necessary to do so in the course of business. Efforts will be made to limit access to such confidential information to only those who need to know the information and such persons will be advised that the information is to be kept confidential. In all cases, the responsibility for determining whether an individual is in possession of Inside Information rests with that individual, and any action on the part of the Company, the Compliance Officer or any other employee or director pursuant to this Policy (or otherwise) does not in any way constitute legal advice or insulate an individual from liability under applicable securities laws. You could be subject to severe legal penalties and disciplinary action by the Company for any conduct prohibited by this Policy or applicable securities laws, as described below in more detail under the heading &#8220;Consequences of Violations.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">Communication by e-mail leaves a physical track of its passage that may be subject to later decryption attempts. All Inside Information being transmitted over the Internet must be secured by the strongest encryption and validation methods reasonably available. When possible, efforts should be made to avoid using e-mail to transmit Inside Information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">Outside parties privy to Inside Information concerning the Company will be told that they must not divulge such information to anyone else, other than in the necessary course of business and that they may not trade in Company Securities until the information is publicly disclosed. Such outside parties will confirm their commitment to non-disclosure in the form of a written confidentiality agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">In order to prevent the misuse or inadvertent disclosure of Inside Information, the procedures set forth below should be observed at all times:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:37pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Documents and files containing Inside Information should be kept in a safe place to which access is restricted to individuals who &#8220;need to know&#8221; that information in the necessary course of business and code names should be used if necessary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Confidential matters should not be disclosed in places where the discussion may be overheard, such as elevators, hallways, restaurants, airplanes or taxis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Confidential documents should not be read or displayed in public places and should not be discarded in a manner that others can retrieve them.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;Directors, officers and employees must ensure they maintain the confidentiality of information in their possession outside of the office as well as inside the office.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;Transmission of documents by electronic means, such as by fax or directly from one computer to another, should be made only where it is reasonable to believe that the transmission can be made and received under secure conditions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;Unnecessary copying of confidential documents should be avoided and documents containing Inside Information should be promptly removed from conference rooms and work areas after meetings have concluded. Extra copies of confidential documents should be shredded or otherwise destroyed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 42pt;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;Access to confidential electronic data should be restricted through the use of passwords.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>9.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>POST TERMINATION TRANSACTIONS.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Policy continues to apply to any and all transactions in Company Securities following termination of your employment or other services to the Company. If you are in possession of material nonpublic information when you are terminated, you may not trade in Company Securities until that information has become public or is no longer material. The Pre-Clearance Procedures in this Policy, however, will cease to apply to transactions in Company Securities upon the expiration of any blackout period applicable at the time of the termination of your employment or other service.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>10.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CONSEQUENCES OF VIOLATIONS.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">The purchase or sale of securities while in possession of Inside Information, or the disclosure of Inside Information to others who then trade in the Company&#8217;s Securities, is prohibited by federal, state and foreign securities laws. Insider trading violations are pursued vigorously by federal, state, and foreign jurisdictions, including, notably, the SEC. Insiders may be subject to penalties of up to $1,000,000 and up to ten (10) years in jail for engaging in transactions in the Company&#8217;s securities at a time when they possess Inside Information regarding the Company, regardless of whether such transactions were profitable. The SEC also has the authority to seek a civil monetary penalty of up to three times the amount of profit gained or loss avoided by illegal insider trading. &#8220;Profit gained&#8221; or &#8220;loss avoided&#8221; generally means the difference between the purchase or sale price of the Company&#8217;s shares and its value as measured by the trading price of the shares a reasonable period after public dissemination of the nonpublic information.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">Insiders may also be liable for &#8220;tipping.&#8221; The SEC has imposed large penalties even when the disclosing person did not profit from the trading. The SEC, the stock exchanges and the Financial Industry Regulatory Authority, Inc. all use sophisticated electronic surveillance techniques to monitor all trades and uncover insider trading.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;text-indent:36pt;">While the regulatory authorities concentrate their efforts on the individuals who trade, or who &#8220;tip&#8221; inside information to others who trade, the federal securities laws also impose potential liability on companies and other &#8220;controlling persons&#8221; if they fail to take reasonable steps to prevent insider trading by company personnel.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">In addition, an individual&#8217;s failure to comply with this Policy may subject the individual to Company-imposed sanctions, including dismissal for cause, whether or not the employee&#8217;s failure to comply results in a violation of law. Needless to say, a violation of law, or even an investigation by a government regulatory body that does not result in prosecution, can tarnish a person&#8217;s reputation and irreparably damage a career.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;"><b>11.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;CERTIFICATION. </b>All persons subject to this Policy must certify their understanding of, and intent to comply with, this Policy.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>SCHEDULE </b>&#8220;<b>A</b>&#8221;<b> INSIDER TRADING POLICY</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 3pt;"><b>ACKNOWLEDGEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">The undersigned acknowledges having read the Insider Trading Policy of <b>EDESA BIOTECH, INC. </b>dated _____________, 2024 (the &#8220;Policy&#8221;) and agrees to comply with such Policy in all respects. The undersigned further acknowledges that all of the undersigned&#8217;s Family Members (as defined in the Policy), and all holding companies and other Controlled Entities (as defined in the Policy) of the undersigned and all persons or companies acting on behalf of or at the request of any of the foregoing are also expected to comply with the Policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 6pt;text-indent:36pt;">The undersigned acknowledges that he or she will continue to comply with the Policy for as long as he or she is subject to the Policy, and that any violation of such Policy may constitute grounds for immediate suspension or dismissal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 42pt;">DATED this<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>day of______________________, 20___.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 50%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>Signature</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>Name (Please Print)</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex_754891.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_754891.htm</title>
	<!-- Generated by ThunderDome Portal - 12/6/2024 10:59:22 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 23.1</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><img alt="mnplogo.jpg" src="mnplogo.jpg"></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We hereby consent to the incorporation by reference in Registration Statement Nos. 333-217480, 333-236121, 333-255485, 333-272176 and 333-279887 on Form S-8, Registration Statement Nos. 333-233567, 333-266604 and 333-268847 on Form S-3 and Registration Statement No. 333-264235 on Form S-1 of our auditor&#8217;s report dated December 13, 2024 with respect to the consolidated financial statements of Edesa Biotech, Inc. as at September 30, 2024 and 2023 and for each of the years in the two year period ended September 30, 2024, as included in the Annual Report on Form 10-K of Edesa Biotech, Inc. for the year ended September 30, 2024 as filed with the United States Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ MNP LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chartered Professional Accountants</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Licensed Public Accountants</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Toronto, Canada</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 13, 2024</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div style="text-align: center;">&nbsp;&nbsp;
<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">
			<div style="text-align: left;"><img alt="footerv1.jpg" src="footerv1.jpg"></div>
			</td>
			<td style="width: 50%;">
			<div style="text-align: right;"><img alt="footerv2.jpg" src="footerv2.jpg"></div>
			</td>
		</tr>

</table>
</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex_754102.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: right;"><b>EXHIBIT 31.1 </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>(18 U.S.C. SECTION 1350)</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">I, Pardeep Nijhawan, certify that:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I have reviewed this Annual Report on Form 10-K of Edesa Biotech, Inc.;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: December 13, 2024</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Pardeep Nijhawan</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pardeep Nijhawan</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, Chief Executive Officer and Corporate Secretary</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex_754103.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: right;"><b>EXHIBIT 31.2</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>(18 U.S.C. SECTION 1350)</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">I, Stephen Lemieux, certify that:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I have reviewed this Annual Report on Form 10-K of Edesa Biotech, Inc.;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: December 13, 2024</p>
			</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Stephen Lemieux</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stephen Lemieux</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex_754104.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: right;"><b>EXHIBIT 32.1</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In connection with the Annual Report of Edesa Biotech, Inc. (the Company) on Form 10-K for the year ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Pardeep Nijhawan, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 4%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 4%;">&nbsp;</td>
			<td style="vertical-align: top; width: 96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 4%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">2.</p>
			</td>
			<td style="vertical-align: top; width: 96%;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: December 13, 2024</p>
			</td>
			<td style="vertical-align: middle; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Pardeep Nijhawan</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pardeep Nijhawan</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director, Chief Executive Officer and Corporate Secretary</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex_754105.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>HTML Editor</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: right;"><b>EXHIBIT 32.2</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. 1350, AS ADOPTED PURSUANT TO SECTION 906</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: center;"><b>OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">In connection with the Annual Report of Edesa Biotech, Inc. (the Company) on Form 10-K for the year ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Stephen Lemieux, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">1.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
			<td style="vertical-align:top;width:auto;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">2.</p>
			</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: middle; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: December 13, 2024</p>
			</td>
			<td style="vertical-align: middle; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>/s/ Stephen Lemieux</i></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stephen Lemieux</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>edsa-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:52PM UTC 2024-12-13--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:edsa="http://www.edsa.com/20240930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.edsa.com/20240930">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edsa-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edsa-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edsa-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edsa-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.edsa.com/20240930/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-and-comprehensive-loss" roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-shareholders-equity" roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-operations" roleURI="http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995451 - Disclosure - Note 1 - Nature of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-preparation" roleURI="http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995452 - Disclosure - Note 2 - Basis of Preparation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies" roleURI="http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995453 - Disclosure - Note 3 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment" roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995454 - Disclosure - Note 4 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-intangible-assets" roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995455 - Disclosure - Note 5 - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-rightofuse-asset-and-liabilities" roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995456 - Disclosure - Note 6 - Right-of-use Asset and Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments" roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995457 - Disclosure - Note 7 - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-capital-shares" roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995458 - Disclosure - Note 8 - Capital Shares</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-government-contributions" roleURI="http://www.edsa.com/20240930/role/statement-note-9-government-contributions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995459 - Disclosure - Note 9 - Government Contributions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-tax" roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995460 - Disclosure - Note 10 - Income Tax</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-financial-instruments" roleURI="http://www.edsa.com/20240930/role/statement-note-11-financial-instruments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995461 - Disclosure - Note 11 - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-related-party-transactions" roleURI="http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995462 - Disclosure - Note 13 - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-subsequent-events" roleURI="http://www.edsa.com/20240930/role/statement-note-13-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995463 - Disclosure - Note 13 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995464 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-tables" roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995465 - Disclosure - Note 4 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-intangible-assets-tables" roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995466 - Disclosure - Note 5 - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-rightofuse-asset-and-liabilities-tables" roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995467 - Disclosure - Note 6 - Right-of-use Asset and Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments-tables" roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995468 - Disclosure - Note 7 - Commitments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-capital-shares-tables" roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995469 - Disclosure - Note 8 - Capital Shares (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-tax-tables" roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995470 - Disclosure - Note 10 - Income Tax (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-nature-of-operations-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995471 - Disclosure - Note 1 - Nature of Operations (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995472 - Disclosure - Note 3 - Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995473 - Disclosure - Note 4 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995474 - Disclosure - Note 4 - Property and Equipment - Schedule of Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-intangible-assets-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995475 - Disclosure - Note 5 - Intangible Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-intangible-assets-schedule-of-intangible-assets-details" roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995476 - Disclosure - Note 5 - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-intangible-assets-estimated-future-amortization-details" roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995477 - Disclosure - Note 5 - Intangible Assets - Estimated Future Amortization (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-rightofuse-asset-and-liabilities-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995478 - Disclosure - Note 6 - Right-of-use Asset and Liabilities (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995479 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Lease Cost (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995480 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Lease Terms and Discount Rates (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995481 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995482 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995483 - Disclosure - Note 7 - Commitments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-commitments-commitments-for-contractual-research-details" roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995484 - Disclosure - Note 7 - Commitments - Commitments for Contractual Research (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-capital-shares-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995485 - Disclosure - Note 8 - Capital Shares (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-capital-shares-schedule-of-warrants-details" roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995486 - Disclosure - Note 8 - Capital Shares - Schedule of Warrants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-capital-shares-warrants-assumptions-details" roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995487 - Disclosure - Note 8 - Capital Shares - Warrants Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-capital-shares-option-activity-details" roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995488 - Disclosure - Note 8 - Capital Shares - Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-capital-shares-schedule-of-options-details" roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995489 - Disclosure - Note 8 - Capital Shares - Schedule of Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-capital-shares-option-assumptions-details" roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995490 - Disclosure - Note 8 - Capital Shares - Option Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-capital-shares-restricted-stock-units-details" roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995491 - Disclosure - Note 8 - Capital Shares - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-capital-shares-vested-restricted-stock-units-details" roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995492 - Disclosure - Note 8 - Capital Shares - Vested Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-government-contributions-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995493 - Disclosure - Note 9 - Government Contributions (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-tax-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995494 - Disclosure - Note 10 - Income Tax (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995495 - Disclosure - Note 10 - Income Tax - Schedule of Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995496 - Disclosure - Note 10 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995497 - Disclosure - Note 10 - Income Tax - Summary of Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-financial-instruments-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995498 - Disclosure - Note 11 - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-related-party-transactions-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995499 - Disclosure - Note 13 - Related Party Transactions (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-subsequent-events-details-textual" roleURI="http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995500 - Disclosure - Note 13 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="edsa_AtTheMarketOfferingAgreementMember" name="AtTheMarketOfferingAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_CIBCMember" name="CIBCMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_CaliforniaSubsidiary401kMember" name="CaliforniaSubsidiary401kMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_CanaccordMember" name="CanaccordMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_CanadaEmergencyBusinessAccountProgramMember" name="CanadaEmergencyBusinessAccountProgramMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" name="CapitalizedCostsPropertyPlantAndEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_ClassAWarrantsMember" name="ClassAWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_ClassBWarrantsMember" name="ClassBWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_ClassOfWarrantOrRightExpiredDuringPeriod" name="ClassOfWarrantOrRightExpiredDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" name="ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" name="ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" name="ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" name="ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal" name="DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" name="DeferredTaxAssetsRightofuseLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" name="DeferredTaxAssetsShareIssuanceAndFinancingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" name="DeferredTaxLiabilitiesDeferredShareIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" name="DeferredTaxLiabilitiesGrantIncomeReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="edsa_DepreciationDecliningBalanceMethodPercentage" name="DepreciationDecliningBalanceMethodPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_DrugSubstanceMember" name="DrugSubstanceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" name="EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" name="EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_EquityOfferingLimitationAmount" name="EquityOfferingLimitationAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="edsa_EquityOfferingMaximumAmount" name="EquityOfferingMaximumAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="edsa_FunctionalAndReportingCurrenciesPolicyTextBlock" name="FunctionalAndReportingCurrenciesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_FurnitureAndEquipmentMember" name="FurnitureAndEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_GovernmentAssistanceAwardAmountNotRepayable" name="GovernmentAssistanceAwardAmountNotRepayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="edsa_GovernmentAssistanceAwardAmountRepayable" name="GovernmentAssistanceAwardAmountRepayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="edsa_GovernmentAssistanceAwardAmountRepyable" name="GovernmentAssistanceAwardAmountRepyable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment" name="GovernmentAssistanceExpirationPeriodAfterLastRepayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal" name="GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant"/>
  <xsd:element id="edsa_GovernmentAssistancePeriodOfRepayment" name="GovernmentAssistancePeriodOfRepayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" name="IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" name="IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_LeaseTermAndDiscountRateTableTextBlock" name="LeaseTermAndDiscountRateTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_LeasesCashFlowInformationTableTextBlock" name="LeasesCashFlowInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" name="LicenseAgreementRelatedToPharmaceuticalProductsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_LicenseAgreementRenewalPeriod" name="LicenseAgreementRenewalPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" name="LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_MaximumContingentObligation" name="MaximumContingentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="edsa_MilestoneExpense" name="MilestoneExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" name="PardeepNijhawanMedicineProfessionalCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_PaymentsForLicensingAndRoyalties" name="PaymentsForLicensingAndRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="edsa_PaymentsForMilestoneRoyaltyAndSublicensing" name="PaymentsForMilestoneRoyaltyAndSublicensing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" name="PrivatePlacementSecuritiesPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_PropertyPlantAndEquipmentAssetsNotInService" name="PropertyPlantAndEquipmentAssetsNotInService" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" name="PropertyPlantAndEquipmentNetIncludingAssetsNotInService" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="edsa_RangeFiveMember" name="RangeFiveMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_RangeFourMember" name="RangeFourMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_RangeOneMember" name="RangeOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_RangeSevenMember" name="RangeSevenMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_RangeSixMember" name="RangeSixMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_RangeThreeMember" name="RangeThreeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_RangeTwoMember" name="RangeTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss" name="SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="edsa_SeriesA1ConvertiblePreferredStockMember" name="SeriesA1ConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts" name="StockIssuedDuringPeriodValueStockIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2025Member" name="TaxYear2025Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2026Member" name="TaxYear2026Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2027Member" name="TaxYear2027Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2028Member" name="TaxYear2028Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2029Member" name="TaxYear2029Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2030Member" name="TaxYear2030Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2031Member" name="TaxYear2031Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2032Member" name="TaxYear2032Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2033Member" name="TaxYear2033Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2034Member" name="TaxYear2034Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2035Member" name="TaxYear2035Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2036Member" name="TaxYear2036Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2037Member" name="TaxYear2037Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2038Member" name="TaxYear2038Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2039Member" name="TaxYear2039Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2040Member" name="TaxYear2040Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2041Member" name="TaxYear2041Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2042Member" name="TaxYear2042Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2043Member" name="TaxYear2043Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TaxYear2044Member" name="TaxYear2044Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_The2019PlanMember" name="The2019PlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_The2021SIFAgreementMember" name="The2021SIFAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_The2023SIFAgreementMember" name="The2023SIFAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TheConstructsMember" name="TheConstructsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_ThreeYearWarrantsMember" name="ThreeYearWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_TwelveMonthWarrantsMember" name="TwelveMonthWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_UnsecuredLineOfCreditMember" name="UnsecuredLineOfCreditMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_UpfrontLicensePayment" name="UpfrontLicensePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_WarrantFiveMember" name="WarrantFiveMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_WarrantFourMember" name="WarrantFourMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_WarrantOneMember" name="WarrantOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_WarrantThreeMember" name="WarrantThreeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_WarrantTwoMember" name="WarrantTwoMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_WarrantsIssuedInPrivatePlacementMember" name="WarrantsIssuedInPrivatePlacementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_WarrantsToPurchaseCommonSharesMember" name="WarrantsToPurchaseCommonSharesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="edsa_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" name="statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" name="statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details13081FEE-3625-46E3-9E41-38B63AB7D9E8" name="statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details13081FEE-3625-46E3-9E41-38B63AB7D9E8" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-10-income-tax-tables" name="statement-statement-note-10-income-tax-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" name="statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-4-property-and-equipment-tables" name="statement-statement-note-4-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-5-intangible-assets-estimated-future-amortization-details" name="statement-statement-note-5-intangible-assets-estimated-future-amortization-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details" name="statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-5-intangible-assets-tables" name="statement-statement-note-5-intangible-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-6-rightofuse-asset-and-liabilities-tables" name="statement-statement-note-6-rightofuse-asset-and-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" name="statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" name="statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" name="statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" name="statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-7-commitments-commitments-for-contractual-research-details" name="statement-statement-note-7-commitments-commitments-for-contractual-research-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-7-commitments-tables" name="statement-statement-note-7-commitments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-8-capital-shares-option-activity-details" name="statement-statement-note-8-capital-shares-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-8-capital-shares-option-assumptions-details" name="statement-statement-note-8-capital-shares-option-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-8-capital-shares-restricted-stock-units-details" name="statement-statement-note-8-capital-shares-restricted-stock-units-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-8-capital-shares-schedule-of-options-details" name="statement-statement-note-8-capital-shares-schedule-of-options-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details" name="statement-statement-note-8-capital-shares-schedule-of-warrants-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details95966B58-974C-4670-A75C-AE9CBB66238E" name="statement-statement-note-8-capital-shares-schedule-of-warrants-details95966B58-974C-4670-A75C-AE9CBB66238E" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-8-capital-shares-tables" name="statement-statement-note-8-capital-shares-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-8-capital-shares-vested-restricted-stock-units-details" name="statement-statement-note-8-capital-shares-vested-restricted-stock-units-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-note-8-capital-shares-warrants-assumptions-details" name="statement-statement-note-8-capital-shares-warrants-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="edsa_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>edsa-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:52PM UTC 2024-12-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation" xlink:href="edsa-20240930.xsd#statement-note-2-basis-of-preparation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-document-and-entity-information" xlink:href="edsa-20240930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets" xlink:href="edsa-20240930.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="edsa-20240930.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="edsa-20240930.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:label="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeOther" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows" xlink:href="edsa-20240930.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity" xlink:href="edsa-20240930.xsd#statement-consolidated-statements-of-changes-in-shareholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="edsa-20240930.xsd#edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" xlink:label="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" xlink:label="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="edsa_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_StockIssuedDuringPeriodValueStockIssuanceCosts" xlink:label="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations" xlink:href="edsa-20240930.xsd#statement-note-1-nature-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanaccordMember" xlink:label="edsa_CanaccordMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:label="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SeriesA1ConvertiblePreferredStockMember" xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2021SIFAgreementMember" xlink:label="edsa_The2021SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2023SIFAgreementMember" xlink:label="edsa_The2023SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ThreeYearWarrantsMember" xlink:label="edsa_ThreeYearWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TwelveMonthWarrantsMember" xlink:label="edsa_TwelveMonthWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_UnsecuredLineOfCreditMember" xlink:label="edsa_UnsecuredLineOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsToPurchaseCommonSharesMember" xlink:label="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edsa_CanaccordMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="edsa_The2023SIFAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="edsa_The2021SIFAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="edsa_UnsecuredLineOfCreditMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LineOfCreditMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_TwelveMonthWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_ThreeYearWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies" xlink:href="edsa-20240930.xsd#statement-note-3-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:label="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_FurnitureAndEquipmentMember" xlink:label="edsa_FurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="edsa_FurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment" xlink:href="edsa-20240930.xsd#statement-note-4-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TheConstructsMember" xlink:label="edsa_TheConstructsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="edsa_TheConstructsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-asset-and-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments" xlink:href="edsa-20240930.xsd#statement-note-7-commitments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-7-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CaliforniaSubsidiary401kMember" xlink:label="edsa_CaliforniaSubsidiary401kMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DrugSubstanceMember" xlink:label="edsa_DrugSubstanceMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:label="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:label="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TheConstructsMember" xlink:label="edsa_TheConstructsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edsa_TheConstructsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="edsa_DrugSubstanceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="edsa_CaliforniaSubsidiary401kMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanaccordMember" xlink:label="edsa_CanaccordMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassAWarrantsMember" xlink:label="edsa_ClassAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassBWarrantsMember" xlink:label="edsa_ClassBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityDistributionAgreementMember" xlink:label="edsa_EquityDistributionAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeFiveMember" xlink:label="edsa_RangeFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeFourMember" xlink:label="edsa_RangeFourMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeOneMember" xlink:label="edsa_RangeOneMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeSevenMember" xlink:label="edsa_RangeSevenMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeSixMember" xlink:label="edsa_RangeSixMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeThreeMember" xlink:label="edsa_RangeThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeTwoMember" xlink:label="edsa_RangeTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2019PlanMember" xlink:label="edsa_The2019PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantFiveMember" xlink:label="edsa_WarrantFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantFourMember" xlink:label="edsa_WarrantFourMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantOneMember" xlink:label="edsa_WarrantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantThreeMember" xlink:label="edsa_WarrantThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantTwoMember" xlink:label="edsa_WarrantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsIssuedInPrivatePlacementMember" xlink:label="edsa_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_ClassAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_ClassBWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edsa_CanaccordMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_EquityDistributionAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantOneMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantTwoMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantThreeMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantFourMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantFiveMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="edsa_The2019PlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeTwoMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeThreeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeFourMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeFiveMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeSixMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeSevenMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-9-government-contributions" xlink:href="edsa-20240930.xsd#statement-note-9-government-contributions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-9-government-contributions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CIBCMember" xlink:label="edsa_CIBCMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:label="edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2023SIFAgreementMember" xlink:label="edsa_The2023SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTextBlock" xlink:label="us-gaap_GovernmentAssistanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="edsa_The2023SIFAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="edsa_CIBCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GovernmentAssistanceTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2025Member" xlink:label="edsa_TaxYear2025Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2026Member" xlink:label="edsa_TaxYear2026Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2027Member" xlink:label="edsa_TaxYear2027Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2028Member" xlink:label="edsa_TaxYear2028Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2029Member" xlink:label="edsa_TaxYear2029Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2030Member" xlink:label="edsa_TaxYear2030Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2031Member" xlink:label="edsa_TaxYear2031Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2032Member" xlink:label="edsa_TaxYear2032Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2033Member" xlink:label="edsa_TaxYear2033Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2034Member" xlink:label="edsa_TaxYear2034Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2035Member" xlink:label="edsa_TaxYear2035Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2036Member" xlink:label="edsa_TaxYear2036Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2037Member" xlink:label="edsa_TaxYear2037Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2038Member" xlink:label="edsa_TaxYear2038Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2039Member" xlink:label="edsa_TaxYear2039Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2040Member" xlink:label="edsa_TaxYear2040Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2041Member" xlink:label="edsa_TaxYear2041Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2042Member" xlink:label="edsa_TaxYear2042Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2043Member" xlink:label="edsa_TaxYear2043Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2044Member" xlink:label="edsa_TaxYear2044Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CanadaRevenueAgencyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2025Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2026Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2027Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2028Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2029Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2030Member" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2031Member" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2032Member" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2033Member" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2034Member" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2035Member" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2036Member" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2037Member" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2038Member" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2039Member" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2040Member" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2041Member" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2042Member" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2043Member" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2044Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-11-financial-instruments" xlink:href="edsa-20240930.xsd#statement-note-11-financial-instruments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-11-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions" xlink:href="edsa-20240930.xsd#statement-note-13-related-party-transactions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-13-subsequent-events" xlink:href="edsa-20240930.xsd#statement-note-13-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-13-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SeriesA1ConvertiblePreferredStockMember" xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsToPurchaseCommonSharesMember" xlink:label="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies" xlink:href="edsa-20240930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_FunctionalAndReportingCurrenciesPolicyTextBlock" xlink:label="edsa_FunctionalAndReportingCurrenciesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="edsa_FunctionalAndReportingCurrenciesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables" xlink:href="edsa-20240930.xsd#statement-note-4-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LeaseTermAndDiscountRateTableTextBlock" xlink:label="edsa_LeaseTermAndDiscountRateTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LeasesCashFlowInformationTableTextBlock" xlink:label="edsa_LeasesCashFlowInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="edsa_LeaseTermAndDiscountRateTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="edsa_LeasesCashFlowInformationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments-tables" xlink:href="edsa-20240930.xsd#statement-note-7-commitments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-7-commitments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual" xlink:href="edsa-20240930.xsd#statement-note-1-nature-of-operations-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanaccordMember" xlink:label="edsa_CanaccordMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal" xlink:label="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingLimitationAmount" xlink:label="edsa_EquityOfferingLimitationAmount" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingMaximumAmount" xlink:label="edsa_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:label="edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountRepyable" xlink:label="edsa_GovernmentAssistanceAwardAmountRepyable" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:label="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SeriesA1ConvertiblePreferredStockMember" xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2021SIFAgreementMember" xlink:label="edsa_The2021SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2023SIFAgreementMember" xlink:label="edsa_The2023SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ThreeYearWarrantsMember" xlink:label="edsa_ThreeYearWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TwelveMonthWarrantsMember" xlink:label="edsa_TwelveMonthWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_UnsecuredLineOfCreditMember" xlink:label="edsa_UnsecuredLineOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsToPurchaseCommonSharesMember" xlink:label="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WorkingCapitalDeficit" xlink:label="edsa_WorkingCapitalDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount" xlink:label="us-gaap_GovernmentAssistanceAwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:label="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edsa_CanaccordMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="edsa_The2023SIFAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="edsa_The2021SIFAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="edsa_UnsecuredLineOfCreditMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LineOfCreditMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_TwelveMonthWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_ThreeYearWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_WorkingCapitalDeficit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EquityOfferingMaximumAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EquityOfferingLimitationAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAwardAmount" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceAwardAmountRepyable" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual" xlink:href="edsa-20240930.xsd#statement-note-3-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:label="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DepreciationDecliningBalanceMethodPercentage" xlink:label="edsa_DepreciationDecliningBalanceMethodPercentage" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_FurnitureAndEquipmentMember" xlink:label="edsa_FurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementRenewalPeriod" xlink:label="edsa_LicenseAgreementRenewalPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="edsa_FurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DepreciationDecliningBalanceMethodPercentage" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_LicenseAgreementRenewalPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual" xlink:href="edsa-20240930.xsd#statement-note-4-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:href="edsa-20240930.xsd#statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:label="edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:label="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementRenewalPeriod" xlink:label="edsa_LicenseAgreementRenewalPeriod" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_UpfrontLicensePayment" xlink:label="edsa_UpfrontLicensePayment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_LicenseAgreementRenewalPeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_UpfrontLicensePayment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TheConstructsMember" xlink:label="edsa_TheConstructsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="edsa_TheConstructsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-asset-and-liabilities-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual" xlink:href="edsa-20240930.xsd#statement-note-7-commitments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CaliforniaSubsidiary401kMember" xlink:label="edsa_CaliforniaSubsidiary401kMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DrugSubstanceMember" xlink:label="edsa_DrugSubstanceMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:label="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:label="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_MaximumContingentObligation" xlink:label="edsa_MaximumContingentObligation" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_MilestoneExpense" xlink:label="edsa_MilestoneExpense" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PaymentsForLicensingAndRoyalties" xlink:label="edsa_PaymentsForLicensingAndRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PaymentsForMilestoneRoyaltyAndSublicensing" xlink:label="edsa_PaymentsForMilestoneRoyaltyAndSublicensing" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TheConstructsMember" xlink:label="edsa_TheConstructsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edsa_TheConstructsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="edsa_DrugSubstanceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="edsa_CaliforniaSubsidiary401kMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_MaximumContingentObligation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_PaymentsForMilestoneRoyaltyAndSublicensing" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligation" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToSuppliers" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_PaymentsForLicensingAndRoyalties" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_MilestoneExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details" xlink:href="edsa-20240930.xsd#statement-note-7-commitments-commitments-for-contractual-research-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInThirdYear" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInFourthYear" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInFifthYear" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanaccordMember" xlink:label="edsa_CanaccordMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassAWarrantsMember" xlink:label="edsa_ClassAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassBWarrantsMember" xlink:label="edsa_ClassBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:label="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityDistributionAgreementMember" xlink:label="edsa_EquityDistributionAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingLimitationAmount" xlink:label="edsa_EquityOfferingLimitationAmount" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingMaximumAmount" xlink:label="edsa_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2019PlanMember" xlink:label="edsa_The2019PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsIssuedInPrivatePlacementMember" xlink:label="edsa_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_ClassAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_ClassBWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="edsa_CanaccordMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_EquityDistributionAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="edsa_The2019PlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EquityOfferingMaximumAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EquityOfferingLimitationAmount" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-schedule-of-warrants-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantFiveMember" xlink:label="edsa_WarrantFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantFourMember" xlink:label="edsa_WarrantFourMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantOneMember" xlink:label="edsa_WarrantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantThreeMember" xlink:label="edsa_WarrantThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantTwoMember" xlink:label="edsa_WarrantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantTwoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantThreeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantFourMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantFiveMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-warrants-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassAWarrantsMember" xlink:label="edsa_ClassAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassBWarrantsMember" xlink:label="edsa_ClassBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_ClassAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_ClassBWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-schedule-of-options-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeFiveMember" xlink:label="edsa_RangeFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeFourMember" xlink:label="edsa_RangeFourMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeOneMember" xlink:label="edsa_RangeOneMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeSevenMember" xlink:label="edsa_RangeSevenMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeSixMember" xlink:label="edsa_RangeSixMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeThreeMember" xlink:label="edsa_RangeThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeTwoMember" xlink:label="edsa_RangeTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeTwoMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeThreeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeFourMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeFiveMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeSixMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="edsa_RangeSevenMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-option-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-restricted-stock-units-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual" xlink:href="edsa-20240930.xsd#statement-note-9-government-contributions-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CIBCMember" xlink:label="edsa_CIBCMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:label="edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:label="edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountRepayable" xlink:label="edsa_GovernmentAssistanceAwardAmountRepayable" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment" xlink:label="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal" xlink:label="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistancePeriodOfRepayment" xlink:label="edsa_GovernmentAssistancePeriodOfRepayment" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2023SIFAgreementMember" xlink:label="edsa_The2023SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount" xlink:label="us-gaap_GovernmentAssistanceAwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:label="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="edsa_The2023SIFAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="edsa_CIBCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAwardAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceAwardAmountRepayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistancePeriodOfRepayment" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:label="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:label="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" xlink:label="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:label="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:label="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" xlink:label="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" xlink:label="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_CanadaRevenueAgencyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2025Member" xlink:label="edsa_TaxYear2025Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2026Member" xlink:label="edsa_TaxYear2026Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2027Member" xlink:label="edsa_TaxYear2027Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2028Member" xlink:label="edsa_TaxYear2028Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2029Member" xlink:label="edsa_TaxYear2029Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2030Member" xlink:label="edsa_TaxYear2030Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2031Member" xlink:label="edsa_TaxYear2031Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2032Member" xlink:label="edsa_TaxYear2032Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2033Member" xlink:label="edsa_TaxYear2033Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2034Member" xlink:label="edsa_TaxYear2034Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2035Member" xlink:label="edsa_TaxYear2035Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2036Member" xlink:label="edsa_TaxYear2036Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2037Member" xlink:label="edsa_TaxYear2037Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2038Member" xlink:label="edsa_TaxYear2038Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2039Member" xlink:label="edsa_TaxYear2039Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2040Member" xlink:label="edsa_TaxYear2040Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2041Member" xlink:label="edsa_TaxYear2041Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2042Member" xlink:label="edsa_TaxYear2042Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2043Member" xlink:label="edsa_TaxYear2043Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2044Member" xlink:label="edsa_TaxYear2044Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2025Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2039Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2040Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2026Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2041Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2042Member" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2027Member" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2044Member" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2028Member" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2029Member" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2030Member" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2031Member" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2032Member" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2033Member" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2034Member" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2035Member" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2036Member" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2037Member" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2038Member" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="edsa_TaxYear2043Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual" xlink:href="edsa-20240930.xsd#statement-note-11-financial-instruments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss" xlink:label="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetReportingCurrencyDenominatedValue" xlink:label="us-gaap_AssetReportingCurrencyDenominatedValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetReportingCurrencyDenominatedValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual" xlink:href="edsa-20240930.xsd#statement-note-13-related-party-transactions-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedRentCurrentAndNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual" xlink:href="edsa-20240930.xsd#statement-note-13-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingMaximumAmount" xlink:label="edsa_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SeriesA1ConvertiblePreferredStockMember" xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsToPurchaseCommonSharesMember" xlink:label="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EquityOfferingMaximumAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>edsa-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:52PM UTC 2024-12-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DocumentAndEntityInformation" xlink:label="edsa_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="edsa_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_DocumentAndEntityInformation" xlink:to="edsa_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="edsa_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="edsa_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-significant-accounting-policies-policies" xlink:label="edsa_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-significant-accounting-policies-policies" xlink:to="edsa_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected income tax recovery</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-4-property-and-equipment-tables" xlink:label="edsa_statement-statement-note-4-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-4-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-4-property-and-equipment-tables" xlink:to="edsa_statement-statement-note-4-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-5-intangible-assets-tables" xlink:label="edsa_statement-statement-note-5-intangible-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-5-intangible-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-5-intangible-assets-tables" xlink:to="edsa_statement-statement-note-5-intangible-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:label="edsa_statement-statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-6-rightofuse-asset-and-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Right-of-use Asset and Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:to="edsa_statement-statement-note-6-rightofuse-asset-and-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-7-commitments-tables" xlink:label="edsa_statement-statement-note-7-commitments-tables" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-7-commitments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Commitments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-7-commitments-tables" xlink:to="edsa_statement-statement-note-7-commitments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-tables" xlink:label="edsa_statement-statement-note-8-capital-shares-tables" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-8-capital-shares-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Capital Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-8-capital-shares-tables" xlink:to="edsa_statement-statement-note-8-capital-shares-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-10-income-tax-tables" xlink:label="edsa_statement-statement-note-10-income-tax-tables" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-10-income-tax-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Income Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-10-income-tax-tables" xlink:to="edsa_statement-statement-note-10-income-tax-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:label="edsa_statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Property and Equipment - Schedule of Property, Plant, and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:to="edsa_statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:label="edsa_statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Intangible Assets - Schedule of Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:to="edsa_statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:label="edsa_statement-statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-5-intangible-assets-estimated-future-amortization-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Intangible Assets - Estimated Future Amortization (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:to="edsa_statement-statement-note-5-intangible-assets-estimated-future-amortization-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Right-of-use Assets and Liabilities - Lease Cost (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:to="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Right-of-use Assets and Liabilities - Lease Terms and Discount Rates (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:to="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected share price volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Right-of-use Assets and Liabilities - Future Minimum Lease Payments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:to="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Right-of-use Assets and Liabilities - Cash Flow Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:to="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-7-commitments-commitments-for-contractual-research-details" xlink:label="edsa_statement-statement-note-7-commitments-commitments-for-contractual-research-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-7-commitments-commitments-for-contractual-research-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Commitments - Commitments for Contractual Research (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-7-commitments-commitments-for-contractual-research-details" xlink:to="edsa_statement-statement-note-7-commitments-commitments-for-contractual-research-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details" xlink:label="edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Capital Shares - Schedule of Warrants (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details" xlink:to="edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life (years) (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-warrants-assumptions-details" xlink:label="edsa_statement-statement-note-8-capital-shares-warrants-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-8-capital-shares-warrants-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Capital Shares - Warrants Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-8-capital-shares-warrants-assumptions-details" xlink:to="edsa_statement-statement-note-8-capital-shares-warrants-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-option-activity-details" xlink:label="edsa_statement-statement-note-8-capital-shares-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-8-capital-shares-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Capital Shares - Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-8-capital-shares-option-activity-details" xlink:to="edsa_statement-statement-note-8-capital-shares-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-schedule-of-options-details" xlink:label="edsa_statement-statement-note-8-capital-shares-schedule-of-options-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-8-capital-shares-schedule-of-options-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Capital Shares - Schedule of Options (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-8-capital-shares-schedule-of-options-details" xlink:to="edsa_statement-statement-note-8-capital-shares-schedule-of-options-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-option-assumptions-details" xlink:label="edsa_statement-statement-note-8-capital-shares-option-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-8-capital-shares-option-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Capital Shares - Option Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-8-capital-shares-option-assumptions-details" xlink:to="edsa_statement-statement-note-8-capital-shares-option-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-restricted-stock-units-details" xlink:label="edsa_statement-statement-note-8-capital-shares-restricted-stock-units-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-8-capital-shares-restricted-stock-units-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Capital Shares - Restricted Stock Units (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-8-capital-shares-restricted-stock-units-details" xlink:to="edsa_statement-statement-note-8-capital-shares-restricted-stock-units-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:label="edsa_statement-statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-8-capital-shares-vested-restricted-stock-units-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Capital Shares - Vested Restricted Stock Units (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:to="edsa_statement-statement-note-8-capital-shares-vested-restricted-stock-units-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:label="edsa_statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Income Tax - Schedule of Income Tax Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:to="edsa_statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="edsa_statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="edsa_statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:label="edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:type="locator"/>
    <link:label xlink:label="edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Income Tax - Summary of Operating Loss Carryforwards (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:to="edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatements" xlink:label="edsa_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="edsa_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_NotesToFinancialStatements" xlink:to="edsa_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="edsa_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="edsa_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:label="edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:type="locator"/>
    <link:label xlink:label="edsa_PropertyPlantAndEquipmentAssetsNotInService-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets not in service</link:label>
    <link:label xlink:label="edsa_PropertyPlantAndEquipmentAssetsNotInService-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount after accumulated depreciation, depletion and amortization of physical assets of assets not in service.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:to="edsa_PropertyPlantAndEquipmentAssetsNotInService-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:label="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:type="locator"/>
    <link:label xlink:label="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService</link:label>
    <link:label xlink:label="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Depreciable assets, net</link:label>
    <link:label xlink:label="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale, including assets not in service. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:to="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange differences on translation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, number of RSU (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, number of RSU (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, number of RSU (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, options, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, options, weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountRepayable" xlink:label="edsa_GovernmentAssistanceAwardAmountRepayable" xlink:type="locator"/>
    <link:label xlink:label="edsa_GovernmentAssistanceAwardAmountRepayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_GovernmentAssistanceAwardAmountRepayable</link:label>
    <link:label xlink:label="edsa_GovernmentAssistanceAwardAmountRepayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Award Amount, Repayable</link:label>
    <link:label xlink:label="edsa_GovernmentAssistanceAwardAmountRepayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met that will be repayable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_GovernmentAssistanceAwardAmountRepayable" xlink:to="edsa_GovernmentAssistanceAwardAmountRepayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetirementPlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetirementPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement, Securities Purchase Agreement [Member]</link:label>
    <link:label xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:to="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, options, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SeriesA1ConvertiblePreferredStockMember" xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-1 Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-1 convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:to="edsa_SeriesA1ConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, options, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsToPurchaseCommonSharesMember" xlink:label="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_WarrantsToPurchaseCommonSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants to Purchase Common Shares [Member]</link:label>
    <link:label xlink:label="edsa_WarrantsToPurchaseCommonSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Name of the class or type of warrant or right outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_WarrantsToPurchaseCommonSharesMember" xlink:to="edsa_WarrantsToPurchaseCommonSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series A-1 Convertible Preferred Shares to Common Shares [Member]</link:label>
    <link:label xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The unique name of a noncash or part noncash stock conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:to="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ForeignCurrencyExchangeRateTranslation1</link:label>
    <link:label xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency Exchange Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_AtTheMarketOfferingAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label xlink:label="edsa_AtTheMarketOfferingAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_AtTheMarketOfferingAgreementMember" xlink:to="edsa_AtTheMarketOfferingAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevolvingCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, number of options (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, number of options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired, number of options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LicensingAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityDistributionAgreementMember" xlink:label="edsa_EquityDistributionAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_EquityDistributionAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
    <link:label xlink:label="edsa_EquityDistributionAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents an equity distribution agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_EquityDistributionAgreementMember" xlink:to="edsa_EquityDistributionAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible asset, net</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantFiveMember" xlink:label="edsa_WarrantFiveMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_WarrantFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Five [Member]</link:label>
    <link:label xlink:label="edsa_WarrantFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Five</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_WarrantFiveMember" xlink:to="edsa_WarrantFiveMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantTwoMember" xlink:label="edsa_WarrantTwoMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_WarrantTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Two [Member]</link:label>
    <link:label xlink:label="edsa_WarrantTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Two</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_WarrantTwoMember" xlink:to="edsa_WarrantTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantOneMember" xlink:label="edsa_WarrantOneMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_WarrantOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant One [Member]</link:label>
    <link:label xlink:label="edsa_WarrantOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_WarrantOneMember" xlink:to="edsa_WarrantOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantFourMember" xlink:label="edsa_WarrantFourMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_WarrantFourMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Four [Member]</link:label>
    <link:label xlink:label="edsa_WarrantFourMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Four</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_WarrantFourMember" xlink:to="edsa_WarrantFourMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Constructs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantThreeMember" xlink:label="edsa_WarrantThreeMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_WarrantThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Three [Member]</link:label>
    <link:label xlink:label="edsa_WarrantThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Three</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_WarrantThreeMember" xlink:to="edsa_WarrantThreeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedLicenseAgreementsGross</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived License Agreements, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedLicenseAgreementsGross" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockConvertibleSharesIssuable</link:label>
    <link:label xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockConvertibleConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockConvertibleConversionPrice</link:label>
    <link:label xlink:label="us-gaap_PreferredStockConvertibleConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockConvertibleConversionRatio-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockConvertibleConversionRatio</link:label>
    <link:label xlink:label="us-gaap_PreferredStockConvertibleConversionRatio-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CanadaRevenueAgencyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada Revenue Agency [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CanadaRevenueAgencyMember" xlink:to="us-gaap_CanadaRevenueAgencyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount" xlink:label="us-gaap_GovernmentAssistanceAwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentAssistanceAwardAmount</link:label>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Award Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAwardAmount" xlink:to="us-gaap_GovernmentAssistanceAwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</link:label>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts, Premiums and Other Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:label="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Costs, Property Plant and Equipment [Member]</link:label>
    <link:label xlink:label="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents capitalized property, plant and equipment expenditures.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:to="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_FunctionalAndReportingCurrenciesPolicyTextBlock" xlink:label="edsa_FunctionalAndReportingCurrenciesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="edsa_FunctionalAndReportingCurrenciesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Functional and Reporting Currencies [Policy Text Block]</link:label>
    <link:label xlink:label="edsa_FunctionalAndReportingCurrenciesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the accounting policy for functional and reporting currencies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_FunctionalAndReportingCurrenciesPolicyTextBlock" xlink:to="edsa_FunctionalAndReportingCurrenciesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax (recovery) expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="us-gaap_LineOfCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:label="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceNonoperatingIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement grant income</link:label>
    <link:label xlink:label="us-gaap_GovernmentAssistanceNonoperatingIncome-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Nonoperating Income, Increase (Decrease)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:to="us-gaap_GovernmentAssistanceNonoperatingIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentDecreaseForgiveness</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Decrease, Forgiveness</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsAtCarryingValue</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon exercise of warrants (in shares)</link:label>
    <link:label xlink:label="edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issued during the period for exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="edsa_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="edsa_StockIssuedDuringPeriodValueExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon exercise of warrants</link:label>
    <link:label xlink:label="edsa_StockIssuedDuringPeriodValueExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued during the period for exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="edsa_StockIssuedDuringPeriodValueExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_UpfrontLicensePayment" xlink:label="edsa_UpfrontLicensePayment" xlink:type="locator"/>
    <link:label xlink:label="edsa_UpfrontLicensePayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_UpfrontLicensePayment</link:label>
    <link:label xlink:label="edsa_UpfrontLicensePayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront License Payment</link:label>
    <link:label xlink:label="edsa_UpfrontLicensePayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of upfront license payment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_UpfrontLicensePayment" xlink:to="edsa_UpfrontLicensePayment-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementRenewalPeriod" xlink:label="edsa_LicenseAgreementRenewalPeriod" xlink:type="locator"/>
    <link:label xlink:label="edsa_LicenseAgreementRenewalPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_LicenseAgreementRenewalPeriod</link:label>
    <link:label xlink:label="edsa_LicenseAgreementRenewalPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Renewal Period</link:label>
    <link:label xlink:label="edsa_LicenseAgreementRenewalPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period for renewal of the license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_LicenseAgreementRenewalPeriod" xlink:to="edsa_LicenseAgreementRenewalPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TheConstructsMember" xlink:label="edsa_TheConstructsMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_TheConstructsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Constructs [Member]</link:label>
    <link:label xlink:label="edsa_TheConstructsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Constructs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TheConstructsMember" xlink:to="edsa_TheConstructsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PaymentsForMilestoneRoyaltyAndSublicensing" xlink:label="edsa_PaymentsForMilestoneRoyaltyAndSublicensing" xlink:type="locator"/>
    <link:label xlink:label="edsa_PaymentsForMilestoneRoyaltyAndSublicensing-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_PaymentsForMilestoneRoyaltyAndSublicensing</link:label>
    <link:label xlink:label="edsa_PaymentsForMilestoneRoyaltyAndSublicensing-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Milestone, Royalty and Sublicensing</link:label>
    <link:label xlink:label="edsa_PaymentsForMilestoneRoyaltyAndSublicensing-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow for milestone, royalty and sublicensing,</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_PaymentsForMilestoneRoyaltyAndSublicensing" xlink:to="edsa_PaymentsForMilestoneRoyaltyAndSublicensing-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_MaximumContingentObligation" xlink:label="edsa_MaximumContingentObligation" xlink:type="locator"/>
    <link:label xlink:label="edsa_MaximumContingentObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_MaximumContingentObligation</link:label>
    <link:label xlink:label="edsa_MaximumContingentObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Contingent Obligation</link:label>
    <link:label xlink:label="edsa_MaximumContingentObligation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of maximum contingent obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_MaximumContingentObligation" xlink:to="edsa_MaximumContingentObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:label="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Related to Pharmaceutical Products [Member]</link:label>
    <link:label xlink:label="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the license agreement related to pharmaceutical products.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:to="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LeasesCashFlowInformationTableTextBlock" xlink:label="edsa_LeasesCashFlowInformationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="edsa_LeasesCashFlowInformationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases, Cash Flow Information [Table Text Block]</link:label>
    <link:label xlink:label="edsa_LeasesCashFlowInformationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of cash flow information for leases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_LeasesCashFlowInformationTableTextBlock" xlink:to="edsa_LeasesCashFlowInformationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingLimitationAmount" xlink:label="edsa_EquityOfferingLimitationAmount" xlink:type="locator"/>
    <link:label xlink:label="edsa_EquityOfferingLimitationAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_EquityOfferingLimitationAmount</link:label>
    <link:label xlink:label="edsa_EquityOfferingLimitationAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Limitation Amount</link:label>
    <link:label xlink:label="edsa_EquityOfferingLimitationAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of limitation on equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_EquityOfferingLimitationAmount" xlink:to="edsa_EquityOfferingLimitationAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanaccordMember" xlink:label="edsa_CanaccordMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_CanaccordMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canaccord [Member]</link:label>
    <link:label xlink:label="edsa_CanaccordMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Canaccord.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_CanaccordMember" xlink:to="edsa_CanaccordMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2019PlanMember" xlink:label="edsa_The2019PlanMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_The2019PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2019 Plan [Member]</link:label>
    <link:label xlink:label="edsa_The2019PlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2019 Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_The2019PlanMember" xlink:to="edsa_The2019PlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentMaturityDate</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:label="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:to="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_MilestoneExpense" xlink:label="edsa_MilestoneExpense" xlink:type="locator"/>
    <link:label xlink:label="edsa_MilestoneExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_MilestoneExpense</link:label>
    <link:label xlink:label="edsa_MilestoneExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Expense</link:label>
    <link:label xlink:label="edsa_MilestoneExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of milestone expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_MilestoneExpense" xlink:to="edsa_MilestoneExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:label="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement to Acquire Global Rights of Pharmaceutical Product [Member]</link:label>
    <link:label xlink:label="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the license agreement to acquire global rights of pharmaceutical product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:to="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingMaximumAmount" xlink:label="edsa_EquityOfferingMaximumAmount" xlink:type="locator"/>
    <link:label xlink:label="edsa_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_EquityOfferingMaximumAmount</link:label>
    <link:label xlink:label="edsa_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Offering, Maximum Amount</link:label>
    <link:label xlink:label="edsa_EquityOfferingMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount allowed to be issued under the equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_EquityOfferingMaximumAmount" xlink:to="edsa_EquityOfferingMaximumAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsIssuedInPrivatePlacementMember" xlink:label="edsa_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_WarrantsIssuedInPrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Private Placement [Member]</link:label>
    <link:label xlink:label="edsa_WarrantsIssuedInPrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrants issued in private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_WarrantsIssuedInPrivatePlacementMember" xlink:to="edsa_WarrantsIssuedInPrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, number of warrant shares (in shares)</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired, number of warrant shares (in shares)</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights cancelled during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:to="edsa_ClassOfWarrantOrRightExpiredDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:to="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights cancelled during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" xlink:to="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Per Share</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per share or per unit amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for option awards nonvested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Intrinsic Value Per Share</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per share or per unit amount by which the current fair value of the underlying stock exceeds the exercise price of options nonvested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, options, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value of options expired.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeOneMember" xlink:label="edsa_RangeOneMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_RangeOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range One [Member]</link:label>
    <link:label xlink:label="edsa_RangeOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range one.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_RangeOneMember" xlink:to="edsa_RangeOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, number of warrant shares (in shares)</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="edsa_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued, number of warrant shares (in shares)</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="edsa_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise price per share of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:to="edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated incremental borrowing rate:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeSevenMember" xlink:label="edsa_RangeSevenMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_RangeSevenMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Seven [Member]</link:label>
    <link:label xlink:label="edsa_RangeSevenMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range seven.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_RangeSevenMember" xlink:to="edsa_RangeSevenMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeSixMember" xlink:label="edsa_RangeSixMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_RangeSixMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Six [Member]</link:label>
    <link:label xlink:label="edsa_RangeSixMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range six.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_RangeSixMember" xlink:to="edsa_RangeSixMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use lease cost, included in general and administrative on the Statements of Operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeThreeMember" xlink:label="edsa_RangeThreeMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_RangeThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Three [Member]</link:label>
    <link:label xlink:label="edsa_RangeThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_RangeThreeMember" xlink:to="edsa_RangeThreeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCostTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeTwoMember" xlink:label="edsa_RangeTwoMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_RangeTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Two [Member]</link:label>
    <link:label xlink:label="edsa_RangeTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_RangeTwoMember" xlink:to="edsa_RangeTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentPeriodEndDate</link:label>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeFiveMember" xlink:label="edsa_RangeFiveMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_RangeFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Five [Member]</link:label>
    <link:label xlink:label="edsa_RangeFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range five.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_RangeFiveMember" xlink:to="edsa_RangeFiveMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeFourMember" xlink:label="edsa_RangeFourMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_RangeFourMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range Four [Member]</link:label>
    <link:label xlink:label="edsa_RangeFourMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents range four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_RangeFourMember" xlink:to="edsa_RangeFourMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityFileNumber</link:label>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal" xlink:label="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal" xlink:type="locator"/>
    <link:label xlink:label="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal</link:label>
    <link:label xlink:label="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Maximum Percentage of Borrowing Base for Outstanding Principal</link:label>
    <link:label xlink:label="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum percentage of the borrowing base for outstanding principal allowed under the covenant of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal" xlink:to="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentType</link:label>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainsLossesOnExtinguishmentOfDebt</link:label>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on payable forgiveness</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:label="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_PardeepNijhawanMedicineProfessionalCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pardeep Nijhawan Medicine Professional Corporation [Member]</link:label>
    <link:label xlink:label="edsa_PardeepNijhawanMedicineProfessionalCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Pardeep Nijhawan Medicine Professional Corporation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:to="edsa_PardeepNijhawanMedicineProfessionalCorporationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2044Member" xlink:label="edsa_TaxYear2044Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2044Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2044 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2044Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the tax year 2044.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2044Member" xlink:to="edsa_TaxYear2044Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:type="locator"/>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fully-vested RSUs (in shares)</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of fully vested equity instruments other than options outstanding that can be converted into shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityShellCompany</link:label>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss" xlink:label="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss</link:label>
    <link:label xlink:label="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis, Ten Percent Change to Foreign Currency Exchange, Impact to Net Income (Loss) and Other Comprehensive Income (Loss)</link:label>
    <link:label xlink:label="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of impact to net income (loss) and other comprehensive income (loss) from 10% change in foreign currency exchange rate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss" xlink:to="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" xlink:label="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" xlink:type="locator"/>
    <link:label xlink:label="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss before recovery of income taxes</link:label>
    <link:label xlink:label="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests</link:label>
    <link:label xlink:label="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" xlink:to="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2023SIFAgreementMember" xlink:label="edsa_The2023SIFAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_The2023SIFAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2023 SIF Agreement [Member]</link:label>
    <link:label xlink:label="edsa_The2023SIFAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2023 SIF Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_The2023SIFAgreementMember" xlink:to="edsa_The2023SIFAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2021SIFAgreementMember" xlink:label="edsa_The2021SIFAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_The2021SIFAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2021 SIF Agreement [Member]</link:label>
    <link:label xlink:label="edsa_The2021SIFAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2021 SIF Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_The2021SIFAgreementMember" xlink:to="edsa_The2021SIFAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:label="edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:type="locator"/>
    <link:label xlink:label="edsa_GovernmentAssistanceAwardAmountNotRepayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_GovernmentAssistanceAwardAmountNotRepayable</link:label>
    <link:label xlink:label="edsa_GovernmentAssistanceAwardAmountNotRepayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Award Amount, Not Repayable</link:label>
    <link:label xlink:label="edsa_GovernmentAssistanceAwardAmountNotRepayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met that will not be repayable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:to="edsa_GovernmentAssistanceAwardAmountNotRepayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityPublicFloat</link:label>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_UnsecuredLineOfCreditMember" xlink:label="edsa_UnsecuredLineOfCreditMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_UnsecuredLineOfCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Line of Credit [Member]</link:label>
    <link:label xlink:label="edsa_UnsecuredLineOfCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents unsecured line of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_UnsecuredLineOfCreditMember" xlink:to="edsa_UnsecuredLineOfCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCurrentReportingStatus</link:label>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityVoluntaryFilers</link:label>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityWellKnownSeasonedIssuer</link:label>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, options, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, options, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value of options outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_StockIssuedDuringPeriodValueStockIssuanceCosts" xlink:label="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_StockIssuedDuringPeriodValueStockIssuanceCosts</link:label>
    <link:label xlink:label="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label xlink:label="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued during the period for issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts" xlink:to="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistancePeriodOfRepayment" xlink:label="edsa_GovernmentAssistancePeriodOfRepayment" xlink:type="locator"/>
    <link:label xlink:label="edsa_GovernmentAssistancePeriodOfRepayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_GovernmentAssistancePeriodOfRepayment</link:label>
    <link:label xlink:label="edsa_GovernmentAssistancePeriodOfRepayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Period of Repayment</link:label>
    <link:label xlink:label="edsa_GovernmentAssistancePeriodOfRepayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of repayment for government assistance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_GovernmentAssistancePeriodOfRepayment" xlink:to="edsa_GovernmentAssistancePeriodOfRepayment-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountRepyable" xlink:label="edsa_GovernmentAssistanceAwardAmountRepyable" xlink:type="locator"/>
    <link:label xlink:label="edsa_GovernmentAssistanceAwardAmountRepyable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_GovernmentAssistanceAwardAmountRepyable</link:label>
    <link:label xlink:label="edsa_GovernmentAssistanceAwardAmountRepyable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Award Amount, Repyable</link:label>
    <link:label xlink:label="edsa_GovernmentAssistanceAwardAmountRepyable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met that will be repayable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_GovernmentAssistanceAwardAmountRepyable" xlink:to="edsa_GovernmentAssistanceAwardAmountRepyable-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment" xlink:label="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment" xlink:type="locator"/>
    <link:label xlink:label="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment</link:label>
    <link:label xlink:label="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government assistance, Expiration, Period After Last Repayment</link:label>
    <link:label xlink:label="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period after last repayment date for expiration of government assistance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment" xlink:to="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal" xlink:label="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal" xlink:type="locator"/>
    <link:label xlink:label="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal</link:label>
    <link:label xlink:label="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Maximum Amount Repayable, Factor of Original</link:label>
    <link:label xlink:label="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The factor of original amount repayable for maximum amount to be repaid for government assistance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal" xlink:to="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts and other receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityRegistrantName</link:label>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" xlink:type="locator"/>
    <link:label xlink:label="ecd_InsiderTradingPoliciesProcLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
	<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems-label" xlink:type="arc"/>

	<link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="locator"/>
	<link:label xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock-label" xlink:type="arc" />

    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xmlns:xml="http://www.w3.org/XML/1998/namespace" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
	<link:label xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xmlns:xml="http://www.w3.org/XML/1998/namespace" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
	<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:type="arc"/>

    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AmortizationOfIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCountry-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCommonStockSharesOutstanding</link:label>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon exercise of restricted share units (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</link:label>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares upon exercise of restricted share units</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingMaturityDate</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, number of options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant assumption</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited, number of options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetReportingCurrencyDenominatedValue" xlink:label="us-gaap_AssetReportingCurrencyDenominatedValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetReportingCurrencyDenominatedValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetReportingCurrencyDenominatedValue</link:label>
    <link:label xlink:label="us-gaap_AssetReportingCurrencyDenominatedValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetReportingCurrencyDenominatedValue" xlink:to="us-gaap_AssetReportingCurrencyDenominatedValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term right-of-use lease liabilities</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value included in long-term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiability</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of right-of-use lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term right-of-use lease liabilities</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value included in current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositsAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" xlink:label="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" xlink:type="locator"/>
    <link:label xlink:label="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares and warrants in equity offering</link:label>
    <link:label xlink:label="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the issuance of common shares and warrants in equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" xlink:to="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" xlink:label="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" xlink:type="locator"/>
    <link:label xlink:label="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common shares and warrants in equity offering (in shares)</link:label>
    <link:label xlink:label="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the shares issued for common shares and warrants in equity offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" xlink:to="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2028</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2029</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WorkingCapitalDeficit" xlink:label="edsa_WorkingCapitalDeficit" xlink:type="locator"/>
    <link:label xlink:label="edsa_WorkingCapitalDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_WorkingCapitalDeficit</link:label>
    <link:label xlink:label="edsa_WorkingCapitalDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working Capital (Deficit)</link:label>
    <link:label xlink:label="edsa_WorkingCapitalDeficit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the working capital (deficit).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_WorkingCapitalDeficit" xlink:to="edsa_WorkingCapitalDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FiniteLivedIntangibleAssetUsefulLife</link:label>
    <link:label xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseRenewalTerm</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepreciationDepletionAndAmortization</link:label>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsNoncurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Authorized unlimited common and preferred shares without par value issued and outstanding: 3,247,389 common shares (September 30, 2023 - 3,075,473)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized, Unlimited [Fixed List]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued and outstanding: 3,075,473 common shares (September 30, 2022 - 2,380,280) (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockNoParValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, No Par Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNoParValue" xlink:to="us-gaap_CommonStockNoParValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of right-of-use lease liabilities, included in accounts payable and accrued liabilities on the Statements of Cash Flow.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other temporary differences</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToSuppliers</link:label>
    <link:label xlink:label="us-gaap_PaymentsToSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Suppliers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliers" xlink:to="us-gaap_PaymentsToSuppliers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockParOrStatedValuePerShare</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</link:label>
    <link:label xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentAdditions</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and other receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ChiefExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Misc other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-capital losses carried forward - Canada</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-capital losses carried forward - U.S.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments (Note 7)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (loss):</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments for issuance costs of common shares and warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedRentCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Rent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRentCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common shares and warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, warrants, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, number of warrant shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, number of warrant shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_IcfrAuditorAttestationFlag</link:label>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InternalRevenueServiceIRSMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentFinStmtErrorCorrectionFlag</link:label>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityInteractiveDataCurrent</link:label>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTextBlock" xlink:label="us-gaap_GovernmentAssistanceTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTextBlock" xlink:to="us-gaap_GovernmentAssistanceTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceTypeDomain" xlink:to="us-gaap_GovernmentAssistanceTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_AuditorName</link:label>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_AuditorLocation</link:label>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Valuation Allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:to="us-gaap_TaxCreditCarryforwardValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligation</link:label>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligationDueInFourthYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligationDueInFourthYear</link:label>
    <link:label xlink:label="us-gaap_ContractualObligationDueInFourthYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2028</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligationDueInFifthYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligationDueInFifthYear</link:label>
    <link:label xlink:label="us-gaap_ContractualObligationDueInFifthYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2029</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligationDueInNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligationDueInSecondYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligationDueInSecondYear</link:label>
    <link:label xlink:label="us-gaap_ContractualObligationDueInSecondYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligationDueInThirdYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligationDueInThirdYear</link:label>
    <link:label xlink:label="us-gaap_ContractualObligationDueInThirdYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">September 30, 2027</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PurchaseObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PurchaseObligation</link:label>
    <link:label xlink:label="us-gaap_PurchaseObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwardsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss per common share - basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ThreeYearWarrantsMember" xlink:label="edsa_ThreeYearWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_ThreeYearWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three Year Warrants [Member]</link:label>
    <link:label xlink:label="edsa_ThreeYearWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents 3-year warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ThreeYearWarrantsMember" xlink:to="edsa_ThreeYearWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining lease term (months): (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TwelveMonthWarrantsMember" xlink:label="edsa_TwelveMonthWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_TwelveMonthWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twelve Month Warrants [Member]</link:label>
    <link:label xlink:label="edsa_TwelveMonthWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents 12-month warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TwelveMonthWarrantsMember" xlink:to="edsa_TwelveMonthWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CIBCMember" xlink:label="edsa_CIBCMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_CIBCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CIBC [Member]</link:label>
    <link:label xlink:label="edsa_CIBCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the CIBC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_CIBCMember" xlink:to="edsa_CIBCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DepreciationDecliningBalanceMethodPercentage" xlink:label="edsa_DepreciationDecliningBalanceMethodPercentage" xlink:type="locator"/>
    <link:label xlink:label="edsa_DepreciationDecliningBalanceMethodPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_DepreciationDecliningBalanceMethodPercentage</link:label>
    <link:label xlink:label="edsa_DepreciationDecliningBalanceMethodPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Declining Balance Method, Percentage</link:label>
    <link:label xlink:label="edsa_DepreciationDecliningBalanceMethodPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of the declining balance method for depreciation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_DepreciationDecliningBalanceMethodPercentage" xlink:to="edsa_DepreciationDecliningBalanceMethodPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:label="edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_CanadaEmergencyBusinessAccountProgramMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada Emergency Business Account Program [Member]</link:label>
    <link:label xlink:label="edsa_CanadaEmergencyBusinessAccountProgramMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Canada Emergency Business Account Program (CEBA).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:to="edsa_CanadaEmergencyBusinessAccountProgramMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_FurnitureAndEquipmentMember" xlink:label="edsa_FurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_FurnitureAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Equipment [Member]</link:label>
    <link:label xlink:label="edsa_FurnitureAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents furniture and equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_FurnitureAndEquipmentMember" xlink:to="edsa_FurnitureAndEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PaymentsForLicensingAndRoyalties" xlink:label="edsa_PaymentsForLicensingAndRoyalties" xlink:type="locator"/>
    <link:label xlink:label="edsa_PaymentsForLicensingAndRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_PaymentsForLicensingAndRoyalties</link:label>
    <link:label xlink:label="edsa_PaymentsForLicensingAndRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived License Agreements, Gross</link:label>
    <link:label xlink:label="edsa_PaymentsForLicensingAndRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow for licensing and royalties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_PaymentsForLicensingAndRoyalties" xlink:to="edsa_PaymentsForLicensingAndRoyalties-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LeaseTermAndDiscountRateTableTextBlock" xlink:label="edsa_LeaseTermAndDiscountRateTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="edsa_LeaseTermAndDiscountRateTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Term and Discount Rate [Table Text Block]</link:label>
    <link:label xlink:label="edsa_LeaseTermAndDiscountRateTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of lessee's lease terms and discount rate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_LeaseTermAndDiscountRateTableTextBlock" xlink:to="edsa_LeaseTermAndDiscountRateTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DrugSubstanceMember" xlink:label="edsa_DrugSubstanceMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_DrugSubstanceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Substance [Member]</link:label>
    <link:label xlink:label="edsa_DrugSubstanceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a drug substance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_DrugSubstanceMember" xlink:to="edsa_DrugSubstanceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CaliforniaSubsidiary401kMember" xlink:label="edsa_CaliforniaSubsidiary401kMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_CaliforniaSubsidiary401kMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">California Subsidiary 401k [Member]</link:label>
    <link:label xlink:label="edsa_CaliforniaSubsidiary401kMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 401(k) retirement savings plan for the California subsidiary.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_CaliforniaSubsidiary401kMember" xlink:to="edsa_CaliforniaSubsidiary401kMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canadian federal and provincial statutory income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:label="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:type="locator"/>
    <link:label xlink:label="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issuance cost booked through equity or capitalization</link:label>
    <link:label xlink:label="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to share issuance costs booked through equity or capitalization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:to="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:label="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issuance and financing costs</link:label>
    <link:label xlink:label="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to share issuance and financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:to="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:label="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:type="locator"/>
    <link:label xlink:label="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-capital losses limitation - U.S.</link:label>
    <link:label xlink:label="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to non-capital losses limitation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:to="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" xlink:label="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts</link:label>
    <link:label xlink:label="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred share issuance costs</link:label>
    <link:label xlink:label="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from deferred share issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" xlink:to="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" xlink:label="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" xlink:type="locator"/>
    <link:label xlink:label="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">edsa_DeferredTaxLiabilitiesGrantIncomeReceivable</link:label>
    <link:label xlink:label="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Grant Income receivable</link:label>
    <link:label xlink:label="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from grant income receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" xlink:to="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:label="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:type="locator"/>
    <link:label xlink:label="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use lease liabilities</link:label>
    <link:label xlink:label="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to right-of-use lease liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:to="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2025Member" xlink:label="edsa_TaxYear2025Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2025Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2025 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2025Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2025.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2025Member" xlink:to="edsa_TaxYear2025Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2027Member" xlink:label="edsa_TaxYear2027Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2027Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2027 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2027Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2027.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2027Member" xlink:to="edsa_TaxYear2027Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2026Member" xlink:label="edsa_TaxYear2026Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2026Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2026 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2026Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2026.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2026Member" xlink:to="edsa_TaxYear2026Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2034Member" xlink:label="edsa_TaxYear2034Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2034Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2034 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2034Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2034.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2034Member" xlink:to="edsa_TaxYear2034Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2033Member" xlink:label="edsa_TaxYear2033Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2033Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2033 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2033Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2033.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2033Member" xlink:to="edsa_TaxYear2033Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassAWarrantsMember" xlink:label="edsa_ClassAWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_ClassAWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class A Warrants [Member]</link:label>
    <link:label xlink:label="edsa_ClassAWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class A Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ClassAWarrantsMember" xlink:to="edsa_ClassAWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2036Member" xlink:label="edsa_TaxYear2036Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2036Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2036 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2036Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2036.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2036Member" xlink:to="edsa_TaxYear2036Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2035Member" xlink:label="edsa_TaxYear2035Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2035Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2035 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2035Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2035.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2035Member" xlink:to="edsa_TaxYear2035Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2029Member" xlink:label="edsa_TaxYear2029Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2029Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2029 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2029Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2029.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2029Member" xlink:to="edsa_TaxYear2029Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2028Member" xlink:label="edsa_TaxYear2028Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2028Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2028 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2028Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2028.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2028Member" xlink:to="edsa_TaxYear2028Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2031Member" xlink:label="edsa_TaxYear2031Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2031Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2031 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2031Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2031.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2031Member" xlink:to="edsa_TaxYear2031Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2030Member" xlink:label="edsa_TaxYear2030Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2030Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2030 [Member[</link:label>
    <link:label xlink:label="edsa_TaxYear2030Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2030.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2030Member" xlink:to="edsa_TaxYear2030Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2042Member" xlink:label="edsa_TaxYear2042Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2042Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2042 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2042Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2042.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2042Member" xlink:to="edsa_TaxYear2042Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2041Member" xlink:label="edsa_TaxYear2041Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2041Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2041 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2041Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2041.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2041Member" xlink:to="edsa_TaxYear2041Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2043Member" xlink:label="edsa_TaxYear2043Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2043Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2043 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2043Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2043.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2043Member" xlink:to="edsa_TaxYear2043Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2038Member" xlink:label="edsa_TaxYear2038Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2038Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2038 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2038Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2038.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2038Member" xlink:to="edsa_TaxYear2038Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassBWarrantsMember" xlink:label="edsa_ClassBWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="edsa_ClassBWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class B Warrants [Member]</link:label>
    <link:label xlink:label="edsa_ClassBWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class B Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_ClassBWarrantsMember" xlink:to="edsa_ClassBWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2037Member" xlink:label="edsa_TaxYear2037Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2037Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2037 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2037Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2037.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2037Member" xlink:to="edsa_TaxYear2037Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2040Member" xlink:label="edsa_TaxYear2040Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2040Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2040 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2040Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2040.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2040Member" xlink:to="edsa_TaxYear2040Member-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2039Member" xlink:label="edsa_TaxYear2039Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2039Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2039 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2039Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2039.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2039Member" xlink:to="edsa_TaxYear2039Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of foreign currency and foreign tax rate differences</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:type="arc"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2032Member" xlink:label="edsa_TaxYear2032Member" xlink:type="locator"/>
    <link:label xlink:label="edsa_TaxYear2032Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Year 2032 [Member]</link:label>
    <link:label xlink:label="edsa_TaxYear2032Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents tax year 2032.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="edsa_TaxYear2032Member" xlink:to="edsa_TaxYear2032Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>edsa-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:52PM UTC 2024-12-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation" xlink:href="edsa-20240930.xsd#statement-note-2-basis-of-preparation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-document-and-entity-information" xlink:href="edsa-20240930.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets" xlink:href="edsa-20240930.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="edsa-20240930.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNoParValue" xlink:label="us-gaap_CommonStockNoParValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNoParValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="edsa-20240930.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:label="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeOther" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows" xlink:href="edsa-20240930.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-n9" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables-n9" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity" xlink:href="edsa-20240930.xsd#statement-consolidated-statements-of-changes-in-shareholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity" xlink:type="extended">
    <link:loc xlink:href="edsa-20240930.xsd#edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" xlink:label="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" xlink:label="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="edsa_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_StockIssuedDuringPeriodValueStockIssuanceCosts" xlink:label="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_StockIssuedDuringPeriodValueStockIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations" xlink:href="edsa-20240930.xsd#statement-note-1-nature-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanaccordMember" xlink:label="edsa_CanaccordMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:label="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SeriesA1ConvertiblePreferredStockMember" xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2021SIFAgreementMember" xlink:label="edsa_The2021SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2023SIFAgreementMember" xlink:label="edsa_The2023SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ThreeYearWarrantsMember" xlink:label="edsa_ThreeYearWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TwelveMonthWarrantsMember" xlink:label="edsa_TwelveMonthWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_UnsecuredLineOfCreditMember" xlink:label="edsa_UnsecuredLineOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsToPurchaseCommonSharesMember" xlink:label="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="edsa_CanaccordMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="edsa_The2023SIFAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="edsa_The2021SIFAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_RevolvingCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="edsa_UnsecuredLineOfCreditMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_LineOfCreditMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_TwelveMonthWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_ThreeYearWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies" xlink:href="edsa-20240930.xsd#statement-note-3-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:label="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_FurnitureAndEquipmentMember" xlink:label="edsa_FurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="edsa_FurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment" xlink:href="edsa-20240930.xsd#statement-note-4-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TheConstructsMember" xlink:label="edsa_TheConstructsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="edsa_TheConstructsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-asset-and-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments" xlink:href="edsa-20240930.xsd#statement-note-7-commitments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-7-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CaliforniaSubsidiary401kMember" xlink:label="edsa_CaliforniaSubsidiary401kMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DrugSubstanceMember" xlink:label="edsa_DrugSubstanceMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:label="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:label="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TheConstructsMember" xlink:label="edsa_TheConstructsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="edsa_TheConstructsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="edsa_DrugSubstanceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="edsa_CaliforniaSubsidiary401kMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanaccordMember" xlink:label="edsa_CanaccordMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassAWarrantsMember" xlink:label="edsa_ClassAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassBWarrantsMember" xlink:label="edsa_ClassBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityDistributionAgreementMember" xlink:label="edsa_EquityDistributionAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeFiveMember" xlink:label="edsa_RangeFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeFourMember" xlink:label="edsa_RangeFourMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeOneMember" xlink:label="edsa_RangeOneMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeSevenMember" xlink:label="edsa_RangeSevenMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeSixMember" xlink:label="edsa_RangeSixMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeThreeMember" xlink:label="edsa_RangeThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeTwoMember" xlink:label="edsa_RangeTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2019PlanMember" xlink:label="edsa_The2019PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantFiveMember" xlink:label="edsa_WarrantFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantFourMember" xlink:label="edsa_WarrantFourMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantOneMember" xlink:label="edsa_WarrantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantThreeMember" xlink:label="edsa_WarrantThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantTwoMember" xlink:label="edsa_WarrantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsIssuedInPrivatePlacementMember" xlink:label="edsa_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_ClassAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_ClassBWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="edsa_CanaccordMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_EquityDistributionAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantOneMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantTwoMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantThreeMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantFourMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantFiveMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="edsa_The2019PlanMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeTwoMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeThreeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeFourMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeFiveMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeSixMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeSevenMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-9-government-contributions" xlink:href="edsa-20240930.xsd#statement-note-9-government-contributions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-9-government-contributions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CIBCMember" xlink:label="edsa_CIBCMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:label="edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2023SIFAgreementMember" xlink:label="edsa_The2023SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTextBlock" xlink:label="us-gaap_GovernmentAssistanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="edsa_The2023SIFAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="edsa_CIBCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GovernmentAssistanceTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2025Member" xlink:label="edsa_TaxYear2025Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2026Member" xlink:label="edsa_TaxYear2026Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2027Member" xlink:label="edsa_TaxYear2027Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2028Member" xlink:label="edsa_TaxYear2028Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2029Member" xlink:label="edsa_TaxYear2029Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2030Member" xlink:label="edsa_TaxYear2030Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2031Member" xlink:label="edsa_TaxYear2031Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2032Member" xlink:label="edsa_TaxYear2032Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2033Member" xlink:label="edsa_TaxYear2033Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2034Member" xlink:label="edsa_TaxYear2034Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2035Member" xlink:label="edsa_TaxYear2035Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2036Member" xlink:label="edsa_TaxYear2036Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2037Member" xlink:label="edsa_TaxYear2037Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2038Member" xlink:label="edsa_TaxYear2038Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2039Member" xlink:label="edsa_TaxYear2039Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2040Member" xlink:label="edsa_TaxYear2040Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2041Member" xlink:label="edsa_TaxYear2041Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2042Member" xlink:label="edsa_TaxYear2042Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2043Member" xlink:label="edsa_TaxYear2043Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2044Member" xlink:label="edsa_TaxYear2044Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_CanadaRevenueAgencyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2025Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2026Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2027Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2028Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2029Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2030Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2031Member" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2032Member" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2033Member" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2034Member" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2035Member" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2036Member" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2037Member" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2038Member" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2039Member" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2040Member" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2041Member" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2042Member" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2043Member" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2044Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-11-financial-instruments" xlink:href="edsa-20240930.xsd#statement-note-11-financial-instruments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-11-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions" xlink:href="edsa-20240930.xsd#statement-note-13-related-party-transactions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-13-subsequent-events" xlink:href="edsa-20240930.xsd#statement-note-13-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-13-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NotesToFinancialStatementsAbstract" xlink:label="edsa_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SeriesA1ConvertiblePreferredStockMember" xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsToPurchaseCommonSharesMember" xlink:label="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies" xlink:href="edsa-20240930.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_FunctionalAndReportingCurrenciesPolicyTextBlock" xlink:label="edsa_FunctionalAndReportingCurrenciesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-significant-accounting-policies-policies" xlink:label="edsa_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="edsa_FunctionalAndReportingCurrenciesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables" xlink:href="edsa-20240930.xsd#statement-note-4-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-4-property-and-equipment-tables" xlink:label="edsa_statement-statement-note-4-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-4-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-5-intangible-assets-tables" xlink:label="edsa_statement-statement-note-5-intangible-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-5-intangible-assets-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LeaseTermAndDiscountRateTableTextBlock" xlink:label="edsa_LeaseTermAndDiscountRateTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LeasesCashFlowInformationTableTextBlock" xlink:label="edsa_LeasesCashFlowInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:label="edsa_statement-statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-6-rightofuse-asset-and-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="edsa_LeaseTermAndDiscountRateTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="edsa_LeasesCashFlowInformationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments-tables" xlink:href="edsa-20240930.xsd#statement-note-7-commitments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-7-commitments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-7-commitments-tables" xlink:label="edsa_statement-statement-note-7-commitments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-7-commitments-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-tables" xlink:label="edsa_statement-statement-note-8-capital-shares-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-8-capital-shares-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-10-income-tax-tables" xlink:label="edsa_statement-statement-note-10-income-tax-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-10-income-tax-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual" xlink:href="edsa-20240930.xsd#statement-note-1-nature-of-operations-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanaccordMember" xlink:label="edsa_CanaccordMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal" xlink:label="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingLimitationAmount" xlink:label="edsa_EquityOfferingLimitationAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingMaximumAmount" xlink:label="edsa_EquityOfferingMaximumAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:label="edsa_GovernmentAssistanceAwardAmountNotRepayable-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountRepyable" xlink:label="edsa_GovernmentAssistanceAwardAmountRepyable-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:label="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SeriesA1ConvertiblePreferredStockMember" xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2021SIFAgreementMember" xlink:label="edsa_The2021SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2023SIFAgreementMember" xlink:label="edsa_The2023SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ThreeYearWarrantsMember" xlink:label="edsa_ThreeYearWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TwelveMonthWarrantsMember" xlink:label="edsa_TwelveMonthWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_UnsecuredLineOfCreditMember" xlink:label="edsa_UnsecuredLineOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsToPurchaseCommonSharesMember" xlink:label="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WorkingCapitalDeficit" xlink:label="edsa_WorkingCapitalDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount" xlink:label="us-gaap_GovernmentAssistanceAwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:label="us-gaap_GovernmentAssistanceNonoperatingIncome-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="edsa_CanaccordMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="edsa_The2023SIFAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="edsa_The2021SIFAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_RevolvingCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="edsa_PardeepNijhawanMedicineProfessionalCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="edsa_UnsecuredLineOfCreditMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_LineOfCreditMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_TwelveMonthWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_ThreeYearWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-n2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-n2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_WorkingCapitalDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EquityOfferingMaximumAmount-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EquityOfferingLimitationAmount-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceAwardAmountNotRepayable-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceAwardAmountRepyable-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceNonoperatingIncome-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual" xlink:href="edsa-20240930.xsd#statement-note-3-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:label="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DepreciationDecliningBalanceMethodPercentage" xlink:label="edsa_DepreciationDecliningBalanceMethodPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_FurnitureAndEquipmentMember" xlink:label="edsa_FurnitureAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementRenewalPeriod" xlink:label="edsa_LicenseAgreementRenewalPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables" xlink:label="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="edsa_CapitalizedCostsPropertyPlantAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="edsa_FurnitureAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DepreciationDecliningBalanceMethodPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_LicenseAgreementRenewalPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual" xlink:href="edsa-20240930.xsd#statement-note-4-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:href="edsa-20240930.xsd#statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:label="edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:label="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService-3" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:label="edsa_statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementRenewalPeriod" xlink:label="edsa_LicenseAgreementRenewalPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_UpfrontLicensePayment" xlink:label="edsa_UpfrontLicensePayment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_LicensingAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_LicenseAgreementRenewalPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_UpfrontLicensePayment-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TheConstructsMember" xlink:label="edsa_TheConstructsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:label="edsa_statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="edsa_TheConstructsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:label="edsa_statement-statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-asset-and-liabilities-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:label="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual" xlink:href="edsa-20240930.xsd#statement-note-7-commitments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CaliforniaSubsidiary401kMember" xlink:label="edsa_CaliforniaSubsidiary401kMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DrugSubstanceMember" xlink:label="edsa_DrugSubstanceMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:label="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:label="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_MaximumContingentObligation" xlink:label="edsa_MaximumContingentObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_MilestoneExpense" xlink:label="edsa_MilestoneExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PaymentsForLicensingAndRoyalties" xlink:label="edsa_PaymentsForLicensingAndRoyalties-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PaymentsForMilestoneRoyaltyAndSublicensing" xlink:label="edsa_PaymentsForMilestoneRoyaltyAndSublicensing-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TheConstructsMember" xlink:label="edsa_TheConstructsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedLicenseAgreementsGross" xlink:label="us-gaap_FiniteLivedLicenseAgreementsGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseObligation" xlink:label="us-gaap_PurchaseObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="edsa_TheConstructsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="edsa_DrugSubstanceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RetirementPlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="edsa_CaliforniaSubsidiary401kMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_MaximumContingentObligation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_PaymentsForMilestoneRoyaltyAndSublicensing-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseObligation-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToSuppliers-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedLicenseAgreementsGross-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_PaymentsForLicensingAndRoyalties-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_MilestoneExpense-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details" xlink:href="edsa-20240930.xsd#statement-note-7-commitments-commitments-for-contractual-research-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-7-commitments-commitments-for-contractual-research-details" xlink:label="edsa_statement-statement-note-7-commitments-commitments-for-contractual-research-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-7-commitments-commitments-for-contractual-research-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInThirdYear-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInFourthYear-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInFifthYear-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanaccordMember" xlink:label="edsa_CanaccordMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassAWarrantsMember" xlink:label="edsa_ClassAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassBWarrantsMember" xlink:label="edsa_ClassBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm" xlink:label="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityDistributionAgreementMember" xlink:label="edsa_EquityDistributionAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingLimitationAmount" xlink:label="edsa_EquityOfferingLimitationAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingMaximumAmount" xlink:label="edsa_EquityOfferingMaximumAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2019PlanMember" xlink:label="edsa_The2019PlanMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsIssuedInPrivatePlacementMember" xlink:label="edsa_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_ClassAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_ClassBWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="edsa_CanaccordMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_EquityDistributionAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="edsa_The2019PlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EquityOfferingMaximumAmount-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EquityOfferingLimitationAmount-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-schedule-of-warrants-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:label="edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriod-n2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" xlink:label="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice" xlink:label="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantFiveMember" xlink:label="edsa_WarrantFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantFourMember" xlink:label="edsa_WarrantFourMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantOneMember" xlink:label="edsa_WarrantOneMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantThreeMember" xlink:label="edsa_WarrantThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantTwoMember" xlink:label="edsa_WarrantTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details" xlink:label="edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantTwoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantThreeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantFourMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantFiveMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightExercisedDuringPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightExpiredDuringPeriod" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightExpiredDuringPeriod-n2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-warrants-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassAWarrantsMember" xlink:label="edsa_ClassAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ClassBWarrantsMember" xlink:label="edsa_ClassBWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-warrants-assumptions-details" xlink:label="edsa_statement-statement-note-8-capital-shares-warrants-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-8-capital-shares-warrants-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_ClassAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_ClassBWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-option-activity-details" xlink:label="edsa_statement-statement-note-8-capital-shares-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-8-capital-shares-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-schedule-of-options-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeFiveMember" xlink:label="edsa_RangeFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeFourMember" xlink:label="edsa_RangeFourMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeOneMember" xlink:label="edsa_RangeOneMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeSevenMember" xlink:label="edsa_RangeSevenMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeSixMember" xlink:label="edsa_RangeSixMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeThreeMember" xlink:label="edsa_RangeThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_RangeTwoMember" xlink:label="edsa_RangeTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-schedule-of-options-details" xlink:label="edsa_statement-statement-note-8-capital-shares-schedule-of-options-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-8-capital-shares-schedule-of-options-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeTwoMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeThreeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeFourMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeFiveMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeSixMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="edsa_RangeSevenMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-option-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-option-assumptions-details" xlink:label="edsa_statement-statement-note-8-capital-shares-option-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-8-capital-shares-option-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-restricted-stock-units-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-restricted-stock-units-details" xlink:label="edsa_statement-statement-note-8-capital-shares-restricted-stock-units-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-8-capital-shares-restricted-stock-units-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:href="edsa-20240930.xsd#statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:label="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:label="edsa_statement-statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-8-capital-shares-vested-restricted-stock-units-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual" xlink:href="edsa-20240930.xsd#statement-note-9-government-contributions-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CIBCMember" xlink:label="edsa_CIBCMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:label="edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountNotRepayable" xlink:label="edsa_GovernmentAssistanceAwardAmountNotRepayable-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceAwardAmountRepayable" xlink:label="edsa_GovernmentAssistanceAwardAmountRepayable-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment" xlink:label="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal" xlink:label="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_GovernmentAssistancePeriodOfRepayment" xlink:label="edsa_GovernmentAssistancePeriodOfRepayment-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_The2023SIFAgreementMember" xlink:label="edsa_The2023SIFAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAwardAmount" xlink:label="us-gaap_GovernmentAssistanceAwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:label="us-gaap_GovernmentAssistanceNonoperatingIncome-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis" xlink:label="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain" xlink:label="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="edsa_The2023SIFAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="edsa_CIBCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GovernmentAssistanceTypeAxis" xlink:to="edsa_CanadaEmergencyBusinessAccountProgramMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceAwardAmountNotRepayable-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceAwardAmountRepayable-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistancePeriodOfRepayment-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceNonoperatingIncome-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="us-gaap_OperatingLossCarryforwardsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:label="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:label="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests" xlink:label="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests-1" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:label="edsa_statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:label="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:label="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" xlink:label="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" xlink:label="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:label="edsa_statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CanadaRevenueAgencyMember" xlink:label="us-gaap_CanadaRevenueAgencyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_CanadaRevenueAgencyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities-n10" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2025Member" xlink:label="edsa_TaxYear2025Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2026Member" xlink:label="edsa_TaxYear2026Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2027Member" xlink:label="edsa_TaxYear2027Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2028Member" xlink:label="edsa_TaxYear2028Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2029Member" xlink:label="edsa_TaxYear2029Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2030Member" xlink:label="edsa_TaxYear2030Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2031Member" xlink:label="edsa_TaxYear2031Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2032Member" xlink:label="edsa_TaxYear2032Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2033Member" xlink:label="edsa_TaxYear2033Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2034Member" xlink:label="edsa_TaxYear2034Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2035Member" xlink:label="edsa_TaxYear2035Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2036Member" xlink:label="edsa_TaxYear2036Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2037Member" xlink:label="edsa_TaxYear2037Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2038Member" xlink:label="edsa_TaxYear2038Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2039Member" xlink:label="edsa_TaxYear2039Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2040Member" xlink:label="edsa_TaxYear2040Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2041Member" xlink:label="edsa_TaxYear2041Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2042Member" xlink:label="edsa_TaxYear2042Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2043Member" xlink:label="edsa_TaxYear2043Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_TaxYear2044Member" xlink:label="edsa_TaxYear2044Member" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:label="edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2025Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2039Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2040Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2026Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2041Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2042Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2027Member" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2044Member" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2028Member" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2029Member" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2030Member" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2031Member" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2032Member" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2033Member" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2034Member" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2035Member" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2036Member" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2037Member" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2038Member" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="edsa_TaxYear2043Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual" xlink:href="edsa-20240930.xsd#statement-note-11-financial-instruments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss" xlink:label="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetReportingCurrencyDenominatedValue" xlink:label="us-gaap_AssetReportingCurrencyDenominatedValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetReportingCurrencyDenominatedValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss-n8" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual" xlink:href="edsa-20240930.xsd#statement-note-13-related-party-transactions-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_ChiefExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedRentCurrentAndNoncurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual" xlink:href="edsa-20240930.xsd#statement-note-13-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_AtTheMarketOfferingAgreementMember" xlink:label="edsa_AtTheMarketOfferingAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:label="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EquityOfferingMaximumAmount" xlink:label="edsa_EquityOfferingMaximumAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_NoteToFinancialStatementDetailsTextual" xlink:label="edsa_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:label="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_SeriesA1ConvertiblePreferredStockMember" xlink:label="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_WarrantsToPurchaseCommonSharesMember" xlink:label="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="edsa_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_AtTheMarketOfferingAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="edsa_PrivatePlacementSecuritiesPurchaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="edsa_SeriesA1ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="edsa_WarrantsToPurchaseCommonSharesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="edsa_EquityOfferingMaximumAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
  </link:presentationLink>

  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>

</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>edsa-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:52PM UTC 2024-12-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets" xlink:href="edsa-20240930.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="edsa-20240930.xsd#statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:label="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeOther" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GovernmentAssistanceNonoperatingIncome" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows" xlink:href="edsa-20240930.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:href="edsa-20240930.xsd#statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:label="edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:label="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="edsa_PropertyPlantAndEquipmentAssetsNotInService" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:href="edsa-20240930.xsd#statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:href="edsa-20240930.xsd#statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details" xlink:href="edsa-20240930.xsd#statement-note-7-commitments-commitments-for-contractual-research-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="us-gaap_ContractualObligationDueInFifthYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="us-gaap_ContractualObligationDueInFourthYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInSecondYear" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInThirdYear" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFourthYear" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFifthYear" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:label="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:label="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:href="edsa-20240930.xsd#statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:label="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:label="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" xlink:label="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="edsa-20240930.xsd#edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" xlink:label="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="edsa_DeferredTaxAssetsRightofuseLeaseLiabilities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="edsa_DeferredTaxLiabilitiesGrantIncomeReceivable" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exh37_01.jpg
<TEXT>
begin 644 exh37_01.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" .V LL# 2(  A$! Q$!_\0
M'P !  (" @,! 0            @)!PH%!@$$"P,"_\0 8Q   0,$ 0$ "0P,
M"0<+! $%!00&!P " P@!"0H1$A,6&%:8UQ05%QDA,5A9E)67UAI14U57EIG1
MTM/5V$%A<7F!D:&VU"(C.3IWL? R-#8X='BSM;?!X20W4O$E)G8G*$+_Q  ;
M 0$  P$! 0$              0(#! 4&!__$ #,1 0 !! $$  0% P('
M   ! @,$$04&$B$Q!Q-!4105(F%Q%B0R""-"0X&2L<'A_]H # ,!  (1 Q$
M/P#?XI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
M I2E I2E I2E I2L?RE);8B)BN&0'<J]3!F^AO4WXL?<\JR*N_GC$@$CL=W-
MMN<D35WXD:/#S=99SFR\7YLF%/9ES8PYQV/%K,0(L<CQ/BFV"'V=VK*&%J="
MDQ<<]ON+.,F?)9WW/FNX[VG38>,BA3FYMPI\63+=;9S .1>I/&C9SXDC%9#N
MD&_+9FSXB.:Y,TP*M*GLYRY<R%6NL(&,O-F'CG-SPH;Z6SG'=CYLR7]W=W%?
MKX<\A;C&5[N(JU=_@IGRY4$78<^3&D%M^[+=;EN')N<>/U67OP=UPM-WIKEZ
MG)=PFXLP8L0M#;GE@:^X#;,#HUN'C)D:YT6KP$N]=SR483GNX&YN;K>+[>>,
MJ;OV9$OP<WW<C\B/(AR\\9,5_/(9-S=3(B@2AR)&!U?"$Y8H4I.43ZLS*,:-
M)9CR*LMV/,TL&/+=AQ9.[YX[\GQ\<6\W9,N.SGCGB3\2;MPA*UPQ#ZY$F(>+
M9/4Z .^TZ01:05<776=X&%\"Y:&5WY<EMUJ3!>N3KE7N=[1=WW5ED4S^M^18
MSV4,]2]L@';+E'8,-N/N.^D3AU"U<.&^_BSGNKL=F?-DYX]S_)PW7\7<<<]N
MV.4WP"I4E1K5; WE1@#)\;4#8[<62S&0*)<&*UQ.!=?QV^<2 /;RF37YLGN7
MDLF2[#<IL3+$_ 7Z\<\7<=NWGCGC[?'/'/']?%>:I^U0VG7QP]1>O,G.3.Y@
MN=1A!-AYK<M^:\"X,V2U.A:Y$ADNR7*A2W-QRC&Y\V;+F#J^<"#+FR(LEW F
MX#CGB[CCGCGM\<^]S0>:ZRD<-REY'FIREXLX"MIIN'A;W[M\J/"<H\QOJ3G!
MWOCO?J/EH\YN_=^O[_ZO[WWK%ZF[O-V:L:BO_O"^O]FL4?WHF>@R52L72U,;
M%A!L97G(BHZ-;"7F_E>7#,UY.].*PXL?.3(L,6L\ >R!QV.WCM7DBEB-!;?S
M;CY4=\NXMYQ%CW7UXX;[>>)!S.MOLAT\8+@3[=,3RTUF*NL5WVXT>7AY.!CC
MFVGP++[[?4BA63P8%-O=9,&2^RVZ[@)74KUDJU&N1IB")4G5H%B?"K2+4V;'
MG2JDJG';E3J4ZC%=?BS8,^*^S)AS8[KL>3'?;?9=S;=QSSA);L;&7#A+M-MJ
MG!(;C;^:Y,?&QLTW(^,0%9CYQ=]'GC8$8K;00IBMR\7W""QI$4NMLR<8T=]]
MG-E!G:E1\ ;-Q<;D<+$*R]XM&2G(D)KV\U'LP'FV%!U$'0*"A)4'+$0EC;)8
MT:!(I4*+49O-EP<8;L.;%C4<VXN<,[L=2#4GIX 6\[=MWJ^(U9KF4^H!KU%P
M7.\E,E.3ONR<)PYQY1;&ST;#:-$.,6?(*".(J++%<"92H'(E*?!DRVA.FE5Q
MD.K!I$V'PPH^E%_23 +@E)<C$QVIV9UKV7UJ:KQ-+\O&%&#!ON=8BC]CJCF?
M)=;QP'Y<6,C;QDQ77IK;<V+FZQSCGCGCCGCW>.>.WQS]OCF@4I2@4KH#NEB+
M8_/L5J/R26$RG1*!I0VXT;;M=[?;AZ0W$D36K%0%C!S!!&0=IE,DOL5*!8!.
M0784]]N?)@MQW<7<]_\ ?H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
MQSQ+\6<R84ACV0F?Q+85AH)1+QM<?'6O4=&Y0V3;0]^+&[<HX*8&DK<(8J%P
MG[TW R\F@4HO5/JC'S97N1K)\=3*PVY*,3O=L2-'+P07%&J^&:90N!KN(;8H
MSI+EP<R-S*$)!+:J2J,'.=-FR8^^X<EG==NSGC@.]4K%C1F^('\N3C&5([0=
M!%3D3XL*((:2+U-V56RFO)"7#=AP9+[\>90P7NT'AAQ9>+,F1NN4*5LMY2$$
M^2_*= I70Y%E&.(B IW1*+X:\?MQ6?;C52G':91 A6=R.\TB;C6!XEI#-@3W
ME#YXBA$BD?%_.98N58<&&RZ^_CBN:<+N:[2M"7.<^) 6N1PBFD N++DZ'@RY
MSF3)B# !W.>^SA66*9<63&A0X>ZSJ;[+K<5EW/'/%!V*E==0NYKDW*?9H\^*
M6.QJC@!=R-U.MP93 ,6ZLAK$VB!1!;?RH1HSN5N'[!2C/CLQKK@Y'A/=?RDS
M=SV*@4I2@4I2@4I2@4I2@4I2@4I2@4KKKM=S78;<+.]Z'Q36:P%+RM-. XMP
M#A I';?;CN5+URF_&G2X.+[[+.<N:^VSBZ^WCGGM\\5V'CGCGCCGCW>.>.WQ
MS]OB@\TI72"<E1^&/YFH5>;;0N=-8S,JENYRZ.TXEP2*=.-AA*50KC+RN3)'
MDXVPY ;:5Y\&-,:*M\VA09<Z@4NQX [O2E*!2E*!2E*!2E*!2E*!2E*!2E*!
M2E*!2E*!2E*!2E*!2E*!2E*!6KWU[NKOK/I6[&/!\J+";V<:9LXI'41 Q^YS
M.TNK.YRP9LJRRI5>F#ML4B3C"67&0)D<"O/A,95 @:8SH;\%FT)7R,NRKE!A
M3UO=J<1"]7>B0M771*!X46W6X<0J_7:,5N?&@NNMMXO2<G%9G+?=9S?9PORK
M;.;N,G%]MH;:?3WZMG34V2E>#8GB*<#+?F:5!"I8VF!([0-,YS,QWH[DR?F,
M,[^7(\4:/ VX,%JI2W&TE<I% ;1H,PT6;'.0PB"&=LQN-,2"P\9\2)%A7*+;
M[UER7'W"2U0H]3Y%UJ+'DYOO3I%"M-:KY3]\NL]479,W_+OOYY^!\F4JT"C
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MQ)C0X I'AD%W'>&TH)W%N$F(S8!LRG\Z"[+PH3 <.<THLQ"\&579F01+L9N
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MF)"7FY6[I+L;(HU*U96%.=II7">UC=P4DO!AV6Z).88).C\))W:%"-MFW)+
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MNR86),\&H)%M/.;%Q;&*@V3</+?5-/&9M9*]5@)FC'*)QKFXI<Z% 5)!T9G
M(7*4.7 $<]++4:+7BSW(UQ<OYVM&KLQ/V*X-=&PLW/+7"*GNF79"@QT1[ KI
M?1:-&Z0;I7.I*LM/A;^42P2F>T@Q1K<6(1F9"&..KEMHBUXUY$14!?!5BR]M
MDZ$T&,EW-ION=V.6+&2:S(L$WS^A;C,".-S*>(6C,@4. U"$,LQ7R23CH(KY
MPXSUN>RM.!IJ*.?09J:KP+,\DA&\]^K')^B8V=U:Q^B9A96N#TD.1-FT%HH[
M(V!*_P!N2 IUU*!(583J.#AQUL%G"V3HG'G6CA19=L8Y81C11-J/8E2WKU4O
MC(S70^)=*HP<4X0L>EG.B>)P&$;V<CD;(?.X7$*!K7&<&ATS@<&)MM@>8*+1
MK;")$.(I$T<UCE5OSPV7O'>8F.V2D-G2Y*F=&[WL$,J94CQG1PQ&)(K+/@W"
M.-Q:\V@WHDCS@ ?C)>TEZ RW<;EQYN7$0+%%X1UCSI_Z9P/.P\+$3H,12;D2
M"98;<B:Z"9A=2M)L,PUI1D""DK/!N.EVFW@1=T9DCV$/9,;85B7?B52?>-<S
MK76K@J/#%?0'1/6PIL7N5-8UMOWUBA?<Q)%>N@8C.T]' K/3P1$41IWR9M&&
M),7CCF<S/I24+""!RX7 @N2 1B?G%BPW9Q:6S#7K2B#M;'0ZY#:'$DOB67P&
M$-AV3+.DN2/.LL%6BWE:Q< 92=[RBXW,4;[*$+%ZI<F:#6N!MU04S93A <M.
MYLY/+FJ*(?CV$6V6:4: ;F^".R#*$IF$V4J9-J"+]F:1'-*TDN)42/D"9+*H
M<K]>#A.Y$_*OU".]7\#1*5 )1H4*8,F4I2@4I2@4I2@4I2@4I2@5B'8..2$P
MP)-T1B2",25E.(I)C@:5(69LB 8O?#-,MA&178TUMRC(C0J"F-4IQX+;LU^'
M%?;BXYOYMK+U*"#.S^JS@V3@$'K::(A$;!P.745PN0FD/.\"XC"6"-C8KEB0
MF^B7MBX65!870RHWS@6T<$'D9=$=-\YE'*!*DM67=QUHA.1M< R*$AQ]ONC7
M9A<9PT*Y2JHG;)K%C5(( )F9%!?FP7ZT.H5'RG"X@3=>:TIB<RUA860*<N$\
M[ SB>SJEK2@J\<>ETSEMML,XB'?%+2"<RZV9&7R0R SV8DZN./V^W! 9;K])
MX9J'1L5S<V#5P]:)1R))J H=:C)7"!@=J97FSF](.''#4Z3;):&G++U_#%E2
M*6RT#1!K3-<S*'S)CQ6JH?2KHWQ[)-.'4,AN!U#XL#S"W6:4$H #4#-QLHE&
M9JJBH16E:(D7AN*I05$\],2U<N:C'>D@E);@AO;E&]M%(21RJ^Q_+5#UU0FJ
M%'HU^#[''LY GX53#(XF8T"T9@$W7Y%CS2D;<RW.ESD>@CND&"*#M:F8]G?8
MC:.I[4VN"Q(YHQ5EF/(6%[2O/NO$S0+.#KP(\?@:_)<C>^&%IZ22#^#.YKRC
M,2E%*1ML*UY->,&7:4H*A7-I/M2_I78\I.I_0$#?R0K!9)R3G&3=D2.9C;HZ
M)2H!:]8\$<-0X*"3)$\RW!7&03L2=5IT5$:B7'X#YPRTW1H!+=;U2E I2E I
M2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I
M2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I
M2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I
M2E I2E I2E I2E I2E I2N&<+C;[2#$'&Z3@AMM\5AX4%#AXDC$!QJ?G)9BX
MSKR1#,G1(\/?<F/'WU1GQX^[OLM[KNKN..0YFE8&\:C6+X1L$?2['_U@IXU&
ML7PC8(^EV/\ ZP4&>:5@;QJ-8OA&P1]+L?\ U@IXU&L7PC8(^EV/_K!09YI6
M!O&HUB^$;!'TNQ_]8*>-1K%\(V"/I=C_ .L%!GFE8&\:C6+X1L$?2['_ -8*
M>-1K%\(V"/I=C_ZP4&>:5@;QJ-8OA&P1]+L?_6"GC4:Q?"-@CZ78_P#K!09Y
MI6!O&HUB^$;!'TNQ_P#6"GC4:Q?"-@CZ78_^L%!GFE8&\:C6+X1L$?2['_U@
MIXU&L7PC8(^EV/\ ZP4&>:5@;QJ-8OA&P1]+L?\ U@IXU&L7PC8(^EV/_K!0
M9YI6!O&HUB^$;!'TNQ_]8*>-1K%\(V"/I=C_ .L%!GFE8&\:C6+X1L$?2['_
M -8*>-1K%\(V"/I=C_ZP4&>:5@;QJ-8OA&P1]+L?_6"GC4:Q?"-@CZ78_P#K
M!09YI6!O&HUB^$;!'TNQ_P#6"GC4:Q?"-@CZ78_^L%!GFE8&\:C6+X1L$?2[
M'_U@IXU&L7PC8(^EV/\ ZP4&>:5@;QJ-8OA&P1]+L?\ U@IXU&L7PC8(^EV/
M_K!09YI6!O&HUB^$;!'TNQ_]8*>-1K%\(V"/I=C_ .L%!GFE8&\:C6+X1L$?
M2['_ -8*>-1K%\(V"/I=C_ZP4&>:5@;QJ-8OA&P1]+L?_6"GC4:Q?"-@CZ78
M_P#K!09YI6!O&HUB^$;!'TNQ_P#6"GC4:Q?"-@CZ78_^L%!GFE8&\:C6+X1L
M$?2['_U@IXU&L7PC8(^EV/\ ZP4&>:5@;QJ-8OA&P1]+L?\ U@IXU&L7PC8(
M^EV/_K!09YI6!O&HUB^$;!'TNQ_]8*>-1K%\(V"/I=C_ .L%!GFE8&\:C6+X
M1L$?2['_ -8*>-1K%\(V"/I=C_ZP4&>:5@;QJ-8OA&P1]+L?_6"GC4:Q?"-@
MCZ78_P#K!09YI6!O&HUB^$;!'TNQ_P#6"GC4:Q?"-@CZ78_^L%!GFE8&\:C6
M+X1L$?2['_U@IXU&L7PC8(^EV/\ ZP4&>:5@;QJ-8OA&P1]+L?\ U@IXU&L7
MPC8(^EV/_K!09YI6!O&HUB^$;!'TNQ_]8*>-1K%\(V"/I=C_ .L%!GFE8&\:
MC6+X1L$?2['_ -8*>-1K%\(V"/I=C_ZP4&>:5@;QJ-8OA&P1]+L?_6"GC4:Q
M?"-@CZ78_P#K!09YI6!O&HUB^$;!'TNQ_P#6"GC4:Q?"-@CZ78_^L%!GFE8&
M\:C6+X1L$?2['_U@IXU&L7PC8(^EV/\ ZP4&>:5@;QJ-8OA&P1]+L?\ U@IX
MU&L7PC8(^EV/_K!09YI6!O&HUB^$;!'TNQ_]8*>-1K%\(V"/I=C_ .L%!GFE
M8&\:C6+X1L$?2['_ -8*>-1K%\(V"/I=C_ZP4&>:5@;QJ-8OA&P1]+L?_6"G
MC4:Q?"-@CZ78_P#K!09YI6!O&HUB^$;!'TNQ_P#6"GC4:Q?"-@CZ78_^L%!G
MFE8&\:C6+X1L$?2['_U@IXU&L7PC8(^EV/\ ZP4&>:5@;QJ-8OA&P1]+L?\
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M[%?^[ZA_C5)?[8IX,]BO_=]0_P :I+_;%!Y]KJ[& _"MJ=^47(_O"T]KJ[&
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M _"MJ=^47(_O"T]KJ[& _"MJ=^47(_O"UX\&>Q7_ +OJ'^-4E_MBG@SV*_\
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MMJ=^47(_O"T]KJ[& _"MJ=^47(_O"UX\&>Q7_N^H?XU27^V*>#/8K_W?4/\
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MY#0I OL4)[T2Q<AP)E5F?#=@R9.,EO//ZW/EE6//''-[P:ULA9F[>[\3#N<
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M_C#ZM4]J^Z<'P$-2/-_C#ZM5-,\X0#5%*#KG.!VX$1WI<:LP>)H@XI+D7+,
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MC_TSZM7\Y-,__FY6J[8)_P"M+V,3_P!T.1__ $C-U8ET$?\ IGU:OYR:9_\
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MNR64U%8<<,RQD:0!5:<D;;AEP.08I5I4%HP0.C6,V.E%X/R-Y4";6'_9<?\
MU 2FNP31P;=&JEJ@=?H_F]PQU*J9[LC$U,LHIG\VX4:;FV#/R*1=*'""-7-A
MNH\5K55HT)^\!I,]HL%OCFFQ&LW&4U0^*_"(;+2!C&XWQ>')ER9\F(<&#I40
MY%COSY<N:^Q,FQ6W9<E^3GCF^^[GGAD,5Q@,>AJ2!L<,,=(;E0V"W&_4+0;R
M-YGQN.Q/CQCS;H3CL9PJALQI4N.Q(O79\%MB?!;QCXMQ6<6A65TZ&^V8AUUG
M;=&397<KC&SK(,Y;".5ZR(@C3!RWXC:SV?"%BN+@TQ8[918A88A-KL4Z>M+J
M2@G%F1)K&<$:@OBX3EA5#3JE1?N5K)MA,.L.P43.K9#8V3VF7DB1>86]CT+
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M D,6BL0-\\S:YWP06G,#B= ^X&SD8HD@=:"TN&QR$=*$\5=HA*/<J/.S3:8
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M0S\AA)&59+62T54FQ^!=SR(6)40TG=;R0SK@DC,&\NMD%/I7'LC/!PHC($2
M/O\ *MZ-9+?#+B  ZU:A"U3DV/QE-(^SH?$.-2D5W"R$B&FZEO0)LQE3D3 [
M.25>Q(NYD11Q*2F&U "<WX^QH)HN,ZCAO76;YG#-86^UAQ$T\CO=,9,1SMIJ
M9S/+<+JTR9P%1V;@8EY*Y;,8^[A34#9XF^.Y\V E#3@T'?,/1 YW&V8WG9X
MM=9O*O7;0T9'B0"R, ,B,V-B+*:$/^L.=#'$A2LZG/G<)<1>?9[.PLMOB[)"
M6X:F!K-XM-TMJ(78V\3)WZ<VS3 3-.].4G-! X&/&$98K"'R^I*MU"#U9+0
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MZ\1;RZ"+@)AL8,^4^FY(;F#LN/Y^U=?3R<"KE$!:3-V$9#G<YM9QARJ+DHD
M$?BXL24VX,.;/?@1I,V6W#ARY;K.+,=]UN=W7%FO#$;IAX/=$U&<TFZ@4%7
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M+=0'L7H9HSCZ_NAD7X],-3K8UD73;;!\R!'UNNL/VLA]/42=&Y!;P>+4M9W
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MJ;.8'LQ'!4Z5SL1M(5%[.PIFTDPNMV >$:=*Q,B@F,(6HL0?/QA":!KK#:$
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M?_AZ[!2@Z_X)M;R; _- _P#P]/!-K>38'YH'_P"'KL%*#K_@FUO)L#\T#_\
M#T\$VMY-@?F@?_AZ[!2@Z_X)M;R; _- _P#P]/!-K>38'YH'_P"'KL%*#K_@
MFUO)L#\T#_\ #T\$VMY-@?F@?_AZ[!2@Z_X)M;R; _- _P#P]/!-K>38'YH'
M_P"'KL%*#K_@FUO)L#\T#_\ #T\$VMY-@?F@?_AZ[!2@Z_X)M;R; _- _P#P
M]/!-K>38'YH'_P"'KL%*#K_@FUO)L#\T#_\ #T\$VMY-@?F@?_AZ[!2@Z_X)
MM;R; _- _P#P]/!-K>38'YH'_P"'KL%*#K_@FUO)L#\T#_\ #T\$VMY-@?F@
M?_AZ[!2@Z_X)M;R; _- _P#P]/!-K>38'YH'_P"'KL%*#K_@FUO)L#\T#_\
M#T\$VMY-@?F@?_AZ[!2@Z_X)M;R; _- _P#P]/!-K>38'YH'_P"'KL%*#K_@
MFUO)L#\T#_\ #T\$VMY-@?F@?_AZ[!2@Z_X)M;R; _- _P#P]/!-K>38'YH'
M_P"'KL%*#K_@FUO)L#\T#_\ #T\$VMY-@?F@?_AZ[!2@Z_X)M;R; _- _P#P
M]/!-K>38'YH'_P"'KL%*#K_@FUO)L#\T#_\ #T\$VMY-@?F@?_AZ[!2@Z_X)
MM;R; _- _P#P]/!-K>38'YH'_P"'KL%*#K_@FUO)L#\T#_\ #T\$VMY-@?F@
M?_AZ[!2@Z_X)M;R; _- _P#P]/!-K>38'YH'_P"'KL%*#K_@FUO)L#\T#_\
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M&E2*'()9!YO2.P3H*35]PJ-S8=W@"0B02F,.;<-XYCDT1#,C=A#& ;+C.WI
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MHT3R7A<#=+3-#7$W#2*Z^_':L$FQ"E8,(I><F/)9PH1JLV'F^R^SB_NK+N.
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M4I&_:(P#,@I:H0+.,2&X,%Z+/.<6'TG--G9@B1\SI, _5_7[O47XW,S&4_7
M@(-AJHT7))P2J?:;>&F@3,5)3)^QWFT)Y3F&+T2SA4Z5'*91W3>,@HDGIE;+
MXY?/Y-,\DGZUOUG/YS/-"GE3B 4\C-]8RS)AT61.>*##B)L)3N147--YQ*
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M*N!6\!LN#)+');AW9 %]P3F2['QQE[EV<.WMZ]H6\\(T5C1S'WET\;F,VMQ
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MMHNC3M-/$-R5B9D//2?GTL;Z*!9RF#2M_LYT.0HI#9B[.&QC/LU02V4RLP2
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M4C4)\.*]?ML.G[M5<XX&@=V1E((]"()2(JCG'')AOM%WM16^+LI>36*/=S.
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MX)F&+L\.9NW<Z4<HD6.*G *$G@CAC=ERZRDAO22<]@LC:CV= J9PL]PX_6Z
M'U8R.9!" 4:_D22N"'5F$*FM*C,>0;BQX0J@U\<H1CN^$BKP=,*7!HPZ_P#(
MJF391@1<F$Z:H34P],*;FBSAD*9%RK,F9@V]X29'4<2(U2!XZJP[0N)^WJ'
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M6=LVFX('VV9DGII#=#CE-AM'89H.8HN6/=2X[>56K*Q[Q4-="1K$(D0,>3+
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MW(6E>F$RM!_1^1BQ[,"V/)CEYH0/K_ FJ3XY.ML(E'NQX;$XFWA(,$3<5Y%
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M2O'..SFWN>;>.Y[?==K^#M_;_P"/>_@]Z@KQUVV[UAVQV5=Y36("V)I&-&'
MXYZ;H,% #*,+C.L>J_,V=<P,H8$?JA^$4EUKKD)Q VN8*MQ@9<@KD_:C//%#
MAXR=OS ;BV2U+F&-&"IP"Y<P!$$AP0X,U]N#EL; 1&;&RC!KBL6]SSE0V"I2
M:35SK%*>ZS+P-]6X>ZYQYLEE\P;;+;.WW-O%O;]_M?Q=O\_/]=?USQV^.>.?
M>Y]SF@U0W;?*74KU7W&WZ:[+D=DYW9GT2BZ'6=E8/+LD]HP%JM.L.;);C9VY
M%3A"D$CS<KDD G+K-RL!>&,8I3Y@ID %0U>F7I4.7KKR78GDY79)D"/[87>C
M3N#7=H3/4]R%*+#./F4\A2'MHUKQ?<7,%W98T8[TE5JQJP56'9!U0<E&NX>P
MG.V$Z1J# 1R0%K;NVV^,6.WCFWBWCCB[CM<\?;X][M?VUYLLLLXYXLMXMXYY
M[?/''':]WM<<?[N.../M<<4%:$8[T:=[8;-Q0WM9DK2VD=3894HE75L%'XX0
M?;FK[77)6=B5L]PR&K'<YFZ]Y@/<-@7S$P0HF>"M TBC@=P1&(:-EU\;)_G*
M+]0M\MLY!V9%.C*QMC-(M<V?!Q)!&KOD9#(9R&WSMC[)VNS<L;K=/<9G\:SS
M"P#X>.,MF#E[8'?RM$X2>86XN!MX-N.RSM\VV]KM^_[O/_OS7FZRR[GMW6\<
M]KW/=H-3%J:P;T;,P]#NO3/:$(>N.C_3K@S4=T.[8Y^28US4=[K/R)X.EI\2
M7&MS-BN34;N>$!V,:#L8TP65B[ KP4/,"FS*>5)CA/*2?-LX(G[7!O)IB<&P
M&ADM[.:Q A;ZG>)8(#/HH^7(T"LO1W+.D"5WVQU)SM*G8TDY4\E.&/Q5D?2
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M;G^:E/Z%3$UMV2/RSKA@G*<X5?FI3F!)WE;*L6R]RFY(1ZLC]612N0DD<Z+
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M?T*>Q!*/D&Y_FI3^A45Y<Z]-D4:/2;M.KU >9.6X(W/*:,39K5BEEJ9,[=F
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M8L6&INCQZXI1OPR UV)D4(9*%VF,AYO$I3"O+-C=BEV(FHH;H5P"TQA:VO,
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MHY!OP>8EHV?<,H'H2'P8$UZG,GLOCEYI-O"]'C'Q/7A/']TLAS#29*A,]#Q
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M3;2/5R,W-GAZ26,\9*D2*MG-B94DHU$[)?K,%O!P-YC!)L:**YV7M+("5N=
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M5S&[9@T2,*VE*=D4QG);W6'W2X8UEDY@D]Q(,0&3\@@D\PYTDE.H<ZNP/1U
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M!'F?]APFO*N#,CI;9PFVIGGEE0$J=0J]'ZW1VX))'N!,P#[KQJLN'+RWG-(
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> I2E I2E I2E I2E I2E I2E I2E I2E I2E!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exh37_02.jpg
<TEXT>
begin 644 exh37_02.jpg
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M(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\
MPS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X
M /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^
MTZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O
M(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\
MPS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X
M /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^
MTZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O
M(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\
MPS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X
M /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^
MTZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O
M(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\
MPS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X
M /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^
MTZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O
M(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\ PS'O(7!^TZ'X /\
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ME27\"Z_VL>IIC[*DOX%U_M8]33'V5)?P+K_:QZFF/LJ2_@77^UCU-,?94E_
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MQH%9E&T_K+I&ZK#6^:J<B#9][>5LS!6QJ\IFK28VPRL" 1K/MVEBZ+859!(
MY<P/VL;-Q,@XBI)9"32GG9?RH^1.F"KR<6+7:FN7?6?Q<-:#C.H!.UL9D-IW
MG.;#4%6DH+QLT5LC^*C14;K>Q#3J7DLY$12<K/A_SX\W:,W4?WFG'<CGD>\O
M [5^X(ZO40[;]NA>O53W7KF=V10;'4.-=E!I;4>!6)7$I6I;L<5H'R,$(/Y
MYI2::G 8I:CX6E0YSU3('+=ETZF \J7D+GM2;XAJW63M;=2G-AZ""#H%L/2:
M:UKV2J.C;OC99_R6\:EGFQG<(O>V'+P7)6=0!%7WSRQ.(=!O)R7?JNU==7.Q
M;0W;7:/<G5AZ_#K<JV0V1IW9YM5]]<6[JO;FO$V,@T#*CQ(4@QO0\R>3\F%W
MO)5?/-'#*3@38HK-A/23+NV5F6C)]T5W3=>>>>O7GG]?/7CGG_KSQ_TX_P#I
MQ_TSSC&,8QC&,8QC&,8QC&,8QC&,8QC&,BVV:5K&\X<7'[5%&A?#A=DUW;PR
MQ>/)1FG%6-4Y5'&]>DZ7>*?,%EG0R51,;,M6KI1>-<KM$T9%D\:=E6_>%@70
MW4>M2X<.@2E!D9*A*\;EV4'Y6+>$"7:/O'803E@6XK#X:=IGNP<RIL(SDI O
M&3QJXA8YBXZ]8.,BU&K11O#]8^)#QS4M9K*Y:EU6KZO+*C)<PF(DI$G15#.(
M7M8$(2CIC"03)D0I14&%ST68$G1U7\0Q9 W1_**3+<=1F46S]'*8#QDZ,# Y
MT$H&@8"/'.FIQMHSTBTB(Y41XU1L>>5)C:G/G5RE9SZEGYU=60<3'S_UK;J]
M^4V,^V0]"7$A0>CNJXY(DLK#5'$,GYCK<+:BDCCI,E*G,IKF$L9:,%JP4Z+S
MRO1**AV$[+-D)1OU2(U>CU3LZF5U.B7=/49OWX-.^R<G4$=0$[JQ7=85#K/'
MZL@H+>6N1+;,K5@;$]7;&((*]L$0N&L2HMYA83M$-XFMKZ<6S6L?-CZ!4QAV
MDS+SBK[:,+:!T$VT4J[Q\69#.[@H6NJEJ2I9&,*)"3A7!Q&4^W&.\ ^(5!.1
MAG/3Z5-B<5-/HMF]Z1JZB?,<Z2=QO=9NM.UD:^4];A/31M806R("S7PW<V+3
MA#R^EHJ3!B]\.2HB_DXUQ"R$=RY;20U-R</)PLIP_@I1FYZ]9"-==F[;LC4\
M;\2OCH#KN:;&BNJ]?#MT1EG+W)#&L,X)H]4>L=[TE^LH1#,&WG^@R,\3RLX_
M>$T1 PT= D\GPPEB&,DY.)BG;)!>)7QTC%X-MD1S5>O8*ZF-G>V6)-XEP3QZ
MT%9:JCU>0*1N#:D"0R-.)YW(+OREA 0T=$%LGT92A-'RTA&1CEG)+GQZ:8/]
M7%=+).@ N8U@4EYZ?Z5--]IJ:AV<^2GLS9\O.1LK*2SLEBYI4^(9HF9RT?-M
MI&(?R"O2(<L6O5%NE$ZWB"\;2].,*$[ZG5WUK.+L1[;3%D@[+&I:WLV2C$H6
M3.O:@V(T;04)Y*%;MH61EUC%1X^A6C2(=JK1S1LV2[(P\2_CH/*>J>A"75.N
M%*LHSD@[5) 0G8B$9(%[EW''UR5A#(1G(,XZ*FRG7HX-UG!(NH9O.B;TH[2S
MM/HMQ-@EI-JN!S&MTV$TN)"+[4,5L *UQ3&>DA!1M6#%JQD)#V)&PT)&/VT*
M_P#K<R'HKF7?3T?+2*SU%>43>)2;]^\<VHQC&,8QC&,8QC&,8QC&,8QC-6SK
MPK>+^0L>;M>7U,$)\R)K)F[?(^"<MLTG$"&R"(A<EDR43E:$!O)5K+.7Q([6
MF>[)\(KQ:;WYE5!BE]';\)2G?WB^T%VEM6*NR_\ 6*N;-M"+BX:$[E$XC,-^
MQ!"CCY.3@(<YAHB6C1ZQ(F%>I(K1D:>Q)(S8]4DD&J*3=/HEURXJ\?VH!M+6
M;.%%*P<K*7';%-7E93KO-%K;ZTVKKZSA&%.F#I!B0MF[)V#LQV$0CV,2E'Q#
MWI'I<S$?(\J+\JR+'ZK:_16RDON"QK >;;*S]6-Z4FK;3^G]2.2K!I.-"1N*
MND>'OJ=1%.8CX]QS)^K.)M1NP8QRLGWC6;9HE7X3\5GCU!;RF]D0_5BM8"Z)
M^5,I]X8QZ,SU2:$=A1[J*."<?%E)=0-%"DICGSQG.$PL/0T_(H/'?1S(J?2E
M^5(EW,\;2]N>/9+QPZCD-7ZUTA.LH>L"I$P 26X>HS0W7O)R,W$U@PD#V$68
M60@0\P,J,E19+$+*)Z,Y'YJ/1EUXF;AK]"E"5B'4! ZQPP_PWIP=J2/H^/&&
MSMW%<]*YCA!(%1A4Y"$6C)!BIV'$N&GK"*<L'R"G;ETS<-G/5-7I@$]I9K 3
M:TB>GTS4D(YUR!(BM(0.K5*1(V+0<8T]+C\_6W:*((^::EK60%9D6@I%G,])
M_P!<.73'E61?O>73WZ3"&Q/B;\=FV-D$EN[":KU[9%BF0Y'"Y>32"Y/$N"J,
MA8ES P+DD9#D_#1<X0#<,Z[Q8P72C%T5C+%)HV@9J.3CV'5KXV%\37CMVLL*
M;M;8+5FOK)L(F%H\-)262<$\4X)86&BG<) ]R-F.S\/&S\Z-Q+M1@+E<NR>%
M(NV18IC\S&\1K#Z-/L?I[K1&N=BG'2HA5]QMJUA6.QK&<Z/R*(MIB/ 3:KH=
MB3P<\^DH;LR: #-L,=V<>P8M7C%/E1\DY>**.>]>:]\1GC<JVMK=J$-U&JQK
M7E[P<",6L/S;><,>2T9%'O23%1Q66,IJ?G(J %)5-"8%8:"DHN-&9EJSF(-L
MPDV31TC^8;Q%^."!I@VU_C]4*[[U=8QC V$:1LHX*9PGG3H50[-10N7LJ;(9
M"S&Q"*M5G;06E6)>U=C321EFD$K'MY>23=9R+>-?2 (IB!U\$M?!* J(<MX>
MOV/%(Y\3(JNKG%2-D60-DD)+Z]Y+2TJ8ST;&N^9(KG9KN\;QL?%O^'44R;,D
MKR<<<<<<<<?JXXXXX_Z<?HSSC&,8QC&,8QC&,8QC&,8QC&,8QC&,B>[T[L6K
M0A:Z[JUHUMQ[S&,1B3M_J3.*_@TWLLQ:SA!-18ATXGR): 'U927AQ9I(CJ)3
M-,H^ ?EHFPD7)%&Z*Z0MO9[8NE_&=0A3LU8H@8[%S.[1;?\ ?]91@<,VB7#^
MKIZ2#\.)AZDY &$!7C$GGRD,<R"\7#/I*/$Q%P+Q<HVYE5Y'MPZ@LW9K92\!
M#Q]$FU]S!+*CIWR!.+0V#K=&M1J\KR'];;>UYKR@HF6GW%?2XP+/&PQL>VD+
M1DQ@/BG!T55_'.T.\/$S<W$N[XZVVULU;GCEMV0@#(<)]MZV=;P:Y@=F&T9"
MP@R:W5K'<UX:\5G9AQ#0S2.@(MB9$5;#)<91L8P8Q+?O)RR+!DU8_,-4J.ZB
M6;+ANRE"!]C79Y-:%N4U4F!.RJ3\B@MVL2D]F9A.O267E(F@+C">937D.M,<
M*X5N<CS>H;!BFD^ 1A/!*5$_:RD9("5/-7-DK8LNDM9#2F-N_(W<^[9R<5*F
M9TV74E8,UJ>_@)>V8>-NM(I.YS68=KD7K2!JCDKDVM@#-Y(RL/+,(;D5FYF8
M<MH:3V(JV1NBC9??Q4ID9WVM%]-*VXQWL[=(/N\:^/3DM^2]F%GW+7EMWV^C
M9Q1+69HW^K':+72=Q^QJROIZNACBY^_A[:(P.ZMT93Y])U.1;:;1B>N<O<44
MWBI0JK4 ;5/<-Y6#-B7<IBB.%2/B8-I&8KL-GIV&F&\&5FT81=FCEY'-^O:N
MMW#EY>->EMH;_KG9BQ;Y (?7N;E FI-KB.5MR;$M@V\O&0P>=15K+O(HS1IA
M9"<Y7MD#EE"%9MTC&$P"2PIT]:1,MC6QE27;HC23C<<;W4V?N:Q:GF08CND*
MNDL@":F[X#9@V'ARR12"IZ*&((7IPA4A)R2=U ZJ+ZG=H8QCA:/,%C2#<D+>
M6R@?ONX'GCS\HMINCZ;5L*FK.\JT36!5W[M>9,+C:5,KE850SB.W#;A#JB%-
M("%;POTA%?GA-@APX[..?E\]]=6P&V$B,WG;<K?5^^2\,J&J=)](;35?:4"R
M$^$"LO9<'<KFT#.XI?O7!A'C"DRY&!QTSE)Q_"PK9C%D$B\41C8]ZY:V V,B
M]S4/#F0;6VELSLK2>T]#:K7?8[-"O2BJ1CJ9<1+HH(Z;F[T'A4/)PJ0L3M6[
M((5L2.KV8C15J8/BMC!N58[AFXZ;LJ!I![1(O+#3ZZ[PO164GUYWH47T601@
M5QB:\=%Q_$#%R(^)A[1N/M^T;VD&[)6.<..DC)2:_9[W3<)H(3MC&,8QC&,8
MQC&,8QC&,8QC'_W_ /?ZLU0/#_;Z&\K=)U[8I]7L=K=9^MFZ1+7M/U]$3+F5
M4>4J?:718_9%L')#]$[RYC)M+@(VD4%B@[#C0%'=GC90BL-_,\S$=K3;[7[1
MT;J?J1Y22+8NR[7[;:L#XGL?6 I:5^A1HF,'NLU]; 5#"5/%PP9%E@C+5+)5
M>"BLC,.329<G\0\,WQ(HZEI2-=QMT=;)+8JC+VT2967M7;.R,7O10UF35K#=
MEL:Z;#0/=(<! 5QQI?3+0. Q:0"0E:.E3X)<5\\DYYEVCW89(\/.LI R#N8X
M'D!D+WC]E^'YPT\ATGIVWIT1;!;OQJO$')F%7=V*3Y:RIN_ T'>=M@B^,<A_
M:LN*K:@@^8@R79J<HE0F[G7$(ZXI>3[40\X9:.BYQY'=N)ZDBO4[;(G=73JM
M39W%VE:-C5;LK3=<A#2[*Q :,MLG$SRO@2>*PFVN9(#K^.[6Q$3;IY !#Z68
MA3.PE>6YN/65!3&Z;HVV$M:@]9[SN!PH'7I7R->7=L3XXG0B!24G;<Y7TJ%U
MU*-KRH@P96&65#(RXP!SMOTJ+.(8I8/":PH2>:;+M()*\K-$3'9Z[92=@DMC
MI&'-Z6HE^HT38T-0*,(ATJ^$G&C/IWX4MXXBW2UB7&Y4D'Z$,1D;2O8E7O&
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MG3 HFI:4=.WK#U7:PIUK"R78FJ]GVTT5BMGUD(&E</5AAY$M(>T*T-.&[_N
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M8<^2S- '6^4V=NXJ0:5V;:_O#12")VZT@FP.!D/0B7C#ZG]/-E$]MZ%'KQ1
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MAKZ))2DT'E3VMTK3K7JIFXI2.(.*Z=I=^2.>MCJ$]IF 9M)!%K6DWW02Y7M
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M737?]FZ#7LY[=GSETIU[\MVR"7/'3OUZ?)3Z\_)^5SSSSG^,8S2OX\9F7?\
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M(]Y/-U[>HLOI?>6$I<DN2];!U&LYP<RS0C#Y^+UR#;[KB)B*4O:!/F),RK%
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MO,M2NEA)QTIHP@KQWX(N>5K==MAQG:OUCX=--67CFM^B/)@S;DO:YGDF4D9
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MVAV'.S [W&)ES+G:\G+';FW(_2.RFMNKYIN?$PMG5?/ZIVU>5_4OJU<EQ\6
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MET!R3EW3V!3B7,V_5?237NMFFVKI-5*X2/!M6%875UMU?6*<E8$ZG+/:_,S
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M;P&^SJM0UQV'[I[=%T^]O0G96%[\Q5H=TW3I/L?L>4"OMT<N.G,M\E93CM(
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M;-^'K1?YE/Y.; VI>K%8A?%;5MK70=?5UP9CMC<  13]>B@3Q88@00Y:)GG
MK!#S""^N@N5#H^3#I1] ]>0A#!0TU&OFTE%L7*$K2($#2Y@-V%*AHK)GP;&$
M,*(&\@/Q+PN%(8NYB.Q9$#9(X:*3$'%E'8?@.Q''Q;QJTG.T'#]I-%US&,N4
M(^M36C7*]9H1)+MH&E;A(:_<]WH'.VE5H/8$R$O5%4UU'@C)E<%+/1MUW711
M6[N(==FMV5124Y[_ "T^G;B1HX)#8@E(S2*$QJ,,3"/'HDM+8^#C&9.418CZ
MWY%(TBGV[9.6FV QR03W(\TDG;EO"\S<OS&IMO63SYZ(SC4K5:S0!C5%DZTT
M#856QA/,&\;6IQ3M>%@!'FA#,31#/%[$-GQV0'6A/-SY(1SLO/MXY.5DIF?F
MI1Z[7?2KY=><8>'B!Z)C(& BX^$@X5@TBH>&B6;>.BHJ,8()M6$;&Q[1-%HQ
M8,FJ239FS;))-VS=)-%%/HETZ]>.RQC&,8QC&,8QC&,8QC&,8QC&,UE^3M)6
M $]2KMF!XA*:IUHW<J.[[VB!B!E2N29U@Q"+7KU(Z6%H)L_FYV)IZQ[#KVZ)
MQ*(B9>0BXBO'I WC^W:(Y<MH(LSRBZLDKFQK:U%"!O;<XJ#6TY6:[!UI$Q,X
M*C!N>&=>"]+:K(VBDP[NWQ5?]K/H!>6 QB753%F *L1';6,>(C:+R'-(JFVJ
MT)V3I -V(%Z"0!-F*88Z]SYU0Y=8A@Y--HJ>ZV/>L9;UM(FE55RP&R6[H<JO
M]2=E8QQ*\3Q6S#!]=1/LW@TE]8 U3UJZS^,O1F2KT&*IFD=T6_B];7L#1D?(
MJNJ2VBKO8/6F<C;R[0'"?*D4)W'6X&ZKVW^_#='AA8@=5!%V;\."LTD5+IW5
M&[I6R?;!>2.HZLHXIK:B;Q&B"D9 F+;&C=DI.E/'],VN%6N*52%1]62P;+(;
M(\F>VL*%23T[A^Q(*VV*NU$^4XR'6=6.J[?C5"@MSO(@06]::0BUN0AU)LBK
M&WU-/R22/A%[I]5"#60$XH3%9Z1GG#EYS] ;Q<8V<RKF1YZL6[)5WVZH]J@5
M[2VT=S@FN>I(E052J#%4H;9[C6_2&U,^;UZ$B(/NU=&U QJ%1$CUKVN[&<-S
M*M-?K#L-0AKAW$Q[8&>Q(*HKWCGL7#MU-VOC:/;**-6ABOKPX2[7UK3.3^KU
MUOFJKYW'DAQ2KA(;96%$R,E'Q+R3AK9!?J9;$2]<148NHP.$$W,>R<IK-4;[
M8QC&,8QC&,8QC&,8QC&,8QC&,8SQS^KG_ISGSQ4+N7J5IMK9?&HFW'T;G88:
MM[<I0IUI)0F1)K*W,:7+>%N6>*SM1@SR)D5-@8J_@(Y'4U.L"D1QD%(2T@#F
M:\8F.O>$<1V(JK<7?:RK'2UYIS7>MQC6F@ O7,%:7H;EPV^H?:TG:TSM&4E%
M0)5I59T&E[BAYP6UJ$8^4Z/Q^%8F-<F0_$NN8U]*_1/)H)2_D>V'U?NH6;S-
M+74U\:I7=5-%LK'R/"VOVWH-L?4?7D5)^>J:?:0BHDD2.*EM@4X6Z<&M8R1\
M-\=OH4URZZ0!6-B;'[-53>E BE&Q(-?FW_E//2&XJIO*0)H*N1*L-7:2U9*=
MDALI,A<3+Y&8KL[L4,@-?80B@QB39G8U:?$PRY:,5EUFN?6J06I1FE6T6M.R
MX^#A<WKSO-H+L] =*C>FAE5L9K'>_DQI"['?82FB +$B:4BZC-!^\1N7C?JJ
MAP'!XZ),D>G>)[QJR]C]@MWJ5M:^*)VEUJ2G[J!-#:RVWMR]K"$0LPBH5:&+
MJ0<!U?ZWCA+/C<2W,K$NFTG05/Q(*+.)MPR5K./ER9E&J+"JK["]1JJW0TEV
M%UC.-G K7I@-[.11AKO>AA19G8Q86DFPMG&EG;; -FVS&D]7AT..PS:TR*_J
MXBTX4A)&;0COX>A.COF-8,72_P!&.,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC* +1WD2^>6^8GJ=X0^=4^9X[HH?
M+X2^7S\WQV_]S<_^+Y'H^5^GG]/I_3GJ]7>1?[?IO_10^"X]7>1?[?IO_10^
M"X]7>1?[?IO_ $4/@N/5WD7^WZ;_ -%#X+CU=Y%_M^F_]%#X+CU=Y%_M^F_]
M%#X+CU=Y%_M^F_\ 10^"X]7>1?[?IO\ T4/@N/5WD7^WZ;_T4/@N/5WD7^WZ
M;_T4/@N/5WD7^WZ;_P!%#X+CU=Y%_M^F_P#10^"X]7>1?[?IO_10^"X]7>1?
M[?IO_10^"X]7>1?[?IO_ $4/@N/5WD7^WZ;_ -%#X+CU=Y%_M^F_]%#X+CU=
MY%_M^F_]%#X+CU=Y%_M^F_\ 10^"X]7>1?[?IO\ T4/@N/5WD7^WZ;_T4/@N
M/5WD7^WZ;_T4/@N/5WD7^WZ;_P!%#X+CU=Y%_M^F_P#10^"X]7>1?[?IO_10
M^"X]7>1?[?IO_10^"X]7>1?[?IO_ $4/@N/5WD7^WZ;_ -%#X+CU=Y%_M^F_
M]%#X+CU=Y%_M^F_]%#X+CU=Y%_M^F_\ 10^"X]7>1?[?IO\ T4/@N/5WD7^W
MZ;_T4/@N/5WD7^WZ;_T4/@N/5WD7^WZ;_P!%#X+CU=Y%_M^F_P#10^"X]7>1
M?[?IO_10^"X]7>1?[?IO_10^"X]7>1?[?IO_ $4/@N/5WD7^WZ;_ -%#X+CU
M=Y%_M^F_]%#X+CU=Y%_M^F_]%#X+CU=Y%_M^F_\ 10^"X]7>1?[?IO\ T4/@
MN/5WD7^WZ;_T4/@N/5WD7^WZ;_T4/@N/5WD7^WZ;_P!%#X+CU=Y%_M^F_P#1
M0^"X]7>1?[?IO_10^"X]7>1?[?IO_10^"X]7>1?[?IO_ $4/@N/5WD7^WZ;_
M -%#X+CU=Y%_M^F_]%#X+CU=Y%_M^F_]%#X+CU=Y%_M^F_\ 10^"X]7>1?[?
MIO\ T4/@N/5WD7^WZ;_T4/@N/5WD7^WZ;_T4/@N/5WD7^WZ;_P!%#X+CU=Y%
M_M^F_P#10^"X]7>1?[?IO_10^"X]7>1?[?IO_10^"X]7>1?[?IO_ $4/@N/5
MWD7^WZ;_ -%#X+CU=Y%_M^F_]%#X+CU=Y%_M^F_]%#X+CU=Y%_M^F_\ 10^"
MX]7>1?[?IO\ T4/@N/5WD7^WZ;_T4/@N/5WD7^WZ;_T4/@N/5WD7^WZ;_P!%
M#X+CU=Y%_M^F_P#10^"X]7>1?[?IO_10^"X]7>1?[?IO_10^"X]7>1?[?IO_
M $4/@N/5WD7^WZ;_ -%#X+CU=Y%_M^F_]%#X+CU=Y%_M^F_]%#X+CU=Y%_M^
MF_\ 10^"X]7>1?[?IO\ T4/@N/5WD7^WZ;_T4/@N/5WD7^WZ;_T4/@N/5WD7
M^WZ;_P!%#X+CU=Y%_M^F_P#10^"Y9JD4;P0'Y5.]G@N](^9GOWB513IUZ,>L
M)RR9<)IN/D-&G7Z5P_ZO^W;_ ,';GYKLCZ>_ZN.)JQC&4?UPW'4O_:+?+6[O
M7:8IUTGL&E@3H8]2OM.=K)]KM+P%N]I3O <C<1P(\C_,Y]7^K+K-$_K3AMZT
MY=1W*WJ]+\6;Y*]$Z;V#A=5K.V7KL.ON=DQ&%;@$HK,]E8V;/TOGP2$*2)I$
MN1$+F35'E)03B2^?@Y BZN6?,0V>?3F?S_6R7E!T#B-AG6J<CM!7+2^V1'W"
MW0.KVG>&[<ZZ1?:9[ "QEUANP)TL#B/Z\K<@G8GX+OG/_9.(;Z9SPASBOC@\
MGFO'DW#;=,:%E&_9.HK5):^F(%>5;2,]P.LY\AA@.P))NR0X9Q45:3$6F"45
M8)OI)?I!IH*/'*;KNJV1H=6GGBCS>G/)J>$&M+L'L'Q^P=[6,$UQ)VE])8;-
MTI3!O9M5=[-%2_V>-%1=NYM:HC,&+8M,8+N@2_X@5>\I.<S:3=#8=8/E%T4I
MBQ*[IB[]CJ[J^Y;%@P&99@,R[F7G:!]I7+= .1,"6.A%QD&3(WZ_#0?='4H+
M])OCCAPQZ=T._';C]6EY4_';25H+TQ;.W-/@5F,#5I7DX+D,VZ:*B99(0L"0
MQS XD^&/>%!&4G$DT(XBYXQDH,?DU7O+)A*.'S5XV;_F(\J?CSG*(,]F(W:V
ML5:4KXVZ5J7&#AQ-,%XNPG*3=Q&!/03D(=J:2920-739\*P<0.OY$MCUTY 9
M;RS+OPOED-=]EJ(VRK*/N+7.SAJV*XDI&3A4R,;6==>&,["K=6\R/3L3)M6$
MX-D<2MW3ZR8\0QD9,L.%F_=TQ2Z.$>RE)]Z]\KVULV/TXU:UTU@"MC[/V]A=
MDIZ)X/=A%M?AX08ZX0%:DDQPXET:?MOF76GHT^<\MNG+6)^AN(5)'CZ=Q)]E
M(_(Q'<N^8&QM8ZIVCH^@Z$.]@%-DWT@,0>U[VT)J'&*&"Q0N8SM>L^:%">EH
M=Y7K/O\ J>QZS@(]FT2RC)A%V9=ICO'QN,(^;7Q4NX(L)H[=:IYF#"G]>1$[
M(0"1<0=.TW:T7.30 /024(,OW!:2$,2,$C],=$T9N;CVP_-=Y9@P]5ON$, N
M7SEZ#U9+Z4=(JWQ(["]V#HP%Q.RHN=XC10'@@5A-MI\E+D7[#U\V=)V PAZQ
M2%UHAE+-RJ<^;F.T3TC^R;K+?*3Y/>WC10UEF'-#3=W#5VVB5#5AO!LK4@IR
MI:JK6OIFV+8MQD/I")-V.TP"MA<J+GXOP_%N74= ._DSK?MVXYZR3T\D%/0=
MT[?AMG2(;6U'ZDT#JUL%,[&3)ZW<"9*+;-*7&G&\<1R<(BWC&L/S5L=TA7S
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M6/I1=8&*#6VD*" X&.TM*@!59%-G511 !#,-A[PBB],TY$K6LL^]G48-\IN
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M$%!?*P(",A,)(@[.4(:_!:\'N:R&!MBS&&3AB1N5XGM??>;Q=;37AQYX>];
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MI;+6?[V:+3W8YD@XGJV=J@1$B.6[=PI"(?D!"?Q\N[&&<4FB]730B7C277O
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MA(#76AG:M:FNK.KOD-,=EJS#;-G3JT")?7(XUIV"%%*O*W%CPQ<Z+3D.V&V
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M"] NTQ(+L:X[^G;Y*R?9^6K,-3NL<)[F(2B8'Y8"+G+22)!/M2<9,CPS4R3
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M;'NUZ_\ W-US^5(C^FQ[M>O_ -S=<_E2(_IL>[7K_P#<W7/Y4B/Z;'NUZ_\
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MIV #]ZQ/;*<5N'+6 ;UMWX:\=Z]+S)2&[$9*#]^&+'Y0G-23V Y^A-/3'_\
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MUVV>LG*?;E-9NNFIUY]';,@^5U_7Z>/1^OT^GC]7^>.>>...>?\ EQZ?3_\
M+]>0I4FR-"7S,VB.TS;H!9L[29N_K6W(@,)HN?D*Z/HM=XUD!(M;1[A=2'FV
M;J/?M5V3OKT4ZN6#YO\ I79NDTL@/;DJVKIFN!ZPSL;#YNWS1"NJPC)Z3;Q[
MLZ.W,5*SB F-(K]^O:3G%(>$EY+JP;\=EN6<>Z6XZ_)2[>C]']Q5;5DG7,-8
MIX,ADI;ITRK&LF)!*-HYR<6#)1<K-L \<27[]>TE//(F#F)!"/;\=EE&L:[6
MXZ_(1[\\23Z>/\^/^_&/E=?\^/\ OQCCGCG]7/'/_3GCG'RNO_Q<?]^/_O\
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M/T=NBG3MQVZ\\?KXY].>[T\?Y\?H]'I_3Q_S_5_W_P"6/3Q_GQ_WXQ\KK_\
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M2*6UT)_*]TU1J:7Z)B95S(& $;2/,@/FJLQQ7L\?R+@209*9S?&Y=N6-X_\
MQLV/"[?7;K,.=R':<<-1O97<2X:0*=N$J^D6D<)DHYY*Z+I =&I%B/I)R<G5
MW2Q8(#;7+&/D^KI U?CBKJ9WU:#WZ [ 59XH[0/+\VLJ*W+$I;8+FM-;+HL,
M;E9_:B-#&<",&%C7>M#54+-+@5"(2)@;3J0_AF58=),?LEJ9R$!(K$?=BQW;
MXQC&,8QC&,8QC&,8QC&,8QGP^"&T&@49XYO,?JK=QM49=LG8N[?E+B*FUR[(
MQY?>Y?9)O9Q5%T3W Z_CD79@YGW5B*0S@5F(Y!OQ$/VG,MS(,&[!PZ1KGL'L
MCY#ZGM,BIV^-S^VJ-]:[ZW:'1.N$<<;8[$U5 GA>[HVN$;3.X_6^C]2=A87?
M]T77\B<C!O"$DYZX@^K%Y$1XS#,VZLJC;VX[=M^KKJ\KI<)&$E7]@$/E8\)P
MH72 2]EHKHXBC>J*(A3T;;J2+2,E^P]--'DA$N&DI'L'KF-5Y1?LFR_95#I<
M@+N';Y_Y&(;Q1.;=MQR\JC<VP][2JY>9V?[SA)XV^ N*.Z<I:9+7*Z#F=C)3
M8ZR$=?B)CP[[*<A=;N$^R/:.X50<:O=$=QMX#_9"E9BR=RXR'V<)[4V<'-M]
M1B_:79P^(HV %H:TE9 .B=&HG3SV.ZJ*5%TB!DAKVV8Z]V@J2I0/9 B.9YR5
M/6$/9K6^2VCI'Q;Z4>80TW?W-N\A3/=>;;W, [#MJ>+*E7U1D"DII>THL(IU
MLW3@6$@'B)L,VF2DCSB5FR&9K!V4N7L:^?.ED-['C L.T'.AKO<+:H^*N7>P
M$[<VY79@?23EPSHR@#V6DS*I*Z@T7?;KU@A &HZ-$Y/F)20;I,Y61GG"W15V
MX=.G/S&Z^6CM%5=L:N>9:T-,S>KZSV*W9LH^O?::6MRG) =FM,?(0K6U'T0'
MSP!"DZ]O1X92B EKH6"#HF@TX=K*1<O(=4FG0O\ GG>,>;"[G18,>:0%V?W#
MV"JZ_08QJT'TQTJAC:9A*4M;51[$UL5=[!0IIE%.1:W>Y(OVL@A/[.>.'T[4
M[\,8I]IP52C>P\Z]OF:NM8G&_,D!;/[B;!5/=(-UIT.TGTR@#:9@J6M[6.6%
M0$CDCQ*H&<:Z%[F[DDGS8\I8-D/EG\_4:PBVXXF!1*%ZQ"EK=F"7>:=,O-U>
MM&;4;8ID_CWCM<$M7-<ZW/GK.HHUO:NIM6RET&!?7C:/D^;*^I8V^G[,!1-^
MBYAAPZAGI.C!$,A,N8Y6$*IV7V)D];O(JE47E1'VM616J]!E[2W&NRF\7D**
M-=[=G[GC6$H1/[QEM':P(J?A;9K7@G&#@%&N"4RH64;-K.:A8^/L)+K ]:([
MCW&7^/3:L,%MU;6IUY46W>KL3,;8&6Z=[;5:Q69 63#RZQ-1]/;^ =,^WW7L
M;?N1^$?V08',B4-:@ERL;AOKZ,19VE&1NU/QP;-A-WZ (/;NV>VMHB%K;?<9
MJH8V E-JV.P;>]BO@S$9 4K"J-GY:GHJ;N774\)YE2JW:93 2A>Y:I3(N^M*
M0=-O6K/Z;NO'''7KQQ^GCCKQQQ_TXX_1GG&,8QC&,8QC&,8QC&,8QC&,8QC&
M,9Q7C%B_323?LVCU)!RW>(IO&Z+E-%VT5ZKM7271;IWZIN6RW3JLW7Z\<*HJ
M]>JB?;KWZ\<\</I"022R3A.(B4UT'KV217Z,&?19&1DNBB,@_25ZI<=TWK]-
M55)ZZZ]NJ[KHHIT744Z]^W'/I[#PW\]RZ[0<'](Y>J2?9SVC&'SW,BLW^B*R
M'*W*'R^7JK3_ -E4=\]OGU&__D]E.4__  YX3%QE)/YI(=@DT>8I:#^;3B(_
MHGS".5.57$/\CJWXZ^JG"O/*BT?Z/HBJG//?NCV[<^G.MB50&3?S3"#4$)"3
MB&K<>(643WA7;^,9<?2$VL'--F?*CADUX^;==&\8^Z))<?-N.J:'_@4XXH/M
MSXPZ;V_*4"R<NK:ND7"U9K4^306N%X.ZT#3>N5E)KGO $H:Y@R0<37ZLR.=B
M/K*-QP\6=H&47A%9Y2,2:-F]UZWIJKZEJ4 HX"$(>&JBK@X6 P8.52YE8N"%
M F*8PXS&].TMW?.'?,7'QS/KT?/UW3]=9'EZZ=+.U%%^\A.X^-?_ $3E\Q8O
M?H+M-^QY=MD''T-\CU4Z)/6G*W3O]'=H]%5>B;E'Y"R?513KU[\<=^W'./0_
M4").%". ZB$_PO()+K3T/Q#2G"TK%(K,$%E)1E\_PI(1K===FDIV7Y<LT5EF
M_3E/HIWZ=C?H OR&8:-.H@]*XUQ$R$^U;]85R0Q[I-FIT@GTP@EQWDFKCI'N
M5>L2Y>]4U.K-=3JS[\(*]N.W>MXB':QW>):QD:WB>_5TFI&-V35*.[]'G=51
M[T[LTTNK;MU=*++]W77LGSPOW65[*\=NRG?GGCJ0(ZI%<0*L-"]X/JET1XAE
M(YCVBNJ*:O59-+B.[(\L^$NBW7JKTZ?,_)ZJ]>O?KQQVXXYX_3R#'W\=TB)"
M'AWL2GT0Z)QCR/9.8[IT:\=.&W7HR71[MNO1OQTZ?,=>J7'"/'7I\WQU^3QZ
M.3S&Q:KEF][,&"CR,Z+I1[OEJW[N8]-UT33<ILU^4^56G1RDFET7Z(=T^JW1
M-/JIQVZ]>O''/QC&,8QC&,8QC&,8QC&,8QC,;;B @RD^9EH+C;29[*N%^95O
M"1:$GRN[ZJ]'2W+Y)MT=<JN>KA;JX4Y5^6MU65ZJ=NW"G;CMV+F)AGSID]>1
ML8\?17=56.=N6;5PZCE%^O7JLHR753[K,^ZW1/IU5[H=T^RG7IUX[\]N.O'H
M]"L .N5'7=:%A5U7KMF^?=U8UBJH[?1W5/HP>.NW='MV7=L>J:75FX6Y[K-N
MJ:?5'OTXZ]>..'-20<,+(D)$_&1YPZ^9@&\Y-.HN)6<_/**NT(5&3?*-^ZWS
MJJ:SE&.Z+]OEJ)JK=$>>W7OVX['K$0B;YS*=(R*Z23]#HV>2/5DTZOGK9/KQ
MQT;N7?"7#ARATZ\<<=$E5.Z?7KQQQQUXXRIFY.DE6;NT>EKG9!?;-?U*](HF
M6,ABC35"M.ME"\<UDVSVK#MRSAI%>1K D]9='!&/17:%>2#B-C.R4PU3053<
M6LBQP?AAYB(Q<3&LQB+AFP^P'T6C;I$M(%FRZ1K6(1C^J?#7I&(1Z71DFSX2
M^C\-NG"/R/D<?)S@OE A+M& TGW%4^TJT[H0P>^[1'3M),8I+A91&,'W'/'+
MQI&HM^%>Z;5HHBS20X[]N$^B7'/7UE'4#8(<2YKU$63;NGZFXE"CB&;(=DI#
MOZ/57#V6^0GV3?*<>CZ#PKSU<]^/_P!+OVXSMGP^/RBG5:2A(:15^B+L.JKZ
M-9.U/H+GC_VEGU[N$5.WT1QQ_P#KM^.?F5>/_P!3IVSD(1L4R7=NFK"/:.7W
M9%1\X0:MD%WG=NEPW;J.U4T^BCCL@ATZH(]ENW?E)+IPGTYZ].O'7CU,8B$C
MF[AK&Q<4P:NEEW+ILQ9-&K=PX=<<<.7#A%NDFFLLXXZ\<+JJ=>RBW'''"G;M
MZ,]+:!&VD8I!LX6$;0RR:Z*L.VCF",8JDZX[?2DE(])'JT[IN>._?Y_IV1YZ
MK<=^WSG';Y7/I]G _ <,6L9Q!Q'$:Q4068Q_$:RX8LU6JGSS55JT^8^CMU&R
MW_FH=T4^G9%3_P :?/7M^G.WXXXXX]'''HXX_1QQQ^KCC_+&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8R)[NK@@MNM"*O1FUSVDI$D]6-%K)J_P"K:9_!PZ4NP=3[
M45?ED"30\)*S\&A(CJ)'Q"NY4<ZRO><@.[.=81SUM\W6MU5US;U,>';5N]8O
MK96N)@9>169*@&RY60)1NW+*J$XL/O4T)9Z$V\<(6<HUAIBR+!X@R[I,=9@F
M#V9@\Z.'PW\[VZO72G*<OS:*M=)+P&(*T]'J:,?+7VUJI^P7CDOJ\FG:=V%U
M>$10<>0\Z^D8FQ6>N@];-YAU4P\RA(IUM -U$(CCKW#HAW%WXUJF8MYX=-@X
M<KO4CJ:JPIEY'J4K_9%)_/%Q%5&N%77YL?3M*6XQGNCI_/DGLRIL:$2"((^7
MG9P]CQMG*+/.G'SKW*P:]TU":A; :4.;>T-U;HQT0&'%)4YNIXZ;*;,!"Y9L
M[J,U?1E>;(5)/5Z%65/ ]@Q@HX-VLB\*;VC(6QX -*')5%]8YR1NZ;Z):12-
MP:J:=S-*>,BM*%MIR25!8$CY,6QY1HH<*#(=;L68V 7M8VM74C>9I-60'0DV
M"^SPV9PXX4="95K8$BT@4771;8@MK"<]=F>OB;2GX7IX[I8>=;N.1SB1DNA\
MA4:5FHQ,KH*W:]8OZ!UU]D;J?M3/B6ZS_21;T:K):SI0/01[-)Q&XOE C(HB
M&-+Z4,'?:(UYO;=^K*=V,9HOG<+$D%6/*QN0J$*SGW<<[8K<!]L7T'4K4Y)!
M_.\QY5!F3L,E6Z\//OD.]6MU:IUHT2K_ &L*]*.K#6'9@ZT:MDD[U)KK 1H>
M(NZ[JR<#V)3M*YJH-%O4#6RZ)B3)5L('G7B+E9=*:<C/T,O=-(YO"<3<C4;2
M[534$5V3U K&J*LOROC"DY77"]:N:0C6UKC.;)M<'@XP');:8\."N\(K9%$E
M<B9LU-Y\K:&L>6/2"16[N6J,PR_,'(QT9XM?,_UDG[./YB+?\S/K/A^Y0:<Q
MG,B575-17K#A?NGPR[2$/,0TNQX<?-_2XV5C7Z'SC5\U55H)=U..2'8W9BPG
M?BNUD\D3BD_'GX\I>3%[\,X\5LRONB0KL6YF(FI!&9UPNM0PE9U&&>/R$>:3
MX).N7(E$Q$(P*9Z1CV3::-D]+=<"7_A]2BP;/@*$VM/ZFT0N\_H2_OJRM8"5
M=0!XP)K1"A^D#RSFTC93(1K6(EAH)#)N=<QIB_APF$E"1E&S_P!)8,OH>H36
M3775<6E0?6JCZKH4-G)]<KF1:I 8= 8"4)G4=&Q#F??Q(U'QS)U,+Q<-$QRL
M@LCW=*,HUBV[*\I-D>O2<L8QC&,8QC&,8QC&,8QC&,8_^_\ [_7FFPDJ6="?
M,YK)8)#<MHV.M;.HOD,4C@XKE(AK6]3C(99GCV2'1BLPP>AX=A&J+<%$J[+C
M&>4(3DT?]V'29(>T$/BL! Z>&P_#4SHQX_-^Z#B6C/R-;%J78YN^R8MX_D;.
MO(Q+-/\ ;*S[K!;04YDN\N<PM4VU7T%)BPY.NWG2H)2M!J$&U(EDR=1LE?S4
MZD* UKV)\6<[JK%0T))[8:BW#+['SX_-.YB3V&&82MJ8L>$O*VWJKUQW/["8
M6M.1R#*W9[Z82<=+/)ASUEVCB3EFWRS<W7ES=6\YV:@]+Z3^0*? -=:G#K!T
MWW&D),6(Z9@)XQMJ?A[0H JFJKN&NV*E[=5'0Z;*3 .S7<2%/#K;K8+%-L[A
M&NNN+$*-OFY]( 6#\;4KN&'U'J9Y#:T=ZG;#'-"F\QKF>5)N[0E>%L3%V!<1
M#WKPO%JCF6TM4E7RHA/2S_FKWXXS;*_1V,VBTNDRTXM;535"P]P1L%%]>;DU
M1M&^]L==];(BP5R\!K/4^1KX-<7)HE.ET3$NH-J!7&A7!39[.+!8B2"*0NPC
M"I@!Z3L'72:$]LWT"IB9%JTF=C;5DH\EV2W$ZC-VW62QW9=Q##[>3&67LWI*
MOW+YNUD$JHHT+<- \13<-V"Y#,<EEDS$<T*3\AZ]M;>O.I>ENS&G>PFRNY8R
M&/K[E+@V\F+^V@G/H#*^-82.D[RM ?AV=76O)(RA913;68/#AOO6D>*/F$##
MM()@8IL)GJ3R,E.RW2]2ZV[O;?;;2FS@D&;.LJD&-7(W547V#%(<XB(C6>V-
M;0$_6N\=K0U@TX*&([BNQ[< J6F_8/C2EZM4C04=+1T>.MXE.JM?HPX'LC0=
M-5_+JO\ 6;6_SO%E54,X<RZDE U["SOAXV!(3>E!J1>K*J-!&L=B;&-*W$(5
M1PHT')%PE5T%WZ)C+.$C_;Y8&Z4\?>65JTBH@M03\6OCD'I&$DG/7I!/9:1W
M8W?>=!0D>)L)CI&])B)?L^[M%S&/W'2%D>DAUBWK=5--?C:KZL#3?R-KT^5:
M":9^.V '=7[07L*HJ"-7=H#'D+I^YVT6 RD7+,F-":_US-U_1Q%T[HGT2:#!
M'8\ 1$HDA'QD/7=BJ3A18?2GQXZ(!'D)WZF@[3O6T6EZ(LW5>3I:3@*<!(I_
M54C,:W"9+*O@!TRA$5A1W(D+MU-O%X;NT5<2;A9ZIV[+J]^_.^W&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QD<6?<%2TK"11'<=GU]5 [/$T*$PL]9!H. T/+F)*
MJJW'12+E">2BV3\DGET5D(:#:+K2<FLDHFR:K]NG?CK5>W:)\?*@93^GMV#U
M"L1TY,24BU_I$Y(H""(B<^A'<J:ETQ3$1)S+ RDBR%[ETS-3ST$54EHJ,(Y#
MJ]4;Q$JNBN)M/O'M9 F):9SE14',0U#PL38 91L9Q!1I-4P^6N2D>CS>%A8!
M\Q,Q",.7C8WAW10AW9('#Y(L:2+^8=<3/3GKG&W_ (NZ*Z)ZA/MI]%:G5"&;
M&H>-;)*\J%#7PPR[LF\.PKA>IGY3'NXSHM'NV\<D+.8)/LY;.DT.62O1SQU4
MXE)Z*^/6CKN:R5.5P PEUUR$M"87%>;!)3!_35>V&L1B<<05A5I49$4)20@:
M]A0M$8Z6KD5#H>?;#)&,,G+EI$2D>WG+78\U,:B(/3^L=B4M*B4&-E/ "%5;
M8 H4MT!2NRMN&FSF"9PLY*NG<,$&\LS$RIZCRX;CI1(M(&87:2KI!IWRMG[
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M^G'7ITZ=.O''7KTZ\<=>O7CCCCCCCC/9C&,8QC&,8QC&,8QC&,8QC&,9K?\
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M[VH5O.X:9V?UNHG9$W#-"J_VFMTQFR_6*_Z:E[/-SNCI2L*JUEJH8M^NJ^L
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MZSO%F\2C2]I#H$@>S6^<[LT)5IF[*'\FH>&GMB+;!V;4P)6=3>/RC-S+)C6
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MT.]D)[Q!VS*M[/;HVE7J?UZ\Z%9>5V/[]V!!Z&%8 JM6*/:M=<=6?I[';[@
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MEX^5>XZU_P"(,UR'ZLV</+HH^Y:>+M9*MK:ZY6J%B>A[.(CZL;=L>/J4(GQ
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M_25BW5!$$U2DB[K<8A1.<3;Q9C#R?9IS-JQ/63Y343D^S_#(/6*1[.SC:]I
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MRSSM'F#?40BL6%A'4I(=FG#B,5-$PALO*IM6[GK%=WZW1IRZZH].>]:2??\
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MZFZ44-*T5U^C.^W9Y+%)J>R'=5?EHX[(TAUYWMVE'/&K45?W_<!3([!6=':
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M_P JR./\0;7#[9)_RK(X_P 0;7#[9)_RK(X_Q!M</MDG_*LCC_$&UP^V2?\
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?,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exh37_03.jpg
<TEXT>
begin 644 exh37_03.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MP  +" .V LL! 1$ _\0 '@ !  (" @,!              <(!@D$!0$#"@+_
MQ !>$   !@(! 0$'$0<" P0$"PD  P0%!@<"" $)$1(5%Q@95]83%!8:(3%1
M5EA9E):7F-/5V%-5<9&3E=1!82)2@0HCH;$D-W31)C(T-CAB=K.UP? G-7=X
M@I*VN/'_V@ ( 0$  #\ ^_@
M
M
M
M
M
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M"[*7($9!RE6RDE%&98W+S[KN>>YY[,O<XXYY]WCCGGGCW_<Y_P#+D?,*Q_\
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M6*[-5/N%96O\WA$H-VWK:E7%G2U;KQ#*P>D;C&9'$Y4Y&F*)"VNG*<TW-O\
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MXZUN\)55O(N3H&PIGY]DYC\S)"GEN.:4)N#:7/P
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M(,N6JDJ29NA!S9&#G9>48GQM4    '9QQ[W''
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M5;POA>V=!7Q5RI1;$0ISEX>R:3FU(PEJLI6UG(F\MXKK) V&-7U'@
M                                               /'9QV]O9QV_#V
M>[_/_KS_ #'D
M        :Q^KANA<6AVH)]XT)7<0M2UG&X:5J2(0><'/B=@>76WI^U05&4<;
M'5J!TQ4XJG8CUIZB?W')V6/JA9F/_"*707K+S6VNHIT]]5JPK.#NU$;:ZOP6
M\[.LY:Z/"F70.8VUK?L7L37<$C!2!<6PGEYQVBB5+T>[(U*KAOD!>2<M/SFD
M49W1K/JW:9W5<[YKW7,WF15B^LKG\'S[-:8N&&55;;IK^9DBN-'4]D2*%-49
MLO.L7/C(J7IX@XN!Y:8@]<T=\T/J:O*BT%ZQ\XEBQ)APZ:X.$(4]%R^.IR9>
M[+']ADU8IYE4MOXUTF3Y1%\C:2Z\Z;2LWKB021O+KLRUE63<K3QQM6J#T*)7
M:J8]9O3>E(M"T=O3J5RBU5^M%2[13*+T)0&Q%FI&RG[+CB]WSN1*E:ZW6.C#
M4#4:R.RAY?)EFU.<*0*8\DG"1F>I$RH''.[;ZPVA%-J*R*D%K2*4);1HQLV>
M0NU55);=O-,+UP?""#V.]+555K"9.96-8._*C E')IF0TI^#"U6:DM.F0."A
M)>*IKQK&[Z4@FQ%;R<IWI^RZ]9+4ALQ7H'6-D.$"D3&1)&F0K&V3H&=Y8R3F
M524N4)7UN;EZ##N\%Z5,:687CJ=Z6758G.]EF6U"+7JEBJ%$\P!GV?U R0GO
M6;U;>F\JM>T:HC=ARQ,Z'*4S?+D[G F)Q?T368G;RT$_C1J9-B6;W>>)S7KG
MT?+-CM/:+U7Q<;0;-@]O'#7:36/**MM^+U@_Q*,1F=&SR9Z\VPYQ]BKFVSH7
M/8VR1!]51M]D38EY>2E9:=2WK6UU-_5B=="CW[8'4.CM5RE]JDWWND1K-*;"
MDU7V]'*J?(DSL$[PL>6Z_P!NKV!DK:UG*OY_'8]$'TR//TA;DV;]@L+2+&Y4
M@=,Y>9>N]TVY.V3I^BMIV+)H] US-&CY RZ\7^J:I=9D@E"6'L]*UJ;S6V!]
MBW2N?%Z LJM8DG=)'PA4G.^:;%J:7]:TY@KZSNBJ>K([92:46X\/<GN1_P!>
MFRAF/7>\G39_"[(E&\9I+ZW<-=DL"SM1J?HK#3"I2]J'*.)&,AE4H%1+N?WT
M:\%N2V!U;M.*\K:@;)6.=S2KG9]--UE)UG7^N=ZS.\I>BK'$O.S%YU+-%?F6
M+'$%?EG$G2E=*&!F2(DYZ920<J3JDQIMC(GN;0$W==9F:.2:1+%VWL+FM@41
MB?6UFMI,CB]>L+!)):IDBETAR)-6CBVM4G9\R6"S38@_.BPU6V-+:N<6UQ2I
M;3@                 ^:QGZGG5!D=6;B[<PK7K32?:O:9;&[55E-:[)L"X
MX7LK+:RU6FCVTS.419P<&6357Q*?8DU925*VN!Z9*Z')%S8D(3*E" K*]LIZ
MV/3^A1L$X?K%G>;9*JTI:V9=+H]2]LS2O:)A.PT?9I+33KL/8L*B$B@U.<3Q
MJ?FY6UX2Z0(_6R-04[.F2!B4)G4^&9AU49E&K;WC@#J;2-?1K5O<;1W6N$S.
M<MEPR!+.FO:J%0&3.J=Q25BTRUT3S<YSEY[! 5^+4VP=*IX0+)LY(FK%8O+O
M,W]1W4)QB$,F:2SUIS3/-JU>D4;1Y5[9A,I4[0-DE?8FZU:X0DZ'82]B7M3I
M&7Q2ZO;ZR-L7;8^ASE2U[(C)A+N9&%>=7G1FT+B3TM$K#F1[N]NUE1R 3YTI
MRW6.D;=E--)'E;:\4IV[7>$HZSLR10,B.O\ R\-D4DC@:JR9W#ACY=N$QG..
M'4-UM^G?LI+*]BU26G.GE+;DTC5;U3/'BA+YB%5V)84IBTNE[?!XY9DLK=FA
MWLJ3MD$E2)Q9'9U:UB20LZF-<EYON/K 7OHG92G=E4-F.E,RHR8-517%85!S
MATQ8)*RMR*TJK<$S5/&%H62%G:4\J0,+HIX;,Y1%C'F*KG%,X(FQZ6*&Y=@1
MJPI;JSRJS^IO,M3W2MXTS:MN\^V"USU_O0A6\&2BP]I=3X14\ZO>"NZ+,\U@
M1QU$W32P4,2<$I92IU<*GDA&69AQ1Y!/4=4+KDT5HY76TK+5G?&U=D];XM#%
M[TQF5=;[_1,4F\Z<F4V*UO;=TPR/^P2 S.411<X/D<C;Y,F=Q<SDZ-M+Y[ZK
MD;6L_74OZX]&:15ILTRUUPXVALSKU (;(7J/^"^W9)1T.FM@'-*R$5Y<-R0J
M/F0>O)9,H\L6.D7CTAF#*XNF9;>BPYQ<71N0+; 3WK1:!5-;LQH2R+9?F:T*
MF9<'N\R6^H[A>H;2S;G531<"1XL2>M4%71%C8GZ*/2(N+.6+RM)?Y!D?%F[(
M^0('! FY4<ZS6A3S6%YVN_V!8-5LNNL8@LXLZ.7115UU/8R2$6D_<1>KIC&J
MWF\#:)I-XY9$CS3L,-<(<S/G#J\K4#7F6F7+DJ<WM#.KOIRWT7(KXE"F](&W
M1JV8E0ZBK[ UEOZ&WV[W-8*1,X5[6T2I1\KQ+/YG)ITVK$KG&RXJS.Z!0@,-
M/6KT/K!TQ0RO%.HEK1+*2CE_X+[1C<&DEQ,] 8MLUHB[(G83!<#Y*TL(2PR6
MUH[P B<QHU+)EA#>[R!T8R(DSE<F.3A("&L@Y;A>7'GMXXY[.SMXXY[/@[>.
MWL'D                      4=WVU@F6UM<TI#(4\Q9D65MN-J+L2^G2TY
MU(0N$/U]O:'6E+&1MY:6EX.-D+RR1U6WL!"LA*V'N9Z<IR<VU)D:L*U*:2]#
M^S]2+ZHFUE%EUQ)VFGMT]D+:)+)7S'-\1ZLOVF\OU.U:J%A)7QKA%S(JX1/Q
M3Q*T)ZY#'D9;K(.6!Y><\$:11'VNG1CWR@>WE ;*[ [!4/>;Q2&&X$8DEJKI
M3L6NNZ]F+9>!2F,Q^;3%!.5,NK2NUM>F9PV.LE+U,TQJ!,\;PD+FFEKFM):6
M+/UU7T--EX)3I-=.5HT6K=BN@ILOTIO7B%VG^;=S=MU6FNG4=GW=J( G4^"M
ML;56*5Z7^MO9<4NQRP0Q%>1V*.;95MTL;OALLN=^<YW5:E+8_1RHWIT,Y*)?
M+<ST5LU;%9ZPO$S<L3XB07A7:]3+$1K8M2F*9+F0G5<JHPD,Q)+.TN[+4_L'
MTOL62N(4\EN,NN/HX4CI1<KT?J;M!L)6\NGU%P665DP&:P3:BHH^8YV<YXNC
MRE45WL2RT]#<$#G#Y@NE3@G5K65KWEP;4O:N3=!.G]**^<&&C=GY#HA3% /J
MVR5KVUI:U4O-?1.'6RG7J8JSR-X22MEAJJ7-S+BA0Y9)9=BW\'K6XLDY>FP.
MN^B?SJYLIIG>6KNPMV22.T=#IIKG;L V;O:=V,TKM2Y; ,V=MK^ETF4>=$4,
M40B>L<&ES%$">(_#E>+(7@:K09MB D^O=-]';>VMG#IWT@]W1JF_:?=-C:!_
MM:JUC:Q6>T;#6?6K\ALY&V)9_F8UK( P32%H9UWFP;HT:I99SBM42!VD# X,
M"5OD'FG.CSO=5JKIZ4,JN?5-[TVZ;.W:Z]:D7)F.SVO8RRJ^<%5FJ&QHL//O
M4JKYDED(16(O924\<.5-,^X4E/KR[1I>Q%I'WNW/H=VT[]+/6C3Y78=-\[":
MK[>3[;F(NJD^S^:0L%[D=V7U+D$&GCU$,*^MQK9W.K[K-CSQ(HADWR-AD341
MDR'KVQ,4H48!(>AE=<CUX=HT^5ETUY)9LOV2RN285T\E;E\0?V+-];%U_%$\
M7VGRM%PV4C-H1PXKOLIGK!'V4F1MG>^'K&M&S,W!KEVUA]%';"8Z;:ITC/)U
MJKMK:-&2>Z9([N.SCYM:SN$#(M%R3ND.C.NVU=;S@S9F+1^HRT+>P>H2SEX/
MM!F:V3&0&1PIB;V_';-IMK_NEJW4&EM"32[*XV(C-<P>UFW:^W+,/L]?=LDD
MKDOQ?Z6;:9<USF[(G.*PI0[/$&DKK:Z]5*'6$QN'."'(E]4O))>QX
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MMS8K*DR=WJ652Y@1HU"Y8O:L&U>X)W@L]I/5&H\$2M">?.8
M    *--/4!HV4;II]'(5Q)YA9"6N[:G<MF32Q.&%61)SI]\J%DD];G3I8F3L
M4DLE#E<D;6R*+1!8^K($1PG3SSB.N+XQ(E\$03JOU]*'^%ODJHJXJMUGN!RM
M-HH7;*:K*UYK&U5M1Q:;3A[.]B[#.'>T(*T3"%5I84PJMVFL,:B)U'8QFH*P
M:W!W8VQQS_6CJ'EW[8M>0*7ZSWAKJFOBJ7V[]:Y3;2VKU+9=%<QI3$^7K(IN
M@4]ESY7\Y1L4\A\NRKV>MS+(<HRZK5F.'*N.R)"V=Y=>Z-BQ>^G[6K7/5^0[
M*VG ZOAEPV?AG:U>4S$X;#;(D4[B]?HTC[.#5;C*I=*7*M)H:2V,T?YCK,A9
M\39-+F58YM"%?%SAU)IT\/=$0>I-&M@;$M6Y:@MVX'RJI%)ZAI>75*UT=:$+
MIJP6:8YVM-8\PNR]'84V;VYC<(:\R!AEK)@5,(LZ/$5<6YW49'6_4PA<NEL!
MAT_I>U*0<I)?$VU+GN=@*(2N1T[M7&XE#["A=0S-WA<FDT<7HKR@4Q;Y%2\_
MB[Z]1F4*U#-$77*/362LD>56;HK9>/;!S"]6F"1M[,@=(6&;4G-KJCT.,4L6
MQXZEXRM!E@))1F;BZ--5OIQ$&D\G.)(:%$_12J*M!BU9#WPPBG<HZE4WY*M&
MRJ=TMN*]=6*/FT^@UEWW#II7"%Y=UE1/SE%[@?:.IAP=<IK=,;K:1L<B87-2
MVJ8\[2IYB\B;:W99LJ2M^#I*=C[O2\ZSW:FM4]:9AM+.H5$H;-K96^SJ(T?
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MR]-8WIDK4NQ8DBG4>=SD,:LYR>):ESC#BC<%*:')'E:G,-Y1&$8K"S"<-H@
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M5#!-?8Q"94?B@0.*IU:>]<G0*VSDM\0MARSDGUV@+5(<RU.=XP
M             :Q^J[NG;VB6ND0N*E*WC%KRQUNB+PUTA<FR>L<W*$<1&?3R
M;8Q;AC7(%!TYSCL#7)H<F5F'MRM\4I4JQ,86=QD7'=[]261Q;=OI^ZVTA'H-
M8-7[/)R9#=%DN*AY,<(7#[.@5E2W6Q;!,6M:F;CUUFYTC<:U9E($QZ=.R0[#
M-"28>M]4(E^%;Q2"4;U2_7%5 V]%1Q>$GK*N;A+7&Y+)9LO5$0K^T+:KWE/D
M?DB.:"J]M$LF,FHTV"XJ5T?>[>[G9EM;265K[N#JI; 0J1[K.S?>72_KB,ZG
M6Y9<$8Z7V FD\AM[V<T5O$(S*TWK9S;[-.(;G2P5#X=&8JN:ZKDF/#O@3PEC
MD@4<=[3[ V?U>HM2%C'1NU8$X,ATRU"TNN*B:/38<8;'VOL;MQ8VQL&;M;V5
MA<7-(RG/[6;4$92JE1Q3:VQ,]=+'^8/J6.-N!R')N>HD]ZWW30%1]1NR-/-8
MC[?UCN"[I ^/-JHZ^AD:L>)6S4\8BM+1B?6O,&9GGKBWP>?ORN3/*-L:%$D>
M8JK?(ZPLD=+.1\]C".IS'["UZWTV%K555]VQ/778MTU_UO<J?F3;+(O?\E=Z
MEU[=:L8$TS9WQZCCB]S:\[OPJ[)?'UQ38C]21%9I\7)(X9G83L'U$-B(!TU2
M-EJLJ:O9%MZVW;5VK,FI23J9'Q 4^Q+WM-%M5I['TBEH<R)+A&CI>YN+Y7K@
M:N.5+HLY15Z68+TZ[+!1PM@>JN[,,RZ7[7KE%(A/XKO2[TW.+'>96<\8*:VU
MZMZ;4Y7$=?6<IG7HB2Y]()?=+0DCZ)[R5MYB2(3DTQ H,9#L2]U6>7<X\Y=G
M;V<=O9\/_F-.T$V.ZD6R-4%[@:U1O4\J@I0W.LYHS7BR8[:2Z\[QJQ&:IRBC
M\XWS'+';*XI^3VTSHL9-"F#&EK;9&)L?XRFDDK-4GO&;5C-%=7IMN3;JOJP-
M@1<?UEO_ %KU;LVD[D69'$OK-=VRD6M&P(S2-K)RW!>R-+G*X;6,I3PQ8@S)
M2XSJ&/$*5K71WE,3*SV :3W[)-F:"36U+&AE8GE1;^S==\ML?X7<-F+71^S-
MO4>P+L>^*M:JY7.[#738\._:HY3]]UZ[UD4F1>MTQ/AXOV3-^\U?ZN%-#)G$
M)=JE;U_+9!GPN]D::15U;U'5TVLJ7G%5PV]Y5[;:3NO7^K(3%W"YN;?6RHDC
MUT2?3#J$;T;,Z>/3Y-&:':U,](Q-LAA,-:KFLUS;;PW6M>2JG=0XZ]ZGQ*(F
M+LFNR$;2V(&Z.GS-EDALKET@**RC#!"&-VG/,=7SU#+TB^U.Q])1>^^FWKE$
M*'C=.NZ'G<V12^/329FV37ALV=UR-6U6_"FLEACJDK)K4+4C X^M><^##\U!
MF/J9FP#5[:[&\-)JTV^GL2\&9$HISFU99'^5REP:VE&V-JY>[ND>>'%M95KO
M"W5(V'2.%/K@T-"QZB#BS.JUK;5"LU&1IVI?K%W3/]+-E-K'.S-#IA/:DT'E
M>WC)K%6""W4=EQ22(H*FFC0T3UUD]@JVV=U\PK>5,$FTJK1N3HB9B8@0X/;.
MK-X:SKP6+U?-1<+2U3K[7S:74O87.V[7L1AN-HJJ]:ZM6:P"I:]U.V-OYVL%
MOCU=S5U<$12.5T_$HPM='MO/9,$LH.0<\%/"]H.+A_0_JG6/MU>E>Q=0JU'<
MX+;U=26Q"*WK*TG]9?U MZ%O:7R.HY^MDY2.O[X<"R'5/#+?0T1ADKH^REC>
MQOQ3^Q<.4D;]YX             -%&O75QEDNICJ76/>4!B,6D&E,WO]QJB.
M0O)\-,MVDH#:UZT)4KJI2NJY<K/L&>W9K=:=?K&YCSP;3G$F/8MR=(H=>$N&
M70KJ&[/2;IO4E?)-,UK(-Y+VM.8T9"J(C[N_)*O<K0K^VK7C4X*(>E[FKD6$
M;B]4TM8=AJUF2TY0L.C_ "D*Y3$KBN4^?[9=0I]ANO&B=X:_2B@X*R[JW) H
M6FL':TYZ;JTKB%3;6B\[\*<)9S'IC"CVZ3E.55,\)S1+)"2G1/+RL;SR#5Y9
M&&%<$/56N9AK'?)P<W/438.3:BUM2-DQ^X-69)*Y%KX_*K@DDG8%U3SK!?)W
MYPC-IPA)%B)8M:6:?OI3C#)O#GI85'CC^4*VQ[)U"IM?+IL=9NJC!7TLT]U7
M@%QI)/?DD5.;L1?6P=>Q9:[&0&@$T>=VY(?6%<."+A'95O/AC@V2]]4Y1&L6
MQ8F;'6<HX];NLMK?.J\T@PJ#9'3RT=@-E[2U6KZQ*1@M[P*9S>$D7/BTXV>>
MU0.,SI?-43C7JE:J3^HOJ)46SF)N2I"3F9@:+(Y[P2#'?K#6GB"M^5 YEETO
MG=7KT[AS+W4-K(S9#"F>4'*CO?[&>-:2L)7D^\X]\<ILJ3Q;A)QQSR?E % ]
M4IUD%R]3*#[&1B(5S M)EE@3VMIA&,W8Y9/Z%JA[GT6L]\D)#RY*$G,S@;["
M6_-\2-7+<V][)_"C2R,#7 [U.PG2TVNNW<O4Y!<6Q5=0^I[B26I<M:32OX,<
M^*&*-.576(^PG)MY/D2M8YG.B;AI]1>3<\RD^;F6JR1IDZ7DHOC)-F;^O-'=
M57ZG:IME9XW;8M?3VY)38]TM\ED-74Y44 D$+AJE\<(-"I!$)78TWETPGK0U
M0>$I)M 6M:W,DV?'::MF$=3MSQ2N]=_MP]4*XVK@EQ0R@IYL[3U#1?86B)K
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M%CW.>>&:A.VRUD1O1#>NX+XXX)<VSUWRW.B7/$LY(XI524\HHXDPO&6@
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MG"RIHXC;EJA ;%(U-7N7+8EBA0,"%BC3RU0] R$(8RF6+K/
M         U)O?3\V@BZ:X*IUKWE+HW5^[II9\X=H&LH!+.[JIYQNY[?)A;B+
M6^\,;8B++ D$FG<KELT8/9Y45JK( ^2%5E&%9*!&UH$.?Q?I5ZEJY79<OO\
MJ*H]I7659P.+5TJOBI(A9;M3M*UA5D2K>%5/%Y)89<VD:H@I>RRFPI'*<G1
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M8N
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M;4_QZ8OZYOX(>&VI_CTQ?US?P0\-M3_'IB_KF_@AX;:G^/3%_7-_!#PVU/\
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M_E:K_P!H._\ O,AQP
M            ;!M1/_F1)/\ [5&__A#2+9  "D1VGIQIIIOA PQ]4,S,[GV+
M<\]G=Y<Y=G;[(^.WL[>SM[..WX!Z_$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O
M.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5
MY](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q
M.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6
M'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GT
MC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.
M\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?5
M7GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/
M$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA
M8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?
M2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D
M[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]
M5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P
M\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.
M%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y
M](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.
M3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'
MU5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC
M#Q.3O.%A]5>?2,/$Y.\X6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,/$Y.\
MX6'U5Y](P\3D[SA8?57GTC#Q.3O.%A]5>?2,6%I^KS*K9'-FS>L7SAP=<G/A
M3PW\MOJ7=)$B7U#DGE<O[OL]:^J>J>JX]O=]SZGQW'=92X  /B:W+V]75[O3
MU:G&_KSZR<?IK72=:[LE8*=#I=B@H2G29UK-7;\H26:MDZPB#PDV2V [%+D"
MR3J6R,'J7):8\K,,%6?.?93FX-_WBZ>FW3>STPZBLSGTJZ6T@N.[J[Z6=JUA
M'9Y([4079'6"-V?+5;K/X54[\U)H"]HVN<.\2?EZ55-'AM,BQ2N/99*$]O=G
MF'=ALTQU7<J,B'5WDE/H=CI[(MQ:CF5ZPZ-=5"15A[%GEDAC975A0*:2).97
MZ*9D(Y2Z0Z!R_"</<:S1$)'&,IS7QU9:R0[<N5S6I*GU UIWDW,9S=G.I=7V
MLU@K=N(8Y0KJ!Z$5'*ZJE%KS"EU-C6 XRYRD\[G1<$6M5+6I(T#\[11&^OS6
MG=9,\L3<XM%J]F3KHZ7>P-?4A4>U^SMRU+N=ISU#G!3']EKJDMY3ZC;;U.UO
M47!"[BJFS9=FHL!A2R$T]3'I$PKGU?'"GQ2SN3,C;U)*,E+LAUIMBRY-T/*7
MN^03J3O%OO73#B%G.UDN#NK53)QL19K(DDZJ:*WTTS)<?(U$BSR>373,WE5F
MY9<JN<^3>>Z&O-^V;V"(Z8O_ &>NS$]S6&78NPNX'2EB-YS(N4.?$DM:*VO&
MURBRV&=N?"CUU(&F<'EEFR9&OS-(=3,,<E>)G/O\>Y]7+--ZP%-ZM-_4-ZDT
M?J*\]5]C]DY,QQ[:QX:S&&;1"V*_9(^R0O/"-F)6"#MK9,G5&FCV2):8400V
MEEN.&*3+@ZM;)M1MA:1KMINDV<MR >,W_P!H,W_U&<]@6Z4\&VM4NKFOK:Z3
MU)4U-2Q]2.J: 2&1)&%+$(,^)T"O*+EJG3)G;.5BHHY+,VW3W>72[M.64!46
MU^S-PU5M7TV^I!:3$BV&N>2W7:^MUY:AT<CG47M&MK=E>:BQF:/S(N5<H,HX
M]OCRW))>SX.\>4-):0EL*BW7O=C:N,5WH3J+>UY3IZV3B/4"T:7O]GJ7UP0R
M':;2#;FK+7M& OTH.S5<'2A.TR)"^TO923C%2@*DE5-"ET4*E;RE5*]D'4_(
MLVR>H1TD-6HML;L7KW6VPN>^BBUE6N%HN-62J3^""CX#/8*4L>$:1Q3GDM#[
M@JY*P5MRGN$KHZ$D<D9K,S>(&A.[%D].1RZQE/7??$YV9K/I]TA2FR=$6;?+
MBS.]MG&7W!)ORST!8DW8VV-)YPH-M&'LB"$/C@VI)2>AG'#:Y+W#!.U>ML+Z
M(VT4MNS+:[0NY=[DVUEE+J(I78R*7]5=]1*QIM$D&P=2-<)V$KZ'3B%NTE01
M-WUNO]J<#(@1GSDX1U!8,+<36_ A0BQ/P6FZ6N)JV\ZQT.7=0/J)RF,=/&+:
M_P DHQAEFT3T]-3PMM'3UQN:1D68CS8229<A*F7&)C4G2X,>2- 44GS,4&X>
MN.<&Z1<AN>YXQHU:-G<?]H"E<FG$7K:=3*V9Y=5.NNB4J=U#(4^N+ZZLV5Q+
MK)<*8D2DK(E(@50GE]4H5J0A:VIN<SLR8;K^Y-C-?=AH!Y1.\NJ#J9LLKV^-
M1';'KW!^O_I!WM!)9:;LWQ2CV:OV.4-];U#&II"7B-Q1D=')G;IW7;X3G)W>
M7MBQ&Y,C9]>M9RFY7Z9W$U676,?@L+C$O;FRF92SSTB6K[2AA\<:USC*G^/E
M,;497S@@DRAU8"8\>O?<U:-N(>>%Y6"W%*5-
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M8NQ([&1R1AB,>?99)WAM88S&&=RD$B?G9:F;VEC8F9&<XNSNZ."LTE*A;FU
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MK-=C'-(@TMPB4YN-TUKB79NSZCJKNO4D?XEL+51TMO<N(->FZR])6VR]*NK
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M((=34->-PIPN*L7>A7,YKLW7O4BCDJJ;GI44U 99<:*(G1514%4GUDTUA7L
M68TQ;T0D.P"ZVHCMJ\2MIE:9LC"1]0RE1&H2TQ')++ER;A/D"B^W^N#U:%Q,
MVT!G5<UH<*^B*;&U>90TZQSK:K3I60]L$@1I,V]CU^D$)5SB)*ER9Z20)2>]
MN]>K.Z=9!DQKJ^V#05:O.C].;7; 6)LTI?7SJM-*R\['==H]IVAOB%05QOU<
M]6QM>2U1*S6ICK>)UU6)30@99%&V9B41XM,VRCEY+?$:1Z)W,[XR&.U#L!H)
MM;:7!IFM5*2N]6&R)F2T+WYCI^6776:"(U7>$NY:TC@>Q09G+236L'V<G%XL
MT2\,*%VD"QMC_?-V0:U>HQL;#]C>;XV-Z?ME$3O'53I7=1=!8&UFOS]B[1)'
M,K+BU7/5'5'"KAARLULE]AM,JKB0V=RBAKR[+*M,CA'?,YC<IX2E7^=IZHU^
MUUM]VI&_+5V_K[7 O3Q!)],W^.7QMC)'J5;E/,WMS"_G'*6L$PD3_85]%L6>
MOSM5E7S3O[&UB5_LA3#((J(<IV2=K(>I==#32.I+!9EF$TW"([TENGL?IXND
M%B;S5PN\(F&O:;.P7RD8SJHB4Q*V]D&.?<,2)7![&02:1XQM! VYIA6<5?I:
M<^7XL&"6)+Z)ZKM\WM.K<D5JU_--=J DO)UB7/%:GA.NDTTWZ?\ )MPU42HH
M^3(8;&6UU0VC?,O>S76(+GUA<$Y9V7)#NR'8F9?U<+!<*MW"BLJ;)U*9CG!J
M;I]PKO4IHL7;O6ZQ)"_LMDSYQ4.6D,ZHQOD5*W1;ED%8,,"L^I+;@3NC;(S&
M(6D/ET)C,H?#S-NE"G*".I%O\VQW'+B!K*8T<ETFQPQ.Q3$[!.R/8F-3/ SM
MYP39/)E&PK6S)S]1+/-X:\(WR>KY+S3)R/GIWEOF0D;F6G+(E*YQ7-QUSO-K
MG#F1GE]^;E.=V(:J:+1HZ*RQ]KS7>NXI"=3*QU!G$'6RU].FMI/-K-MCMLSE
MBB3/R&7N;!#F3DU-5&MM>71J>HDD^O1B4TEUY^HS';(*?]EMJ?6\&,L=MW'6
M:R'3%,ZV8:@(2W0M9*3)221X+S;[A2SV7()BZR=NN:V$\RA.NMA;S=]C*)G6
MLLEFK%?EN*]VDDMK::WIN#=MV(9\JTPVHGE,5'N1'[.B=;ZA5-+XO>$1K)JA
M]+0J%&+F];$TK= )0_PQB?WF0S[/3=3K(U2<:_UUN3>.:VU8+9T_^=JTTBLF
M_)*RUI9IO4-T\32.66:IMQ8[G4QN(>^N<Q+9X] %+$:@8HO,ECI$$K/$HHN2
MVWE<8D^K.U%C4#2,ZO=HI9%MOT:I>TQM_N.X;(X;3;KMN](K?;6BEEA2Z62X
MR&SQDK2$&SF'K)&LBRM7@N<%+64:^NF2R+*\A5T0ND>GOM=5MD;"2[;RZ=I-
MH:;DRFT+VMV:PF90];4>^K[7E<2>L9A,CZK:(3'YO551G1M4DB[&O9UC9B\<
MO_+P]/#JX_O0>Q:CSW?Z=<<IR^=MI79\XU?V.=M\J]MZT-@GR/9;$L$-IY6O
M4VY ;.=CH1"[X99F[3Q.=$(8U-"./1\M/@E8&N-D0XU5)?42ED$2[,;>)-HK
M3VBKR6,.NM=+^F$STI*[VB*:26-E'9FLER^HF*GU2>.6SL45=2>*M#S$K 1R
MC-)".((3E'BX:\2-6KM=T_J\L*R=M-I;KV8D5L.%WTXIU6A[+%3K5L=NJ&"/
M<YZ?NO#[>+?&J@:92FJQ21(;*DTC<77E?'7E.ED+:W/33RWOR+-Q-U$]:F\I
M,T7#NHLA<FGU;790]8Q);0N<@OC<Q#/'!P:ZS:+)YL[3W7'7B)1RGU\"Q?G5
M3'+5MNY+!G+:FET F"2?QIBK^,-[>_2Y8D2A^=TT+;<U>IC&V6$]?/=$MKE#
M595KU[!4Z^PM/;<*JM7,CZXE,;9W!EF5UL-405*\R+U=$O8I;*:U-</8):UB
M1Z4URT[L39)9*XB[.-UG(=F%= ;*.6\4 1S7?B97.1(FJA+$6+"KL@%GM^.O
MFM[]!KZ2Q$RGI#!_8:V8-*?&$TM[(H)*",A+UNM5FZ^ZHP5PJ>V]GTDMMWH0
M[M;,69*G>^[OF<I?=J%V737Q2VJ2LE$P>BHK8"(Q^FZF,)H>DCK9%CI),_8B
MR,J=]>R%-E]L*WLK5&S=G*WUAG>U!D&G6H&MULW#ZC;USW/9"5M(W5:(!M)<
M54.<TE$ME<6N@S4Q=8RPO*L5#,J6/$?C#LSQ[.0,C)EA./2BFU&/&[G4(AFI
MMS7/:NK46HK0=_KEIL:T[GM"O(E,)>\;DI+&.HYTNA]D#OS%9&9$XQG+')J<
M%J-5/VB1,N:WN8PF:FBI]^736]'2+=9%66[Q&JMD.=MWF[SKI<;IU%6MZ5SM
MG,)8>HY+?*!@622+;#2^NMNDYJ1Z,(J&>6+'T[Q/'YM705N>VMSCB>#;TMQJ
M?K.ZA><GFVV%0;PQ*&ZGG].+6&MK!NXB(5IL5*-)J)E3;5U7UW!522H9HK+N
M5W:&2^8O,6)WB+56IZN0OK&QQJ3RMU<_2]SS:A7O'*^+!MMBKW;1'ORRQZKH
M8=,-]G:<+M;L;1C**)M,&UXA")QU5E.N,VH TW*R+!7HE+,QO#S-)C+9I'+,
MC2 QCFR/616#?G9[Q9%P;G-G59)G.^#;/*PA$[O+!D;8&B9=@.*G72^I5[DL
MI.):IQBH$E32FH;+AK)'W8^9$UV^M<N<;#DDL(>J+;Z7[.U55R-U]F=I1+82
MI^G7KE)J@?I[L)NRBL65V$IUI;K27VUJ70NN\88X),3^)RY]X[HNR\+,FJ1K
MG%?/*.PXDRUY&LS)/]+?3(/4K<-\W=5EF=P^;_62]$+LL.."G-.OHW78W%R2
MF88\$J$JHS@W(H]-W2<SGC+@K+GC'LXTDQ>F]BT&@NO$MN#8^=/W3J?-A9^F
MVUU\B505>P3.O:?.VJG"N.RQ-9F<6?+">:N8+&;X\X7DD:\6:=D50^R&31:6
MM2>'K&Q]GJX[$<7&Y;8;-IK.N5CT%0]4*Y8W<4E8;"M2*L,9:$.@VL,BUYAD
MGG%=O[5,(%KN[6L\SQ[7D1YS9(0XVYG#&^1K,"I.O0/M>]/JMANXUO:=1*<V
M1M59U+L%E=<AHB<AG]U7W%[8D-90[8C4QDJ:'V)81<HCEPFQM"Q<-Z]MC3W(
MFA:OY8&?O^C.P3N;8?CE3MR5BLJLYW9EX[1P^TR>G9U::"HZUDDWOJS)SR\T
M#MS:-<UGQ'JU(E7>"\[8KS7UF,G#+%) V/$IL1\@\7G"W)XG48C$G:-CO0YG
MQSDY[*UTB7I;'CT;9J1E.%Y5E>VUEQZ^R^1R$NR&5[86..[=H3YW3MW(DT6:
M9-=,$CLZL9CXSD\24NSC'WTLU"Y:UMPKYD)>[LTEL3E<YKFWH1U$M;*_(8IA
M?>Y3W=S;3J"^J3KV7.D7H"$12#ZBU)I[9%?+95(VV562ZVHWV,Q3UR6/$B1V
M#(V2-QZV%-0:=QJ&Z%[9MMH;&OFP]G]2?8VDYXY3F^+DED.>Z.7V%NM'V>K7
M6JY%+EM8-U?,Y-?5TOCV:.'H'=E=F5N?6]^*<E"A4J@O41UK&3[==(%[=+)V
M/DV]R>>;#F=1&"V7*KS?(]#]@L]'=CV^<YRJ%392XU=5*YFL3B31NAVNNTT1
M9I!3JT\^+MKY$&UH6-FS?:&K-F++ZG2\O6/8SQ:9JV]-TW)++7"GH?;T:D#L
M9L&_\,3%(&R788^L6Q*Y\IG%P,CZM(]GHN#2BCL..<,AJPL)WL6)ZC:TM:J2
MR&*-[_N!LTHZK;]=\VN*MFAIVZ-CS@JY:K:L+3".P=]BNOLAEIO+Q6CQ#V.&
M5;,(WC1JF7JB4DA<F]ZQ>Q938"K3C5@RP]J6OP>);>V\SK%ILR5=1RGJ)M>L
M$+Q$&^MH^=M[%42'85//JN4*)83JK);7CT\CUN0=>K<"4$QD,-99 =PKM="W
M&?N%M\2#;O72^=F.E_T>\86QR+8K8!':99Z[=Z10789B)<.'N/,+U.H962Z"
M.,M4GPN//S2LGLML1;#8G*+<L_E\NALTRRC7RT]EZ*@LOV,8M-*[AO23XMU/
M'K2O6=RZO-<K#V-WX5;.2*)359+9+:T>(=6QM@K9;<UAK[A-([3#/D6@<VMI
MB$?S988G"?3)7<6BME49<.V[UKQ76Y.P\6KNT9U?&R_-.(;#EVH2AYA4(I><
MNLP2/,WJERN=K8XB3C/'64QATFSW9U/M+LX5V\OL,SQQ#8,+D%7:WNG42NS;
M2'M2_HY:1S?4)]KVP=B(T[SS:%XK:2.>Q,M:GFK',ETMG<I#)BJ541N*6"HD
MSHH:G4E>RQ5R[_SI:J_4IB6R$YU)ZD6R.Q%D;,,6XFJ.N>HED5VTQBZ[=@<0
MJ/9)@Z=FO5K6>Y1FI87*6:O'-6_W2KD)$TC\@C<ECC@7D\LY;0EP?9-P\3=+
M['=H5UD$_J4]E]V/DEV?@,*15(ALG;VF+VI2OY#5D>C3J<AI7A%)=4MA](HV
M=FY7%)9V8W5DYHI*H>%6<IELD:4")QGKK,64Q(K:UWK*<*5T8AJR 6S,4TCL
MF^-IZ5URDLK*=X(R-\-)CNGL+<K1OK8E$AS7.%>5HYV'!VIJCCS)'U@9)W*3
MTB9ATF3*%I[MU>C,TO6;;&2*^[1Z .^<2K_A9<NSL7=[6O*E9-+5356CK$$$
M]1D3B6EQ)D6*YK5,^1R%RGQ#09E9#++G-L-/PD+J$7I#%,0L''7RS+*3&5!H
MY6Z[4V;3;:_?R03><NB>LY/,T%G:?UC337@GM1_;9<:EBUOWAL/<\Y41Z6UP
M8RSV)QVOXPN72/8:HLVHU^SEF/NW]M[=L.TZ>]-7U^C4/H::7&T9V!K^[5G0
MSFVE4[5D56FTA;<2G-JK;O;-HG69QB0'MD?RE)$C=8K'8S UC!$])TI*J/H;
M1S9:AG^YDVR5I;[[=5<_-T@M^U76L)'!),[[ZN3'6[Q2SG*O!"SP,J7PBOI
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M6EOKQ^E>$+-P5PZ 2Q$<<XRV,58Z8/,?:R7+G@J/MC@W$-V9I3@?SC98
M                                              >.SCX./Y!V<=G9
MV<=GO=G9[G9\'8//9Q\' \=SC\''\N [..WM[..WX>SW0[..WM[..WX>SW?@
M_P#(>>>..??XXY_C[H\=G';V]G';\/9[OO=GO_P]S^ =G'/O\<<_] [G'_EX
M_EQ\'9_Y>Y_ .SCX./Y<!V<>]V<=G'O<=G'N!V<?!Q_(>>SCM[>SCMY]_G_4
M
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MJAOEUAD-4,V;$?L3347:XXTU5;?:Z+,%,:*AT%-=X7C"YV="8SE,.&PG92
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MYGQT+A5<(E"2,P9BC<3BL=CE?UU"(=&H^T-?/K-FCR4US<GIZ4N3NMM*
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MFRM">H>D^YD
M   4VW?UJ?MNZKB]!Y/#>U5#+[7@#ALBDYD$LB\FEM'PQSSFSQ7T+>X9ZT>F
MQUGLMCT-BTA7IY#%E"2OG.9YMKU@[\MZ53J8WNZ<JK7G6;J$OFJ/,Q65[L)I
M!)H98]?3&SKZV(M!UOB"/17-03J$*+:DUGOKFB-@TJG<4F,;+DS0G-Q8Z],:
MVM7Z@[&$S3/^GKMYL;8['>6PEBZ[(;%@4KTL8X!':B;+!;X4;5^N^\U.[<W%
M+),X2I$X2#FQ+52U$R,D)@Z$DV)5X>BX:ULSD^#XY2E),4[T$L^5['SFY4<N
M@:5@E.]VHVU:1L5'R#OLGAVO>N+;3,GCRC EC,1XR9Z?D1CHPEE*SFHQISQS
M<7-O6<\H^+T;6U,]7WJ[LC1D;<&IID=ST'<-3Q]V?<E>#*UO=BUY(H>U.+OF
M@2KEV#6B7O"=2X9HD2M7BD*.Y3)5!W&!6<+3G5^;S9]T&2+9#'.:[U5E'-AV
M1'\SW7A1.9O%J+E-75=DT)RV[A*L:HQ+9FOGV7#VJ0<)G>.19P3MZQQ2$YMU
MDFZ4V INV80I7#TJ:K&:KJZD\?G_  >Y<+GB?R.5V>UR^'F)3D);1FDCD=B\
M(>B%+:Y+'' Z4J2GI"VILV%0[:N['UIZB4PW57[!.[9IK;53U[(T'&JT L>W
MKYC:>D6CAK-:9%9IU?QVD9%$I-L+)2'1_3E3UWD+CA"8PK(AM?\ L;(73)\F
M'6S'I];2/3O:>O[)8E$IM'+PV^;=M9NN<F^>Y[)1\ARMV+;"6E2<9;TQ/-=N
M;+8=O1ERS268YR!N?(9"9V]LJ"&NKM'X^]CWZV:N=0M@V0DMY[7-.FMKOEC*
M9+$9#8K#;]]KY34="NBU2L:*;UVK9[I-CAD+8<.$T?SG*[V4(9/:<A;^)7.Y
M0\'M,3:8][-<]!MK(,]Z1U5<]ET9(-6NG O<E^O:J"-<X2W/;!T<I:>:V47S
M;K<[D)8=!>*QI>RY,GD7$.?IEC8LU3,SV9A%VLM8RG[GP
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M0QF'IBSI+)V="?L0
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MC.Y[O+E
M   _')>&66&>6/'.>'//.&7/';SCSSCSCSSC\'/..66/;[_9EEQ[W//;^P
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M 'JW?34_X@=^F?\ >K=]-3_B!WZ9_P!ZMWTU/^('?IG_ 'JW?34_X@=^F?\
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M 'JW?34_X@=^F?\ >K=]-3_B!WZ9_P!ZMWTU/^('?IG_ 'JW?34_X@=^F?\
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M[..>YRR+RRXXY[.>.>SGW>..>.WW^.WD@ #2>K_^5JO_ &@[_P"\R''
M                                                  !L&U$_^9$D
M_P#M4;_^$-(MD  -<9^JMG&'G&8GQ?N3#3,\>UU5\<]SGGEEQV\=Z^>SGLY]
MWW>1ZO%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\
M;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2
ML_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/R
ML/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^
M[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\
M;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2
ML_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/R
ML/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^
M[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\
M;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2
ML_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/R
ML/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^
M[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\
M;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2
ML_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/R
ML/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^
M[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\
M;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2
ML_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/R
ML/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^
M[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\ ;Q;^[+/RL/%2L_\
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ML<I4^15%L>ZGEQ%"5"'/@U>1($V.:69E1[AM:2^>7Y-SC],H
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M?^V.ZI:ZO+\M6N[QHNP(]7U?PK29]>YO FUGG3)3T@VT-=HZ<UW!,D<T):)
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MGJ),E;'AY8K'CT(30V'G,]P50BR7F(GLY[4%*#715RG0'YX%EDXY98<&L.K
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MV#DK&VOK'4*UV+DW,UY?UW?IECN<F2P-36C?/'9'7;I.D,ZY-CQ=^P
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M?Y''4,U<8HE@ZF;-3^L>TL/L^+QQQ*8T6U$
M
M
M
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MC5.(F_\ $002A6_*HZ])WY$A4M1*M4GL2
M                      _!G'/.&?''';SSCSQQQ_T_Z_\ 3W.?=&@VK>CM
M8%7ZK[04\UW5&3K:F-Q4?,-3+'-CCKDU:^UGIY)H)+M.J[6-6:G)4XEUF]19
M^.D&;1FC1/*68O;:G)+;51J7GE,_2%L*!$TTX5_:\).?:6J#IB1%O+E;#(3D
M<WL+1"YMD+9LB5RER0+>^"0FZU^P2QP)6I4R]R;9"WN*IQ3*R7+#)/:"D- )
M;5+]I\ZK[ 8'8K6>X=_+->2TK0XD9RA'N/8%KS6/M;9D<HRX0*8618B1 \GJ
M^#2G,YM4&H<2<#R\<>WVYU*V3MN>2:0578FM<ZJZQ8-&HE,=<=WJ)?=@J?BD
MGB:B3\HK5JQJ99]#>]+Q(&R1E,\_A3PE6LLNXCL=<T;Y&5Z9SR=M>L;Z<NT,
M=M*_-78#:" BBI?TJ-,=+9Q?EL5?(']^F6;9*]ZV.=/-1'M,R:(VW3*MX=/T
MV!-?OID@8V9%8U=K7!T.113%GFMA*VZ0$?K+8%UE#030CO32J^UVQK0[RNJ'
M62[(QM]<VL@U76S-.G.4&PQ*Q(YYBHF3!9/L4YG;"QJLX*A1^O2$T^3^_P F
M]M*IUDKO3MSV6K;BA]>X90E:4^VL=3KVZ2SR+4+>-!SZ#2*Z7IUD<A-33&(U
MC2!E?I$];YL$?ELIF3W.Y"G1HB66'LN+P[I47D@V0B%ZV'?,7L=PA4JW"6>R
MR0>&M\L>91C9:$V#%HBWKRIA;$KK.N4M5HY+&(WQ#:E@T4B4C:H]B^)BXXH)
M31O*S,AZ>V4QTQT&U+FCI!IBUZEO.G:RQ"Y/%,7Z'6FT:SQ)KC4B9<(R[<*T
MW"29YM^9Z%.]E+4R4DS$I<2?EQR(PF72SR9D&PM8:[/=<5'KKL!:>KNPW@J1
MPS-O15C>5'[%5=:EEK8(1'^$+<C@=SPVM6_A7$^"$Z:*6CPYRIHPR;YF^HD5
M':XUKVKDE\ZVZT-T*ED7USU$N#J 2 J26+2DAB3LEAUXT]LY6%3KU%Q)YW(*
MGMG+OK>Z'&-(ZJ(4O\B@O)\IM=HI>9QPV"2&U\\Z4MBR6J:]@K3;D.1OE>]/
MG5K49"XN$9>E30YSW6JZJUN4F6+$Z=R3+$T1EBFNBV U(0::\M!+MDY8XK\T
MG")1*,?Z?ML%[JQK:99+Z<KKA%8SO8=A/M$Q:Q*XLR](^Y5L[P]JI&]D;;.R
M*DMB,Q&0.S:\MUK3. .E@+6*OX2R(&N+/>#A+\N[VTT&M2[9EM ;5]JP>&5_
MO5K5$-5]FD$PACY))7'X1%C+:8U4PIAQ:9(RM:>8/U<WA.8J8WR]$M8VI\;X
M?,",EF#:]QN06CU3UP<-=%6RG*I^0O:&[ME)->+ 0C3*4YL<8GNMJJ@:.-N1
MBDPSU\Y(S*Z4+CER?N$YI3DG+Q+Q,),YRMJ
M                        @7:J0O<1U?V0E<9=%C')(Q0MP2&/O3<=DG<&
M=[9:]D3DU.B$_#_C(6-Z],G5I3L/^(L\G#/'W<>!\Y&F]V7X=>>CC&S.W4QB
M$B?Z<.V)V5\>NYZ7EU#W/KPVTXY)9JZ4#&FFR+*FTGGR&Y)+5KXS(XB3#G.
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MS;6!,R%UH_M#-&_7<^S-,DJ/?&
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M3](%_,I7ICI,G2.Q%U0
M
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M1Y3J8P3,GE9X4E&Q\&N*7QE=CD@;^$'L#1UC8\'=6S+!TQ=,U7,A7O'&: Q
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M]^SFN_\ +#VD+JY\N*_?LYKO_+#VD+JY\N*_?LYKO_+#VD+JY\N*_?LYKO\
MRP]I"ZN?+BOW[.:[_P L/:0NKGRXK]^SFN_\L/:0NKGRXK]^SFN_\L/:0NKG
MRXK]^SFN_P#+#VD+JY\N*_?LYKO_ "P]I"ZN?+BOW[.:[_RP]I"ZN?+BOW[.
M:[_RP]I"ZN?+BOW[.:[_ ,L/:0NKGRXK]^SFN_\ +#VD+JY\N*_?LYKO_+#V
MD+JY\N*_?LYKO_+#VD+JY\N*_?LYKO\ RP]I"ZN?+BOW[.:[_P L/:0NKGRX
MK]^SFN_\L/:0NKGRXK]^SFN_\L/:0NKGRXK]^SFN_P#+#VD+JY\N*_?LYKO_
M "P]I"ZN?+BOW[.:[_RP]I"ZN?+BOW[.:[_RP]I"ZN?+BOW[.:[_ ,L/:0NK
MGRXK]^SFN_\ +#VD+JY\N*_?LYKO_+#VD+JY\N*_?LYKO_+#VD+JY\N*_?LY
MKO\ RP]I"ZN?+BOW[.:[_P L/:0NKGRXK]^SFN_\L/:0NKGRXK]^SFN_\L/:
M0NKGRXK]^SFN_P#+#VD+JY\N*_?LYKO_ "P]I"ZN?+BOW[.:[_RP]I"ZN?+B
MOW[.:[_RP]I"ZN?+BOW[.:[_ ,L/:0NKGRXK]^SFN_\ +#VD+JY\N*_?LYKO
M_+#VD+JY\N*_?LYKO_+#VD+JY\N*_?LYKO\ RP]I"ZN?+BOW[.:[_P L/:0N
MKGRXK]^SFN_\L/:0NKGRXK]^SFN_\L/:0NKGRXK]^SFN_P#+#VD+JY\N*_?L
MYKO_ "P]I"ZN?+BOW[.:[_RP]I"ZN?+BOW[.:[_RP]I"ZN?+BOW[.:[_ ,L/
M:0NKGRXK]^SFN_\ +#VD+JY\N*_?LYKO_+#VD+JY\N*_?LYKO_+#VD+JY\N*
M_?LYKO\ RP]I"ZN?+BOW[.:[_P L/:0NKGRXK]^SFN_\L/:0NKGRXK]^SFN_
M\L/:0NKGRXK]^SFN_P#+#VD+JY\N*_?LYKO_ "P]I"ZN?+BOW[.:[_RP]I"Z
MN?+BOW[.:[_RP]I"ZN?+BOW[.:[_ ,L/:0NKGRXK]^SFN_\ +#VD+JY\N*_?
MLYKO_+#VD+JY\N*_?LYKO_+'T,](+I-U[TA**LBBZYMN97 U6/;*NV5K]-6-
MD87!M<%</B</R:$J9B,-3'(\$T33K,3S<N#^3U9Q?/'J>&'(VS    #5;U'+
MRW&UXC,ON6G;$U@KFHJOJ[F0-4?MNOI_:=F;+["+G=W21#6V'M42L&N>(27.
ML$L=C41>XXGM6?RJ=S-,W-$$3IHWF1*MFL7<'=WC4==9 R91E^<V)H<'N-YK
MB'/./NZUO3J7)DS<DN!:9QR:5AIR#)<G++(5\I^5!6&)9F./'>C3Z_\ 4'LN
MK^IO.];+2CL9)U(.C.MD%BUM($RI,^UQLI?A5DKX#';)5FK#$&<%N+*#+H-#
MW[!(BX9;1*AT15\JS;$;SD>&4[U:' _7F'3F>4M85OS^.:[R7:C9=32"""M,
M?INCV^U;5@3%*SV:?V*P/4E>I BJ&Q')AA,*QDK^\):UF1F):1P,CC2_2=U7
M]SKRU=U,K2\]1$4&G4OF]N0-O:VV5M"Y^:)K7:^ SZRWAJCI:!W8S4TCEK'#
M"6N*NIRK-*C7NB<Y2D.+YYXQAB7=4"?N/47H2G*C0,LQU%?==%]I6<[LD*?)
M5:TLG$KH2W=BJ[BU7IVASX,5+D59UY$7YPCY+ XN;^=:,8;&LSA1GGP7,\2Z
MN=5NC!?#U-**O2"*=:F&A+#NIC3'TU9+K6]-;!N$T;F>U9H36-M2G%D05=E7
M,Z<;UA>/*ZQ:ZC\=4R0F*R)B-)<.<<DW5TIQE-<[>3--RK=?H[JUN!L8T<-]
M40Q6=?=>ZQV?K7!%-RTS+UUT-3@;#) KN!>W54U2&"-2*Y&=0IL=#*XM#VF#
M*K6R%WZKK;%)A846GFGFS\&1TW8- PZY90]+=?%S173)M'(8S%Z1F2M+';P>
MWN2IG=YE!!$QCD0:WR30<IF?3UK<OPX8/9#GKQU4->V2JH;<"J(W$9&)S4VY
MUR-"-/'H9D^$1?1CE7Q;J)Q3&S\E 2^OOK(WFO4J9R5M[OQD7S(W2)]N7&$0
MR+K!1^(\V*IE.FNUD?9*BJJF]BK->W([7GDB'ZX7L[2!B@-G+F]!>Z]Y5O2A
MSA5A9.M8M;>MFK4W0&0J%"/E>?'FM\W%    HKU+-AIKJII1<]\UY(8?$99!
M\JX)02R?L9LDAD61RZV8)!WV2R%B)?8R8YM["P25S=LTWL@:,,LT9>1BTDO'
M/(:VJ>ZJ\AA<AN1[FM_U/U$=;:RI1DL:07EII0RZO%M=6C(+F@=2Q6CWK%]O
MJQ*TF+]8#?-5LY8$:&;1F3QUI@<J/?6Q<B>XGD;8V==9.CZHM$^I+;K29UK*
MX6[53'+R122S-:>'6GI#=+P0WP5'Q$T5WJ)E:B$MC=8G8<M=*DC\P)BM>S>-
MNBPH]_)D\8C<&Q/J_P GA\LN<S82N5<:R==L;FUMUHJE?(-;*H(4L.N*)0JM
M"=3>ZIYM KB"A6GR4QY&Z)EZ>%$E2.70N,P=IFB=;(9.QV(PZPM&/D3,L"N*
M?OFT(*P:A\[MV/(XHFI].GKVER72ZHPZ-ZXN16^R<2.Q6&9T5,8V[QJ)G/#-
MGV$N['*GQM)5FDXK;76EI6CLTJ2TJ;LR$/2:H"=C99&938FL<=DT<U_>GAV0
M0F=MC,\WPB53^2S1OCDO=VVJ8!C(;"1<0>4-3FS)G8^%I)GR;AZGKVKEE3MF
MN=1S&4U5(=\:%U"EVR;F1!%U5+'*8R)C+LUFCC*58B*S<,6=N=\HBWV"HA.<
M;)LI$XQ_A.L2ID[FME7J$[&[#T<^4RR5<XM51U1-4UBK+<VH?-:;9VV:*C=8
MMA#.:]A3A4U.2N'O,=26AD^2Q:KN.9NW-=PI% %4?=4^#_-HRXMU76OJ7;%,
MSWIFFX@=6[;([FH;J"V%/W'3"2Q-3$I0;J?9VML=@UA1)_N"S8RAKUJ<X?9$
MO3SVK'I_FDLC%KNT?KXYZ-3,+U),9]LCJVT_7D6IJT,J?NAVI&WZRUPMLBW%
M1=;PQB:8GM(_MK#7B-C9)W84<E-JR^-%NK=(+8B-2M$S=J^CKJPJ%&#FZOS8
MS'_BQ>K;4U;I)H\/5.VLABK!LM(M.HC-)1)Z!@,3L;8R&OTC02V)M#O-+G9B
MXS%6:+Q22V)[/9SA'&=7%8M*$9)'$Q0L\5D&$<=:V@7A!3A4#K2>3R96UG>R
M7B#-UB:VL"IK?=<9BP0:QH/&)E+[O8*SN*Q71VD;>YUK$:>FLT.G,1]4EN*U
MF9>4Z@_<BG.Y4)R#^2C2.3BBS>2#^,,3R>3,.,N2CL2\S,,32^WN#,<3,\>,
M^.>.,LN..WGW                 (JO979R"DK@7TIBU9W&@K">KJH*?6TU
MX9#K(1Q9T4PA.\-1"M >Y-:B2E-A#@B(7(SU*0PXDE4G,SQ-PTSINJK9,_V(
MT=<*Q00<[4NU*FU#DFRSJI;%JN41:=]0ECN-NUG9HY(N'7!N:<F:QZRC##+V
M->VKUZI):<6SY5MIQZ'!RBU@ZOU]*IVF2L]?9VFW65LEK_%H#%(Y 87'VR+:
MS7GNIN/K= [%\(<LV*B3A-; M"&ZQEO[.Q\P5GC,*6.\=?EKU*VB4.C1#+1:
MJ]5!PE:!C;=G:IF%=)95-M^F^(7TG3P4JGI1']+[ELUK?R"6)IL*26<Q&M%1
MQ5,M4O\ )8<TM4BDT1G.*/A 09%^)!)"#JP5HVQE1)K3H6_J@Q=:NJ:]:S8I
M0FJEVD5H4S<5MP6F&.7,R.+6D\HHZ\1*76;7Q]DPN8N3$_Q=GF3">A+D#@>K
M;$/LM[J/.<;VYI#5^JZ6FTUY=-WR]1-@9:N)@")HBW#MH0X[KLC[ C7.WXT]
MN&:=@?(B[/:U9$W3'"+U]=C&VL"V;**?2S^&NH/O--*"VYJRB>-UM8M'JYE6
MN,NMI1/]BJDXM#&7S9DLR.0]%#8_B?=U,)6S+AB=U[T?SPK=SS.&W/CA,67E
MF86BW5<FM>:AUY?%^:_3B<.SDP[(3.2SNL&>-4M4<@J37RQ'B+1VVHSELK9D
M/,:'K8Z!$,%N4M1BB4R&>OL7<7U64L-9&#%[7W@IW=J+WW<\KJFKZHMAYCT"
M9*Y=IO<:\J ,T 9,[@I^,7;6B1,V+IYC8KQR^1"3$(G4Q%!^[C<CX2(G%/RU
M+\7M/4ZP=_;4J6J>H9'I,CA3SL_K?=C'5.N\<3M#FA8[-YVTSB)>B2AV:"G-
M2X.1+M,;)1U3/US*K1\+7:J[ >DR5G)),X3RZMZB#'76PM9:OVE6%EI7N:V1
M']?6^Z5A%=1&)3JXUE1J;0/?895;M8F5T.5/.N#4[1=):#-!WB'HK 2KXIFX
MGM[0ODA<':^=6>*+-.C;MO\ C4L6V#573UJ[?N[^*SC+ 3''6$V.^7=&T['7
M"%_G:54;+4[G0LP-4LL@5-#(0B<(X81+%IZQS3M$GN?5MUM:]I#M9#DSB8H2
M7Y'=6ET^QG-,%)D]\RAI:5[3&2*K4V81>SG%._C\S5VNL-LK%7&D5D+LV0TS
MEC;'J4-FTP            !K-V;Z?4\O_9V [/1?<&RJ@>ZL@IL1KB")*JHZ
MU8'"'MR<5ZN26=&62WH5+TK1:$C;U22,*ILC(+?VZ)H,HZRKVYL>) G=;[0R
M,RZ/JY ?)['=IXF=,HYRS(G./15C+C&+3%F=E>\$9T<:FU0Y<2F0('.9+.7<
MQ9DV+WU2T,W*-A1-R!-G@I9.-%J@L^3;<.]D&.TNCVX]:U+6-B1!3RF1(F1J
MI]!/DL<>HD[(BRWEIE!*R>FOS:_E*N'&-R)@87N/GH7%"6HQJ+&>CQ#813\<
MJ"%[,WI&$:[6'/3R]I0C15NXR:_J,]F=C35(CD"Z00]Y]ALZ9UMQ6VW,LZA?
M>U<B;[(DAQR%8\IXR[1Z^]NZO06V637N-&JEL6CNN5P5U;</964A&>A79UK&
MY'%F2(N1;D6JRXCQK7(S2E').6*WN4:?#$_N<C>[UNPKH8:]0RIRJ?(N"\5;
M'WRV&]7DA;RPMT[)BEY:O(M.X]#6:3)67U1F:Z0HEAB,8J_,I(HQ19Q9!FXI
MEB$T]ORRF)]'>"1UOM=C47M-N(OL! =<*BO*)P&MJ8I".3"G-=9#<#YC54>:
M:7A,&1P6)V^FN%[CEN*&HI5)W>-=\F>-2*+(WC$IMY+WT<ZH=H9):P3W'9[=
M6&6MNTFI]50[A-'%V%+T?M!/Z&L99!8H[+4)K@Z,-2N]%-[%4R-^R6&,,(?L
MHHO5.B*.L!J6QEL]/^!VXZ[,NKO.Y>UF[.R/4Z228IN3,V9<=4ZD3%AF<1(8
M^5*0S(TF3K&!.CD/*_D_,I*>=DVY)SN"\\*W*>CS"EK,OACALE=+G6Z"K-XJ
M>K6!+V:K<&^M(?O=@L.L?UB\M4):I)*G>++W!1Q$'*8.SOD2SI&IM7DJEI3R
M\/TX6CTW:ZM-IV0:'2PIJVD[*:E:^ZBR0U E8LS8_$=>7^\)!'I0R^N$1F)L
MA?5%YOA#P2NX.;2R69JY1)R<\U>1NQL   $![.4 P[/TQ(Z5DSZ[QMEDCY7K
MXI>&(M$:YISJ[L>)62WD$X.!)Z3DI>Y1%(WK.3"LL\42I1D1S@?P7GBV<U_8
M-H*2F-'R9\=XVRS)7#5BUZ8BT9KJESADYC4Z18)RW D])EBK71E,A4^JE9<X
MI%!^17<G<%Y8UXFV@+%)=AYE?,7N>R:U3VX[53(;R@$4:J\4H+'D%-(VUFBS
MLWS.01!WG]='2"(,,:@%BX0B1-F,JA,::4"#F./'?!^7X/).F1#ECB3-(7<$
MV@=LL^Q^PNQ$4L$N*UW,R&HS9TI*FM6LW>%3B-/L6DD%<2VQ@<&[-4D221LD
M44C#PF?<2D3@W.N0N?3?@+JS74T+K5M!W.O'15)HI*I#(CXZZR3**DNEXO*Z
MR\UA#*V-YLX=G&]I(>H;TK4W0] 6V-*%CC[4UD\(</S:/3I8)S.&.PH9>%F4
M[)S:!AVLME.D,8ZT>%]B537[G('>%9I5TZADH55[8$1636P,8U/H28W.;8GG
M+USFF5KD,:7L.+R'IB,+C8[,_P =V(N"(5$U;;P3=HS7]O:ZW<8>NO.(N#>Z
MO1Q\O=8>ILCB&3=Z;N)@^Q;F5&<IYXO<Y VN:=M4$QU+/FR>I"^[9S75QUK?
MEI:T7E5[%,(:P6-6K? 90@?H!/UL7<99!K KZT(G,H7,&4]TAT>?(^M.;4$B
MB;\W^O6%\2HW-_;'F'JLZ9]=U=)X+.<;7M*<3R.PC<V/S::37*)'/=JS+>*8
MT9-[8L>2)8W'(U&V%S:W.B(\AB$;A<?CT4:65P4H<VH\U,2JSK*_=#6FWACC
MD?(NZQ$:)CU^U1H0]:L@-)2:4&MNH#8RM=?.$<G4HKUWG=>,LLP8TBVS(/ 9
M-'V"2NGKAQ;\F)2[23-^M+*NFY )% 7:+H+)FT=EA&Y\_P!Z*[L1(TPUW<Z\
MN*PG&8<O* F.25A>(I*(:KB5@SFO71FD34I4.,4E+IZBX-SY@W/*#%+<Z9)5
MQTYC2LKV@MMVB<FCEAQFWD,K@=!SYAL,NRWY4_.4D9(7,*L=8?5<TA>"]?'J
MJ>8$S-[9#HN<E;G)@E"YI:75%LHB,8:H3%(S#&+!3@QQ&/LT89L%JQ4XK,&I
MA;DS4WXJW!<<H6KU.*1(3PH6K#SE2HWC,]0:8:9GGSD(
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M9H<UQ%BGQ ZVFJ!2AQCS1-977#;,D[*]3,EP-S4DQ&0R2'.^P$
M
M
M
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MG44D9+,TNBW)>PNN;@WG*L6QXP;[*@
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M(JJ4*%Z_)W5(.*YS7YO&/"+%3BZ%D>LBS$IARBU@
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MLFE@*&ZGQ3-'2%VAR^K84CL5S96Z#PA'54U:V-C0J[%,*XEJ/?N
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M?56$FD);C(TB-U3W'
M
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M)F#&H02R8;'V0QI421QY*/<TIT64G+DF.:=,J1&Y<*,=@8
M                                                      \9=USQ
MSW//'&7^G//N\<?[]G^O\/\ 7X>/?&L[12P=D)'??4)@.R=AQ*;O-1WA3[-#
MF^OXRMBD"@L7G.LU46;S#XTF>G5[D3QBW.4M5<.LJD#EBME+UZ_?$K'$6M<A
MB3)LQXYXYX[>.>.>.?>YXY[>.?\ KP,#M1WEC!65AO<"9O9%.6B#RQSAD?\
M7;2@Y?98@87!7'6;A>_+&YB1<NCP2C0\*WIP0M*;U?U9Q6)DF!QV'S7P:_\
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MN5>W7/?JSMI;IT17\X80!EF,SZDM5VY#(WE)/8?.7[5]VCD-B<O;TU@1&'6
MUM3AF4?+&EAE$=8G^/'/RIB=RW/)N+<EE(]Q=H;)@^T74:52>U^J-&H)1EB4
M3":I7ZAEZ]D:]UPNG^J6O\I;$=FOUV,RMCC:QVMB>JW=]?IRJ+KMK:7Y"HD[
M@A9^%GJ=OCMW=FJ8NBA-9;'BS+,=R;;U8Z?<;?RE]AXL^M[;L7;16[T@O:3E
MQ^,P)Q?6IOCC'J?93T6Y,C^ZIK$R*KB"-K-!"$2^8K\8RWCW?N/8[7*!UG Z
MA@4];K5ZD%$VG7\CMB6NU+R]=K&V4AA%;*YD#/5!,V4DK'&4+3F"*X,+4K9D
MTG/4.SPY'L_+>NQBK>J1M_:*B]+[KZ@4-@UFHZ;'33VLI_7J+ODBF5A,$RVN
ML"]&2P75<BA=,*)C-6^,LL3D;S*6.*G25^60^DH>=6T/5S.V9.PQ#9?K]O$R
M6+J1;6STR=*UD+=1_-MJ)X71SM-'?E&AJF->S-R:9!#+2AU<6#65GX1PQ,:]
MU5.68EX83U;<>8[+&YV1*Q3F3]4N_:CAISA;^O56GSR<4/0FQM,Q> 6_)%$?
M/BUR[#5+K](J_L:5OE9%*&J5UFYW9 7PJ4QV.N['/B%KPD2LD5Y8>%#ON4KL
MZP5$-9#+411%OG_K<S"2)H$X/3I$/7A:@W H]C62)J9GKE*K28IU>:5>@X.;
MU!QS=PL<RTN#FKS4                5]/UGK/U[L0[-6<SBS_M&K97"V91
M#)],HA*E#G'*XC]4,;M$)+'7MN>J_=VJ%19D0HG2&+61<0N1]^"S^'0TU5G8
M##'N,>,>WM[.WW?A[>>>>?A_UY^'G^/(Q>=0>)V9"I;74\86V50>>1I\ATQC
M#PGQ5M$BB\E;%3,_,;HESYXQ4-[JUK52%81ESQP:G/,PYYX[KM%+8_TR]16.
MNK>K)PBEB3UDO&/0^(SY]MB^KVMBQ#(G6[NXR"KHS%K/L.QI)8$!9:MD+JMD
ME=(X-(H]Q$I.=E*&K(F1<Y.F7!RZ8&IV57)*OQ;;?(-17&KV$(MY-L7?2;9'
MPVN,0SKMRLH[8\FQ<+H4R-QK<SFN5N:B:&H3X'@1%,D7>5(D1D6\IBG*YU]J
MV$TQ4D<*B=<UXRDL$582UKFZ&(T)9IJDXY<\/BUS?'QV<5RA4YO3Z^.3B]/;
MLL6NKLO6."Q2I-DX       %/]A]&J%V8E\?L:<%VA#K-C,;70AOM"BKON'7
MNQU4"<EW?5= 'Z94M-H.]R:$&N_:\IXS(E3FV-CN:J<VDE M7+CU."/73)T[
M<F*OHPSU_)Z^CU<UHX4NA:*KMJVJR32ZH'AZ.DKY6EIF0F;,BRV(F^R-8ZO[
MRFL-5(USB\2*7."A?FIF4L,>9*==)M>7E!9K6LB"K!NM[8.C]H)PA1R!_0I5
MUQZZ8T+A4KZWDI'(G!D:XX7K13Y9L8:.$<>=2XXIP<VU5B]O'"S &KILZEM1
M\WPPALQ<(Y-FZS6O"OW>X+?<ZVK]-=#@I=[7-IR!JISG&J;<9N[K5KDM>:U;
MXR\,IZY>3$UT>1.*]*IF.C=6JLU\-G[C!S9\\RNT36$R>V#9UG3^VK$DA439
MS6&)-RR9V+(9&]DLD6;%"TMA84"E&SMZQT>W<M%R\OSTX+^D+TPU^(UV@NK:
M>*.2>IJW=JYDL.3%2N3XRMIF%5V(Q6U#YOC.^7;F7J)FFLF/-\Q<I(J>#G-\
M><UYKP>N)<W A3,]KU?#+KJVRZ:L-M.=H!;E?S*L)TU)EZYJ4ND-GL=<HK)F
MXAT;3TKDW'+65V7)BE[>I3K49AO"A(>2>7@9C['^L8+*ZR=J<E4;;)/6L@A*
MNN9#$9 GQ=FA^A+BR9QQSCSRF6<F\.+>Y,AIS<N+4\F<J2#C>#<LN<\N>:AU
M9TT-3:I=7UW31NQ[*/>*TE-+MZ6_[VN[8AIA5/38I(FEE85RSW98$Z;(%#9&
M@;VUK?6V,)6XYX:&U U.:I6WI2DV/(8NFWJLQP^6PLV/6!*D4S\!:1V>[$N:
MVK(F9$;UIGR2S:.@S1-)U,I!)F:"5_-4IKZW19L<TS:XK75]4OQ;LI>W(]1E
M=G:&ZUW! MFZUGT-<'>)[>6%%;5O!(5*9.VK7NP(/$*AA$0D\?=FYV2N<)<X
MXRT35YS0?$53/DA>HT6_$<X.RQ:K/XMC: ZR6A+$,N?XG)6=277T2J61Q^ V
M38]:P:R*J@+JYO,&K2V8' I5'8C9\&BBM]D29HC<U9WANP89/*XFH)41242!
MD<>UDFCNO<GC$KBJM@DK<FE^R#;MHN=8_.YE'I$VWVTKH^X-\XC[\SO:-R8\
MTYT9;"^&9 >4Q9IO79!K;G@L4<9Q"]]*[4)ZYCQI++:T561F.7/#6]UKJ_KL
MK-\.ANPMMNEWW'$G1\@$\CCL[1R<6&\+G9>TN"Q0E1EXMY#5@@[RLQC?ECST
MW=3G3-4J;(3(8&\<3"MIW'))5MB3^L)/7LDJ:F4VO,+.K=_@LD8G.$-B:E$Y
MM;/$>8U":/2:+N#HWR-K="UZCNI==M3:->M8)?IXOBR\VAY[74ZJZ7QTR4RI
M2_R",V:F>R)^J>)VN>5<X=99,%$D?GF1S=SD*R7/<C=W&1N;RK>EJE<9(-PT
M_!;VINS:%LEM4/%9V_6\PJ>>LR5R7M"IV@\\C3C$9.UD.[4H2.C8<N8G5:E+
M<6Y6F7HS#<5*102H++,Q@BS-$-<[:L(JRY>Q3+!_5Q.&0.:-L7M.SH3#+;A5
M=/3K(8)%;J@D1EK-$;:8HNZ/\@[WH)VSO91[3('Z,NO#C%WAP95''G.@^N$^
M=II)G-BF3'-)O>K-LFJL""V=8< GT>N1DI&*:X$RJ%3"&R5E?(B2Y4E#FRO9
M%'V56FCDF85;V0_M3CD]N62CLX[HSK=%2U)3)#71-Z]H*7:U.!ZF:3-V<76K
MY[*W.=3;!\>'M_<GE_F<MF3V\RB2V*]N#A.GU_=G)W=7]6O7*3S.CGO3[UJL
M)KJEK<F:P8WQ3U5<41&G.M[EMJKGYXI$Q&P(EU2SM^KR9QEVGT%<\(PR*%;1
M*U;IF4O1F.+<I0+7!T/78_,^FCJ/-[ ;;#<(=,F54V6?2%U80N%VY:T)J1;;
MNNJN&FU'8SM3T7F+76;K*HRVU]#HV:O7Q8_![C<<8FQ](<N\;*>WWW
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M>U*_4EB7!6GR.)PQ-PYYRT
M         %=MOT2QRU,VA;FY(I7N"_7:[$2% B(-5+%JQ56LF(3)$B8C',]0
MJ4G&8$IR"<,S33<\"R\,L\N,>=$U;4WMQ%IATHENT=ME6Q1D?KN-R&@BH/0+
M95KA3^WI.N+[$:TK_8EV+=IK)U58RB!2Z8,C1)6=U@:-3:\<9HU/D)I<GC*7
M*L] &[=22DK!5S/:+9: V4]:73=LV]+C52[L6E+Z?V+<[$JM&IESLURBSBFZ
M%2^$+U-PMC?%M,D\/.?:+.DLRAW#,F@U0R!/*%.)WF9W-T]I=8+'<22#4AU*
MK;AS#;T<V&W1GU'3Y+/]!)ME&I%"S;O7-5DLT <KM4,55K6.R7&QX:5.W"TJ
MVC%DR."3N9Q,[&<C-XXIJ5J9.*=FNW$DV$O'2#=^;V\2_6';L[?7*U8K$JL1
M5^XM<.G#V[1N+V:Q1U?)"JH9D#$V\NTM0-BC)I>WO)<H6RZ^QRAW[9SI\2ZF
MI+OK*J)JG?6'KG*=6[:.UCC4T9E,\T8VUC1;0P.]H2C"U5ZL^S&*E(W;Q=H<
M.5?L\@M%PJMM5HO"OL-!WFO+18.T;OJO$7^WISN,1LRJZ76KTBZ?I,6D>PR+
MPD[TN/%LF3Y/:S?#U6$>L&?J[))U];+'CU_8+V!)3KFYK\D"%@66*\XW%Y*V
M'278?<SE.-FC9@S=8Q+2:>/(K#MQ?6"+5M\UC9EDHB[339SYG5SI E$U6+G1
MOE#I%7!<V2DA":T21N4H4Q1.8](J0V:W6].*UD\IMV_FHFBF64RC9.;2G;>/
MYJ["PGJE%Q"[MUMV=42J,TCLP])W5_>90U4-8)D-(:HNJ:U]=P!B3UTWG08[
MVM?#GU/X(OC?C Q5M1]0UTJ2?LDML_9J1%&4.50$YCB#)53""M8CIM7FN4[E
M;/'YW4TG5R"R;9D\J<R7_B9))'S(V"(1.YM&QK;KSH78,ZM;81FA-U.6PJ_<
M"<V79^[#PC267%5;VS:S-,F1T79,:L>J8>MBZF>)2O8=E%(9*IM&*AXL#A\D
M7,9.<-G5D2V]:]Z.K,]31ZO^R[>RJVLHU(IM$2)E15X=Y9E8<6B)]B3)2EB-
MQVO67$/KU[XE=U2=GA$JN-@BS+-I,S,;=8A24MMU.TQ')I85]:W+[I=[[XJB
MH>K_ &%':V>&&Z=X,(C#:JN;I'.2^.'QRR;*>8A<,@KV5[//F49A]BS?(IC/
M5SB:P"!N+;5=COT7?HU3N4_@NBVHU!01!M&P2"+:V[EJG$Y5=VZT&;FS8=HF
MS>ULL$1L]&PJ6W//MAX?FJ-?*RJJ86;6%3MD7>I(\(&*7+NX60N]M96#-Y#8
MD/E^U4LWEPNARAO3FD&I,>HERMIEC]A1J25=4+U?JMZA;=FAULEKFYW<ON5N
MV7XN1MS>871Z)E<D?L.2XQ)_/K-5M?;94)KE3;OJ<JV()O"W],>KLX.4)?YG
M:$IAG%OPFQ(T]:SEQ^JYH]+:TK26-3B]ON-<<Q>.1)9)LW)P+>%$@3N#L8HR
MB$.MTH(B<ZH+XV(FVECE;6G1&RZN'H=ZT4QKR%YM=Y&VDY,-K7)/Y1L<WN\D
MEQ6N+5M-%ZKS0Q^M(<6[/2E1$UDELHU+M/Z.[6T-E5;9F1?BTCH.\;^[)/5>
MNUQXV"9.)%!%9<%*C;\>Z6H058$B8UJ1/SA&9+*35[L]L)"!<M=7-28:M/VZ
M@                                               <\=O'/'/O<^Y
MR/QR7AEV=UCQSV<=G';QV]G'^P<%X<=O'&&/'=<=SS[GO\>[[G/^WN\^X/'J
M17_)C_(/4B_^3'^7_7_S]T/4B_<_X,?<][W/X?\ C[G'N^^//!1?'/;QACQS
MQV=G/9[W9SV\=GP>[SVAR67ESSSSACSSS[_// 8EX8\\\XX\<<\^_P \?[^[
MS_/GW?X^Z')>'//.7.&/.7/O\]GN\^YV?S[/]??_ )!R7ASQSCSACV<\]USQ
MV>YV]G9V]G\/<'GN<>Y[GN>.Y[.SN>SW.S^ _/J)7_)C_+_S^'_J'J)7_)C[
MW9[W^GN_^_G^8\\EX<]G;CQSW/''&/;Q[W''O=GP!R47S[O.&///P]GN]GO=
MG;\'^WO?RX#U/#LYQ[C'N>>>.>>.SW.WCWN>SX1YQPPQYYYQQXXYY]_GC_7^
M/P_]?X>\/T       "/LK:JK'++'*S*^QRQYYQRQRF<<XRQRXY[.<<N.7+CG
MCGCGCGCGCGCMXY]SD>/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI
M&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZ
MZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]
M^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<Z
MO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G
M.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53
MYSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E
M4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"
MY5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#
MPN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,
M@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_
MS(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1
MO\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^N
MD;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?
MKI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.K
MWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YS
MJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^
M<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5
M/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN
M53YSJ]^ND;_,@\+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\
M+E4^<ZO?KI&_S(/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(
M/"Y5/G.KWZZ1O\R#PN53YSJ]^ND;_,@\+E4^<ZO?KI&_S(90QR6.2=,:LC3^
MR2%(0?RF/5,;JA=DQ*G@O WE.:>@/4%%G\%&E&<E9Y<&<%F89\X]SGCSSW0
M ^3QR_\ WBO_ /;57_WY@X0
M                  -UW3-_]4<Y_P#XC*__ /&8R-D0  TJJ^FE;RA4I/PG
M%<<8GJ#CL>,E<F[KC$PS+/CC+LB_/';QQEQQSV<\\=OO<\CC^3-N#X\UO]+D
MWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2
MY-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_
MTN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\U
MO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/
M-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/
MCS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N
M#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS
M;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY
M,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX
M>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWH
MN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-
MZ+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN
M3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]
M+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;
M_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS
M6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X
M\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@
M^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,V
MX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3
M-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'
MDS;@^/-;_2Y-Z+AY,VX/CS6_TN3>BX>3-N#X\UO]+DWHN'DS;@^/-;_2Y-Z+
MAY,VX/CS6_TN3>BXV!:CT'*-?83(HQ*7=A>%;Q*CGY.>P&N!J<M,8T-+?ZB=
MRX-[<;P?P:WF9\\8%&%^IYX?\?=<Y8XVP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MVJS&Y>GY5-ZT@E6B4>J)E!6!Q6>/$G
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MYOYR8HUQSPXML
M        X^"1(6<8IP3)\%!W&'!Q^!)>)QO!7N%\&&\8\9Y\%\<]F'&67/&/
M'N8]G'N#D
M
-              /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>footer2.jpg
<TEXT>
begin 644 footer2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  R 6@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MN!^.7B36_"'PSU?6/#UW:VFJ6JJT1N[<SK(Q( C"AEY8D#KWJ;XD?$:+X7_#
MTZSJ<D,FH,L5K;PLPC6XO),*B#)X!8_@ ?2E?1L=M4CN**\(\$_M#7<GPPT*
M]U6SB\0^,+B*[:ZM=#94MQ]F<B:3>QPL8&W!)Y)%4/!/[45LNF^&-/UR%[[Q
M!J"V\M\MJ\8-F+IBT"[,[I"(RI;:.!R:K3O_ %_2%TO_ %H?0U%?/GAW]I2>
M'P?/J]UI-YKKK*][<_9 D26%I)<-' C%B-SD ':.2.:Z&Y^/MM:IJSV%C?>(
M+N.XO1%I\4:0>3#:86>1I&;&S?G#'DDXQ2Z7?]=U\NH[:V/8J*^?OAU^T[:Z
MC)X9\/ZK#)J'B.]:"'4&M6CQ:S3KYD:>7G<P5&7<RC"Y&:ZKXF>+_$&E_$7P
MQH=MJT'AC1-2C<+JL]C]J6>[#J$M22RB,LNX@G[Q&!3:::7=V_K].^EMR;JS
M?;7^OZTZGJ]%>):7^T1>R27L=YX1O&EFU^;0M&AM)4=[YH5/FR-SB-5*/DGC
M&*@_X:^\&+>7^]9CIEK%*W]HPR1R(TD;A&0J&RF7.U6; 8]*6_\ 7E?\F4TT
M[/\ K6WYIGNE%>&:/^TE=^+/$GAG2M"\)W%R-0U"XM+Z9KN,QVT<,0<R(ZDK
M(/G4<'@AEZBK?Q6^)NIZ5\4O#_@_3=>C\.I=6+WDUVVD2:@78RK'''A2!'G+
M'<QQQ1KIY[?=<5UKY?YV/:**\?;]HK3[2[C\S1=2GT5[:]GBUF-%VW7V1-TS
M1Q [BIP0K=":-'^.6K>(?%_@O2K'PFYLM=M)]0N+HWL3_9K9=HCD&TD,&9L8
M[4;VMU_X/^3#97?]?U='L%%</\9_$VM^$?A_?:IH,6^\ADB$DWD&?[/"7 EF
M$0(+[%RVW/:L?2/BQI^@Z-,NI:X/$QM-%.OR:Q9VJPQ2VQ8A %#$;CCUYI7W
M\O\ *_Y?D^P[:I+K_P ,>H45XAJ7Q\O$\7:=8Z-I4VL6MUJ?V&\64I!_9\<5
ML)IY-V3YFW?'D8&,FN@^&/Q]T3XK>(+O3M'MIFMX[87D%\)$DCEB+E,L%),;
M$C(5N2O--:Z(3TU_KL>GT5X#XO\ BIXR\-Z]X]C6_P!.?2],GTVT@G^PMC3C
M<-F2:4[OWBI&0Q^Z >O%9/A7XW>)_'%Y+X6TC6K"6\M;K4#/XI-CF$VEN$"L
ML._!9W?;G=C",:5]+_UW_+7\KCM_7KM_EZGTI17R_#\>O&WB3P)J'B/3Y=/T
MU/#MC;2WT<EJ9?[2N9"#Y:?,/+0H5((R<N/3GZ2U#[3<:-/]FN5TZZ>$E+AX
MQ((6Q]XJ2-V/3(JY)Q3;)BU*UNI>HKP+X<?%3Q7;^%=)U+7[S_A,-7\0R3C2
MM&TS3DLV$<3L#([F0@+M ))XRP'>MB/]J#P_<*DL.EZE)9Q:4FKW]T8U"643
M221!&Y^:0O$P"CKP:0_Z_K]#V6BO(I?VB+2P\RTU'PUK%EKOVJUMH='VI)/,
M+G<8G&#@#Y'W GY=IS67>?M)S"\\,_9O#%PME=2:C_;4D\Z!]-CLP5D8 9$@
M\S: 1USQS2_K]?U#^OZ_0]QHKA/ 7Q5C\;:Q<Z;+HM]HETMI'J%NM[MS/:R$
MA)/E)VG(Y4\C(JIXX\3>(=0\=:;X,\,75MI-S+9/J5[JEU;_ &CR85<(J1Q[
ME!=F/4G  /6CJEW_ $W^ZSOZ!=:^7]+[[H]&HKPW0_CGJ>@ZA?\ A;6[.3Q1
MXFM]8FTNTETF 0K=A+:.YWNK,1%A9-I.2,CWI&_:<C;6-#F3P]=#PQ=Z =<N
M]1:1?,MLRB*.$1C[S,YP,=<C%&]K=?\ *_Y(/7^M;'N=%>.-^T8MO<RZ?=>$
M=6AUHW]OI]MIJO%)),\T;2@DAL(%5<OG[N12Q?'N+_2_L&G:AXBO6FNI%T^V
MCCC-K;VS>5.S.6PP$BLH/5CP/6E=?U\G^3N/^OS_ ,F>Q45EZ#XCLO$?ANQU
MRS=C87ELEW$SC!\MEW#(['!KY@_X:V\36?P_\9>=I-I<^-H6N+_0[:-&%N^E
MG<8+N8^BA3NQU8J!UIR]UM/== BN9)K9_P!?UZH^LZ*^>D^,'B30O$UP?%>J
MIH]AI^EQW2V8T@[=6D2W\RY,4Y?"_,1A<$X!ZUWOP^M_'^MQZ5XAUW7K"TM;
MV(7$GA^VT[<(4=<I']H+Y++D9;;@\\55M6NW]?I_G8B^B??^G]UT>D45Y1\3
M/%GB+2/&FA:?X;UJUNKZZN(5D\/?8?-?[.6Q-/)*'S$JKD@D<D <YXY.W^.W
MBC6O!ND+H]E;WGBE4O;W58EB)2&VMII8\!0<[Y6154>['M477+S?UYOT+L[V
M_K7H?0=%>)? WXL:GXT\6ZGHUYK=EXDBBTFTU,W=C9FW2UEE9PUL?F.XKM!S
MP1G!%>VU;BX[DIW"BBBI&%%%% !1110!@^,O!MAXYTNWL-1:86T-Y;WP6%]I
M9X95E0'CE=RC([BJOBCX<Z+XSUW2-2UJW_M%=+$AMK*XP]L)' 'FE".7 R >
MVX^M9'QT\1ZWX2^&>KZOX?O+>RU2U56A:YM_.61BP58PN1RQ('7O7*_'?XJZ
MI\.])\.6UM>R07UX));^XL=.-]<0PQPEFD6 '[I?"ECP,U+DHJ_9E:WL3ZE^
MR]X7NEO(K"_U;0[6^^V)=V^FSK$DL-R5:2+&WY5RN1MP1D\UKZ;\!M%T/7I]
M1TR_OK"&ZLXK*YLXO+,<JQP>0C;BA96" #Y2.@KAU\6?$;Q%_P (';:9XGL+
M36]:LX;^^LDTR.>&WM!R\Y??D%\JJKTW$XR :ZGX9ZKXPUSQ_P"('N?$MOK/
M@[3=UFCC34MWFO V7V.K'*1CY2>[$^E7RVO#U_#]+O[_ #(O]OT_']=/N78J
MP_LO>'H4M+<ZUK;:?$UG+-8_:$$5W):X\EY<)D\*H(! .!QFGWG[,NA7>G_8
MEUW7;6WD@NK.Y$%RBM<V\\IE:)VV9P&)P1@X."37.>)OB1XYL=4\4+X8U!?&
M%E:V;#SK+2U*V%XTZ*D:$-^_VQF1F&>-H]<5HV?CSQ)?3_#;^Q_%MIKEIK>I
MRPWDDVD^1))#&CO*FW=^Z9 A7D$YI)<]GW_71W_S[>0Y>[IV_35?\!;W.Q\(
M_!?2O _BRZUG1[Z\MH;H)YVFD1M"SK$L0?)3>#M5> V,\U8\6?"F+QIK]M>:
MEKVJR:5#/#<_V&KQBT:2)@R,?DW_ '@"1NZBL'XT^+?$6@WFF6_A/6()->GD
MC6#PZ;,3-=@R 2.[YS%&$W?-TR._2N)\&_'+6]:\86EAJ&O6=J^I6FH376FR
M6/EG0/(8!&ED8C=U (;&<@CBCFO9]K_AK_PW;R!I137>WX_UKW\SU#PU\&])
M\-ZII]\M[?WLFGW-Y=6J74BE8FN3^\Z*,]6 SS\QK"M/V;?#]GX3U3PS'J&H
M#0[IUDMK7]U_H+++YBF-MF3ANF\MQQ7*P_$?Q1_PA6N7UQXNCAB2_,>AZFNC
M*9]841 [(K?=R/-R PZ@>G->V>#+G5[SPGH\^OV\=IK<EK&]Y!"<JDI4;@/Q
MH45;TM_G^%OEIW"^MN]_PT_7\SG]+^%<&FZ[H&L/K6HW5_I-K-:;I/*5+B.1
M@Q#JJ 9! P5QT[TFH?"F*\^(4OBVW\0ZSI]Q<00VUS8VTL?V:>.(N5#*R%A]
M]L[6%8_Q]U[Q-X>T71'\+:Y!I&I:AJMOID27%BMRLS2OCG+#;A0YX]*[#1=2
MO-'TB\_X2*X 731F75IU2".X0+N:7:"0BCD<_P!W-%[KF?1_\/\ F#3V[_TO
MR.)T']G?3/#=ZE[9>(=<%W:V,NFZ=))/&XT^!W#E8E*8SP!ELG Q5?3OV=K7
MPJL5SX:\0:EIVJQV$^G?:9&1E9)KCSY'VA0 X8MMVX STKFK7XZ:_P"+O$'C
M^;2[G3]&\*Z'H"7]G=7,7G3N[%V%PZ;AB-DC;:O!XR<9Q68_QY\1F[T/1-1O
M7TB:TTJPN]?UJSTK[3%%<77^K0J6Q''P<M\Q&1QCFB/2VG_!YO\ )W]5U8Y:
M7;]?_2?\U_PQ[IXN\)77B;3+>TM?$6J:"\1^:XT]H]\HQ@AMZ,/?CO7 7/[+
MOAB:SBL(=2UBSTG['!975C;W*K'=K%)YBF0[<Y+$[@" <GBI/BUXZU[PYXR\
M.:=!J4OASP_/$3=ZZ=+%Y"T[2+'% QS^ZR23NQCD5YW?_M,ZOX5U][S6;N-X
MDN-3BNO"\=B5N+*"U5S'.TO??M4XQ@B48Z4DUOZ_AI^OZB:TU\E]^OZ?H>K6
MGP#T.S\0#58[_4MWVJ]N7MVE4Q.+J-(Y8R-N=N(UQSD8ZUM_#/X9VWPOT<Z5
M8ZE>7M@@5+>&Z6+_ $>-1A4!1%)P.[9-<O\ !#QYJ_CC^TVUG4)H]6BBBEDT
M:XTP6HM5E7=&R-N)D0CC<<'@Y Z5S!^('C)? /BO5KKQ+;PW5CKTVG:9]BTE
M)&O@-J1PHC/RS2,1NSV/3%5K'W>R_5*WRN)6EKY_HW_7^1Z;<_#.%;?6AINL
MZEI%UJ]]]NNKRW:-I"=@3RQO0@)@# QQ7/WW[.OA^:#3HK'4-5T<6]K-97+V
M-PJO?PRL&D69BI)+,,Y&",G%8V@:]\1+#QSHOAW7/$.E75P?#DVH:F(=/V""
M?>%C<'=RN[>,=]F<UV'P/\0ZYXL^&NF:OXAN(;K4;IYF\ZW@\E&C$K+&P7)Q
ME5!Z]Z22_KYQ_1^5AM]_Z^U?\OF9EY^S_H3:T]]:75Y:V1-O+_8:R 6#S6Z!
M+=V3;N(4*GR[L':,BNRTOPW<1^#5T74]2GU&YDMG@N;[.V1RX.YAZ8W<>F!7
M+?'SX@77PY^'[:A83BUU"ZO;:Q@F^RM=&(RRJK.(E!9]J[FVCTK7^'NJ:E=Z
M7:_;KZ;789H/M*:S)8_80V6($9@/S*0!GD"E?F373_@?Y?H'PM-?U_3_ %,K
M5O@GIMYIOARVTW5M4T"XT*U:QMKW3Y5$S0,JJZ,64@[MJG.,Y&14,/[/OA2U
M\,Z]H4"74-EK$$-O*5F^>)8E 0QG'!#9?G.6)/>L"3XTZCXJ^,NA>&O"CV+^
M'3'>-?:E,0YN9(D VP 'E4D9 S=SD#H37%R?'WQ5I_AG1;2YN?M^JZI<:E=_
MVGI>E>:8=,M9 OFB#=@L=PZMT!.">*.;KWU_K\_2[*MT[:?U_6^AZSH/P1TG
M2=:LM;O-2U+6M<M[HW;:A?2J7E?R6A4,%4#:J,V% &"2:I?\,[^'EAL8%O=3
M$%OIUYIDD?GJ?M$5Q()'9SMSO#JK!ACIWK/^(GQ"UC0OAOX8U31=4GN[:^>.
M2]\26^EBX%O:>6TC3M ", @ <=,]*XKQ+\=->\.:TBGQ#:S06T^FPVEG_9OS
MZ]%<!2]PC _NU&X@;>A0YZTW:]GWM]_Z?UT)O:/,MK7^[^OQ\STOP[\&Y?"^
MN6.I0>)=2OYPR+?7%^RM-<01HPA@!55"HK-N/&6/6MCQI\,8/%FM66M6NL:E
MX=UJUA>U%]I;H&DA8AC&ZNK*1N (XR"*\_\ @[\9[[XI>+%GGO+C2M.O([BX
MTO2Y=-VQW=K&_E^:MP3EG!P2N !GC(YJ#QYX\\7^&?&VN2Z=XIL;G0-!LI;_
M %*UNM.1$C=D/V6T$P;)D=MI/&<$=V%$GLY>;_S_ *^0U'5I>G^7]?H=UH?P
M1T#P_+#/;37S7B6]U"]W+/NEEDN"IEN';',IV@ ] . ,5DWW[./AZZM)K6#4
M-4LK633+73!%!,N$%M)YD,JY4X<,<^A[BO*?#?QX\;:G87/VS5$L-/;4+.QG
MUK4='-O+IDCQ-),KVY/W,F-4D; ))STJYJ'[46J?\*;:XT>6QU+QM(\T4-Q.
MGDVZ0K<&".[EC)RHD.W:@Y)/H#3LT[K=6_+3[N;_ "$M=._^?^<3U?PK\!]#
M\+^((-<^WZIJ>K1WMQJ#7-]<!S)/-"D+L0% P$08 P!DXK+/[-FC0QQ)9Z]K
ME@/+NK:X:WN$5KFWGG::2%SLZ;V.",-@]:]6T\S&QMC<E6N/+7S&48!; SC\
M:\9^+OQRU#X9_%#0+:2. >"X;5I_$%VR%I+;S'\NW8$=!O'(QSN%)Z-1^01U
M7-\ST3PQX+ET7PWJ&CW5_)/;W#2) L(V+:6Y4)'%'Z!5 Y]235:Z^$OAZZ\&
MVWAG[.T5A!;068EC($SP1.KK&SXR5)7D=\FO"+S]H#XFZK#X@GT?1[""XDU^
MUT_1=*N8R9A;K ;BX$YSQ(T87 '"F1<]#6WXU_:3NO[)U_5- O+6UTRWL-*C
M@GN(/,,5W>S;=S#N(X]Q*>JT7;_#\M+_ 'VUZNSW#E2T7G^=G_7;5:'I]S\'
M+'6-<DOM>U;4?$%JJS);:9>M']FMUE7:VU54$G:2H+$X!JWX ^&TO@'$$?BC
M6M7TV&$6]K8ZE+'(EN@^Z P0,Q  &6)X%<?X!^+&H6/@WQ5KGBF\;6-'TJZ\
MNPU:WTYK6345*K\J0$\G>=BD<,35O6_CK>:#9^5=>#KY=>%I+J4FE_:X<06:
M?\MI9<[4R<J%Y.01[T74/N_2_P"7W!;FZ=?Z_3UT-GPC\'XO!OBS5-<M?$NM
M7)U.ZDN[JSNI(GB=F& ,^6'VJ.%&[C%2^%_@YHO@E?%<FA3WEA?^([M[VYOO
M,#R1.PP%CW A47DA<8R3ZUU?AO61XB\/:9JJP26JWUK%<B";[\>] VUO<9P:
MT:;CROE?16^6FGX+[A74O>[Z_P#!_$Y?P1\/['P.M_+#/<:AJ6H2B:]U&\*F
M:=@,+G: H '   %=1112&%%%% !1110 4444 87C#P;I_CC3;:PU/SOLT%Y;
MWP6%]FZ2&594#>J[E&1W%<GXL^!]CXNU/^T9_$6OV5ZT,UI--97,<;36LC;C
M;M^[/R YQC##)Y->DT4#N]CD?#WPNT3PK<:I/I8N+66^M(;$.LN3;00Q[(XX
M21\BCEN_S$FJTGPGTZ/P%:>$=/U+5='TN"%X#+87"I<2AE8,7D*G+$L6R,'=
MS[5V]%#][<2]VUCS/1?@B?#?A:+0M,\<>*;6UA*>3()[?S(D52-BX@ P<Y.0
M3D9S6GH_P>T/05T?[#+?13:5;7,%O,9]S[Y\&6=B1\TI.3N/J>*[FBFW?5BL
MM#S3P_\  VV\-^,M0\26WBSQ-+>:A(LEU#<74+Q2E4"*#^ZW!0!G:& SS6=K
MG[-FB^)K><ZKXA\0W>IS2Q.=4-U$)U2-MRP@>7L\O=R5*G=@9)P*]<HI=O(9
MY4W[/]NWB33]>;QKXL;5+.V%HDS7=N0T>\L05,& 3G!*A<@ =J]448 &<^YI
M:*.EA=;F%XB\&Z?XHU+0[V_\UWT>[^VVT:OA#+L*AF&.<!CCWJPGAVWFTF[T
MW47?6K2Z:3S8]0"R!D<DF,C: 4 . ".@YS6K11TM_7]:#ZW/,[7]G/P'IMKX
MK@T[18M*7Q-"MOJ#6*K"3"J[?*3"_*N,\?[1I_B#X#Z#X@\1-J<E]JEI!/';
M1WNF6MPJ6M[]G.8#*I4L=OL1GOFO2:* //=6^#L7B"YM!JWBCQ!J.FP-'(^E
MS3Q""=XVWHTFV,,<,%. 0/E%,?X'Z-J4FLRZY?ZEXBGU*TEL#+J$J9M[>3[R
M1;$4+VY.3\HYKT6B@=S@_!?PCM?!>H-?QZ]K6IZA,5%S=:A.CO<1HFR.-\(!
MM0$D;<')))-3:7\(=!TI?#Z1F[EBT.ZN+VVCFFW*T\S,S2.,?,PWMM],UVU%
M.XCF;KX?:7>>(-8UF0W'V_5-.72YI%DQL@!<@)Q\IR['/K6GX7\.V?A'PWI>
MAZ>'6QTZVCM(/,;<VQ%"C<>YP.36G12Z6_K^M6!A>(O!NG^*-3T"^O3-YNB7
MAOK9(Y-J&7RGC^<8^8 2,0/7![5H6^FF&^OIWN[BXCNMN+>8J8X0%P0@ R >
MIR3S5VB@#@=-^!/@;1?& \3Z9X>LM+UA;1[1)K.!(O+5V)=U 7ASGEJSM6_9
M]T#4-)T2PL]0U?15TNTFT])]/N526:VF(,L4A93D,5!R "#T(KT^BEY?UU_S
M?WL.M^O]?Y'G6K?!>WU+1H=%@\3^(-+T..-K<Z=97$21M 5"^3DQE@H48X.?
MF/-6(?@YI"Z]87]S>ZA?66F!1IVCW$B&SLRJ;%**%#$@=-S'&<]>:[VBF'2Q
MYAX6^ .D>$+V&YL=;UPFU7R;".:Y1EL;<R"1H(AL^XQ !W9;  !%:&I?!/P_
MJGA#7?#\LE\(M9OFU*YO5G_TD7!D#JZOC^ J@4$$ *!7?T4?U^OYZ^NH'F<7
MP+M+?2[RUB\4>(8[K4;C[1J>I"XB-S??($".QCP%"@ ! N/K3M>_9Q^'/B33
M].L[[PKI\B6)@\N3R$,K+$<HCN069<]03S7I5%']?=L'E_6HV.-88U1%"(HP
MJJ,  =JP(_ ND+XBUC698#=W6JQ6\5Q'<XDB"PY*!5(XY;/U /:NAHH\P\CB
MM-^$>@Z7XB@UN+[4]]%>W6H9DFRK37"*CLPQSA44+Z 5DZ/^SWX/T&ZN9K*W
MN8A<:]_PD4D)GW1FYV%0NTC_ %8W,P3H"2:]+HHVM;II\M/\E]P;[_UO_F_O
M9ROC3X>6?CJQNK&_OK^"RG@6)8+6546&19!(DZ?*2)%8#!SCCI7&^)_V;M(\
M91A=7\2>)+B273CI5],EXD;W]OYAD"RE8QT8G&W;P<'->N44+35#N1V\"6MO
M%#&-L<:A%'H ,"I***"=M$%%%% PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>footerv1.jpg
<TEXT>
begin 644 footerv1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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6B@ Q1BBB@ HHHH *,444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>footerv2.jpg
<TEXT>
begin 644 footerv2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>logosmall.jpg
<TEXT>
begin 644 logosmall.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  [ 'D# 2(  A$! Q$!_\0
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MXJCT]%_7X'KG[6<Y\(_!/X%> E3R'M]%;6+J/UDF;'/_ 'RWYU?USX'R2?\
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$H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>mnplogo.jpg
<TEXT>
begin 644 mnplogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !' (L# 2(  A$! Q$!_\0
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MMJD=G:_:+X:=8RSB.1(D #[%."6D<\^E?H[13/,I9/"E3G!3^+38_%+]G?\
M9_\ &>M?'3P-:ZOX.U[3]+&JPS7-Q>:;-%$D<;;SN9E &=N.?6OVI8')XJ2B
MD>A@<#' Q<8N]R+:?2C:?2I:*#T@HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331458168880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 11, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EDESA BIOTECH, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Spy Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Markham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">L3R 5H6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-9600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, without par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EDSA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,056,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,467,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">MNP LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Toronto, Canada<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001540159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331450596304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,037,320<span></span>
</td>
<td class="nump">$ 5,361,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts and other receivable</a></td>
<td class="nump">270,908<span></span>
</td>
<td class="nump">626,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">367,394<span></span>
</td>
<td class="nump">448,912<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,675,622<span></span>
</td>
<td class="nump">6,436,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Long-term deposits</a></td>
<td class="nump">41,151<span></span>
</td>
<td class="nump">173,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net</a></td>
<td class="nump">2,078,848<span></span>
</td>
<td class="nump">2,180,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">18,361<span></span>
</td>
<td class="nump">91,373<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,813,982<span></span>
</td>
<td class="nump">8,890,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,812,960<span></span>
</td>
<td class="nump">1,747,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term right-of-use lease liabilities</a></td>
<td class="nump">19,867<span></span>
</td>
<td class="nump">74,714<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,832,827<span></span>
</td>
<td class="nump">1,821,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term right-of-use lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,773<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,832,827<span></span>
</td>
<td class="nump">1,841,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized unlimited common and preferred shares without par value issued and outstanding: 3,247,389 common shares (September 30, 2023 - 3,075,473)</a></td>
<td class="nump">47,236,024<span></span>
</td>
<td class="nump">46,643,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">13,576,757<span></span>
</td>
<td class="nump">13,039,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(242,613)<span></span>
</td>
<td class="num">(214,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(58,589,013)<span></span>
</td>
<td class="num">(52,418,968)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">1,981,155<span></span>
</td>
<td class="nump">7,048,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 3,813,982<span></span>
</td>
<td class="nump">$ 8,890,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331458913824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br> $ / shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common Stock, Shares Authorized, Unlimited [Fixed List]</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common Stock, No Par Value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued and outstanding: 3,075,473 common shares (September 30, 2022 - 2,380,280) (in shares)</a></td>
<td class="nump">3,247,389<span></span>
</td>
<td class="nump">3,075,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="nump">3,247,389<span></span>
</td>
<td class="nump">3,075,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331450678784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 2,881,967<span></span>
</td>
<td class="nump">$ 4,794,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,132,777<span></span>
</td>
<td class="nump">4,428,209<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(7,014,744)<span></span>
</td>
<td class="num">(9,222,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceNonoperatingIncome', window );">Reimbursement grant income</a></td>
<td class="nump">698,277<span></span>
</td>
<td class="nump">581,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">153,498<span></span>
</td>
<td class="nump">289,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Misc other income</a></td>
<td class="nump">14,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss</a></td>
<td class="num">(21,042)<span></span>
</td>
<td class="num">(21,742)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="nump">845,499<span></span>
</td>
<td class="nump">849,143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(6,169,245)<span></span>
</td>
<td class="num">(8,373,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,170,045)<span></span>
</td>
<td class="num">(8,374,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Exchange differences on translation</a></td>
<td class="num">(27,965)<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (6,198,010)<span></span>
</td>
<td class="num">$ (8,375,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares (in shares)</a></td>
<td class="nump">3,197,423<span></span>
</td>
<td class="nump">2,858,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (2.93)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in income from government assistance, classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331458421072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,170,045)<span></span>
</td>
<td class="num">$ (8,374,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">186,049<span></span>
</td>
<td class="nump">183,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">537,492<span></span>
</td>
<td class="nump">1,246,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on payable forgiveness</a></td>
<td class="num">(14,766)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Increase (Decrease) in Operating Capital [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Accounts and other receivable</a></td>
<td class="nump">356,339<span></span>
</td>
<td class="nump">562,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">197,136<span></span>
</td>
<td class="nump">301,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">17,590<span></span>
</td>
<td class="num">(556,270)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,890,205)<span></span>
</td>
<td class="num">(6,636,483)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common shares and warrants</a></td>
<td class="nump">729,387<span></span>
</td>
<td class="nump">4,345,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">770,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for issuance costs of common shares and warrants</a></td>
<td class="num">(107,824)<span></span>
</td>
<td class="num">(285,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="num">(29,532)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">592,031<span></span>
</td>
<td class="nump">4,830,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(25,903)<span></span>
</td>
<td class="nump">76,850<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(4,324,077)<span></span>
</td>
<td class="num">(1,729,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">5,361,397<span></span>
</td>
<td class="nump">7,090,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 1,037,320<span></span>
</td>
<td class="nump">$ 5,361,397<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331453933216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">2,380,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 42,473,099<span></span>
</td>
<td class="nump">$ 11,176,345<span></span>
</td>
<td class="num">$ (213,602)<span></span>
</td>
<td class="num">$ (44,044,553)<span></span>
</td>
<td class="nump">$ 9,391,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares', window );">Issuance of common shares and warrants in equity offering (in shares)</a></td>
<td class="nump">580,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount', window );">Issuance of common shares and warrants in equity offering</a></td>
<td class="nump">$ 3,400,191<span></span>
</td>
<td class="nump">944,828<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,345,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common shares upon exercise of warrants (in shares)</a></td>
<td class="nump">100,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Issuance of common shares upon exercise of warrants</a></td>
<td class="nump">$ 994,618<span></span>
</td>
<td class="num">(224,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon exercise of restricted share units (in shares)</a></td>
<td class="nump">13,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common shares upon exercise of restricted share units</a></td>
<td class="nump">$ 75,920<span></span>
</td>
<td class="num">(75,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_StockIssuedDuringPeriodValueStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="num">$ (300,677)<span></span>
</td>
<td class="num">(28,358)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(329,035)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,246,457<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,246,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,046)<span></span>
</td>
<td class="num">(8,374,415)<span></span>
</td>
<td class="num">(8,375,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">3,075,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 46,643,151<span></span>
</td>
<td class="nump">13,039,265<span></span>
</td>
<td class="num">(214,648)<span></span>
</td>
<td class="num">(52,418,968)<span></span>
</td>
<td class="nump">7,048,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_StockIssuedDuringPeriodValueStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="num">(136,514)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(136,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">537,492<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27,965)<span></span>
</td>
<td class="num">(6,170,045)<span></span>
</td>
<td class="num">(6,198,010)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares (in shares)</a></td>
<td class="nump">171,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares</a></td>
<td class="nump">$ 729,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">729,387<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">3,247,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 47,236,024<span></span>
</td>
<td class="nump">$ 13,576,757<span></span>
</td>
<td class="num">$ (242,613)<span></span>
</td>
<td class="num">$ (58,589,013)<span></span>
</td>
<td class="nump">$ 1,981,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information pertaining to the issuance of common shares and warrants in equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information pertaining to the shares issued for common shares and warrants in equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_StockIssuedDuringPeriodValueStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period for issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_StockIssuedDuringPeriodValueStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331542635584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arr Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b><a href="#" id="I9B" title="I9B"></a>Item 9B. OTHER INFORMATION.</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><span style="-sec-ix-hidden:c32"><span style="-sec-ix-hidden:c33"><span style="-sec-ix-hidden:c34"><span style="-sec-ix-hidden:c35">None</span></span></span></span>&#160;of the Company's directors and officers adopted, modified, or terminated a Rule 10b-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended September 30, 2024 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">ecd_Rule10b51ArrAdoptedFlag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">ecd_NonRule10b51ArrAdoptedFlag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">ecd_Rule10b51ArrTrmntdFlag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">ecd_NonRule10b51ArrTrmntdFlag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331459281328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331565604640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><b>1. Nature of operations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Edesa Biotech, Inc. (the Company or Edesa) is a biopharmaceutical company focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The Company is organized under the laws of British Columbia, Canada and is headquartered in Markham, Ontario. It operates under its wholly owned subsidiaries, Edesa Biotech Research, Inc., an Ontario, Canada corporation, and Edesa Biotech USA, Inc., a California, USA corporation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s common shares trade on The Nasdaq Capital Market in the United States under the symbol &#8220;EDSA&#8221;.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Going Concern</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These consolidated financial statements have been prepared on a going concern basis which presumes the realization of assets and the discharge of liabilities in the normal course of operations for at least the next twelve months.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For the year ended September 30, 2024, the Company incurred a comprehensive loss of $6.2 million resulting in an accumulated deficit of $58.6 million. For the year ended September 30, 2024, the Company had a net cash outflow from operating activities of $4.9 million and ended the year with $1.0 million in cash and cash equivalents and a net working capital deficit of $0.2 million. Subsequent to the year end, the Company received proceeds of $1.5 million from the sale of Preferred Shares to the Pardeep Nijhawan Medicine Professional Corporation (PN MPC). The Company&#8217;s ability to continue as a going concern is dependent on obtaining additional funding through financings, other strategic activities as well as via grants, to fund the development of its drug candidates. There can be no assurance that the Company will be successful in raising the necessary financing. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company&#8217;s ability to continue as a going concern.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and, therefore, be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements. These adjustments could be material.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Liquidity</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s operations have historically been funded through issuances of common shares, exercises of common share purchase warrants, convertible preferred shares, convertible loans, government grants and tax incentives.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In August 2022 the Company filed a $150.0 million shelf registration statement, under which the Company entered into an equity distribution agreement with Canaccord for $20.0 million in gross proceeds, subject to certain offering limitations that&#160;allowed&#160;the Company to offer and sell common shares having an aggregate gross sales price of up to $8.4 million (Canaccord ATM). The Canaccord ATM was terminated in October 2024.&#160;In October 2024, the Company entered into an At The Market Offering Agreement with H.C. Wainwright &amp; Co., LLC as a sales agent (HCW ATM) pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $3.87 million in gross proceeds.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s primary use of cash and cash equivalents is to fund operating expenses, which consist of research and development (R&amp;D) and general and administrative (G&amp;A) expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change in accounts payable and accrued expenses. Net cash used in operating activities was $4.9 million and $6.6&#160;million for the years ended September 30, 2024 and 2023, respectively. The Company incurred net losses of $6.2 million and $8.4 million for the years ended September 30, 2024 and 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2024, the Company entered into a Securities Purchase Agreement with PN MPC, an entity controlled by Pardeep Nijhawan, the Company&#8217;s Chief Executive Officer, Secretary and member of the board of directors of the Company, pursuant to which the Company agreed to issue and sell to PN MPC in a private placement, up to $5 million of shares (Preferred Shares) of the Company&#8217;s newly designated Series A-1 Convertible Preferred Shares, stated value $10,000 per share, each of which is initially convertible into approximately 2,903 common shares (Conversion Shares), without par value, of the Company (Common Shares) at a conversion price of $3.445 per Conversion Share, and warrants (Warrants) to purchase Common Shares (Warrant Shares) at an exercise price of $3.445 per Warrant Share. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of Common Shares equal to 75% of the underlying Conversion Shares at a combined purchase price of $10,272.13 per Preferred Share and related Warrants. Under the Purchase Agreement, PN MPC&#160;has purchased 150 Preferred Shares initially convertible into an aggregate of 435,414 Conversion Shares and Warrants to purchase up to an aggregate of 326,560 Warrant Shares for an aggregate purchase price of $1,540,819. The Warrants expire <span style="-sec-ix-hidden:c277">five</span> years from the issuance date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2023, the Company entered into a multi-year contribution agreement (2023 SIF Agreement) with the Canadian Government&#8217;s Strategic Innovation Fund (SIF). Under the 2023 SIF Agreement, the Government of Canada committed up to C$23 million in partially repayable funding. Of the C$23 million committed by SIF, up to C$5.8 million is not repayable by the Company. The remaining C$17.2 million is conditionally repayable starting in 2029 only if and when the Company earns gross revenue. See Note 9. In February 2021, the Company signed a contribution agreement with the Canadian government&#8217;s SIF (2021 SIF Agreement), the Company was eligible to receive cash reimbursements up to C$14.1 million in the aggregate for certain R&amp;D expenses related to the EB05 clinical development program. All potential funding available under the 2021 SIF Agreement has been received. For the years ended September 30, 2024 and 2023, the Company recorded grant income of $0.7 million and $0.6 million respectively related to the 2023 SIF Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2023, the Company entered into a $10.0 million revolving credit agreement with Pardeep Nijhawan Medicine Professional Corporation (Credit Agreement), providing an unsecured revolving credit facility, with a credit limit of $3.5 million (Credit Limit) which is available immediately. The line of credit bears interest at the Canadian Imperial Bank of Commerce US Base-Interest Rate plus 3% per annum and has a maturity date of March 31, 2026, unless terminated earlier by either party with 90 days&#8217; notice. Advances under the line of credit are tied to a borrowing base (Borrowing Base) consisting of eligible grant receivables from SIF, future potential license fee receivables and any other accounts receivable. At no time shall the aggregate principal amount of all advances outstanding exceed the lesser of (i) the Credit Limit and (ii) an amount equal to 85% of the Borrowing Base. No amounts have been drawn upon from the Credit Agreement. The Credit Agreement was terminated in October 2024.</p>











<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In March 2023, the Company entered into an equity distribution agreement with Canaccord, as sales agent, pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $20 million in gross proceeds, subject to certain offering limitations that currently allows the Company to offer and sell common shares having an aggregate gross sales price of up to $8.4 million. At September 30, 2024, the Company sold a total of 171,916&#160;common shares pursuant to the agreement for gross proceeds of approximately $0.7&#160;million.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In November 2022, the Company completed a private placement of units consisting of 384,475 common shares, 12-month warrants to purchase up to an aggregate of 192,248 common shares and 3-year warrants to purchase up to an aggregate of 192,248 common shares. The gross proceeds from this offering are approximately $3.0 million, before offering expenses.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331457627136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Basis of Preparation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>2. Basis of preparation</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Edesa Biotech Research, Inc. and Edesa Biotech USA, Inc. All intercompany balances and transactions have been eliminated upon consolidation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331459304288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>3. Significant accounting policies</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Use of estimates</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period or year. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are valuation of accounts and other receivable; valuation and useful lives of property and equipment; intangible assets; right-of-use assets; deferred income taxes; the determination of fair value of share-based compensation; the determination of fair value of warrants in order to allocate proceeds from equity issuances; and forecasting future cash flows for assessing the going concern assumption.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Functional and reporting currencies</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company&#8217;s and its wholly owned subsidiary&#8217;s, Edesa Biotech USA, Inc., functional currency. The functional currency of the Company&#8217;s wholly owned subsidiary, Edesa Biotech Research, Inc., as determined by management, is Canadian dollars.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Cash and cash equivalents</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Cash and cash equivalents consist of demand deposits with financial institutions held in checking, savings and money market mutual funds and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Accounts and other receivables</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company assesses the collectability of its accounts receivables through a review of its current aging and payment terms, as well as an analysis of its historical collection rate, general economic conditions and credit status of the government agencies. Accounts and other receivables include reimbursement grant income for the Company&#8217;s federal grant with the Canadian government&#8217;s SIF and Harmonized Sales Tax (HST) refunds receivables. As of September 30, 2024, all outstanding accounts, grants and HST refunds receivables were deemed to be fully collectible, and therefore, <span style="-sec-ix-hidden:c304">no</span> allowance for doubtful accounts was recorded.</p>












<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Property and equipment&#160;</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Property and equipment are recorded at historical cost less accumulated depreciation and any accumulated impairment losses. Depreciation is recorded to write off the cost of assets less their residual values over their useful lives, using the declining balance and straight-line methods. Maintenance and repair expenditures that do not improve or extend the life are expensed in the period incurred. Any gain or loss arising on the disposal or retirement of an item of property and equipment is recognized as the difference between the sales proceeds and the carrying amount of the asset. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. The Company capitalizes expenditures greater than $5,000. The Company changed its depreciation policy to straight line depreciation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The depreciation policy for the principal asset categories are calculated as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Computer equipment 30% declining balance method or straight line 3 years</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Furniture and equipment 20% declining balance method&#160;or straight line for 4 years</p>
			</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Intangible assets</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Intangible assets represent the exclusive world-wide rights to know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights, acquired by entering into a license agreement with a pharmaceutical development company. Unless earlier terminated, the term of the license agreement will remain in effect for 25 years from the date of first commercial sale of licensed products containing the Constructs. Subsequently, the license agreement will automatically renew for <span style="-sec-ix-hidden:c311">five</span>-year periods unless either party terminates the agreement in accordance with its terms. Intangible assets are stated at their historical cost, amortized on a straight-line basis over their expected useful lives, which is 25 years, and subject to impairment review at the end of each year.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Impairment of long-lived assets</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Long-lived assets are tested for impairment when indicators of impairment exist. When a significant change in the expected timing or amount of the future cash flows of the financial asset is identified, the carrying amount of the financial asset is reduced and the amount of the write-down is recognized as a loss.&#160;</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Right-of-Use assets and liabilities</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company recognizes right-of-use (ROU) assets and liabilities on the balance sheet for operating leases with terms longer than 12 months. The Company follows the ongoing practical expedient not to recognize ROU assets and liabilities for short-term leases. The ROU assets are initially measured at cost and amortized using the straight-line method through the end of the lease term. The ROU liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the Company's incremental borrowing rate.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Fair value measurement</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company uses the fair value measurement framework for valuing financial assets and liabilities. See Note 11.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Reimbursement Grant Income</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Reimbursement grant income is recognized based on the reimbursement rate included in the government contribution agreement when allowable expenses have been incurred.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Research and development</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Research and development expenses principally consist of (i) contract research organizations for clinical trial management services, (ii) contract manufacturing organizations for manufacturing the drug compound(s) for use in clinical trials and (iii) salaries of employees directly involved in research and development efforts. Research and development costs are expensed as incurred.</p>












<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Share-based compensation</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company has equity incentive plans under which various types of equity-based awards including share options, restricted shares and restricted share unit awards may be granted to employees, non-employee directors and non-employee consultants and warrants that may be granted as compensation to non-employees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company recognizes compensation expense for all share-based awards based on the estimated grant-date fair values. For restricted share unit awards to employees, the fair value is based on the 5-day volume weighted average price (VWAP) of the Company&#8217;s common shares up to the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The fair value of share options is determined using the Black-Scholes option pricing model. The Company utilizes a dividend yield of <span style="-sec-ix-hidden:c313">zero</span> based on the fact that the Company has never paid cash dividends and has no current intention of paying cash dividends. The Company elected an accounting policy to record forfeitures as they occur. See Note 8 for a discussion of the assumptions used by the Company in determining the grant date fair value of options granted under the Black-Scholes option pricing model, as well as a summary of the share option activity under the Company&#8217;s share-based compensation plan for all years presented.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The provisions of the Company&#8217;s share-based compensation plans do not require the Company to settle any options or restricted share units by transferring cash or other assets, and therefore the Company classifies the awards as equity.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Translation of foreign currency transactions</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s reporting currency is the U.S. dollar. The financial statements of the wholly owned Canadian subsidiary is measured using the Canadian dollar as the functional currency. Assets and liabilities of the Canadian operation have been translated at year-end exchange rates and related revenue and expenses have been translated at average exchange rates for the year. Accumulated gains and losses resulting from the translation of the financial statements of the Canadian operation are included as part of accumulated other comprehensive loss, a separate component of shareholders&#8217; equity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">For other transactions denominated in currencies other than the Company&#8217;s functional currency, the monetary assets and liabilities are translated at the year-end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. Non-monetary balance sheet and related income statement accounts are remeasured into U.S. dollar using historical exchange rates. All of the exchange gains or losses resulting from these other transactions are recognized in the statements of operations and comprehensive loss.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Income taxes</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company assesses the likelihood of the financial statement effect of a tax position that should be recognized when it is more likely than not that the position will be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information available as of the reporting date. The Company is subject to examination by taxing authorities in Canada and the U.S. Management does not believe that there are any uncertain tax positions that would result in an asset or liability for taxes being recognized in the accompanying financial statements. The Company recognizes tax-related interest and penalties, if any, as a component of income tax expense.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company accounts for income taxes on a tax jurisdictional basis. The Company files income tax returns in Canada, the provinces of British Columbia and Ontario, the U.S. and the state of California.</p>












<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Earnings (loss) per share</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Basic earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the year.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The computation of diluted earnings (loss) per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings (loss) per share. The dilutive effect of convertible securities would be reflected in diluted earnings per share by application of the &#8220;if converted&#8221; method. The dilutive effect of outstanding share options and warrants and their equivalents would be reflected in diluted earnings per share by application of the treasury stock method. However, conversion of outstanding share options and warrants would have an antidilutive effect on loss per share for the years ended September 30, 2024 and 2023 and are therefore excluded from the computation of diluted loss per share. See Note 8 for share options and warrants at September 30, 2024 and 2023.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Segmented information</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s operations comprise a single reportable segment engaged in the research and development, manufacturing and commercialization of innovative pharmaceutical products. As the operations comprise a single reportable segment, amounts disclosed in the consolidated financial statements for net loss, comprehensive loss, depreciation and total assets also represent segmented amounts.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Adoption of recent accounting pronouncements</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On October 1, 2022, the Company adopted Accounting Standards Update ASU 2021-10 Disclosure by Business Entities About Government Assistance, modifying ASC Topic 832, Government Assistance. The amendments in ASU 2021-10 require disclosure of information about certain types of government assistance received. The Company expanded its disclosures related to government assistance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Future accounting pronouncements</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In November 2023, the FASB issued Accounting Standards Update ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of&#160;Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation&#160;table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.</p>


<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331459140176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>4. Property and equipment</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Property and equipment, net consisted of the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2023</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,945</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,945</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,603</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,603</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,548</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,548</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(52,548</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,846</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciable assets, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,702</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets not in service</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,702</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Depreciation expense amounted to $8,702 and $4,328 for the years ended September 30, 2024 and 2023, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331457705184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>5. Intangible assets</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Acquired license</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In April 2020, the Company entered into a license agreement with a pharmaceutical development company to obtain exclusive world-wide rights to know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights. Unless earlier terminated, the term of the license agreement will remain in effect for 25 years from the date of first commercial sale of licensed products containing the Constructs. Subsequently, the license agreement will automatically renew for <span style="-sec-ix-hidden:c368">five</span>-year periods unless either party terminates the agreement in accordance with its terms.</p>











<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the license agreement, the Company is exclusively responsible, at its expense, for the research, development manufacture, marketing, distribution and commercialization of the Constructs and licensed products and to obtain all necessary licenses and rights. The Company is required to use commercially reasonable efforts to develop and commercialize the Constructs in accordance with the terms of a development plan established by the parties.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company has determined that the license has multiple alternative future uses in research and development projects and sublicensing in other countries or for other disease indications. The value of the acquired license is recorded as an intangible asset with amortization over the estimated useful life of 25 years and evaluation for impairment at the end of each reporting period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The required upfront license payment of $2.5 million was paid by issuance of Series A-1 Convertible Preferred Shares, which have been fully converted to common shares. The value of the license includes acquisition legal costs. See Note 7 for license commitments.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Intangible assets, net consisted of the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024 </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023 </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Constructs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,529,483</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,529,483</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated amortization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(450,635</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(349,463</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intangible assets, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,078,848</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,180,020</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Amortization expense amounted to $101,172 for each of the years ended September 30, 2024, and 2023, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">Total estimated future amortization of intangible assets for each fiscal year is as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,572,988</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,078,848</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331542514496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Right-of-use Asset and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>6. Right-of-Use Asset and Liabilities</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Related party ROU asset and liability</i>&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company leases a facility used for executive offices from a related company. The original lease expired in December 2022 and the Company executed a <span style="-sec-ix-hidden:c405">two</span>-year term extension through December 31, 2024.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The components of lease cost were as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use lease cost, included in general and administrative on the Statements of Operations</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">78,073</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,358</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>









<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Lease terms and discount rates were as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remaining lease term (months):</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Estimated incremental borrowing rate:</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>%</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>%</b></td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The approximate future minimum lease payments under operating leases at September 30, 2024 were as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">20,019</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">20,019</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less imputed interest</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">152</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of right-of-use lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">19,867</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value included in current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">19,867</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value included in long-term liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Cash flow information was as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for amounts included in the measurement of right-of-use lease liabilities, included in accounts payable and accrued liabilities on the Statements of Cash Flow.</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77,954</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,222</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331458017936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>7. Commitments</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and other commitments</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company has commitments for contracted research organizations who perform clinical trials for the Company&#8217;s ongoing clinical studies and other service providers. Aggregate future contractual payments at September 30, 2024 are as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">212,667</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">34,667</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">34,666</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">282,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>









<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>License and royalty commitments</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In April 2020, through its Ontario subsidiary, the Company entered into a license agreement with a third party to obtain exclusive world-wide rights to certain know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights. An intangible asset for the acquired license has been recognized. See Note 5 for intangible assets. Under the license agreement, the Company is committed to payments of up to an aggregate amount of $356 million contingent upon meeting certain milestones outlined in the license agreement, primarily relating to future potential commercial approval and sales milestones. The Company also has a commitment to pay royalties based on any net sales of products containing the Constructs in the countries where the Company directly commercializes the products containing the Constructs and a percentage of any sublicensing revenue received by the Company and its affiliates in the countries where it does not directly commercialize the products containing the Constructs. <span style="-sec-ix-hidden:c451"><span style="-sec-ix-hidden:c452">No</span></span> milestone, royalty or sublicensing payments were made to the third party during the years ended September 30, 2024 and 2023. In connection with this license agreement and pursuant to a purchase agreement entered into in April 2020, the Company acquired drug substance of one of the Constructs for an aggregate purchase price of $5.0 million. <span style="-sec-ix-hidden:c454"><span style="-sec-ix-hidden:c455">No</span></span> expense was recorded during the years ended September 30, 2024 and September 30, 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In 2016, through its Ontario subsidiary, the Company entered into a license agreement with a third party to obtain exclusive rights to certain know-how, patents and data relating to a pharmaceutical product. The Company will use the exclusive rights to develop the product for therapeutic, prophylactic and diagnostic uses in topical dermal applications and anorectal applications. <span style="-sec-ix-hidden:c456">No</span> intangible assets have been recognized under the license agreement with the third party. Under the license agreement, the Company is committed to payments of various amounts to the third party upon meeting certain milestones outlined in the license agreement, up to an aggregate amount of $18.4 million. Upon divestiture of substantially all of the assets of the Company, the Company shall pay the third party a percentage of the valuation of the licensed technology sold as determined by an external objective expert. The Company also has a commitment to pay the third party a royalty based on net sales of the product in countries where the Company, or an affiliate, directly commercializes the product and a percentage of sublicensing revenue received by the Company and its affiliates in the countries where it does not directly commercialize the product. <span style="-sec-ix-hidden:c458"><span style="-sec-ix-hidden:c459">No</span></span> license or royalty payments were made to the third party during the years ended September 30, 2024 and 2023, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In March 2021, through its Ontario subsidiary, the Company entered into a license agreement with the inventor of the same pharmaceutical product to acquire global rights for all fields of use beyond those named under the 2016 license agreement. For the years ended September 30, 2024 and 2023, the Company recorded expenses of $100,000 and $50,000, respectively, as a result of meeting milestones outlined in the 2021 license agreement. The Company is committed to remaining payments of up to an aggregate amount of $68.9 million, primarily relating to future potential commercial approval and sales milestones. In addition, if the Company fails to file an investigational new drug application or foreign equivalent (IND) for the product within a certain period of time following the date of the agreement, the Company is required to remit to the inventor a fixed license fee quarterly as long as the requirement to file an IND remains unfulfilled.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Retirement savings plan 401(k) contributions</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Executive officers and employees of the California subsidiary are eligible to receive the Company&#8217;s non-elective safe harbor employer contribution of 3% of eligible compensation under a 401(k) plan to provide retirement benefits. Employees are 100% vested in employer contributions and in any voluntary employee contributions. Contributions to the 401(k) plan were $17,870 and $16,872 during the years ended September 30, 2024 and 2023, respectively.</p>











<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331459528160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Capital Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>8. Capital shares</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Equity offerings</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On November 2, 2022, the Company completed a private placement of units consisting of 384,475 common shares, Class A warrants to purchase up to an aggregate of 192,248 common shares and Class B warrants to purchase up to an aggregate of 192,248 common shares. Net proceeds from the offering were $2.9 million, which were allocated between the relative fair values of the common shares (using a fair value of $2.7 million) and the common share purchase warrants (using a total fair value of $1.2 million). The warrants became exercisable December 23, 2022. The Class A warrants have an exercise price of $10.50 per share and will expire on December 23, 2025. The Class B warrants have an exercise price of $7.00 per share and expired on December 23, 2023. The warrants are considered contracts on the Company&#8217;s own shares and are classified as equity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Equity distribution agreement</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On March 27, 2023, the Company entered into the Canaccord ATM, pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $20.0 million in gross proceeds, subject to certain offering limitations that currently allow the Company to offer and sell common shares having an aggregate gross sales price of up to $8.4 million. The Company has no obligation to sell any of the common shares and may at any time suspend sales or terminate the equity distribution agreement in accordance with its terms. During the year ended September 30, 2024, the Company sold a total of 171,916 common shares pursuant to the agreement for gross proceeds of approximately $0.7 million. During the year ended September 30, 2023, the Company sold a total of 196,401 common shares pursuant to the agreement for gross proceeds of approximately $1.3 million. The Canaccord ATM was terminated on October 3, 2024.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>At The Market Offering Agreement</i></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 14pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On October 4, 2024, the Company entered into an At The Market Offering Agreement with H.C. Wainwright &amp; Co., LLC as a sales agent (HCW ATM) pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $3.87 million in gross proceeds. The Company has no obligation to sell any of the common shares and may at any time suspend sales or terminate the equity distribution agreement in accordance with its terms. Subsequent to the year ended September 30, 2024, the Company sold a total of 220,269 common shares pursuant to the agreement for net proceeds of approximately $0.6 million after deducting sales agent commissions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Black-Scholes option valuation model</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company uses the Black-Scholes option valuation model to determine the fair value of share-based compensation for share options and compensation warrants granted and the fair value of warrants issued. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company calculates expected volatility based on historical volatility of the Company&#8217;s share price. When there is insufficient data available, the Company uses a peer group that is publicly traded to calculate expected volatility. The Company adopted interest-free rates by reference to the U.S. treasury yield rates. The Company calculated the fair value of share options granted based on the expected life of 5 years considering expected forfeitures during the option term of 10 years. Expected life of warrants is based on warrant terms. The Company did not and is <span style="-sec-ix-hidden:c498">not</span> expected to declare any dividends. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company&#8217;s warrants and share options.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Warrants</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">A summary of the Company&#8217;s warrants activity is as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Warrant Shares (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Exercise Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2022</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">521,718</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">28.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">384,496</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8.75</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(100,760</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7.65</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(84,545</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">37.29</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">720,909</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">19.51</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(111,192</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">7.26</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">609,717</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">21.74</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>









<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The weighted average contractual life remaining on the outstanding warrants at September 30, 2024 is 29 months.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table summarizes information about the warrants outstanding at September 30, 2024:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Warrants (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Prices </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiry Dates</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">1,687</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22.40</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c667">January 2025</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">173,614</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.50</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c670">December 2025</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">15,627</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c673">February 2026</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">27,399</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31.94</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c676">March 2027</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">391,390</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24.64</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c679">September 2027</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">609,717</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 59%;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">There were no warrants issued during the year ended September 30, 2024. The fair value of warrants issued during the year ended September 30, 2023 were estimated using the Black-Scholes option valuation model using the following assumptions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended September 30,2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Class A Warrants</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Class B Warrants</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.54</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (years)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">3.14</p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">1.14</p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected share price volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90.73</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>









<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Share options</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company adopted an Equity Incentive Compensation Plan in 2019 (the 2019 Plan) administered by the independent members of the Board of Directors, which amended and restated prior plans. Options, restricted shares and restricted share units are eligible for grant under the 2019 Plan. The total number of shares available for issuance under the terms of the 2019 Plan is 642,737. The remaining number of shares available to grant at September 30, 2024 is 141,099.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s 2019 Plan allows options to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the option term is not to exceed 10 years and the exercise price of each option is determined by the independent members of the Board of Directors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Options have been granted under the 2019 Plan allowing the holders to purchase common shares of the Company as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Options (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Exercise Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Grant Date Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2022</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">314,853</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">32.62</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">23.94</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">118,579</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7.47</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.23</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(12,779</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">22.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">16.23</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,973.20</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,973.20</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">420,615</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">18.84</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,401</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">15.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">10.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(35,674</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">33.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">25</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">383,040</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">24.93</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">18.33</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">There were <span style="-sec-ix-hidden:c568"><span style="-sec-ix-hidden:c569">no</span></span> options exercised during the years ended September 30, 2024 or September 30, 2023.&#160;The intrinsic value of options outstanding at September 30, 2024 was $200.00.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The weighted average contractual life remaining on the outstanding options at September 30, 2024 is&#160;80 months.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table summarizes information about the options under the 2019 Plan outstanding and exercisable at September 30, 2024:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Options (#) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable at<br/>
			September 30, 2024 (#) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Range of Exercise Prices </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiry Dates</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">374</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">374</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">246.96</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c725">March 2025</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">37,719</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">37,719</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c729">August 2027</span> - <span style="-sec-ix-hidden:c730">Dec 2028</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">43,031</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">43,031</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c734">Feb 2030</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">51,006</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">51,006</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52.08 - 56.49</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c739">September 2030</span> - <span style="-sec-ix-hidden:c740">Oct 2030</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">81,041</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">81,013</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36.75 - 40.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c745">March 2025</span> - <span style="-sec-ix-hidden:c746">Sep 2031</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">58,753</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">52,957</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.97</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c750">March 2025</span> - <span style="-sec-ix-hidden:c751">Feb 2032</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black; text-align: right;">111,116</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">62,288</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.10 - 10.01</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c756">March 2025</span> - <span style="-sec-ix-hidden:c757">Oct 2033</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">383,040</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">328,388</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 23%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 23%;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The options exercisable at September 30, 2024 had a weighted average exercise price of $27.55 and an intrinsic value of $66.00 and a weighted average remaining life of 76 months. There were 54,652 options at September 30, 2024 that had not vested with a weighted average exercise price of $9.24 and an intrinsic value of $134.00 and a weighted average remaining life of 102 months.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The fair value of options granted during the years ended September 30, 2024 and 2023 was estimated using the Black-Scholes option valuation model using the following assumptions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.92</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.62% - 4.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (years)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5</p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5</p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected share price volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">97.26</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95.3% - 97.34</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>









<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The Company recorded $0.5 million and $1.2 million of share-based compensation expenses for the years ended September 30, 2024 and 2023, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As of September 30, 2024, the Company had approximately $0.1 million of unrecognized share-based compensation expense, which is expected to be recognized over a period of 24 months.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Restricted share units</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company's 2019 Plan allows restricted share units (RSUs) to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the RSU term is not to exceed 10 years. The fair value is based on the 5-day VWAP of the Company's common shares up to the date of grant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The following is a summary of changes in the status of RSUs from October 1, 2022 through September 30, 2024:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of RSU (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Grant Date Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2022</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 65.6%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">46,602</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Converted to common shares</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(13,557</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">5.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">33,045</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">30,159</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">4.56</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">63,204</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5.10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">The following table summarizes information about the RSUs under the 2019 Plan outstanding and exercisable at September 30, 2024:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of RSU (#) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiry Date</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fully-vested RSUs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">63,204</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">August 2033 - September 2034</p>
			</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The RSUs that were granted in the current year was for compensation to the Company&#8217;s Chief Executive Officer who is receiving 50% of his salary in RSUs. In the comparative period, RSUs were granted in lieu of cash bonuses for certain employees and in lieu of payments on consulting invoices for services prior to the appointment of the new Chief Financial Officer. All RSUs that were granted vested immediately upon the grant date. The outstanding RSUs can be converted to common shares by the holder at any time prior to the expiry date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">There is <span style="-sec-ix-hidden:c646">no</span> future unrecorded compensation expense for the RSUs.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331457930256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Government Contributions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTextBlock', window );">Government Assistance [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>9. Government Contributions</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>SIF</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Reimbursement grant income for the Company&#8217;s federal grant with the Canadian government&#8217;s SIF is recorded based on the claim period of eligible costs.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>











<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2023, the Company entered into the 2023 SIF Agreement with the Canadian Government. Under the 2023 SIF Agreement, the Government of Canada committed up to C$23 million in partially repayable funding toward (i) conducting and completing the Company&#8217;s Phase 3 clinical study of its experimental drug EB05 in critical-care patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 or other infectious agents, (ii) submitting EB05 for governmental approvals and manufacturing scale-up, following, and subject to, completing the Phase 3 study and (iii) conducting two non-clinical safety studies to assess the potential long-term impact of EB05 exposure (the Project). Of the C$23 million committed by SIF, up to C$5.8 million is not repayable by the Company. The remaining C$17.2 million is conditionally repayable starting in 2029 only if and when the Company earns gross revenue. The repayable portion would be payable over fifteen (15) years based on a percentage rate of the Company&#8217;s annual revenue growth. The maximum amount repayable under the Agreement is 1.4 times the original repayable amount. In addition, the Company is entitled to partial reimbursement of certain eligible expenses under the Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the Agreement, the Company agreed to certain financial and non-financial covenants and other obligations in relation to the Project. Pursuant to the Agreement, certain customary events of default, such as the Company&#8217;s or Edesa Biotech Research&#8217;s breach of their covenants and obligations under the Agreement, their insolvency, winding up or dissolution, and other similar events, may permit the Government of Canada to declare an event of default under the Agreement. Upon an event of default, subject to applicable cure, the Government of Canada may exercise a number of remedies, including suspending or terminating funding under the Agreement, demanding repayment of funding previously received and/or terminating the Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The funding and any associated conditional repayments are not secured by any assets of Edesa Biotech Research or the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Agreement will expire on the later of December 31, 2042 or the date of the last repayment, unless earlier terminated, subject to certain provisions that extend three (3) years beyond the term or early termination of the Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Under the October 2023 SIF Agreement the Company recorded grant income of $0.7 million and $0.6 million for the years ended September 30, 2024 and September 30, 2023, respectively.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Canada Emergency Business Account</i></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;">During year ended September 30, 2024, the Company recognized a $20,000 Canadian dollar gain from loan forgiveness related to its Canada Emergency Business Account (CEBA) loan. This forgiveness was granted upon successful repayment of $40,000 Canadian dollar of the loan balance, in accordance with CEBA program terms. The forgiven amount is recorded as other income in the consolidated statements of operations. The CEBA loan has been fully repaid and closed with CIBC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331551941584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Tax<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><b>10. Income Tax</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The reconciliation of the combined Canadian federal and provincial statutory income tax rate to the approximate effective tax rate is as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss before recovery of income taxes</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(6,169,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(8,374,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canadian federal and provincial statutory income tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26.5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>%</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26.5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected income tax recovery</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,635,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,219,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effect of foreign currency and foreign tax rate differences</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(58,200</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(207,200</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">147,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">339,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share issuance cost booked through equity or capitalization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(89,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital losses limitation - U.S.</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">899,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(38,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(94,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,549,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,372,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax (recovery) expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">800</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">800</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>











<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Components of the net deferred tax asset or liability</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Deferred taxes are provided as a result of temporary differences that arise due to the difference between the income tax values and the carrying amount of assets and liabilities. Approximate deferred tax assets and liabilities are as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital losses carried forward - Canada</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">15,547,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">13,943,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital losses carried forward - U.S.</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">742,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">731,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,504,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,371,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share issuance and financing costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">381,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">585,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">25,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other temporary differences</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">21,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">44,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Subtotal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">18,200,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">16,699,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(18,074,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(16,466,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total net deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">126,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">233,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(3,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(5,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(24,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant Income receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(71,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(153,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred share issuance costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(48,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(53,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(126,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(233,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred taxes</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Realization of the deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. It is more likely than not that a tax benefit will not be realized. Accordingly, net deferred tax assets have been fully offset by a valuation allowance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Non-capital losses, capital losses, and research and development credits generated by Edesa Biotech USA, Inc. prior to changes in share ownership that occurred as a result of the reverse acquisition are substantially limited. It is unlikely that tax losses totaling $32.7&#160;million and credits totaling $0.6 million will be utilized to offset potential future taxable income before expiration and they are excluded from deferred tax assets above.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>











<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The approximate Canadian non-capital losses carried forward at September 30, 2024 expire as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">16,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">41,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">84,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">171,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">507,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2030</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">633,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2031</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">504,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2032</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">496,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2033</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">79,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2034</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,432,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2035</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,628,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2036</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,637,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2037</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,564,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2038</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,580,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2039</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,279,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2040</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,904,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2041</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9,366,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2042</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">16,191,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2043</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,890,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2044</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">6,260,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">C$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">58,262,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Share issuance and financing costs will be fully amortized in 2027.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The U.S. non-capital losses carried forward at September 30, 2024 totaled approximately $3.42&#160;million, which do not expire for federal taxes. The U.S. state research and development tax credits carried forward at September 30, 2024 totaled approximately $0.6 million, which do not expire for state taxes. The approximate U.S. state non-capital losses carried forward at September 30, 2024 expire as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2039</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">70,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2040</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">150,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2041</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">68,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2042</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2044</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">41,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">335,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331457930256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>11. Financial instruments</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>(a) Fair values</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<div>&#160;</div>









<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">There are three levels of inputs that may be used to measure fair value:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt; text-align: justify;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Level 3 - Unobservable inputs for the asset or liability that are supported by little or no market activity.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The carrying value of certain financial instruments such as cash and cash equivalents, accounts and other receivable, accounts payable and accrued liabilities approximates fair value due to the short-term nature of such instruments.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>(b) Interest rate and credit risk</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not believe that the results of operations or cash flows would be affected to any significant degree by a significant change in market interest rates, relative to interest rates on cash and cash equivalents due to the short-term nature of these balances.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company is also exposed to credit risk at year end from the carrying value of its cash and cash equivalents and accounts and other receivable. The Company manages this risk by maintaining bank accounts with Canadian Chartered Banks, U.S. banks believed to be credit worthy and money market mutual funds of U.S. government securities. The Company&#8217;s cash is not subject to any external restrictions. The Company assesses the collectability of accounts and receivables through a review of the current aging and terms, as well as an analysis of historical collection rates, general economic conditions and credit status of government agencies. Credit risk for the reimbursement grant and HST refunds receivable are not considered significant since amounts are due from the Canadian government&#8217;s SIF and the Canada Revenue Agency.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>(c) Foreign exchange risk</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company and its subsidiary have balances in Canadian dollars that give rise to exposure to foreign exchange (FX) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks. At September 30, 2024, the Company and its Canadian subsidiary had assets denominated in Canadian dollars of approximately C$0.04 million and the U.S. dollar exchange rate at this date was equal to 1.3517 Canadian dollars. Based on the exposure at September 30, 2024, a 10% annual change in the Canadian/U.S. exchange rate would impact the Company&#8217;s loss and other comprehensive loss by approximately $0.04 million.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>(d) Liquidity risk</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331542476080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>12. Related party transactions</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">During each of the years ended September 30, 2024 and 2023, the Company paid cash of $78,000 and $82,000, respectively, for a ROU lease from a company controlled by the Company's CEO. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by both parties. On December 31, 2022, the Company executed a <span style="-sec-ix-hidden:c979">two</span>-year lease extension through December 31, 2024 in accordance with the terms of the original lease agreement. Rents of approximately $30,000 and $15,000 were payable at September 30, 2024, and September 30, 2023, respectively.&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company agreed to pay a monthly standby fee for the term of the Credit Agreement, which amounted to $51,000 in September 2024 and nil in September 2023.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331459307664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><b>13. Subsequent events</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On October 4, 2024, the Company entered into an At The Market Offering Agreement with H.C. Wainwright &amp; Co., LLC as a sales agent (HCW ATM) pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $3.87 million in gross proceeds. The Company has no obligation to sell any of the common shares and may at any time suspend sales or terminate the equity distribution agreement in accordance with its terms. Subsequent to the year ended September 30, 2024, the Company sold a total of 220,269 common shares pursuant to the agreement for net proceeds of approximately $0.6 million after deducting sales commissions.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In October 2024, the Company entered into a Securities Purchase Agreement with PN MPC, an entity controlled by Pardeep Nijhawan, the Company&#8217;s Chief Executive Officer, Secretary and member of the board of directors of the Company, pursuant to which the Company agreed to issue and sell to PN MPC in a private placement, up to $5 million of shares (Preferred Shares) of the Company&#8217;s newly designated Series A-1 Convertible Preferred Shares, stated value $10,000 per share, each of which is initially convertible into approximately 2,903 common shares (Conversion Shares), without par value, of the Company (Common Shares) at a conversion price of $3.445 per Conversion Share, and warrants (Warrants) to purchase Common Shares (Warrant Shares) at an exercise price of $3.445 per Warrant Share. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of Common Shares equal to 75% of the underlying Conversion Shares at a combined purchase price of $10,272.13 per Preferred Share and related Warrants. Under the Purchase Agreement, PN MPC has purchased 150 Preferred Shares initially convertible into an aggregate of 435,414 Conversion Shares and Warrants to purchase up to an aggregate of 326,560 Warrant Shares for an aggregate purchase price of $1,540,819. The Warrants expire <span style="-sec-ix-hidden:c998">five</span> years from the issuance date.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">As a result of the foregoing transactions&#160;and as of the date of this filing, the Company believes it has shareholders&#8217; equity of at least $2.5 million and therefore satisfies the minimum Nasdaq listing requirement set forth in Nasdaq Listing Rule 5550(b)(1).</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331453823600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Use of estimates</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period or year. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are valuation of accounts and other receivable; valuation and useful lives of property and equipment; intangible assets; right-of-use assets; deferred income taxes; the determination of fair value of share-based compensation; the determination of fair value of warrants in order to allocate proceeds from equity issuances; and forecasting future cash flows for assessing the going concern assumption.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_FunctionalAndReportingCurrenciesPolicyTextBlock', window );">Functional and Reporting Currencies [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Functional and reporting currencies</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company&#8217;s and its wholly owned subsidiary&#8217;s, Edesa Biotech USA, Inc., functional currency. The functional currency of the Company&#8217;s wholly owned subsidiary, Edesa Biotech Research, Inc., as determined by management, is Canadian dollars.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Cash and cash equivalents</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Cash and cash equivalents consist of demand deposits with financial institutions held in checking, savings and money market mutual funds and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Accounts and other receivables</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company assesses the collectability of its accounts receivables through a review of its current aging and payment terms, as well as an analysis of its historical collection rate, general economic conditions and credit status of the government agencies. Accounts and other receivables include reimbursement grant income for the Company&#8217;s federal grant with the Canadian government&#8217;s SIF and Harmonized Sales Tax (HST) refunds receivables. As of September 30, 2024, all outstanding accounts, grants and HST refunds receivables were deemed to be fully collectible, and therefore, <span style="-sec-ix-hidden:c304">no</span> allowance for doubtful accounts was recorded.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Property and equipment&#160;</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Property and equipment are recorded at historical cost less accumulated depreciation and any accumulated impairment losses. Depreciation is recorded to write off the cost of assets less their residual values over their useful lives, using the declining balance and straight-line methods. Maintenance and repair expenditures that do not improve or extend the life are expensed in the period incurred. Any gain or loss arising on the disposal or retirement of an item of property and equipment is recognized as the difference between the sales proceeds and the carrying amount of the asset. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. The Company capitalizes expenditures greater than $5,000. The Company changed its depreciation policy to straight line depreciation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The depreciation policy for the principal asset categories are calculated as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Computer equipment 30% declining balance method or straight line 3 years</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 27pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Furniture and equipment 20% declining balance method&#160;or straight line for 4 years</p>
			</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Intangible assets</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Intangible assets represent the exclusive world-wide rights to know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights, acquired by entering into a license agreement with a pharmaceutical development company. Unless earlier terminated, the term of the license agreement will remain in effect for 25 years from the date of first commercial sale of licensed products containing the Constructs. Subsequently, the license agreement will automatically renew for <span style="-sec-ix-hidden:c311">five</span>-year periods unless either party terminates the agreement in accordance with its terms. Intangible assets are stated at their historical cost, amortized on a straight-line basis over their expected useful lives, which is 25 years, and subject to impairment review at the end of each year.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Impairment of long-lived assets</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Long-lived assets are tested for impairment when indicators of impairment exist. When a significant change in the expected timing or amount of the future cash flows of the financial asset is identified, the carrying amount of the financial asset is reduced and the amount of the write-down is recognized as a loss.&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Right-of-Use assets and liabilities</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company recognizes right-of-use (ROU) assets and liabilities on the balance sheet for operating leases with terms longer than 12 months. The Company follows the ongoing practical expedient not to recognize ROU assets and liabilities for short-term leases. The ROU assets are initially measured at cost and amortized using the straight-line method through the end of the lease term. The ROU liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the Company's incremental borrowing rate.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Fair value measurement</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company uses the fair value measurement framework for valuing financial assets and liabilities. See Note 11.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Reimbursement Grant Income</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Reimbursement grant income is recognized based on the reimbursement rate included in the government contribution agreement when allowable expenses have been incurred.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Research and development</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Research and development expenses principally consist of (i) contract research organizations for clinical trial management services, (ii) contract manufacturing organizations for manufacturing the drug compound(s) for use in clinical trials and (iii) salaries of employees directly involved in research and development efforts. Research and development costs are expensed as incurred.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Share-based compensation</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company has equity incentive plans under which various types of equity-based awards including share options, restricted shares and restricted share unit awards may be granted to employees, non-employee directors and non-employee consultants and warrants that may be granted as compensation to non-employees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company recognizes compensation expense for all share-based awards based on the estimated grant-date fair values. For restricted share unit awards to employees, the fair value is based on the 5-day volume weighted average price (VWAP) of the Company&#8217;s common shares up to the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The fair value of share options is determined using the Black-Scholes option pricing model. The Company utilizes a dividend yield of <span style="-sec-ix-hidden:c313">zero</span> based on the fact that the Company has never paid cash dividends and has no current intention of paying cash dividends. The Company elected an accounting policy to record forfeitures as they occur. See Note 8 for a discussion of the assumptions used by the Company in determining the grant date fair value of options granted under the Black-Scholes option pricing model, as well as a summary of the share option activity under the Company&#8217;s share-based compensation plan for all years presented.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The provisions of the Company&#8217;s share-based compensation plans do not require the Company to settle any options or restricted share units by transferring cash or other assets, and therefore the Company classifies the awards as equity.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translations Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Translation of foreign currency transactions</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s reporting currency is the U.S. dollar. The financial statements of the wholly owned Canadian subsidiary is measured using the Canadian dollar as the functional currency. Assets and liabilities of the Canadian operation have been translated at year-end exchange rates and related revenue and expenses have been translated at average exchange rates for the year. Accumulated gains and losses resulting from the translation of the financial statements of the Canadian operation are included as part of accumulated other comprehensive loss, a separate component of shareholders&#8217; equity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">For other transactions denominated in currencies other than the Company&#8217;s functional currency, the monetary assets and liabilities are translated at the year-end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. Non-monetary balance sheet and related income statement accounts are remeasured into U.S. dollar using historical exchange rates. All of the exchange gains or losses resulting from these other transactions are recognized in the statements of operations and comprehensive loss.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Income taxes</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company assesses the likelihood of the financial statement effect of a tax position that should be recognized when it is more likely than not that the position will be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information available as of the reporting date. The Company is subject to examination by taxing authorities in Canada and the U.S. Management does not believe that there are any uncertain tax positions that would result in an asset or liability for taxes being recognized in the accompanying financial statements. The Company recognizes tax-related interest and penalties, if any, as a component of income tax expense.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company accounts for income taxes on a tax jurisdictional basis. The Company files income tax returns in Canada, the provinces of British Columbia and Ontario, the U.S. and the state of California.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Earnings (loss) per share</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">Basic earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the year.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The computation of diluted earnings (loss) per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings (loss) per share. The dilutive effect of convertible securities would be reflected in diluted earnings per share by application of the &#8220;if converted&#8221; method. The dilutive effect of outstanding share options and warrants and their equivalents would be reflected in diluted earnings per share by application of the treasury stock method. However, conversion of outstanding share options and warrants would have an antidilutive effect on loss per share for the years ended September 30, 2024 and 2023 and are therefore excluded from the computation of diluted loss per share. See Note 8 for share options and warrants at September 30, 2024 and 2023.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Segmented information</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">The Company&#8217;s operations comprise a single reportable segment engaged in the research and development, manufacturing and commercialization of innovative pharmaceutical products. As the operations comprise a single reportable segment, amounts disclosed in the consolidated financial statements for net loss, comprehensive loss, depreciation and total assets also represent segmented amounts.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Adoption of recent accounting pronouncements</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">On October 1, 2022, the Company adopted Accounting Standards Update ASU 2021-10 Disclosure by Business Entities About Government Assistance, modifying ASC Topic 832, Government Assistance. The amendments in ASU 2021-10 require disclosure of information about certain types of government assistance received. The Company expanded its disclosures related to government assistance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"><i>Future accounting pronouncements</i></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In November 2023, the FASB issued Accounting Standards Update ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of&#160;Income Statement Expenses (&#8220;ASU 2024-03&#8221;), which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation&#160;table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_FunctionalAndReportingCurrenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the accounting policy for functional and reporting currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_FunctionalAndReportingCurrenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331542329904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">September 30, 2023</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Computer equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,945</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,945</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Furniture and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,603</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,603</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,548</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,548</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated depreciation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(52,548</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(43,846</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Depreciable assets, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,702</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets not in service</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total property and equipment, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,702</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331459139680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024 </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023 </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The Constructs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,529,483</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,529,483</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: accumulated amortization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(450,635</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(349,463</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total intangible assets, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,078,848</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,180,020</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">101,172</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,572,988</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,078,848</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331458156768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Right-of-use Asset and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use lease cost, included in general and administrative on the Statements of Operations</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">78,073</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,358</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_LeaseTermAndDiscountRateTableTextBlock', window );">Lease Term and Discount Rate [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Remaining lease term (months):</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Estimated incremental borrowing rate:</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>%</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>%</b></td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">20,019</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total lease payments</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">20,019</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less imputed interest</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">152</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value of right-of-use lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">19,867</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value included in current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">19,867</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Present value included in long-term liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_LeasesCashFlowInformationTableTextBlock', window );">Leases, Cash Flow Information [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for amounts included in the measurement of right-of-use lease liabilities, included in accounts payable and accrued liabilities on the Statements of Cash Flow.</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77,954</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">79,222</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_LeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease terms and discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_LeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_LeasesCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash flow information for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_LeasesCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331459266192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Year Ending</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">212,667</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">34,667</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">34,666</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">September 30, 2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">282,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Subparagraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331632858000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Capital Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Warrant Shares (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Exercise Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2022</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">521,718</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">28.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Issued</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">384,496</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">8.75</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Exercised</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(100,760</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7.65</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(84,545</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">37.29</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">720,909</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">19.51</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(111,192</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">7.26</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">609,717</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">21.74</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Warrants (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercise Prices </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiry Dates</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">1,687</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22.40</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c667">January 2025</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">173,614</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10.50</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c670">December 2025</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">15,627</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">56.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c673">February 2026</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">27,399</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">31.94</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c676">March 2027</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;">391,390</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">24.64</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c679">September 2027</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">609,717</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 18%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 59%;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended September 30,2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Class A Warrants</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Class B Warrants</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.54</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (years)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">3.14</p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">1.14</p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected share price volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">90.73</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Options (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Exercise Price</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Grant Date Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2022</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">314,853</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">32.62</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">23.94</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">118,579</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7.47</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.23</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(12,779</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">22.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">16.23</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,973.20</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">1,973.20</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">420,615</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">25.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">18.84</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">500</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">4.10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3.10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,401</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">15.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">10.70</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(35,674</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">33.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">25</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">383,040</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">24.93</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">18.33</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of Options (#) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Exercisable at<br/>
			September 30, 2024 (#) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Range of Exercise Prices </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiry Dates</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">374</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">374</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">246.96</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c725">March 2025</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">37,719</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">37,719</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c729">August 2027</span> - <span style="-sec-ix-hidden:c730">Dec 2028</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">43,031</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">43,031</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c734">Feb 2030</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">51,006</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">51,006</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52.08 - 56.49</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c739">September 2030</span> - <span style="-sec-ix-hidden:c740">Oct 2030</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">81,041</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">81,013</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36.75 - 40.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c745">March 2025</span> - <span style="-sec-ix-hidden:c746">Sep 2031</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">58,753</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">52,957</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.97</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c750">March 2025</span> - <span style="-sec-ix-hidden:c751">Feb 2032</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black; text-align: right;">111,116</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">62,288</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 23%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.10 - 10.01</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"><span style="-sec-ix-hidden:c756">March 2025</span> - <span style="-sec-ix-hidden:c757">Oct 2033</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">383,040</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 23%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">328,388</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 23%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 23%;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30, 2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.92</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.62% - 4.18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life (years)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5</p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">&#160;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5</p>

			<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;">&#160;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected share price volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">97.26</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95.3% - 97.34</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0.00</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of RSU (#)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted Average Grant Date Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2022</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 65.6%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">46,602</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Converted to common shares</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(13,557</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">5.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2023</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">33,045</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5.60</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">30,159</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">4.56</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Balance - September 30, 2024</b></p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">63,204</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5.10</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock', window );">Share-Based Compensation Arrangements by Share-Based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of RSU (#) </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiry Date</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fully-vested RSUs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">63,204</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">August 2033 - September 2034</p>
			</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331450335232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Tax (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss before recovery of income taxes</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(6,169,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(8,374,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canadian federal and provincial statutory income tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26.5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>%</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26.5</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected income tax recovery</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,635,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,219,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effect of foreign currency and foreign tax rate differences</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(58,200</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(207,200</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Permanent differences</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">147,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">339,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share issuance cost booked through equity or capitalization</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(89,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital losses limitation - U.S.</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">899,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(38,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(94,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,549,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,372,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Income tax (recovery) expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">800</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">800</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>September 30,<br/>
			2023</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital losses carried forward - Canada</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">15,547,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">13,943,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-capital losses carried forward - U.S.</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">742,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">731,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,504,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,371,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share issuance and financing costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">381,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">585,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use lease liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">25,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other temporary differences</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">21,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">44,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Subtotal</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">18,200,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">16,699,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less: valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(18,074,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(16,466,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total net deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">126,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">233,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Property and equipment</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(3,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(5,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(24,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant Income receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(71,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">(153,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred share issuance costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>&#160;</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(48,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(53,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(126,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>)</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(233,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net deferred taxes</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><b>$</b></td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Operating Loss Carryforwards [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">C$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">16,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">41,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">84,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2028</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">171,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2029</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">507,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2030</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">633,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2031</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">504,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2032</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">496,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2033</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">79,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2034</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,432,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2035</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,628,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2036</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,637,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2037</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,564,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2038</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,580,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2039</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">1,279,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2040</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">5,904,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2041</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">9,366,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2042</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">16,191,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2043</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">7,890,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2044</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">6,260,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">C$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">58,262,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2039</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">70,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2040</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">150,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2041</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">68,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2042</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">6,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2044</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">41,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">335,000</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331446360288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Nature of Operations (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 04, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 02, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 13, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,198,010)<span></span>
</td>
<td class="num">$ (8,375,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,418,968<span></span>
</td>
<td class="nump">58,589,013<span></span>
</td>
<td class="nump">52,418,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,890,205)<span></span>
</td>
<td class="num">(6,636,483)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_WorkingCapitalDeficit', window );">Working Capital (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by (Used in) Operating Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,890,205<span></span>
</td>
<td class="nump">6,636,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,170,045<span></span>
</td>
<td class="nump">$ 8,374,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 729,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.51<span></span>
</td>
<td class="nump">$ 21.74<span></span>
</td>
<td class="nump">$ 19.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceNonoperatingIncome', window );">Government Assistance, Nonoperating Income, Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 698,277<span></span>
</td>
<td class="nump">$ 581,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Pardeep Nijhawan Medicine Professional Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal', window );">Debt Instrument, Covenant, Maximum Percentage of Borrowing Base for Outstanding Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=edsa_UnsecuredLineOfCreditMember', window );">Unsecured Line of Credit [Member] | Pardeep Nijhawan Medicine Professional Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Pardeep Nijhawan Medicine Professional Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=edsa_The2023SIFAgreementMember', window );">The 2023 SIF Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAwardAmount', window );">Government Assistance, Award Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_GovernmentAssistanceAwardAmountNotRepayable', window );">Government Assistance, Award Amount, Not Repayable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_GovernmentAssistanceAwardAmountRepyable', window );">Government Assistance, Award Amount, Repyable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceNonoperatingIncome', window );">Government Assistance, Nonoperating Income, Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=edsa_The2021SIFAgreementMember', window );">The 2021 SIF Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAwardAmount', window );">Government Assistance, Award Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_TwelveMonthWarrantsMember', window );">Twelve Month Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ThreeYearWarrantsMember', window );">Three Year Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=edsa_CanaccordMember', window );">Canaccord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingLimitationAmount', window );">Equity Offering, Limitation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=edsa_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_PrivatePlacementSecuritiesPurchaseAgreementMember', window );">Private Placement, Securities Purchase Agreement [Member] | Warrants to Purchase Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series A-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement [Member] | Series A-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | At The Market Offering Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="nump">$ 3,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="nump">220,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement, Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,540,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred Stock, Convertible, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,272.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement, Securities Purchase Agreement [Member] | Warrants to Purchase Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement, Securities Purchase Agreement [Member] | Series A-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement, Securities Purchase Agreement [Member] | Series A-1 Convertible Preferred Stock [Member] | Conversion of Series A-1 Convertible Preferred Shares to Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred Stock, Convertible, Shares Issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred Stock, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of the borrowing base for outstanding principal allowed under the covenant of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_EquityOfferingLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of limitation on equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_EquityOfferingLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_EquityOfferingMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount allowed to be issued under the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_EquityOfferingMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_GovernmentAssistanceAwardAmountNotRepayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met that will not be repayable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_GovernmentAssistanceAwardAmountNotRepayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_GovernmentAssistanceAwardAmountRepyable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met that will be repayable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_GovernmentAssistanceAwardAmountRepyable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information pertaining to the working capital (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in income from government assistance, classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=edsa_PardeepNijhawanMedicineProfessionalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=edsa_PardeepNijhawanMedicineProfessionalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=edsa_UnsecuredLineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=edsa_UnsecuredLineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=edsa_The2023SIFAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=edsa_The2023SIFAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=edsa_The2021SIFAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=edsa_The2021SIFAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_TwelveMonthWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_TwelveMonthWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ThreeYearWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_ThreeYearWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edsa_CanaccordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edsa_CanaccordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=edsa_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=edsa_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_PrivatePlacementSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=edsa_PrivatePlacementSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantsToPurchaseCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantsToPurchaseCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=edsa_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331446823184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables', window );">Allowance for Doubtful Accounts, Premiums and Other Receivables</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_LicenseAgreementRenewalPeriod', window );">License Agreement, Renewal Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=edsa_CapitalizedCostsPropertyPlantAndEquipmentMember', window );">Capitalized Costs, Property Plant and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property, Plant and Equipment, Additions</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_DepreciationDecliningBalanceMethodPercentage', window );">Depreciation, Declining Balance Method, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=edsa_FurnitureAndEquipmentMember', window );">Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_DepreciationDecliningBalanceMethodPercentage', window );">Depreciation, Declining Balance Method, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_DepreciationDecliningBalanceMethodPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the declining balance method for depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_DepreciationDecliningBalanceMethodPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_LicenseAgreementRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for renewal of the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_LicenseAgreementRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=edsa_CapitalizedCostsPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=edsa_CapitalizedCostsPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=edsa_FurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=edsa_FurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331446791008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 8,702<span></span>
</td>
<td class="nump">$ 4,328<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331446822640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Property and Equipment - Schedule of Property, Plant, and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 52,548<span></span>
</td>
<td class="nump">$ 52,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(52,548)<span></span>
</td>
<td class="num">(43,846)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService', window );">Depreciable assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_PropertyPlantAndEquipmentAssetsNotInService', window );">Assets not in service</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">46,945<span></span>
</td>
<td class="nump">46,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,603<span></span>
</td>
<td class="nump">$ 5,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_PropertyPlantAndEquipmentAssetsNotInService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets of assets not in service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_PropertyPlantAndEquipmentAssetsNotInService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale, including assets not in service. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331459536672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Intangible Assets (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,172.0<span></span>
</td>
<td class="nump">$ 101,172.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_LicenseAgreementRenewalPeriod', window );">License Agreement, Renewal Period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_UpfrontLicensePayment', window );">Upfront License Payment</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_LicenseAgreementRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for renewal of the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_LicenseAgreementRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_UpfrontLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront license payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_UpfrontLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331459072416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">$ (450,635)<span></span>
</td>
<td class="num">$ (349,463)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="nump">2,078,848<span></span>
</td>
<td class="nump">2,180,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=edsa_TheConstructsMember', window );">The Constructs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">The Constructs</a></td>
<td class="nump">$ 2,529,483<span></span>
</td>
<td class="nump">$ 2,529,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=edsa_TheConstructsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=edsa_TheConstructsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331458413584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Intangible Assets - Estimated Future Amortization (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">September 30, 2025</a></td>
<td class="nump">$ 101,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">September 30, 2026</a></td>
<td class="nump">101,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">September 30, 2027</a></td>
<td class="nump">101,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">September 30, 2028</a></td>
<td class="nump">101,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">September 30, 2029</a></td>
<td class="nump">101,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,572,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total intangible assets, net</a></td>
<td class="nump">$ 2,078,848<span></span>
</td>
<td class="nump">$ 2,180,020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331446800944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Right-of-use Asset and Liabilities (Details Textual)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331443892272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Right-of-use Assets and Liabilities - Lease Cost (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Right-of-use lease cost, included in general and administrative on the Statements of Operations</a></td>
<td class="nump">$ 78,073<span></span>
</td>
<td class="nump">$ 82,358<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331458680896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Right-of-use Assets and Liabilities - Lease Terms and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term (months): (Month)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">15 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Estimated incremental borrowing rate:</a></td>
<td class="nump">9.20%<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331457722816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Right-of-use Assets and Liabilities - Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">September 30, 2025</a></td>
<td class="nump">$ 20,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">20,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of right-of-use lease liabilities</a></td>
<td class="nump">19,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Present value included in current liabilities</a></td>
<td class="nump">19,867<span></span>
</td>
<td class="nump">$ 74,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Present value included in long-term liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331458791360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Right-of-use Assets and Liabilities - Cash Flow Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of right-of-use lease liabilities, included in accounts payable and accrued liabilities on the Statements of Cash Flow.</a></td>
<td class="nump">$ 77,954<span></span>
</td>
<td class="nump">$ 79,222<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331460675056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Commitments (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=edsa_CaliforniaSubsidiary401kMember', window );">California Subsidiary 401k [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 17,870<span></span>
</td>
<td class="nump">$ 16,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=edsa_TheConstructsMember', window );">The Constructs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_MaximumContingentObligation', window );">Maximum Contingent Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_PaymentsForMilestoneRoyaltyAndSublicensing', window );">Payments for Milestone, Royalty and Sublicensing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=edsa_TheConstructsMember', window );">The Constructs [Member] | Drug Substance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliers', window );">Payments to Suppliers</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember', window );">License Agreement Related to Pharmaceutical Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_MaximumContingentObligation', window );">Maximum Contingent Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedLicenseAgreementsGross', window );">Finite-Lived License Agreements, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_PaymentsForLicensingAndRoyalties', window );">Finite-Lived License Agreements, Gross</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember', window );">License Agreement to Acquire Global Rights of Pharmaceutical Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_MaximumContingentObligation', window );">Maximum Contingent Obligation</a></td>
<td class="nump">68,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_MilestoneExpense', window );">Milestone Expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_MaximumContingentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum contingent obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_MaximumContingentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_MilestoneExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_MilestoneExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_PaymentsForLicensingAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for licensing and royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_PaymentsForLicensingAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_PaymentsForMilestoneRoyaltyAndSublicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for milestone, royalty and sublicensing,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_PaymentsForMilestoneRoyaltyAndSublicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedLicenseAgreementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedLicenseAgreementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to suppliers for goods and services during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=edsa_CaliforniaSubsidiary401kMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=edsa_CaliforniaSubsidiary401kMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edsa_TheConstructsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edsa_TheConstructsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=edsa_DrugSubstanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=edsa_DrugSubstanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331450776528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Commitments - Commitments for Contractual Research (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">September 30, 2025</a></td>
<td class="nump">$ 212,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">September 30, 2026</a></td>
<td class="nump">34,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">September 30, 2027</a></td>
<td class="nump">34,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">September 30, 2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">September 30, 2029</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation</a></td>
<td class="nump">$ 282,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331450236048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Capital Shares (Details Textual) - USD ($)<br> $ / shares in Units, Pure in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 02, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 27, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 729,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.51<span></span>
</td>
<td class="nump">$ 21.74<span></span>
</td>
<td class="nump">$ 19.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm', window );">Class of Warrant or Right, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">80 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">76 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Intrinsic Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">102 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-Based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=edsa_The2019PlanMember', window );">The 2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | The 2019 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=edsa_CanaccordMember', window );">Canaccord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingLimitationAmount', window );">Equity Offering, Limitation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassAWarrantsMember', window );">Class A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 23,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassBWarrantsMember', window );">Class B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 23,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantsIssuedInPrivatePlacementMember', window );">Warrants Issued in Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,475<span></span>
</td>
<td class="nump">384,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_EquityDistributionAgreementMember', window );">Equity Distribution Agreement [Member] | Canaccord [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,916<span></span>
</td>
<td class="nump">196,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingLimitationAmount', window );">Equity Offering, Limitation Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_AtTheMarketOfferingAgreementMember', window );">At The Market Offering Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">220,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount</a></td>
<td class="nump">$ 3,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_EquityOfferingLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of limitation on equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_EquityOfferingLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_EquityOfferingMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount allowed to be issued under the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_EquityOfferingMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount by which the current fair value of the underlying stock exceeds the exercise price of options nonvested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards nonvested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=edsa_The2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=edsa_The2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=edsa_CanaccordMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=edsa_CanaccordMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantsIssuedInPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantsIssuedInPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=edsa_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=edsa_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331449404912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Capital Shares - Schedule of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, number of warrant shares (in shares)</a></td>
<td class="nump">720,909<span></span>
</td>
<td class="nump">521,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="nump">609,717<span></span>
</td>
<td class="nump">720,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Balance, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 19.51<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 21.74<span></span>
</td>
<td class="nump">$ 19.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Issued, number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice', window );">Issued, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Exercised, number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice', window );">Exercised, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ClassOfWarrantOrRightExpiredDuringPeriod', window );">Expired, number of warrant shares (in shares)</a></td>
<td class="nump">111,192<span></span>
</td>
<td class="num">(84,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice', window );">Expired, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="nump">$ 37.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ClassOfWarrantOrRightExpiredDuringPeriod', window );">Expired, number of warrant shares (in shares)</a></td>
<td class="nump">111,192<span></span>
</td>
<td class="num">(84,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice', window );">Expired, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="nump">$ 37.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, number of warrant shares (in shares)</a></td>
<td class="nump">609,717<span></span>
</td>
<td class="nump">720,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Balance, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 21.74<span></span>
</td>
<td class="nump">$ 19.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantOneMember', window );">Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Jan. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, number of warrant shares (in shares)</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Balance, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantTwoMember', window );">Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="nump">173,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, number of warrant shares (in shares)</a></td>
<td class="nump">173,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Balance, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantThreeMember', window );">Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="nump">15,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Feb. 28,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, number of warrant shares (in shares)</a></td>
<td class="nump">15,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Balance, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantFourMember', window );">Warrant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="nump">27,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 31.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Mar. 31,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, number of warrant shares (in shares)</a></td>
<td class="nump">27,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Balance, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 31.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantFiveMember', window );">Warrant Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="nump">391,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 24.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Sep. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, number of warrant shares (in shares)</a></td>
<td class="nump">391,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Balance, warrants, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 24.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ClassOfWarrantOrRightExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights cancelled during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ClassOfWarrantOrRightExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights cancelled during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331453820800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Capital Shares - Warrants Assumptions (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassAWarrantsMember', window );">Class A Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant assumption</a></td>
<td class="nump">0.0454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassAWarrantsMember', window );">Class A Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant assumption</a></td>
<td class="nump">3.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassAWarrantsMember', window );">Class A Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant assumption</a></td>
<td class="nump">0.9073<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassAWarrantsMember', window );">Class A Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant assumption</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassBWarrantsMember', window );">Class B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant assumption</a></td>
<td class="nump">0.0476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassBWarrantsMember', window );">Class B Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant assumption</a></td>
<td class="nump">1.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassBWarrantsMember', window );">Class B Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant assumption</a></td>
<td class="nump">0.897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassBWarrantsMember', window );">Class B Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant assumption</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_ClassBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331454518848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Capital Shares - Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, number of options (in shares)</a></td>
<td class="nump">420,615<span></span>
</td>
<td class="nump">314,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 25.6<span></span>
</td>
<td class="nump">$ 32.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue', window );">Balance, options, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 18.84<span></span>
</td>
<td class="nump">$ 23.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, number of options (in shares)</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">118,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 7.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, options, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 5.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, number of options (in shares)</a></td>
<td class="num">(2,401)<span></span>
</td>
<td class="num">(12,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 22.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited, options, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 10.7<span></span>
</td>
<td class="nump">$ 16.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, number of options (in shares)</a></td>
<td class="num">(35,674)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 33.18<span></span>
</td>
<td class="nump">$ 1,973.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue', window );">Expired, options, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 1,973.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, number of options (in shares)</a></td>
<td class="nump">383,040<span></span>
</td>
<td class="nump">420,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, options, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 24.93<span></span>
</td>
<td class="nump">$ 25.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue', window );">Balance, options, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 18.33<span></span>
</td>
<td class="nump">$ 18.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331458496160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Capital Shares - Schedule of Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="nump">383,040<span></span>
</td>
<td class="nump">420,615<span></span>
</td>
<td class="nump">314,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)</a></td>
<td class="nump">328,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 24.93<span></span>
</td>
<td class="nump">$ 25.6<span></span>
</td>
<td class="nump">$ 32.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 24.93<span></span>
</td>
<td class="nump">$ 25.6<span></span>
</td>
<td class="nump">$ 32.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeOneMember', window );">Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)</a></td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 246.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 246.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeTwoMember', window );">Range Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="nump">37,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)</a></td>
<td class="nump">37,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeTwoMember', window );">Range Two [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Aug. 31,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Aug. 31,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeTwoMember', window );">Range Two [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Dec. 31,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Dec. 31,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeThreeMember', window );">Range Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="nump">43,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)</a></td>
<td class="nump">43,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 22.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Feb. 28,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 22.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Feb. 28,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeFourMember', window );">Range Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="nump">51,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)</a></td>
<td class="nump">51,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">$ 52.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 56.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeFourMember', window );">Range Four [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Sep. 30,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Sep. 30,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeFourMember', window );">Range Four [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Oct. 31,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Oct. 31,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeFiveMember', window );">Range Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="nump">81,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)</a></td>
<td class="nump">81,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">$ 36.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 40.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeFiveMember', window );">Range Five [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeFiveMember', window );">Range Five [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Sep. 30,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Sep. 30,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeSixMember', window );">Range Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="nump">58,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)</a></td>
<td class="nump">52,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 25.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 25.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeSixMember', window );">Range Six [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeSixMember', window );">Range Six [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Feb. 28,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Feb. 28,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeSevenMember', window );">Range Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)</a></td>
<td class="nump">111,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)</a></td>
<td class="nump">62,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 10.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeSevenMember', window );">Range Seven [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeSevenMember', window );">Range Seven [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Oct. 31,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</a></td>
<td class="text">Oct. 31,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=edsa_RangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331443307920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Capital Shares - Option Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</a></td>
<td class="nump">3.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</a></td>
<td class="nump">4.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected share price volatility</a></td>
<td class="nump">97.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</a></td>
<td class="nump">95.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</a></td>
<td class="nump">97.34%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years) (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331555683840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Capital Shares - Restricted Stock Units (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, number of RSU (in shares)</a></td>
<td class="nump">30,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 4.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, number of RSU (in shares)</a></td>
<td class="nump">63,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, number of RSU (in shares)</a></td>
<td class="nump">33,045<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, number of RSU (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Balance, number of RSU (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331453871728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Capital Shares - Vested Restricted Stock Units (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber', window );">Fully-vested RSUs (in shares)</a></td>
<td class="nump">63,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested equity instruments other than options outstanding that can be converted into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331449733360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Government Contributions (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceNonoperatingIncome', window );">Government Assistance, Nonoperating Income, Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 698,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 581,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=edsa_The2023SIFAgreementMember', window );">The 2023 SIF Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAwardAmount', window );">Government Assistance, Award Amount</a></td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_GovernmentAssistanceAwardAmountNotRepayable', window );">Government Assistance, Award Amount, Not Repayable</a></td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_GovernmentAssistanceAwardAmountRepayable', window );">Government Assistance, Award Amount, Repayable</a></td>
<td class="nump">$ 17,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_GovernmentAssistancePeriodOfRepayment', window );">Government Assistance, Period of Repayment</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal', window );">Government Assistance, Maximum Amount Repayable, Factor of Original</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment', window );">Government assistance, Expiration, Period After Last Repayment</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceNonoperatingIncome', window );">Government Assistance, Nonoperating Income, Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=edsa_CanadaEmergencyBusinessAccountProgramMember', window );">Canada Emergency Business Account Program [Member] | CIBC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Debt Instrument, Decrease, Forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_GovernmentAssistanceAwardAmountNotRepayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met that will not be repayable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_GovernmentAssistanceAwardAmountNotRepayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_GovernmentAssistanceAwardAmountRepayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met that will be repayable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_GovernmentAssistanceAwardAmountRepayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period after last repayment date for expiration of government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The factor of original amount repayable for maximum amount to be repaid for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_GovernmentAssistancePeriodOfRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of repayment for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_GovernmentAssistancePeriodOfRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in income from government assistance, classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=edsa_The2023SIFAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=edsa_The2023SIFAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=edsa_CanadaEmergencyBusinessAccountProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=edsa_CanadaEmergencyBusinessAccountProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=edsa_CIBCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=edsa_CIBCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331455127728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Income Tax (Details Textual)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating Loss Carryforwards, Valuation Allowance</a></td>
<td class="nump">$ 32,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Tax Credit Carryforward, Valuation Allowance</a></td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">335,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member] | Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">3,420,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331459534064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Income Tax - Schedule of Income Tax Reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests', window );">Net loss before recovery of income taxes</a></td>
<td class="num">$ (6,169,000)<span></span>
</td>
<td class="num">$ (8,374,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Canadian federal and provincial statutory income tax rate</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected income tax recovery</a></td>
<td class="num">$ (1,635,000)<span></span>
</td>
<td class="num">$ (2,219,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Effect of foreign currency and foreign tax rate differences</a></td>
<td class="num">(58,200)<span></span>
</td>
<td class="num">(207,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">147,000<span></span>
</td>
<td class="nump">339,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization', window );">Share issuance cost booked through equity or capitalization</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="num">(89,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation', window );">Non-capital losses limitation - U.S.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">899,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(38,000)<span></span>
</td>
<td class="num">(94,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,549,000<span></span>
</td>
<td class="nump">1,372,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (recovery) expense</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to non-capital losses limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to share issuance costs booked through equity or capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331461675024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">$ 1,504,000<span></span>
</td>
<td class="nump">$ 1,371,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts', window );">Share issuance and financing costs</a></td>
<td class="nump">381,000<span></span>
</td>
<td class="nump">585,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_DeferredTaxAssetsRightofuseLeaseLiabilities', window );">Right-of-use lease liabilities</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">18,200,000<span></span>
</td>
<td class="nump">16,699,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(18,074,000)<span></span>
</td>
<td class="num">(16,466,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total net deferred tax assets</a></td>
<td class="nump">126,000<span></span>
</td>
<td class="nump">233,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(24,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_DeferredTaxLiabilitiesGrantIncomeReceivable', window );">Grant Income receivable</a></td>
<td class="num">(71,000)<span></span>
</td>
<td class="num">(153,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts', window );">Deferred share issuance costs</a></td>
<td class="num">(48,000)<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(126,000)<span></span>
</td>
<td class="num">(233,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember', window );">Canada Revenue Agency [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Non-capital losses carried forward - Canada</a></td>
<td class="nump">15,547,000<span></span>
</td>
<td class="nump">13,943,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Non-capital losses carried forward - U.S.</a></td>
<td class="nump">$ 742,000<span></span>
</td>
<td class="nump">$ 731,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_DeferredTaxAssetsRightofuseLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to right-of-use lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_DeferredTaxAssetsRightofuseLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to share issuance and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from deferred share issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_DeferredTaxLiabilitiesGrantIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from grant income receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_DeferredTaxLiabilitiesGrantIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331450676128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Income Tax - Summary of Operating Loss Carryforwards (Details) - Sep. 30, 2024<br></strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CAD ($)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,262,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,279,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2040 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,904,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2041 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,366,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2042 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,191,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2044 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,260,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2028 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2029 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2030 [Member[</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2033 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2034 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,432,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2035 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,628,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2036 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,637,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,564,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,580,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Tax Year 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,890,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 335,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member] | Tax Year 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member] | Tax Year 2040 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member] | Tax Year 2041 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member] | Tax Year 2042 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member] | Tax Year 2044 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=edsa_TaxYear2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=edsa_TaxYear2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331458429968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Financial Instruments (Details Textual)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetReportingCurrencyDenominatedValue', window );">Net Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Currency Exchange Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss', window );">Sensitivity Analysis, Ten Percent Change to Foreign Currency Exchange, Impact to Net Income (Loss) and Other Comprehensive Income (Loss)</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impact to net income (loss) and other comprehensive income (loss) from 10% change in foreign currency exchange rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetReportingCurrencyDenominatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reporting currency-denominated asset value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetReportingCurrencyDenominatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331453847504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Related Party Transactions (Details Textual) - Chief Executive Officer [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRentCurrentAndNoncurrent', window );">Accrued Rent</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45331461640048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Subsequent Events (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 04, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 729,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.74<span></span>
</td>
<td class="nump">$ 19.51<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=edsa_SeriesA1ConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series A-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_AtTheMarketOfferingAgreementMember', window );">At The Market Offering Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_edsa_EquityOfferingMaximumAmount', window );">Equity Offering, Maximum Amount | $</a></td>
<td class="nump">$ 3,870,000<span></span>
</td>
<td class="nump">$ 3,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="nump">220,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_PrivatePlacementSecuritiesPurchaseAgreementMember', window );">Private Placement, Securities Purchase Agreement [Member] | Warrants to Purchase Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_PrivatePlacementSecuritiesPurchaseAgreementMember', window );">Private Placement, Securities Purchase Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred Stock, Convertible, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,272.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,540,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_PrivatePlacementSecuritiesPurchaseAgreementMember', window );">Private Placement, Securities Purchase Agreement [Member] | Subsequent Event [Member] | Warrants to Purchase Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_PrivatePlacementSecuritiesPurchaseAgreementMember', window );">Private Placement, Securities Purchase Agreement [Member] | Subsequent Event [Member] | Series A-1 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_PrivatePlacementSecuritiesPurchaseAgreementMember', window );">Private Placement, Securities Purchase Agreement [Member] | Subsequent Event [Member] | Series A-1 Convertible Preferred Stock [Member] | Conversion of Series A-1 Convertible Preferred Shares to Common Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred Stock, Convertible, Shares Issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Preferred Stock, Convertible, Conversion Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_edsa_EquityOfferingMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount allowed to be issued under the equity offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">edsa_EquityOfferingMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>edsa_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=edsa_SeriesA1ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=edsa_SeriesA1ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=edsa_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=edsa_PrivatePlacementSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=edsa_PrivatePlacementSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantsToPurchaseCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=edsa_WarrantsToPurchaseCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M1@4A7:#Y6_S((BW! Q%C/->/_D:C@2FU,J4B'-BPJ]^V,'3]ZB\Q79#*='!
MZ&XT'X_^TO(R&@E,J96G3HM,X-3*!%])%+6?J;1ALH_B1 YN 9HF2:H?W0YH
MWC'M+*S1)&!*K8RM2 ).K23PA472B6&>!W>>:&'!2A6PC+I^4VIE6(7K=VJY
M?B_E7,T'Y9- V5 FHV>JAP8K?B.Z*@^N:DSM&*;?*4R_4\OT3ZD@/'\.IN8<
M\1:CEAJL6$7-J/LWI5:F5KA_IY;[S[HC\K @"Z8/2@=T[AAM8]\G4D:*!+F@
MEI[1!&!*K4RO2  .;. W].8QCB)TE2;RXT3?/W_NB0!<UAC6,9* 4R0!!S;Q
M&UC7,>$+-9K]*17$4F:G>(6IOLW!@I6SW'!=8VS'B 1.$0D<V,A/O<D]&J5!
M*!A'(R&(C.?9PX%)A!=::C_Y; "N:TSM&.[?*=R_ YOWW=.424@Q]4.90;.)
MVVS?->?9_*W\8<C737Q7++5/B@^<IAJFT9!@2JT,LP@)3JU'"/.E=+U@?X5E
MJF$930BFU,K+$8J$X-9*"+/T,0I]V4D9UGH/6*7Q&@2C86&CULO4U)JGEZ%M
M6[V^/3B_Z+SHZ!1!P*T5!+:S$X+YSR>;20KT*15R;*-9:G\74I1DN[5K9N"S
M-*:7J_7W[M?M]L_ZO>)V-V".$0S<(ABXL(W?_@I,0AZCZ5@+!E:P!ZYV$@TN
M:]Q^CI$$W+T50;!OWV*JFLDX4'Y[-T,W-S,M)K-K?8YA_=W"^KNP9=]B4C.T
MZE=0BPJ6>&"<4<%.9'*@.,!:9$;]OBFU,K+"[[NU_+XG3027CF)* _**/A+M
MC^$!*<NR[%Y7_M,^ H"+&U,[AO%W"^/OPCY].Y$Q"1/U+. ;P1Q<$G1 KMVV
M!NV*8<RH\3>E5L96&'^WYH*@?6X3N5.;, ^(52V?@LL:$SN&Z7<+T^_6-OT9
ML<WRLVIFL-SDFY:846=O2JU,K'#V+FS)1Q)7D".K2),'!"H]/5S7&)-13]_9
M6^FM9B.R%?,)\M4R@7S1]V[O;E7^*%N+WBD.SY?TWV(UF9&@B#S)4NOT3 ZU
M/%\EGV\(MLK6C3\R(5B<O5T2'!"N#I"?/S$FMAOJ!+O_JS#\#U!+ P04
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MKC:3H!=L#Z[9NK#N()J.2[J&)=B;<J%Q%[4L.1,@#5.2:%A-@O/>V7SHXGW
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M,VD%S/]K(?33Q"[07"$N_@=02P,$%     @ K86-63ZS\$H3!@  \2$  !@
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M&YEI#\>(N ZB>HDN.LW%94AX&1)=D5&[&B?'BOHMZTWW,-.,ZCLG"\11"UN
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M_4KA]#+7R"W8*Q)3S4M$ ZG?5?4[XS3XR\B7&/BH%$NJ?;58@/*2:'*.3/X
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MA5.&V?[HK-,\M6O'\ W= *BV/K*"(RY0J;BO%QY^-FD)0@6J[FF<!87"R#H
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M+'/^'*#U ;R_,:Q":_@"W0=F^A]02P,$%     @ K86-67K+IRSF$P  N3D
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MQ:QX< ?)-.RCY))?]\%@M:\A#=5L6=,<"9I6;($=LK)UK9R?%%U3@S_1^,9
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M<K @\R?\[5:QFM1]<?SS[:='5 ^P 6=,8A.\1\!$!+49=A"QXH3"<X&2!(*
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M,3)S/S2/9(R>:=X?J,5]96+6.G ^,C?A%#8NY30B6),I:!*Z3W#C&,IN2(F
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M??+X2*[OQ"\(9/SCO)EM6[OBCTNM4//2 +R?6X2)\(462+_6?/7_4$L#!!0
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M/AE-!P<?=(GE2X"$V?44LV>*Z^PBXCW6(QBG,61IEE_ &_<ECP/>^$+)#LC
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MBTFO/2G6+\'6\18^MP%G:WPL\1%%C@6P7UAT2_?"#C:?9;/_ 5!+ P04
M" "MA8U9!6BCH@H$  "G"0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6R=5MMNXS80?<]7#-1MT0*.9<MV[+BV@22[00MDNT$N+8JB#[0TLHGPHI)4
MG/Q]AZ2L.!O'O;S8E#AS> [G#*G91IL'NT9T\"2%LO-D[5PU35.;KU$RV]45
M*IHIM9',T:-9I;8RR(J0)$6:]7HGJ61<)8M9>'=M%C-=.\$57ANPM93,/)^C
MT)MYTD^V+V[X:NW\BW0QJ]@*;]'=5]>&GM(6I> 2E>5:@<%RGISUI^=#'Q\"
M?N6XL3MC\$J66C_XAY^+>=+SA%!@[CP"H[]'O$ A/!#1^*O!3-HE?>+N>(M^
M&;23EB6S>*'%;[QPZWDR2:# DM7"W>C-3]CH&7F\7 L;?F$38X?#!/+:.BV;
M9&(@N8K_[*G9AYV$2>^=A*Q)R +ON%!@^9$YMI@9O0'CHPG-#X+4D$WDN/)%
MN76&9CGEN<4OVB&<P#&$<ASK\KBV"&?6DA^8*N"*LR47W'&TL]31@CXMS1OP
M\PB>O0/>S^"S5FYMX9,JL'@-D!+3EFZVI7N>'42\Q:H+@UX'LEXV/( W:.4/
M M[@@'P+3L,E5TSEG FX=<PAV<[M%1SAAOOA? =-;<5RG"?4(A;-(R:+[[[I
MG_1^/$!VV)(='D)?7"&5!3OPI4+#'%<KN$(RI(4_[O#)P;G0^<.?^T@?A-U/
M^J3[XHC[]QP!-RAHLPJHF''/<//E'E@;)YJX9[A;(UQH63'U#"(R9E"R/,Z2
MWPJ@TP7P"?/:]RCHLN0Y195&2PHUS2IYQ.@&0&WXBFHF(B(E5]Q0#%?P$7.4
M2S3>(UF@XG8(Q%4HDH';Z #E<;7R%:>5&[Q<6P<;-$B*B)V@P\M.C\A^+F)O
M/?CVU>#H52N]P'6(7"[J(K)<H:(JBL"/%=39W#I?52]?!<8O1O2TFJ)K9>$#
MC">=WGA @TG6&8PFT0?@T$@;  MN<UTK!Y1"^_A_=: _U;W/1(L/W\O0T3],
M80#]T=$GZ[@,U2%Q)M E44MMR-L^TQ.8PFDW@V^;7[_CK*J,?@J)4-:N)GI^
M!V0MFZ4J]AR5UW1P&-"MX[?^<?!6PUN=OR,S_NRAS+<"1_33Z?5/C^ZT:WW4
M+MS,^9X#+JLZ2J0M0#)&?Y0=7?M>H2U^9*+VE@7SMNQBIU?ZIYW)R?BKM%U'
MY+4Q?N8_)0FM5L>A,+MI'^A OV!V#27M X7%R]O?@AO:GJ]WJ#F>_Z4K F[%
M>&Q:)KW/["M.WKR2]-?1#_^\-Z\[@^5YQ*1:L*7 V")Y;FHL7JG<VR>!WB6)
MZ_H^&7=.1T,_..UD=!CL.X33G<M3HEF%3P0+@4.\1]NW[5?(6;Q\7\+C)\QG
M9NA,LB2PI-1>=SQ*HO+M@]-5N(J7VM'%'H9K^I)"XP-HOM1T'S4/?H'VVVSQ
M-U!+ P04    " "MA8U9BVS'N>T&  #J$0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6S%6&UOW#82_MY?06S=(@'L?;.]ZZ:V@3@ON #7-DC2.QP.
M]X$KC23"%*F0E-=[O_Z>(2596Z^-H$!Q@.$51<YP7IYYAM3EUKI;7Q$%<5]K
MXZ\F50C-J]G,9Q75TD]M0P8SA76U#!BZ<N8;1S*/0K6>+>?SU:R6RDRN+^.[
MC^[ZTK9!*T,?G?!M74NWNR%MMU>3Q:1_\4F55> 7L^O+1I;TF<+OS4>'T6S0
MDJN:C%?6"$?%U>3UXM7-&:^/"_ZA:.M'SX(]V5A[RX,/^=5DS@:1IBRP!HF?
M.WI#6K,BF/&UTSD9MF3!\7.O_7WT';YLI*<W5O]3Y:&ZFEQ,1$Z%;'7X9+=_
MH\Z?<]:76>WC?[%-:\_/)B)K?;!U)PP+:F72K[SOXC 2N)@_(;#L!);1[K11
MM/*M#/+ZTMFM<+P:VO@ANAJE89PRG)3/P6%602Y<_VH#B;4X$6]L7:N < =_
M.0O0S/.SK--RD[0LG]"R6(I?K F5%^],3OF^@AE,&NQ:]G;=+)_5^)F:J3B=
M'XOE?'GVC+[3P<_3J._T&3^]"%:\5T::3$DM/@<9Z$F'D[JSP^JX5%[Y1F9T
M-4$M>')W-+G^\?O%:O[S,\:>#<:>/:?]>I0+(4V.W)B@3$FP&TZ\53[3UK>.
MQ+^_T'T0-]IFM_\YY,2SVQQV8CT=0T%\PGOILBK:84-%3F2CZ2\5\?)&FIVH
MI-^; V-@;()#Y5$N7*\)#"*-^J_DJO1B6UG1D&-Z$1DL5!E2$QP2E#2$AQU^
M_/YBN5C_[(4UI44\'M;[T.8<F@<CV1N5D6B<O5,Y.3\5K\O248F<BZ(-'+W>
MN!8:&KGKXAT$L =@;*"E!Z"06"[9( T6\Z^^^Q=<8:S#BN\>+3\71V*Y6!ZO
M5NO'DRMQ>G9X9IUF5H]G+L3)XY<_X27VN5@>S^=S\7<X:SS%"#B[DSKL]I+Q
MP8C7C5.:)2$?*F?;LA(*4[^9()VRX.6-5[D"-1^/HRX@3PX)5 ;E(X7N=T(T
M8_F L0+P 1GE<@3286NLM)N GB#H/M.M!_,R/>O\!/1&PC%7QG+,R,5EM\9N
M3RJ[/8:",  _!Z4!.%HR_,?+:VLLBL @<Q*UL;$Q_2^2V<8'UV;!OSR&S=B=
ML\3>)<MYD/8') Q[)4VI-IH3[-$%>]#)[&NKV._>8<;WAHA[469+()CR*;!"
M(G+H>13\HS;L\3L8,6E\%+G].*N^?+A:X.L 25N(MN$W$EUL +&L;8O@8_+H
M]'R%WJ UM[FLYXH (8QK=(98*WWDE"9T%8-P=3V:,_N4?8 ,>K72N[TL=/73
M6,X44RG;32ZRJFRXY&)><N$E-AMM.=TC#)2XC5&5(ZAVGG<@YJQRTT59PW?(
M&&0H:87CV"GG1$>GX5PT;P\"O6L9Q\JQMBW8@?;BGB/+6="[D1?(K8]KOF$'
M]E,RA2%X ><8-HS5[@..[LBTQ- AU$(N-KL]&U@)UZ(L"J65Y%[UA.4JB-QB
M9&QXPO)O-'P*W/(?F&$Y7ZS^/YSPIXD $:\D3F49M2&V@,[A?81M412B]2DD
MAW;-D1=MFW'(>@)PLHFZN0AL4^TT'R"S9(V2I;&>AU">4F6;: 9JO4Y5@)AT
M+2XBQ%C.U1^F1CGX)?9&L//BK\@$2R@## 8X!X#RV,N:GHABC'#B/U%JN\%,
M%S,.CD10"T4Z3]2$W3:TLW R5!8# [VY: ?:8W0]MFLJWG=$NT,O]? #!\>#
MK1>*\7"Z[S9SL&,)NF]8<33E:#&?QV[(,D?G\?F8#QX-Q<._1NPBW> 53NTL
MTM/C,[3(.3ED_Y=GN-M1W17=M[/XZF+Z4T_C?P'S F,RSU6(VE6Q%\U"*AWK
M >S#9XB(%>"[C#"%2H/K5>[:<HQ>'.08#KCWH**!%6S->'OQX=>W+X<NV@.*
M48AXRJ'.09C*YA&+N.1U)ZN>I7(.30?3I[NEHZY#IX"K"-L]I$LX=#]JX06Z
M]=<6;$0.@044<(0H^9>E.G5]$^I# 7>Z='J NF@U)C2W_D] 3K?<RSN8[D6C
M(7 V7[RX?9E.EVK3)@YX=T]9RQB$6P6L<8D6J&ZTW5&";W0/%([8&25'%1^/
MGZ15.EA$;V,;.7@X-M:<I$OO'==XP0<7MT$PNKW<GF6\[^D/_'_0#TAQ2:4<
MIS*6O5/10>[0Z5@-0X88;,A0H;BOO!N<8KM1DS\(1E.JJ(-6I&"HU.+OK&Z9
M]'9#=/;73N-]Z$&T2_K8PBUWRJ/%^OABW9$!&MS%>BGRUO48^V;:&?/'5!RZ
MWLU&]V]48QF_,OC4NM-5?'@[?,AXG>[O#\O35Q"T@9*1IJF Z'RZ/I\DZNT'
M:#3Q-K^Q(=@Z/E8DD21>@/G"@ANZ 6\P?-ZY_A]02P,$%     @ K86-60\T
MVSK%#0  2"D  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&ULU5I;;]O(
M%7[GKQAXDUT;H&G>)683 [:3[*9H+HB3#8JB#R-R)+&A2"TO5MQ?W^^<(2E2
MEF7OI6C[8$LB9\[]\ITAGV^*\FNU5*H6WU997KTX6M;U^MG9614OU4I65K%6
M.>[,BW(E:_PL%V?5NE0RX4VK[,RU[?!L)=/\Z/PY7_M0GC\OFCI+<_6A%%6S
M6LGR]E)EQ>;%D7/47?B8+I8U73@[?[Z6"W6MZL_K#R5^G?54DG2E\BHM<E&J
M^8NC"^?9I4_K><$OJ=I4@^^"-)D5Q5?Z\29Y<6230"I3<4T4)#YNU)7*,B($
M,7YM:1[U+&GC\'M'_37K#EUFLE)71?8E3>KEBZ/ID4C47#99_;'8_*Q:?0*B
M%Q=9Q?_%1J_U[",1-U5=K-K-D&"5YOI3?FOM,-@PO6^#VVYP66[-B*5\*6MY
M_KPL-J*DU:!&7UA5W@WATIR<<EV7N)MB7WW^KJB5F(I3<277:2TS<;V4I:J>
MG]4@3DO.XI;0I2;DWD/(<<7;(J^7E7B5)RH9$SB#5+UH;B?:I7N0XK5:6\*S
M3>':KG^ GM>KZC$][X"JE:@+\3K-91ZGI&PM:X40J_<JK,GY^\E1MCRKUC)6
M+XZ0#I4J;]31^???.:']XP%A_5Y8_Q#U\U>_-FE]*_[^27VKQ656Q%__L4_$
M@T3VBSBU>E]7[&O1\BKF<U6F^:(2[W/QKKA1JYDJA<OVQ_]ZJ<15L5K+_%;$
M^,Q4K1(AQ;I,;V!%L<[ B&P)0J+)T[K",B1O58,F7?.FONE/ MJ\0CYJYJ:X
MRF15B0NQD64IX0GRT+HIXR5R331K^BF1O8M%J1;$!Y2<R#5=?SJFA%5)2^SR
M#Q.SQ#L4Q'59Q$HEE9B7Q8H-T-E(;%2IQ!/7BI"468;Z8HK-,HV7^H;,X#%)
M]IFI>J-4SIM+E4FJ06(NTU+<R*R!U)" [HU5.6XJ8B('*VDA^$TZ?B>L[^[6
MK;*]!7I:=4$^WZ'H6&Y/T1*?EH.-,Q7+E1+JFRKCM)*S3(F7*FZCPM-AH;?<
M<>%20DL8NMVK*$CBEJ%M!;98@X86F+380 "L7:?X#4UVN01#+I>/XC*Q[%TF
MFGZRCX&WHSEMX=A-%.W U[I$^ZAH[R -OO]NZCJ3'W%Y,PI"WD["IO.44J02
MBC/,ZC(M05*4Z:S1?0FQJ/,&:?=6PGW"G6BQQDF')2Q.FB.*^8;,91P792(N
M/KTUR?55 _DIR'4L#G>O9)OA+"+:8F:V88T>2UOHT]R)PWI9%LUBR3E3GX+<
M*3KW5V2&&I<,RI1%*5<"**%-LR>N;=E=:$%FL2@+N*]+*1,P8/9/M&9:&ZNR
M!G[8DLO2%0H4F8=DD#4Z85E"_^R64VLST@P$QHKM*($PX008YKT6II*9JK91
MTPH^M?Q.[C;P6D;(*Y&#V2Q+%RP<+6>&='=O(I-(9'FHP**2K:NF J1*6NXP
M&-R*SDYB$0%U,$92 C+D<W0P1&Q:+P556B*!HO6R8?,1F5LE2X0,6K% (ZUU
MO'?==!Q859$E?7V@BCAQS,@)=U09AA?MWLI$3A][EZC(-7Y]2P&<%-SVQ-Z6
MKD?+Z3T@9Q2:ONW\N7(ZEK?C_6&6H4946W]Q,7D?UP7+K$UKB8N:][W5F?*^
MB^F+89YWF_Q]_A@E.L+V08(<!C];5Y;X@C3:E(1$Q?=RM?X1-"U3_/6O5U2%
M9!MR -O8=/SSU1=2Z>1_K7!XUG1R?^'X?TO)ZV968;_:!N0?R$S7M4TWC'Y3
MQ.=#(+,O+\/>V'(.H3'3)$W,H&T8+L0RK6@6@U*7P'I?3Z_C9<'V6K-%"%1H
M'ZR*1&4C/S45!X5ZW$[HD2CM NV ,6AAM4]I%DL8B6)$U+M)7=WP-6'M[-&2
MOL<OZ(.Z<XNBQBSZ95"Y48DEWN^5M *F0VR46LHT7S>,?I=(0-BV[7"$^  &
MFE4K4YK'69-T]0^P!&L@B&Y#-P5AQ(S1PM" L<SB!K=@M'['=JW0QH!82\1H
M 4J(E\'M-A%V<4L+&8DQ2L=2PU1<24G(JIG/TS@EWR>8+(6\D6E&*' <HNQ9
M3 %*<7&E'*:&G5)8(BMCV '@B8*=&GVGQ3XEQ@K+!#[411 B5?7I'$$M2K;
M[);. W"9$JX-^L_6M05.2E9->2MN4X7,X=7WV'&?U\>QTT5(;]N1N[)TSGL"
MSN>JQXODUWX1 G*NTKJA+$VV/:\->XIP[F.VI@%\N$M]$(=;.=J+7849JI>D
M">IAS5&=5OSU2T?BHCMYN2\<MOB7@I;B!B108.<%8:[JF?&NX5J%[2W1]K1
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MKFPE<@T&QTXH0M=TIX37.9Q/*61M9[BCE<8SNG#TW*GI8<NG@6,?=!I*&1V
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M"U>5AUG2,&[86I50"W-V\K/@NB75"2B!?*V$)EY\-?H(^4*8#%L)")7WXEX
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M7GUOM'_*\##=<;-P!D2VYVFIE9<^*[<P0F=EIY/\$5"BXY8R#H6K*_T?Q=(
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MD7)KR''5CG?9:&2<43+QI[C^7>!@1G.YIH@B(>7=GQ%:PX/=LBEE*CAE$PF
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MXJ?T'6U8GKY&_B8]V@L\4P5$Y]-W;R; E[_PI9OH:OZJMG(QNHHO2Q2T\K0
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M1#P!G>C4.*B@JMDOYYP%BC:X*RIA-@A"V\;0 +:5Y*1('T_;S0#%H7E9=G"
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MTDYR2, 8?1&V+\CR"^(*EWB4*&B?7V?9-=(N*#.(*+>C(>I44UM ##$ T0)
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MD@S)_?I* @SFC!*H[@5LX^_;U;?2:A=U5Y1]YPL @9[3).,]9R%$?NNZ/%I
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M?JM+G0U #]U=CUT+%V"!^UU&5XBIMR6;NM#J:[34BV1JHDP$D[\2B1/]SU0
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MZQWH?&.HN7K#!QB>IOP%4$L#!!0    ( *V%C5E7EUD._ (  !\*   9
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MUX.\N5(W.. Z0+U?,'6HEQU]1ZCNA,%?4$L#!!0    ( *V%C5DA+&*]'0,
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ML:%0;7]K Y2U:Q%+B:;AN&%I?@F@;()97TG3)KK =IW^)Y/] E!+ P04
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M[_G>L\^SK;$/KD8D>&J4=O.H)FHOX]@5-3;"G9@6-:]4QC:">&HWL6LMBC*
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M](4!HWK J.N-/JL'G'4=<%X/..\Z0.T]/W*]SD/6#W;G1UM]?KC5SH^W^OR
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M;].T>/ZAFN IS;XMEWWY?U!+ P04    " "MA8U9X^,0*UH&  !'+0  &0
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M[FXIT=W =@ZJQ@_)1J$=.6^6=L=!NP1[OU5V4'K'S=WPU4C? 5!+ P04
M" "MA8U9WU/D_F\$  "D%P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6R]6%UOVS84_2N$-@P=D$8?_HHSVX C*UN I@V2='L8]D!+U[90B71)VDZ
M_?B1E")+C<S:*;$\1!3%>RYY#B_I>T<[RK[P%8! 3WE&^-A9";&^=%T>KR#'
M_)RN@<@O"\IR+.0K6[I\S0 GVBC/W,#S^FZ.4^),1KKOCDU&=".RE, =0WR3
MYY@]7T%&=V/'=UXZ[M/E2J@.=S):XR4\@/B\OF/RS:U0DC0'PE-*$(/%V)GZ
MEY'?509ZQ)\I['BMC=12YI1^42\WR=CQU(P@@U@H""P?6P@ARQ22G,?7$M2I
M?"K#>OL%_5HO7BYFCCF$-/LK3<1J[%PX*($%WF3BGN[^@')!/847TXSK_VA7
MC.W+P?&&"YJ7QG(&>4J*)WXJB:@9!,$!@Z T"(XUZ)0&G6,-NJ5!]UB#7FF@
ME^X6:]?$S;# DQ&C.\34:(FF&II];2WY2HG:* ^"R:^IM!.3CU0 &J+WZ'>Z
M!4;D%A HI$2P=+Y12G+T;@8"IQE'C_ D-CC[=>0*Z5B9NW'IY*IP$AQPXJ-;
M";GB*"())"WVX7?L P. *U=<+3MX6?958$3\%(MSU/'/4. %'11.9^C=SVT+
M"\TP#["6,)Z&Z:+/#X=@9J? ')Y-=#Q,IWTV#;(ZU1[I:-SN =S:UIARGG*!
M20QGZ",E\KQB6*1DB6Y(3'/9*9_RO.*@MDW1:MTO1H?J<+SD:QS#V)&G'P>V
M!6?RRT]^W_NM3:,"K*?!U,&XG?2'%\%@,'*W=0UL^HQ>^^Q=^%YG6/EL,-VM
MF.X:F7Y<02'>P\TUFBX9@&;][UO(Y\#^:6/2"'@JDS;!9C;!(DM@#55ZE2J]
MM^S_Z0ZS!$USNB&B39G>JRT2=#S]U]R8H='[J:S;!(LL@358[U>L]W^4=74&
M"70/:_R,YQFTB5#XZ#?BM$T#XUQ.U< F6&0)K*'!H-)@\.,:&/D?O H"?Q"T
M"6"<R*D"V 2++($U!+BH!+AXBP!WP%*:(+HHR%??V\@W8_L]] R8\;:+P&AY
MJAHVP2)+8 TUAI4:P[>H<8N?TGR3EP&QCX<S="WS(,J43I]8NDP)SMID*IP.
MZS%RWOTF/(P3.U40FV"1);"&(+ZW3U^\8R7!-4FBIW6J?IE24@7+="& H0^8
M"W/0?,=AYW#0F"U/%<DJ6F0+K2E3+<OT_^\4PNSQU%^^)5K]HAJT7%,SJUZC
M%J_]IM<FW\&>[\#(=X@)3C"*<F!+(/$SNMIP.81S-(UC?4K=,;ID.*]R"_0O
M"F^N0F.N879Z,N4VT696T2);:$WY]@FW;\ZX9S 7,@ZX8!L5,V?H)1+DE4+9
M,MV"TK)5(JN9M56TF?\Z:0Y>AUADRVF3^WT*[IMS\.IRX.K>_D#)\OTCL!PI
M35H9MYJ!6T6;E6AUQKMMC%O-KMU:-5*?/ZH,S)$^=HH*7=5;E9JGNL#Z37^H
M2M"ZRKF'*>K7MU@& >$H@X6$],X'<H6L* D7+X*N=<US3H6@N6ZN "? U #Y
M?4&I>'E1#JK"_.0_4$L#!!0    ( *V%C5FEI;^UN0(  "$(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;*V676_3,!2&_XH5$-JDL:3IUSK:2%LG
MQ!"#J=W&!>+"34X;:XX=;*?I)'X\QTX6%=9&J-"+QDY\7C_GM>.3<2G5HTX!
M#-ED7.B)EQJ3G_N^CE/(J#Z5.0A\LI0JHP:[:N7K7 %-7%#&_3 (!GY&F?"B
ML;MWJZ*Q+ QG FX5T4664?5T"5R6$Z_C/=^8L55J[ T_&N=T!7,P]_FMPI[?
MJ"0L Z&9%$3!<N)==,XO1W:\&_# H-1;;6(S64CY:#O7R<0++!!PB(U5H'A9
MPQ0XMT*(\:/6])HI;>!V^UG]O<L=<UE0#5/)O[+$I!/OS",)+&G!S4R6'Z#.
MIV_U8LFU^R=E/3;P2%QH([,Z& DR)JHKW=0^; 6$X9Z L X('7<UD:.\HH9&
M8R5+HNQH5+,-EZJ+1C@F[*+,C<*G#.-,]%D:()V O"77(I89D#NZ(4=78"CC
MFMS!QA24'X]]@W/9"#^N=2\KW7"/[ASR4](-3D@8A#UR/[\B1Z__D/$1M>$-
M&][0Z?;VZ'[)05'#Q(I\DEJ3*57J";=F256B3\@#Y05UJWW!<;M1$<,N]&J*
MOIO"[MIUU V'@?V-_?4.N&X#UVV%L]Y-%23,_ ;VUUR5^F"+:]!"U6NH>JU4
MN'MQ;PJWLA\+Q73"JC?BVPUD"U#?=Z&T2MJ3XESG-(:)AT>!!K4&+WKSJC,(
MWK6L<;\![A^\QKM8^R]LZW;[>VT;-!2#?[.-_,1WQH 2E),9K$$40.9H!8N!
M'%W/YL>M!K=.?J#!PR:UX7\U>/C2X%ZX?V.>-1AGK1AS0_'PH2)!C!A-W.?R
M# V@*D[)GO>KU>=6A -]'C4)C@X[#RXR60BS"W?TXFC:>03X6R>^+9XW5*V8
MT(3#$@.#TR$JJ*H@51TC<U<$%M)@27'-%&LX*#L GR\E%H*Z8^M*\U40_0)0
M2P,$%     @ K86-69B][QJO P  0PL  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3,N>&ULC9;;;N,V$(9?A1!ZD0"-=;)E>6$;V"1;-!?;!G&WO6:DL46L
M1&I)RG;Z]!U2LJQ$A^V-+5(SP^\?D<-9GX3\KC( 3<Y%SM7&R;0N/[FN2C(H
MJ)J)$CB^V0M94(U#>7!5*8&FUJG(W<#S(K>@C#O;M9U[EMNUJ'3..#Q+HJJB
MH/+M'G)QVCB^<YEX88=,FPEWNR[I 7:@OY7/$D=N&R5E!7#%!"<2]AOGL__I
MP0^,@[7XF\%)=9Z)D?(JQ'<S>$HWCF>(((=$FQ 4_X[P 'EN(B''CR:HTZYI
M'+O/E^B_6?$HYI4J>!#Y/RS5V<:)'9+"GE:Y?A&GWZ$1M##Q$I$K^TM.C:WG
MD*126A2-,Q(4C-?_]-PDHN/@1R,.0>,0?'28CSB$C4-HA=9D5M8CU72[EN)$
MI+'&:.;!YL9ZHQK&S6?<:8EO&?KI[1]" _$]<D>>>"(*('_1,PYVN%W2*@<B
M]MT7+Y (GK"<4?L-;AY!4Y:K6_3XMGLD-[_<KEV-5":VFS0$]S5!,$+@!^2K
MX#I3Y M/(7T?P$4YK:;@HND^F(RX@W)&0N]7$GC!? #HX?^[AQ,X89OBT,:;
MCZ48#V,NE"*O@,<.</,GX@CRS>26U;G5] QJ*'5UY(6-;$[D<7L7^='*\[RU
M>^Q*&C",P^6\:_@.?M["SR?A'RBG*:.<["$%27-">4I**8Y(SG"H--65%JCF
M*H5(JF%(3;V4'W8HO5D0+3YH^:G9.R6+5LEB4LF7<XFE ])WH,VG&()=]#/J
M1^&BG_H!PR#P5Z.ICUK@:!IXOT=@LTO,MF$'CO5 2N#)F_T(E\E+PDG*T,&\
M']Y*]6)1%W,1!STU V:!MPS&Q"Q;,<M),<^ -9<#US_#7/;6]^?+?M+[9F$X
MGO*XI8PG*7<9Q0/*E*HH\I%$*$W,%82[1F=25(>,P(^*:3R[DB2T9)KF[%];
M#(>TQ'W(J"^E;W47CTM9M5)6TU5'\+N&T%8?4"1G!0YMY<9Z/=O-AIA7/9J/
MO'V+>#7.ZWO7F\B;)/Y39R '[P^OGZ$P[B=RR&XU7@+]SAWI3Q?!C/(#[@M.
MCC2OZ@S2'#L@LTL&B?W^+E[,!\KVD&%H3ML8<W!E#B:9GZY5[N92YFX)8!'D
M:I@YZ-6QN,\[;52SNIUVI !YL%V:PM-4<5W?XNULVPE^MOW/A_E[TR':-N<:
MIFXOOU)Y8!RW-.PQI#=;(I&L.[9ZH$5IFYY7H;&%LH\9=KD@C0&^WPML?)J!
M6:#MF[?_ 5!+ P04    " "MA8U9X/2Y^D<$  #)#P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6RMEU%OVS80Q[\*H0U# LR1*,FRG=D&T@3K K19
M$#?;P[ '6CK;1"71)2D[^?8[RHIL3Q27 7VQ1>GN]..)=W]RNA?RJ]H :/)2
MY*6:>1NMM]>^K](-%$Q=B2V4^&0E9,$T#N7:5UL)+*N=BMP/@R#Q"\9+;SZM
M[SW*^514.N<E/$JBJJ)@\O4#Y&(_\ZCW=N.)KS?:W/#GTRU;PP+T\_91XLAO
MHV2\@%)Q41()JYEW0Z]OZ=@XU!9_<-BKDVMBIK(4XJL9W&<S+S!$D$.J30B&
M?SNXA3PWD9#C6Q/4:]]I'$^OWZ+_6D\>)[-D"FY%_B?/]&;FC3V2P8I5N7X2
M^]^@F=#0Q$M%KNI?LF]L X^DE=*B:)R1H.#EX9^]-(DX<:!QCT/8.(3O=8@:
MAZB>Z(&LGM8=TVP^E6)/I+'&:.:BSDWMC;/AI?F,"RWQ*4<_/7\0&@@-R(#<
MEZDH@'QA+SA8X'+)JAR(6)$[6(&4D-6/;I0"K0@K,_*)LR7/N>:@R,4=:,9S
M=8F^SXL[<O'CY=37R&?>XJ<-RX<#2]C#LH#M%8F"GTD8A+'%_?;][M&YNX]9
M:5,3MJD)ZWAQ3[PG4,!DNJDGF\$.E_P6%[ F&O.08D*X5K9)'J(.ZZBFBG9S
M.@SB( BF_NYT-A:[:$1/[<ZPHQ8[<F(O-DP"X4I5K$RAAE_Q$J]YN2:I4';H
M0\SD!"8:TRYSUVPX'O8BQRUR[,ZTJ;6!6 TJ!20'9GZ/B\N&&W<YNK!=H["?
M==BR#IVLO^L-2**AV J)?8]D?(7E 9AJ*^BPRV!):]<JCGM)DY8T<2^$:JF%
M9KD-*^F\D(ZQ\W?)+(9),IGTPHU:N)$3[A,H=4UV+*_8H9WG*"AFP=IH1QV(
M 1T'(TM-V2R3.$EZ><<M[]C)^\5DDI2HJ]E;.S1M@-7MT,8\[B8N3+K 7;,P
MBGII)RWMQ$G[*%'GI7ZMJQ^^5;QN7#;,23=A89?28M4/28.C]@3OK_O^5#91
MSEYO*7>;6=A?1O1$(JD3\Z-DV/4;?920 M^Q96Y=J4VD,X:1I>!M=G3HR.E1
MM*A;M5JU5N<ZT-OYFWAG*/'8@FRQ<Q$?]8JZ!>M06F=E]1_=GW9E:&"M+INA
MJ[[H4;&H6[(>_M4)>D"[$M1!=)F<PQTEBKHUZI:5+&/D"?<L907D9HWR]$K^
M^@S%$N3?5E!G0'.6N%9;EL+,P\." KD#;_[3#S0)?K'NT[Y3M//I'W6/NH7O
M092#E&VY65:YP+:B2,JDY/BE\-RS9S+#7>HA1]9<6#1O.(Q'EN5EL8PFL6-]
M'>61NO7QOM0@2YS VT=<8)HXUO'%_=/BTOTMG9'_][?\3M'.\W"47>K6W7=]
MR^>KQ94U$^/.%GL46^3-9A=9=N+^R3G+''(_,[GFI<(MZPH=@ZL11I"'<^-A
MH,6V/GHMA<:#7'VYP;,V2&. SU<"CU_-P)SFVM/[_!]02P,$%     @ K86-
M64 ?3UOC!0  R#<  !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&ULM9MM
MCYM&%(7_"J)5E4CM O."[:UM*?$J:JJF766;5E74#ZP]ME%X<8?Q>B/UQW?
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M1LCR#?KU;9ZKIXWR9J[ZYKWE/U!+ P04    " "MA8U9\W#@,*D"  "J!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6RM5=MNVS ,_17"*X86Z.)+
MW';H' .ILV$!=@F:=GM6'286:DN>).?R]Z-LUTBZ)&N!OEBBQ'-$'IE4M)+J
M46>(!M9%+O3 R8PIKUU7IQD63/=DB8)VYE(5S)"I%JXN%;)9#2IR-_"\2[=@
M7#AQ5*]-5!S)RN1<X$2!KHJ"J<T-YG(U<'SG:>&6+S)C%]PX*MD"IVCNRXDB
MR^U89KQ H;D4H' ^<(;^]2BT_K7#+XXKO34'F\F#E(_6&,\&CF<#PAQ38QD8
M#4M,,,\M$87QI^5TNB,M<'O^Q/ZESIUR>6 :$YG_YC.3#9R/#LQPSJK<W,K5
M5VSSN;!\J<QU_855Z^LYD%;:R*(%4P0%%\W(UJT.6X @.  (6D#P4D"_!?2?
M ?SP "!L ;74;I-*K<.(&19'2JY 66]BLY-:S!I-Z7-AKWUJ%.URPIGXAS0(
MO@\?X L73*2<Y3 6VJB*[M9H.!VA83S7<(=K4['\#$Z "[C+9*69F.GS9W;D
M&HK*<KMI&\%-$T%P(((IECWH>^<0>$$(]],1G)Z<[:%)7D.3# _1C%Y.T]^%
MNR1MIV_0Z1O4?.$A?:ERAUJCV:O,4:RM^&M=LA0'#I6T1K5$)W[_SK_T/NW3
MIR&[J,ELM2_CT(O<Y7;N;W3>CA+]3HG^42622BD4Z08^K].,B07"+3.X3Y6C
M/*]5Y2W)1@V9'VYI[/?Z%_Y5I_..-&$G37A4FJEMH]3_N-G 4+!\HSD5UAT*
MF*!*J0XA:10S$JC;42\3\(^<YS N*!-CG>Q?-Q:I+!!.OTFMSX!J$WZ:#!4D
MLJ!4,WOD$G>]]EU&^-^_*CF:W&LE?B.RYA[<K<9H7['O3"VXT)#CG.B]WA7E
MI9J7H3&,+.M>^2 -==YZFM%CBLHZT/Y<4K]L#=M^N^<Y_@M02P,$%     @
MK86-69;SZ5R^ @  O <  !D   !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL
MK55=;YLP%/TK%INF3NK*9]HJ2Y":T&F3VC5*VNUAVH,#EV 5,+--DO[[71O*
MLB9!G;07L,T]Q^=<FWM'&RX>90:@R+;(2SFV,J6JH6W+.(."RC->08E?4BX*
MJG J5K:L!-#$@(K<]ASGW"XH*ZUP9-9F(ASQ6N6LA)D@LBX**IXFD//-V'*M
MYX4Y6V5*+]CAJ*(K6(!ZJ&8"9W;'DK "2LEX202D8^O*'48#'6\"OC'8R)TQ
MT4Z6G#_JR9=D;#E:$.00*\U \;6&*>2Y)D(9OUI.J]M2 W?'S^R?C'?TLJ02
MICS_SA*5C:U+BR20TCI7<[[Y#*T?(S#FN31/LFEC'8O$M52\:,&HH&!E\Z;;
M-@\[ /?\",!K =Y+0' $X+< _[6 H 4$)C.-%9.'B"H:C@3?$*&CD4T/3#(-
M&NVS4A_[0@G\RA"GPJ]< 7%]\H',(:<*$C*C0CV1>T%+2<W92'(2@:(LE^0>
MMJJF^7L,GV8,4G*]A;C6)T?NTI3%(,B/6RB6('YBR,,B(B=OWX]LA4+U=G;<
MBIHTHKPCHER/W/)299)<EPDD?Q/8Z+"SZ3W;G'B]C NHSHCOG!+/\8(#@J:O
MA_L'X%$_/((8X:Z!>SUN_.[0?,,7'.&[JT!0Q<H5N0&\\Z=X#%@&)!S*=,,T
M,$RZ!JS#BTO'<4;V>M?^?M2EMQ<5]:K2!6HH*QK#V,(*)$&LP0K?O7'/G8\]
MGH/.<]#K^0:D!+2ZYWT.)6QHCG=3%(<2T$O[>M%-GOXG6=1OV"-/0(7L2=V@
M2]V@E^DJCD6-?S9F2AW*T&#O\'UG_XKL1[F#_2O2J^1?KXB]4]<*$"O3'R2)
M>5VJYM_O5KL6=&4J[XOUB3N<-IWD#TW3UVZI6#$L<3FD2.F<7: !T?2*9J)X
M9:KGDBNLQ6:887L%H0/P>\JQ@K83O4'7L,/?4$L#!!0    ( *V%C5E,@(TC
MH@<  $-%   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;,V<6V_CMA:%
M_PKA#HH9((TEVK+C:1(@B2ZG#S-C3*8M#HKSH-AT+(PD>B@JR0#GQQ_J$MTL
MTU&[TM,\));,_6W*7-X4EQ2=/W+Q-=DR)LE3%,;)Q6@KY>[]>)RLMBSRDU.^
M8[%Z9\-%Y$NU*>['R4XP?YT'1>&8&L9L'/E!/+H\S_<MQ>4Y3V48Q&PI2))&
MD2^^7[.0/UZ,S-'SCL_!_59F.\:7YSO_GMTR^>MN*=36N**L@XC%2<!C(MCF
M8G1EOO<F1A:0M_@M8(])XS7)#N6.\Z_9QB_KBY&1]8B%;"4SA*_^/+ ;%H89
M2?7C6PD=53FSP.;K9[J;'[PZF#L_83<\_#U8R^W%Z&Q$UFSCIZ'\S!__Q<H#
MLC+>BH=)_IL\EFV-$5FEB>11&:QZ$ 5Q\==_*C^(1@!=' B@90#M!$P/99B4
M 9-.P&1R(&!:!DR[7;(.!%AE@/72@%D9,.L&T ,!\S)@G@]6\>GF0V/[TK\\
M%_R1B*RUHF4O\O'-H]6(!'$FQ5LIU+N!BI.7'[EDQ)R0G\AM>I>P;RF+)7$>
MU.^$O+69](,P(5_8DTS]\-WY6*J46>!X5>)O"CP]@#?)!Q[+;4*<>,W6/?'V
MD7BJ 8S5L58'3)\/^)IJB9]6\I08TQ-"#3HEO][:Y.V;=R39^H(E?<?W MK$
M[-#>D'%)/ RV]>!;ME-@XR"XA^B\G#C1D]R7DZB>Y.E)5^E]]?'1YZ/4#/*D
M4O4DYTX/<)UO:2"_DT^;#1-!?']"/OA/091&Y"KBJ1+X?\F;GLY>:Z'9I/ ^
MV?DK=C%253]AXH&-+G_\P9P9/_<)!PFSD3 '"7.1,*^ 63DLFT0?+DW+*'[.
MQP\]@IA6@IAJ!7$K^>HK^25)4K8F=IJ)@BR5-OCZA/SFARD[(1_5M)DW2 [)
M0YMBJ#R0,'NZ][G-Z6)R-J\^M&+@D3E=),P#P5K:L"IM6%IMW(1^DA"^(;_[
M0OBJ.G!!\E.R$^(\,;$*$D:6(EBQ1IND:I2K15<"K[79A\H&";,+V+PA&VJ>
MSJ<=U>RW,A>GEMENY5I[$J1G[28>J.^M09Y5@SS3%P#U95??[*N?3'+#XP<F
M9' 79N/*U!0A5%$H*L0?'UATQ\1_^L91FV#H.")A-A+F(&$N$N:!8"W]S"O]
MS+7ZZ0CEA"Q]D=6 6^E+M3.?0[(9A=QF=>!H3= F&ZJE^?ZLV9HQ"Y$@4SI(
MF(N$>2!82R1GE4C.]$6FLX2JRHG2 Z  :9,/%0T29B-A#A+F(F$>"-;2UJ+2
MUN+O+$#:9$.UM'A1 4*F=) P%PGS0+"62$RCMG,,K4RN)/FR96J]*[XR62V
MR=6]8"SJEJ1#Y:I/,/J\0Q4#I=E0F@.EN5":AZ*UU=4P"\W7\%5*:K- J,7I
M?HFX>6E#6]_/P2..I+E0FH>BM4><UB-._[1QDL\T2<<Y.3SEE)EFS24B->AL
MT16!MD>#:P.2YD!I+I3FH6AMI=26JZGW7"$6F[GO ,Z,OD(!=5>A- =*<Z$T
M#T5K:Z1V84V]#;L4P8,Z727+4.7(3D=4$6$KI169K8V6J5AM_83UGZU4SIOD
M=<L;'D4\+BN1_OP%ZMY":3:4YD!I+I3FH6AM_=5.K_FGK=Z/:2:=[+V&(F_\
M,%35[.Y[G^_[-HC+V>Z=?MZ#&L EK3F+3NC,FNV=(2&S.E":"Z5Y*%I;4[6Q
M;.J=Y;]2TX:MP* &-)1F0VD.E.9":1Z*UE9;;4.; WWHAIGXO)'?)O39EP'O
ME1'4>RYIIMFH1\;IW.I6(ZC[#*6Y4)J'HK7U43O0YA$+NC@3*D[#3\KKEB^W
M!?7TP>(XV[]T:- Y/34G77U '60HS872/!2MK8_:13:/V<A\Q=@Z(1O!HUPF
M?IQ=V58"\</\"G?I\1Q:H$&-8[/'.;:FQIFYZ.H#:AY#:2Z4YJ%H[9OC:O^8
MZOWC5SF;^>NK-WVOA\H.2K.A- =*<Z$T#T5K:[-VGZG>?7[M&W7TZ0>+K+SQ
MEC97:J?3:??4")K5@=)<*,U#T=KRJ:ULJK>R_R^+?WV?!FMJWT+O7?Q#LSI0
MF@NE>2A:6U.UZ4WUIG>E##]>/TOC4RH3J;;S"V1?F(C(VW\S7_3=/7^MQP^6
MA[ZS%OFN^M%_,SK4 8?27"C-0]':@JD=</IZ#O@KWUZD[_E@+4(=<BC-@=)<
M*,U#T=KZK!URJG?(@==[]9D&ZVG?]S:MO7D/:GI#:2Z4YJ%H;9G4IC<]<CLU
MXF*O/L=@@<SVO 3+Z+EV;$/3.E":"Z5Y*%I;)+5738]YU?^(N4Y%-'SQ_!S_
M6'QA2$@^Q*& VNI0F@VE.5":"Z5Y*%I;\;7[3O7NN_[J3,.;]S/!:2=/J!%?
MTEJW7BV,K@D/S>E :2Z4YJ%H;9G4)CP=>"_WH8MXA9MUU+>">O(E[;AO!;7D
MH3072O-0M/:_,M>6_$1OR6OFN%9-43O3G1)-0S^Z"J//.E0U):U98:83:VIV
M_IG0AF9UH#072O-0M$(UX\8C'B(F[O.G=R1DE=UV73SMH=I;/2'D*G\NQKAN
M7CQ>Y(,O[H,X(2';J-#L8OV(B.*)'<6&Y+O\@1%W7$H>Y2^WS%\SD350[V\X
ME\\;68+JN2F7_P-02P,$%     @ K86-67,61AUD P  D!8   T   !X;"]S
M='EL97,N>&ULW5C1;MHP%/V5*%VG5IH((6L@*R!M2)4F;5.E]F%OE2$.6'*<
MS#$=[.OG:X<0J"^B?5CI0"6V3\ZYQ]<WB=-AI=:<WBTH5=XJYZ(:^0NERD]!
M4,T6-"=5IRBIT$A6R)PHW97SH"HE)6D%I)P'O6XW#G+"A#\>BF5^DZO*FQ5+
MH49^T@QY]O U'?EA_-'WK-RD2.G(?[AX_VM9J.MWGCV>?3@[ZSY<7N^/7QC@
MT@^<HE='B':ZN*[&,.EX5]J<?JZ%+/$<H_4=M$ZWX770>(.CIG)@)IAP<ER.
M#B8)$^]WG=-M)0HZ&#ETD[OM=!V(W4/H.VQ##NH2'0^S0FPK-?+M@%8G.?4>
M"1_Y$\+95#)@921G?&V'>S P*W@A/:4O$1TNA)'JCX5#VX.KI];)F2BDB6TC
MV-]I??H>L.F!0<9Y8[#GVX'QL"1*42EN=,><; :?0%[=OE^7VN%<DG78N_*W
M!'/00::%3*ELPH3^9F@\Y#0#.Y+-%W!411D J%21ZT;*R+P0Q'C8,.J&EIU1
MSN_@UO(SV]%>9:UU,Q4CFJ8V5#>MC.V ?EO-:K=EXQ?I>B5[+-27I9Z.,'TH
M<WHK:<96IK_*&@.8>HBKD[+DZ\^<S45.[>2/#C@>D@W/6Q22_='1H%1F>H!*
MWWND4K%9>^2W).4]7:E-.:TRW'/O#7K^MWF>4T$EX6W3NO9/.<LO=EP_BU_#
ML[FM[#MVFHSZI^^QWG^<NLGX+9A\$\L].'V347+Z'NL]Z8F;[+_:G?TY)L.W
M8+)WDB:#>D_9VKCN;%N;40]>#T;^#WC9X-N@WG3)N&*B[BU8FE+Q9/>JY169
MZM?M'7U]?DHSLN3JO@%'_K;]G:9LF2?-6;>0B/JL;?L;3$]OA3?O)CH6$RE=
MT712=^5\:IJ>;NBH]0<(^\B-^;@1C&,Q-P(8%@=S@'$L"XOS/\UG@,['8IBW
M@1,9H)P!RK$L%S(Q7RR.FY/HCWNF21)%<8QE=#)Q.IA@>8MC^'.K8=Z @<6!
M2,_+-;[:>(4<K@-L30]5"#93O!*QF>*Y!L2=-V DB7NUL3C P%8!JQV([XX#
M->7F1!&L*N8-NX)Q)$DP!&K17:-QC&0GAJ][?;"K)(J2Q(T YG8011@"5R..
M8 [  X9$D7D.[CV/@LUS*MC^#WK\%U!+ P04    " "MA8U9EXJ[',     3
M @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/
MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"
MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%"
M:4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0
MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( *V%C5GS
MW"3LM 0  "4G   /    >&PO=V]R:V)O;VLN>&ULQ9I;<YLX%(#_BH:G]"%K
M<W,N4W<F3=*N9W823YQ)'SLRR+:F(+F22-K^^CV">BML.+,OB"<;(>#C",ZG
M"^_?I/JVEO(;^5$60L^#G3'[Z\E$9SM64OV7W#,!>S92E=3 IMI.]%XQFNL=
M8Z8L)M%T.IN4E(O@P_O#N99JXFY(PS+#I8!"6_#"V9O^L]]NDE>N^9H7W/R<
M!_7_@@6DY(*7_!?+Y\$T('HGW_Z6BO^2PM!BE2E9%/,@;':\,&5X=E*\LI#/
M=*WK$D/73Q1 YL%L"B?<<*5-7:,^/P7&5P:5FZW*R$^\,$S=4<,^*UGMN=C:
MT\!=3)S;J.-P^&V">*W^3QCE9L,S=B>SJF3"-'%4K+" 0N_X7@=$T)+-@T,5
M<B-R<B\,!(DL1',JJ&OO%"Z]R)N[-H#KQ%!=<]BA%GD-/ASD+6S+@N=P]9Q\
MI 45&2-U<+4#&"& T6B Y&Q)'<@8@8P]0JXLA#U $[DACWNF',@$@4Q&@[RE
M>N= I@AD.A[DCKHOS0R!G T+N1":YTR19T5SR"[D1BDJM@VI0WB!$%[X)5Q"
M3#/.-*&0BY;N WF)0%X."_D @B$A.2</U%2*'=Z6IJ*#>(4@7GE C #Q(]6\
M?@J7BNVI.LG@4RR%3SU Q@"YXEO!X2!JI9-EL@+IB*V+B9IF8-74F E@0L\"
MFAEL:!_&^^\5W]LC74S,-^' PJDQ4\!<0']%;.W5R8W6;2&&F&S"@6U3$\Z
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M3544MU#V*/Z1-#]\Y77X0NW#OU!+ P04    " "MA8U9$R?LNN\!  "E(@
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=J[3NM %(7A5XG\ $SV
M+< 1H:*A1;R %287D<26/0AX>Z)0A&51G ;-JJRQY>V_^F2-??>4]VW9=<=Q
MN^O'V<=A?QR7S;:4_E]*XVJ;#^UXU?7Y>+JR[H9#6T[+89/Z=O7:;G+2^7R1
MAI\SFON[GS-GSY]]_I^)W7J]6^6';O5VR,?RR^#TW@VOXS;GTLR>VV&3R[))
M'_O+Z3&=#W)UFMS,'E^6S?#X(DVJ':00I/6##(*L?I!#D-</"@B*^D$+"%K4
M#[J&H.OZ03<0=%,_Z!:";NL'R1QEG!,D3; FT%J0:R'P6A!L(1!;D&PA,%L0
M;2%06Y!M(7!;$&XAD%N0;B&P6Q!O(=!;46\ET%M1;R706R<OVP1Z*^JM!'HK
MZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'K;
M9+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]G4!O
M1[V=0&]'O9U ;Y]L=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z!VH=Q#H
M':AW$.@=J'<0Z!VH=Q#H':AW$.@=DX^5!'H'ZAT$>@?J'01Z!^H=?ZGW6#[W
M>;ST?*_Q^7])=3G=FR^//R^_3Z*$BS/."?Y*N?\"4$L#!!0    ( *V%C5EB
M(^<8V $  $@B   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:74^#,!0&X+^R
M<&M&UZ_Y$>>->JM>^ <JG TRH$W;S?GO+4Q--$I<9N)[ X&VYSVTR7/%Y>.+
MHS#9M4T7%ED5H[M@+!05M2;DUE&71I;6MR:F1[]BSA1KLR(F9K,Y*VP7J8O3
MV-?(KBYO:&DV39S<[M+K4-MND7EJ0C:YWD_LLQ:9<:ZI"Q/3.-MVY9>4Z5M"
MGE8.<T)5NW"2)F3LVX1^Y.> MW7W6_*^+FGR8'R\,VV:Q78-"_&EH9"/E_BF
M1[M<U@65MMBT:4D>G"=3AHHHMDV^+WHRGAS3#M/^RH_.'\J,!::9#]ZZD$[,
MT^%Q[T?2KYZZ5(A\K,<_\2,QE3[Z^Z@_[9+*7V:G[7VV?CV<1V##[?@]_GS&
M'_4/[$. ]"%!^E @?6B0/N8@?9R"]'$&TL<Y2!]\AM((BJ@<A52.8BI'096C
MJ,I16.4HKG(46#F*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL D56@2*K1)%5
MHL@J4625*+)*%%DEBJP215:)(JM$D56BR*I09%4HLBH4616*K I%5H4BJT*1
M5:'(JE!D52BR:A19-8JL&D56C2*K1I%5H\BJ4635*++J_Y3UR=KU7__;T-_S
MUM3=>SX;?B"Y>@502P$"% ,4    " "MA8U9!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *V%C5FF
M_>R)[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( *V%C5F97)PC$ 8  )PG   3              "  <T!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ K86-6<HT)7A9!P
MMS   !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( *V%C5F";X%C;P4  $X6   8              " @9T/
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "MA8U9>ZN-
M(LT"  !Z!P  &               @(%"%0  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ K86-672%/;"A!   +Q   !@
M ("!11@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( *V%
MC5E@8WZG8 4  $X4   8              " @1P=  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    " "MA8U9/K/P2A,&  #Q(0  &
M        @(&R(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ K86-69U%$'IG @  %P<  !@              ("!^R@  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( *V%C5D\N%?>$ (  -T$   8
M              " @9@K  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    " "MA8U9GYV1]LL-  !P)0  &               @('>+0  >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ K86-68HUAY'L @
M; 8  !D              ("!WSL  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    " "MA8U9>LNG+.83  "Y.0  &0              @($"
M/P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( *V%C5FY
MSX:4!0,  +4&   9              " @1]3  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ K86-6:^^N7+<!0  H@T  !D
M     ("!6U8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *V%C5G";VAF4@<  ' 2   9              "
M@5M]  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ K86-
M625H(MUT"   <A4  !D              ("!Y(0  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    " "MA8U9G<M>%T$#   O!P  &0
M        @(&/C0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( *V%C5G<[9\[# 8  .4-   9              " @0>1  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ K86-65ZMD!J%%0  /T0
M !D              ("!2I<  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    " "MA8U99R$JEZ<"  #D!0  &0              @($&K0
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( *V%C5D1#XVZ
MV@(  !\'   9              " @>2O  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ K86-6?@LCTRR P  \@D  !D
M ("!];(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " "M
MA8U9H-Y5E%X"  !=!0  &0              @('>M@  >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( *V%C5EU^X1E:08  ! 2   9
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M970S,2YX;6Q02P$"% ,4    " "MA8U95Y=9#OP"   ?"@  &0
M    @(&DX@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M *V%C5DA+&*]'0,  *0+   9              " @=?E  !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ K86-61-PD9M\ @  < 8  !D
M             ("!*^D  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    " "MA8U9ZLL'Y94"  #9"   &0              @('>ZP  >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( *V%C5EY6K&\#@(
M $$$   9              " @:KN  !X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ K86-63!HR1Y2 @  #04  !D              ("!
M[_   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "MA8U9
M/Y#4:RX"   8!0  &0              @(%X\P  >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( *V%C5D[H[8HO (  $,(   9
M      " @=WU  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ K86-62^[$T%L @  8@4  !D              ("!T/@  'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "MA8U99]BLG2P%  !#'@
M&0              @(%S^P  >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( *V%C5DD@1)[)P(  .H%   9              " @=8  0!X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ K86-6::?Y8PF
M$0  /_\  !D              ("!- ,! 'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    " "MA8U9X^,0*UH&  !'+0  &0
M@(&1% $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( *V%
MC5F_@$%F&0,  +D-   9              " @2(; 0!X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ K86-6?ZZ7>+< P  2!   !D
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M=#4P+GAM;%!+ 0(4 Q0    ( *V%C5G?4^3^;P0  *07   9
M  " @3DV 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @
MK86-6:6EO[6Y @  (0@  !D              ("!WSH! 'AL+W=O<FMS:&5E
M=',O<VAE970U,BYX;6Q02P$"% ,4    " "MA8U9F+WO&J\#  !#"P  &0
M            @('//0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4
M Q0    ( *V%C5G@]+GZ1P0  ,D/   9              " @;5! 0!X;"]W
M;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ K86-64 ?3UOC!0
MR#<  !D              ("!,T8! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX
M;6Q02P$"% ,4    " "MA8U9\W#@,*D"  "J!P  &0              @(%-
M3 $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( *V%C5F6
M\^E<O@(  +P'   9              " @2U/ 0!X;"]W;W)K<VAE971S+W-H
M965T-3<N>&UL4$L! A0#%     @ K86-64R C2.B!P  0T4  !D
M     ("!(E(! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4
M" "MA8U9<Q9&'60#  "0%@  #0              @ '[60$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( *V%C5F7BKL<P    !,"   +              "
M 8I= 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *V%C5GSW"3LM 0  "4G   /
M              "  7-> 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "M
MA8U9$R?LNN\!  "E(@  &@              @ %48P$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "MA8U98B/G&-@!  !((@  $P
M            @ %[90$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0@!"
+  42  "$9P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>175</ContextCount>
  <ElementCount>319</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>86</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995451 - Disclosure - Note 1 - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations</Role>
      <ShortName>Note 1 - Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995452 - Disclosure - Note 2 - Basis of Preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation</Role>
      <ShortName>Note 2 - Basis of Preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995453 - Disclosure - Note 3 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies</Role>
      <ShortName>Note 3 - Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995454 - Disclosure - Note 4 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment</Role>
      <ShortName>Note 4 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Note 5 - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-5-intangible-assets</Role>
      <ShortName>Note 5 - Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995456 - Disclosure - Note 6 - Right-of-use Asset and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities</Role>
      <ShortName>Note 6 - Right-of-use Asset and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Note 7 - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-7-commitments</Role>
      <ShortName>Note 7 - Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995458 - Disclosure - Note 8 - Capital Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-8-capital-shares</Role>
      <ShortName>Note 8 - Capital Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995459 - Disclosure - Note 9 - Government Contributions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-9-government-contributions</Role>
      <ShortName>Note 9 - Government Contributions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995460 - Disclosure - Note 10 - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-10-income-tax</Role>
      <ShortName>Note 10 - Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995461 - Disclosure - Note 11 - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-11-financial-instruments</Role>
      <ShortName>Note 11 - Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995462 - Disclosure - Note 13 - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions</Role>
      <ShortName>Note 13 - Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995463 - Disclosure - Note 13 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-13-subsequent-events</Role>
      <ShortName>Note 13 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995464 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Note 4 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables</Role>
      <ShortName>Note 4 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995466 - Disclosure - Note 5 - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables</Role>
      <ShortName>Note 5 - Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-5-intangible-assets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Note 6 - Right-of-use Asset and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables</Role>
      <ShortName>Note 6 - Right-of-use Asset and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995468 - Disclosure - Note 7 - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-7-commitments-tables</Role>
      <ShortName>Note 7 - Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-7-commitments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995469 - Disclosure - Note 8 - Capital Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables</Role>
      <ShortName>Note 8 - Capital Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-8-capital-shares</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995470 - Disclosure - Note 10 - Income Tax (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables</Role>
      <ShortName>Note 10 - Income Tax (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-10-income-tax</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995471 - Disclosure - Note 1 - Nature of Operations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual</Role>
      <ShortName>Note 1 - Nature of Operations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995472 - Disclosure - Note 3 - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995473 - Disclosure - Note 4 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual</Role>
      <ShortName>Note 4 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995474 - Disclosure - Note 4 - Property and Equipment - Schedule of Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details</Role>
      <ShortName>Note 4 - Property and Equipment - Schedule of Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Note 5 - Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual</Role>
      <ShortName>Note 5 - Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995476 - Disclosure - Note 5 - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details</Role>
      <ShortName>Note 5 - Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Note 5 - Intangible Assets - Estimated Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details</Role>
      <ShortName>Note 5 - Intangible Assets - Estimated Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995478 - Disclosure - Note 6 - Right-of-use Asset and Liabilities (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual</Role>
      <ShortName>Note 6 - Right-of-use Asset and Liabilities (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995479 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details</Role>
      <ShortName>Note 6 - Right-of-use Assets and Liabilities - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995480 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Lease Terms and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details</Role>
      <ShortName>Note 6 - Right-of-use Assets and Liabilities - Lease Terms and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995481 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details</Role>
      <ShortName>Note 6 - Right-of-use Assets and Liabilities - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995482 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details</Role>
      <ShortName>Note 6 - Right-of-use Assets and Liabilities - Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995483 - Disclosure - Note 7 - Commitments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual</Role>
      <ShortName>Note 7 - Commitments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-7-commitments-tables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995484 - Disclosure - Note 7 - Commitments - Commitments for Contractual Research (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details</Role>
      <ShortName>Note 7 - Commitments - Commitments for Contractual Research (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Note 8 - Capital Shares (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual</Role>
      <ShortName>Note 8 - Capital Shares (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995486 - Disclosure - Note 8 - Capital Shares - Schedule of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details</Role>
      <ShortName>Note 8 - Capital Shares - Schedule of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Note 8 - Capital Shares - Warrants Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details</Role>
      <ShortName>Note 8 - Capital Shares - Warrants Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995488 - Disclosure - Note 8 - Capital Shares - Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details</Role>
      <ShortName>Note 8 - Capital Shares - Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995489 - Disclosure - Note 8 - Capital Shares - Schedule of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details</Role>
      <ShortName>Note 8 - Capital Shares - Schedule of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995490 - Disclosure - Note 8 - Capital Shares - Option Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details</Role>
      <ShortName>Note 8 - Capital Shares - Option Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995491 - Disclosure - Note 8 - Capital Shares - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details</Role>
      <ShortName>Note 8 - Capital Shares - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995492 - Disclosure - Note 8 - Capital Shares - Vested Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details</Role>
      <ShortName>Note 8 - Capital Shares - Vested Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995493 - Disclosure - Note 9 - Government Contributions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual</Role>
      <ShortName>Note 9 - Government Contributions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-9-government-contributions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995494 - Disclosure - Note 10 - Income Tax (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual</Role>
      <ShortName>Note 10 - Income Tax (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Note 10 - Income Tax - Schedule of Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details</Role>
      <ShortName>Note 10 - Income Tax - Schedule of Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995496 - Disclosure - Note 10 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 10 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Note 10 - Income Tax - Summary of Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details</Role>
      <ShortName>Note 10 - Income Tax - Summary of Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995498 - Disclosure - Note 11 - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual</Role>
      <ShortName>Note 11 - Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-11-financial-instruments</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995499 - Disclosure - Note 13 - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual</Role>
      <ShortName>Note 13 - Related Party Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="edsa20240930_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995500 - Disclosure - Note 13 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual</Role>
      <ShortName>Note 13 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.edsa.com/20240930/role/statement-note-13-subsequent-events</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>edsa-20240930.xsd</File>
    <File>edsa-20240930_cal.xml</File>
    <File>edsa-20240930_def.xml</File>
    <File>edsa-20240930_lab.xml</File>
    <File>edsa-20240930_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="edsa20240930_10k.htm">edsa20240930_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>footer2.jpg</File>
    <File>footerv1.jpg</File>
    <File>footerv2.jpg</File>
    <File>logosmall.jpg</File>
    <File>mnplogo.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="543">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="6">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "edsa20240930_10k.htm": {
   "nsprefix": "edsa",
   "nsuri": "http://www.edsa.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "edsa-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "edsa-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "edsa-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "edsa-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "edsa-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "edsa20240930_10k.htm"
     ]
    }
   },
   "keyStandard": 271,
   "keyCustom": 48,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 58,
   "hidden": {
    "total": 50,
    "http://fasb.org/us-gaap/2024": 34,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://www.edsa.com/20240930": 6,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "contextCount": 175,
   "entityCount": 1,
   "segmentCount": 86,
   "elementCount": 510,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 543,
    "http://xbrl.sec.gov/dei/2024": 36,
    "http://xbrl.sec.gov/ecd/2024": 6,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.edsa.com/20240930/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows",
     "longName": "004 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity",
     "longName": "005 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
     "longName": "995451 - Disclosure - Note 1 - Nature of Operations",
     "shortName": "Note 1 - Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation",
     "longName": "995452 - Disclosure - Note 2 - Basis of Preparation",
     "shortName": "Note 2 - Basis of Preparation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
     "longName": "995453 - Disclosure - Note 3 - Significant Accounting Policies",
     "shortName": "Note 3 - Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment",
     "longName": "995454 - Disclosure - Note 4 - Property and Equipment",
     "shortName": "Note 4 - Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets",
     "longName": "995455 - Disclosure - Note 5 - Intangible Assets",
     "shortName": "Note 5 - Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities",
     "longName": "995456 - Disclosure - Note 6 - Right-of-use Asset and Liabilities",
     "shortName": "Note 6 - Right-of-use Asset and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.edsa.com/20240930/role/statement-note-7-commitments",
     "longName": "995457 - Disclosure - Note 7 - Commitments",
     "shortName": "Note 7 - Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
     "longName": "995458 - Disclosure - Note 8 - Capital Shares",
     "shortName": "Note 8 - Capital Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
     "longName": "995459 - Disclosure - Note 9 - Government Contributions",
     "shortName": "Note 9 - Government Contributions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:GovernmentAssistanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:GovernmentAssistanceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
     "longName": "995460 - Disclosure - Note 10 - Income Tax",
     "shortName": "Note 10 - Income Tax",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments",
     "longName": "995461 - Disclosure - Note 11 - Financial Instruments",
     "shortName": "Note 11 - Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions",
     "longName": "995462 - Disclosure - Note 13 - Related Party Transactions",
     "shortName": "Note 13 - Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
     "longName": "995463 - Disclosure - Note 13 - Subsequent Events",
     "shortName": "Note 13 - Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies",
     "longName": "995464 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables",
     "longName": "995465 - Disclosure - Note 4 - Property and Equipment (Tables)",
     "shortName": "Note 4 - Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables",
     "longName": "995466 - Disclosure - Note 5 - Intangible Assets (Tables)",
     "shortName": "Note 5 - Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables",
     "longName": "995467 - Disclosure - Note 6 - Right-of-use Asset and Liabilities (Tables)",
     "shortName": "Note 6 - Right-of-use Asset and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.edsa.com/20240930/role/statement-note-7-commitments-tables",
     "longName": "995468 - Disclosure - Note 7 - Commitments (Tables)",
     "shortName": "Note 7 - Commitments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables",
     "longName": "995469 - Disclosure - Note 8 - Capital Shares (Tables)",
     "shortName": "Note 8 - Capital Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables",
     "longName": "995470 - Disclosure - Note 10 - Income Tax (Tables)",
     "shortName": "Note 10 - Income Tax (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
     "longName": "995471 - Disclosure - Note 1 - Nature of Operations (Details Textual)",
     "shortName": "Note 1 - Nature of Operations (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
     "longName": "995472 - Disclosure - Note 3 - Significant Accounting Policies (Details Textual)",
     "shortName": "Note 3 - Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-09-30_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-CapitalizedCostsPropertyPlantAndEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentAdditions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual",
     "longName": "995473 - Disclosure - Note 4 - Property and Equipment (Details Textual)",
     "shortName": "Note 4 - Property and Equipment (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details",
     "longName": "995474 - Disclosure - Note 4 - Property and Equipment - Schedule of Property, Plant, and Equipment (Details)",
     "shortName": "Note 4 - Property and Equipment - Schedule of Property, Plant, and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual",
     "longName": "995475 - Disclosure - Note 5 - Intangible Assets (Details Textual)",
     "shortName": "Note 5 - Intangible Assets (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "i_2020-04-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details",
     "longName": "995476 - Disclosure - Note 5 - Intangible Assets - Schedule of Intangible Assets (Details)",
     "shortName": "Note 5 - Intangible Assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details",
     "longName": "995477 - Disclosure - Note 5 - Intangible Assets - Estimated Future Amortization (Details)",
     "shortName": "Note 5 - Intangible Assets - Estimated Future Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual",
     "longName": "995478 - Disclosure - Note 6 - Right-of-use Asset and Liabilities (Details Textual)",
     "shortName": "Note 6 - Right-of-use Asset and Liabilities (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details",
     "longName": "995479 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Lease Cost (Details)",
     "shortName": "Note 6 - Right-of-use Assets and Liabilities - Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details",
     "longName": "995480 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Lease Terms and Discount Rates (Details)",
     "shortName": "Note 6 - Right-of-use Assets and Liabilities - Lease Terms and Discount Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "edsa:LeaseTermAndDiscountRateTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "edsa:LeaseTermAndDiscountRateTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details",
     "longName": "995481 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Future Minimum Lease Payments (Details)",
     "shortName": "Note 6 - Right-of-use Assets and Liabilities - Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details",
     "longName": "995482 - Disclosure - Note 6 - Right-of-use Assets and Liabilities - Cash Flow Information (Details)",
     "shortName": "Note 6 - Right-of-use Assets and Liabilities - Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "edsa:LeasesCashFlowInformationTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "edsa:LeasesCashFlowInformationTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual",
     "longName": "995483 - Disclosure - Note 7 - Commitments (Details Textual)",
     "shortName": "Note 7 - Commitments (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details",
     "longName": "995484 - Disclosure - Note 7 - Commitments - Commitments for Contractual Research (Details)",
     "shortName": "Note 7 - Commitments - Commitments for Contractual Research (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
     "longName": "995485 - Disclosure - Note 8 - Capital Shares (Details Textual)",
     "shortName": "Note 8 - Capital Shares (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "edsa:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details",
     "longName": "995486 - Disclosure - Note 8 - Capital Shares - Schedule of Warrants (Details)",
     "shortName": "Note 8 - Capital Shares - Schedule of Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-09-30",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details",
     "longName": "995487 - Disclosure - Note 8 - Capital Shares - Warrants Assumptions (Details)",
     "shortName": "Note 8 - Capital Shares - Warrants Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details",
     "longName": "995488 - Disclosure - Note 8 - Capital Shares - Option Activity (Details)",
     "shortName": "Note 8 - Capital Shares - Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "i_2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2022-09-30",
      "name": "edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details",
     "longName": "995489 - Disclosure - Note 8 - Capital Shares - Schedule of Options (Details)",
     "shortName": "Note 8 - Capital Shares - Schedule of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details",
     "longName": "995490 - Disclosure - Note 8 - Capital Shares - Option Assumptions (Details)",
     "shortName": "Note 8 - Capital Shares - Option Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details",
     "longName": "995491 - Disclosure - Note 8 - Capital Shares - Restricted Stock Units (Details)",
     "shortName": "Note 8 - Capital Shares - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details",
     "longName": "995492 - Disclosure - Note 8 - Capital Shares - Vested Restricted Stock Units (Details)",
     "shortName": "Note 8 - Capital Shares - Vested Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "name": "edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "name": "edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual",
     "longName": "995493 - Disclosure - Note 9 - Government Contributions (Details Textual)",
     "shortName": "Note 9 - Government Contributions (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "us-gaap:GovernmentAssistanceNonoperatingIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember",
      "name": "edsa:GovernmentAssistanceAwardAmountRepayable",
      "unitRef": "CAD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:GovernmentAssistanceTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
     "longName": "995494 - Disclosure - Note 10 - Income Tax (Details Textual)",
     "shortName": "Note 10 - Income Tax (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:OperatingLossCarryforwardsValuationAllowance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details",
     "longName": "995495 - Disclosure - Note 10 - Income Tax - Schedule of Income Tax Reconciliation (Details)",
     "shortName": "Note 10 - Income Tax - Schedule of Income Tax Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "edsa:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30",
      "name": "edsa:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
     "longName": "995496 - Disclosure - Note 10 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Note 10 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details",
     "longName": "995497 - Disclosure - Note 10 - Income Tax - Summary of Operating Loss Carryforwards (Details)",
     "shortName": "Note 10 - Income Tax - Summary of Operating Loss Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "CAD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "CAD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual",
     "longName": "995498 - Disclosure - Note 11 - Financial Instruments (Details Textual)",
     "shortName": "Note 11 - Financial Instruments (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:AssetReportingCurrencyDenominatedValue",
      "unitRef": "CAD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-09-30",
      "name": "us-gaap:AssetReportingCurrencyDenominatedValue",
      "unitRef": "CAD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual",
     "longName": "995499 - Disclosure - Note 13 - Related Party Transactions (Details Textual)",
     "shortName": "Note 13 - Related Party Transactions (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2023-10-01_2024-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
     "longName": "995500 - Disclosure - Note 13 - Subsequent Events (Details Textual)",
     "shortName": "Note 13 - Subsequent Events (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "i_2022-08-31",
      "name": "edsa:EquityOfferingMaximumAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-7",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edsa20240930_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and other receivable",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "us-gaap_AccruedRentCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRentCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccruedRentCurrentAndNoncurrent",
        "terseLabel": "Accrued Rent",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r48",
      "r81"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details": {
       "parentTag": "edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Less: accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r125",
      "r430"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r58",
      "r132",
      "r425",
      "r452",
      "r453"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r15",
      "r352",
      "r355",
      "r397",
      "r448",
      "r449",
      "r621",
      "r622",
      "r623",
      "r633",
      "r634",
      "r635",
      "r636"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r583",
      "r820"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r633",
      "r634",
      "r635",
      "r636",
      "r768",
      "r821"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r266"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r302"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables",
        "terseLabel": "Allowance for Doubtful Accounts, Premiums and Other Receivables",
        "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AmortizationOfIntangibleAssets",
        "terseLabel": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r205",
      "r211",
      "r570"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_AssetReportingCurrencyDenominatedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetReportingCurrencyDenominatedValue",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetReportingCurrencyDenominatedValue",
        "terseLabel": "Net Assets",
        "documentation": "The reporting currency-denominated asset value."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r87",
      "r127",
      "r150",
      "r179",
      "r183",
      "r193",
      "r194",
      "r199",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r347",
      "r349",
      "r364",
      "r421",
      "r500",
      "r566",
      "r567",
      "r583",
      "r599",
      "r670",
      "r671",
      "r781"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r133",
      "r150",
      "r199",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r347",
      "r349",
      "r364",
      "r583",
      "r670",
      "r671",
      "r781"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_AtTheMarketOfferingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "AtTheMarketOfferingAgreementMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At The Market Offering Agreement [Member]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r606"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_AuditorLocation",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r606"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_AuditorName",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r606"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r67",
      "r68"
     ]
    },
    "edsa_CIBCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "CIBCMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CIBC [Member]",
        "documentation": "Represents the CIBC."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_CaliforniaSubsidiary401kMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "CaliforniaSubsidiary401kMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Subsidiary 401k [Member]",
        "documentation": "Represents the 401(k) retirement savings plan for the California subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_CanaccordMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "CanaccordMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canaccord [Member]",
        "documentation": "Represents Canaccord."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_CanadaEmergencyBusinessAccountProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "CanadaEmergencyBusinessAccountProgramMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada Emergency Business Account Program [Member]",
        "documentation": "Represents the Canada Emergency Business Account Program (CEBA)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CanadaRevenueAgencyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CanadaRevenueAgencyMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada Revenue Agency [Member]",
        "documentation": "Designated tax department of the government of Canada."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_CapitalizedCostsPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "CapitalizedCostsPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Costs, Property Plant and Equipment [Member]",
        "documentation": "Represents capitalized property, plant and equipment expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
        "terseLabel": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r123",
      "r556"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r64",
      "r147"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r64",
      "r147"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net change in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r64"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "documentation": "Person with designation of chief executive officer."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ClassAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ClassAWarrantsMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Warrants [Member]",
        "documentation": "Class A Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ClassBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ClassBWarrantsMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class B Warrants [Member]",
        "documentation": "Class B Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r129",
      "r130",
      "r131",
      "r150",
      "r171",
      "r172",
      "r174",
      "r176",
      "r181",
      "r182",
      "r199",
      "r225",
      "r227",
      "r228",
      "r229",
      "r232",
      "r233",
      "r236",
      "r237",
      "r241",
      "r244",
      "r251",
      "r364",
      "r457",
      "r458",
      "r459",
      "r460",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r488",
      "r509",
      "r530",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r614",
      "r628",
      "r637"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodStartLabel": "Balance, warrants, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Balance, warrants, weighted average exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "edsa_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_ClassOfWarrantOrRightExercisedDuringPeriod",
        "negatedLabel": "Exercised, number of warrant shares (in shares)",
        "documentation": "The number of warrants or rights exercised during period."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, warrants, weighted average exercise price (in dollars per share)",
        "documentation": "Exercise price per share of warrants or rights exercised during period."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ClassOfWarrantOrRightExpiredDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ClassOfWarrantOrRightExpiredDuringPeriod",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired, number of warrant shares (in shares)",
        "terseLabel": "Expired, number of warrant shares (in shares)",
        "documentation": "The number of warrants or rights cancelled during period."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired, warrants, weighted average exercise price (in dollars per share)",
        "terseLabel": "Expired, warrants, weighted average exercise price (in dollars per share)",
        "documentation": "Exercise price per share of warrants or rights cancelled during period."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_ClassOfWarrantOrRightIssuedDuringPeriod",
        "terseLabel": "Issued, number of warrant shares (in shares)",
        "documentation": "The number of warrants or rights issued during period."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice",
        "terseLabel": "Issued, warrants, weighted average exercise price (in dollars per share)",
        "documentation": "Exercise price per share of warrants or rights issued during period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class of Warrant or Right, Outstanding (in shares)",
        "label": "us-gaap_ClassOfWarrantOrRightOutstanding",
        "periodStartLabel": "Balance, number of warrant shares (in shares)",
        "periodEndLabel": "Balance, number of warrant shares (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm",
        "terseLabel": "Class of Warrant or Right, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments (Note 7)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r82",
      "r423",
      "r487"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r218",
      "r219",
      "r549",
      "r663",
      "r665"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r590",
      "r591",
      "r593",
      "r594",
      "r595",
      "r596",
      "r633",
      "r634",
      "r636",
      "r768",
      "r819",
      "r821"
     ]
    },
    "us-gaap_CommonStockNoParValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNoParValue",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, No Par Value (in dollars per share)",
        "documentation": "Face amount per share of no-par value common stock."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "xbrltype": "authorizedUnlimitedItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "documentation": "Indicates whether number of common shares permitted to be issued is unlimited. Acceptable value is \"Unlimited\"."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued and outstanding: 3,075,473 common shares (September 30, 2022 - 2,380,280) (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r488",
      "r506",
      "r821",
      "r822"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorized unlimited common and preferred shares without par value issued and outstanding: 3,247,389 common shares (September 30, 2023 - 3,075,473)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r424",
      "r583"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss and comprehensive loss",
        "totalLabel": "Net comprehensive loss",
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r135",
      "r137",
      "r142",
      "r416",
      "r435",
      "r436"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ContractualObligation",
        "totalLabel": "Contractual Obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_ContractualObligationDueInFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInFifthYear",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ContractualObligationDueInFifthYear",
        "terseLabel": "September 30, 2029",
        "documentation": "Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInFourthYear",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ContractualObligationDueInFourthYear",
        "terseLabel": "September 30, 2028",
        "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ContractualObligationDueInNextTwelveMonths",
        "terseLabel": "September 30, 2025",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInSecondYear",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ContractualObligationDueInSecondYear",
        "terseLabel": "September 30, 2026",
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInThirdYear",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ContractualObligationDueInThirdYear",
        "terseLabel": "September 30, 2027",
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r616",
      "r632"
     ]
    },
    "edsa_ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series A-1 Convertible Preferred Shares to Common Shares [Member]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion",
        "terseLabel": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r32",
      "r51",
      "r75",
      "r247"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r154",
      "r155",
      "r234",
      "r239",
      "r404",
      "r411",
      "r420",
      "r557",
      "r559"
     ]
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r668"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r668",
      "r669"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1",
        "terseLabel": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal",
        "terseLabel": "Debt Instrument, Covenant, Maximum Percentage of Borrowing Base for Outstanding Principal",
        "documentation": "The maximum percentage of the borrowing base for outstanding principal allowed under the covenant of the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentDecreaseForgiveness",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentDecreaseForgiveness",
        "terseLabel": "Debt Instrument, Decrease, Forgiveness",
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtInstrumentMaturityDate",
        "terseLabel": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r571",
      "r770",
      "r771"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Subtotal",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Net deferred taxes",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsNet",
        "totalLabel": "Total net deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-capital losses carried forward - Canada",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-capital losses carried forward - U.S.",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other temporary differences",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "edsa_DeferredTaxAssetsRightofuseLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "DeferredTaxAssetsRightofuseLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use lease liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to right-of-use lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_DeferredTaxAssetsShareIssuanceAndFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "DeferredTaxAssetsShareIssuanceAndFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance and financing costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to share issuance and financing costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Less: valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "DeferredTaxLiabilitiesDeferredShareIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_DeferredTaxLiabilitiesDeferredShareIssuanceCosts",
        "negatedLabel": "Deferred share issuance costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from deferred share issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_DeferredTaxLiabilitiesGrantIncomeReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "DeferredTaxLiabilitiesGrantIncomeReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_DeferredTaxLiabilitiesGrantIncomeReceivable",
        "negatedLabel": "Grant Income receivable",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from grant income receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements",
        "negatedLabel": "Right-of-use assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment",
        "negatedLabel": "Property and equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount",
        "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
        "terseLabel": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage",
        "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Depreciation",
        "terseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28"
     ]
    },
    "edsa_DepreciationDecliningBalanceMethodPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "DepreciationDecliningBalanceMethodPercentage",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_DepreciationDecliningBalanceMethodPercentage",
        "terseLabel": "Depreciation, Declining Balance Method, Percentage",
        "documentation": "Represents the percentage of the declining balance method for depreciation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DepreciationDepletionAndAmortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r179",
      "r184",
      "r194",
      "r566",
      "r567"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r606"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentFinStmtErrorCorrectionFlag",
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r606",
      "r608"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentPeriodEndDate",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentType",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "edsa_DrugSubstanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "DrugSubstanceMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Drug Substance [Member]",
        "documentation": "Represents a drug substance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss per common share - basic and diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r170",
      "r171",
      "r174",
      "r175",
      "r176",
      "r178",
      "r342",
      "r345",
      "r359",
      "r360",
      "r417",
      "r437",
      "r561"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r177"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canadian federal and provincial statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r311",
      "r333",
      "r577"
     ]
    },
    "edsa_EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-capital losses limitation - U.S.",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to non-capital losses limitation."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issuance cost booked through equity or capitalization",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to share issuance costs booked through equity or capitalization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityCommonStockSharesOutstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityCurrentReportingStatus",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables",
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments",
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-tables",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual",
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityFileNumber",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityInteractiveDataCurrent",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityPublicFloat",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityRegistrantName",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityShellCompany",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityVoluntaryFilers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityWellKnownSeasonedIssuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r119",
      "r139",
      "r140",
      "r141",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r169",
      "r180",
      "r200",
      "r201",
      "r217",
      "r253",
      "r331",
      "r332",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r384",
      "r386",
      "r397",
      "r434",
      "r448",
      "r449",
      "r450",
      "r466",
      "r530"
     ]
    },
    "edsa_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Distribution Agreement [Member]",
        "documentation": "Represents an equity distribution agreement."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_EquityOfferingLimitationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "EquityOfferingLimitationAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_EquityOfferingLimitationAmount",
        "terseLabel": "Equity Offering, Limitation Amount",
        "documentation": "Amount of limitation on equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_EquityOfferingMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "EquityOfferingMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_EquityOfferingMaximumAmount",
        "terseLabel": "Equity Offering, Maximum Amount",
        "documentation": "The maximum amount allowed to be issued under the equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r578"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
        "negatedLabel": "Less: accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r202",
      "r210",
      "r570"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
        "terseLabel": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r823"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
        "terseLabel": "September 30, 2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r553",
      "r570"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
        "terseLabel": "September 30, 2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r553",
      "r570"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
        "terseLabel": "September 30, 2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r553",
      "r570"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
        "terseLabel": "September 30, 2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r553",
      "r570"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
        "terseLabel": "September 30, 2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r553",
      "r570"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r214",
      "r414",
      "r415",
      "r553"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Constructs",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r210",
      "r415",
      "r570"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r214",
      "r553"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible asset, net",
        "totalLabel": "Total intangible assets, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r658"
     ]
    },
    "us-gaap_FiniteLivedLicenseAgreementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedLicenseAgreementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FiniteLivedLicenseAgreementsGross",
        "terseLabel": "Finite-Lived License Agreements, Gross",
        "documentation": "Gross carrying amount as of the balance sheet date of certain rights acquired to exercise a certain privilege or pursue a particular business or occupation and which is deemed to have a finite economic life."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r658"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312"
     ]
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ForeignCurrencyExchangeRateTranslation1",
        "terseLabel": "Currency Exchange Rate",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange loss",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r367",
      "r368",
      "r369",
      "r527"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "edsa_FunctionalAndReportingCurrenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "FunctionalAndReportingCurrenciesPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Functional and Reporting Currencies [Policy Text Block]",
        "documentation": "Represents the accounting policy for functional and reporting currencies."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_FurnitureAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "FurnitureAndEquipmentMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Equipment [Member]",
        "documentation": "Represents furniture and equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GainsLossesOnExtinguishmentOfDebt",
        "negatedTerseLabel": "Gain on payable forgiveness",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r30",
      "r31"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r511"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650"
     ]
    },
    "us-gaap_GovernmentAssistanceAwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceAwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GovernmentAssistanceAwardAmount",
        "terseLabel": "Government Assistance, Award Amount",
        "documentation": "Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "edsa_GovernmentAssistanceAwardAmountNotRepayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "GovernmentAssistanceAwardAmountNotRepayable",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_GovernmentAssistanceAwardAmountNotRepayable",
        "terseLabel": "Government Assistance, Award Amount, Not Repayable",
        "documentation": "Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met that will not be repayable."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_GovernmentAssistanceAwardAmountRepayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "GovernmentAssistanceAwardAmountRepayable",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_GovernmentAssistanceAwardAmountRepayable",
        "terseLabel": "Government Assistance, Award Amount, Repayable",
        "documentation": "Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met that will be repayable."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_GovernmentAssistanceAwardAmountRepyable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "GovernmentAssistanceAwardAmountRepyable",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_GovernmentAssistanceAwardAmountRepyable",
        "terseLabel": "Government Assistance, Award Amount, Repyable",
        "documentation": "Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met that will be repayable."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "GovernmentAssistanceExpirationPeriodAfterLastRepayment",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_GovernmentAssistanceExpirationPeriodAfterLastRepayment",
        "terseLabel": "Government assistance, Expiration, Period After Last Repayment",
        "documentation": "Period after last repayment date for expiration of government assistance."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal",
        "terseLabel": "Government Assistance, Maximum Amount Repayable, Factor of Original",
        "documentation": "The factor of original amount repayable for maximum amount to be repaid for government assistance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistanceNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement grant income",
        "terseLabel": "Government Assistance, Nonoperating Income, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in income from government assistance, classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "edsa_GovernmentAssistancePeriodOfRepayment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "GovernmentAssistancePeriodOfRepayment",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_GovernmentAssistancePeriodOfRepayment",
        "terseLabel": "Government Assistance, Period of Repayment",
        "documentation": "Period of repayment for government assistance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance [Text Block]",
        "documentation": "The entire disclosure for government assistance."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTypeAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Axis]",
        "documentation": "Information by type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTypeDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Assistance, Type [Domain]",
        "documentation": "Type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_IcfrAuditorAttestationFlag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r606"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r72"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r84",
      "r86",
      "r418",
      "r432",
      "r563",
      "r566",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ]
    },
    "edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss before recovery of income taxes",
        "label": "edsa_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r311",
      "r312",
      "r321",
      "r328",
      "r577",
      "r766"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r311",
      "r312",
      "r321",
      "r328",
      "r577",
      "r766"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r766"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r766"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r307",
      "r311",
      "r318",
      "r319",
      "r320",
      "r322",
      "r327",
      "r334",
      "r336",
      "r337",
      "r338",
      "r462",
      "r577"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expense",
        "totalLabel": "Income tax (recovery) expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r100",
      "r168",
      "r169",
      "r179",
      "r185",
      "r194",
      "r310",
      "r311",
      "r335",
      "r438",
      "r577"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r308",
      "r309",
      "r322",
      "r323",
      "r326",
      "r330",
      "r456"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r577",
      "r761"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of foreign currency and foreign tax rate differences",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r314",
      "r577",
      "r761"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected income tax recovery",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r577"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Permanent differences",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317",
      "r761"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r761",
      "r762"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables",
        "negatedTerseLabel": "Accounts and other receivable",
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
        "terseLabel": "Accounts payable and accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r609"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r611"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r611"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r605",
      "r611"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r215",
      "r216",
      "r552",
      "r553"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares and warrants in equity offering",
        "documentation": "Information pertaining to the issuance of common shares and warrants in equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares and warrants in equity offering (in shares)",
        "documentation": "Information pertaining to the shares issued for common shares and warrants in equity offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "edsa_LeaseTermAndDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "LeaseTermAndDiscountRateTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Term and Discount Rate [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease terms and discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_LeasesCashFlowInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "LeasesCashFlowInformationTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Cash Flow Information [Table Text Block]",
        "documentation": "Tabular disclosure of cash flow information for leases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables",
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments",
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-tables",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual",
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "terseLabel": "September 30, 2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "terseLabel": "Less imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining lease term (months): (Month)",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r776"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseRenewalTerm",
        "terseLabel": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r43",
      "r44",
      "r45",
      "r47",
      "r48",
      "r49",
      "r50",
      "r150",
      "r199",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r348",
      "r349",
      "r350",
      "r364",
      "r486",
      "r562",
      "r599",
      "r670",
      "r781",
      "r782"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and shareholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r83",
      "r427",
      "r583",
      "r630",
      "r648",
      "r772"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r122",
      "r150",
      "r199",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r348",
      "r349",
      "r350",
      "r364",
      "r583",
      "r670",
      "r781",
      "r782"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_LicenseAgreementRelatedToPharmaceuticalProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "LicenseAgreementRelatedToPharmaceuticalProductsMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Related to Pharmaceutical Products [Member]",
        "documentation": "Represents the license agreement related to pharmaceutical products."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_LicenseAgreementRenewalPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "LicenseAgreementRenewalPeriod",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_LicenseAgreementRenewalPeriod",
        "terseLabel": "License Agreement, Renewal Period",
        "documentation": "Period for renewal of the license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement to Acquire Global Rights of Pharmaceutical Product [Member]",
        "documentation": "Represents the license agreement to acquire global rights of pharmaceutical product."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r306",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r660",
      "r661",
      "r662",
      "r760"
     ]
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r46",
      "r629",
      "r668",
      "r669"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r46",
      "r629",
      "r668"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r46"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_MaximumContingentObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "MaximumContingentObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_MaximumContingentObligation",
        "terseLabel": "Maximum Contingent Obligation",
        "documentation": "Amount of maximum contingent obligation."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r117",
      "r118",
      "r220",
      "r221",
      "r222",
      "r223",
      "r259",
      "r303",
      "r363",
      "r412",
      "r446",
      "r447",
      "r454",
      "r478",
      "r479",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r550",
      "r551",
      "r569",
      "r572",
      "r574",
      "r578",
      "r579",
      "r580",
      "r581",
      "r585",
      "r672",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r578"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r578"
     ]
    },
    "edsa_MilestoneExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "MilestoneExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_MilestoneExpense",
        "terseLabel": "Milestone Expense",
        "documentation": "Amount of milestone expense."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r117",
      "r118",
      "r220",
      "r221",
      "r222",
      "r223",
      "r259",
      "r303",
      "r363",
      "r412",
      "r446",
      "r447",
      "r454",
      "r478",
      "r479",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r550",
      "r551",
      "r569",
      "r572",
      "r574",
      "r578",
      "r579",
      "r580",
      "r585",
      "r672",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r101"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "negatedLabel": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r66",
      "r85",
      "r120",
      "r134",
      "r136",
      "r141",
      "r150",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r173",
      "r199",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r342",
      "r345",
      "r360",
      "r364",
      "r433",
      "r508",
      "r528",
      "r529",
      "r597",
      "r670"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (loss):"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r563",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use lease cost, included in general and administrative on the Statements of Operations",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r582"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseLiability",
        "terseLabel": "Present value of right-of-use lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term right-of-use lease liabilities",
        "terseLabel": "Present value included in current liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term right-of-use lease liabilities",
        "terseLabel": "Present value included in long-term liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in the measurement of right-of-use lease liabilities, included in accounts payable and accrued liabilities on the Statements of Cash Flow.",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r392"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated incremental borrowing rate:",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r582"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLossCarryforwardsValuationAllowance",
        "terseLabel": "Operating Loss Carryforwards, Valuation Allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange differences on translation",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r434"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Misc other income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "edsa_PardeepNijhawanMedicineProfessionalCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "PardeepNijhawanMedicineProfessionalCorporationMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pardeep Nijhawan Medicine Professional Corporation [Member]",
        "documentation": "Represents Pardeep Nijhawan Medicine Professional Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_PaymentsForLicensingAndRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "PaymentsForLicensingAndRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_PaymentsForLicensingAndRoyalties",
        "terseLabel": "Finite-Lived License Agreements, Gross",
        "documentation": "Amount of cash outflow for licensing and royalties."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_PaymentsForMilestoneRoyaltyAndSublicensing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "PaymentsForMilestoneRoyaltyAndSublicensing",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_PaymentsForMilestoneRoyaltyAndSublicensing",
        "terseLabel": "Payments for Milestone, Royalty and Sublicensing",
        "documentation": "Amount of cash outflow for milestone, royalty and sublicensing,"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "negatedLabel": "Payments for issuance costs of common shares and warrants",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToSuppliers",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToSuppliers",
        "terseLabel": "Payments to Suppliers",
        "documentation": "Payments of cash to suppliers for goods and services during the current period."
       }
      }
     },
     "auth_ref": [
      "r626",
      "r627"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759"
     ]
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PreferredStockConvertibleConversionPrice",
        "terseLabel": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PreferredStockConvertibleConversionRatio",
        "terseLabel": "Preferred Stock, Convertible, Conversion Ratio",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PreferredStockConvertibleSharesIssuable",
        "terseLabel": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PreferredStockParOrStatedValuePerShare",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r236"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_PrivatePlacementSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "PrivatePlacementSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement, Securities Purchase Agreement [Member]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common shares and warrants",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r457"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r196",
      "r413",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r555",
      "r573",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r617",
      "r666",
      "r667",
      "r673",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r196",
      "r413",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r555",
      "r573",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r617",
      "r666",
      "r667",
      "r673",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentAdditions",
        "terseLabel": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_PropertyPlantAndEquipmentAssetsNotInService": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "PropertyPlantAndEquipmentAssetsNotInService",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets not in service",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets of assets not in service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r395"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r95",
      "r98",
      "r99"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details": {
       "parentTag": "edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r124",
      "r431"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r395",
      "r419",
      "r431",
      "r583"
     ]
    },
    "edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "PropertyPlantAndEquipmentNetIncludingAssetsNotInService",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_PropertyPlantAndEquipmentNetIncludingAssetsNotInService",
        "totalLabel": "Depreciable assets, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale, including assets not in service. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r95",
      "r98",
      "r429"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r395"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PurchaseObligation",
        "terseLabel": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r117",
      "r118",
      "r220",
      "r221",
      "r222",
      "r223",
      "r254",
      "r259",
      "r292",
      "r293",
      "r294",
      "r303",
      "r363",
      "r409",
      "r410",
      "r412",
      "r446",
      "r447",
      "r454",
      "r478",
      "r479",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r550",
      "r551",
      "r569",
      "r572",
      "r574",
      "r578",
      "r579",
      "r580",
      "r581",
      "r585",
      "r591",
      "r664",
      "r672",
      "r770",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "edsa_RangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "RangeFiveMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Five [Member]",
        "documentation": "Represents range five."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_RangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "RangeFourMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Four [Member]",
        "documentation": "Represents range four."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r117",
      "r118",
      "r220",
      "r221",
      "r222",
      "r223",
      "r254",
      "r259",
      "r292",
      "r293",
      "r294",
      "r303",
      "r363",
      "r409",
      "r410",
      "r412",
      "r446",
      "r447",
      "r454",
      "r478",
      "r479",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r550",
      "r551",
      "r569",
      "r572",
      "r574",
      "r578",
      "r579",
      "r580",
      "r581",
      "r585",
      "r591",
      "r664",
      "r672",
      "r770",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788"
     ]
    },
    "edsa_RangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "RangeOneMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range One [Member]",
        "documentation": "Represents range one."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_RangeSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "RangeSevenMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Seven [Member]",
        "documentation": "Represents range seven."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_RangeSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "RangeSixMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Six [Member]",
        "documentation": "Represents range six."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_RangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "RangeThreeMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Three [Member]",
        "documentation": "Represents range three."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_RangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "RangeTwoMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Two [Member]",
        "documentation": "Represents range two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r255",
      "r401",
      "r402",
      "r422",
      "r428",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r505",
      "r507",
      "r537"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r401",
      "r402",
      "r403",
      "r404",
      "r422",
      "r428",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r505",
      "r507",
      "r537"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r255",
      "r401",
      "r402",
      "r422",
      "r428",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r505",
      "r507",
      "r537",
      "r780"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r400",
      "r402",
      "r405",
      "r463",
      "r464",
      "r465",
      "r512",
      "r513",
      "r514",
      "r534",
      "r536"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RepaymentsOfDebt",
        "negatedLabel": "Repayment of debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RepaymentsOfLongTermDebt",
        "terseLabel": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r460"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r154",
      "r155",
      "r234",
      "r239",
      "r404",
      "r411",
      "r420",
      "r558",
      "r559"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r553",
      "r566",
      "r789"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r76",
      "r426",
      "r451",
      "r453",
      "r461",
      "r489",
      "r583"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r169",
      "r200",
      "r201",
      "r217",
      "r331",
      "r332",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r351",
      "r353",
      "r354",
      "r356",
      "r358",
      "r384",
      "r386",
      "r448",
      "r450",
      "r466",
      "r821"
     ]
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r574",
      "r615",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r574",
      "r615",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r554",
      "r560"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r577",
      "r761"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r657"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r77"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r659"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r197",
      "r564",
      "r565",
      "r568"
     ]
    },
    "edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss",
        "negatedLabel": "Sensitivity Analysis, Ten Percent Change to Foreign Currency Exchange, Impact to Net Income (Loss) and Other Comprehensive Income (Loss)",
        "documentation": "Amount of impact to net income (loss) and other comprehensive income (loss) from 10% change in foreign currency exchange rate."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_SeriesA1ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "SeriesA1ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A-1 Convertible Preferred Stock [Member]",
        "documentation": "Series A-1 convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, number of RSU (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodStartLabel": "Balance, number of RSU (in shares)",
        "periodEndLabel": "Balance, number of RSU (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodStartLabel": "Balance, weighted average grant date fair value (in dollars per share)",
        "periodEndLabel": "Balance, weighted average grant date fair value (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r280"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fully-vested RSUs (in shares)",
        "documentation": "Number of fully vested equity instruments other than options outstanding that can be converted into shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected share price volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue",
        "periodStartLabel": "Balance, options, weighted average grant date fair value (in dollars per share)",
        "periodEndLabel": "Balance, options, weighted average grant date fair value (in dollars per share)",
        "documentation": "Weighted average grant-date fair value of options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Per Share",
        "documentation": "Per share or per unit amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
        "negatedLabel": "Expired, number of options (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired, options, weighted average grant date fair value (in dollars per share)",
        "documentation": "Weighted average grant-date fair value of options expired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Forfeited, number of options (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, number of options (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, options, weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Intrinsic Value Per Share",
        "documentation": "Per share or per unit amount by which the current fair value of the underlying stock exceeds the exercise price of options nonvested."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards nonvested, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)",
        "periodStartLabel": "Balance, number of options (in shares)",
        "periodEndLabel": "Balance, number of options (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)",
        "periodStartLabel": "Balance, options, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Balance, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, options, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r270",
      "r289",
      "r290",
      "r291",
      "r292",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
        "terseLabel": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (years) (Year)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited, options, weighted average grant date fair value (in dollars per share)",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r148"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r129",
      "r130",
      "r131",
      "r150",
      "r171",
      "r172",
      "r174",
      "r176",
      "r181",
      "r182",
      "r199",
      "r225",
      "r227",
      "r228",
      "r229",
      "r232",
      "r233",
      "r236",
      "r237",
      "r241",
      "r244",
      "r251",
      "r364",
      "r457",
      "r458",
      "r459",
      "r460",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r488",
      "r509",
      "r530",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r614",
      "r628",
      "r637"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r52",
      "r55",
      "r56",
      "r119",
      "r139",
      "r140",
      "r141",
      "r156",
      "r157",
      "r158",
      "r160",
      "r165",
      "r167",
      "r169",
      "r180",
      "r200",
      "r201",
      "r217",
      "r253",
      "r331",
      "r332",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r384",
      "r386",
      "r397",
      "r434",
      "r448",
      "r449",
      "r450",
      "r466",
      "r530"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables",
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments",
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-tables",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual",
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r180",
      "r386",
      "r413",
      "r455",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r510",
      "r511",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r530",
      "r592"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-cash-flows",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables",
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments",
      "http://www.edsa.com/20240930/role/statement-note-11-financial-instruments-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions",
      "http://www.edsa.com/20240930/role/statement-note-13-related-party-transactions-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-2-basis-of-preparation",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies",
      "http://www.edsa.com/20240930/role/statement-note-3-significant-accounting-policies-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-estimated-future-amortization-details",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-commitments-for-contractual-research-details",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-tables",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-activity-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-option-assumptions-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-options-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-vested-restricted-stock-units-details",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual",
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r180",
      "r198",
      "r386",
      "r413",
      "r455",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r507",
      "r510",
      "r511",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r530",
      "r592"
     ]
    },
    "edsa_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon exercise of warrants (in shares)",
        "documentation": "The number of shares issued during the period for exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r76",
      "r457",
      "r530",
      "r544"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon exercise of restricted share units (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r76"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r76",
      "r276"
     ]
    },
    "edsa_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon exercise of warrants",
        "documentation": "Value of stock issued during the period for exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares",
        "terseLabel": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r52",
      "r76",
      "r466",
      "r530",
      "r544",
      "r598"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common shares upon exercise of restricted share units",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r76"
     ]
    },
    "edsa_StockIssuedDuringPeriodValueStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "StockIssuedDuringPeriodValueStockIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_StockIssuedDuringPeriodValueStockIssuanceCosts",
        "negatedLabel": "Issuance costs",
        "documentation": "Value of stock issued during the period for issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets",
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-changes-in-shareholders-equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total shareholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r69",
      "r490",
      "r506",
      "r531",
      "r532",
      "r583",
      "r599",
      "r630",
      "r648",
      "r772",
      "r821"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-balance-sheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r149",
      "r235",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r249",
      "r250",
      "r253",
      "r357",
      "r533",
      "r535",
      "r548"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r407"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r407"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r407"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r408"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-tables",
      "http://www.edsa.com/20240930/role/statement-note-4-property-and-equipment-tables",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-tables",
      "http://www.edsa.com/20240930/role/statement-note-6-rightofuse-asset-and-liabilities-tables",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-tables",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TaxCreditCarryforwardAmount",
        "terseLabel": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_TaxCreditCarryforwardValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TaxCreditCarryforwardValuationAllowance",
        "terseLabel": "Tax Credit Carryforward, Valuation Allowance",
        "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "edsa_TaxYear2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2025Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2025 [Member]",
        "documentation": "Represents tax year 2025."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2026Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2026 [Member]",
        "documentation": "Represents tax year 2026."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2027Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2027 [Member]",
        "documentation": "Represents tax year 2027."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2028Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2028 [Member]",
        "documentation": "Represents tax year 2028."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2029Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2029 [Member]",
        "documentation": "Represents tax year 2029."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2030Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2030 [Member[",
        "documentation": "Represents tax year 2030."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2031Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2031 [Member]",
        "documentation": "Represents tax year 2031."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2032Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2032 [Member]",
        "documentation": "Represents tax year 2032."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2033Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2033 [Member]",
        "documentation": "Represents tax year 2033."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2034Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2034 [Member]",
        "documentation": "Represents tax year 2034."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2035Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2035 [Member]",
        "documentation": "Represents tax year 2035."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2036Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2036 [Member]",
        "documentation": "Represents tax year 2036."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2037Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2037 [Member]",
        "documentation": "Represents tax year 2037."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2038Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2038 [Member]",
        "documentation": "Represents tax year 2038."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2039Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2039 [Member]",
        "documentation": "Represents tax year 2039."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2040Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2040 [Member]",
        "documentation": "Represents tax year 2040."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2041Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2041Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2041 [Member]",
        "documentation": "Represents tax year 2041."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2042Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2042Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2042 [Member]",
        "documentation": "Represents tax year 2042."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2043Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2043 [Member]",
        "documentation": "Represents tax year 2043."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TaxYear2044Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TaxYear2044Member",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax",
      "http://www.edsa.com/20240930/role/statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2044 [Member]",
        "documentation": "Represents the tax year 2044."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_The2019PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "The2019PlanMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2019 Plan [Member]",
        "documentation": "Represents the 2019 Plan."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_The2021SIFAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "The2021SIFAgreementMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2021 SIF Agreement [Member]",
        "documentation": "Represents the 2021 SIF Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_The2023SIFAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "The2023SIFAgreementMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions",
      "http://www.edsa.com/20240930/role/statement-note-9-government-contributions-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2023 SIF Agreement [Member]",
        "documentation": "Represents the 2023 SIF Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TheConstructsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TheConstructsMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets",
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-schedule-of-intangible-assets-details",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The Constructs [Member]",
        "documentation": "Represents the Constructs."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_ThreeYearWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "ThreeYearWarrantsMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Year Warrants [Member]",
        "documentation": "Represents 3-year warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r644",
      "r645",
      "r647"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_TwelveMonthWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "TwelveMonthWarrantsMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twelve Month Warrants [Member]",
        "documentation": "Represents 12-month warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-7-commitments",
      "http://www.edsa.com/20240930/role/statement-note-7-commitments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "edsa_UnsecuredLineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "UnsecuredLineOfCreditMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Line of Credit [Member]",
        "documentation": "Represents unsecured line of credit."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_UpfrontLicensePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "UpfrontLicensePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-5-intangible-assets-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_UpfrontLicensePayment",
        "terseLabel": "Upfront License Payment",
        "documentation": "Amount of upfront license payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r93",
      "r94",
      "r96",
      "r97"
     ]
    },
    "edsa_WarrantFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "WarrantFiveMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Five [Member]",
        "documentation": "Warrant Five"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_WarrantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "WarrantFourMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Four [Member]",
        "documentation": "Warrant Four"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant One [Member]",
        "documentation": "Warrant One"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Three [Member]",
        "documentation": "Warrant Three"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Two [Member]",
        "documentation": "Warrant Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantsAndRightsOutstanding",
        "terseLabel": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-schedule-of-warrants-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants and Rights Outstanding, Maturity Date",
        "label": "us-gaap_WarrantsAndRightsOutstandingMaturityDate",
        "terseLabel": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-warrants-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant assumption",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantsAndRightsOutstandingTerm",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r769",
      "r770",
      "r771"
     ]
    },
    "edsa_WarrantsIssuedInPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "WarrantsIssuedInPrivatePlacementMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares",
      "http://www.edsa.com/20240930/role/statement-note-8-capital-shares-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Issued in Private Placement [Member]",
        "documentation": "Represents warrants issued in private placement."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_WarrantsToPurchaseCommonSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "WarrantsToPurchaseCommonSharesMember",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations",
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events",
      "http://www.edsa.com/20240930/role/statement-note-13-subsequent-events-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to Purchase Common Shares [Member]",
        "documentation": "Name of the class or type of warrant or right outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of common shares (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r176"
     ]
    },
    "edsa_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "WorkingCapitalDeficit",
     "crdr": "debit",
     "presentation": [
      "http://www.edsa.com/20240930/role/statement-note-1-nature-of-operations-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "edsa_WorkingCapitalDeficit",
        "terseLabel": "Working Capital (Deficit)",
        "documentation": "Information pertaining to the working capital (deficit)."
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-10-income-tax-schedule-of-deferred-tax-assets-and-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Income Tax - Schedule of Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-10-income-tax-schedule-of-income-tax-reconciliation-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Income Tax - Schedule of Income Tax Reconciliation (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-10-income-tax-summary-of-operating-loss-carryforwards-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Income Tax - Summary of Operating Loss Carryforwards (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-10-income-tax-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-10-income-tax-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Income Tax"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-4-property-and-equipment-schedule-of-property-plant-and-equipment-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Property and Equipment - Schedule of Property, Plant, and Equipment (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-4-property-and-equipment-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-4-property-and-equipment-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Property and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-5-intangible-assets-estimated-future-amortization-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-5-intangible-assets-estimated-future-amortization-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Intangible Assets - Estimated Future Amortization (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-5-intangible-assets-schedule-of-intangible-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Intangible Assets - Schedule of Intangible Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-5-intangible-assets-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-5-intangible-assets-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-6-rightofuse-asset-and-liabilities-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-6-rightofuse-asset-and-liabilities-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Right-of-use Asset and Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-6-rightofuse-assets-and-liabilities-cash-flow-information-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Right-of-use Assets and Liabilities - Cash Flow Information (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-6-rightofuse-assets-and-liabilities-future-minimum-lease-payments-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Right-of-use Assets and Liabilities - Future Minimum Lease Payments (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-6-rightofuse-assets-and-liabilities-lease-cost-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Right-of-use Assets and Liabilities - Lease Cost (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-6-rightofuse-assets-and-liabilities-lease-terms-and-discount-rates-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Right-of-use Assets and Liabilities - Lease Terms and Discount Rates (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-7-commitments-commitments-for-contractual-research-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-7-commitments-commitments-for-contractual-research-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Commitments - Commitments for Contractual Research (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-7-commitments-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-7-commitments-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-8-capital-shares-option-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-8-capital-shares-option-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Capital Shares - Option Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-8-capital-shares-option-assumptions-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-8-capital-shares-option-assumptions-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Capital Shares - Option Assumptions (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-8-capital-shares-restricted-stock-units-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-8-capital-shares-restricted-stock-units-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Capital Shares - Restricted Stock Units (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-8-capital-shares-schedule-of-options-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-8-capital-shares-schedule-of-options-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Capital Shares - Schedule of Options (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-8-capital-shares-schedule-of-warrants-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-8-capital-shares-schedule-of-warrants-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Capital Shares - Schedule of Warrants (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-8-capital-shares-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-8-capital-shares-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Capital Shares"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-8-capital-shares-vested-restricted-stock-units-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-8-capital-shares-vested-restricted-stock-units-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Capital Shares - Vested Restricted Stock Units (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-note-8-capital-shares-warrants-assumptions-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-note-8-capital-shares-warrants-assumptions-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Capital Shares - Warrants Assumptions (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "edsa_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.edsa.com/20240930",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "830",
   "SubTopic": "30",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-4"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-4"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Subparagraph": "(a)",
   "Publisher": "SEC"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001171843-24-006946-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-24-006946-xbrl.zip
M4$L#!!0    ( *V%C5DD%=5@&Q4  &P) 0 1    961S82TR,#(T,#DS,"YX
M<V3M75MOXSJ2?E]@_X/6+W,6&+6ON;C1?0;.K1$@:0>)>\[,TT"1:9O;LN1#
M2;F<7[]5I"1+-B53-MV1$C\$<'BK*GY%5K%XT9=_O,P=XXDPGWKNUT;[4ZMA
M$-?VQM2=?FW\># '#^?7UPW##RQW;#F>2[XV7*_QC]__^[^^_(]I?B,N859
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M2.I?+HYM.67%@2IVZ'!4*BK4F$S*"@55J$LK+-."D;(R014?%@5;(84-C*"
M06&%#QYZP-<7YMBS0_[#<L=@.P(:O)HX%MF<4VD86._'_77Q"D.PI]YJPEO,
MW1(ML8Y26?_^WFJU#-.XB&BE?P[<L7')R1K72[)?FBNTUM@(?3(>NK_SWRNC
M(JH<E2BJF-4\]7JKZ,IK1JDQG&HHV^ ,> X=\]GYT7+X^LR?$1+X6R)<U*(N
M=-L Z4-,$7Z?IV@:9X*F\<!I'J"5 &$N+%B9!#,24)!X#TBO$M %?$<=>..W
MNPP/_WO0! Y4DNR;WL1$PQ0M"7!&!KB!CQDN&9Z(Z7B^%MTH2U*7MG2+M"7)
M\ UO8@P3I@Q@"DJFF#)N@*F#]DB@M"U_9DX<[WD/:I)J6Y<^]-3UX1RH&U=(
M_0"\#)R9Y4YA+4U=F/!AFIUYSI@PWR1_AN!:[4$9BNGI4I"C$@HB.#*H"_9F
MR='?C$O.TL?5&EC&$[-MNE80,I*=[[?4BZ(6]2#?[Q_UCM"IO*"^#28(Z, _
MWX&N@:G?.>6LF?C@ '? X?,I'YM "KR]71:%12UJ!+@C!1A3SY RXGNWI/S!
M >Z:/IVZ= *^,Z[6;;YO1=VIN8 )T:9DI\&\N7&-L'>EL'/?<,F$,4B8,.XB
M)CZX!O3,*&[U*H(U8-<6F+L+\+EM:L2[)\4;4^\BVMS%OXQI?W"8C\"I"L"7
MX7M$EN]O'_G);4XCN$=2<#'U.B%K##C9#X[KL<GH=!9X$VA1 ,&'G$.M1^K0
M8,<97*%UC:@?2U''U'OD GT&X$/@S@?WS9*/#ZX&)QA@F=. +UQV03S;D$9P
M3Z3@GO#E5T+P@Z-X:MK6@@:6(Y:_.P&YUI9&+$^E6&+JN: I%LL?'<Z^.?6>
M"'/CL(<X]+?K$KF@58T0]Z408^JWA#H&3I;4/SC8[1:X1  >,0/K9:<02*8A
M?9 >M^21CQ;WJI"@,;)>/CJ*;1,8LUR;6N(D*PMW-JFY;6K$-B>JA<E7,6U
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MMV3^2%B#?T?Y:T.I)'4<?.XC)H,*$]" AT*^,2]<?&T@YO0S!<UJ&.(3KN.
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M[Q>$__+]W>7%])&1^F"42Q/M8*^.H#/R4.[TJ3,2,\*5K@N^2OI$A)23^(;
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MP#!&)%_"=X4WX9KS0E?2W3+(?QK -$^N^..R_ZI86B1I++9/23AP5DC \)^
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M?AO=>[\*[=&;;'TE0LQ@T$<3NY'HSD-P)42D901[LUAJAK)L$K'X&"(>C,]
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MJ9/_*AH^( 4!LAZ_.?W>3EP*G+,X6_W>AOGZ7<SM\<S+;T+S^F?)ZYS>0VJ
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MR06XLDS!$XJI@"FKX%S35?0"$<0=94=]BZD)I4K#2Q$H53#:%9'<C1*Q-]F
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MKB&\.3=1S6EQ=1(WR6*FS;?Y;SNWZZ(=/49I!I?)SE@A4CUM[ST5R?G>@$[
MFOTN= *_UZVH=5Z&"=[N5EHD[4A$=7 %OLYM.ZNJ>S;VM%I",'\KN=F;0Y5=
MVT:QOW??-G ;Q2LH5[0!3$XF,\AFQJPP-DV+8W,S7P-:8L-:C<WF_&MG;]!/
MGQ?8[-]W?>Q='+.OB+T+V&L-;'-N!;=1*ER;6XGK066Q4=1Z?$[G[T;M>(7K
MZH$5Z3^I]1/.*3J!MY<MGM>VKVR!A]Q0&G!O+CM)13[.S0.;5"L'.\>!V?88
MJ-VMI31Q;#'] 3I4.]2Q\W,O2:Y;+^N70"':2=XR?8;YNQ.7YE$>IU%VGG,<
M(BN_/$G+.&/ENJ!3UW,TO\;>B5.CXKQF5 .#='"0#9#P%W=TIX,9\MA?I<&R
MI-50QL?V'['U 44GOIP?20WCL6!Q5JR*,CTWXQ8^@7<F)Z&ZJD6X/;%LG N&
M]\I._[&&7(242W]ZMQ:.P?2U,N6/,+?*)CMW7O1* "!=!#9NE#D8%^Y"V35=
M\;\**Q[EA,K1)MW11@VP +?!U&6+X1CK+\=F^F$IB\])^7Q$:A8O1TV]%S6#
M5Z*4WH:R^B*4WW>@9O+XT_233S8>>C*6AM/E*F,OE-[0XC&-:?^VO'TE3^S
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MSHA*A2'YUZVNW*CIT1X7#9.RZ^?GSCBMR0<5]QMADJ[W.O/T5"(!BL:/(IK
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M>*2R''C:/&0"J<0[CC+OX9&6X$E#-K)X11)2D5?UCQN++&_NK@NX\9F]--T
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M090=LV+%9'+.<!#.I!^,IXZAYUK1:DRD 44:5*0+BW1PX<-^?L9O'!O49TD
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M. :STE:!NF[WY;M':T9](/5(BY:OUT6T0&%>&G$U:N-71QH8G7INFSA.$-N
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MY:\&,)NS9W6&,S07O4G=7R.H/BXTXAKJ )27FX)# P*G\@E2UL:Z]N4WCV'
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MP,O$$<O,K@1H3X[*L<L\@C07+&^/"*1)/GV&U]2&SCDGVV-/4H;Z]16;&02
M"<Q8' VFV$&'.I'DR9L:0)B"RM-2P[29%]ZR?WRYY1A&7BK7^-*V/=]0<*U
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MH%",L5D<ZO+J6]?T!E,$E+]$YPM,4G"?/" @$"HQ=$OIQUOW+D,]%JD\!<R
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M>.KW:K0!Z 1J><[H=>\)D<J(;((_D5^M=6']1KK0HLZ\8!Q?<[IPYYK>M8P
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MB9:H1>N1#1N<QCNT.MQ.#^EIU1^UYIJM*LFB8MOD1%B0P1]H@]Z-!,_(';N
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M+]@,Z6:1;G(]^B9\^1ZR?@#'L,_+C2VL[USV!B1YS1C,9O6EQ%)):B#!(6^
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MF:I;1NFAIAPU&D0%U\V@KIMI^;! GR/R%94SNA'7H;0G@NJ/]ADM'Q%I\]?
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MH;E>"&H<:U C9+N&P$3HB1/:3HQ6S/IN.^$X6L$O[[1?WMD4]$$+=L??3F#
M@EU/V@B '!-'V"] S=]AWU^\GY/$];3VX$56>H]%W[(&G<'C/*C'^6'!K@9G
M]Z#%'">(;-B0Y0N=90A4KM"3I-IWT^W%O/=W2G5/'>=!MDH.CMKW*DJ%ATYS
MA1?/_,@"&OF)_^))EE+_@T]YA'ZOH4^UX'\._N?@?P[^9_MB!K-!? $IN)V=
M=CN[E&^J9P@<94)X#^;N$:5^ZUDK]CVNJ"C3)?N0DWG%ZH8FT?X'[<_CJO0>
MBQY7#3J#QW50CZN2P:;T^;2=G1I"8M_#LK]3LX:T+)@X+Q'Y-XK()9V@X?64
M/-&]S-,6BF_H\GWXAK)G]!GGY4+#<PAXZ"B0Z%401B4#-;&XXK:UT7K8:#A_
MH&_N[Z/73QL/[]]P?YQ_P^[Q'?SJP:_NGE]=38$*?O7C\:N'+L9.^_*<S73K
M5S\_HN327O6=(\H[[5E#/L+DU'[,J@%[0'@$7(LE#@9N_#=>#>#+ J.G?B56
M"&VHN_)_F9#T:5'B>55LC(RZB6661H]IEI8IZMJ+1/\%AH(970D,48QPVY5R
M7P!$Y0S-5HA0(<Z?KE%4H$U=T@,B2XX[1#++D@_M#M7Q[-N(< 16/M :O<)F
M#/R!UNA](%%>1'%]-^+I>O\O@I1T]0<$SV7P7(8N$\$;J:\8:^PY&'Y2^(*2
MW&&INW?[XM+M3XY"'F_(XPV^_X,N*VH&A6W/1/'.,,\8Q9,8%[HW&'9[B34/
MA3J1P4MA)]>RV[<#)5KV(1Z&;*>W6\T9)8=C/_$'!MLTV*9=LFHZKI9@Q!Z/
M$1M2:IQ6JUTLCY.=6ZZJT-1$639_2](BQA5] N4#Z;:.ZO_%SJG::H0']=MU
M]1OZ/7M6R=7$R&IXDLG1]B?E*"5OLD7SXU^(?2.43)_I;Y_0^0;_.PK_+2(Q
MXEZLK?N88+H$T\6,Z0+>58(Y$\R98,X$<T8I0" ^R[V3%06#3U47<,\<W)25
M+>D77E;+S7&R:OI"#VD-*KW7(6-0@^Y@"[IK"RI]SMY,00TALF@)7F\H7V_:
MQ1?G%4]?ATZW5#0-)0_8ZD+W<982=X7D?LFWE@-*+EYB.G2Z9#_IL,Y[EB6^
M.52"C/W7T6[1?E81 O57'$YRBY,;G,<ZS.SF6>(G^%M&: V9/KJ#NR6X6X*[
MQ0EWRZB2,G6TR %;,;A::*MK;AQA]X5>%/8C[+T - >.L+F"FI5QA$T4E"T7
M][S#<50L)O,,?YND^1R399=FQ[V]SR%OL *]P0OLKA<8]!E[\_XJ"(T5W\Q6
M<0(Y9 X'!Q],\,$,[8.!+:#@>PF^E^![<<+WXGXB1_LQ9E8A_W5"ARS3\HTK
M6;,+%^A9AA1I!5J"DCRHDGP692D],/,TNJ\>BS1)([+^Z</)5_[US+ 9/9!V
M3JHG]HHRRF/$IT<PK <BKM.X[F?X1% MOYM^$@_X=A%1-2-&59G&479+<"*^
MU;K3@P9@Y %/XS^KE*#?,_P897=,Q2IF\U9JX%SI/[4'%C]'+RP"=X9SMHE3
M:F:/6?H4M5Q++1NN%T#FD95FJ"AQCC:],5MI.1C3*P$N]L_CD+H]="\Q:42+
M?IEIGMSA=90Q1;^-2-F<7K'<>]GK-VO>M*;OI/M0MB5!0JID=J]$"VZSW*=.
M>NEE%YNX(.6>/4Q_VIV!](?_;/:$&;E'Y)F"T'(0RH:9HK%@GZIY?=&J0H#&
M&O4R3 F)Z!97RQZEZ ;GT>XW^TV5A-T0-9]BE--S-*<J?L(V=9(^5HR<VRS*
M+ZA"B]>(L'1L@MAOJ=:R/TB8VM;MH9:RD21$%Y^CDEI,^=,;@O.<[N=_L"M&
M\J=-NGKTQ'-+]?@&MS#:: 8-K?M_+"C%&_8D!8(]/-G^A4B'VMW;^UT/.);.
ML\3/]LQ]P/?5:I6E5# Y'+2,M$5S1>)%5""N LL?:*T%<$FU?@8?$W-V^[JP
M':UHL&6Z)0V,Q<-#K,-\K*-W.A_HRV;S/6U'(,K"L9Y%:$*SWQ!M.6!>:I-A
M)7-H['  #SBL>J#X@HMXM\0]F9J^H"6/WP%.'U^"F5+1@;FP?(&#+QLP-]G8
M<8 </+#PT'"9WRXND!["4,.E?(\!L*X1+E_$#7)Q@=S*'_LV!%?XE&/GOBPS
M$XE8RB44KD!@/Q'+N5H)U=C\@$5N3D*C'T,^PAHWN7_\" O8 '&.(RQ>4XY?
M'5']FE:>#1@?]6M^G<1'EL,%QN/7T>,Q8!0<C.)OOJ/81YX%&,U/QX*F8C*/
MS7J _7]3JY+^3*F-8A:$FS J*&T+S<K<[B^R4DF@3V@H,[!3B]O]^X&*</L2
M$T,9"&<[@J0I0*UC+753;*7EO$)7^64Z+Q?_ILBJ</%VIJ7,)@%EN"*Z3+U.
M=8XK8*=+^ .<X_ >T06?:'VWW53GN'I8I$2/J=>9H6]BJ-GOIV:_A_,VI(_Y
MGSX6BO5#C*B++:^OA!Q1U*B+5G.$(2,-/>D(8T@ZILT1!I4TS-H!PTJN-FT%
MN3#,>EI_F\31*J5X38H%Y;)K\Q7HXPQY3=7(";[107VCT_)A@3Y'Y"LJ9W.Z
MG%E8=1MYYA?KPV?UTB4FC^*8[CNBMC"M0_IX>185Q?1?=0& J'V!:%Q?9)P"
MR>",ZXN,V7SS_!FI$U!G5<D2G!,J! ?WC[U>U;:WQ[;<W-KGHWMM77'Q9\7V
M@;38Q>'D:P,\J3<"MTOP.EVFFX.ZK:$ 8,8 Z&U?M0V[ RE[,_Q8&]+<L_/Q
M-"I8P'C)TCHV6MAKTOCI>C=DDR$S_1:19+:J$QHN7A")TX+9]%<LEIP7:?Q'
ME%4LO:&>V,;EX"_M]6MVI?8&Y\^HH/N*.8 DKW03G@X[NVD:^NY>]..'DT]U
MXI"H=U'[H!X(V)[E5T51,9&Y)>DSN\XSBV+)0:0V<_ &1F?U?0Z$FFWEFM.B
M039L<!KOT&J3L_MZ9A_2PVVZI#S7;!.FK'X12MI78WMW.+7)E@)X]5;!RJD$
MC1):QY@-G;:IMP**I>/M4R_L50*889^#C:J"Z,X8H]<_%IN_%B<JO,F>92MD
MWT;K3<5V_MG\'L45J7N8GT59AI+3]2'9*@C GVH)BVUR[Z9BMWTS>]4VZCVC
M>&!NR_V_G^&BI(; OU%YAV+\E*=_H82#TF#O\PT_JOJF.+G$9/,K-HZW^,P2
M81OI$L=?&S58V!Q1.MYL S%Y$R[KK;= #;<<:+,%4O=A@PW3C6-$S9!+@I?,
M &$-$&;D/LKHV=AX>K@\R"9::S+'/'HQTX+9*OM"=XCB[OZ+\(. YIA-'ZN!
MK*EADCV;[_6S$:X%^$2S_.@Z%RZCE-1^ERD5LN76=;5"[&.=I\]I@O+DCBXF
M'AQ#O]=6.J0N7Z_:7QW3FU;E A.!;M3[>T:.UW.49LQE2O6/WYFN/#!LAZ\;
M&WKO?<T'SL$WYEC?8*J]?:38[L7>WCJJ!T*3^SY7\2MX#.V\37D"TC.'?)5Y
MS![E,O!XR <] 5-2#V[,,!%0?3S?IDSIT"_2&EC,@V<M#_?"L2$HW;-YX:3>
MH=6G9*28OWICWBHA ^'*>=O8L3N0D5IK.Z=VPNM"'1I.*0$C15@]Q^C'@:#6
MH"04S7G5_+UVKS3Q^O.*-,TSJ+;2[& WZ%O])S[6D,G6)$9 W)[;>GLL\AT'
MR@]RB^-ZJ]3\E&_GVN*K>BS0GQ5=)Q?/,H>T<*Q-JB7Y I+1MBD7&Y.R\<:I
M;UJ-[CF0)<@+QQNE?ANX9IW&FEZ[NR.:PX!HBJ45*R+I<U2R8/WZG._JADZ'
M<3>N&N%P]4BH'>=U@!=F*N).28%CAV<K_^UY=]BDY],7*.4)@5@RV&=T9 H;
M5M:/?$%&=@?0,:P=N5*Y+Q^*B0[>@"3O 0+3S;UIBJ(B-9#4*V^ D4H*,'O=
M%T! 9S.P3'BXIB=.8R*L61ZNQ8FKF.C4;ODB.>+;Q>3U86/?52"VI;SK@3?2
M #F%=0KO?=E4X "I=NWP!B&09BOU]X]]7^EN*W<2DM%?DR4H(O5%-*3^.F"A
MT7!MQ%P3"O]O%Q3>*2CI?."+$B)=%PJ%/F!,E&\F<F5M]-<V5_DR(E<@@.8_
M#><\=+8KI5Z:TG"[J;- ]5QD/]Q>["R"ZK6DPYD\SH*DE6LVG-;O+$XJB3W#
MZ;_.PM-+4Y3A="-G<=/-KAI.AW(.*M7VD&!HQG]+HT9/3S Z_MRZ:*X*#JZF
M>J30#U64"0?3'Z7?>%\).,CCMPN&;#0-Q]$CTV'H)AYP4/VQ,TRU^(!CZX^1
MTKUX#(Z:/R:*L<X><'#';]0X5#0,AWW\!E-?,JW9^P<.]?BM+SNW"<#=W,$"
MZ[$5"1QVSVRUX3N5P*$=OX76.[3*74O@:(_?CK-QG0D<W_&;=$Y<?P('W!\[
M3^_""CA2_MAVQGK4P\'UQ[:SVZM^A[B5.TN+>(&2*D,3/)]\VP0YMU=];@G5
MO< 4\NP&!/.WF<)I"U>;#GJUJ3 CX8W_[X LQ=F3_#<K5(M:'/?QJ.&86:5$
M^P-PYXZ$W$G>Y_5TT+?JR@KL0:-GI-<K ULI>!]T !/_?JH-<O6 ESRG5T8V
M;[Y,GY'T4L3W@WHD %=$3L"[0?T1,,OE +P;T]_K'^@@.0$MHWHDX1N6$W X
MIH?7[W3#/K3$?:+[?;+]*^C"U8='=/7AR9'R_=.1\OVS.WS+&W;*IKDDO3UP
MXY!,]L"-'4D+[<^'H=-4HUK0BAY7%[<AE,30R-;_1K9*K:F4-5Q?T D=[[IV
M,N/X&X8K2G8<#X[W8;CZ8]?QX+F#AJLT=AP1GH=PN-IBUP'A^&Q]V5---%1Q
M?!MUN:'*JBD5*2-2NIAKHFKX#[=JGA%YQ&XFY*CZ>H9;5V.4)E5_YW#*S-A$
M3-5#/IS2XURN7)>X]W"JD,,"INOE H,U_N36WO(1P)C!<U8_-9CE5)TK-V.=
M1PV6]@8&2[F*T)(2V@=*@GPI,%[*I8!CP4N2RP=74<?B/NR.4!_RY$&[E&XI
MEW"DQE]1UU]2)!PU97V^L88N<J?.0]T@-!PG9>U]?#BIYHI8+EIYC85&NRY*
M?16M0)YMJV@%3ELH6AF^:(5S0=2[;&OA15+=R>#<R?2.#.'=38;R:2$"K)=/
M"U\:(9_V*/)I/Z.HJ$@M,E?YJBK;NNRUKAC]!SC!'RLNU^+K_42K_-2JR!\X
MHV=I1C=P)9:$<ZUR=9<67R\)8EUR$-VV2F4IE#_ *G^'MV](N&F_I\<B[<(M
M3CXAY+?ZGM]Z( (<+G0><;19KB#5+62YABS7D.4*.D.Q^HGE"S8A ]B%.Z\=
MQT0N)# UU1<\NFPH4'/$E]1'*_>E.XY)%_F1.1]\R;3O@A' F^%+^GT?HB3S
MS_FR[$PDHCN^JEQ.1'<I=Z6[6\)RP!?77H%)%)=T<9?KOF*]DL?:"O."R H1
MWD$CO!W[ 4L;6K=%.X=^IUY7B6,"2*M1Q3  %9O$+QM *;_;:!*!9'O4RQ\
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M"^\ ;Q_1UZOOT3/*)2]O&=/;Z],7V<L/1_3U:LG-Y[PQO;U>=.MY^PBCY16
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MFU.TF,VO<?[$.K.Q798;OFH?;FE%ASC,"+TZ.MI2"*\<3WA%NM=CW3W5%X1
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M* W%$IK&M9N"B&G=O%98CR\=;_@^H8-E_SO!@DN$V@9;BJ^_(V9O[=P@7HZ
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M*P$G$ ).!B3@1P@!/PY(P$<( 1\'). G" $_#4@ 9"<\'-0K 9"=\'!0KP1
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M6:KB*9W^=8"OVO86J"_&T:\K *Z_KRS>P3=_9?_W&!6(_O;_!U!+ P04
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M'H1;!^U*;!SA?R]Y6Q=A<)WZHMGH[#5!TMU&@R#);6>O;#N4C;O\I-R2#94
M:/>%=S0=/CNON)L2X+06W0[];:;-1Z(KL 9#Q/ W5NY\BJE.!39H44W5IS[5
ML:$&4%<5"ML/,5PB_AHK&_Z^$7N@A0DJ&"B^E/Z.0Q G]"?5FGV28*!C3 +#
MD7Q64.*V^@O5J\3K@GUHT4Y%:6'9\?DO^5SNXH^/U$?YMP])F5%_@2"+$G1^
M'F4[5+_+OM/;=-6CNRIE/O^-^ELM\B$'"PT;% D$&+@<;32%'=11-#@&8%N
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MUUU&UUZOGW#W0?SFB_PBEK?[&Q>&XP'.@V&::(90_.+T82BPE/[$NT/ N]=
M-*N-VXF04,T#2^#Q=#8P": 9#YH?LF^*\MH5Y>4HKUU1WJKS/%)Q_Q7ZH!YC
MX]$W0'0KP.Y*@?JFZ.W1G.[MT=L*,+FW3V]/UNEN131X \2V LQM'*)OBM*>
MK,.]$4I; ;;VQBGMT3SMVHM_G$5"T+P4$2=OQ%I8 =XV&;)OBO(>S>/>*.6M
M *][^Y0G/UK]6J)9)#-VD+>&H97/#)X70^N3X;L8AM8@NW).%*U3EN2".%KU
MS)MY,;0V&32+X6?E,QCFQ,_Z9"),ZKM,$UU%-+2CPK ]QPDC5R5NIIW8<ST[
M&MW8OKCL4G2;P_J_IW".$P\;87=2#'>O^%@13,$L.[,Q?,PX^=.5T8F@DPO.
M!."SA?17JE-T18;OE0Q?+T\/J'JGWCJH:.\]T5Y^^ SB?UG*#_#39KW16M#Q
MN&K$\2Q.PZ?A20+VA?'4?D-XFM?%MF9X4J<ZC^-4N.?!5>3=@4"X\FUGA=GO
M@B;&C-.M/"Y=$Y?&/R<+U/5"XQ3III- GQUS1<7>Q-TTC:KPZ#-,%+X6B<>>
M]EP"[['M>]TP"CP[@Q^@YL=JX[K\,%IOFG:D]V'&5=A^L]:20C%&TRZ[;91-
M/0(.8?BKYP#XA%;<;\.V VI])'[VPX[MDVP#87?5MZ,!<$'0\AW;OXI"-W56
MG+^7GE<2P=-/O;9^PXH,5I4,5E<Z5#2S%C3S>KTD'LUGKH5O8ZY:6 JO%3?A
M%R&3N0Y:<9.*,EZ8,EY-+VWNUYNM^DZS(H=7)H=,^U0H>4;M4Q[C,KH1T1V<
MG'!]$J4]-,9@,4>&Y2=0Q6U?'(>PJVAU<8Y!FK)32G27G/7I@9II]%4"LO<A
M9BI2>\ND]GK^%%AVMZ*O-TA?AAM&XOC%W3!K0!0K@*C5E3D55M\,>Z]0N6*<
M5.46D-$HK:0K3(.ZA1/&MH/Y1_&7D?D-=UXS/EAMC,U_J"Q$/7ZZYTLL6))M
MZ)ER\,P+O$1\]>XP4P+>V/,ZOFC'L4C@V-_LW\*($V'6[/(M<*P7OY([SU,[
M4&'RQ3&YY&@A\6I6:)047 2I[,GR@I[V9;TEU*H?33SEL^E"$BWSZ$(%:;LD
M76BU&F N6:.H*/U5*?WY$&NXG.&GR0AS@9)VX&+6^A#W]V6D*_;/T@@ E$8"
MOC_S'O!?*X[1.4Z587+R\=9+Q:A0^?*H7'*EZ2*W$GM0IXF(]'=O"(\3SO;V
M[F.%Q-6[B9/<EY4.]/K:_NLG"E=4\-J:\#-U=UA4?7I++)L\,U,.M_*8G)+F
M4"'U!9#Z^DSZ*110:6%O ?DEPUKF0KX]]!+;Q]$]QV&<Q!-_\P:(0M9X+73@
M9Z.45QF^8M3M-O4_<:I55;?[3&B6P)X'S1(9RU+9%6XGE]I3J[A?A1V]C:X(
M$X[S?#'OYA+U\#FP=2_\._$-?MA_(_B:=*"5QYBK.PTMWG=MU;"UI,9!3U><
M")KS\,GEI>IE':-VFA7RGM1R:9G9/Z!"(SXBX7K)F>W0! Z9KG47^G=>T,M_
M)W.IOWH!B/R2GUW9D2O$\,+[K6_?XX V%PX?"-#\NB)&0-K^<1@-P\C.1ONM
M&J8U4QT[GIGO-04\$Y$_]]*3X"N)[3%0?C:*)!)Z1L]*19P5<:ZADV#'+#:8
MR&9-6%;D.TY?%<W.T,]RW/?I^ME$0OT> %6D\'E%L07:F0*9-T^WSZ(($"EB
M6[5ZZ^-_?@[O1!10W00<B(O<M$>51@&WFC?G9RO>,E:A<]IIS/'&96=Z)KQ)
M0"\OR,DLY"8!1H3[D:Z)S,UY V\4<;MY' 8 C 0#OU>1Z(H(B)R>DEP%'8SB
M]Q1><7H'_Z617OA\M1$^$0P2VW,"X^F,9 (T,ZE;"M9G"\<NE5=HFEN$8J8X
MXML)7,)O=O1#))==P(69<;#BY+9<+"^T[K06U;,ANBZ4UOA8.;">A \"X/)<
M^?2ZU:J,:"WMC*[F;LHETFS5FSLO+5S?3LSRC4KC9?#I5PK:[B[BH"'J7Y:Q
MJ_R+FBAXC@*FL80!_!E+5V-B@T7EGMI1 %)KQ>. 4\]B.@C+#O5\+/\YLBBG
MHZWM..D@I9KLRZ0O(OPZ$GV$UYTX#YQPL.(#M.;$Y-SG?%/(=5TO(>?&E>VY
MYX',,WH;")UVMK>$1/AS$ :&5%USQ(V=9^61-2G@5@G$-UE<\CAT5X+T&07I
MVA)%)8#?+_(KP;U62,Z5>U>B?:T:+LR'MDI$OXRM^SK(K43M^B.Q$IFOC:Q)
M_7\K@?AV&P,OC.Y*D+Z4K;M.1%$)X/>+_$IPKQ6254Y()=I?P-9M+5>3G@]M
ME8A^&5OW=9!;B=KU1V(E,E<"69PLM6*9D7)3RSLC54.OVAD?4Z+]TP?OX5,D
MXC"-'!'#D?'OOK!=VH#KW<%'^-___5_-_<9G^0E_].>?AE:<C'PX7Q?>5N_:
M \\??;+^^_<T3#[? N''UH6XMZ[#@1WPAY\M>C+V_A"?K&9KF'RV!G;4\X)/
M5@/^V-#+#'&1)[X>W\@?W-F1![#X9 5A-+#]_*(6PJ%N^UX//G $IBG#1G[J
M''V_.+\]/;%N;MNWIS<_?>C 9]$'.'7GZ.;T^/OU^>WYZ8W5OCBQ3O_G^!_M
MBY]/K>/+;]_.;V[.+R_H\94XQ;_MN \J61(&->MD^WC;:C7V=@]79'_+1'=K
MKHWH_VM. ]K9Y?4WZR>X"4$87*0#N#J.)6_,M>A.#&!N6(&-U]T5WJ>3$!0I
MP2FV&\0ZG-;&$?SB%[IBV8N/9N'B;X7#_^US=FP"?^[0\LSRR"6W*K$[OK Z
M8017_.\;L&='^/[0!C4AZ.F_XZ'MJ+_EENX]-^DCPAM_E8#S F16"-8'6.3/
M?_KSG_[T4]()7>!52:1^1OG,CNTK,"?AD![&9]W"NUL'M%WZ4H-B(A7YHJLP
M/@>QU"SZN&;% /3N. T3WI>#\G80I+9_+89AE$C4[VS @H"8!"0(G "$P*=.
M&/H=V_=# -D#XNCP8'?_<Y$X+$T=")0/B3L!='::A*\*NO;%Q??V5^OZ].KR
M^M:Z^GY]\[U]<6O=7EK +6^!)5K-'>ORVFKN;;I;UN69=?N/4\M@I)J)MH]O
M\>OFX<YNV=GA?R.D-?A?)K4/1-!OB9,]E>6?A9$%MIO5]6*X>-9(V)$EX*ZZ
M2V)I5Z1*G+*[1!+X;H[ /[GP37V ;9_PYW77'M5Q&W41;!S=B&'"RO%.HV;A
M4J_,$5\979?7E01X8Q* IK>1V9V3 GOS28'=]94"M]?MBYMS8O>5)'A]UJ(D
M0:+IT6([T.I&X8!W:N7_)PFM]\5^T<_B4<\*$)C %X,49=.G)\K*4S+:S^"%
M%_0^R0'VT>9OUG<.]IN'ZRWUYC.W)H-]&>"]%CTO1MI.L*98@OA@X^CTY/2F
M;7TYO[P]/?Y'S3J_.-Y>%-@O1'^;IP^VD]#!K+!K1?I EAU;\5 XZ IR+2^P
MO"2VG+X=P>^VIFV\L.-Y:,38F=Q81C69O?QQ>8I$.?@>(8-,C61,_Y@@(_>T
M]E)"E5\BX))QWSH.?;BVGEU;"AO N(ENAD/N7ZJ'CT;'H:O(]N.X;N#P0_@V
MU)NQ4-ZURPEYHD8P];07']KFSZ5 _5,)[,J)EXYB@8P),51D_99&7NQZ-+06
MJ=DSCTV/13T[\/Z@O[?*-EV^S/GV]?;-MG4Z&/KA"-8YESY2AU]\$6YO/58G
M6!'->G4OQ#+(O^VZD8AC^3_86:HIB?X0/6(-ZV8X@AN71DF1N)=S_>3"Q_#/
MR^@VO _DZLW&QA'V!NG;@_&%+R^6NSC?9;5R\Y&W?9E;N@KCQ/;_7V]H<*%F
M:^/HZ\ZUM?>/_64RFLVG;1LQUXZ$;6YT9^.H]7%,A]IZ(H"^AF"H7O7#(*^V
M-7<WCCXV&O7#_49C&EP6YJ 2%<@MAQ'P2V]H^Y9X$$Z:>'>H$@"7@UMO!Z[U
MAS>$T[AB <:9Z4?__5\?6\V#SS%@R!=#/)_4<VO(I?T4&91E XCS2[PR.WT-
M!0?#.]A6#_0 6(85,A&!#C9,HSA%S0PL)'B"1$^SM=G90N2AD=5VDD]KXLE9
M )Y\O4F@\#[JZ#;X1)X&^4&$3=\_:=_#5)G#>ZUWPB0)!R"HA@]6'/J>:T6]
MSF:C9N%_MCY;93XC)=QV=OXZYN-X'=/QUDM\TMN%[?0M!WN[S'+4% Z&YY(0
M_JN!W/'?+0-NK96!6V03P[D9#3JAOR#(<F=Z :BM#+5=2".1B$T\@#$8]."#
MP+KO>_!)QJJF.,O*)-,ZG/Y)0EWR\U&SU:$;JX3ZWL81)]E8-V!8HQ9][R7]
M,$VLH1U9=[:?BG%AO_RKO0YW]DGPE]>=;[L"_CZZ:6[:3P#P(HQ@#6C\%E2(
MY=#YJ>0-AE.L>3!N<" +4=;&A1V[]N]CU@9EGUG</]'Z^O7XJ2[X=Z@?]G+Z
MH74!JO=Z.7KG).J-H_/ 19<,Z*,CR^D+(!SX_H?E\>D-UZ8'!HUU#YII_4<
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MA?;I>P&*9G[('@ 3QH_MCN=C[ *V$':(1"+1PZ[K(8ZQP$[R=[8?4\$B_ >
M[,#[NZG/'>\'(D)["^A:3:_ =\*/W!2.Y6!G:SRT7$OWU1_Z-@$IP>AP3R$A
M)&!X=SC$C&% ?=;Q61JV@I,L<!J+[P,XN(2G9OD>L!1JR(X[),C$'EQ(&XX6
M10A3.?DEXOE6TI'-&S)QAN>6V4_XE>_]GGHN0@:W-A01I> !X9A[4^\(8@%B
MY4[X>"CXT.%:3$>V>2<*R^ \0,I#2.//0UV-]%D.FQD,1>)1#!-.[L;P$J$
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M*BQJQY^L;W)K)P+M4!"_O9$:3SKT(B*%RE"8\QJ>!Z7@O&<,&S?P]$MC'\F
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M385"_C0A1Y5(H[)0ODXGHA0J,L;T_.)8VK:3+EU&"T;Y!N88"[Z0^#@*9O&
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MKBG5B>UF613!)<5(%#3Q66^YNH.+%M/N5WK2PL6S^TRKW'JR3]G]TZU![:
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M&Z1M#YDE7.,7HQ^)WT;3KB+R,:#YU+4=]G#D,BSRFA(O177Y_]U+/LN>?["
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MU5N4_ZJG0_F]S'N*8(?1R#A!FC@8-A\ 7TCE4"JUU803I5#AQN:2IKO6=OK
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MG[QW/3XS /4<&PLE*#B0%[CJ=5B"T0MIY?DR*,9+3LH3$I3*-L"*"ZP(08'
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ML!/$G,M!:'[T[+;3,GTE<(XQ:#SI74'D#V#N3402/:X9Q$;A7N=0DJ-;XP6
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M'OJ9M,,D0UL>::9A,C?_UWZ_@0<YI3:3*+O*T@CO"H5:>ETAG%QWK'0CK3E
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MS3T43$.T=-B$\"C8^I(RH#0BAGP7[&1N'E<3S(908]@;X"JA<I2 &UX=P1_
M!B5Y4/ZAV%"<2B&\O"IKWH $%ACQ!0<LFNT*/TC.G2Q,2W4MAQ<LG$K9L^66
M*5&V%*X!'XRS4QGDD^71GB^NI)F,ETLX?8+=A=L6 S6:\9\K\ O\=_AY4^\$
MM1M,(H %VM.3KDQ*=PXSU+/Q?(\-+YQ:SRO-1;X@-AGIMA(N17IO^BMC;/CR
M<^R8[YZ_N+@ *KJF6,*.-*3E<-"5A7Z7J_/YNA=EU9;8W9CBA0K+_0:[RFT
M75^Z$2CP#O]_S,1LPU'/+0JDJAT>)BOM#+^%P2'88F9\IQ3%BP_&U?;JL' R
M:W0YKG\;D7NX:B5]"U& ,<0Z&DZP$=NITN?X46CM=Q)<B-D@G@B>1(KK=PS
MD1R0O9V(37B5KV\J0A[P?#X+0ZIW$B49/EJ^!V5CO*17SRZ_XQ^M/T#3$&QR
M7?8:4:R^4$&C#O/:[#>!V4V<*8B@4\/@<E0LH!SN=9\@-8O;C-++;5@,EF .
MEZE:![.*]IG,&/>?%'"X!4GA\L#SWG^/O?_BYM!29%$M7O"B;1=7?=7>$ O:
M!1QU%])$E,<+R12\8+HN31Q>4'9Q@_=S22O>VJ(?/SJQM"_U/'NF$7[PXVCS
M!I,Q:*^FZ_ 1+E!O325+W^7$ ):6E=L-BS\$<[>,!133EJB/0&YV9=W?W-ZQ
M49E9)D-3*>KP*'8FAVVF1S(7O@!TE$3>?7D,1R D*07HZXGU/FR6K3Q+",5Z
MJ55"%7@QT),$&IN''%R98E^D"::]K@/!:5(*G[;J3=WNBPX@2#[V=;G4=\$_
M"^MD[Y#R8B*I0[3ETA@NG\R[2K9**Z(\%2>LPHD>2\SVP/I,;QTBET@'@/:5
M$\V>\4,?$'[HRQD_-..'3BDB9<'\$HZ!<1!3WKX3"!-]3!\? '\"_XU+'[B$
M2!YI!+3M44",3&EM5G(ZW)$F^L"(I?]PN9A<=C[>R+,+XRUVJ[YI^:P(*S9F
MH<A*$2;BC$X&8F,Z(*$472PX21WS<;+QO***HIL1JS@EF%Q6YZF$M'.8MAQ\
M5C/OEL0/CT7>/AP[PYL0&0AE]//6HF3#; \^EDFGYZXON8E)CGOU.>($C 03
M^7' +<R"<_[$CD?JV\[(\6G!Q\TT^V?RMAVJR6IP0-%T2KU!E1C,/?O'J8MD
MY1(P\E-RDN5 3(7Z+0Y7>,,F]4H%P[ K9.F31\XSY_UGAC6H"QT.^;%?C'.8
MEDW2P86\YR'VU#)A".=O4+_G&:/O.E$K,K\\GUM")&M=:$^R)GMYU1+)=#>]
M="0C;PKJ5ELF7(:>P_5[YSI7E.Z\S*ILDVF^,[+:K^8\YSWGT2(.3*0HO^$G
MVI&6 65^]N[ VUD[8<.>R<G-SA0:*23!OJUJF?94+1,\!?4-<92AX81%&\ZK
M=R3[$9EFW9#!).EX*6O@G\<,N"M$*EXARLHL8TW*':= U4"IC-KX/3H0LF\#
M3IW1Y47+*-KZ$%J=+U[5(@;3.:8< LE8I1-6WEA)R=K<(!J22AEB"'XXTA\8
M]'Z[#H3%@\M7%P^->1&RN0)"B3R(;)W\C V0'X04DC506O\6'2VI,HY=SJT!
M;?F2EKT0E%+DN*J)WYAA1(*KX%\)TY$;'/_F3$^S2+GE;J(-JM1[-N_X^^WX
M%TJ]R<@;YE_2DKD7;9".(ZQ(P]ID:8X<*X#2XLR++H#GVT1&QB1A?"G?MJ:S
M$@QD3-&@20,A]A'5%^@S3R'HCNXJ7KL/+8T70HQZS>1R1R"HHROY,T2J!XG'
M$"7-8@^=0#X ?\.ST2O$Q:YB:^2#'Y]>/1S8)>,D%>X-NYZ#<)*#PN16?<MN
M&!BJ2J,ZU:V0;6Z+EI...UR(:\9FF=DY&I/SP]8I(Q6_9L @8].Z5\ND[!-U
MD/%<1#D 27M-4_[SY=W;B/GA<+>E_0M*SJI4@0E\+IE-,68_]KM5&-2#I\]_
M?$@5I;*L[WA)A$FONX(7UV5TIQ[\^-/E0Z6*8S;D-L&&) M=0'0/BO/\G$<5
MOLY+X_F/\M>'7!_"M^.X*[.;O!S11,L4AW2),3AVH&TG%PS!S&U>E*4!GR/F
M-\'ESC;NGK%R.+<&30UY=9U=NTV;K1I9783J7[_.P@VN?Z<H+2[>-)W56SVJ
M @46JEE2;&P^#'LL^SPR&6=VM(?+$GDP Z%B&Z5\;P"RI_6F^^"9?XC%]\Q@
MZ;42QW)G"^.Y=+BOGONR0RQ'G<.D:_!&XI.8PCYI#_/%*B,%7M/6:$GZ1XWZ
MB;$6"!J%4XQG7E"B'/U(8^5BC=8-\@.*O7@9\JJ.CHO-7SMHJ,:%8C=)ZHD-
MG)V+2MXS0V@'>0"G#F)''IJZ-0YE8A2<@2JPH"[II+Y+^CV?A:!!"[\])7#2
M#[( "?!)!L;68=LY>OP5S%;CGE;#P69<A<_Z/#@2,$PYGT(12LD:CWJ^)'1^
MT^OJ/*QLIQ2:HUYZZGS"0I.$#QK% 73VB1^(#VVXSLN@,X6_X;AJ\FP]=H7"
M',.Y=STHJG$U_6U>T/5ZW3?Q!.3-&$:EW^TK(PI]^V6"V]"2"B.=XK(W7[WE
MM([;KJKI!0Y<+&VF#W,TV2Y#[H8,H2#_)>Q&VFIW&1O2Z 6565]1]L<YK_..
MNG^6YEE8W?4A.*5S5N8=_!?CGE'B*'!!A2@>OLE=SG"@QY^#K^4,W:6Y3G2X
M+>5.[><%)W>+,(B"3O[H"%ETCH:Z2 HE)Q').0TNX[[,^";Y>,)7LURL*&8A
MAV.H#\+MK]0.1AY:<FGJM)537[<P;T @B7^$H\/MB>GW=CG%!M;T"%<K&)\9
M_/1N;1I=]AJK9).KW[4!\X^DZ6C>[^KF=3AM)$3A] &QME*T'CQ?.C_"O(?/
MRPMJA#J2J6O.@@5'@X_48@BJL^Y;=FD*8X['ZB9OFZF0MS6ZE.-8N+@NL2AN
M<'*G!*M.ZUQ2%,0<S6*<8=R?/?H_V@UG*TJ@0 :R$?PFG&1_E28#^)S.[^Z&
M>BJIB+KG2E (#; PU8D+Z[%:GAY#LJK/?^U%,I?F!Z7Y)X_FTOQ<FC_IYES6
MS;Y&M)<0L,XNSSL<04"]+;YN0B35!C^^+OO=JLB6Z@ZL98HY-=T#-Q>.JB>/
M'OW>Y5[(L#+U-XZL$"P03/Z.D@.4GRXV1<9PZV>;O,U(TJ3+@P>DW(++\/[6
MYV C_XE*_D4]>7\&Y_D+_'QU8=\-WRB+L HJ&GWX@_\J*BS_%8(C N]]B=,N
M6VOR)QQC<M?D;B8@02E91%+X2AN55[A'=H-GKC+&#R?CX['-B_&>]#*]@;*I
MW0PZ8ZF7&L+&8% 75_M#6*@]]2S\$&+5FVRWC.OF^T]>+C[[[O.EA;1TV?T-
M>;(5)[2#I_+DBR_/OGCTZ&SQY>>/'O%'E)M%"FK*>L'#P'>^#+<^6WSVV:/%
MUWW34$?'5=?DI!W]/\&]KGOHZXTWTO]\?KEX=/%).B#E%,XV&Q#%ANL3O7!.
MJV?%B^<\>&P<D%/V@W5OQ"64+Q.^IX9+1(7<#+EMZH.)@ CA?J O73$Z0]EA
MGKWAU4OY>ZN:7#V[?"@Y"4XZ@M"D;P P"3]&ALG@#*KME9*C<*M3>L_]B#SD
MX&'S5GE!-=T(E@C.L#1YY'YDAL:B$C))6C4]^"#LXJ06.^^O^Q^8%U; GP_,
M]STPJ:J/_H^^(3F92*RD&P<YN2@+2GLF)ZFLF/VC_9A5%2]F_E+8?M]02?/Q
MH[/_7N(#(<"C7+-E"9//_']\ (G,ZO #7] U]DW]YA";1CP S><OK3H8-O_Y
MXJJ'RE-\D/$7&-40)X -0-\F5V*WPE;;-MA)895HKG/PH'HCV$T:O]\QG+MN
MVM^U^?J,HTM09K=U77&9.FOK*MR!("!D);@+FM.(;?(HR7 DG1_&:9G\P5C"
M#9G<G8RUW5DY*YP2>I=B=YR5O8CIF? (<J-PSZ<7+\=WVV0-V_OG^LS)[#.6
M/8^T5>T-&JB#D<\3HBD,#R2A?GXK]E&2PX+,?Y67C%+L62S=O^9L1<)*O>-G
M B%[3MPTUK:$-D<9,%BX<CH(F^PZC[\__2!1M(T3^FYA\A/IV!('TSW8Y$/-
M9\+]SX2K\,42_<M:B[CD5-%\+KQS("4&F?H!E6BDE>F-I1[)Q GI"-=2MUI(
M?=F7I%BS.GNB*3;SU*QICK4=J%(DD S6A"/$#X'D]B$,*DCES'SI1&%Z8T(,
MP+75T< Q*P\7J1,A9U&QH1%=28'WTT>?/EB96-)5UJRR*F_/?GI3Y@?7LF5:
M5-SE#+UQ/K',VU9M"N[NI"\0E94]$)$\=%32UW(;_,1ZH/NLS/%,KL* '9!&
M40TQX7_4MT 3B7R^<FBQB6+=H(V;I:0L.6PHA&<=CCN9P;FUYP/*'SZ>\X?O
MDS_\>Z[27V4$A&+/%L7F/W_[_/'%;Q<@AY%_WX38\C]_^Z_A,[_+_O@\.,Z+
MQQ?GBY?/K_Y[\<W%Y:N?7EZ=_[JGXM]M_J:.N9.36OSQ4@PI@79448=ESZ+#
MF/)L:B"@E4L$+2QJM'1&VZCV)3-CG(H&_ K.Y_]?]^H54V,-]^$3;+-0J)4
M(ZN-DT C%S32B:WR<)X.B2$C;^,X%AKG,2XXK'MIQY2+ZM( ,#[?($:3IB:D
M5LC!IRY@INW;Y.MB(S V]J_U!&\M[A"8]SV?53-%>+R*DK858<, &*-<3@1.
M'KNB--ZT[/8P<1FIS EK&8<FT2\BI%_.54;*[>QL95CT(DND-$)8OT(X[,UZ
MT:$2J,J^$3!J.A4,"2/(_U!!4)N.&!^FD")Z1%N]S% %Y=TP%<&]D4P7??,N
M?"#W.GO79;TBF*\?9:Y\"'EU6S0U$SY9SUKP+*X5GWU)GL[9XR\MQ:8^D711
MA= GSX@@]CE7VR<'WBZ8^H#>(:%[VN5@:TWLI^7T9F+0@/0DZH:,$^*(*1S7
ME[TO(I-,)IO>/U%.=\PS[$-#!B-1-B3\)7B==G=&,9G350*_9<M&*++"?1@O
M2B07R6OC%8(+KR5GR,\)SD*TF'EZ#79U:^0U06')"0ZXTOS6P_8C#I^SLJY!
MT!&W+''+Y%"9$H>?*.?ET]_+IZ_B!K\(#\=\43]D8".S;SZF;RK\/WB?O=%/
MJ.RDH!F/#"0V_0'(ORT,OM_FR=(^_Y4UL7Y]'^!$,!R9?E_2IIICX'=B0GN5
MF"6F30[W:1>O\\/1$P3KEO>M-RW#8Z!/#_E@$C=\Y"H[<WINXWC@0S/<B5*6
M?/;M%2B.]E*W+]QACK/Q?&J73+I%IR.3DZ_"E]X'+[9CD60$(O_YVT>_79"#
MOV>Z7?NYW6=K_7DJPL-X"\3<=),WX2;_\IM_^<UO_J-;U9O#'_^CLU@(3(/K
MK-2GZ^H]/DR?W0RN_>3W;U^<W>;(EQ]_@6?%']]Y\;X5R_#6I7Q\W%]^_OLO
M>?)I:,<?(.N[^@-\ *OED^=X%LZ%:XC23;;D"P"^JEUOI[83BL*#*AQ0NX5T
M7P@ ,KBQ/9AO?$MV6:.P%YR--1^\](^].>W3F@RXDGZ5I0<(/$PI&V:S9L8_
M]#CAD'8^"MKEA0V</R/D7N?#5QC^V]"J#__E1?\[;*UY7\_[^A]D7\,!KG)!
MTZB\C>MJV_:5QH4"]L4>=-M%RR>N:]JW2PPZFIP>2>R+Y@#DCLU,7VG339,1
M(&"=@?V(9&PJ#)5T*\CSUZ@!&%8F#2=5WZ5D6H'F+$'5U^7)?:?T<I>)DHK(
M4#*)0PR>7%9@-@6S*?BX3 &74"@S<%L@72/MS.NU5$!H"_GN\;?NWWJ%,W32
M,#3)?LLG&A];5N!J"F424IU6AF7SWY#H\-X"3 #*3YL:D4*=9BO8XJ6Y!O)C
M*+?P)TLG7(,CN_+Z19IPPO>E-6ORT5A+E_J41].T$."3I&)&?]<.YQ!Z5#E-
M.P4?DJ$+7SFH>GDR=9O9%LVVZ".S122IYK<UVR.?'^\B1:QV*HJ(!67#LPUU
ML:Q!H1VV>=/OE5#?J*3*;-^*J2&HC5W.)]/IJNL#M2/IM\+?P-(*?X'\#[(=
MG X4 F"R>X)<3NR.%93+.8Z8-^Q'M6$OU$O8]B&J?_']Q9,E4Q6^^O[EIWSF
MA1\N_^_E]X\?L0=!#.YTSH+%7=QQ<>&5'(YS^P;6J.IX%K?I8;S*_?VU-@1P
MI'V@LNK/ HW)HL8W[\1Y)WY,._$9M?@6$G0?"[;5>VT]!ZBIW10,R:3#% 0W
MZQNNJH(%_EK0MMK(OZ9,'-SCU<$Q4BZ52 B\QT,"T C;-'51I8L3'9KNX/S?
M8=:0M_J\<^>=^S'MW*GXV2B/A+67\]BZ9=?9GGW.@@-+@-G(WPV;EO:I$SI)
MA8DC\95ZSF(J1,)$H/_ X6NE?ARH,H::#W%__D)!(H:G2JCBI,1&ER.+572G
MS-*\V^?=_C'M=CVG9<OKAI](B1T[Q%/I9FZB6(,[.Y+3]=4VNZT;V73%>J2"
MXL]FH_&6M#B:7MBR./KO)@<]HK">TF[5G-5=&@YKW#OOW'GG?DP[]T\,8$S*
M96B"Z!23AMV02J**L[L15590F4C4ZP08_9%IQ7.B)*;$-S951SUN7:*&;-SN
M)K^M6?1X)I<'9B<)UF93SQMRWI ?V8;4)$]L D+QRON\VT2%EAE!(V9ZWQ4[
M*?HN?68Y"A"A'W#-6FO]'@VGRM5-OP8RDL1@X8MO%=I]I-@][\!Y!WY$.Y"9
M'=W>TJ6_JZMZ7;)F>=@<].)]&JH0SM3\C3"E1E;EQ2Z<G$77,X4DX)WH/FB'
M=V+D)Y=BW)$,3= U-7%S%69=M]("08"0CE7.#K'0G-+T#X2V1DQZ(Z3(O*/G
M'?TQ[6BMP(Z.4<]4W8^UZ+C'J$8+C?^:9HKV>8/PD?J%6\9&%V52<:6TL\#-
M=GE.<(YL U&FA3)5L\E0J#6 %H-AS+MQWHT?TVYTR2)9_%R.B262P098N@XV
MGT4U-9NB91FPMKC-EV",9AF*G;:O6QN%!W:ASRJ!=@&(56REUIJA)4+A5_P)
M$4 70K3QD#B3S"A43B4?R84=28(I 8E#7QB^F\C5" X^@?@J=ON,1O1>IB)Y
M9>_?&S.WU0_;ZI_,;?4?'BWG?%K-I]5[GE:"_YTXB,B9.U77@,@Z$BEZ3K"E
MKZ[KM(@QR+*PJ\DQWDU]QU5*$_MP!=3D2Q;5J=P0BJ;"\N6T+^G:+(J:YG^;
MO V76\=:R*CED,^;MYU4L^,ZFX*/R12<Z G@G:A-=EDGK3B=<$"I?3#MHP'<
M-^Y<<T 7[;K>6S/[^)(%(P[;GFA7"Z&,:.ILLY0,$==P8J>_I'U&&9_\V&!,
M1I+&!,&S-1/9U>!,F'!5DQ+-V.%]V],K=]X$3\)L269+\A%9$DHQ$^EWT]X4
M>SWS:<.$C=W>9 UGDV^"G\_4/!2"@$'8UV/W.&:[Q:'N'7,DOLX:1-(*7%3;
MLL\KP"5\:Y'Q$H,MIS5&D;36&^Z^#1NWBZ1Q1*;CF @B@TCZ $PUXXAEYCT\
M[^&/: ^S-Z"X8F1WJ4SJ@($_9NTF^_/B4AI^?V!//7'!:;_)QTPF4-B8RJ+M
MQMM*5$GQ5Z;(I#TXH@!QE$]E$>ZW<3HYZ395'JTI@JCTD^I&2!UJXOS/N+<2
M:6UY: 5S6'=SE5]GW#:$*.*]3_?W3U1]L"P\[\PDM_HCJ'<6+X4#+;P"8F'^
MVIBLOC$FJQ>UDV/0%?G2+\69KN\H!V(Q4X9$RA"B^IE7RL1*N<+KL5>S//U.
M9;9)?1>OZ'QQT2VNPE>A%[?XY-%R\>31DT_E*I!L#N:UWXGX+!$AKPMH5OS;
M9U^<?[X(SUU"O^5/<M>;@ICC:%T2<1MS76S\2XZ:>TIYH:JY\/4FCIW\#:U;
M;C/U?R;EB_4-'0IW64,2TV@GK>#B,%B7A"@P W(U_]>R1HO--4$)F?L/,M5R
M-&5O,*60;6_CTX5HMN[R(4C"X924[ *TZ<=T!&.A=E1R,M9CBK*U3K61TS?R
M;=1;WW$PP%W\BN3J'^PN^5-^TE[Y+<(UO3R1KK;] B-+Q/N@.&SW-?.Z:)%,
MR^L$(6WSG+45N/TC:[GTJ+<>O5'5E\Q?3U7X3B9[PTK?B[B>J!!>2TO8F(Y%
MEHZ=#6GZ-@0>%+DU6=LU?4SWAEEH:V+NYWS+GLE3CY#!Z!Y(I+^A"Y$I<:8>
M63)*B%FRBQ!E;JO<CJ [L6;<4U?2P.@<25O;<9J(* <-4_])USV$G4B_H__.
MVV.\/;[.1'(2_K>T+NU+6$C@G6&/X@ZRH]QO'-T$(JO.%? N!"IW@%-GOB=J
M7U-FL0 U$E:99.FTW#'5OD3+>PP=H_5_+W:D%%0.%Q1JKDVX,JV+8.9_S LF
M*"3[2R.V4=&7X,0@V<A\PE:;/SK6"4CZD6;2\"^(7:/H,W&YHI7;"6W3A%<E
MT^]X1A.K5N&L]>_NB!MVOO!]-=*XFKACNFWYU0V[V#1'W89U-_+DZ*MT>(;Y
MQQ*#-D^XY3?,.L'\L>C 82KIG;]"N"[WQTP7@O2& Z+<R2CU&"/Q1'B9\&?]
M[8W'NV[=#Y5L% $,"[?1OG='Z-#MA[^#64[YTS9UOX(21=9$5:;X7NPHQ<'"
M)4W1>+]7O# J^'\5IP(SD4R$S(-,PT0B[\.9>G5622(O&("_Y)O1.Y##_J_F
M^M,;6Q=[T+4,/2;_JD[X1QOX8V%@P;^_EJQR=P-=)_/(FIAQT"(VM.>**%6D
M@I7'ZT['N/.<BZBLU^NLO1%&\_ /.C."+>8,VO34C2EN 1;+-VW4:Z'HFV;Q
MA84G5YSI>N"59HCA]B$]THL?%S^\N)SXXQ(>TOCZWUW^:7'QZH>IR[%-]1V*
MQ+,;UD\AV^KEOV>[_5=/XXQ#XQF7#0_XR>+J^3>+"VV+7B:(LU@2!,MA+X8T
M+@>>1TX!I=G(X.?EP>%</'Y"8/?NQCT,Z[:8@K61]8OP5UA&:_JFUBMQG. G
M0N-I@,GGOG=MO.",H X,X,:L1UT^='4'QPI[URW'>OYS?+Z6<O9$"?A;/=.F
MPT*_DL67/T8DSFK<C* X0MK,+O2DA($X<QR$"C_;AJR'8RG?$=:+\Z:*CA1:
MYV <5KX2?<H*8PP\O<!'ZBH0>39><A*/B!60$8</XG4(FUXXK2LR+Q1L]R'F
MTK2Q$>6S05M*RU[8Q'![2D)%"P,?&"H=!=]47X+16 9_1 @[O5]CHG()AV:&
M!#Q\/1!J$>1&&#UDBH@8^_ML_9IN[0@YPAW:Q!GMVRGKMW24G-PDM<*U/"TG
M$] W2<-424IKFQ&J6_H_E([?W:]=4(J=>(,F3F%6FWNG$W@.LH[E=&>ZV/>F
MBYW3P&]-<-7PN8\<,G:P<^J+:VK#EJ\DN$/WR3HL,E(Z5<WA8:?7*C\$4[QX
M@6SLDVGCRABC.XQ3#U!1? Y+='A%P@!8;VC7;W"F);(E]T%'NB3I1-!M@;(H
M[%2^>XY#?R#OUW49#+_JCA/]H4"4D':^/LH1LY2GE2N.4XT3JW_"U=61@[YF
M&1]U2:WPP:RO>JO))&U]LPV>W"9"3KN*RH*\#L;FUSQ"+TSKSW8Z[''RLQ,P
M6* :V.2KSODUH!82L@_)*X%R"+#8'92\X>+T5+V^S:O,G#*"P#3%>NB-^GH"
M,+M:3:N&Y[74YH*/SARZ\8EIC+35P\XNB"@PN":PZ,'1YPR)%%!VV>LX;2P3
M%%W2O+IF85G[1%C<UR2Z3FTQ=4F[3C90%B)#7M#<'9ZM)?643" L33I[=Z(M
MHAX3'T"L"43I91*/C'AFA&W1PR<6"* :#QK[&+(H\U[FDEMQ()L>=A[\P'"B
M'MQ"T!#GKFY>"XT4G9=+.SBQD<.#] TGZ,>'8 1/:<00H5&BZ?YW*.7\HG33
MW&WSY).YV^;#Z[;Y<+;+<0_;6=_$V;8V/PXHQ\>-G!JK/'Z4,A!)+6PR7@1Q
MSK'R8S-=*KQG9>7(T81G8 >-P]V5G'9V$#J./3KS0M30@3/K-CZNX\4JB]=Y
M^>ZBE8(60,I?$_SPKVB,-\5^DM\/O[J[J7<&J# 2ZN2[RYB_XFK7A"/AJC<:
M=$D6!A=VJ3.>)A];^X/>!V#)RZ>B\2JK7A-%]_K@ ?L61F4EE)<!:!#F7S^G
MCF8I5D0.BN@MZY9E )(\0[ANT3@W@+[=#P_Q$5AOJJ!4-Y*]I8*Z]*TR&10^
MFK<LAWVG#Y^N=G@]"NB;_=UQSN%EL#B(C<8VATP)8ZDW1<F!A,AFFPKDR>V=
MNF)A9Q15^ 6Y772 M7HQZ[T0FLU)/I\YN#_R%G^&84$K'26V$?M2\7>IJ)*L
M<B5YEU/2:=;:\" B]<DE^,H52@F:7,IH&ZXHE:.2?.'5(F6[A0D/EWO7*'GI
M45:I;T^YR5H 7V@[4GKRH^>ECM-7572(30+VPIUBF7=)W0N-ZX6P.,!(L&@S
M(+TKF0KKI62J&U<RYGY&3J8SZCE++2_CT/)(N3ZJ2&,TLF&02V6[.PF(/E\\
M3:8-B\$"DZ5%2&K.-<NS"5]Y0W@?C7Y68?VY>H9ORW2G,@:LCQ<#4IA<8=U3
MZS!1H^TH7M1\_$*BO"6OY*P5B.+ ,G$L&B)-%U<EX11\F3SXI/BF!:SGBXMQ
MO)B&N;(XTH4%"U@SZE1\#AV??YTQ7!N_3TDA19Y0$U@&)O"-H.9]DXSZ :/%
M+1Z +.UWWU_B'L*Q2"WR;5;V&-UQTVQ)"\7RM$2;N.,C8#JCJ+G<::LN)SLV
MO:)IVE@HX6)3K+$,9E G2=L=TMQTRM;,[RPNW(R7]3"![>?FE_K,IZGIYB/,
M'V&O4MAE"%_O4F47PN%BBLLZ+.8&"P1OC"I92F4"TK&)EO'3>-LAP=*)0";N
M\D&Y-P+6]&O9FK95$3]"20[=KA$RG&/;42KW.&A>/Q,L_QWI:M".1N(:E>/\
M.MA.GR:CM4UABJ_UL6_-OAAEVBO=;7XZO)V)70*Q%S9)CH?K]=>\T.$-(GP8
MU$N+?<[J[5=3 PUS2 DYDB(P'6'9@ON^:7N-9KRJ<)24CQU$*7) 7WEL&O0>
M*.<XW7-26]PJ3+^$@A0IR3'@[,@JO/.Q*KH;:,I>%]\\SW5\[Y%M@2/X@:7D
M&2_((MVQ_)H<#;3DLCTZ.N@XR5KQ8*+E0=6D=<E-^ZZ'[EVLUS704E3ZOCL&
M>K;WTG:"U,>\:"-5/>ELU;:BZ%"5I3:QH)9'C@'&_ I01VI PTQV#4S'J83H
M]$H;%M)/IEGT;/6Y#<$EXPPK;KD[=86TB"R6Z*;RLV@@JC#I#3MNHT.:]FG%
M"0]W3D?S0)(ZR?D=CS!,!P X9/ VN#>A(4MB3LX4QQBL'OG*P+O4B7P! 3OB
M2ET.UFGT'Z*1,6/LIG8^S$Y4\I$LP@92IK]Q/XGL/=3I<G6ZGGW]Z+/%@_#U
M8.'V3;\*UWDXY59-U^B9^>\@P4&%E%E/EFSDTU=4D>&/J>M.2Y[:1MDT$)]8
M45*@7\4VS\3'P5 EXXC(#*X4O*4<D)M-\*'H7S4?VBC];[2];")52<T*TC33
MV#E&-V8O,1SB90%?(*MLD'-VX$2.N5I\DZ^:GE!%3QX]>0S#3]/_;).WV>+K
M@I*!-XN7ZA^1VRL]1?3Q%-1'#C-*7_3G;^-B#J^(FS/80&T&R_KRWQY_>OY8
M,:$XX>H*+UHPGIP(Y9J\.A-BEQ4U0&5^.>RE?ABLVYDY;U'&E%.,.!1O?:(@
M7/S((Z_"D2H00+]'$G3CXR&ZT5/IQO;J-5 1]!WZ..JWVI^6.3P#@1LWB*AB
M=7:3[S+M%W)%2)T<8E8HZKZ%-8&("W;1[]R^,AT8'25C[(01E',Y[OEH]TY/
M2'QR>XD(<FT9D,&Y#DLJK$QZVV%!4#AV$3:M;]W@@<>RZ*D)A5P=I.KTZ<+U
M-*7"BG4*\V349VQEW$F7N_J[[G$94HFZ+^;5X4I/#68NK'[HA=5/Y\+J7%@]
MOEU^JA8_K;N:K.WC)X#??_)NY]XG?Y5SK]_3+R[_+5Q.SS[#KM/UP<L5?<3A
M>=C5A/$V&SA ATQ79*TT(V8>$0U%CP>X:N>+GT]C]O/D21P3;G YZ;Q;<A.6
M4E3GE+0()U@K[!F5SD?X;1[>!^4BZ'3JZ)-(G=S16<C&5P_R==&L^UT+D4/T
MZR'H9J65I^$TX#:*QWB/GW%'2=G64NB-HY6K15@[S5+8Y&?Q-]'/=:D<=R1"
M25U8#\,E:<;\$8W#E4N4^OKUKC=YM@EQ7S7@4K$)4;Y@<FZDK+(=182H*F?\
MC; !8M*JJ%JBZN]R[HYLPY[)Z0V04Z=_,Z#[U)UTF*>AGYI"MU%SUJ,23XJ
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M%BH\:,4MJMP0RHFXM!F<N_<40:/EBM2?<TE""X$.QB5";;'FJ/LYD:>_E/Y
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M";3.R\A1<:EK_:E/)+R,Z_E"US/-_^5P_N>3['03U+WYAZQ7RM$.+28DS14
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M"^9.>;%<, O>7D1!&;O4K5;;8$P5"DGO*T4VX/7S6],N77*KI^I+DRIA=9.
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MUM!IV==[83XZ&K1)D@%$&9R<\4W&82C::#Q8DY-^)C=]WL4'XZMCYTJ"!B%
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M>X!=47M^_3-]=?=,#X!=DO*;;*,J%8LD7@8S/3W]<O75XWF^!<9\W\YOA"E
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MHTGELK[F@G,T0\ U7DE3^,TNJQ]"KT?&;<9X40K]0QJVSI#U^2T(8(,L@/M
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M,\7!B+\-F3-A]10X$? S<<>UM$,KBHC9S+GEE>3$\E*L+!E#+.:=AII!3+4
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MK_1NU2Y,BZPQ^)^,45-3S3G.DB_W]]*]O3T:-4L2*[2L<D9.EYG'/9X:6Y,
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M>U^%FF'^+NJ"4DSSN[YB-SE'-Y72%[JBK"3J$4F(6C9M*V_22DR?35J%P%(
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MDJBE1S+[CF0EL];9Y(%5)I1D6G295JQR;LTFPY;=ZJ&U!3Y1/LUSKG#7>$K
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M1W%9Y!_XC+[*??U_W2QOU@I((Z2:/\44BX2[^4@I&CE%/O@'*"!A! =\1N"
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M')7H7Y'Y*]14"D>:.4LPUKY>-@.R1_0M3'FBD- &9@PEEN7\5:[6+V[>1!M
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MK^KI^F]_63;N9_IQJF_FL>Y<U<ME/7="M/B8 $*<--=7CYQ+1_][_$WR(6]
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MV1=?$)6>Q"F,HQK+@O90[D1=*'7M'$2=J8'A%#! \5L!YP+#XD3O"$GEC$J
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M)L?717MQ+@,CX=5UA=S"D= L"M!UCRQ<*;^/FJV4Z /C/3G^<Y;&,4*XT<>
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M1N,G*/3)(LT"HUY"+N!-C.+ILX$%Y@4((N:-- R*L34><F).";29N_>*HC=
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MJD>1JV&!"YT<M6HCTU[Q%4]RV2^]TQ'G^+*KG)1'2['<XM<WTR]N[@(V1HM
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M:K6R<?3]'3EFR;[UW$>KC]@=$4!7$( RS!;UJXC[75-(8-AJ/SX;D,!\[Y$
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M)@[O,^J:YZ:'/DL L!O3H@RNCND/M:.W[S9UK@OOX/K+.2@26S&)<<>>3,\
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M"#:7J[6?<;W:R 5D"(:FH]5_EJM*0GMJ"Q1$+ KJC,O!/@N8-[(<JH>00V=
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M-P]9U\%Z_ -2-TR7$HCMG7HE:\3+7_S+];X?=\Q'[1Q[P8P]F(N?-=&R!0K
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M_5/>&DN-!R^XJ"96;.&A4F(%6,4W_5-,XXYOL_')R<\U4(AM6*#/71]L0%H
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ML"Z<L^,0& QHRZ@X7'P UPD@I;&BI%ZL+P*JM-M';R@A-I8>G#:#&(QXE<Q
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M8:;&H^<%%'.V!D[6+LV_&,R&(.9_0@0QX&U>D V+*YF.V3<1DSPV]N"]#B)
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M^2J45<0Z6M>Q=H\GGKHX?C?V OOK$N(B>X=="4(4HC8LA3W9()=Z3&C W,P
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M32R6Y_:.--'4R[66WBIO;ZRNZL&Y2YJ3@J%@["H,B3C$86K]J1Z<5$=P@%;
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M&F&_@50X3[V-7 (3"B-WME/>$1KUH)4ACOF>XW!1,>G UW.]O6<#F_6UBQ>
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M,'381*O7+H8>HI(E,3,BVRR.W.<1QD8SY++] LTPF57#^T^)0U9G^+904(9
MA"5!9@YV2TBW !14G/&O)+5C=!HE.JKD; ,^_GPF5\BR@0G<L"?@U7$0I@;F
M$V"(]DQ*+J[LB?E@^XEA-A_^]R_LAUS0WBO;II^WX4^G0=%[\*A-!CVIR1QO
M=$C!:5P\YSFP1F!(49_Y))CN:=@W:#I:'>WQW!0AWM0SP+)*8=&*5">%\DN@
M?$Y/RTB*X=FDFK8EP;%3!TRDTGUOX&%-);^:L LO&'H6<[+!S'%H\]I#$T37
M$Z9 6-JKC1VH<*C#[(RVZM')?Y@?MP')H#LZ(SB2A1/RW65/E.-FBYY0$=@@
M'J/K>G'/&2J(C;!W9/(&YIF[LJ_#'(["ICO5G?DU"L;ZE(S29Z+.DM>FOFI>
M#X"F@A@MSDHH!CFFN:*I"M2X#^TXX'FAZ;>TW?ALX@Z?Y/6=X#'XO.@\([F?
M3*R=?Y+9SCL:+ JP+.X.F,87#07:$PJIY/F3[*6H9RKI7S%;Y2F8<0-%1<]+
MT#,-: _HN M8_,PS"**Z;]$Q>7*:&M=@^#!A@55%$HPT&])TL,-N3%28&T$9
MJ#S"-]$4*#O&"!TCF"P5)$*%:(DK0X<63@!= 42Z*]K5OCZDE$BP=^E/A[MK
M"_K85ENM1KU9KI9KU49=]KA@ZGTH_YJ_?-*?-*U#*U-X)3TW9@E338)?HR:T
MJ<:UHE7LC/:WF=ZP<>^RI$DL/C3.YDGEVF1[OT:-''*[U78*TK#ZV2>)["M
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MI4*]ER+40]H%8(60WY:R6<(BWS''%',B!7]^P?^=*J,!AK5MB'_\A6$!5GN
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MNR46P!10,#^'O0RV>X>[C;Z,V&IM;;Y:K;12W'QC[%Q/J(KX2TF3[&V,>1@
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MM;X'@.9P#L%<F '5/#EM5+K9@GS>@-HW-7QZ.Z$$W+@VWDM+>&[&=<$"$:@
MS:1>KY;J[92@W2J:B16/?^;62])RFT6YB9WKYPOZ-ZD#( _X 99,44>N&,^F
M0CO7I51SZ5/,K92<8>OO\H,VM(F'C0DMI]T"1K;.3.FFS0_2N)BA5B3((_(
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M0X :UIK"2Y)83A(+9+<R5$&[>&+,BB@H11!SD@NK_H>VJ>,E +:/?4<; N8
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M(=UX,71FZ<K$8*8NE1-A^'2GFJ_!2&Y#;/><ZR+ K755F#+P\6I:58$(#$L
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M.0:/1V@X)'4,)A>9_X0&?<WWP-YB+LW\M#'0 3 "$QKTFHFE.Z@K?>C?7SS
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MA'4[H"O KT+_4*^U:&YS:]:5]9$/;IZ:L33N'HTFG(#H!*.7T^23:ED^\,D
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MG05::2-3*643F\[-"&((:(3@9,J4X'("B$N^M+ZV$G<PSG@/X]I+%/-*Q-8
M_EFV:MKL@ODP^/MU^1\/N;P?-[9E@SY LNR:-K^FW5JMS(\?B,Q69/%9 ,G9
M+GX/ 3+?LB,"2!A\Y33-%L4'YIORE@#K7"S7 9W$+$J<[67V0*!=7@)+?48E
M6CGS7<-"*=37-#0CTW(+$@&3]4^Q,[BDG7Y1N.J"^YHIYR\+$TMS3._9@HV
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MU>_6.4_@R9J,JBTVGSHT;-\KR_3=V:/"X'DL:U0XP2Q-UH+J/; W/D<MJON
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ME2'CX*F/WSXK@:KW:Y7^EZ8%!E^=_#X+RC\NTD&)][$V(!]OS[\9UL\I:J1
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M@D_E$@?4.'OF1^6ALOZL&1HKA[/ZIA-LX$8R9LQUU@CI7-D.@UTGK8#Y9V^
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MQ7X"F?5"J52&-?8#3!D9UMR3OC7_+&"&%5PJ85VTHXIR._]B)_JK-U0]V.3
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M51JM6F<>%K-77@%5*)8Y$E%\:J,I4 B 9?T&@+00+%/5/BXM?R?P)N'*+8B
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MV!3:G_M_?6'=2%BE6SN^"?LRL)R%"=<&[$&EL''U?:7M6R7/X* 2*YUQ6XW
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M*"[P.XCS$',"P0M0*@/]4L<3E@& Q!WB5!S/R5'@TMQ8&OQ#P8.)RR21QQ
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M.V"SY'T92SNA9'#5LN1)',T<@[P3N":Z4$VYZ'Y5;"C+=08&&Y>\!H'2H5/
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M$6BI?M^GFU3?D0HKA^G[L?]05!,U>^?W4?QN#13#XIEB]5RC=OLO*8XANX"
MDRS;+YVZ(]\>N,>>?3#TW*_FE=2-V<'QD3]<&8LC6\G+]4%34&%PW#O[=NT-
M+<Q;MCL>B*)BWKIAMLM?_?T'4$L#!!0    ( *V%C5F5ARY+;@0  -,3   -
M    97A?-S4T,3 U+FAT;>U874_C.!1]AE]Q56EG0$KZ";M#6RJ%DD(U3%LU
M09I]=!.'>.78&=L%.K]^KY.V0&%@8,4P*R&U2FM?^QX?GWMLI9N:C/>Z*25Q
M;WNK:YCAM'<:?CD#/V9&JFZM;,*^C!H"44J4IN:P,C>)^ZG2*UL%R>AA)9$J
M(\:-J:&185)4()+"4('1AG*:IU+00R$KO>UNK4S8G<EX =HL>#%<&#<A&>.+
M-GSX-I>F$[*,:AC1*YC*C(BRT8&BV0%-%4LZ4(S3[#MM0Z.>FP[D)(Z9N&A#
MG0FH5QM,="":*RU5&\C<R(Y%D#\W[0.)BH9+HA@1I@W"+I]W("/J@@G,GIOU
MUVW8>$.OC4LXN\!>Q2Y2@TBZLY[_]71X- RAU:PVN[59KUO+>]MO@K#2^R!F
M.N^\'8(['$6H':I*DOK^-!P.AGTO'(Y',!Y >.I#_W3H#V P''FC_M [PV:,
M\*<P.9\&Y]XHA' ,C4]P7@VJ_2HT6OMU![P O./Q)/2/[X0%?K^8^:#^Y]ON
MP0\96*XY\*9'WL@/W/'7,_]O\/JA9:-9K[^A=@Y^I79N\_//7!N6+!Z5]%!8
M'Q*E)\$5,RF8E((GQ)QPF-)<*@,R0<.CFL 1DVA?J0-#$55AQT;V9983L=@%
M'#Y $(C._8S@5#'/@A(%5,0TAH#FAF8SJJ"%0FO6FWL.$ T)X]BY3AQ0-"-F
M&%) 1 S^-7JJN"C29$QK"Q(_-C(FAD)*%45T!9(2["Z"<R PZ*A4P!G-&)U?
M.]!/&4U@P 01$<.5C9.$18@%!]]:A8.:4I8S!W+TQ#E2"T;>JI)@2519+0B?
MQ!*7%=\)7P5AM:SF#XB:$4&U.[[F= %>5)!J=>E@/S'MQX3Q<4,2'SLW8BBT
M<$<*2R4L][Q^7WR&S#B%F50Q58>5.AY$E//EL;#^KW,2K?X_ &D#T2:@*Q:;
M%'_6_UCB<#E-3+LX7Y8-A<6W5R?.UO86GJ\*?]AGO$IY:7<C(GRI:"/SY=3K
M<1C^:\NYK.9&M2#3IJ^9^/>%C<G"=6E ,N=\@?6>Y=P6V+KH%/TV9XIFZ*?:
MZE*O5;Y#L+ 5-/9WXMVUEF]*=%V>2T$W#EI['5NXF^S@L]C<%^SQ2KO/I_GN
MR/\ X<UDUOQ_R8R)\I9KM6-OMX0)M$96^O5*@X0I%&&NJ+9R<VPWX1QGP[/<
M.C-VY*@_[12CDK5CXX1XZ;93VX,!H^:\5*O,J2IRZ@TWOT?>4@)XPRX\\-UP
MGZH$R%@<<]J!<G[8Q_D?T]43*)^D[1A%T(9C&I47A4:KO"@\HP@V$;=>%_#1
MHOT8N'+/W9DT1F983?DU:,D9RO=BMH,7"/O9[< 3:]C[ZW47T66]FJYMWIFZ
M-=9[N8T_K)R?]O('M_'%HU^;P'O,O;/V$ZS]X$K^SMY/L;<S40QYRY&X>Q3N
M_B8'7\PN(>)$Z\/*F1>$[L0[\=VCJ>]]MB^9;O5.3@;A=*,M35PEK^XWVL,2
M)B>C\R\WV3#"OC=[X($H:O8]&EI9\3+O7U!+ P04    " "MA8U9FX1_[#L$
M  #>#0  #0   &5X7S<U-#@Y,2YH=&W55U%SVC@0?DY^Q1Z=2U\PV!@(P0XS
MA!"&:4(8('./-\*6L7JVY$HB"??K;V6;!D+H=6XNTY8'+.VN]EOM2I_7?JS3
MI.?'E(2]TQ-?,YW0'GW^\[S5[%PX-=3Z]4*(VM\L"T:44TDT#6&Y@46\YB&5
MUR*E,!52DP0L<!KU=KUA-YK@V-W61;?1@.D=6%;/3ZDF$,1$*JHO*VL=69U*
M*>4DI9>52,B4:"NDF@::"5Z!0'!-.5IKFM L%IQ><E'IG?KU(F1_*<(-*+U)
M\N5<6XK]3;N.G6DOGT8D9<FF^W'!4JI@0I]@)E+"/WH9"4/&5UV;<:@YC'O&
M:[;GJEP+9U_60GNO/!1"#UY (4<M!(]$,L)U%[C94N)!2N2*\2[D)IH^:XLD
M;(4"R5:Q1G!_V1L^QVS)-#3<FN/7ESV_GO5.?VQ0+%T!23#_*<\2L1*US]FJ
M DH&^Y)OAOHJ1N^M,FU#*R,K S/J2N^,+U7FO2<"YGYP/YD/)PNXOX'QY'HX
M'>(?3F?#T7B^&,Z&US!]N+H=#Z _&-P_3!;CR0ANQK.[G3K%<AM;3$W^,/?9
MLX='.!&R"Q_L_.?!D@1_K:3 FV.]5CVQ4,>F9/;O:"<DWBU3+$Y?2N5F&NRC
M1_7PF/\4R=XY6I_72K-HLP_Z!X682HJ,@O==X7T'+4#'%!@/A,P$$@ZR@6$<
M22,TY(%1P8RNF-*E<JZ1E5*S=B)4#5S7M1K.>;-C5XNQVW8:3CEN(;NURO$Y
M6K6!\+"<7G0ZYX#^;C!TF%N=ZK_#N&ZK?5ZZ:[?;=O/%7;O3:>ZZ<W/548^E
MPW:SX;9V5CD@(A!K"60=,BWDV8<.1NTI3 <F1T.8$_(U#6BZI!(<MPHY 3\Q
M':.-RI!.MRDU&18)*Y9$C!,>,.1MM8U"&:QA2!6!*R:0B.,JC'E0 Z* :)C3
M3!<HKEVBF!WAH-@:4CA0$L3&BX';4*1[4RPST4\B%T!&)1,A4'Q[A&^XK!HP
MK'VR-OIR<9_S-08Z*[:\38YC6Y^.16QBV<9P%,M 12Q!79XM8__ F4E.7AB%
M2X*U9)KAT&QP^(QO,+ZB,!!IRI3"$M:^=5U^TBNYAU!7=;B;3.'V=OJK;V6
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MCE\-[V9F;,KH\._[AR^_'K]Z^?5BY:!:HWE1#X-&T1B$C"'HE:?_0@:%+_
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M6X^W3N@X#42%B+E[]>K=_M4^[<JQRD"J45VIR@M4-3LRHMJ*(!3P(FK*S/$
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M1H\DL5*0R6"IZS5TF.%X^X!8O4?=*XN^3[89>FNAKQD0%!X@?I\AM [6).@
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M<(PI@,JD ]X&LOW(-28G&1@( ^_)9= HI]TYYF&^)N? TT7$D8<2\-!VQ:_
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M0M^ZTE4!+,K/;(Z&6X^0AB3NZ+X1<;BUJQ/GJU%8A:HTV=!9:K:]X43L&0B
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M6,]4.B'$J<(%%KB"JA*)((VCCVZ:$[0RHKL(7*AV*0=-2X%>1U?ZXHY'"]/
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M_[Z4T0)D7(X!].^C@#@'-RBQZTK^=S9!+ W8B Z+E -<OD2PV+4P!!'FH(=
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MUNTMGRQZZTMULO=MR,,M6]\K+P^.WO8C+=#"P-U-4J0QIBP*]'%4U5UJRFW
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M?[DHJ*@HJ6C_Y0)1!/P;P$9%?4V6YK+.0UH'+_;K<J_I..XDYE1U7!*2-R.
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MQH897P ("KWMW&]A"B1TMQ73RF>/!0W'2XIK2W'/"&LU[(J3<B"AYE59/?:
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MK[9<@GEPR,95]>9P! $R8O=N9F?4ZD X'LC\YZ?E_Z]17DS]%U!+ P04
M" "MA8U9O,P-B=D2   @%   #    &9O;W1E<G8Q+FIP9Z58>S24:]]^A)R2
MG!)M5 @YO6680F;O"DD:A[ IYI64,<:DG(V9G9*<LCM@QZ[)*84A,4;3-).<
M<@XQF6'&C)!39@BC.7W37N_^OG^^]:[O<-WWM=:]UN^ZG_6[UN^W[N=^'LDG
MR22PXY2KNRL@(R,#_%,Z  D;V.>2"+\$ )Z>P $  !2E,0U 5KJ2D8Z_(&$
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M;,DRD]+V[_YUC0!*LVQ_EM?R+@*D&B\9%ZU+ORF;E4K9I_NWL,A,*C*3[9,
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MM*LTB04?N8>U0C,J[FI?H-\U_R2]PCG:1E=MQ%)1'31BU]SLBBEL@28DK#A
M;D,(ES-#^;D<E!I?@3U"NU/X=DZ=9MV/UTXK7W&9M<*32#A[E%F9(:GZC1O/
M/Z!5 O#-:#?%>]$IW(&TI6\39YBT#H-=&6W)KO7_4$'&&*=+@ ^ZF)7S!XSL
M=R^'UF_ F99\4]YE-JT=HHLP5*ES4HEY*CR66&<3QML]X6*?F_*32O3EC"Y7
M3:-]1E%(W"'1$GYEE90@U(P\"OZ9,D@+\2/FO2-=RB^/5$Q'U<0YZIKDVT@
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M1X1EQ@_,V&^,61Q8IH^LP3)B#SN!GXS!FZ:0%!Q*GWQ<],"K;-,OJD8"L"4
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MC+BPXK.\0HYN^YK]\<A.QN5;G6&L1I*C$(C-<?O>5^J;YP&CXB D[BF+_M*
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M#@3MBIEMZ;:*\Y!F$L<IW(2!1M!TY5I2ZYC-SM J&*_\\E"09/U]_(<3\7'
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M!W_\(V<[Y>I[SG9*P']HD'#\?P!02P,$%     @ K86-6>M8Y(!9"0  "0H
M  T   !L;V=O<VUA;&PN:G!GG9)Y/-3[&L=_LYDQ=LU0R%36<G!DS95!!\FU
M)FM(*KLI);MI2)83PD$YU=C74")T1+:RI,E80S*C#)KA9XF)8>XXK[O\<U_W
M=>_]?)_O7\_S?5[/^_-]N./<&4#TC)F%&0"!0( +O -P)X%3  P*W0N>X+Q
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M^!<6C.>X@*]WY?:9WX+Z<3T[*B Q5<L&Y^LX\894X;:8%[V('@A2#D5^F"W
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ME-!EUAYV[-0?L?X+Y=B"DSZ/M])1J>_>+7CEO#'H#395W]1L3=YN;C7'=RR
M$]@L$^7P.QR+\R[#&X^K;JM,]R&G+U!>I:S ]H#*X= )\/*QCX/SWF7$YI*7
MC9S:M',6]I2+IZ-5-A,-DXRZS'V#9YD4:X\-'/,F9G,6'[\FG3>T?"[A'6HK
MN$J)![!&C9>0S#,J"C!I[A"LU+:+7!2:M9%W[8'2JFX ,THE48L#M^L09^A-
M6AJ;!GS>D50V$-V4)D>5J> !%,)7O[UL*TP3N#J;G1:U\/70>N@[['>1ZAJ\
MA'9A/XB!F?8SG3@3WT>W.GF ( 6,YP&B=NVB:Z*E,U'T]U9.5TN^W W<_H*_
MXT3H:#/!>C'S5SM51+&2LTD'/N6K9ZU(ET3LMM;\B*19:S%)1?R7G\T#9'9W
M(O<8PR2<#U%=93SU;0+BOW>NDI1+G5(D(U_W2Z:F9#V>>4$9F6&>T9/'=R#9
M1WK+2A(U/T5I'[0B,&S>W4.R!E$Y>&&L&M<"K*'#I(K#N4.C8;0+W-X'\AQ]
M25PYORD$LB(R/)BPQ,$/;XN:1H).L;+4C) /8E@$4 MY&T_7WGYF=#Z;@#4[
M7MW-AG_4]TW>:INSGZ?P@+I@QX)B,SUP_UAJMB>X60[& I5H^K:F@OM9IJ*5
M#Z$]3(ZF(FPAQ'^VG^IQI1BSCF,_W^CBZP:^GZK1*?)_FK6<,52'#%W>B>^(
M8EN";"\/&&*RJN9D7Z1$1,'!"%"55(^G9;3*K)CKSI+@9OKHRJ8K:A>/ZBKN
MO*)22>C+?2^&UG^GL>L*E9W.4NF!35 I,P)!=<J'/Z)<&O_6"%N:30^Z90O5
ML*Z@UXPS&I%!>,+D0+MK2HS-=OT7'L D?)[2:*TLUX4C/M8 #=-Y8Z;")(5E
MU"4\V<U" Q/-E2N[3WN['+;$L3E2DGT_#)YT$Y/N*8_%364!4IRQ[ZC.&0D4
M9IB2K_SQ^EL.==N*JZ"&BIS-6-CA2K?,TGQ(OCAR=:6EF@=(X$\XDN/V%966
M%2_:H"Q3HARV+%=".(BV'B=ZVT3K["DO,1\T\;9\''04\8O  PH)']I,D,$H
M81[0<8-] B-NHYI3-EJ4Y0/[%;)K58'K@/+D 60O\Z#O8%)[JUR:=</T-,XV
M<#';/WE+U^,)WV=@KATU,*F#\\JX'G,HTVB"8O?@[MC:P5,@-H3M$J*(@SNM
MAQ"Y5&_T'+[>KLLH:%*SU6MLRMS^VJ]O+21ZVZ*\A30_BL72=;9X=;[F:%3J
M^T/=9SF#^Q9#U7E 7.6>FR]?&'+%W$NKDQ:MG[FDUOF%9F6H1"+X1?(1_;6L
M*;W0GFBKW^-T("AM5*L".@-=*;NQCG823:GN?=/,GOB)?U5 ]HH]AD5_Y)BS
M#.?TVZA1IL(V#5;B CA/.I[F;K*8R,#\[<YVP#!N^J<&A6",?@81E@Y<U4ZV
MVH)EM2YM)W 1Y>UM$\->8&*5U4NTXNAC8NYA":-S$4^-'*\-1^N!*9S&T7J'
MJ&HWMMOC;^C>+TVQ^.3Q&NYUF(S=_+AC!![Q>6;N5T$DGFQ!=P4XTN H2_EJ
M /MX>OTMJZNB:9I8*)==2+H=F/DM)/W5D.D!G(/YV.>M<HYW :BQ_0B"K9Q1
M0.W ,KT"'S7$YOLX_1KK04EA3;3NM:IBT%9W_\39N34V<!1M!+E>A9Y-DPCM
M0V._>@N*^04#:R?K<> #'1OI)\O_8#8\":W<+[ZJU)^;-"8KB_],&B D^)EE
MT,N[PT7!XB,Z1N]M=WVA8#8O4+97G&/G,0D=&_FJS+0B^L2@<^;7C/%7L_>K
M$G69)MU^2DU,0O(Z3HPEYC/7&#EI7Q+P*+)MZ.'Q/0S"Z+Q;I=0G-J$03RN:
M-G)5B!TF]I%-GJ#+O,][=2<\0/ZE5 .VQ! X\*QII" &-JO5U9\IJIQ9AB/N
MRBMS5_90R2&LDNZN'W1;]FQYN+(5W=S\0/M&H&GP9)$M'A"FH\(OS;#0_&:5
M8_:D1W[W@,)E&[DWS>9%R#41^[((^N6;/NZGG'Z4ZJU8[&YN?KC%0.>F!>5.
M>EA4=65L$;?8C!UO;C##-T3!"T5S8YN*YZH9G]UP%Z,;<[JU'I7,/K D*[MC
M$]&A&MLC\C4"0P-J77'1P:JPD;%EY.W6/9>(^#B.0?&\XO%,<*CNQ\& G5F]
M^YUKGAV=DC)%Y-XXI^A)0/<M+**WVD!A>N,=<QBC+5FQ@WHIYE %0\F67INS
M]X87H=)D7;/-$7E19?RO[[2EPGQ35E\'5]?@4<WP4_\Y_RI]W[RB!VE'Z;;H
MA6JD<^V0_\J5,-572=P;U*X:TA<AS\(M"6575YBQ6SC1GIBB78*#_-K'QF!0
M%!69MM!P&;_0:4F6W$9> $)>?E-^*W#E)!U^H(]LKUJKG+D&X\@NTUUJ:9_A
M%+.EMJ>H'V/9V=)>EE)%EYGV@\79P9!V]2"*14_K8G$N8ZA_GRN"Y>(1P]7Z
MELU!4.G1R>8.K)N=WF7Q]);SWFG.>VR,FJ/NU3X_W =*G':1@L4PD1,S&QZL
M\"[2/67E06,>(/[3^\CM85PQ=Y[MFB7"R>$&.W\H#'J)@,5L5Q0GZ+P^;C:>
MY.?V>9IR)W9<[]D<LE8O=<'<M-07Y>?C5?8D+*2<^O<+F8D_$FT$:9KH%=%8
M$<[)!U5H&A(NT*6M9=?4/J R19H1TS;N^9K>\][E3'TFX4,XE=K.56\ SS!O
MMEOL9GX@/:>&_N47UA_ZR>W#LY^RMG(-^\F]U]YC-A>03-WNA]PAKFS+&'9_
MU9SWGSE#,RT]1>7.$I9#1\9-#L<_[/+W^#F*@)L_AW?I+)T_[VIU0,614[#=
M&@N Q)F-^Z/KX5*8 (_1M<5($=*DKUF/UV#0OL"X1VZ0OA#E]:U^FWV-NQ/2
MCA349C0T(J%Y-%*7<[FR ,L"OP"+X %='I,%#?S/CG,)=Z!-B*L,1G?&-%0H
M/2%-ZMUY$G" 82JK#EAT']4HN390&ILV>&IU?R"SU.7J&;!NG..VS>^Y(3Q@
MUT^4DKDDNA(\YC>\5O.\T_A]][<\H]/J$0VKKW-/[**FX= ;I?&]C)+B]!_^
M5PW:NWL.;:I-XK0G<3K>VL=5BU.T@7]C0GD3_P!02P$"% ,4    " "MA8U9
M)!758!L5  !L"0$ $0              @ $     961S82TR,#(T,#DS,"YX
M<V102P$"% ,4    " "MA8U9ZTC-?EX,  #0L0  %0              @ %*
M%0  961S82TR,#(T,#DS,%]C86PN>&UL4$L! A0#%     @ K86-6<A-EM#@
M5P  0)$' !4              ( !VR$  &5D<V$M,C R-# Y,S!?9&5F+GAM
M;%!+ 0(4 Q0    ( *V%C5D-T9W3^G   .%Z!@ 5              "  >YY
M  !E9'-A+3(P,C0P.3,P7VQA8BYX;6Q02P$"% ,4    " "MA8U9P?E91-E<
M  #O&0@ %0              @ $;ZP  961S82TR,#(T,#DS,%]P<F4N>&UL
M4$L! A0#%     @ K86-66UPK*YUI ( [%(; !0              ( !)T@!
M &5D<V$R,#(T,#DS,%\Q,&LN:'1M4$L! A0#%     @ K86-6<I@7"<7"
M@B\   T              ( !SNP# &5X7S<U-#$P,BYH=&U02P$"% ,4
M" "MA8U9-=[W3?L'  !<+P  #0              @ $0]0, 97A?-S4T,3 S
M+FAT;5!+ 0(4 Q0    ( *V%C5GDHDJPC00   $4   -              "
M 3;] P!E>%\W-30Q,#0N:'1M4$L! A0#%     @ K86-696'+DMN!   TQ,
M  T              ( ![@$$ &5X7S<U-#$P-2YH=&U02P$"% ,4    " "M
MA8U9FX1_[#L$  #>#0  #0              @ &'!@0 97A?-S4T.#DQ+FAT
M;5!+ 0(4 Q0    ( *V%C5EFKAM-S#4  *). 0 -              "  >T*
M! !E>%\W-34U-S$N:'1M4$L! A0#%     @ K86-65A::9ST 0  ;P<   T
M             ( !Y$ $ &5X7S<U-3DS-BYH=&U02P$"% ,4    " "MA8U9
MIO9,V3L7   &;0  #0              @ $#0P0 97A?-S4U.3,W+FAT;5!+
M 0(4 Q0    ( *V%C5EX[&2)1AL  $$<   +              "  6E:! !F
M;V]T97(R+FIP9U!+ 0(4 Q0    ( *V%C5F\S V)V1(  " 4   ,
M      "  =AU! !F;V]T97)V,2YJ<&=02P$"% ,4    " "MA8U9HWO0FJ$-
M  #?#@  #               @ ';B 0 9F]O=&5R=C(N:G!G4$L! A0#%
M  @ K86-6>M8Y(!9"0  "0H   T              ( !II8$ &QO9V]S;6%L
M;"YJ<&=02P$"% ,4    " "MA8U957I[[[T-  !\#@  "P
G@ $JH 0 ;6YP;&]G;RYJ<&=02P4&     !, $P"&!   $*X$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>edsa20240930_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:edsa="http://www.edsa.com/20240930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="edsa-20240930.xsd" xlink:type="simple"/>
    <context id="d_2023-10-01_2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantsToPurchaseCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="d_2024-10-01_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantsToPurchaseCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">edsa:ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">edsa:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="d_2024-10-01_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">edsa:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:PrivatePlacementSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="i_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">edsa:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="d_2024-10-01_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="i_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="i_2023-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2044Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2044Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2042Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2041Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2040Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2039Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2044Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2044Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2042Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2041Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2040Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2039Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2038Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2037Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2036Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2035Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2034Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2033Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2032Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2031Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2030Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2029Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2028Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2027Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">edsa:TaxYear2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-CanadaEmergencyBusinessAccountProgramMember_LineOfCreditFacilityAxis-CIBCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:CanadaEmergencyBusinessAccountProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">edsa:CIBCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:The2023SIFAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:The2023SIFAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:The2023SIFAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:The2023SIFAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i_2022-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">edsa:RangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="d_2024-09-30_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2019PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">edsa:The2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_PlanNameAxis-The2019PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">edsa:The2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2023-03-27_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-02</instant>
        </period>
    </context>
    <context id="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ClassAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-02</instant>
        </period>
    </context>
    <context id="i_2022-11-02_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-02</instant>
        </period>
    </context>
    <context id="d_2022-11-02_2022-11-02_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-02</endDate>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">edsa:CaliforniaSubsidiary401kMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">edsa:CaliforniaSubsidiary401kMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementRelatedToPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementRelatedToPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2016-12-31_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:LicenseAgreementRelatedToPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">edsa:DrugSubstanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">edsa:DrugSubstanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2020-04-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">edsa:DrugSubstanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-TheConstructsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-TheConstructsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2020-04-30_TypeOfArrangementAxis-TheConstructsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">edsa:TheConstructsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i_2022-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TheConstructsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">edsa:TheConstructsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TheConstructsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">edsa:TheConstructsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2020-04-01_2020-04-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i_2020-04-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i_2020-04-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edsa:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edsa:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2024-09-30_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-CapitalizedCostsPropertyPlantAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">edsa:CapitalizedCostsPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-11-01_2022-11-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="i_2022-11-30_ClassOfWarrantOrRightAxis-ThreeYearWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:ThreeYearWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="i_2022-11-30_ClassOfWarrantOrRightAxis-TwelveMonthWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">edsa:TwelveMonthWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="d_2023-03-01_2023-09-30_CounterpartyNameAxis-CanaccordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i_2023-03-31_CounterpartyNameAxis-CanaccordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i_2023-10-31_CreditFacilityAxis-RevolvingCreditFacilityMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">edsa:PardeepNijhawanMedicineProfessionalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_CreditFacilityAxis-RevolvingCreditFacilityMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">edsa:PardeepNijhawanMedicineProfessionalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2023-10-31_CreditFacilityAxis-LineOfCreditMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">edsa:PardeepNijhawanMedicineProfessionalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="i_2023-10-31_CreditFacilityAxis-UnsecuredLineOfCreditMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">edsa:UnsecuredLineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">edsa:PardeepNijhawanMedicineProfessionalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="i_2021-02-28_GovernmentAssistanceTypeAxis-The2021SIFAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">edsa:The2021SIFAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">edsa:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">edsa:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="i_2024-08-31_CounterpartyNameAxis-CanaccordMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">edsa:CanaccordMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="i_2022-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="d_2024-10-01_2024-12-13_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">edsa:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-13</endDate>
        </period>
    </context>
    <context id="i_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="i_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i_2024-12-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="i_2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001540159</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2023-10-01_2024-09-30" id="ixv-11437">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2023-10-01_2024-09-30" id="ixv-11438">2024</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="d_2023-10-01_2024-09-30" id="ixv-11439">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="d_2023-10-01_2024-09-30" id="ixv-11440">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d_2023-10-01_2024-09-30" id="ixv-11441">0001540159</dei:EntityCentralIndexKey>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      id="c998">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i_2022-12-31_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember"
      id="c979">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="c646"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember"
      id="c757">2033-10-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember"
      id="c756">2025-03-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember"
      id="c751">2032-02-28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember"
      id="c750">2025-03-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      id="c746">2031-09-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      id="c745">2025-03-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      id="c740">2030-10-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      id="c739">2030-09-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      id="c734">2030-02-28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_RangeAxis-MaximumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      id="c730">2028-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_RangeAxis-MinimumMember_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      id="c729">2027-08-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      id="c725">2025-03-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2022-10-01_2023-09-30"
      decimals="-3"
      id="c569"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2023-10-01_2024-09-30"
      decimals="-3"
      id="c568"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFiveMember"
      id="c679">2027-09-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFourMember"
      id="c676">2027-03-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantThreeMember"
      id="c673">2026-02-28</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantTwoMember"
      id="c670">2025-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantOneMember"
      id="c667">2025-01-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c498"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <edsa:PaymentsForLicensingAndRoyalties
      contextRef="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember"
      decimals="-3"
      id="c459"
      unitRef="USD">0</edsa:PaymentsForLicensingAndRoyalties>
    <edsa:PaymentsForLicensingAndRoyalties
      contextRef="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember"
      decimals="-3"
      id="c458"
      unitRef="USD">0</edsa:PaymentsForLicensingAndRoyalties>
    <us-gaap:FiniteLivedLicenseAgreementsGross
      contextRef="i_2016-12-31_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember"
      decimals="-3"
      id="c456"
      unitRef="USD">0</us-gaap:FiniteLivedLicenseAgreementsGross>
    <us-gaap:PaymentsToSuppliers
      contextRef="d_2022-10-01_2023-09-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember"
      decimals="-3"
      id="c455"
      unitRef="USD">0</us-gaap:PaymentsToSuppliers>
    <us-gaap:PaymentsToSuppliers
      contextRef="d_2023-10-01_2024-09-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember"
      decimals="-3"
      id="c454"
      unitRef="USD">0</us-gaap:PaymentsToSuppliers>
    <edsa:PaymentsForMilestoneRoyaltyAndSublicensing
      contextRef="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-TheConstructsMember"
      decimals="-3"
      id="c452"
      unitRef="USD">0</edsa:PaymentsForMilestoneRoyaltyAndSublicensing>
    <edsa:PaymentsForMilestoneRoyaltyAndSublicensing
      contextRef="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-TheConstructsMember"
      decimals="-3"
      id="c451"
      unitRef="USD">0</edsa:PaymentsForMilestoneRoyaltyAndSublicensing>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i_2022-12-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember"
      id="c405">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <edsa:LicenseAgreementRenewalPeriod
      contextRef="d_2020-04-01_2020-04-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember"
      id="c368">P5Y</edsa:LicenseAgreementRenewalPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c313"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <edsa:LicenseAgreementRenewalPeriod
      contextRef="d_2023-10-01_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember"
      id="c311">P5Y</edsa:LicenseAgreementRenewalPeriod>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="i_2024-09-30"
      decimals="-3"
      id="c304"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      id="c277">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:CommonStockNoParValue
      contextRef="i_2023-09-30"
      decimals="-3"
      id="c83"
      unitRef="USDPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="i_2024-09-30"
      decimals="-3"
      id="c82"
      unitRef="USDPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="d_2022-10-01_2023-09-30" id="c81">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="d_2023-10-01_2024-09-30" id="c80">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="d_2023-10-01_2024-09-30" id="c36">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2023-10-01_2024-09-30" id="c35">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2023-10-01_2024-09-30" id="c34">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2023-10-01_2024-09-30" id="c33">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2023-10-01_2024-09-30" id="c32">false</ecd:Rule10b51ArrAdoptedFlag>
    <dei:DocumentType contextRef="d_2023-10-01_2024-09-30" id="c2">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2023-10-01_2024-09-30" id="c3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2023-10-01_2024-09-30" id="c4">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2023-10-01_2024-09-30" id="c5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2023-10-01_2024-09-30" id="c6">001-37619</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="d_2023-10-01_2024-09-30" id="c7">EDESA BIOTECH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2023-10-01_2024-09-30" id="c8">CA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="d_2023-10-01_2024-09-30" id="c9">100 Spy Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2023-10-01_2024-09-30" id="c10">Markham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="d_2023-10-01_2024-09-30" id="c11">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="d_2023-10-01_2024-09-30" id="c12">L3R 5H6</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2023-10-01_2024-09-30" id="c13">289</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2023-10-01_2024-09-30" id="c14">800-9600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2023-10-01_2024-09-30" id="c15">Common Shares, without par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2023-10-01_2024-09-30" id="c16">EDSA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2023-10-01_2024-09-30" id="c17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2023-10-01_2024-09-30" id="c18">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2023-10-01_2024-09-30" id="c19">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2023-10-01_2024-09-30" id="c20">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2023-10-01_2024-09-30" id="c21">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2023-10-01_2024-09-30" id="c22">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2023-10-01_2024-09-30" id="c23">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2023-10-01_2024-09-30" id="c24">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2023-10-01_2024-09-30" id="c25">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="d_2023-10-01_2024-09-30" id="c26">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="d_2023-10-01_2024-09-30" id="c27">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i_2024-03-31"
      decimals="0"
      id="c28"
      unitRef="USD">11056198</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2024-12-11"
      decimals="INF"
      id="c29"
      unitRef="Share">3467658</dei:EntityCommonStockSharesOutstanding>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2023-10-01_2024-09-30" id="c30">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;&lt;a href="#" id="I9B" title="I9B"&gt;&lt;/a&gt;Item 9B. OTHER INFORMATION.&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;span style="-sec-ix-hidden:c32"&gt;&lt;span style="-sec-ix-hidden:c33"&gt;&lt;span style="-sec-ix-hidden:c34"&gt;&lt;span style="-sec-ix-hidden:c35"&gt;None&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&#160;of the Company's directors and officers adopted, modified, or terminated a Rule 10b-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended September 30, 2024 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).&lt;/p&gt;
</ecd:MtrlTermsOfTrdArrTextBlock>
    <dei:AuditorFirmId contextRef="d_2023-10-01_2024-09-30" id="c39">1930</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2023-10-01_2024-09-30" id="c40">MNP LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2023-10-01_2024-09-30" id="c41">Toronto, Canada</dei:AuditorLocation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2024-09-30"
      decimals="0"
      id="c45"
      unitRef="USD">1037320</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2023-09-30"
      decimals="0"
      id="c46"
      unitRef="USD">5361397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i_2024-09-30"
      decimals="0"
      id="c47"
      unitRef="USD">270908</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i_2023-09-30"
      decimals="0"
      id="c48"
      unitRef="USD">626543</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-09-30"
      decimals="0"
      id="c49"
      unitRef="USD">367394</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2023-09-30"
      decimals="0"
      id="c50"
      unitRef="USD">448912</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-09-30"
      decimals="0"
      id="c51"
      unitRef="USD">1675622</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2023-09-30"
      decimals="0"
      id="c52"
      unitRef="USD">6436852</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-09-30"
      decimals="0"
      id="c54"
      unitRef="USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-09-30"
      decimals="0"
      id="c55"
      unitRef="USD">8702</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i_2024-09-30"
      decimals="0"
      id="c56"
      unitRef="USD">41151</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i_2023-09-30"
      decimals="0"
      id="c57"
      unitRef="USD">173490</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-09-30"
      decimals="0"
      id="c58"
      unitRef="USD">2078848</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-09-30"
      decimals="0"
      id="c59"
      unitRef="USD">2180020</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2024-09-30"
      decimals="0"
      id="c60"
      unitRef="USD">18361</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2023-09-30"
      decimals="0"
      id="c61"
      unitRef="USD">91373</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="i_2024-09-30"
      decimals="0"
      id="c62"
      unitRef="USD">3813982</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2023-09-30"
      decimals="0"
      id="c63"
      unitRef="USD">8890437</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2024-09-30"
      decimals="0"
      id="c65"
      unitRef="USD">1812960</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i_2023-09-30"
      decimals="0"
      id="c66"
      unitRef="USD">1747150</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2024-09-30"
      decimals="0"
      id="c67"
      unitRef="USD">19867</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2023-09-30"
      decimals="0"
      id="c68"
      unitRef="USD">74714</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-09-30"
      decimals="0"
      id="c69"
      unitRef="USD">1832827</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2023-09-30"
      decimals="0"
      id="c70"
      unitRef="USD">1821864</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2024-09-30"
      decimals="0"
      id="c72"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2023-09-30"
      decimals="0"
      id="c73"
      unitRef="USD">19773</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2024-09-30"
      decimals="0"
      id="c74"
      unitRef="USD">1832827</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2023-09-30"
      decimals="0"
      id="c75"
      unitRef="USD">1841637</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c84"
      unitRef="Share">3247389</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c85"
      unitRef="Share">3247389</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c86"
      unitRef="Share">3075473</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c87"
      unitRef="Share">3075473</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i_2024-09-30"
      decimals="0"
      id="c88"
      unitRef="USD">47236024</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2023-09-30"
      decimals="0"
      id="c89"
      unitRef="USD">46643151</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-09-30"
      decimals="0"
      id="c90"
      unitRef="USD">13576757</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2023-09-30"
      decimals="0"
      id="c91"
      unitRef="USD">13039265</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2024-09-30"
      decimals="0"
      id="c92"
      unitRef="USD">-242613</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2023-09-30"
      decimals="0"
      id="c93"
      unitRef="USD">-214648</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-09-30"
      decimals="0"
      id="c94"
      unitRef="USD">-58589013</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2023-09-30"
      decimals="0"
      id="c95"
      unitRef="USD">-52418968</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-09-30"
      decimals="0"
      id="c96"
      unitRef="USD">1981155</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30"
      decimals="0"
      id="c97"
      unitRef="USD">7048800</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-09-30"
      decimals="0"
      id="c98"
      unitRef="USD">3813982</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2023-09-30"
      decimals="0"
      id="c99"
      unitRef="USD">8890437</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c103"
      unitRef="USD">2881967</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c104"
      unitRef="USD">4794549</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c105"
      unitRef="USD">4132777</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c106"
      unitRef="USD">4428209</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c107"
      unitRef="USD">-7014744</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c108"
      unitRef="USD">-9222758</us-gaap:OperatingIncomeLoss>
    <us-gaap:GovernmentAssistanceNonoperatingIncome
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c110"
      unitRef="USD">698277</us-gaap:GovernmentAssistanceNonoperatingIncome>
    <us-gaap:GovernmentAssistanceNonoperatingIncome
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c111"
      unitRef="USD">581039</us-gaap:GovernmentAssistanceNonoperatingIncome>
    <us-gaap:InterestIncomeOther
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c112"
      unitRef="USD">153498</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c113"
      unitRef="USD">289846</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c114"
      unitRef="USD">14766</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c115"
      unitRef="USD">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c116"
      unitRef="USD">-21042</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c117"
      unitRef="USD">-21742</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c118"
      unitRef="USD">845499</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c119"
      unitRef="USD">849143</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c120"
      unitRef="USD">-6169245</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c121"
      unitRef="USD">-8373615</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c122"
      unitRef="USD">800</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c123"
      unitRef="USD">800</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c124"
      unitRef="USD">-6170045</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c125"
      unitRef="USD">-8374415</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c126"
      unitRef="USD">-27965</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c127"
      unitRef="USD">-1046</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c128"
      unitRef="USD">-6198010</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c129"
      unitRef="USD">-8375461</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c130"
      unitRef="Share">3197423</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c131"
      unitRef="Share">2858929</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c132"
      unitRef="USDPerShare">-1.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c133"
      unitRef="USDPerShare">-2.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c137"
      unitRef="USD">-6170045</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c138"
      unitRef="USD">-8374415</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c140"
      unitRef="USD">186049</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c141"
      unitRef="USD">183471</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c142"
      unitRef="USD">537492</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c143"
      unitRef="USD">1246457</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c144"
      unitRef="USD">14766</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c145"
      unitRef="USD">-0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c147"
      unitRef="USD">-356339</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c148"
      unitRef="USD">-562770</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c149"
      unitRef="USD">-197136</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c150"
      unitRef="USD">-301504</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c151"
      unitRef="USD">17590</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c152"
      unitRef="USD">-556270</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c153"
      unitRef="USD">-4890205</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c154"
      unitRef="USD">-6636483</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c156"
      unitRef="USD">729387</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c157"
      unitRef="USD">4345017</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c158"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c159"
      unitRef="USD">770532</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c160"
      unitRef="USD">107824</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c161"
      unitRef="USD">285438</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c162"
      unitRef="USD">29532</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c163"
      unitRef="USD">-0</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c164"
      unitRef="USD">592031</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c165"
      unitRef="USD">4830111</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c166"
      unitRef="USD">-25903</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c167"
      unitRef="USD">76850</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c168"
      unitRef="USD">-4324077</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c169"
      unitRef="USD">-1729522</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-09-30"
      decimals="0"
      id="c170"
      unitRef="USD">5361397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2022-09-30"
      decimals="0"
      id="c171"
      unitRef="USD">7090919</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-09-30"
      decimals="0"
      id="c172"
      unitRef="USD">1037320</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-09-30"
      decimals="0"
      id="c173"
      unitRef="USD">5361397</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:SharesOutstanding
      contextRef="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c176"
      unitRef="Share">2380280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c177"
      unitRef="USD">42473099</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c178"
      unitRef="USD">11176345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c179"
      unitRef="USD">-213602</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c180"
      unitRef="USD">-44044553</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2022-09-30"
      decimals="0"
      id="c181"
      unitRef="USD">9391289</us-gaap:StockholdersEquity>
    <edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c182"
      unitRef="Share">580876</edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingShares>
    <edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c183"
      unitRef="USD">3400191</edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount>
    <edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c184"
      unitRef="USD">944828</edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount>
    <edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c185"
      unitRef="USD">0</edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount>
    <edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c186"
      unitRef="USD">0</edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount>
    <edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c187"
      unitRef="USD">4345019</edsa:IssuanceOfCommonSharesAndWarrantsInEquityOfferingAmount>
    <edsa:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c188"
      unitRef="Share">100760</edsa:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <edsa:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c189"
      unitRef="USD">994618</edsa:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <edsa:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c190"
      unitRef="USD">-224087</edsa:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <edsa:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c191"
      unitRef="USD">770531</edsa:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c192"
      unitRef="Share">13557</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-1"
      id="c193"
      unitRef="USD">75920</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-1"
      id="c194"
      unitRef="USD">-75920</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c195"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <edsa:StockIssuedDuringPeriodValueStockIssuanceCosts
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c197"
      unitRef="USD">300677</edsa:StockIssuedDuringPeriodValueStockIssuanceCosts>
    <edsa:StockIssuedDuringPeriodValueStockIssuanceCosts
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c198"
      unitRef="USD">28358</edsa:StockIssuedDuringPeriodValueStockIssuanceCosts>
    <edsa:StockIssuedDuringPeriodValueStockIssuanceCosts
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c199"
      unitRef="USD">-0</edsa:StockIssuedDuringPeriodValueStockIssuanceCosts>
    <edsa:StockIssuedDuringPeriodValueStockIssuanceCosts
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c200"
      unitRef="USD">-0</edsa:StockIssuedDuringPeriodValueStockIssuanceCosts>
    <edsa:StockIssuedDuringPeriodValueStockIssuanceCosts
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c201"
      unitRef="USD">329035</edsa:StockIssuedDuringPeriodValueStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c204"
      unitRef="USD">1246457</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c205"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c207"
      unitRef="USD">1246457</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c210"
      unitRef="USD">0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c211"
      unitRef="USD">-1046</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2022-10-01_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c212"
      unitRef="USD">-8374415</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c213"
      unitRef="USD">-8375461</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c214"
      unitRef="Share">3075473</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c215"
      unitRef="USD">46643151</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c216"
      unitRef="USD">13039265</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c217"
      unitRef="USD">-214648</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c218"
      unitRef="USD">-52418968</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-09-30"
      decimals="0"
      id="c219"
      unitRef="USD">7048800</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c220"
      unitRef="Share">171916</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c221"
      unitRef="USD">729387</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c222"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c223"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c224"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c225"
      unitRef="USD">729387</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <edsa:StockIssuedDuringPeriodValueStockIssuanceCosts
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c227"
      unitRef="USD">136514</edsa:StockIssuedDuringPeriodValueStockIssuanceCosts>
    <edsa:StockIssuedDuringPeriodValueStockIssuanceCosts
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c228"
      unitRef="USD">-0</edsa:StockIssuedDuringPeriodValueStockIssuanceCosts>
    <edsa:StockIssuedDuringPeriodValueStockIssuanceCosts
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c229"
      unitRef="USD">-0</edsa:StockIssuedDuringPeriodValueStockIssuanceCosts>
    <edsa:StockIssuedDuringPeriodValueStockIssuanceCosts
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c230"
      unitRef="USD">-0</edsa:StockIssuedDuringPeriodValueStockIssuanceCosts>
    <edsa:StockIssuedDuringPeriodValueStockIssuanceCosts
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c231"
      unitRef="USD">136514</edsa:StockIssuedDuringPeriodValueStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c233"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c234"
      unitRef="USD">537492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c235"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c237"
      unitRef="USD">537492</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c239"
      unitRef="USD">0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c240"
      unitRef="USD">0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c241"
      unitRef="USD">-27965</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-10-01_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c242"
      unitRef="USD">-6170045</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c243"
      unitRef="USD">-6198010</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c244"
      unitRef="Share">3247389</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-09-30_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c245"
      unitRef="USD">47236024</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-09-30_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c246"
      unitRef="USD">13576757</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-09-30_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c247"
      unitRef="USD">-242613</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-09-30_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c248"
      unitRef="USD">-58589013</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-09-30"
      decimals="0"
      id="c249"
      unitRef="USD">1981155</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations contextRef="d_2023-10-01_2024-09-30" id="c250">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&lt;b&gt;1. Nature of operations&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Edesa Biotech, Inc. (the Company or Edesa) is a biopharmaceutical company focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The Company is organized under the laws of British Columbia, Canada and is headquartered in Markham, Ontario. It operates under its wholly owned subsidiaries, Edesa Biotech Research, Inc., an Ontario, Canada corporation, and Edesa Biotech USA, Inc., a California, USA corporation.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company&#x2019;s common shares trade on The Nasdaq Capital Market in the United States under the symbol &#x201c;EDSA&#x201d;.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;These consolidated financial statements have been prepared on a going concern basis which presumes the realization of assets and the discharge of liabilities in the normal course of operations for at least the next twelve months.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;For the year ended September 30, 2024, the Company incurred a comprehensive loss of $6.2 million resulting in an accumulated deficit of $58.6 million. For the year ended September 30, 2024, the Company had a net cash outflow from operating activities of $4.9 million and ended the year with $1.0 million in cash and cash equivalents and a net working capital deficit of $0.2 million. Subsequent to the year end, the Company received proceeds of $1.5 million from the sale of Preferred Shares to the Pardeep Nijhawan Medicine Professional Corporation (PN MPC). The Company&#x2019;s ability to continue as a going concern is dependent on obtaining additional funding through financings, other strategic activities as well as via grants, to fund the development of its drug candidates. There can be no assurance that the Company will be successful in raising the necessary financing. These conditions indicate the existence of a material uncertainty that may cast significant doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and, therefore, be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying consolidated financial statements. These adjustments could be material.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company&#x2019;s operations have historically been funded through issuances of common shares, exercises of common share purchase warrants, convertible preferred shares, convertible loans, government grants and tax incentives.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In August 2022 the Company filed a $150.0 million shelf registration statement, under which the Company entered into an equity distribution agreement with Canaccord for $20.0 million in gross proceeds, subject to certain offering limitations that&#160;allowed&#160;the Company to offer and sell common shares having an aggregate gross sales price of up to $8.4 million (Canaccord ATM). The Canaccord ATM was terminated in October 2024.&#160;In October 2024, the Company entered into an At The Market Offering Agreement with H.C. Wainwright &amp;amp; Co., LLC as a sales agent (HCW ATM) pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $3.87 million in gross proceeds.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company&#x2019;s primary use of cash and cash equivalents is to fund operating expenses, which consist of research and development (R&amp;amp;D) and general and administrative (G&amp;amp;A) expenditures. Cash used to fund operating expenses is impacted by the timing of when the Company pays these expenses, as reflected in the change in accounts payable and accrued expenses. Net cash used in operating activities was $4.9 million and $6.6&#160;million for the years ended September 30, 2024 and 2023, respectively. The Company incurred net losses of $6.2 million and $8.4 million for the years ended September 30, 2024 and 2023.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In October 2024, the Company entered into a Securities Purchase Agreement with PN MPC, an entity controlled by Pardeep Nijhawan, the Company&#x2019;s Chief Executive Officer, Secretary and member of the board of directors of the Company, pursuant to which the Company agreed to issue and sell to PN MPC in a private placement, up to $5 million of shares (Preferred Shares) of the Company&#x2019;s newly designated Series A-1 Convertible Preferred Shares, stated value $10,000 per share, each of which is initially convertible into approximately 2,903 common shares (Conversion Shares), without par value, of the Company (Common Shares) at a conversion price of $3.445 per Conversion Share, and warrants (Warrants) to purchase Common Shares (Warrant Shares) at an exercise price of $3.445 per Warrant Share. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of Common Shares equal to 75% of the underlying Conversion Shares at a combined purchase price of $10,272.13 per Preferred Share and related Warrants. Under the Purchase Agreement, PN MPC&#160;has purchased 150 Preferred Shares initially convertible into an aggregate of 435,414 Conversion Shares and Warrants to purchase up to an aggregate of 326,560 Warrant Shares for an aggregate purchase price of $1,540,819. The Warrants expire &lt;span style="-sec-ix-hidden:c277"&gt;five&lt;/span&gt; years from the issuance date.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In October 2023, the Company entered into a multi-year contribution agreement (2023 SIF Agreement) with the Canadian Government&#x2019;s Strategic Innovation Fund (SIF). Under the 2023 SIF Agreement, the Government of Canada committed up to C$23 million in partially repayable funding. Of the C$23 million committed by SIF, up to C$5.8 million is not repayable by the Company. The remaining C$17.2 million is conditionally repayable starting in 2029 only if and when the Company earns gross revenue. See Note 9. In February 2021, the Company signed a contribution agreement with the Canadian government&#x2019;s SIF (2021 SIF Agreement), the Company was eligible to receive cash reimbursements up to C$14.1 million in the aggregate for certain R&amp;amp;D expenses related to the EB05 clinical development program. All potential funding available under the 2021 SIF Agreement has been received. For the years ended September 30, 2024 and 2023, the Company recorded grant income of $0.7 million and $0.6 million respectively related to the 2023 SIF Agreement.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In October 2023, the Company entered into a $10.0 million revolving credit agreement with Pardeep Nijhawan Medicine Professional Corporation (Credit Agreement), providing an unsecured revolving credit facility, with a credit limit of $3.5 million (Credit Limit) which is available immediately. The line of credit bears interest at the Canadian Imperial Bank of Commerce US Base-Interest Rate plus 3% per annum and has a maturity date of March 31, 2026, unless terminated earlier by either party with 90 days&#x2019; notice. Advances under the line of credit are tied to a borrowing base (Borrowing Base) consisting of eligible grant receivables from SIF, future potential license fee receivables and any other accounts receivable. At no time shall the aggregate principal amount of all advances outstanding exceed the lesser of (i) the Credit Limit and (ii) an amount equal to 85% of the Borrowing Base. No amounts have been drawn upon from the Credit Agreement. The Credit Agreement was terminated in October 2024.&lt;/p&gt;











&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In March 2023, the Company entered into an equity distribution agreement with Canaccord, as sales agent, pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $20 million in gross proceeds, subject to certain offering limitations that currently allows the Company to offer and sell common shares having an aggregate gross sales price of up to $8.4 million. At September 30, 2024, the Company sold a total of 171,916&#160;common shares pursuant to the agreement for gross proceeds of approximately $0.7&#160;million.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In November 2022, the Company completed a private placement of units consisting of 384,475 common shares, 12-month warrants to purchase up to an aggregate of 192,248 common shares and 3-year warrants to purchase up to an aggregate of 192,248 common shares. The gross proceeds from this offering are approximately $3.0 million, before offering expenses.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
</us-gaap:NatureOfOperations>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2023-10-01_2024-09-30"
      decimals="-5"
      id="c252"
      unitRef="USD">-6200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-09-30"
      decimals="-5"
      id="c253"
      unitRef="USD">-58600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-10-01_2024-09-30"
      decimals="-5"
      id="c254"
      unitRef="USD">-4900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-09-30"
      decimals="-6"
      id="c255"
      unitRef="USD">1000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <edsa:WorkingCapitalDeficit
      contextRef="i_2024-09-30"
      decimals="-5"
      id="c256"
      unitRef="USD">-200000</edsa:WorkingCapitalDeficit>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-10-01_2024-12-13_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c257"
      unitRef="USD">1500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <edsa:EquityOfferingMaximumAmount
      contextRef="i_2022-08-31"
      decimals="-7"
      id="c258"
      unitRef="USD">150000000</edsa:EquityOfferingMaximumAmount>
    <edsa:EquityOfferingMaximumAmount
      contextRef="i_2024-08-31_CounterpartyNameAxis-CanaccordMember"
      decimals="-7"
      id="c259"
      unitRef="USD">20000000</edsa:EquityOfferingMaximumAmount>
    <edsa:EquityOfferingLimitationAmount
      contextRef="i_2024-08-31_CounterpartyNameAxis-CanaccordMember"
      decimals="-5"
      id="c260"
      unitRef="USD">8400000</edsa:EquityOfferingLimitationAmount>
    <edsa:EquityOfferingMaximumAmount
      contextRef="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember"
      decimals="-4"
      id="c261"
      unitRef="USD">3870000</edsa:EquityOfferingMaximumAmount>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2023-10-01_2024-09-30"
      decimals="-5"
      id="c262"
      unitRef="USD">-4900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2022-10-01_2023-09-30"
      decimals="-5"
      id="c263"
      unitRef="USD">-6600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="d_2023-10-01_2024-09-30"
      decimals="-5"
      id="c264"
      unitRef="USD">-6200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2022-10-01_2023-09-30"
      decimals="-5"
      id="c265"
      unitRef="USD">-8400000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-10-01_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="-6"
      id="c266"
      unitRef="USD">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c267"
      unitRef="USDPerShare">10000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c268"
      unitRef="Share">2903</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c269"
      unitRef="USDPerShare">3.445</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c270"
      unitRef="USDPerShare">3.445</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="2"
      id="c271"
      unitRef="Pure">0.75</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c272"
      unitRef="USDPerShare">10272.13</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-10-01_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c273"
      unitRef="Share">150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c274"
      unitRef="Share">435414</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c275"
      unitRef="Share">326560</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-10-01_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="c276"
      unitRef="USD">1540819</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:GovernmentAssistanceAwardAmount
      contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-6"
      id="c278"
      unitRef="CAD">23000000</us-gaap:GovernmentAssistanceAwardAmount>
    <us-gaap:GovernmentAssistanceAwardAmount
      contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-6"
      id="c279"
      unitRef="CAD">23000000</us-gaap:GovernmentAssistanceAwardAmount>
    <edsa:GovernmentAssistanceAwardAmountNotRepayable
      contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-5"
      id="c280"
      unitRef="CAD">5800000</edsa:GovernmentAssistanceAwardAmountNotRepayable>
    <edsa:GovernmentAssistanceAwardAmountRepyable
      contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-5"
      id="c281"
      unitRef="CAD">17200000</edsa:GovernmentAssistanceAwardAmountRepyable>
    <us-gaap:GovernmentAssistanceAwardAmount
      contextRef="i_2021-02-28_GovernmentAssistanceTypeAxis-The2021SIFAgreementMember"
      decimals="-5"
      id="c282"
      unitRef="CAD">14100000</us-gaap:GovernmentAssistanceAwardAmount>
    <us-gaap:GovernmentAssistanceNonoperatingIncome
      contextRef="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-5"
      id="c283"
      unitRef="USD">700000</us-gaap:GovernmentAssistanceNonoperatingIncome>
    <us-gaap:GovernmentAssistanceNonoperatingIncome
      contextRef="d_2022-10-01_2023-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-5"
      id="c284"
      unitRef="USD">600000</us-gaap:GovernmentAssistanceNonoperatingIncome>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i_2023-10-31_CreditFacilityAxis-RevolvingCreditFacilityMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember"
      decimals="-7"
      id="c285"
      unitRef="USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i_2023-10-31_CreditFacilityAxis-UnsecuredLineOfCreditMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember"
      decimals="-5"
      id="c286"
      unitRef="USD">3500000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2023-10-01_2023-10-31_CreditFacilityAxis-LineOfCreditMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember"
      decimals="2"
      id="c287"
      unitRef="Pure">0.03</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="d_2023-10-01_2024-09-30_CreditFacilityAxis-RevolvingCreditFacilityMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember"
      id="c288">2026-03-31</us-gaap:DebtInstrumentMaturityDate>
    <edsa:DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal
      contextRef="i_2023-10-31_CreditFacilityAxis-RevolvingCreditFacilityMember_LineOfCreditFacilityAxis-PardeepNijhawanMedicineProfessionalCorporationMember"
      decimals="2"
      id="c289"
      unitRef="Pure">0.85</edsa:DebtInstrumentCovenantMaximumPercentageOfBorrowingBaseForOutstandingPrincipal>
    <edsa:EquityOfferingMaximumAmount
      contextRef="i_2023-03-31_CounterpartyNameAxis-CanaccordMember"
      decimals="-7"
      id="c290"
      unitRef="USD">20000000</edsa:EquityOfferingMaximumAmount>
    <edsa:EquityOfferingLimitationAmount
      contextRef="i_2023-03-31_CounterpartyNameAxis-CanaccordMember"
      decimals="-5"
      id="c291"
      unitRef="USD">8400000</edsa:EquityOfferingLimitationAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-03-01_2023-09-30_CounterpartyNameAxis-CanaccordMember"
      decimals="INF"
      id="c292"
      unitRef="Share">171916</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-03-01_2023-09-30_CounterpartyNameAxis-CanaccordMember"
      decimals="-5"
      id="c293"
      unitRef="USD">700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-11-01_2022-11-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c294"
      unitRef="Share">384475</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-11-30_ClassOfWarrantOrRightAxis-TwelveMonthWarrantsMember"
      decimals="INF"
      id="c296"
      unitRef="Share">192248</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-11-30_ClassOfWarrantOrRightAxis-ThreeYearWarrantsMember"
      decimals="INF"
      id="c298"
      unitRef="Share">192248</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2022-11-01_2022-11-30_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-6"
      id="c299"
      unitRef="USD">3000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="d_2023-10-01_2024-09-30" id="c300">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;2. Basis of preparation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and include the accounts of the Company and its wholly owned subsidiaries, Edesa Biotech Research, Inc. and Edesa Biotech USA, Inc. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2023-10-01_2024-09-30" id="c302">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;3. Significant accounting policies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Use of estimates&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period or year. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are valuation of accounts and other receivable; valuation and useful lives of property and equipment; intangible assets; right-of-use assets; deferred income taxes; the determination of fair value of share-based compensation; the determination of fair value of warrants in order to allocate proceeds from equity issuances; and forecasting future cash flows for assessing the going concern assumption.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Functional and reporting currencies&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company&#x2019;s and its wholly owned subsidiary&#x2019;s, Edesa Biotech USA, Inc., functional currency. The functional currency of the Company&#x2019;s wholly owned subsidiary, Edesa Biotech Research, Inc., as determined by management, is Canadian dollars.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Cash and cash equivalents consist of demand deposits with financial institutions held in checking, savings and money market mutual funds and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Accounts and other receivables&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company assesses the collectability of its accounts receivables through a review of its current aging and payment terms, as well as an analysis of its historical collection rate, general economic conditions and credit status of the government agencies. Accounts and other receivables include reimbursement grant income for the Company&#x2019;s federal grant with the Canadian government&#x2019;s SIF and Harmonized Sales Tax (HST) refunds receivables. As of September 30, 2024, all outstanding accounts, grants and HST refunds receivables were deemed to be fully collectible, and therefore, &lt;span style="-sec-ix-hidden:c304"&gt;no&lt;/span&gt; allowance for doubtful accounts was recorded.&lt;/p&gt;












&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Property and equipment&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Property and equipment are recorded at historical cost less accumulated depreciation and any accumulated impairment losses. Depreciation is recorded to write off the cost of assets less their residual values over their useful lives, using the declining balance and straight-line methods. Maintenance and repair expenditures that do not improve or extend the life are expensed in the period incurred. Any gain or loss arising on the disposal or retirement of an item of property and equipment is recognized as the difference between the sales proceeds and the carrying amount of the asset. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. The Company capitalizes expenditures greater than $5,000. The Company changed its depreciation policy to straight line depreciation.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The depreciation policy for the principal asset categories are calculated as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Computer equipment 30% declining balance method or straight line 3 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Furniture and equipment 20% declining balance method&#160;or straight line for 4 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Intangible assets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Intangible assets represent the exclusive world-wide rights to know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights, acquired by entering into a license agreement with a pharmaceutical development company. Unless earlier terminated, the term of the license agreement will remain in effect for 25 years from the date of first commercial sale of licensed products containing the Constructs. Subsequently, the license agreement will automatically renew for &lt;span style="-sec-ix-hidden:c311"&gt;five&lt;/span&gt;-year periods unless either party terminates the agreement in accordance with its terms. Intangible assets are stated at their historical cost, amortized on a straight-line basis over their expected useful lives, which is 25 years, and subject to impairment review at the end of each year.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Impairment of long-lived assets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Long-lived assets are tested for impairment when indicators of impairment exist. When a significant change in the expected timing or amount of the future cash flows of the financial asset is identified, the carrying amount of the financial asset is reduced and the amount of the write-down is recognized as a loss.&#160;&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Right-of-Use assets and liabilities&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company recognizes right-of-use (ROU) assets and liabilities on the balance sheet for operating leases with terms longer than 12 months. The Company follows the ongoing practical expedient not to recognize ROU assets and liabilities for short-term leases. The ROU assets are initially measured at cost and amortized using the straight-line method through the end of the lease term. The ROU liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the Company's incremental borrowing rate.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Fair value measurement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company uses the fair value measurement framework for valuing financial assets and liabilities. See Note 11.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Reimbursement Grant Income&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Reimbursement grant income is recognized based on the reimbursement rate included in the government contribution agreement when allowable expenses have been incurred.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Research and development&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Research and development expenses principally consist of (i) contract research organizations for clinical trial management services, (ii) contract manufacturing organizations for manufacturing the drug compound(s) for use in clinical trials and (iii) salaries of employees directly involved in research and development efforts. Research and development costs are expensed as incurred.&lt;/p&gt;












&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Share-based compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company has equity incentive plans under which various types of equity-based awards including share options, restricted shares and restricted share unit awards may be granted to employees, non-employee directors and non-employee consultants and warrants that may be granted as compensation to non-employees.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company recognizes compensation expense for all share-based awards based on the estimated grant-date fair values. For restricted share unit awards to employees, the fair value is based on the 5-day volume weighted average price (VWAP) of the Company&#x2019;s common shares up to the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The fair value of share options is determined using the Black-Scholes option pricing model. The Company utilizes a dividend yield of &lt;span style="-sec-ix-hidden:c313"&gt;zero&lt;/span&gt; based on the fact that the Company has never paid cash dividends and has no current intention of paying cash dividends. The Company elected an accounting policy to record forfeitures as they occur. See Note 8 for a discussion of the assumptions used by the Company in determining the grant date fair value of options granted under the Black-Scholes option pricing model, as well as a summary of the share option activity under the Company&#x2019;s share-based compensation plan for all years presented.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The provisions of the Company&#x2019;s share-based compensation plans do not require the Company to settle any options or restricted share units by transferring cash or other assets, and therefore the Company classifies the awards as equity.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Translation of foreign currency transactions&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company&#x2019;s reporting currency is the U.S. dollar. The financial statements of the wholly owned Canadian subsidiary is measured using the Canadian dollar as the functional currency. Assets and liabilities of the Canadian operation have been translated at year-end exchange rates and related revenue and expenses have been translated at average exchange rates for the year. Accumulated gains and losses resulting from the translation of the financial statements of the Canadian operation are included as part of accumulated other comprehensive loss, a separate component of shareholders&#x2019; equity.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;For other transactions denominated in currencies other than the Company&#x2019;s functional currency, the monetary assets and liabilities are translated at the year-end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. Non-monetary balance sheet and related income statement accounts are remeasured into U.S. dollar using historical exchange rates. All of the exchange gains or losses resulting from these other transactions are recognized in the statements of operations and comprehensive loss.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Income taxes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company assesses the likelihood of the financial statement effect of a tax position that should be recognized when it is more likely than not that the position will be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information available as of the reporting date. The Company is subject to examination by taxing authorities in Canada and the U.S. Management does not believe that there are any uncertain tax positions that would result in an asset or liability for taxes being recognized in the accompanying financial statements. The Company recognizes tax-related interest and penalties, if any, as a component of income tax expense.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company accounts for income taxes on a tax jurisdictional basis. The Company files income tax returns in Canada, the provinces of British Columbia and Ontario, the U.S. and the state of California.&lt;/p&gt;












&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Earnings (loss) per share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Basic earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the year.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The computation of diluted earnings (loss) per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings (loss) per share. The dilutive effect of convertible securities would be reflected in diluted earnings per share by application of the &#x201c;if converted&#x201d; method. The dilutive effect of outstanding share options and warrants and their equivalents would be reflected in diluted earnings per share by application of the treasury stock method. However, conversion of outstanding share options and warrants would have an antidilutive effect on loss per share for the years ended September 30, 2024 and 2023 and are therefore excluded from the computation of diluted loss per share. See Note 8 for share options and warrants at September 30, 2024 and 2023.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Segmented information&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company&#x2019;s operations comprise a single reportable segment engaged in the research and development, manufacturing and commercialization of innovative pharmaceutical products. As the operations comprise a single reportable segment, amounts disclosed in the consolidated financial statements for net loss, comprehensive loss, depreciation and total assets also represent segmented amounts.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Adoption of recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;On October 1, 2022, the Company adopted Accounting Standards Update ASU 2021-10 Disclosure by Business Entities About Government Assistance, modifying ASC Topic 832, Government Assistance. The amendments in ASU 2021-10 require disclosure of information about certain types of government assistance received. The Company expanded its disclosures related to government assistance.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Future accounting pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In November 2023, the FASB issued Accounting Standards Update ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of&#160;Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;), which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation&#160;table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.&lt;/p&gt;


&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2023-10-01_2024-09-30" id="c639190829575506">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Use of estimates&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period or year. Actual results could differ from those estimates. Areas where significant judgment is involved in making estimates are valuation of accounts and other receivable; valuation and useful lives of property and equipment; intangible assets; right-of-use assets; deferred income taxes; the determination of fair value of share-based compensation; the determination of fair value of warrants in order to allocate proceeds from equity issuances; and forecasting future cash flows for assessing the going concern assumption.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
</us-gaap:UseOfEstimates>
    <edsa:FunctionalAndReportingCurrenciesPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c966581253800766">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Functional and reporting currencies&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company&#x2019;s and its wholly owned subsidiary&#x2019;s, Edesa Biotech USA, Inc., functional currency. The functional currency of the Company&#x2019;s wholly owned subsidiary, Edesa Biotech Research, Inc., as determined by management, is Canadian dollars.&lt;/p&gt;
</edsa:FunctionalAndReportingCurrenciesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c836664419973752">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Cash and cash equivalents&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Cash and cash equivalents consist of demand deposits with financial institutions held in checking, savings and money market mutual funds and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.&lt;/p&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="d_2023-10-01_2024-09-30" id="c1422156294653866">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Accounts and other receivables&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company assesses the collectability of its accounts receivables through a review of its current aging and payment terms, as well as an analysis of its historical collection rate, general economic conditions and credit status of the government agencies. Accounts and other receivables include reimbursement grant income for the Company&#x2019;s federal grant with the Canadian government&#x2019;s SIF and Harmonized Sales Tax (HST) refunds receivables. As of September 30, 2024, all outstanding accounts, grants and HST refunds receivables were deemed to be fully collectible, and therefore, &lt;span style="-sec-ix-hidden:c304"&gt;no&lt;/span&gt; allowance for doubtful accounts was recorded.&lt;/p&gt;
</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c1387511810497948">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Property and equipment&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Property and equipment are recorded at historical cost less accumulated depreciation and any accumulated impairment losses. Depreciation is recorded to write off the cost of assets less their residual values over their useful lives, using the declining balance and straight-line methods. Maintenance and repair expenditures that do not improve or extend the life are expensed in the period incurred. Any gain or loss arising on the disposal or retirement of an item of property and equipment is recognized as the difference between the sales proceeds and the carrying amount of the asset. The estimated useful lives, residual values and depreciation methods are reviewed at the end of each year, with the effect of any changes in estimate accounted for on a prospective basis. The Company capitalizes expenditures greater than $5,000. The Company changed its depreciation policy to straight line depreciation.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The depreciation policy for the principal asset categories are calculated as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Computer equipment 30% declining balance method or straight line 3 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;Furniture and equipment 20% declining balance method&#160;or straight line for 4 years&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="d_2024-09-30_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-CapitalizedCostsPropertyPlantAndEquipmentMember"
      decimals="-3"
      id="c305"
      unitRef="USD">5000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <edsa:DepreciationDecliningBalanceMethodPercentage
      contextRef="d_2023-10-01_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="1"
      id="c306"
      unitRef="Pure">0.30</edsa:DepreciationDecliningBalanceMethodPercentage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      id="c307">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <edsa:DepreciationDecliningBalanceMethodPercentage
      contextRef="d_2023-10-01_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember"
      decimals="1"
      id="c308"
      unitRef="Pure">0.20</edsa:DepreciationDecliningBalanceMethodPercentage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndEquipmentMember"
      id="c309">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c327390431310141">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Intangible assets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Intangible assets represent the exclusive world-wide rights to know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights, acquired by entering into a license agreement with a pharmaceutical development company. Unless earlier terminated, the term of the license agreement will remain in effect for 25 years from the date of first commercial sale of licensed products containing the Constructs. Subsequently, the license agreement will automatically renew for &lt;span style="-sec-ix-hidden:c311"&gt;five&lt;/span&gt;-year periods unless either party terminates the agreement in accordance with its terms. Intangible assets are stated at their historical cost, amortized on a straight-line basis over their expected useful lives, which is 25 years, and subject to impairment review at the end of each year.&lt;/p&gt;
</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember"
      id="c310">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="i_2024-09-30" id="c312">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c668638655877454">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Impairment of long-lived assets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Long-lived assets are tested for impairment when indicators of impairment exist. When a significant change in the expected timing or amount of the future cash flows of the financial asset is identified, the carrying amount of the financial asset is reduced and the amount of the write-down is recognized as a loss.&#160;&lt;/p&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c694622031279516">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Right-of-Use assets and liabilities&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company recognizes right-of-use (ROU) assets and liabilities on the balance sheet for operating leases with terms longer than 12 months. The Company follows the ongoing practical expedient not to recognize ROU assets and liabilities for short-term leases. The ROU assets are initially measured at cost and amortized using the straight-line method through the end of the lease term. The ROU liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the Company's incremental borrowing rate.&lt;/p&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c1411762973614573">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Fair value measurement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company uses the fair value measurement framework for valuing financial assets and liabilities. See Note 11.&lt;/p&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c795091054421726">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Reimbursement Grant Income&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Reimbursement grant income is recognized based on the reimbursement rate included in the government contribution agreement when allowable expenses have been incurred.&lt;/p&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2023-10-01_2024-09-30" id="c270227033747032">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Research and development&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Research and development expenses principally consist of (i) contract research organizations for clinical trial management services, (ii) contract manufacturing organizations for manufacturing the drug compound(s) for use in clinical trials and (iii) salaries of employees directly involved in research and development efforts. Research and development costs are expensed as incurred.&lt;/p&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2023-10-01_2024-09-30" id="c928472350889880">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Share-based compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company has equity incentive plans under which various types of equity-based awards including share options, restricted shares and restricted share unit awards may be granted to employees, non-employee directors and non-employee consultants and warrants that may be granted as compensation to non-employees.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company measures the cost of equity-settled transactions by reference to the fair value of the equity instruments at the date at which they are granted.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company recognizes compensation expense for all share-based awards based on the estimated grant-date fair values. For restricted share unit awards to employees, the fair value is based on the 5-day volume weighted average price (VWAP) of the Company&#x2019;s common shares up to the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The fair value of share options is determined using the Black-Scholes option pricing model. The Company utilizes a dividend yield of &lt;span style="-sec-ix-hidden:c313"&gt;zero&lt;/span&gt; based on the fact that the Company has never paid cash dividends and has no current intention of paying cash dividends. The Company elected an accounting policy to record forfeitures as they occur. See Note 8 for a discussion of the assumptions used by the Company in determining the grant date fair value of options granted under the Black-Scholes option pricing model, as well as a summary of the share option activity under the Company&#x2019;s share-based compensation plan for all years presented.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The provisions of the Company&#x2019;s share-based compensation plans do not require the Company to settle any options or restricted share units by transferring cash or other assets, and therefore the Company classifies the awards as equity.&lt;/p&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c938865703043656">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Translation of foreign currency transactions&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company&#x2019;s reporting currency is the U.S. dollar. The financial statements of the wholly owned Canadian subsidiary is measured using the Canadian dollar as the functional currency. Assets and liabilities of the Canadian operation have been translated at year-end exchange rates and related revenue and expenses have been translated at average exchange rates for the year. Accumulated gains and losses resulting from the translation of the financial statements of the Canadian operation are included as part of accumulated other comprehensive loss, a separate component of shareholders&#x2019; equity.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;For other transactions denominated in currencies other than the Company&#x2019;s functional currency, the monetary assets and liabilities are translated at the year-end rates. Revenue and expenses are translated at rates of exchange prevailing on the transaction dates. Non-monetary balance sheet and related income statement accounts are remeasured into U.S. dollar using historical exchange rates. All of the exchange gains or losses resulting from these other transactions are recognized in the statements of operations and comprehensive loss.&lt;/p&gt;
</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c271959260953430">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Income taxes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the tax bases of assets and liabilities and their financial statement reported amounts using enacted tax rates and laws in effect in the year in which the differences are expected to reverse. A valuation allowance is provided against deferred tax assets when it is determined to be more likely than not that the deferred tax asset will not be realized.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company assesses the likelihood of the financial statement effect of a tax position that should be recognized when it is more likely than not that the position will be sustained upon examination by a taxing authority based on the technical merits of the tax position, circumstances, and information available as of the reporting date. The Company is subject to examination by taxing authorities in Canada and the U.S. Management does not believe that there are any uncertain tax positions that would result in an asset or liability for taxes being recognized in the accompanying financial statements. The Company recognizes tax-related interest and penalties, if any, as a component of income tax expense.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company accounts for income taxes on a tax jurisdictional basis. The Company files income tax returns in Canada, the provinces of British Columbia and Ontario, the U.S. and the state of California.&lt;/p&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c1519160923970575">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Earnings (loss) per share&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Basic earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the year.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The computation of diluted earnings (loss) per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings (loss) per share. The dilutive effect of convertible securities would be reflected in diluted earnings per share by application of the &#x201c;if converted&#x201d; method. The dilutive effect of outstanding share options and warrants and their equivalents would be reflected in diluted earnings per share by application of the treasury stock method. However, conversion of outstanding share options and warrants would have an antidilutive effect on loss per share for the years ended September 30, 2024 and 2023 and are therefore excluded from the computation of diluted loss per share. See Note 8 for share options and warrants at September 30, 2024 and 2023.&lt;/p&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c1216021672145377">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Segmented information&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company&#x2019;s operations comprise a single reportable segment engaged in the research and development, manufacturing and commercialization of innovative pharmaceutical products. As the operations comprise a single reportable segment, amounts disclosed in the consolidated financial statements for net loss, comprehensive loss, depreciation and total assets also represent segmented amounts.&lt;/p&gt;
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2023-10-01_2024-09-30" id="c1664667839609038">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Adoption of recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;On October 1, 2022, the Company adopted Accounting Standards Update ASU 2021-10 Disclosure by Business Entities About Government Assistance, modifying ASC Topic 832, Government Assistance. The amendments in ASU 2021-10 require disclosure of information about certain types of government assistance received. The Company expanded its disclosures related to government assistance.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Future accounting pronouncements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In November 2023, the FASB issued Accounting Standards Update ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of&#160;Income Statement Expenses (&#x201c;ASU 2024-03&#x201d;), which requires public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. This guidance is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to provide enhancements to annual income tax disclosures. The standard will require more detailed information in the rate reconciliation&#160;table and for income taxes paid, among other enhancements. The standard is effective for years beginning after December 15, 2024 and early adoption is permitted. The Company is currently evaluating the impact of the guidance on the consolidated financial statements and disclosures.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2023-10-01_2024-09-30" id="c331">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;4. Property and equipment&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Property and equipment, net consisted of the following:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;September 30, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,945&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,945&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,603&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,603&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52,548&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52,548&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(52,548&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,846&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Depreciable assets, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,702&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets not in service&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total property and equipment, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,702&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Depreciation expense amounted to $8,702 and $4,328 for the years ended September 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2023-10-01_2024-09-30" id="c349">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;September 30, 2023&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Computer equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,945&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;46,945&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Furniture and equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,603&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,603&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52,548&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52,548&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: accumulated depreciation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(52,548&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(43,846&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Depreciable assets, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8,702&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Assets not in service&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total property and equipment, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8,702&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="0"
      id="c351"
      unitRef="USD">46945</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      decimals="0"
      id="c352"
      unitRef="USD">46945</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="0"
      id="c353"
      unitRef="USD">5603</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-09-30_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="0"
      id="c354"
      unitRef="USD">5603</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2024-09-30"
      decimals="0"
      id="c355"
      unitRef="USD">52548</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2023-09-30"
      decimals="0"
      id="c356"
      unitRef="USD">52548</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2024-09-30"
      decimals="0"
      id="c357"
      unitRef="USD">52548</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2023-09-30"
      decimals="0"
      id="c358"
      unitRef="USD">43846</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <edsa:PropertyPlantAndEquipmentNetIncludingAssetsNotInService
      contextRef="i_2024-09-30"
      decimals="0"
      id="c359"
      unitRef="USD">0</edsa:PropertyPlantAndEquipmentNetIncludingAssetsNotInService>
    <edsa:PropertyPlantAndEquipmentNetIncludingAssetsNotInService
      contextRef="i_2023-09-30"
      decimals="0"
      id="c360"
      unitRef="USD">8702</edsa:PropertyPlantAndEquipmentNetIncludingAssetsNotInService>
    <edsa:PropertyPlantAndEquipmentAssetsNotInService
      contextRef="i_2024-09-30"
      decimals="0"
      id="c361"
      unitRef="USD">0</edsa:PropertyPlantAndEquipmentAssetsNotInService>
    <edsa:PropertyPlantAndEquipmentAssetsNotInService
      contextRef="i_2023-09-30"
      decimals="0"
      id="c362"
      unitRef="USD">0</edsa:PropertyPlantAndEquipmentAssetsNotInService>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2024-09-30"
      decimals="0"
      id="c363"
      unitRef="USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2023-09-30"
      decimals="0"
      id="c364"
      unitRef="USD">8702</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c347"
      unitRef="USD">8702</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c348"
      unitRef="USD">4328</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="d_2023-10-01_2024-09-30" id="c365">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;5. Intangible assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Acquired license&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In April 2020, the Company entered into a license agreement with a pharmaceutical development company to obtain exclusive world-wide rights to know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights. Unless earlier terminated, the term of the license agreement will remain in effect for 25 years from the date of first commercial sale of licensed products containing the Constructs. Subsequently, the license agreement will automatically renew for &lt;span style="-sec-ix-hidden:c368"&gt;five&lt;/span&gt;-year periods unless either party terminates the agreement in accordance with its terms.&lt;/p&gt;











&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Under the license agreement, the Company is exclusively responsible, at its expense, for the research, development manufacture, marketing, distribution and commercialization of the Constructs and licensed products and to obtain all necessary licenses and rights. The Company is required to use commercially reasonable efforts to develop and commercialize the Constructs in accordance with the terms of a development plan established by the parties.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company has determined that the license has multiple alternative future uses in research and development projects and sublicensing in other countries or for other disease indications. The value of the acquired license is recorded as an intangible asset with amortization over the estimated useful life of 25 years and evaluation for impairment at the end of each reporting period.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The required upfront license payment of $2.5 million was paid by issuance of Series A-1 Convertible Preferred Shares, which have been fully converted to common shares. The value of the license includes acquisition legal costs. See Note 7 for license commitments.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Intangible assets, net consisted of the following:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024 &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2023 &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Constructs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,529,483&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,529,483&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: accumulated amortization&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(450,635&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(349,463&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total intangible assets, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,078,848&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,180,020&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;Amortization expense amounted to $101,172 for each of the years ended September 30, 2024, and 2023, respectively.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;Total estimated future amortization of intangible assets for each fiscal year is as follows:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Year Ending&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;101,172&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;101,172&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;101,172&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;101,172&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2029&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;101,172&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Thereafter&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;1,572,988&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;2,078,848&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i_2020-04-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember"
      id="c367">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="i_2020-04-30" id="c369">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <edsa:UpfrontLicensePayment
      contextRef="d_2020-04-01_2020-04-30_FiniteLivedIntangibleAssetsByMajorClassAxis-LicensingAgreementsMember"
      decimals="-5"
      id="c370"
      unitRef="USD">2500000</edsa:UpfrontLicensePayment>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c386">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024 &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2023 &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Constructs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,529,483&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,529,483&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: accumulated amortization&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(450,635&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(349,463&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total intangible assets, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,078,848&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,180,020&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2024-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TheConstructsMember"
      decimals="0"
      id="c388"
      unitRef="USD">2529483</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i_2023-09-30_FiniteLivedIntangibleAssetsByMajorClassAxis-TheConstructsMember"
      decimals="0"
      id="c389"
      unitRef="USD">2529483</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2024-09-30"
      decimals="0"
      id="c390"
      unitRef="USD">450635</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i_2023-09-30"
      decimals="0"
      id="c391"
      unitRef="USD">349463</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-09-30"
      decimals="0"
      id="c392"
      unitRef="USD">2078848</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2023-09-30"
      decimals="0"
      id="c393"
      unitRef="USD">2180020</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2023-10-01_2024-09-30"
      decimals="-6"
      id="c377"
      unitRef="USD">101172000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="d_2022-10-01_2023-09-30"
      decimals="-6"
      id="c378"
      unitRef="USD">101172000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c394">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Year Ending&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;101,172&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;101,172&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;101,172&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;101,172&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2029&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;101,172&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Thereafter&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;1,572,988&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;2,078,848&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i_2024-09-30"
      decimals="0"
      id="c396"
      unitRef="USD">101172</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i_2024-09-30"
      decimals="0"
      id="c397"
      unitRef="USD">101172</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i_2024-09-30"
      decimals="0"
      id="c398"
      unitRef="USD">101172</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i_2024-09-30"
      decimals="0"
      id="c399"
      unitRef="USD">101172</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i_2024-09-30"
      decimals="0"
      id="c400"
      unitRef="USD">101172</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i_2024-09-30"
      decimals="0"
      id="c401"
      unitRef="USD">1572988</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i_2024-09-30"
      decimals="0"
      id="c402"
      unitRef="USD">2078848</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="d_2023-10-01_2024-09-30" id="c403">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;6. Right-of-Use Asset and Liabilities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Related party ROU asset and liability&lt;/i&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company leases a facility used for executive offices from a related company. The original lease expired in December 2022 and the Company executed a &lt;span style="-sec-ix-hidden:c405"&gt;two&lt;/span&gt;-year term extension through December 31, 2024.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The components of lease cost were as follows:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Right-of-use lease cost, included in general and administrative on the Statements of Operations&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;78,073&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;82,358&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;









&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;Lease terms and discount rates were as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Remaining lease term (months):&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Estimated incremental borrowing rate:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The approximate future minimum lease payments under operating leases at September 30, 2024 were as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Year Ending&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;20,019&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease payments&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;20,019&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less imputed interest&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;152&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value of right-of-use lease liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;19,867&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value included in current liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;19,867&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value included in long-term liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;Cash flow information was as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years Ended &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash paid for amounts included in the measurement of right-of-use lease liabilities, included in accounts payable and accrued liabilities on the Statements of Cash Flow.&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;77,954&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;79,222&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c420">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Right-of-use lease cost, included in general and administrative on the Statements of Operations&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;78,073&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;82,358&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c422"
      unitRef="USD">78073</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c423"
      unitRef="USD">82358</us-gaap:OperatingLeaseCost>
    <edsa:LeaseTermAndDiscountRateTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c424">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Remaining lease term (months):&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Estimated incremental borrowing rate:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</edsa:LeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="i_2024-09-30" id="c426">P3M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="i_2023-09-30" id="c427">P15M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2024-09-30"
      decimals="3"
      id="c428"
      unitRef="Pure">0.092</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2023-09-30"
      decimals="3"
      id="c429"
      unitRef="Pure">0.092</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c430">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Year Ending&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;20,019&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total lease payments&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;20,019&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less imputed interest&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;152&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value of right-of-use lease liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;19,867&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value included in current liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;19,867&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Present value included in long-term liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2024-09-30"
      decimals="0"
      id="c432"
      unitRef="USD">20019</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2024-09-30"
      decimals="0"
      id="c433"
      unitRef="USD">20019</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2024-09-30"
      decimals="0"
      id="c434"
      unitRef="USD">152</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2024-09-30"
      decimals="0"
      id="c435"
      unitRef="USD">19867</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2024-09-30"
      decimals="0"
      id="c436"
      unitRef="USD">19867</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2024-09-30"
      decimals="0"
      id="c437"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <edsa:LeasesCashFlowInformationTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c438">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years Ended &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash paid for amounts included in the measurement of right-of-use lease liabilities, included in accounts payable and accrued liabilities on the Statements of Cash Flow.&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;77,954&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;79,222&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</edsa:LeasesCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c440"
      unitRef="USD">77954</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c441"
      unitRef="USD">79222</us-gaap:OperatingLeasePayments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2023-10-01_2024-09-30" id="c442">
&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;7. Commitments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Research and other commitments&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has commitments for contracted research organizations who perform clinical trials for the Company&#x2019;s ongoing clinical studies and other service providers. Aggregate future contractual payments at September 30, 2024 are as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Year Ending&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;212,667&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;34,667&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;34,666&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2029&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;282,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;









&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;License and royalty commitments&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In April 2020, through its Ontario subsidiary, the Company entered into a license agreement with a third party to obtain exclusive world-wide rights to certain know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensing rights. An intangible asset for the acquired license has been recognized. See Note 5 for intangible assets. Under the license agreement, the Company is committed to payments of up to an aggregate amount of $356 million contingent upon meeting certain milestones outlined in the license agreement, primarily relating to future potential commercial approval and sales milestones. The Company also has a commitment to pay royalties based on any net sales of products containing the Constructs in the countries where the Company directly commercializes the products containing the Constructs and a percentage of any sublicensing revenue received by the Company and its affiliates in the countries where it does not directly commercialize the products containing the Constructs. &lt;span style="-sec-ix-hidden:c451"&gt;&lt;span style="-sec-ix-hidden:c452"&gt;No&lt;/span&gt;&lt;/span&gt; milestone, royalty or sublicensing payments were made to the third party during the years ended September 30, 2024 and 2023. In connection with this license agreement and pursuant to a purchase agreement entered into in April 2020, the Company acquired drug substance of one of the Constructs for an aggregate purchase price of $5.0 million. &lt;span style="-sec-ix-hidden:c454"&gt;&lt;span style="-sec-ix-hidden:c455"&gt;No&lt;/span&gt;&lt;/span&gt; expense was recorded during the years ended September 30, 2024 and September 30, 2023.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In 2016, through its Ontario subsidiary, the Company entered into a license agreement with a third party to obtain exclusive rights to certain know-how, patents and data relating to a pharmaceutical product. The Company will use the exclusive rights to develop the product for therapeutic, prophylactic and diagnostic uses in topical dermal applications and anorectal applications. &lt;span style="-sec-ix-hidden:c456"&gt;No&lt;/span&gt; intangible assets have been recognized under the license agreement with the third party. Under the license agreement, the Company is committed to payments of various amounts to the third party upon meeting certain milestones outlined in the license agreement, up to an aggregate amount of $18.4 million. Upon divestiture of substantially all of the assets of the Company, the Company shall pay the third party a percentage of the valuation of the licensed technology sold as determined by an external objective expert. The Company also has a commitment to pay the third party a royalty based on net sales of the product in countries where the Company, or an affiliate, directly commercializes the product and a percentage of sublicensing revenue received by the Company and its affiliates in the countries where it does not directly commercialize the product. &lt;span style="-sec-ix-hidden:c458"&gt;&lt;span style="-sec-ix-hidden:c459"&gt;No&lt;/span&gt;&lt;/span&gt; license or royalty payments were made to the third party during the years ended September 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In March 2021, through its Ontario subsidiary, the Company entered into a license agreement with the inventor of the same pharmaceutical product to acquire global rights for all fields of use beyond those named under the 2016 license agreement. For the years ended September 30, 2024 and 2023, the Company recorded expenses of $100,000 and $50,000, respectively, as a result of meeting milestones outlined in the 2021 license agreement. The Company is committed to remaining payments of up to an aggregate amount of $68.9 million, primarily relating to future potential commercial approval and sales milestones. In addition, if the Company fails to file an investigational new drug application or foreign equivalent (IND) for the product within a certain period of time following the date of the agreement, the Company is required to remit to the inventor a fixed license fee quarterly as long as the requirement to file an IND remains unfulfilled.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Retirement savings plan 401(k) contributions&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Executive officers and employees of the California subsidiary are eligible to receive the Company&#x2019;s non-elective safe harbor employer contribution of 3% of eligible compensation under a 401(k) plan to provide retirement benefits. Employees are 100% vested in employer contributions and in any voluntary employee contributions. Contributions to the 401(k) plan were $17,870 and $16,872 during the years ended September 30, 2024 and 2023, respectively.&lt;/p&gt;











&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c467">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Year Ending&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;212,667&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;34,667&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;34,666&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;September 30, 2029&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;282,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="i_2024-09-30"
      decimals="0"
      id="c469"
      unitRef="USD">212667</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="i_2024-09-30"
      decimals="0"
      id="c470"
      unitRef="USD">34667</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="i_2024-09-30"
      decimals="0"
      id="c471"
      unitRef="USD">34666</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="i_2024-09-30"
      decimals="0"
      id="c472"
      unitRef="USD">0</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="i_2024-09-30"
      decimals="0"
      id="c473"
      unitRef="USD">0</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligation
      contextRef="i_2024-09-30"
      decimals="0"
      id="c474"
      unitRef="USD">282000</us-gaap:ContractualObligation>
    <edsa:MaximumContingentObligation
      contextRef="i_2020-04-30_TypeOfArrangementAxis-TheConstructsMember"
      decimals="-6"
      id="c450"
      unitRef="USD">356000000</edsa:MaximumContingentObligation>
    <us-gaap:PurchaseObligation
      contextRef="i_2020-04-30_ProductOrServiceAxis-DrugSubstanceMember_TypeOfArrangementAxis-TheConstructsMember"
      decimals="-6"
      id="c453"
      unitRef="USD">5000000</us-gaap:PurchaseObligation>
    <edsa:MaximumContingentObligation
      contextRef="i_2016-12-31_TypeOfArrangementAxis-LicenseAgreementRelatedToPharmaceuticalProductsMember"
      decimals="-5"
      id="c457"
      unitRef="USD">18400000</edsa:MaximumContingentObligation>
    <edsa:MilestoneExpense
      contextRef="d_2023-10-01_2024-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember"
      decimals="0"
      id="c460"
      unitRef="USD">100000</edsa:MilestoneExpense>
    <edsa:MilestoneExpense
      contextRef="d_2022-10-01_2023-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember"
      decimals="0"
      id="c461"
      unitRef="USD">50000</edsa:MilestoneExpense>
    <edsa:MaximumContingentObligation
      contextRef="i_2024-09-30_TypeOfArrangementAxis-LicenseAgreementToAcquireGlobalRightsOfPharmaceuticalProductMember"
      decimals="-5"
      id="c462"
      unitRef="USD">68900000</edsa:MaximumContingentObligation>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="d_2023-10-01_2024-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember"
      decimals="2"
      id="c463"
      unitRef="Pure">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
      contextRef="d_2023-10-01_2024-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember"
      decimals="0"
      id="c464"
      unitRef="Pure">1</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2023-10-01_2024-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember"
      decimals="0"
      id="c465"
      unitRef="USD">17870</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2022-10-01_2023-09-30_RetirementPlanNameAxis-CaliforniaSubsidiary401kMember"
      decimals="0"
      id="c466"
      unitRef="USD">16872</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2023-10-01_2024-09-30" id="c475">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;8. Capital shares&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Equity offerings&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;On November 2, 2022, the Company completed a private placement of units consisting of 384,475 common shares, Class A warrants to purchase up to an aggregate of 192,248 common shares and Class B warrants to purchase up to an aggregate of 192,248 common shares. Net proceeds from the offering were $2.9 million, which were allocated between the relative fair values of the common shares (using a fair value of $2.7 million) and the common share purchase warrants (using a total fair value of $1.2 million). The warrants became exercisable December 23, 2022. The Class A warrants have an exercise price of $10.50 per share and will expire on December 23, 2025. The Class B warrants have an exercise price of $7.00 per share and expired on December 23, 2023. The warrants are considered contracts on the Company&#x2019;s own shares and are classified as equity.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Equity distribution agreement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;On March 27, 2023, the Company entered into the Canaccord ATM, pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $20.0 million in gross proceeds, subject to certain offering limitations that currently allow the Company to offer and sell common shares having an aggregate gross sales price of up to $8.4 million. The Company has no obligation to sell any of the common shares and may at any time suspend sales or terminate the equity distribution agreement in accordance with its terms. During the year ended September 30, 2024, the Company sold a total of 171,916 common shares pursuant to the agreement for gross proceeds of approximately $0.7 million. During the year ended September 30, 2023, the Company sold a total of 196,401 common shares pursuant to the agreement for gross proceeds of approximately $1.3 million. The Canaccord ATM was terminated on October 3, 2024.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;At The Market Offering Agreement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 14pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;On October 4, 2024, the Company entered into an At The Market Offering Agreement with H.C. Wainwright &amp;amp; Co., LLC as a sales agent (HCW ATM) pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $3.87 million in gross proceeds. The Company has no obligation to sell any of the common shares and may at any time suspend sales or terminate the equity distribution agreement in accordance with its terms. Subsequent to the year ended September 30, 2024, the Company sold a total of 220,269 common shares pursuant to the agreement for net proceeds of approximately $0.6 million after deducting sales agent commissions.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Black-Scholes option valuation model&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company uses the Black-Scholes option valuation model to determine the fair value of share-based compensation for share options and compensation warrants granted and the fair value of warrants issued. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company calculates expected volatility based on historical volatility of the Company&#x2019;s share price. When there is insufficient data available, the Company uses a peer group that is publicly traded to calculate expected volatility. The Company adopted interest-free rates by reference to the U.S. treasury yield rates. The Company calculated the fair value of share options granted based on the expected life of 5 years considering expected forfeitures during the option term of 10 years. Expected life of warrants is based on warrant terms. The Company did not and is &lt;span style="-sec-ix-hidden:c498"&gt;not&lt;/span&gt; expected to declare any dividends. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company&#x2019;s warrants and share options.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;A summary of the Company&#x2019;s warrants activity is as follows:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of Warrant Shares (#)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2022&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;521,718&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;28.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 64%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Issued&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;384,496&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;8.75&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(100,760&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7.65&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(84,545&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;37.29&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;720,909&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;19.51&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(111,192&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;7.26&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;609,717&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;21.74&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;









&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;The weighted average contractual life remaining on the outstanding warrants at September 30, 2024 is 29 months.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;The following table summarizes information about the warrants outstanding at September 30, 2024:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of Warrants (#)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise Prices &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%; border-bottom: 1px solid black;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiry Dates&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;1,687&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22.40&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c667"&gt;January 2025&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;173,614&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10.50&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c670"&gt;December 2025&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;15,627&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;56.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c673"&gt;February 2026&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;27,399&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;31.94&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c676"&gt;March 2027&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;"&gt;391,390&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24.64&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c679"&gt;September 2027&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;609,717&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 18%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 59%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;There were no warrants issued during the year ended September 30, 2024. The fair value of warrants issued during the year ended September 30, 2023 were estimated using the Black-Scholes option valuation model using the following assumptions:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended September 30,2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Class A Warrants&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Class B Warrants&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk free interest rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.54&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life (years)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&#160;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;3.14&lt;/p&gt;

			&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&#160;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;1.14&lt;/p&gt;

			&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected share price volatility&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;90.73&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;89.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected dividend yield&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;









&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Share options&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company adopted an Equity Incentive Compensation Plan in 2019 (the 2019 Plan) administered by the independent members of the Board of Directors, which amended and restated prior plans. Options, restricted shares and restricted share units are eligible for grant under the 2019 Plan. The total number of shares available for issuance under the terms of the 2019 Plan is 642,737. The remaining number of shares available to grant at September 30, 2024 is 141,099.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company&#x2019;s 2019 Plan allows options to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the option term is not to exceed 10 years and the exercise price of each option is determined by the independent members of the Board of Directors.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Options have been granted under the 2019 Plan allowing the holders to purchase common shares of the Company as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of Options (#)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2022&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;314,853&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;32.62&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;23.94&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 50.4%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;118,579&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7.47&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.23&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(12,779&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;22.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16.23&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(38&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;1,973.20&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;1,973.20&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;420,615&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;25.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;18.84&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;500&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4.10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3.10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,401&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;10.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(35,674&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;33.18&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;25&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;383,040&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;24.93&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;18.33&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;There were &lt;span style="-sec-ix-hidden:c568"&gt;&lt;span style="-sec-ix-hidden:c569"&gt;no&lt;/span&gt;&lt;/span&gt; options exercised during the years ended September 30, 2024 or September 30, 2023.&#160;The intrinsic value of options outstanding at September 30, 2024 was $200.00.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;The weighted average contractual life remaining on the outstanding options at September 30, 2024 is&#160;80 months.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;The following table summarizes information about the options under the 2019 Plan outstanding and exercisable at September 30, 2024:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of Options (#) &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercisable at&lt;br/&gt;
			September 30, 2024 (#) &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Range of Exercise Prices &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%; border-bottom: 1px solid black;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiry Dates&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;374&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;374&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;246.96&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c725"&gt;March 2025&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;37,719&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;37,719&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;C$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15.12&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c729"&gt;August 2027&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c730"&gt;Dec 2028&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;43,031&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;43,031&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22.12&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c734"&gt;Feb 2030&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;51,006&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;51,006&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52.08 - 56.49&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c739"&gt;September 2030&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c740"&gt;Oct 2030&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;81,041&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;81,013&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;36.75 - 40.18&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c745"&gt;March 2025&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c746"&gt;Sep 2031&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;58,753&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;52,957&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25.97&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c750"&gt;March 2025&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c751"&gt;Feb 2032&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black; text-align: right;"&gt;111,116&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"&gt;62,288&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.10 - 10.01&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c756"&gt;March 2025&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c757"&gt;Oct 2033&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;383,040&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;328,388&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 23%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 23%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The options exercisable at September 30, 2024 had a weighted average exercise price of $27.55 and an intrinsic value of $66.00 and a weighted average remaining life of 76 months. There were 54,652 options at September 30, 2024 that had not vested with a weighted average exercise price of $9.24 and an intrinsic value of $134.00 and a weighted average remaining life of 102 months.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The fair value of options granted during the years ended September 30, 2024 and 2023 was estimated using the Black-Scholes option valuation model using the following assumptions:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk free interest rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.92&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.62% - 4.18&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life (years)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&#160;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;5&lt;/p&gt;

			&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&#160;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;5&lt;/p&gt;

			&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected share price volatility&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;97.26&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;95.3% - 97.34&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected dividend yield&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;









&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company recorded $0.5 million and $1.2 million of share-based compensation expenses for the years ended September 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;As of September 30, 2024, the Company had approximately $0.1 million of unrecognized share-based compensation expense, which is expected to be recognized over a period of 24 months.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Restricted share units&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company's 2019 Plan allows restricted share units (RSUs) to be granted to directors, officers, employees and certain external consultants and advisers. Under the 2019 Plan, the RSU term is not to exceed 10 years. The fair value is based on the 5-day VWAP of the Company's common shares up to the date of grant.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The following is a summary of changes in the status of RSUs from October 1, 2022 through September 30, 2024:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of RSU (#)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2022&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 65.6%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;46,602&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Converted to common shares&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(13,557&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;5.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;33,045&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;5.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;30,159&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;4.56&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;63,204&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;5.10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;The following table summarizes information about the RSUs under the 2019 Plan outstanding and exercisable at September 30, 2024:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 60%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of RSU (#) &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiry Date&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 60%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fully-vested RSUs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;63,204&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;August 2033 - September 2034&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The RSUs that were granted in the current year was for compensation to the Company&#x2019;s Chief Executive Officer who is receiving 50% of his salary in RSUs. In the comparative period, RSUs were granted in lieu of cash bonuses for certain employees and in lieu of payments on consulting invoices for services prior to the appointment of the new Chief Financial Officer. All RSUs that were granted vested immediately upon the grant date. The outstanding RSUs can be converted to common shares by the holder at any time prior to the expiry date.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;There is &lt;span style="-sec-ix-hidden:c646"&gt;no&lt;/span&gt; future unrecorded compensation expense for the RSUs.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-11-02_2022-11-02_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c477"
      unitRef="Share">384475</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassAWarrantsMember"
      decimals="INF"
      id="c478"
      unitRef="Share">192248</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassBWarrantsMember"
      decimals="INF"
      id="c479"
      unitRef="Share">192248</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2022-11-02_2022-11-02_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c480"
      unitRef="USD">2900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-11-02_2022-11-02_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c481"
      unitRef="USD">2700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember"
      decimals="-5"
      id="c482"
      unitRef="USD">1200000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassAWarrantsMember"
      decimals="INF"
      id="c483"
      unitRef="USDPerShare">10.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassAWarrantsMember"
      id="c484">2025-12-23</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassBWarrantsMember"
      decimals="INF"
      id="c485"
      unitRef="USDPerShare">7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="i_2022-11-02_ClassOfWarrantOrRightAxis-ClassBWarrantsMember"
      id="c486">2023-12-23</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <edsa:EquityOfferingMaximumAmount
      contextRef="i_2023-03-27_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember"
      decimals="-7"
      id="c487"
      unitRef="USD">20000000</edsa:EquityOfferingMaximumAmount>
    <edsa:EquityOfferingLimitationAmount
      contextRef="i_2023-03-27_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember"
      decimals="-5"
      id="c488"
      unitRef="USD">8400000</edsa:EquityOfferingLimitationAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2023-10-01_2024-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember"
      decimals="INF"
      id="c489"
      unitRef="Share">171916</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2023-10-01_2024-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember"
      decimals="-5"
      id="c490"
      unitRef="USD">700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-10-01_2023-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember"
      decimals="INF"
      id="c491"
      unitRef="Share">196401</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2022-10-01_2023-09-30_CounterpartyNameAxis-CanaccordMember_SubsidiarySaleOfStockAxis-EquityDistributionAgreementMember"
      decimals="-5"
      id="c492"
      unitRef="USD">1300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <edsa:EquityOfferingMaximumAmount
      contextRef="i_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember"
      decimals="-4"
      id="c493"
      unitRef="USD">3870000</edsa:EquityOfferingMaximumAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-10-01_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember"
      decimals="INF"
      id="c494"
      unitRef="Share">220269</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-10-01_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember"
      decimals="-5"
      id="c495"
      unitRef="USD">600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c496">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c497">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="d_2023-10-01_2024-09-30"
      id="c7C4025B2-7ACE-4B79-8DAB-5A47A66C42F6">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of Warrant Shares (#)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2022&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;521,718&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;28.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 64%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Issued&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;384,496&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;8.75&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Exercised&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(100,760&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7.65&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(84,545&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;37.29&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;720,909&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;19.51&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(111,192&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;7.26&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;609,717&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;21.74&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of Warrants (#)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercise Prices &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%; border-bottom: 1px solid black;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiry Dates&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;1,687&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22.40&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c667"&gt;January 2025&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;173,614&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10.50&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c670"&gt;December 2025&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;15,627&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;56.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c673"&gt;February 2026&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;27,399&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;31.94&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c676"&gt;March 2027&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; border-bottom: 1px solid black;"&gt;391,390&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;24.64&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 59%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c679"&gt;September 2027&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;609,717&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 18%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 59%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c649"
      unitRef="Share">521718</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c650"
      unitRef="USDPerShare">28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <edsa:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c651"
      unitRef="Share">384496</edsa:ClassOfWarrantOrRightIssuedDuringPeriod>
    <edsa:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c652"
      unitRef="USDPerShare">8.75</edsa:ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice>
    <edsa:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c653"
      unitRef="Share">100760</edsa:ClassOfWarrantOrRightExercisedDuringPeriod>
    <edsa:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c654"
      unitRef="USDPerShare">7.65</edsa:ClassOfWarrantOrRightExercisedDuringPeriodExercisePrice>
    <edsa:ClassOfWarrantOrRightExpiredDuringPeriod
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c655"
      unitRef="Share">-84545</edsa:ClassOfWarrantOrRightExpiredDuringPeriod>
    <edsa:ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c656"
      unitRef="USDPerShare">37.29</edsa:ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c657"
      unitRef="Share">720909</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c658"
      unitRef="USDPerShare">19.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <edsa:ClassOfWarrantOrRightExpiredDuringPeriod
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c659"
      unitRef="Share">111192</edsa:ClassOfWarrantOrRightExpiredDuringPeriod>
    <edsa:ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c660"
      unitRef="USDPerShare">7.26</edsa:ClassOfWarrantOrRightExpiredDuringPeriodExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c661"
      unitRef="Share">609717</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c662"
      unitRef="USDPerShare">21.74</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <edsa:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm contextRef="d_2023-10-01_2024-09-30" id="c513">P29M</edsa:ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantOneMember"
      decimals="INF"
      id="c665"
      unitRef="Share">1687</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantOneMember"
      decimals="INF"
      id="c666"
      unitRef="USDPerShare">22.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantTwoMember"
      decimals="INF"
      id="c668"
      unitRef="Share">173614</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantTwoMember"
      decimals="INF"
      id="c669"
      unitRef="USDPerShare">10.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantThreeMember"
      decimals="INF"
      id="c671"
      unitRef="Share">15627</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantThreeMember"
      decimals="INF"
      id="c672"
      unitRef="USDPerShare">56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFourMember"
      decimals="INF"
      id="c674"
      unitRef="Share">27399</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFourMember"
      decimals="INF"
      id="c675"
      unitRef="USDPerShare">31.94</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFiveMember"
      decimals="INF"
      id="c677"
      unitRef="Share">391390</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-WarrantFiveMember"
      decimals="INF"
      id="c678"
      unitRef="USDPerShare">24.64</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c680"
      unitRef="Share">609717</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c681">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended September 30,2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Class A Warrants&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Class B Warrants&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk free interest rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.54&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life (years)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&#160;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;3.14&lt;/p&gt;

			&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&#160;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;1.14&lt;/p&gt;

			&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected share price volatility&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;90.73&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;89.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected dividend yield&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c683"
      unitRef="Pure">0.0454</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c684"
      unitRef="Pure">0.0476</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c685"
      unitRef="Pure">3.14</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c686"
      unitRef="Pure">1.14</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="4"
      id="c687"
      unitRef="Pure">0.9073</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="c688"
      unitRef="Pure">0.897</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassAWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c689"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2024-09-30_ClassOfWarrantOrRightAxis-ClassBWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c690"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2024-09-30_PlanNameAxis-The2019PlanMember"
      decimals="INF"
      id="c538"
      unitRef="Share">642737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2024-09-30_PlanNameAxis-The2019PlanMember"
      decimals="INF"
      id="c539"
      unitRef="Share">141099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2024-09-30_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2019PlanMember"
      id="c540">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c691">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of Options (#)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2022&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;314,853&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;32.62&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;23.94&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 50.4%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;118,579&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7.47&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.23&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(12,779&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;22.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16.23&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(38&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;1,973.20&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;1,973.20&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;420,615&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;25.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;18.84&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;500&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4.10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3.10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,401&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;10.70&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(35,674&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;33.18&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;25&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;383,040&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;24.93&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;18.33&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c693"
      unitRef="Share">314853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c694"
      unitRef="USDPerShare">32.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue
      contextRef="i_2022-09-30"
      decimals="INF"
      id="c695"
      unitRef="USDPerShare">23.94</edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c696"
      unitRef="Share">118579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c697"
      unitRef="USDPerShare">7.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c698"
      unitRef="USDPerShare">5.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c699"
      unitRef="Share">12779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c700"
      unitRef="USDPerShare">22.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c701"
      unitRef="USDPerShare">16.23</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c702"
      unitRef="Share">38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c703"
      unitRef="USDPerShare">1973.2</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue
      contextRef="d_2022-10-01_2023-09-30"
      decimals="INF"
      id="c704"
      unitRef="USDPerShare">1973.2</edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c705"
      unitRef="Share">420615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c706"
      unitRef="USDPerShare">25.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c707"
      unitRef="USDPerShare">18.84</edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c708"
      unitRef="Share">500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c709"
      unitRef="USDPerShare">4.1</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c710"
      unitRef="USDPerShare">3.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c711"
      unitRef="Share">2401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c712"
      unitRef="USDPerShare">15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c713"
      unitRef="USDPerShare">10.7</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c714"
      unitRef="Share">35674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c715"
      unitRef="USDPerShare">33.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c716"
      unitRef="USDPerShare">25</edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c717"
      unitRef="Share">383040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c718"
      unitRef="USDPerShare">24.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c719"
      unitRef="USDPerShare">18.33</edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2024-09-30"
      decimals="0"
      id="c570"
      unitRef="USD">200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2023-10-01_2024-09-30" id="c571">P80M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="d_2023-10-01_2024-09-30" id="c720">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td colspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of Options (#) &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Exercisable at&lt;br/&gt;
			September 30, 2024 (#) &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Range of Exercise Prices &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%; border-bottom: 1px solid black;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiry Dates&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;374&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;374&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;246.96&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c725"&gt;March 2025&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;37,719&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;37,719&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;C$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;15.12&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c729"&gt;August 2027&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c730"&gt;Dec 2028&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;43,031&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;43,031&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22.12&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c734"&gt;Feb 2030&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;51,006&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;51,006&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;52.08 - 56.49&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c739"&gt;September 2030&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c740"&gt;Oct 2030&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;81,041&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;81,013&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;36.75 - 40.18&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c745"&gt;March 2025&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c746"&gt;Sep 2031&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;58,753&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;52,957&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;25.97&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c750"&gt;March 2025&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c751"&gt;Feb 2032&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black; text-align: right;"&gt;111,116&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;"&gt;62,288&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 23%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.10 - 10.01&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 23%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c756"&gt;March 2025&lt;/span&gt; - &lt;span style="-sec-ix-hidden:c757"&gt;Oct 2033&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;383,040&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 23%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;328,388&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 23%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 23%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c722"
      unitRef="Share">374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c723"
      unitRef="Share">374</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeOneMember"
      decimals="INF"
      id="c724"
      unitRef="USDPerShare">246.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c726"
      unitRef="Share">37719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c727"
      unitRef="Share">37719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeTwoMember"
      decimals="INF"
      id="c728"
      unitRef="USDPerShare">15.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c731"
      unitRef="Share">43031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c732"
      unitRef="Share">43031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeThreeMember"
      decimals="INF"
      id="c733"
      unitRef="USDPerShare">22.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c735"
      unitRef="Share">51006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c736"
      unitRef="Share">51006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c737"
      unitRef="USDPerShare">52.08</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFourMember"
      decimals="INF"
      id="c738"
      unitRef="USDPerShare">56.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c741"
      unitRef="Share">81041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c742"
      unitRef="Share">81013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c743"
      unitRef="USDPerShare">36.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeFiveMember"
      decimals="INF"
      id="c744"
      unitRef="USDPerShare">40.18</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember"
      decimals="INF"
      id="c747"
      unitRef="Share">58753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember"
      decimals="INF"
      id="c748"
      unitRef="Share">52957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSixMember"
      decimals="INF"
      id="c749"
      unitRef="USDPerShare">25.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember"
      decimals="INF"
      id="c752"
      unitRef="Share">111116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember"
      decimals="INF"
      id="c753"
      unitRef="Share">62288</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember"
      decimals="INF"
      id="c754"
      unitRef="USDPerShare">4.1</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2023-10-01_2024-09-30_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-RangeSevenMember"
      decimals="INF"
      id="c755"
      unitRef="USDPerShare">10.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c758"
      unitRef="Share">383040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c759"
      unitRef="Share">328388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c610"
      unitRef="USDPerShare">27.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c611"
      unitRef="USDPerShare">66</edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValuePerShare>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2023-10-01_2024-09-30" id="c612">P76M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c613"
      unitRef="Share">54652</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c614"
      unitRef="USDPerShare">9.24</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c615"
      unitRef="USDPerShare">134</edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValuePerShare>
    <edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm contextRef="d_2023-10-01_2024-09-30" id="c616">P102M</edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c760">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk free interest rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.92&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.62% - 4.18&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected life (years)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&#160;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;5&lt;/p&gt;

			&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;&#160;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;5&lt;/p&gt;

			&lt;p style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt;"&gt;&#160;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected share price volatility&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;97.26&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;95.3% - 97.34&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected dividend yield&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0.00&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2023-10-01_2024-09-30"
      decimals="4"
      id="c762"
      unitRef="Pure">0.0492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="d_2023-10-01_2024-09-30"
      decimals="4"
      id="c763"
      unitRef="Pure">0.0362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="d_2023-10-01_2024-09-30"
      decimals="4"
      id="c764"
      unitRef="Pure">0.0418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c765">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      id="c766">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2023-10-01_2024-09-30"
      decimals="4"
      id="c767"
      unitRef="Pure">0.9726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="d_2023-10-01_2024-09-30"
      decimals="3"
      id="c768"
      unitRef="Pure">0.953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="d_2023-10-01_2024-09-30"
      decimals="4"
      id="c769"
      unitRef="Pure">0.9734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c770"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c771"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2023-10-01_2024-09-30"
      decimals="-5"
      id="c627"
      unitRef="USD">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2022-10-01_2023-09-30"
      decimals="-5"
      id="c628"
      unitRef="USD">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2024-09-30"
      decimals="-5"
      id="c629"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2023-10-01_2024-09-30" id="c630">P24M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2023-10-01_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      id="c631">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c772">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of RSU (#)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted Average Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2022&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 65.6%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;46,602&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Converted to common shares&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(13,557&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;5.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;33,045&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;5.60&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;30,159&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;4.56&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Balance - September 30, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;63,204&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;5.10&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2022-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c774"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2022-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c775"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c776"
      unitRef="Share">46602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c777"
      unitRef="USDPerShare">5.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c778"
      unitRef="Share">13557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2022-10-01_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c779"
      unitRef="USDPerShare">5.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c780"
      unitRef="Share">33045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2023-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c781"
      unitRef="USDPerShare">5.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c782"
      unitRef="Share">30159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2023-10-01_2024-09-30"
      decimals="INF"
      id="c783"
      unitRef="USDPerShare">4.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c784"
      unitRef="Share">63204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2024-09-30"
      decimals="INF"
      id="c785"
      unitRef="USDPerShare">5.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c786">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 60%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of RSU (#) &lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%; border-bottom: 1px solid black;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiry Date&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 60%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Fully-vested RSUs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;63,204&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 18%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;"&gt;August 2033 - September 2034&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock>
    <edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
      contextRef="i_2024-09-30_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c788"
      unitRef="Share">63204</edsa:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber>
    <us-gaap:GovernmentAssistanceTextBlock contextRef="d_2023-10-01_2024-09-30" id="c789">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;9. Government Contributions&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;SIF&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Reimbursement grant income for the Company&#x2019;s federal grant with the Canadian government&#x2019;s SIF is recorded based on the claim period of eligible costs.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;











&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In October 2023, the Company entered into the 2023 SIF Agreement with the Canadian Government. Under the 2023 SIF Agreement, the Government of Canada committed up to C$23 million in partially repayable funding toward (i) conducting and completing the Company&#x2019;s Phase 3 clinical study of its experimental drug EB05 in critical-care patients with Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 or other infectious agents, (ii) submitting EB05 for governmental approvals and manufacturing scale-up, following, and subject to, completing the Phase 3 study and (iii) conducting two non-clinical safety studies to assess the potential long-term impact of EB05 exposure (the Project). Of the C$23 million committed by SIF, up to C$5.8 million is not repayable by the Company. The remaining C$17.2 million is conditionally repayable starting in 2029 only if and when the Company earns gross revenue. The repayable portion would be payable over fifteen (15) years based on a percentage rate of the Company&#x2019;s annual revenue growth. The maximum amount repayable under the Agreement is 1.4 times the original repayable amount. In addition, the Company is entitled to partial reimbursement of certain eligible expenses under the Agreement.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Under the Agreement, the Company agreed to certain financial and non-financial covenants and other obligations in relation to the Project. Pursuant to the Agreement, certain customary events of default, such as the Company&#x2019;s or Edesa Biotech Research&#x2019;s breach of their covenants and obligations under the Agreement, their insolvency, winding up or dissolution, and other similar events, may permit the Government of Canada to declare an event of default under the Agreement. Upon an event of default, subject to applicable cure, the Government of Canada may exercise a number of remedies, including suspending or terminating funding under the Agreement, demanding repayment of funding previously received and/or terminating the Agreement.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The funding and any associated conditional repayments are not secured by any assets of Edesa Biotech Research or the Company.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Agreement will expire on the later of December 31, 2042 or the date of the last repayment, unless earlier terminated, subject to certain provisions that extend three (3) years beyond the term or early termination of the Agreement.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Under the October 2023 SIF Agreement the Company recorded grant income of $0.7 million and $0.6 million for the years ended September 30, 2024 and September 30, 2023, respectively.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Canada Emergency Business Account&lt;/i&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt;"&gt;During year ended September 30, 2024, the Company recognized a $20,000 Canadian dollar gain from loan forgiveness related to its Canada Emergency Business Account (CEBA) loan. This forgiveness was granted upon successful repayment of $40,000 Canadian dollar of the loan balance, in accordance with CEBA program terms. The forgiven amount is recorded as other income in the consolidated statements of operations. The CEBA loan has been fully repaid and closed with CIBC.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:GovernmentAssistanceTextBlock>
    <us-gaap:GovernmentAssistanceAwardAmount
      contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-6"
      id="c791"
      unitRef="CAD">23000000</us-gaap:GovernmentAssistanceAwardAmount>
    <us-gaap:GovernmentAssistanceAwardAmount
      contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-6"
      id="c792"
      unitRef="CAD">23000000</us-gaap:GovernmentAssistanceAwardAmount>
    <edsa:GovernmentAssistanceAwardAmountNotRepayable
      contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-5"
      id="c793"
      unitRef="CAD">5800000</edsa:GovernmentAssistanceAwardAmountNotRepayable>
    <edsa:GovernmentAssistanceAwardAmountRepayable
      contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-5"
      id="c794"
      unitRef="CAD">17200000</edsa:GovernmentAssistanceAwardAmountRepayable>
    <edsa:GovernmentAssistancePeriodOfRepayment
      contextRef="d_2023-10-01_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      id="c795">P15Y</edsa:GovernmentAssistancePeriodOfRepayment>
    <edsa:GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal
      contextRef="i_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="INF"
      id="c796"
      unitRef="Pure">1.4</edsa:GovernmentAssistanceMaximumAmountRepayableFactorOfOriginal>
    <edsa:GovernmentAssistanceExpirationPeriodAfterLastRepayment
      contextRef="d_2023-10-01_2023-10-31_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      id="c797">P3Y</edsa:GovernmentAssistanceExpirationPeriodAfterLastRepayment>
    <us-gaap:GovernmentAssistanceNonoperatingIncome
      contextRef="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-5"
      id="c798"
      unitRef="USD">700000</us-gaap:GovernmentAssistanceNonoperatingIncome>
    <us-gaap:GovernmentAssistanceNonoperatingIncome
      contextRef="d_2022-10-01_2023-09-30_GovernmentAssistanceTypeAxis-The2023SIFAgreementMember"
      decimals="-5"
      id="c799"
      unitRef="USD">600000</us-gaap:GovernmentAssistanceNonoperatingIncome>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-CanadaEmergencyBusinessAccountProgramMember_LineOfCreditFacilityAxis-CIBCMember"
      decimals="0"
      id="c800"
      unitRef="CAD">20000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="d_2023-10-01_2024-09-30_GovernmentAssistanceTypeAxis-CanadaEmergencyBusinessAccountProgramMember_LineOfCreditFacilityAxis-CIBCMember"
      decimals="0"
      id="c801"
      unitRef="CAD">40000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2023-10-01_2024-09-30" id="c802">
&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;10. Income Tax&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;The reconciliation of the combined Canadian federal and provincial statutory income tax rate to the approximate effective tax rate is as follows:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;
			2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;
			2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss before recovery of income taxes&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(6,169,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(8,374,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Canadian federal and provincial statutory income tax rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;26.5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;26.5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected income tax recovery&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(1,635,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,219,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Effect of foreign currency and foreign tax rate differences&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(58,200&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(207,200&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Permanent differences&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;147,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;339,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share issuance cost booked through equity or capitalization&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;36,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(89,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-capital losses limitation - U.S.&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;899,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(38,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(94,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,549,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,372,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Income tax (recovery) expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;800&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;800&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;











&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;Components of the net deferred tax asset or liability&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Deferred taxes are provided as a result of temporary differences that arise due to the difference between the income tax values and the carrying amount of assets and liabilities. Approximate deferred tax assets and liabilities are as follows:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;
			2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;
			2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-capital losses carried forward - Canada&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,547,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;13,943,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-capital losses carried forward - U.S.&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;742,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;731,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development tax credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,504,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,371,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share issuance and financing costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;381,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;585,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Right-of-use lease liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;25,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other temporary differences&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;21,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;44,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Subtotal&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,200,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16,699,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(18,074,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(16,466,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total net deferred tax assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;126,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;233,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(3,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Right-of-use assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(5,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(24,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Grant Income receivable&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(71,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(153,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred share issuance costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(48,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(53,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(126,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(233,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred taxes&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Realization of the deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. It is more likely than not that a tax benefit will not be realized. Accordingly, net deferred tax assets have been fully offset by a valuation allowance.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Non-capital losses, capital losses, and research and development credits generated by Edesa Biotech USA, Inc. prior to changes in share ownership that occurred as a result of the reverse acquisition are substantially limited. It is unlikely that tax losses totaling $32.7&#160;million and credits totaling $0.6 million will be utilized to offset potential future taxable income before expiration and they are excluded from deferred tax assets above.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;











&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The approximate Canadian non-capital losses carried forward at September 30, 2024 expire as follows:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;C$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;41,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;84,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;171,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2029&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;507,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2030&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;633,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2031&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;504,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2032&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;496,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2033&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;79,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2034&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,432,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2035&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,628,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2036&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,637,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2037&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,564,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2038&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,580,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2039&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,279,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2040&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,904,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2041&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;9,366,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2042&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16,191,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2043&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7,890,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2044&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,260,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;C$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;58,262,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Share issuance and financing costs will be fully amortized in 2027.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The U.S. non-capital losses carried forward at September 30, 2024 totaled approximately $3.42&#160;million, which do not expire for federal taxes. The U.S. state research and development tax credits carried forward at September 30, 2024 totaled approximately $0.6 million, which do not expire for state taxes. The approximate U.S. state non-capital losses carried forward at September 30, 2024 expire as follows:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2039&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;70,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2040&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;150,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2041&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;68,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2042&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2044&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;41,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;335,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c885">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Years Ended&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;
			2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;
			2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss before recovery of income taxes&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(6,169,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(8,374,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Canadian federal and provincial statutory income tax rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;26.5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;26.5&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected income tax recovery&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(1,635,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,219,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Effect of foreign currency and foreign tax rate differences&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(58,200&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(207,200&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Permanent differences&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;147,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;339,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share issuance cost booked through equity or capitalization&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;36,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(89,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-capital losses limitation - U.S.&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;899,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(38,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(94,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,549,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,372,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Income tax (recovery) expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;800&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;800&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <edsa:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c887"
      unitRef="USD">-6169000</edsa:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests>
    <edsa:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c888"
      unitRef="USD">-8374000</edsa:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterests>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-10-01_2024-09-30"
      decimals="3"
      id="c889"
      unitRef="Pure">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2022-10-01_2023-09-30"
      decimals="3"
      id="c890"
      unitRef="Pure">0.265</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c891"
      unitRef="USD">-1635000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c892"
      unitRef="USD">-2219000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c893"
      unitRef="USD">-58200</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c894"
      unitRef="USD">-207200</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c895"
      unitRef="USD">147000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c896"
      unitRef="USD">339000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <edsa:EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c897"
      unitRef="USD">36000</edsa:EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization>
    <edsa:EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c898"
      unitRef="USD">-89000</edsa:EffectiveIncomeTaxReconciliationShareIssuanceCostBookedThroughEquityOrCapitalization>
    <edsa:EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation
      contextRef="d_2023-10-01_2024-09-30"
      decimals="-3"
      id="c899"
      unitRef="USD">0</edsa:EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation>
    <edsa:EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c900"
      unitRef="USD">899000</edsa:EffectiveIncomeTaxReconciliationNoncapitalLossesLimitation>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c901"
      unitRef="USD">-38000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c902"
      unitRef="USD">-94000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c903"
      unitRef="USD">1549000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c904"
      unitRef="USD">1372000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2023-10-01_2024-09-30"
      decimals="0"
      id="c905"
      unitRef="USD">800</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2022-10-01_2023-09-30"
      decimals="0"
      id="c906"
      unitRef="USD">800</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2023-10-01_2024-09-30" id="c907">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;
			2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;September 30,&lt;br/&gt;
			2023&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-capital losses carried forward - Canada&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,547,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;13,943,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Non-capital losses carried forward - U.S.&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;742,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;731,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development tax credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,504,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,371,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share issuance and financing costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;381,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;585,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Right-of-use lease liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;25,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other temporary differences&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;21,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;44,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Subtotal&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,200,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16,699,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less: valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(18,074,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(16,466,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total net deferred tax assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;126,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;233,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Property and equipment&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(3,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Right-of-use assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(5,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(24,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Grant Income receivable&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(71,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(153,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred share issuance costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(48,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(53,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(126,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;)&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(233,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net deferred taxes&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i_2024-09-30_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember"
      decimals="0"
      id="c909"
      unitRef="USD">15547000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i_2023-09-30_IncomeTaxAuthorityNameAxis-CanadaRevenueAgencyMember"
      decimals="0"
      id="c910"
      unitRef="USD">13943000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i_2024-09-30_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"
      decimals="0"
      id="c911"
      unitRef="USD">742000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i_2023-09-30_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"
      decimals="0"
      id="c912"
      unitRef="USD">731000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2024-09-30"
      decimals="0"
      id="c913"
      unitRef="USD">1504000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2023-09-30"
      decimals="0"
      id="c914"
      unitRef="USD">1371000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <edsa:DeferredTaxAssetsShareIssuanceAndFinancingCosts
      contextRef="i_2024-09-30"
      decimals="0"
      id="c915"
      unitRef="USD">381000</edsa:DeferredTaxAssetsShareIssuanceAndFinancingCosts>
    <edsa:DeferredTaxAssetsShareIssuanceAndFinancingCosts
      contextRef="i_2023-09-30"
      decimals="0"
      id="c916"
      unitRef="USD">585000</edsa:DeferredTaxAssetsShareIssuanceAndFinancingCosts>
    <edsa:DeferredTaxAssetsRightofuseLeaseLiabilities
      contextRef="i_2024-09-30"
      decimals="0"
      id="c917"
      unitRef="USD">5000</edsa:DeferredTaxAssetsRightofuseLeaseLiabilities>
    <edsa:DeferredTaxAssetsRightofuseLeaseLiabilities
      contextRef="i_2023-09-30"
      decimals="0"
      id="c918"
      unitRef="USD">25000</edsa:DeferredTaxAssetsRightofuseLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2024-09-30"
      decimals="0"
      id="c919"
      unitRef="USD">21000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2023-09-30"
      decimals="0"
      id="c920"
      unitRef="USD">44000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2024-09-30"
      decimals="0"
      id="c921"
      unitRef="USD">18200000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2023-09-30"
      decimals="0"
      id="c922"
      unitRef="USD">16699000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2024-09-30"
      decimals="0"
      id="c923"
      unitRef="USD">18074000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2023-09-30"
      decimals="0"
      id="c924"
      unitRef="USD">16466000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2024-09-30"
      decimals="0"
      id="c925"
      unitRef="USD">126000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2023-09-30"
      decimals="0"
      id="c926"
      unitRef="USD">233000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2024-09-30"
      decimals="0"
      id="c927"
      unitRef="USD">2000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2023-09-30"
      decimals="0"
      id="c928"
      unitRef="USD">3000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2024-09-30"
      decimals="0"
      id="c929"
      unitRef="USD">5000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i_2023-09-30"
      decimals="0"
      id="c930"
      unitRef="USD">24000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <edsa:DeferredTaxLiabilitiesGrantIncomeReceivable
      contextRef="i_2024-09-30"
      decimals="0"
      id="c931"
      unitRef="USD">71000</edsa:DeferredTaxLiabilitiesGrantIncomeReceivable>
    <edsa:DeferredTaxLiabilitiesGrantIncomeReceivable
      contextRef="i_2023-09-30"
      decimals="0"
      id="c932"
      unitRef="USD">153000</edsa:DeferredTaxLiabilitiesGrantIncomeReceivable>
    <edsa:DeferredTaxLiabilitiesDeferredShareIssuanceCosts
      contextRef="i_2024-09-30"
      decimals="0"
      id="c933"
      unitRef="USD">48000</edsa:DeferredTaxLiabilitiesDeferredShareIssuanceCosts>
    <edsa:DeferredTaxLiabilitiesDeferredShareIssuanceCosts
      contextRef="i_2023-09-30"
      decimals="0"
      id="c934"
      unitRef="USD">53000</edsa:DeferredTaxLiabilitiesDeferredShareIssuanceCosts>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i_2024-09-30"
      decimals="0"
      id="c935"
      unitRef="USD">126000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i_2023-09-30"
      decimals="0"
      id="c936"
      unitRef="USD">233000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2024-09-30"
      decimals="0"
      id="c937"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2023-09-30"
      decimals="0"
      id="c938"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i_2024-09-30"
      decimals="-5"
      id="c854"
      unitRef="USD">32700000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="i_2024-09-30"
      decimals="-5"
      id="c855"
      unitRef="USD">600000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="d_2023-10-01_2024-09-30"
      id="c537D2A42-9AA7-49F8-96D7-689351A148B1">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;C$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2026&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;41,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2027&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;84,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2028&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;171,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2029&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;507,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2030&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;633,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2031&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;504,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2032&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;496,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2033&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;79,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2034&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,432,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2035&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,628,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2036&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,637,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2037&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,564,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2038&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,580,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2039&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,279,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2040&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,904,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2041&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;9,366,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2042&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16,191,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2043&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;7,890,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2044&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,260,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;C$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;58,262,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2039&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;70,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2040&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;150,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2041&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;68,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2042&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;2044&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;41,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;335,000&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2025Member"
      decimals="0"
      id="c941"
      unitRef="CAD">16000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2026Member"
      decimals="0"
      id="c942"
      unitRef="CAD">41000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2027Member"
      decimals="0"
      id="c943"
      unitRef="CAD">84000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2028Member"
      decimals="0"
      id="c944"
      unitRef="CAD">171000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2029Member"
      decimals="0"
      id="c945"
      unitRef="CAD">507000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2030Member"
      decimals="0"
      id="c946"
      unitRef="CAD">633000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2031Member"
      decimals="0"
      id="c947"
      unitRef="CAD">504000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2032Member"
      decimals="0"
      id="c948"
      unitRef="CAD">496000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2033Member"
      decimals="0"
      id="c949"
      unitRef="CAD">79000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2034Member"
      decimals="0"
      id="c950"
      unitRef="CAD">1432000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2035Member"
      decimals="0"
      id="c951"
      unitRef="CAD">1628000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2036Member"
      decimals="0"
      id="c952"
      unitRef="CAD">1637000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2037Member"
      decimals="0"
      id="c953"
      unitRef="CAD">1564000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2038Member"
      decimals="0"
      id="c954"
      unitRef="CAD">2580000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2039Member"
      decimals="0"
      id="c955"
      unitRef="CAD">1279000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2040Member"
      decimals="0"
      id="c956"
      unitRef="CAD">5904000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2041Member"
      decimals="0"
      id="c957"
      unitRef="CAD">9366000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2042Member"
      decimals="0"
      id="c958"
      unitRef="CAD">16191000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2043Member"
      decimals="0"
      id="c959"
      unitRef="CAD">7890000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYear2044Member"
      decimals="0"
      id="c960"
      unitRef="CAD">6260000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="0"
      id="c961"
      unitRef="CAD">58262000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_IncomeTaxAuthorityNameAxis-InternalRevenueServiceIRSMember"
      decimals="-4"
      id="c877"
      unitRef="USD">3420000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-5"
      id="c878"
      unitRef="USD">600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2039Member"
      decimals="0"
      id="c964"
      unitRef="USD">70000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2040Member"
      decimals="0"
      id="c965"
      unitRef="USD">150000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2041Member"
      decimals="0"
      id="c966"
      unitRef="USD">68000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2042Member"
      decimals="0"
      id="c967"
      unitRef="USD">6000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember_TaxPeriodAxis-TaxYear2044Member"
      decimals="0"
      id="c968"
      unitRef="USD">41000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2024-09-30_IncomeTaxAuthorityAxis-ForeignCountryMember"
      decimals="0"
      id="c969"
      unitRef="USD">335000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="d_2023-10-01_2024-09-30" id="c970">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;11. Financial instruments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;(a) Fair values&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;div&gt;&#160;&lt;/div&gt;









&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;There are three levels of inputs that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt; text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt; text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 27pt; text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;Level 3 - Unobservable inputs for the asset or liability that are supported by little or no market activity.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The carrying value of certain financial instruments such as cash and cash equivalents, accounts and other receivable, accounts payable and accrued liabilities approximates fair value due to the short-term nature of such instruments.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;(b) Interest rate and credit risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in interest rates. The Company does not believe that the results of operations or cash flows would be affected to any significant degree by a significant change in market interest rates, relative to interest rates on cash and cash equivalents due to the short-term nature of these balances.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company is also exposed to credit risk at year end from the carrying value of its cash and cash equivalents and accounts and other receivable. The Company manages this risk by maintaining bank accounts with Canadian Chartered Banks, U.S. banks believed to be credit worthy and money market mutual funds of U.S. government securities. The Company&#x2019;s cash is not subject to any external restrictions. The Company assesses the collectability of accounts and receivables through a review of the current aging and terms, as well as an analysis of historical collection rates, general economic conditions and credit status of government agencies. Credit risk for the reimbursement grant and HST refunds receivable are not considered significant since amounts are due from the Canadian government&#x2019;s SIF and the Canada Revenue Agency.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;(c) Foreign exchange risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company and its subsidiary have balances in Canadian dollars that give rise to exposure to foreign exchange (FX) risk relating to the impact of translating certain non-U.S. dollar balance sheet accounts as these statements are presented in U.S. dollars. A strengthening U.S. dollar will lead to a FX loss while a weakening U.S. dollar will lead to a FX gain. The Company has not entered into any agreements or purchased any instruments to hedge possible currency risks. At September 30, 2024, the Company and its Canadian subsidiary had assets denominated in Canadian dollars of approximately C$0.04 million and the U.S. dollar exchange rate at this date was equal to 1.3517 Canadian dollars. Based on the exposure at September 30, 2024, a 10% annual change in the Canadian/U.S. exchange rate would impact the Company&#x2019;s loss and other comprehensive loss by approximately $0.04 million.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;i&gt;(d) Liquidity risk&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;Liquidity risk is the risk that the Company will encounter difficulty raising liquid funds to meet commitments as they fall due. In meeting its liquidity requirements, the Company closely monitors its forecasted cash requirements with expected cash drawdown.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:AssetReportingCurrencyDenominatedValue
      contextRef="i_2024-09-30"
      decimals="-4"
      id="c972"
      unitRef="CAD">40000.00</us-gaap:AssetReportingCurrencyDenominatedValue>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i_2023-09-30"
      decimals="INF"
      id="c973"
      unitRef="Pure">1.3517</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <edsa:SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss
      contextRef="i_2024-09-30"
      decimals="-4"
      id="c974"
      unitRef="USD">-40000.00</edsa:SensitivityAnalysisTenPercentChangeToForeignCurrencyExchangeImpactToNetIncomeLossAndOtherComprehensiveIncomeLoss>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2023-10-01_2024-09-30" id="c975">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;12. Related party transactions&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;During each of the years ended September 30, 2024 and 2023, the Company paid cash of $78,000 and $82,000, respectively, for a ROU lease from a company controlled by the Company's CEO. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by both parties. On December 31, 2022, the Company executed a &lt;span style="-sec-ix-hidden:c979"&gt;two&lt;/span&gt;-year lease extension through December 31, 2024 in accordance with the terms of the original lease agreement. Rents of approximately $30,000 and $15,000 were payable at September 30, 2024, and September 30, 2023, respectively.&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;The Company agreed to pay a monthly standby fee for the term of the Credit Agreement, which amounted to $51,000 in September 2024 and nil in September 2023.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2023-10-01_2024-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember"
      decimals="0"
      id="c977"
      unitRef="USD">78000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2022-10-01_2023-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember"
      decimals="0"
      id="c978"
      unitRef="USD">82000</us-gaap:OperatingLeaseExpense>
    <us-gaap:AccruedRentCurrentAndNoncurrent
      contextRef="i_2024-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember"
      decimals="0"
      id="c980"
      unitRef="USD">30000</us-gaap:AccruedRentCurrentAndNoncurrent>
    <us-gaap:AccruedRentCurrentAndNoncurrent
      contextRef="i_2023-09-30_RelatedPartyTransactionsByRelatedPartyAxis-ChiefExecutiveOfficerMember"
      decimals="0"
      id="c981"
      unitRef="USD">15000</us-gaap:AccruedRentCurrentAndNoncurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2023-10-01_2024-09-30" id="c982">
&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&lt;b&gt;13. Subsequent events&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;On October 4, 2024, the Company entered into an At The Market Offering Agreement with H.C. Wainwright &amp;amp; Co., LLC as a sales agent (HCW ATM) pursuant to which the Company may offer and sell, from time to time, common shares through an at-the-market equity offering program for up to $3.87 million in gross proceeds. The Company has no obligation to sell any of the common shares and may at any time suspend sales or terminate the equity distribution agreement in accordance with its terms. Subsequent to the year ended September 30, 2024, the Company sold a total of 220,269 common shares pursuant to the agreement for net proceeds of approximately $0.6 million after deducting sales commissions.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;In October 2024, the Company entered into a Securities Purchase Agreement with PN MPC, an entity controlled by Pardeep Nijhawan, the Company&#x2019;s Chief Executive Officer, Secretary and member of the board of directors of the Company, pursuant to which the Company agreed to issue and sell to PN MPC in a private placement, up to $5 million of shares (Preferred Shares) of the Company&#x2019;s newly designated Series A-1 Convertible Preferred Shares, stated value $10,000 per share, each of which is initially convertible into approximately 2,903 common shares (Conversion Shares), without par value, of the Company (Common Shares) at a conversion price of $3.445 per Conversion Share, and warrants (Warrants) to purchase Common Shares (Warrant Shares) at an exercise price of $3.445 per Warrant Share. The Preferred Shares and the Warrants are being sold together in a fixed combination of one Preferred Share and a Warrant to purchase a number of Common Shares equal to 75% of the underlying Conversion Shares at a combined purchase price of $10,272.13 per Preferred Share and related Warrants. Under the Purchase Agreement, PN MPC has purchased 150 Preferred Shares initially convertible into an aggregate of 435,414 Conversion Shares and Warrants to purchase up to an aggregate of 326,560 Warrant Shares for an aggregate purchase price of $1,540,819. The Warrants expire &lt;span style="-sec-ix-hidden:c998"&gt;five&lt;/span&gt; years from the issuance date.&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-align: justify;"&gt;As a result of the foregoing transactions&#160;and as of the date of this filing, the Company believes it has shareholders&#x2019; equity of at least $2.5 million and therefore satisfies the minimum Nasdaq listing requirement set forth in Nasdaq Listing Rule 5550(b)(1).&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <edsa:EquityOfferingMaximumAmount
      contextRef="i_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember"
      decimals="-4"
      id="c984"
      unitRef="USD">3870000</edsa:EquityOfferingMaximumAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-10-01_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember"
      decimals="INF"
      id="c985"
      unitRef="Share">220269</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-10-01_2024-10-04_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AtTheMarketOfferingAgreementMember"
      decimals="-5"
      id="c986"
      unitRef="USD">600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-10-01_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="-6"
      id="c987"
      unitRef="USD">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember"
      decimals="INF"
      id="c988"
      unitRef="USDPerShare">10000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c989"
      unitRef="Share">2903</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c990"
      unitRef="USDPerShare">3.445</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c991"
      unitRef="USDPerShare">3.445</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="2"
      id="c992"
      unitRef="Pure">0.75</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c993"
      unitRef="USDPerShare">10272.13</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-10-01_2024-10-31_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c994"
      unitRef="Share">150</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i_2024-10-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesA1ConvertiblePreferredSharesToCommonSharesMember_StatementClassOfStockAxis-SeriesA1ConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c995"
      unitRef="Share">435414</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-10-31_ClassOfWarrantOrRightAxis-WarrantsToPurchaseCommonSharesMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="c996"
      unitRef="Share">326560</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-10-01_2024-10-31_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementSecuritiesPurchaseAgreementMember"
      decimals="0"
      id="c997"
      unitRef="USD">1540819</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
